fluorouracil has been researched along with Carcinoma, Epidermoid in 3195 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Apatinib mesylate combined with chemotherapy for the treatment of patients with gastroesophageal junction adenocarcinoma was safe and effective, with improved survival benefit compared with control." | 9.30 | Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma. ( Chen, J; Hua, Z; Lu, B; Lu, C; Qu, C; Sun, Z; Tong, R; Zhang, J, 2019) |
| "This phase II trial evaluated the efficacy of cisplatin and fluorouracil (CF)-based combination neoadjuvant chemotherapy on the outcome of patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC)." | 9.24 | Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). ( Doki, Y; Fujitani, K; Hirao, M; Kimura, Y; Kobayashi, K; Makino, T; Miyata, H; Mori, M; Motoori, M; Satoh, T; Shiraishi, O; Tamura, S; Yamasaki, M; Yano, M; Yasuda, T, 2017) |
| "A combination of cetuximab plus pemetrexed was marginally effective and well tolerated in patients with advanced esophageal squamous cell carcinoma as the second-line treatment." | 9.20 | Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. ( Han, Y; Shang, M; Shi, SB; Tian, J; Xu, J, 2015) |
| "Palliative chemotherapy with cisplatin/5-fluorouracil (5FU) is the commonest regimen employed for metastatic and recurrent head and neck squamous cell carcinoma (SCCHN) and nasopharyngeal carcinoma (NPC)." | 9.17 | Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. ( Aslan, NM; Chee Ee Phua, V; Ismail, F; Kua, VF, 2013) |
| "We performed a phase II trial of docetaxel in combination with capecitabine to evaluate the antitumor response, toxicity, and survival in pre-treated patients with advanced esophageal squamous cell carcinoma." | 9.17 | Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma. ( Li, X; Lin, S; Lin, W; Lin, Y; Wang, H, 2013) |
| "This randomized clinical study was to assess and compare the efficacy and safety of two chemoradiotherapy (cisplatin + 5-fluorouracil + radiotherapy and cisplatin + docetaxel + radiotherapy) regimens in patients with unresectable local advanced oesophageal squamous cell carcinoma." | 9.16 | Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. ( Chen, H; Zhang, T; Zhao, T, 2012) |
| "To compare the efficacy and feasibility of neoadjuvant chemoradiotherapy with docetaxel plus cisplatin or with cisplatin plus fluorouracil in the treatment of local advanced esophageal squamous cell carcinoma." | 9.16 | [Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma]. ( Chen, MY; Chen, Z; Luo, JC; Wei, L; Wu, S, 2012) |
| "To evaluate the efficacy of concurrent oral capecitabine with accelerated hypofractionated radical radiotherapy in locally advanced squamous cell carcinoma of the head and neck (SCCHN)." | 9.15 | Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study. ( Birzgalis, A; Homer, J; Jegannathen, A; Lee, L; Mais, K; Ryder, WD; Slevin, N; Sykes, A; Yap, B, 2011) |
| "We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia." | 9.14 | A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. ( Drew, PA; Jamieson, GG; Liu, JF; Wu, TC; Zhu, GJ, 2009) |
| "The comparative study among granisetron alone and granisetron combined with hydroxyzine hydrochloride or dexamethasone was undertaken for the prevention of nausea and vomiting during chemotherapy including cisplatin in patients with advanced head and neck carcinomas." | 9.08 | [Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin]. ( Enomoto, H; Furukawa, M; Ikema, Y; Kawai, S; Kohno, H; Kubota, A; Makino, Y; Matsuda, H; Tsukuda, M; Yago, T, 1995) |
| "Our trial shows that the standard treatment for most patients with epidermoid anal cancer should be a combination of radiotherapy and infused 5-fluorouracil and mitomycin, with surgery reserved for those who fall on this regimen." | 9.08 | Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. ( , 1996) |
| "Stomatitis caused by a combined chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP) is a serious problem in the course of treatment for patients with oral carcinoma." | 9.08 | [Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease combine (Elase)]. ( Kumagai, S; Mori, S; Morikawa, H; Sakaki, K; Sato, A; Song, ST, 1997) |
| "We conducted a phase II clinical trial of 5-fluorouracil (5 day continuous infusion), cis-diamminedichloroplatinum and etoposide in previously untreated patients with metastatic carcinoma of unknown primary origin." | 9.07 | Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. ( Abbruzzese, JL; Faintuch, J; Frost, P; Raber, MN; Sumrall, C, 1991) |
| "The clinical and pathologic response of carcinoma in situ of the vulva in a 42-year-old woman treated with topical 5-fluorouracil is reported." | 8.75 | Topical 5-fluorouracil in the treatment of carcinoma in situ of the vulva. ( Carson, TE; Hoskins, WJ; Wurzel, JF, 1976) |
| "Salvage concurrent chemoradiotherapy (60 Gy in 30 fractions) with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy was an effective and safe treatment for locoregional recurrence after curative resection of esophageal squamous cell carcinoma, especially in those approaching a complete response." | 8.12 | Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma. ( Akimoto, T; Daiko, H; Fujita, T; Fujiwara, H; Hojo, H; Ito, R; Kojima, T; Nakamura, N; Nakamura, Y; Sunakawa, H; Yano, T; Yoshino, T, 2022) |
| "We identified 5700 subjects who filled prescriptions for 5-fluorouracil or imiquimod for treatment of actinic keratosis in 2007." | 7.91 | Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study. ( Asgari, MM; Chren, MM; Friedman, GD; Neugebauer, R; Sokil, M; Su, KA; Zhu, Z, 2019) |
| "This study documents the clinical efficacy and toxicity of S-1 and paclitaxel (S1/PTX) in patients with unresectable or postoperative recurrent esophageal squamous cell carcinoma (ESCC) who had been previously treated with fluorouracil (5FU), cisplatin, and docetaxel." | 7.88 | A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy. ( Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y, 2018) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic agent used to treat a variety of gastric cancers including oesophageal squamous cell carcinoma (OSCC), for which the 5-year mortality rate exceeds 85%." | 7.88 | Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. ( Damelin, LH; Jivan, R; Mavri-Damelin, D; Mynhardt, C; Peres, J; Prince, S; Veale, RB, 2018) |
| "5-Fluorouracil (5-FU) is used for the clinical treatment of esophageal squamous cell carcinomas (ESCCs), yet it also induces chemoresistant cancer cells during treatment, which leads to the failure of the therapy." | 7.85 | A novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cell line Eca-109/5-FU with significant drug resistance-related characteristics. ( Chen, Z; Ge, J; Jiang, H; Li, X; Ma, Q; Shi, Y; Wang, J; Wang, M; Wang, Z; Zhang, C, 2017) |
| " This study was aimed to compare the differences in pathologic response and survival between docetaxel/cisplatin and fluorouracil/cisplatin as neoadjuvant CRT in locally advanced esophageal squamous cell carcinoma (SCC)." | 7.85 | Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. ( Fu, JH; Li, Y; Liu, MZ; Liu, SL; Xi, M; Yang, YD; Zhang, L; Zhang, P, 2017) |
| "The anticancer efficacy of docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy has been reported to be better than that of conventional regimens for advanced or relapsed esophageal squamous cell carcinoma (ESCC), and may become a standard therapy for this disease." | 7.85 | Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. ( Kawada, K; Kawano, T; Miyawaki, Y; Nakajima, Y; Okada, T; Tokairin, Y, 2017) |
| "Docetaxel, cisplatin and fluorouracil (DCF) is a candidate neoadjuvant chemotherapy (NAC) regimen for esophageal squamous cell carcinoma (ESCC)." | 7.85 | The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. ( Baba, H; Baba, Y; Hiyoshi, Y; Kurashige, J; Sakamoto, Y; Watanabe, M; Yoshida, N, 2017) |
| "Fulminant myocarditis is a rare but potentially life-threatening illness caused by 5-fluorouracil cardiotoxicity." | 7.83 | Rapid Extracorporeal Membrane Oxygenation Overcomes Fulminant Myocarditis Induced by 5‑Fluorouracil. ( Amraotkar, AR; DeFilippis, AP; Grubb, KJ; Pachika, A, 2016) |
| "The authors previously reported the safety and short-term efficacy of ablative fractional laser (AFXL)-assisted delivery of topical fluorouracil in the treatment of superficial basal cell carcinoma (sBCC) and squamous cell carcinoma in situ (SCCis)." | 7.83 | Ablative Fractional Laser-Assisted Topical Fluorouracil for the Treatment of Superficial Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ: A Follow-Up Study. ( Gan, SD; Hsu, SH; Konnikov, N; Liang, CA; Nguyen, BT, 2016) |
| "To retrospectively evaluate the efficacy and toxicity of definitive concurrent chemoradiotherapy (dCRT) with cisplatinum/paclitaxel versus cisplatinum/5-fluorouracil in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who received nonsurgical treatment." | 7.83 | Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients. ( Guo, J; Han, X; Hu, G; Liu, L; Tang, N; Wang, Y; Wang, Z; Zhang, Q, 2016) |
| "To investigate the effects of nimotuzumab (h-R3) with cisplatin (DDP) or fluorouracil (5-FU) on human esophageal squamous cell carcinoma (ESCC) EC1 cells." | 7.81 | Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells. ( Huo, XQ; Ji, YH; Li, GJ; Li, WW; Lu, P; Mu, YL; Wu, JQ; Yang, XY, 2015) |
| "Definitive chemoradiotherapy (CRT) with 5-fluorouracil (5-FU) and cisplatin (CDDP) is one of the standard therapies for esophageal squamous cell carcinoma (ESCC); however, inter-individual variations in clinical outcomes have yet to be investigated." | 7.80 | Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Azuma, T; Hirai, M; Kuwahara, A; Miki, I; Minegaki, T; Nakamura, T; Nishiguchi, K; Okuno, T; Omatsu, H; Sakaeda, T; Tamura, T; Yamamori, M, 2014) |
| "Five patients with primary colorectal adenocarcinoma or anal squamous cell carcinoma were started on a 2-weeks-on, 1-week-off capecitabine dosing regimen in addition to other chemotherapeutic agents and/or radiation." | 7.78 | Capecitabine-induced chest pain relieved by diltiazem. ( Ambrosy, AP; Fisher, GA; Kunz, PL; Witteles, RM, 2012) |
| " In this study, 49 Japanese patients with esophageal squamous cell carcinoma (ESCC) were followed up for 5 years after treatment with a definitive 5-fluorouracil (5-FU)/cisplatin (CDDP)-based chemoradiotherapy (CRT), and the effects of genotypes of vascular endothelial growth factor (VEGF) were retrospectively revaluated in terms of prediction of long-term survival." | 7.78 | VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Kuwahara, A; Manabe, Y; Miki, I; Nakamura, T; Nishiguchi, K; Okuno, T; Sakaeda, T; Tamura, T; Yamamori, M, 2012) |
| "Inhibition of TP may be beneficial in decreasing angiogenesis-dependent growth and migration of cholangiocarcinoma but may diminish the response to 5-fluorouracil chemotherapy." | 7.76 | Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. ( Jearanaikoon, P; Limpaiboon, T; Miwa, M; Pairojkul, C; Sripa, B; Tantimavanich, S; Thanasai, J, 2010) |
| "A recent meta-analysis study showed that post-operative adjuvant chemotherapy with UFT, an oral combination drug composed of tegafur [prodrug of 5-fluorouracil (5-FU)] and uracil [inhibitor of dihydropyrimidine dehydrogenase (DPD)] was associated with improved survival in patients with lung adenocarcinomas, but not in those with lung squamous cell carcinomas." | 7.75 | Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung. ( Araki, O; Chida, M; Honma, K; Ishihama, H; Karube, Y; Masawa, N; Miyoshi, S; Seki, N; Tamura, M; Umezu, H, 2009) |
| "Hyperammonemia or hyperammonemic leukoencephalopathy sometimes occurs as an adverse event after 5-fluorouracil (5-FU) chemotherapy." | 7.74 | The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases. ( Asakage, T; Kikuta, S; Kubota, A; Nakao, K; Sugasawa, M, 2008) |
| "Topical therapeutic options for cutaneous squamous cell carcinoma in situ include 5-fluorouracil cream and imiquimod cream." | 7.73 | Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. ( Mings, SM; Ondo, AL; Pestak, RM; Shanler, SD, 2006) |
| "A case of arsenical keratosis with multiple lesions of Bowen's disease and squamous cell carcinoma is described." | 7.72 | Successful treatment of multiple premalignant and malignant lesions in arsenical keratosis with a combination of acitretin and intralesional 5-fluorouracil. ( Khandpur, S; Sharma, VK, 2003) |
| "Myocardial ischemia induced by 5-fluorouracil (5-FU) is a relatively rare, but potentially serious, occurrence." | 7.70 | Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report. ( Akpek, G; Hartshorn, KL, 1999) |
| "We present the case of a patient with a locally advanced hypopharyngeal carcinoma who developed a severe cytomegalovirus (CMV) colitis after his first chemotherapy course with 5-fluorouracil (5-FU), docetaxel and cisplatin." | 7.70 | Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer. ( Colpaert, C; Schrijvers, D; Van den Brande, J; Vermorken, JB, 1999) |
| "We report a case of double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin." | 7.69 | [A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin]. ( Akiyama, S; Hibi, K; Ito, K; Kasai, Y; Kondo, K; Nonami, T; Takagi, H, 1995) |
| "Fifteen patients with potentially resectable adenocarcinoma of the esophagus were treated with two cycles of preoperative chemotherapy with 5-fluorouracil (5-FU) and cisplatin (DDP)." | 7.68 | A pilot study of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and postoperative radiation therapy and/or chemotherapy in adenocarcinoma of the esophagus. ( Bromberg, C; Carey, RW; Choi, NC; Grillo, HC; Hilgenberg, AD; Logan, DL; Mathisen, DJ; Wain, JC, 1991) |
| "A case of palmar-plantar erythrodysesthesia syndrome (PPES) observed during a 120-h infusion of 5-fluorouracil (5-FU) is presented." | 7.67 | Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. ( Bellmunt, J; Hidalgo, R; Navarro, M; Solé, LA, 1988) |
| "Seven adult men with biopsy-confirmed erythroplasia of Queyrat (EQ) were cured of their disease with topically applied 5-fluorouracil (5-FU) under occlusion." | 7.65 | Erythroplasia of Queyrat: treatment with topical 5-fluorouracil. ( Carson, TE; Goette, DK, 1976) |
| "The MTDs were determined as 5FU 800 mg/m(2) on RT days 1-4 and 29-32 and MMC 8 mg/m(2) on days 1 and 29 when combined with IMRT/VMAT with SIB and cetuximab in locally advanced anal cancer." | 6.80 | Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. ( Gunnlaugsson, A; Guren, MG; Johnsson, A; Leon, O; Radu, C, 2015) |
| "To assess the feasibility and activity of radio-chemotherapy with mitomycin C (MMC) and cisplatin (CDDP) in locally advanced squamous cell anal carcinoma with reference to radiotherapy (RT) combined with MMC and fluorouracil (5-FU)." | 6.74 | Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). ( Bosset, JF; Collette, L; Haustermans, K; Koswig, S; Maingon, P; Matzinger, O; Mineur, L; Mueller, RP; Radosevic-Jelic, L; Roelofsen, F; Van Der Steen-Banasik, EM; Van Houtte, P, 2009) |
| "Thirteen patients with previously untreated squamous cell carcinoma of the hypopharynx, T3 or T4, were included." | 6.71 | Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome. ( Agostini, D; Babin, E; Bequignon, A; Chesnay, E; Constans, JM; Moreau, S; Regeasse, A; Sobrio, F, 2003) |
| "3 mg of ramosetron (RAM) combined with 8 mg of dexamethasone (DEX) and 0." | 6.71 | [A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone]. ( Horiuchi, C; Ikeda, Y; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Tanigaki, Y; Tsukuda, M; Yoshida, T, 2005) |
| "Patients with locally advanced bladder cancer or who are not medically fit for surgery are a therapeutic dilemma." | 6.70 | Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. ( Al-Sarraf, M; Balcerzak, SP; Crawford, ED; Forman, J; Glass, TR; Grossman, HB; Hussain, MH; Jones, J; Sakr, W; Smith, DC, 2001) |
| "Six of 40 patients with metastatic colorectal cancer obtained an objective response (15%; 95% confidence interval, 6-30%)." | 6.69 | Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. ( Avallone, A; Blackie, R; Budillon, A; Caponigro, F; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lucia, L; De Vita, F; Gravina, A; McLeod, H; Morsman, J, 1999) |
| "Differentiating a KA from a squamous cell carcinoma (SCC) is important for treatment implications but is often challenging." | 6.61 | Treatment of Solitary Keratoacanthoma of the Nose With Intralesional Methotrexate and Review of the Literature ( Doerfler, L; Hanke, CW, 2019) |
| "Data from OGSG1003, a randomized phase-II trial comparing two regimens of neoadjuvant chemotherapy, cisplatin and fluorouracil plus Adriamycin and cisplatin and fluorouracil plus docetaxel, for locally advanced esophageal squamous cell carcinoma were used." | 5.69 | The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003. ( Aoyama, S; Doki, Y; Fujitani, K; Hamakawa, T; Hirao, M; Kimura, Y; Makino, T; Miyata, H; Motoori, M; Shiraishi, O; Sugimura, K; Takeno, A; Tanaka, K; Yamasaki, M; Yamashita, K; Yano, M; Yasuda, T, 2023) |
| " cSCC chemoprevention activity of sunscreen and 5-fluorouracil-based (5-FU) actinic keratosis (AK) treatments has been demonstrated in randomized controlled trials (RCTs) in immunocompetent populations but not in OTRs." | 5.51 | Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments). ( Ahmed, I; Bowden, SJ; Gaunt, C; Gaunt, P; Green, AC; Harwood, CA; Hasan, ZU; Hogan, S; Homer, V; Ismail, F; Jefferson-Hulme, Y; Kentley, J; Lear, JT; Matin, RN; Milligan, A; Mitchell-Worsford, L; Proby, CM; Thomson, J; Van-de-Velde, V; Wheatley, K; Whitmarsh, T, 2022) |
| "Oesophageal squamous cell carcinoma (ESCC) is the sixth most common cause of cancer-associated death in the world and novel therapeutic alternatives are urgently warranted." | 5.43 | Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway. ( Bai, L; Chen, DL; Chen, LZ; Ju, HQ; Lu, YX; Mo, HY; Sheng, H; Wang, DS; Wang, F; Wu, QN; Xie, D; Xu, RH; Yu, HE; Yun, JP; Zeng, ZL, 2016) |
| "Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2) tyrosine kinase domains." | 5.39 | Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models. ( Bachman, KE; Fei, M; Greshock, J; Hou, W; Liu, L; Liu, P; Moon, H; Qin, X; Wang, H; Ye, BC; Zang, CY; Zhang, P; Zhu, X, 2013) |
| "Histological examinations revealed squamous cell carcinoma." | 5.37 | [A case of advanced esophageal cancer with multiple liver metastases accompanying poorly general conditions and serious liver dysfunctions, successfully treated using concurrent radiotherapy and chemotherapy with low-dose nedaplatin and 5-fluorouracil]. ( Fukui, T; Itoh, Y; Kawada, S; Takeda, H; Yoshioka, T, 2011) |
| "Squamous cell cancer of the anal canal (anal cancer) is a rare disease but with worldwide increasing incidence." | 5.37 | Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. ( Abbas, A; Fakih, M; Nehme, E, 2011) |
| "In Japan, esophagectomy after two courses of 5-fluorouracil plus cisplatin is regarded a standard strategy for treating stage II or III esophageal squamous cell carcinoma (ESCC)." | 5.34 | An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus. ( Hattori, N; Hayashi, M; Iwata, N; Kanda, M; Kodera, Y; Koike, M; Nakayama, G; Omae, K; Shimizu, D; Tanaka, C; Yamada, S, 2020) |
| "Avascular-differentiated regions in squamous cell carcinoma offer sanctuary to some hypoxic but viable tumor cells (carbonic anhydrase IX and Ki67 positive) that escape therapy because of limited drug delivery." | 5.32 | Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. ( Azrak, R; Bhattacharya, A; Cao, S; Durrani, FA; Mazurchuk, R; Pendyala, L; Rustum, YM; Slocum, HK; Spernyak, JA; Tóth, K, 2004) |
| "Apatinib mesylate combined with chemotherapy for the treatment of patients with gastroesophageal junction adenocarcinoma was safe and effective, with improved survival benefit compared with control." | 5.30 | Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma. ( Chen, J; Hua, Z; Lu, B; Lu, C; Qu, C; Sun, Z; Tong, R; Zhang, J, 2019) |
| "5-Fluorouracil is an S-phase-specific, synthetic pyrimidine antimetabolite, which is used as a cytostatic agent for a variety of malignant lesions, either singly or in multidrug regimens." | 5.30 | Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. ( Ahmad, M; Aziz, SA; Iqbal, K; Jalal, S; Mohi-ud-Din, K; Tramboo, NA, 1998) |
| "Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2." | 5.28 | Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. ( Coia, LR; Engstrom, PF; Hanks, GE; Paul, AR; Stafford, PM, 1991) |
| "A case of an exquisitely painful squamous cell carcinoma of the bladder is reported." | 5.26 | Dramatic palliation for painful, fixed bladder squamous cell carcinoma with 5-fluorouracil infusion. ( Confer, DJ; Gillespie, L; Smith, RB, 1977) |
| "The relation between the induction of delayed hypersensitivity reactions to 5-FU following treatment with topical 5-FU and the cure rate for cutaneous neoplasms showed a trend toward correlation." | 5.25 | Delayed hypersensitivity to 5-fluorouracil following topical chemotherapy of cutaneous cancers. ( Ichinose, H; Krementz, ET; Litwin, MS; Mansell, PW, 1975) |
| "This phase II trial evaluated the efficacy of cisplatin and fluorouracil (CF)-based combination neoadjuvant chemotherapy on the outcome of patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC)." | 5.24 | Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). ( Doki, Y; Fujitani, K; Hirao, M; Kimura, Y; Kobayashi, K; Makino, T; Miyata, H; Mori, M; Motoori, M; Satoh, T; Shiraishi, O; Tamura, S; Yamasaki, M; Yano, M; Yasuda, T, 2017) |
| "Patients with SCC of anal cancer T2-4N0M0 or T (any) N1-3M0, with good performance status and normal blood and renal function, were treated with capecitabine 825 mg/m(2) bid during radiotherapy associated with a single dose of mitomycin 15 mg/m(2) on day 1." | 5.22 | Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal. ( Alex, AK; Bariani, G; Braghirolli, MI; Hoff, PM; Moniz, CM; Nahas, C; Oliveira, SC; Riechelmann, R, 2016) |
| "This study compared the efficacy and toxicity of Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil (5-FU) in patients of recurrent squamous cell carcinoma of head and neck (SCCHN) treated with palliative intent." | 5.20 | Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma. ( Ghatak, A; Gupta, S; Husain, N; Jamal, N; Khan, H; Kushwaha, VS; Negi, MP, 2015) |
| "To evaluate toxicity, local control, and survival of anal cancer patients treated with helical tomotherapy (HT) and concurrent 5-fluorouracil and mitomycin-C (5FU/MMC)." | 5.20 | Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer. ( Doll, C; Field, C; Ghosh, S; Joseph, K; Mulder, K; Nijjar, T; Nijjar, Y; Schiller, D; Severin, D; Syme, A; Tankel, K; Usmani, N; Warkentin, H; Wong, C, 2015) |
| "A combination of cetuximab plus pemetrexed was marginally effective and well tolerated in patients with advanced esophageal squamous cell carcinoma as the second-line treatment." | 5.20 | Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. ( Han, Y; Shang, M; Shi, SB; Tian, J; Xu, J, 2015) |
| "Patients with previously untreated thoracic AEC who had T4 tumors or M1 lymph node metastasis (M1 LYM), or both, received intravenous infusions of docetaxel (35 mg/m(2)) and cisplatin (40 mg/m(2)) on day 1 and a continuous intravenous infusion of 5-fluorouracil (400 mg/m(2)/day) on days 1 to 5, every 2 weeks, plus concurrent radiation." | 5.19 | Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). ( Azuma, M; Hayakawa, K; Higuchi, K; Ishido, K; Ishiyama, H; Katada, C; Katada, N; Koizumi, W; Komori, S; Sasaki, T; Tanabe, S, 2014) |
| "Newer radiation techniques, and the application of continuous 5-FU exposure during radiation therapy using oral capecitabine may improve the treatment of anal cancer." | 5.17 | Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. ( Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Dewit, L; Schellens, JH, 2013) |
| "The results of our trial--the largest in anal cancer to date--show that fluorouracil and mitomycin with 50." | 5.17 | Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. ( Begum, R; Cunningham, D; Essapen, S; Falk, S; Glynne-Jones, R; Gollins, S; James, RD; Kadalayil, L; Ledermann, J; Leslie, M; Maughan, T; McDonald, A; Meadows, HM; Myint, AS; Saunders, MP; Sebag-Montefiore, D; Wilson, C, 2013) |
| "Palliative chemotherapy with cisplatin/5-fluorouracil (5FU) is the commonest regimen employed for metastatic and recurrent head and neck squamous cell carcinoma (SCCHN) and nasopharyngeal carcinoma (NPC)." | 5.17 | Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. ( Aslan, NM; Chee Ee Phua, V; Ismail, F; Kua, VF, 2013) |
| "The long-term update of US GI Intergroup RTOG 98-11 anal cancer trial found that concurrent chemoradiation (CCRT) with fluorouracil (5-FU) plus mitomycin had a significant impact on disease-free survival (DFS) and overall survival (OS) compared with induction plus concurrent 5-FU plus cisplatin." | 5.17 | Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. ( Ajani, JA; Benson, AB; Gunderson, LL; Haddock, MG; Mayer, RJ; Moughan, J; Pedersen, JE; Rich, TA; Thomas, CR; Willett, CG; Winter, KA, 2013) |
| "We performed a phase II trial of docetaxel in combination with capecitabine to evaluate the antitumor response, toxicity, and survival in pre-treated patients with advanced esophageal squamous cell carcinoma." | 5.17 | Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma. ( Li, X; Lin, S; Lin, W; Lin, Y; Wang, H, 2013) |
| "A multi-institutional phase 2 trial assessed the utility of dose-painted intensity modulated radiation therapy (DP-IMRT) in reducing grade 2+ combined acute gastrointestinal and genitourinary adverse events (AEs) of 5-fluorouracil (5FU) and mitomycin-C (MMC) chemoradiation for anal cancer by at least 15% compared with the conventional radiation/5FU/MMC arm from RTOG 9811." | 5.17 | RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. ( Esthappan, J; Goodyear, MD; Haddock, MG; Kachnic, LA; Myerson, RJ; Parikh, PJ; Rotman, M; Safran, H; Willett, CG; Willins, J; Winter, K, 2013) |
| "This randomized clinical study was to assess and compare the efficacy and safety of two chemoradiotherapy (cisplatin + 5-fluorouracil + radiotherapy and cisplatin + docetaxel + radiotherapy) regimens in patients with unresectable local advanced oesophageal squamous cell carcinoma." | 5.16 | Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. ( Chen, H; Zhang, T; Zhao, T, 2012) |
| "To compare the efficacy and feasibility of neoadjuvant chemoradiotherapy with docetaxel plus cisplatin or with cisplatin plus fluorouracil in the treatment of local advanced esophageal squamous cell carcinoma." | 5.16 | [Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma]. ( Chen, MY; Chen, Z; Luo, JC; Wei, L; Wu, S, 2012) |
| "The United Kingdom Coordinating Committee on Cancer Research anal cancer trial demonstrated the benefit of combined modality treatment (CMT) using radiotherapy (RT), infusional 5-fluorouracil, and mitomycin C over RT alone." | 5.15 | "Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I). ( Adams, R; Glynne-Jones, R; Gollins, S; James, R; Jitlal, M; McDonald, A; Meadows, HM; Northover, JM; Sebag-Montefiore, D, 2011) |
| "To evaluate the efficacy of concurrent oral capecitabine with accelerated hypofractionated radical radiotherapy in locally advanced squamous cell carcinoma of the head and neck (SCCHN)." | 5.15 | Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study. ( Birzgalis, A; Homer, J; Jegannathen, A; Lee, L; Mais, K; Ryder, WD; Slevin, N; Sykes, A; Yap, B, 2011) |
| "We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia." | 5.14 | A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. ( Drew, PA; Jamieson, GG; Liu, JF; Wu, TC; Zhu, GJ, 2009) |
| "Accumulating data indicate that docetaxel plus cisplatin and 5-fluorouracil has certain effect on advanced gastric or gastro-oesophageal junction adenocarcinoma." | 5.14 | A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma. ( Guo, JF; Nie, XY; Peng, J; Wang, B; Wu, F; Xing, H; Zhang, B; Zhu, GY, 2010) |
| "Patients with previously untreated anal canal cancers with T3 or T4 tumors and/or extensive nodal involvement (bulky N2 or N3) received two 28-day cycles of induction treatment with infusional FU plus cisplatin followed by two 28-day cycles of FU plus mitomycin C with concurrent split-course radiation." | 5.13 | Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). ( Budinger, S; Colacchio, TA; Day, JM; Ellerton, J; Goldberg, RM; Hopkins, J; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Shank, B; Tepper, J; Valone, F, 2008) |
| "Patients with squamous cell carcinoma or adenocarcinoma of the esophagus initially received capecitabine, carboplatin, and paclitaxel with RT (1." | 5.12 | A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. ( Bendell, JC; Blobe, GC; Czito, BG; D'Amico, TA; Fernando, NH; Harpole, DH; Honeycutt, W; Hurwitz, HI; Kelsey, CR; Morse, MA; Willett, CG; Yu, D, 2007) |
| "Cumulative gastrointestinal toxicities and neutropenia were the DLTs of docetaxel, capecitabine, and carboplatin." | 5.11 | Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. ( Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY, 2005) |
| " At CDDP 50 mg/m2, raltitrexed 3 mg/m2, 5-FU 900 mg/m2, four out of six patients showed DLT, which was in all cases grade 4 neutropenia." | 5.09 | Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG). ( Avallone, A; Budillon, A; Caponigro, F; Comella, G; Comella, P; De Rosa, V; Di Gennaro, E; Ionna, F; Manzione, L; Mozzillo, N; Rivellini, F, 2000) |
| "Forty-four patients with carcinoma of the esophagus or gastroesophageal junction were prospectively entered into a phase II trial of preoperative 5-fluorouracil, cisplatin, and interferon alfa with concurrent external beam radiotherapy before esophagectomy." | 5.09 | Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma. ( Gooding, WE; Lew, JI; Posner, MC; Ribeiro, U; Safatle-Ribeiro, AV, 2001) |
| "These studies demonstrate that the concurrent addition of modest dose cisplatin and infusional dose fluorouracil to radiation in the definitive, preoperative, and palliative settings contribute to high rates of durable dysphagia-free survival, with overall survival comparable to (and possibly better than) the chemoradiation arm of the recently reported Intergroup Study, but at the cost of less morbidity." | 5.08 | Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. ( Ackland, SP; Burmeister, BH; Denham, JW; Devitt, P; Gill, PG; Hamilton, CS; Jamieson, GG; Lamb, DS; O'Brien, M; Yeoh, E, 1995) |
| "The comparative study among granisetron alone and granisetron combined with hydroxyzine hydrochloride or dexamethasone was undertaken for the prevention of nausea and vomiting during chemotherapy including cisplatin in patients with advanced head and neck carcinomas." | 5.08 | [Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin]. ( Enomoto, H; Furukawa, M; Ikema, Y; Kawai, S; Kohno, H; Kubota, A; Makino, Y; Matsuda, H; Tsukuda, M; Yago, T, 1995) |
| "Our trial shows that the standard treatment for most patients with epidermoid anal cancer should be a combination of radiotherapy and infused 5-fluorouracil and mitomycin, with surgery reserved for those who fall on this regimen." | 5.08 | Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. ( , 1996) |
| "Stomatitis caused by a combined chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP) is a serious problem in the course of treatment for patients with oral carcinoma." | 5.08 | [Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease combine (Elase)]. ( Kumagai, S; Mori, S; Morikawa, H; Sakaki, K; Sato, A; Song, ST, 1997) |
| "Eighteen patients with esophageal carcinoma (16 adenocarcinoma, two squamous cell carcinoma) were treated with two cycles of induction chemotherapy consisting of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 (3-hour infusion), cisplatin 20 mg/m2/d x 4 days, and 5-fluorouracil 1 g/m2/d (continuous infusion x 4 days) separated by a 28-day interval before surgical resection." | 5.08 | Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. ( Belani, CP; Day, R; Ferson, PF; Keenan, RJ; Kim, R; Landreaneau, RJ; Lembersky, B; Luketich, JD; Posner, M; Ramanathan, RK; Seeger, J, 1997) |
| "Preoperative chemotherapy with a combination of cisplatin and fluorouracil did not improve overall survival among patients with epidermoid cancer or adenocarcinoma of the esophagus." | 5.08 | Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. ( Ajani, J; Estes, N; Ginsberg, R; Gunderson, L; Haller, DG; Kelsen, DP; Kocha, W; Minsky, BD; Mortimer, J; Pajak, TF; Roth, JA; Sheahan, DG, 1998) |
| " Leukopenia was severe in the first two steps of treatment, with WHO grade IV toxicity occurring in 41% of patients; however, this decreased to 10% when vindesine was deleted from the chemotherapy regimen in the last two steps." | 5.07 | Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study. ( Bauer, J; Bernasconi, S; Leyvraz, S; Monnier, P; Pasche, P, 1994) |
| "This phase III prospective, randomized, and stratified trial was undertaken to evaluate the efficacy of four courses of combined fluorouracil (1000 mg per square meter of body-surface area daily for four days) and cisplatin (75 mg per square meter on the first day) plus 5000 cGy of radiation therapy, as compared with 6400 cGy of radiation therapy alone, in patients with squamous-cell carcinoma or adenocarcinoma of the thoracic esophagus." | 5.07 | Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. ( al-Sarraf, M; Brindle, J; Byhardt, R; Cooper, J; Davis, L; Emami, B; Herskovic, A; Leichman, L; Martz, K; Vaitkevicius, V, 1992) |
| "We conducted a phase II clinical trial of 5-fluorouracil (5 day continuous infusion), cis-diamminedichloroplatinum and etoposide in previously untreated patients with metastatic carcinoma of unknown primary origin." | 5.07 | Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. ( Abbruzzese, JL; Faintuch, J; Frost, P; Raber, MN; Sumrall, C, 1991) |
| "Laser therapy appears the best option among nonsurgical approaches for actinic cheilitis, and PDT showed higher efficacy when sequentially combined with 5% imiquimod." | 5.05 | Treatments of actinic cheilitis: A systematic review of the literature. ( Cornacchia, L; Lai, M; Longo, C; Pampena, R; Pellacani, G; Peris, K, 2020) |
| "Because of biochemical and tissue culture evidence casting doubt on the physiologic relevance of reported synergy afforded by sequential administration of methotrexate (MTX) followed by 5-fluorouracil (5-FU), a randomized controlled clinical trial was conducted in 108 patients with advanced cancer, including 70 with squamous cell carcinoma (SCC) of the head and neck, nine with SCC of other primary sites, 24 with colorectal, and five with gastric adenocarcinomas." | 5.05 | Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration. ( Coates, AS; Fox, RM; Hedley, D; Raghavan, D; Swanson, C; Tattersall, MH, 1984) |
| " Keratoacanthomas had high cure rates with intralesional agents: 98% for 5FU, 91% for methotrexate, 100% for bleomycin, 100% for IFN alpha (α)-2, 83% for IFN α-2a, and 100% for IFN α-2b." | 4.89 | Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons. ( Chitwood, K; Cohen, G; Etzkorn, J, 2013) |
| "The combination of cisplatin and continuous-infusion 5-fluorouracil is the standard regimen for the treatment of both squamous cell carcinoma and adenocarcinoma." | 4.81 | [Chemotherapy for the patients with esophageal cancer]. ( Ando, N; Shih, CH, 2002) |
| " Two patients with nasopharyngeal carcinoma complicated by collagen diseases (dermatomyositis in one, and Sjögren's syndrome with mixed connective tissue disease in the other) were given radiotherapy combined with chemotherapy consisting of cis-platinum and 5-fluorouracil." | 4.79 | Retropharyngeal abscess after radiation therapy and cis-platinum, 5-fluorouracil treatment for nasopharyngeal carcinoma with collagen disease: report of two patients and a review of the literature. ( Asakura, K; Hareyama, M; Hattori, A; Horikoshi, T; Hyodo, K; Imai, K; Koshiba, H; Morita, K; Nagakura, H; Oouchi, A; Sakata, K; Shido, M; Tamakawa, M; Tanaka, S, 1996) |
| " From October 1985 to October 1987, 43 patients with local-regional esophageal cancer (adenocarcinoma in 21, squamous cell in 22) were treated with cisplatin, vinblastine, and 5-fluorouracil chemotherapy concurrent with 4,500 cGy radiation therapy for 21 days before transhiatal esophagectomy 3 weeks later." | 4.78 | Chemotherapy and radiation therapy before transhiatal esophagectomy for esophageal carcinoma. ( Bromberg, J; Forastiere, AA; Orringer, MB; Perez-Tamayo, C; Takasugi, BJ; Urba, S, 1990) |
| "The clinical and pathologic response of carcinoma in situ of the vulva in a 42-year-old woman treated with topical 5-fluorouracil is reported." | 4.75 | Topical 5-fluorouracil in the treatment of carcinoma in situ of the vulva. ( Carson, TE; Hoskins, WJ; Wurzel, JF, 1976) |
| "This study aimed to clarify the impact of the average relative dose intensity (RDI) of neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-NAC) for resectable locally advanced esophageal squamous cell carcinoma (ESCC)." | 4.31 | Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients. ( Hiraki, Y; Imano, M; Kato, H; Momose, K; Shinkai, M; Shiraishi, O; Yasuda, A; Yasuda, T, 2023) |
| "Studies comparing 5-fluorouracil (5-FU), imiquimod, and photodynamic therapy with aminolevulinic acid (PDT-ALA) have evaluated the efficacy of destroying actinic keratosis (AK)." | 4.12 | A comparison of invasive squamous cell carcinoma greater than 1 year after treatment with 5-fluorouracil, imiquimod, or photodynamic therapy with aminolevulinic acid. ( Cheng, B; Etzkorn, JR; Giordano, CN; Higgins, HW; Miller, CJ; Shin, TM; Sobanko, JF; Veerabagu, S, 2022) |
| "Salvage concurrent chemoradiotherapy (60 Gy in 30 fractions) with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy was an effective and safe treatment for locoregional recurrence after curative resection of esophageal squamous cell carcinoma, especially in those approaching a complete response." | 4.12 | Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma. ( Akimoto, T; Daiko, H; Fujita, T; Fujiwara, H; Hojo, H; Ito, R; Kojima, T; Nakamura, N; Nakamura, Y; Sunakawa, H; Yano, T; Yoshino, T, 2022) |
| "Topical 5-fluorouracil (5-FU) is a valuable treatment of actinic keratosis (AK), but its use is limited by bothersome side effects." | 3.96 | Group clinic for chemoprevention of squamous cell carcinoma: a pilot study. ( Beatson, M; Landow, SM; Leader, N; Shaw, FM; Weinstock, MA, 2020) |
| "Between 2000 and 2015, a total of 112 consecutive patients with UICC stage I-IV anal cancer received chemoradiotherapy with 5‑fluororuracil and mitomycin C (CRT)." | 3.91 | Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus. ( Fietkau, R; Grützmann, R; Matzel, KE; Ott, OJ; Raptis, D; Schmidt, M; Schneider, I; Semrau, S; Strnad, V; Uter, W, 2019) |
| "We identified 5700 subjects who filled prescriptions for 5-fluorouracil or imiquimod for treatment of actinic keratosis in 2007." | 3.91 | Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study. ( Asgari, MM; Chren, MM; Friedman, GD; Neugebauer, R; Sokil, M; Su, KA; Zhu, Z, 2019) |
| " Here, we report the case of a successfully treated patient with thoracic esophageal cancer who had esophageal perforation during docetaxel, cisplatin, and 5-fluorouracil chemotherapy." | 3.91 | Successful Stenting Followed by Surgery for Perforated Esophageal Cancer Due to Chemotherapy. ( Doki, Y; Kobayashi, T; Makino, T; Mori, M; Tanaka, K; Yamasaki, M, 2019) |
| "Definitive chemoradiation with concurrent 5-fluorouracil (5-FU)/mitomycin C (MMC) is an effective treatment for localized anal cancer, but it is associated with significant acute long-term treatment-related toxicity." | 3.91 | Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. ( Adams, J; Allen, JN; Baglini, C; Ben-Josef, E; Blaszkowsky, LS; Clark, JW; DeLaney, TF; Drapek, LC; Hong, TS; Jiang, W; Metz, JM; Murphy, JE; Parikh, AR; Plastaras, JP; Ryan, DP; Wo, JY; Yeap, BY, 2019) |
| "During a regular MR control, the patient developed anaphylactic reaction to Gadolinium, and after that a rectosigmoid ischemia with total necrosis of the posterior rectal wall was diagnosed and surgically treated with Hartmann procedure." | 3.91 | Hypovolemic shock after pelvic radiotherapy. A rare combination leading to a devastating complication. ( Calvisi, G; Carlei, F; Di Sibio, A; Di Staso, M; Giuliani, A; Lombardi, L; Marchese, M; Romano, L; Romanzi, F; Schietroma, M, 2019) |
| "This study documents the clinical efficacy and toxicity of S-1 and paclitaxel (S1/PTX) in patients with unresectable or postoperative recurrent esophageal squamous cell carcinoma (ESCC) who had been previously treated with fluorouracil (5FU), cisplatin, and docetaxel." | 3.88 | A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy. ( Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y, 2018) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic agent used to treat a variety of gastric cancers including oesophageal squamous cell carcinoma (OSCC), for which the 5-year mortality rate exceeds 85%." | 3.88 | Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. ( Damelin, LH; Jivan, R; Mavri-Damelin, D; Mynhardt, C; Peres, J; Prince, S; Veale, RB, 2018) |
| " We investigated the prognostic role of baseline hemoglobin (Hb) in a cohort of anal cancer patients submitted to CT-RT with 5-fluorouracil and mitomycin C." | 3.88 | The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. ( Andrikou, K; Arcadipane, F; Casadei Gardini, A; Casadei, C; Cascinu, S; Cassoni, P; Fornaro, L; Franco, P; Iorio, GC; Martini, S; Mistrangelo, M; Montagnani, F; Ricardi, U; Scartozzi, M, 2018) |
| "5-Fluorouracil (5-FU) is used for the clinical treatment of esophageal squamous cell carcinomas (ESCCs), yet it also induces chemoresistant cancer cells during treatment, which leads to the failure of the therapy." | 3.85 | A novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cell line Eca-109/5-FU with significant drug resistance-related characteristics. ( Chen, Z; Ge, J; Jiang, H; Li, X; Ma, Q; Shi, Y; Wang, J; Wang, M; Wang, Z; Zhang, C, 2017) |
| " This study was aimed to compare the differences in pathologic response and survival between docetaxel/cisplatin and fluorouracil/cisplatin as neoadjuvant CRT in locally advanced esophageal squamous cell carcinoma (SCC)." | 3.85 | Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. ( Fu, JH; Li, Y; Liu, MZ; Liu, SL; Xi, M; Yang, YD; Zhang, L; Zhang, P, 2017) |
| "NRG Oncology RTOG 0529 assessed the feasibility of dose-painted intensity modulated radiation therapy (DP-IMRT) to reduce the acute morbidity of chemoradiation with 5-fluorouracil (5FU) and mitomycin-C (MMC) for T2-4N0-3M0 anal cancer." | 3.85 | Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529. ( Abitbol, A; Chang, A; Chen, Y; Crane, CH; Doncals, DE; Fisher, B; Johnson, D; Kachnic, L; Michalski, J; Moughan, J; Myerson, R; Narayan, S; Olsen, JR; Schefter, TE, 2017) |
| "The anticancer efficacy of docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy has been reported to be better than that of conventional regimens for advanced or relapsed esophageal squamous cell carcinoma (ESCC), and may become a standard therapy for this disease." | 3.85 | Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. ( Kawada, K; Kawano, T; Miyawaki, Y; Nakajima, Y; Okada, T; Tokairin, Y, 2017) |
| "Docetaxel, cisplatin and fluorouracil (DCF) is a candidate neoadjuvant chemotherapy (NAC) regimen for esophageal squamous cell carcinoma (ESCC)." | 3.85 | The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. ( Baba, H; Baba, Y; Hiyoshi, Y; Kurashige, J; Sakamoto, Y; Watanabe, M; Yoshida, N, 2017) |
| "Fifty-six anal cancer patients from 2 institutions received definitive radiation therapy (median primary dose of 54 Gy) using intensity modulated radiation therapy (IMRT, n=49) or 3-dimensional (3D) conformal therapy (n=7) with concurrent 5-fluorouracil (5-FU) and mitomycin C." | 3.85 | Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors. ( Aggarwal, S; Bazan, JG; Chang, DT; Golden, DW; Kopec, M; Lee, AY; Liauw, SL; Pelizzari, CA, 2017) |
| "The purpose of this study was to analyze outcomes for the treatment of locally advanced temporal bone cancer by means of concomitant chemoradiotherapy (CCRT) with a combination of cisplatin (CDDP), 5-fluorouracil (5-FU), and docetaxel (TPF)." | 3.83 | Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone. ( Ejima, Y; Hasegawa, S; Hashikawa, K; Kenji, Y; Kiyota, N; Kohmura, E; Nibu, K; Nomura, T; Otsuki, N; Sakakibara, S; Sasaki, R; Shinomiya, H; Yamashita, D, 2016) |
| " We found that fluorouracil (5-FU)-resistant esophageal squamous cell carcinoma cell lines, established through exposure to increasing concentrations of 5-FU, showed upregulation of Id1, IGF2, and E2F1." | 3.83 | Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance. ( Chan, KT; Chan, KW; Cheung, AL; Guan, XY; He, QY; Law, S; Lee, NP; Li, B; Li, YY; Qin, YR; Tam, PY; Tsao, SW; Xu, WW; Yuen, HF, 2016) |
| "Fulminant myocarditis is a rare but potentially life-threatening illness caused by 5-fluorouracil cardiotoxicity." | 3.83 | Rapid Extracorporeal Membrane Oxygenation Overcomes Fulminant Myocarditis Induced by 5‑Fluorouracil. ( Amraotkar, AR; DeFilippis, AP; Grubb, KJ; Pachika, A, 2016) |
| "The authors previously reported the safety and short-term efficacy of ablative fractional laser (AFXL)-assisted delivery of topical fluorouracil in the treatment of superficial basal cell carcinoma (sBCC) and squamous cell carcinoma in situ (SCCis)." | 3.83 | Ablative Fractional Laser-Assisted Topical Fluorouracil for the Treatment of Superficial Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ: A Follow-Up Study. ( Gan, SD; Hsu, SH; Konnikov, N; Liang, CA; Nguyen, BT, 2016) |
| "To retrospectively evaluate the efficacy and toxicity of definitive concurrent chemoradiotherapy (dCRT) with cisplatinum/paclitaxel versus cisplatinum/5-fluorouracil in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who received nonsurgical treatment." | 3.83 | Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients. ( Guo, J; Han, X; Hu, G; Liu, L; Tang, N; Wang, Y; Wang, Z; Zhang, Q, 2016) |
| "To investigate the effects of nimotuzumab (h-R3) with cisplatin (DDP) or fluorouracil (5-FU) on human esophageal squamous cell carcinoma (ESCC) EC1 cells." | 3.81 | Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells. ( Huo, XQ; Ji, YH; Li, GJ; Li, WW; Lu, P; Mu, YL; Wu, JQ; Yang, XY, 2015) |
| "Concomitant chemoradiotherapy of 5-fluorouracil and cisplatin with radiotherapy is a highly effective and well-tolerated treatment of anal cancer." | 3.81 | Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma. ( El-Hadaad, HA; Roshdy, S; Wahba, HA, 2015) |
| "Concurrent chemoradiotherapy with 5-fluorouracil (5-FU) and mitomycin-C (MMC) is standard treatment for anal cancer." | 3.81 | Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C. ( Aleshin, A; Goldman, K; Lien, WW; Rao, AR; White, EC, 2015) |
| "The use of cetuximab in combination with platinum (P) plus 5-fluorouracil (F) has previously been demonstrated to be effective in the treatment of metastatic squamous cell cancer of head and neck (SCCHN)." | 3.80 | Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution. ( Alves, MP; Avezedo, I; de Mello, RA; Dinis, J; Gerós, S; Moreira, F, 2014) |
| " We examined the effects of celecoxib, a COX-2 inhibitor, in enhancing the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma (ESCC) by reducing the COX-2 activity." | 3.80 | A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. ( Akanuma, N; Akutsu, Y; Hanari, N; Hoshino, I; Hu, X; Isozaki, Y; Komatsu-Akimoto, A; Matsubara, H; Mori, M; Mutallip, M; Qin, W; Yusup, G, 2014) |
| "Definitive chemoradiotherapy (CRT) with 5-fluorouracil (5-FU) and cisplatin (CDDP) is one of the standard therapies for esophageal squamous cell carcinoma (ESCC); however, inter-individual variations in clinical outcomes have yet to be investigated." | 3.80 | Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Azuma, T; Hirai, M; Kuwahara, A; Miki, I; Minegaki, T; Nakamura, T; Nishiguchi, K; Okuno, T; Omatsu, H; Sakaeda, T; Tamura, T; Yamamori, M, 2014) |
| "Between 1976 and 2008, 116 patients with T2 node-negative anal cancer were treated curatively with RT alone (n=48) or by combined chemoradiation therapy (CRT) (n=68) incorporating mitomycin C and 5-fluorouracil." | 3.79 | Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control. ( Allal, AS; Betz, M; Bieri, S; Ris, F; Roche, B; Roth, AD; Zilli, T, 2013) |
| "A 61-year-old man, with a tuberous sclerosis, experienced severe acute reactions during a concomitant chemoradiotherapy regimen after 22Gy and one cycle of 5-fluorouracil-cisplatinum." | 3.79 | [Hypersensitivity to radiation therapy in a patient with tuberous sclerosis: biological considerations about a clinical case]. ( Baruch-Hennequin, V; Duchemain, B; Duchemann, B; Hennequin, C; Quero, L; Rivera, S; Wong, S, 2013) |
| " Surgery Division of Verona University, 155 consecutive patients with locally advanced esophageal cancers (90 SCC, 65 adenocarcinoma) were treated with a single protocol of neoadjuvant CRT (docetaxel, cisplatin, and 5-fluorouracil with 50." | 3.79 | Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center. ( Casella, F; de Manzoni, G; Giacopuzzi, S; Pasini, F; Verlato, G; Weindelmayer, J; Zanoni, A; Zhao, E, 2013) |
| "Five patients with primary colorectal adenocarcinoma or anal squamous cell carcinoma were started on a 2-weeks-on, 1-week-off capecitabine dosing regimen in addition to other chemotherapeutic agents and/or radiation." | 3.78 | Capecitabine-induced chest pain relieved by diltiazem. ( Ambrosy, AP; Fisher, GA; Kunz, PL; Witteles, RM, 2012) |
| " In this study, 49 Japanese patients with esophageal squamous cell carcinoma (ESCC) were followed up for 5 years after treatment with a definitive 5-fluorouracil (5-FU)/cisplatin (CDDP)-based chemoradiotherapy (CRT), and the effects of genotypes of vascular endothelial growth factor (VEGF) were retrospectively revaluated in terms of prediction of long-term survival." | 3.78 | VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Kuwahara, A; Manabe, Y; Miki, I; Nakamura, T; Nishiguchi, K; Okuno, T; Sakaeda, T; Tamura, T; Yamamori, M, 2012) |
| "Fifty-six patients with squamous cell carcinomas of the esophagus were treated between April 1989 and September 1993 in the Centre Hospitalier Universitaire in Brest, France with two courses of preoperative concomitant radiochemotherapy, separated by a 2-week interval, and followed by surgery (each course 18." | 3.78 | Preoperative concomitant radiochemotherapy in squamous cell carcinoma of the esophagus: results of a study of 56 patients. ( Labat, JP; Lozac'h, P; Lucas, B; Malhaire, JP; Simon, H; Topart, P; Volant, A, 1996) |
| "Cisplatin-/5-fluorouracil-resistant oesophageal squamous cell carcinoma (SCC) and adenocarcinoma (EAC) cell lines were established, and the impact of ectopic upregulation of miR-106a and miR-148a on response to both drugs was assessed." | 3.77 | Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. ( Haier, J; Hummel, R; Hussey, DJ; Kist, J; Michael, MZ; Smith, C; Watson, DI, 2011) |
| "Palliative chemoradiotherapy using 5-fluorouracil plus cisplatin combined with concurrent 40 Gy irradiation effectively improved the symptom of dysphagia in Stage IVB esophageal cancer with acceptable toxicity and favorable survival." | 3.77 | Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. ( Doi, T; Fuse, N; Ikeda, E; Kaneko, K; Kojima, T; Minashi, K; Nihei, K; Ohtsu, A; Onozawa, M; Tahara, M; Yano, T; Yoshino, T, 2011) |
| "Inhibition of TP may be beneficial in decreasing angiogenesis-dependent growth and migration of cholangiocarcinoma but may diminish the response to 5-fluorouracil chemotherapy." | 3.76 | Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. ( Jearanaikoon, P; Limpaiboon, T; Miwa, M; Pairojkul, C; Sripa, B; Tantimavanich, S; Thanasai, J, 2010) |
| "A recent meta-analysis study showed that post-operative adjuvant chemotherapy with UFT, an oral combination drug composed of tegafur [prodrug of 5-fluorouracil (5-FU)] and uracil [inhibitor of dihydropyrimidine dehydrogenase (DPD)] was associated with improved survival in patients with lung adenocarcinomas, but not in those with lung squamous cell carcinomas." | 3.75 | Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung. ( Araki, O; Chida, M; Honma, K; Ishihama, H; Karube, Y; Masawa, N; Miyoshi, S; Seki, N; Tamura, M; Umezu, H, 2009) |
| " In the absence of evidence of a dose-response curve for platinum, the lower dosage schedules that can be used with acceptable toxicity on an outpatient basis should be selected." | 3.75 | Chemotherapy for squamous cell carcinoma of the head and neck: a progress report. ( Glick, JH; Taylor, SG; Zehngebot, LM, 1980) |
| "Hyperammonemia or hyperammonemic leukoencephalopathy sometimes occurs as an adverse event after 5-fluorouracil (5-FU) chemotherapy." | 3.74 | The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases. ( Asakage, T; Kikuta, S; Kubota, A; Nakao, K; Sugasawa, M, 2008) |
| "In head and neck cancer including hypopharyngeal cancer, cisplatin and 5-fluorouracil (5-FU) usually have been used as neoadjuvant chemotherapeutic agents." | 3.73 | Effects of cisplatin, 5-fluorouracil, and radiation on cell cycle regulation and apoptosis in the hypopharyngeal carcinoma cell line. ( An, WG; Chon, KM; Goh, EK; Kim, YS; Lee, BJ; Roh, HJ; Wang, SG, 2005) |
| "Topical therapeutic options for cutaneous squamous cell carcinoma in situ include 5-fluorouracil cream and imiquimod cream." | 3.73 | Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. ( Mings, SM; Ondo, AL; Pestak, RM; Shanler, SD, 2006) |
| "A case of arsenical keratosis with multiple lesions of Bowen's disease and squamous cell carcinoma is described." | 3.72 | Successful treatment of multiple premalignant and malignant lesions in arsenical keratosis with a combination of acitretin and intralesional 5-fluorouracil. ( Khandpur, S; Sharma, VK, 2003) |
| "Despite its significant toxicity for esophageal fistula, this concurrent CT-RT protocol of protracted 5-fluorouracil infusion and cisplatin appears feasible and effective for T4 esophageal cancer with or without fistulas." | 3.71 | Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. ( Kanamori, S; Nakamatsu, K; Nishimura, Y; Shigeoka, H; Suzuki, M; Yagyu, Y, 2002) |
| "Myocardial ischemia induced by 5-fluorouracil (5-FU) is a relatively rare, but potentially serious, occurrence." | 3.70 | Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report. ( Akpek, G; Hartshorn, KL, 1999) |
| "An 83-year-old Caucasian man with cutaneous T-cell lymphoma developed an aggressive squamous cell carcinoma of the left forearm, which recurred and metastasized after Mohs micrographic surgery and systemic chemotherapy with cis-platin and 5-fluorouracil." | 3.70 | Invasive squamous cell carcinoma with sporotrichoid metastasis in a patient with cutaneous T cell lymphoma treated with chronic extracorporeal photopheresis. ( Beer, R; Elizeri, Y; Gmyrek, R; Grossman, ME; Oster, MW; Schneiderman, P; Silvers, DN, 1999) |
| "We present the case of a patient with a locally advanced hypopharyngeal carcinoma who developed a severe cytomegalovirus (CMV) colitis after his first chemotherapy course with 5-fluorouracil (5-FU), docetaxel and cisplatin." | 3.70 | Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer. ( Colpaert, C; Schrijvers, D; Van den Brande, J; Vermorken, JB, 1999) |
| "The aim of this study was to demonstrate the value of the level of platinum in lymphocytes, plasma and saliva, in order to predict neutropenia during the same cycle after cisplatin chemotherapy." | 3.70 | [Pharmacologic markers predictive of neutropenia chemically induced by cisplatin (CDDP)]. ( Brès, J; Constans, B; Cupissol, D; Gau, F; Gory-Delabaere, G; Nouguier-Soulé, J, 1999) |
| "We report a case of double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin." | 3.69 | [A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin]. ( Akiyama, S; Hibi, K; Ito, K; Kasai, Y; Kondo, K; Nonami, T; Takagi, H, 1995) |
| "Thirty-two patients with resectable (clinical stage IIa, n = 17; IIb, n = 1; III, n = 14) squamous cell cancer (n = 15) or adenocarcinoma (n = 17) were treated with neoadjuvant chemotherapy (cisplatin, 5-fluorouracil, leukovorin), resection, and postoperative chemoradiotherapy (hydroxyurea, 5-fluorouracil; 50-66 Gy)." | 3.69 | Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction. ( Drinkard, LC; Ferguson, MK; Haraf, DJ; Hoffman, PC; Reeder, LB; Vokes, EE, 1995) |
| " To improve local control and decrease metastases, a 7-month regimen was used with standard-dose radiotherapy (RT), cisplatin (DDP), and continuous infusion (CI) 5-fluorouracil (5-FU) in patients with locoregional squamous/adenocarcinoma of the esophagus." | 3.69 | Chemoradiotherapy of esophageal carcinoma. ( Cummings, G; Gaspar, LE; Herskovic, AM; Khanuja, PS; Kinzie, JL; Kraut, MJ; Lattin, PB; Poplin, EA; Steiger, Z; Vaitkevicius, VK, 1994) |
| "Forty-two consecutive patients with anal canal cancer were treated with 15 fractions of 30-Gy photon beam radiation therapy administered anteroposterior-posteroanterior in conjunction with chemotherapy with 5-fluorouracil and mitomycin C." | 3.69 | Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy. ( Anderson, PJ; Frost, DB; Kagan, AR; Latino, F; Peddada, AV; Rao, AR; Shah, KH; Smith, DE, 1994) |
| "We have investigated the effects of 5-fluorouracil (5-FU) on cell growth, DNA synthesis, morphological changes, DNA fragmentation and Fas antigen expression of cultured human uterine cervical carcinoma cells (OMC-1 squamous-cell carcinoma and OMC-4 adenocarcinoma)." | 3.69 | Growth inhibition and apoptotic cell death in uterine cervical carcinoma cells induced by 5-fluorouracil. ( Inoki, C; Kumagai, K; Orino, I; Ueda, M; Ueki, K; Ueki, M, 1997) |
| "Between December 1988 and August 1992, 68 patients with adenocarcinoma (n = 39) and squamous carcinoma (n = 29) of the esophagus were entered prospectively in a treatment protocol to receive two cycles of cisplatin, 5-fluorouracil, etoposide, leucovorin, and 3,000 cGy of radiation to the involved esophagus and adjacent mediastinum, followed by resection." | 3.68 | Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma. ( Adkins, RB; Hoff, SJ; Johnson, DH; Merrill, WH; Murray, MJ; Sawyers, JL; Stewart, JR, 1993) |
| "Of 13 patients with adenocarcinoma treated with 5-fluorouracil, adriamycin, and mitomycin (FAM), nine showed minor histological changes compared with 14 control cases." | 3.68 | Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy. ( Allen, SM; Darnton, SJ; Edwards, CW; Matthews, HR, 1993) |
| "Forty-three patients with locoregional squamous cell carcinoma or adenocarcinoma of the esophagus or cardia were treated with fluorouracil (5-FU), cisplatin, and bolus vinblastine concurrent with radiation administered over 21 days." | 3.68 | Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. ( Forastiere, AA; Orringer, MB; Perez-Tamayo, C; Urba, SG; Zahurak, M, 1993) |
| "A 63-year-old male had undergone combination chemotherapy including adriamycin, cisplatin, mitomycin C, 5-fluorouracil and vindesine for six months for double cancer of esophagus and stomach." | 3.68 | [Chemotherapy-associated hemolytic uremic syndrome--a case report]. ( Kanamaru, R; Kikuchi, H, 1992) |
| "From October 1986 to January 1991, 47 patients with esophageal cancer (29 squamous, 18 adenocarcinoma) were treated with simultaneous radiotherapy (3000 or 3600 cGy) and chemotherapy (infusional 5-fluorouracil, cisplatin) delivered during a 5-week period." | 3.68 | Preoperative chemotherapy and radiotherapy for esophageal carcinoma. ( Andrus, CH; Baue, AE; Johnson, FE; Naunheim, KS; Petruska, P; Roy, TS; Schlueter, JM, 1992) |
| "Fifteen patients with potentially resectable adenocarcinoma of the esophagus were treated with two cycles of preoperative chemotherapy with 5-fluorouracil (5-FU) and cisplatin (DDP)." | 3.68 | A pilot study of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and postoperative radiation therapy and/or chemotherapy in adenocarcinoma of the esophagus. ( Bromberg, C; Carey, RW; Choi, NC; Grillo, HC; Hilgenberg, AD; Logan, DL; Mathisen, DJ; Wain, JC, 1991) |
| "Acute myocardial infarction was observed in two patients receiving standard intravenous doses of 5-fluorouracil (5-FU)-based chemotherapy." | 3.68 | Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. ( Esparaz, B; Green, D; Kies, M; Kuzel, T, 1990) |
| "Two VPM-CisCF chemotherapy regimens (vincristine (VCR), peplomycin (PEP), methotrexate (MTX), cis-diamminedichloroplatinum (II) (CDDP), cytosine arabinoside (Ara-C) and 5-fluorouracil (5-FU), established using human bladder cancer xenografts in nude mice were applied for advanced urothelial cancer." | 3.67 | [Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II), cytosine arabinoside and 5-fluorouracil, for advanced urothelial cancer]. ( Hida, S; Okada, K; Ooishi, K; Yamauchi, T; Yoshida, O, 1985) |
| " Treatment regimens usually employed cis-diammine-dichloroplatinum (CDDP) plus peplomycin for squamous cell carcinoma, and CDDP plus vindesine for adenocarcinoma." | 3.67 | [Combination chemotherapy including cisplatin in lung cancer by bronchial artery infusion]. ( Inoue, F; Mimura, H; Miyake, M; Mori, T; Orita, K; Takeda, I; Tanaka, N, 1988) |
| "This article presents a patient affected with epidermoid carcinoma of the soft palate who developed a dilated myocardiopathy with aortic embolism and fatal left cardiac failure after treatment with cisplatin (100 mg/m2, day 1) and 5-fluorouracil (1 g/m2/day i." | 3.67 | Lethal cardiac toxicity after cisplatin and 5-fluorouracil chemotherapy. Report of a case with necropsy study. ( Almenarez, J; Blázquez, J; Diaz-Rubio, E; Fariña, J; Furió, V; Martin, M, 1989) |
| "The watery diarrhea-hypokalemia-achlorhydria syndrome associated with ectopic secretion of vasoactive intestinal peptide has only been conclusively documented with tumors originating in the pancreas or sympathetic chain." | 3.67 | Watery diarrhea-hypokalemia-achlorhydria syndrome and carcinoma of the esophagus. ( Douglas, MC; Hurley, R; Kalnins, R; Moran, L; Shulkes, A; Smallwood, RA; Watson, KJ, 1985) |
| "Neoadjuvant therapy combining 5-fluorouracil, mitomycin C, and moderate-dose radiotherapy was given preoperatively to 29 patients with adenocarcinoma of the rectum, 3 patients with squamous cell cancer, and 1 patient with basaloid carcinoma of the anus." | 3.67 | Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer. ( Muff, NS; Shetabi, H; Smith, DE, 1986) |
| "We report 5 cases of invasive squamous cell bladder cancer treated with preoperative mitomycin C and 5-fluorouracil in combination with preoperative external beam radiation therapy (the Nigro regimen), and the subsequent apparent cure of 3 of the 5 patients." | 3.67 | A new treatment for invasive squamous cell bladder cancer: the Nigro regimen: preoperative chemotherapy and radiation therapy. ( Gee, WF; Medina, WD; Mendiondo, OA; Patterson, JM; Ray, EH, 1988) |
| "A case of palmar-plantar erythrodysesthesia syndrome (PPES) observed during a 120-h infusion of 5-fluorouracil (5-FU) is presented." | 3.67 | Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. ( Bellmunt, J; Hidalgo, R; Navarro, M; Solé, LA, 1988) |
| "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function." | 3.67 | Allergic reaction to 5-fluorouracil infusion. ( Sridhar, KS, 1986) |
| "Nineteen patients with locally advanced bladder cancer were treated with irradiation and concomitant 5-fluorouracil intravenous infusion with or without bolus mitomycin." | 3.67 | Treatment of advanced bladder carcinoma with irradiation and concomitant 5-fluorouracil infusion. ( Aziz, H; Braverman, A; Choi, K; Laungani, GB; Macchia, R; Rosenthal, J; Rotman, M; Silverstein, M, 1987) |
| " Adenocarcinoma related to diethylstilbestrol exposure in utero is a recently recognized type of vaginal lesion, and melanoma and sarcoma occur rarely in the vagina." | 3.66 | Malignant tumors of the vagina. Classification and approach to treatment. ( Gerbie, MV, 1983) |
| "Arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation achieves a definite objective improvement in patients with estrogen-resistant adenocarcinoma of the prostate." | 3.65 | Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder. ( Hoffman, AA; Nevin, JE, 1975) |
| "A carcinostatic substance (5-fluorouracil) was instilled into the mediastinal lymph nodes, the pleural cavity or the internal thoracic artery by continuous perfusion before operation on patients with bronchial carcinoma." | 3.65 | [Continuous local application of cytostatics for bronchial carcinoma and mediastinal lymph node metastasisization (author's transl)]. ( Inoguchi, T; Kita, T; Kuwano, K; Yamasaki, I; Yazuka, K, 1976) |
| " In squamous cell cancer of the lung 48 patients were administered methotrexate (90 mg per course), 18 patients with adenocarcinoma--5-fluoruracil, 29 patients with undifferentiated cancer-cyclophosphane (3 g of each substance)." | 3.65 | [Late results of lung cancer therapy (according to material from the Kazakh Scientific Research Institute of Oncology and Radiology)]. ( Abisatov, KhA; Khan, SV, 1976) |
| "Seven adult men with biopsy-confirmed erythroplasia of Queyrat (EQ) were cured of their disease with topically applied 5-fluorouracil (5-FU) under occlusion." | 3.65 | Erythroplasia of Queyrat: treatment with topical 5-fluorouracil. ( Carson, TE; Goette, DK, 1976) |
| "Anal squamous cell carcinoma (ASCC) is a rare tumor; it accounts for about 2% of gastrointestinal tumors." | 3.11 | Capecitabine in the treatment of anal squamous cell carcinoma. ( Radka, L; Zdeňka, P, 2022) |
| "Anal squamous cell carcinoma (ASqCC) is a rare malignancy, traditionally treated with combined chemoradiation, with a continuous infusion of 5-fluorouracil (5-FU) and mitomycin C (MMC)." | 3.01 | Comparison of intravenous 5-Fluorouracil with Oral Capecitabine in the Treatment of Anal Squamous Cell Carcinoma Using Modern Radiation Techniques. ( Ben David, MA; Grinberg, V; Hod, K; Kalmus, Y; Levin, D; Lipski, Y; Pfeffer, RM; Schlosser, S; Zalmanov, S, 2023) |
| "A prospective open-label phase II trial was conducted to evaluate the efficacy of hyperthermia combined with induction chemotherapy in patients with locally advanced resectable oral squamous cell carcinoma (OSCC)." | 3.01 | A multicenter randomized phase II trial of hyperthermia combined with TPF induction chemotherapy compared with TPF induction chemotherapy in locally advanced resectable oral squamous cell carcinoma. ( Chen, Y; Ge, M; Guo, W; He, Y; Ju, H; Ma, X; Meng, J; Qiu, W; Ren, G; Song, H; Wu, Y; Zhuang, Q, 2021) |
| "The proportion of elderly patients in esophageal cancer is now growing, but there is a lack of evidence in term of treatment standard for this group of patients, which is what we aim to obtain through this prospective phase III study." | 2.90 | A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. ( Chang, X; Chen, J; Deng, L; Ge, X; Han, C; Li, C; Liang, J; Lin, Y; Ni, W; Pang, Q; Sun, X; Wang, L; Wang, P; Wang, W; Wang, X; Xiao, Z; Zhang, W; Zhao, Y; Zhou, Z, 2019) |
| "Inoperable oral cavity squamous cell carcinoma (SCC) is a highly invasive disease associated with the extensive destruction of locoregional tissues and a dismal prognosis." | 2.84 | Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: A phase II study. ( Chang, PM; Chen, MH; Chu, PY; Lu, HJ; Tai, SK; Wang, LW; Yang, MH, 2017) |
| "5-Fluorouracil (5-FU) is a widely used drug for the therapy of cancer." | 2.84 | The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma. ( Chen, F; Chen, W; Feng, X; Luo, Q; Meng, G; Wang, H; Zhang, H, 2017) |
| "Data of 179 patients with N3 HNSCC from two GORTEC randomized trials (96-01 and 99-02) were pooled." | 2.84 | Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials. ( Alfonsi, M; Aupérin, A; Bardet, E; Bourhis, J; Calais, G; Deprez, P; Geoffrois, L; Gery, B; Graff, P; Grégoire, V; Lapeyre, M; Maingon, P; Martin, L; Pignon, T; Rives, M; Sire, C; Tao, Y; Verrelle, P, 2017) |
| "Esophageal stenosis was identified as a candidate stratification factor for randomized trials of unresectable LAESCC patients." | 2.84 | Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303). ( Ando, N; Fukuda, H; Igaki, H; Ishikura, S; Katayama, H; Kato, H; Kato, K; Kawano, T; Kimura, Y; Kitagawa, Y; Kojima, T; Kosugi, S; Nakamura, K; Okabe, H; Okuno, T; Shinoda, M; Toh, Y; Tsubosa, Y; Wakabayashi, M, 2017) |
| "Patients with LAHNSCC were randomized to receive concomitant treatment alone [CCRT (Arm A1) or CET/RT (Arm A2)], or three cycles of induction docetaxel/cisplatin/5 fluorouracil (TPF) followed by CCRT (Arm B1) or followed by CET/RT (Arm B2)." | 2.84 | Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. ( Alterio, D; Azzarello, G; Bertoni, F; Bidoli, P; Bonetti, A; Bunkheila, F; Campostrini, F; Casanova, C; Chiappa, F; Cipani, T; Codecà, C; D'Ambrosio, C; Da Corte, D; Emiliani, E; Ferrari, D; Foa, P; Frattegiani, A; Gava, A; Ghi, MG; Guaraldi, M; Koussis, H; Loreggian, L; Massa, E; Mastromauro, C; Mione, CA; Morelli, F; Niespolo, RM; Nolè, F; Orecchia, R; Paccagnella, A; Parisi, S; Pieri, G; Polsinelli, M; Rossetto, C; Rulli, E; Valduga, F; Verri, E, 2017) |
| "For these patients with metastatic esophageal cancer, chemotherapy is generally indicated." | 2.84 | Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus. ( Hayata, K; Iwahashi, M; Katsuda, M; Matsumura, S; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H, 2017) |
| " Here, we investigated the efficacy of calcipotriol, a topical TSLP inducer, in combination with 5-fluorouracil (5-FU) as an immunotherapy for actinic keratosis." | 2.84 | Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. ( Cornelius, LA; Cunningham, TJ; Demehri, S; Eliane, JP; Kopan, R; Manivasagam, S; Mirzaalian, H; Saavedra, AP; Schaffer, A; Tabacchi, M; Tuchayi, SM; Turkoz, A; Wallendorf, M, 2017) |
| "Purpose Squamous cell carcinoma of the anal canal (SCCAC) is characterized by high locoregional failure (LRF) rates after definitive chemoradiation (CRT), associated with anogenital human papilloma virus, and often appears in HIV infection." | 2.84 | Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. ( Aboulafia, D; Fitzgerald, TJ; Henry, DH; Kachnic, L; Lee, JY; Mitsuyasu, R; Palefsky, J; Rajdev, L; Ratner, L; Sparano, JA; Wachsman, W, 2017) |
| "Purpose Squamous cell carcinoma of the anal canal (SCCAC) is characterized by high locoregional failure (LRF) rates after sphincter-preserving definitive chemoradiation (CRT) and is typically associated with anogenital human papilloma virus infection." | 2.84 | Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). ( Armstrong, KI; Benson, AB; El-Rayes, BF; Fitzgerald, TJ; Garg, MK; Kalnicki, S; Mitchell, EP; Moriarty, DJ; Mulcahy, MF; Nabbout, NH; Onitilo, AA; Palefsky, J; Sparano, JA; Whittington, R; Zhao, F, 2017) |
| "Anal cancer is considered a rare tumor, accounting for 6 % of digestive cancers and about 2000 new cases per year in France." | 2.82 | [Anal cancer: Focus on current treatment and future perspective]. ( Combet-Curt, V; Delhiat, AC; Vendrely, V, 2022) |
| " The primary outcome was all-grade, all-cause treatment-emergent adverse events (TEAEs)." | 2.82 | Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen. ( Adkins, D; Aguilar, JL; Bryant, K; Chang, SC; Chen, E; Chin, S; Ernst, S; He, S; Lee, HJ; Misiukiewicz, K; Obasaju, CK; Soulières, D, 2016) |
| "The prognosis of esophageal cancer patients is still unsatisfactory." | 2.82 | Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma. ( Matsuhashi, N; Miyazaki, T; Okumura, N; Tanahashi, T; Tanaka, Y; Yamada, A; Yamaguchi, K; Yoshida, K, 2016) |
| "Esophageal stenosis was the only significant risk factor for esophageal fistula formation both in univariate (P = 0." | 2.82 | Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer: A Supplementary Analysis of JCOG0303. ( Fukuda, H; Honma, Y; Igaki, H; Kato, K; Kitagawa, Y; Mizusawa, J; Nakamura, K; Shinoda, M; Sudo, K; Tsubosa, Y; Tsushima, T, 2016) |
| "Two patients with HPV-unrelated HNSCC treated with APF declined CRT and remained free of relapse at 36 and 28months of follow-up." | 2.82 | nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. ( Adkins, D; Daly, M; Gay, HA; Jackson, R; Ley, J; Michel, L; Nussenbaum, B; Paniello, R; Rich, J; Thorstad, W; Trinkaus, K; Uppaluri, R; Wildes, TM, 2016) |
| "Patients with esophageal squamous cell carcinoma were treated with escalating radiation dose of 4 levels, with a simultaneous integrated boost (SIB) to the pre-treatment 50% SUVmax area of the primary tumor." | 2.80 | Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by (18)FDG-PET/CT for esophageal cancer. ( Cai, XW; Feng, W; Fu, XL; Liu, Q; Yao, ZF; Yu, W; Zhang, Q; Zhang, YJ; Zhu, ZF, 2015) |
| "Patients with stage III/IV resectable head and neck squamous cell carcinoma were randomized to surgery followed by RT or CCRT." | 2.80 | Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. ( Ang, MK; Hwang, J; Iyer, NG; Lim, WT; Sivanandan, R; Soo, KC; Tan, DS; Tan, EH; Tan, HK; Tan, NC; Tan, VK; Wang, W; Wee, J, 2015) |
| "This multicenter trial included esophageal cancer patients with clinical T4 disease and/or unresectable regional lymph node metastasis." | 2.80 | Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). ( Ando, N; Fukuda, H; Ishikura, S; Kato, H; Kato, K; Kawano, T; Kimura, Y; Kosugi, S; Minashi, K; Nakamura, K; Okabe, H; Shinoda, M; Toh, Y; Tsubosa, Y, 2015) |
| "Thirty-four patients with unresectable esophageal cancer were enrolled and received DNF therapy." | 2.80 | Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer. ( Fukuchi, M; Ieta, K; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Saito, K; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T, 2015) |
| " Adverse events, treatment response and follow-up data were collected." | 2.80 | Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer. ( Li, QL; Qiu, MQ; Wang, T; Yang, JS, 2015) |
| "The data from two phase III trials for oesophageal cancer were used." | 2.80 | Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer. ( Ando, N; Fukuda, H; Hayashi, K; Igaki, H; Kataoka, K; Kato, K; Kitagawa, Y; Mizusawa, J; Nakamura, K; Ozawa, S, 2015) |
| "The treatment for squamous cell carcinoma of the anus changed dramatically during the study period." | 2.80 | The Effect of the UK Coordinating Centre for Cancer Research Anal Cancer Trial (ACT1) on Population-based Treatment and Survival for Squamous Cell Cancer of the Anus. ( Aravani, A; Downing, A; Finan, PJ; Lawton, S; Morris, EJ; Sebag-Montefiore, D; Thomas, JD, 2015) |
| "The MTDs were determined as 5FU 800 mg/m(2) on RT days 1-4 and 29-32 and MMC 8 mg/m(2) on days 1 and 29 when combined with IMRT/VMAT with SIB and cetuximab in locally advanced anal cancer." | 2.80 | Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. ( Gunnlaugsson, A; Guren, MG; Johnsson, A; Leon, O; Radu, C, 2015) |
| "Chemoradiotherapy (CRT) for squamous cell carcinoma of the anus (SCCA) may cause significant toxicity, and concerns exist about its tolerability in the elderly." | 2.79 | Impact of advancing age on treatment and outcomes in anal cancer. ( Chander, S; Chu, J; Foo, M; Heriot, A; Lee, MT; Leong, T; Link, E; Michael, M; Ngan, SY; Tomaszewski, JM; Tran, PK, 2014) |
| "Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN) overexpresses αvβ5 integrin." | 2.79 | Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). ( Bethe, U; Brümmendorf, TH; Clement, PM; Delord, JP; Erfán, J; Gauler, TC; Hicking, C; Iglesias, L; Keilholz, U; Krauss, J; Mesía, R; Peyrade, F; Remenar, E; Schafhausen, P; Vermorken, JB, 2014) |
| "To evaluate efficacy and side effects of glycididazole sodium (CMNa) combined with chemotherapy (cisplatin plus 5-FU/folic acid, PLF) and radiotherapy in treating patients with locally advanced nasopharyngeal carcinoma." | 2.79 | Glycididazole sodium combined with radiochemotherapy for locally advanced nasopharyngeal carcinoma. ( Chen, DP; Li, MY; Liang, YY; Liu, JQ; Qi, B; Yin, WJ, 2014) |
| "A database of esophageal cancer was queried for nonmetastatic patients with adenocarcinoma treated between 2000 and 2011 with CRT." | 2.79 | Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus. ( Almhanna, K; Freilich, J; Fulp, WJ; Hoffe, SE; Karl, RC; Meredith, K; Shridhar, R; Yue, B, 2014) |
| "Twenty-nine patients of oral mucosa squamous cell carcinoma pathologically diagnosed between 2006 and 2012 were enrolled into this study." | 2.79 | [Grade IV myelosuppression after induction chemotherapy of TPF on oral cancer: clinical analysis of 29 cases]. ( Jin, J; Li, RX; Liu, SH; Wang, LP; Wang, Y; Ye, MC; Zhou, Y; Zhu, WZ; Zuo, Y, 2014) |
| "Nab-paclitaxel (A) is a novel albumin-bound paclitaxel with a superior therapeutic index to docetaxel." | 2.79 | Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx. ( Bayley, A; Chan, K; Chen, EX; Chin, S; Diaz-Padilla, I; Hope, A; Hossain, M; Kim, J; Loong, HH; Palma, D; Razak, AR; Read, N; Siu, LL; Waldron, J; Wang, L; Winquist, E, 2014) |
| " Patients received 2-weekly docetaxel (30 mg/m(2) [dose level (DL)1] or 40 mg/m(2) [DL2] with a 3 + 3 design in phase I, on days 1 and 15) in combination with fixed-dose CF (80 mg/m(2) cisplatin, day 1; 800 mg/m(2) fluorouracil, days 1-5) repeated every 4 weeks." | 2.79 | Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). ( Chin, K; Doki, Y; Fujitani, K; Hironaka, S; Kato, K; Kii, T; Kitagawa, Y; Kojima, T; Kusaba, H; Matsushita, H; Mizusawa, J; Nakamura, T; Okuno, T; Seki, S; Taira, K; Taniki, T; Tomori, A; Tsubosa, Y; Tsushima, T; Ura, T, 2014) |
| "Fluorouracil and cisplatin have been used most frequently as neoadjuvant therapy for esophageal cancer." | 2.79 | The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study. ( Ba-Ssalamah, A; Hejna, M; Kandioler, D; Kappel, S; Kührer, I; Mittlböck, M; Pluschnig, U; Schoppmann, SF; Wolf, B; Wrba, F; Zacherl, J; Zwrtek, R, 2014) |
| "Resistant HNSCC cell lines were generated by exposure to an EGFR TKI, gefitinib, in vitro." | 2.78 | A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. ( Al-Lazikani, B; Box, C; Box, GM; Brandon, Ade H; Eccles, SA; Gowan, S; Harrington, KJ; Mendiola, M; Rogers, SJ; Valenti, M; Wilkins, A, 2013) |
| "An analysis of surgically resected esophageal cancer patients after nCRT was performed to determine an association between the number of LNs resected and survival." | 2.78 | Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy. ( Almhanna, K; Chuong, MD; Hoffe, SE; Karl, RC; Meredith, K; Shridhar, R; Weber, JM, 2013) |
| "Squamous cell carcinoma is the most common malignant change." | 2.78 | Characteristics and treatment outcomes of patients with malignant transformation arising from mature cystic teratoma of the ovary: experience at a single institution. ( Khemapech, N; Oranratanaphan, S, 2013) |
| "Penis cancer is rare and clinical trial evidence on which to base treatment decisions is limited." | 2.78 | Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). ( Bahl, A; Barber, J; Burnett, S; Carrington, B; Chester, JD; Cruickshank, C; Elliott, T; Hall, E; Harland, SJ; Nicholson, S; Pickering, L; Thomson, A; Waters, R, 2013) |
| " This study evaluated the efficacy and feasibility of induction nab-paclitaxel and cetuximab given with PF (ACPF) followed by definitive chemoradiation (CRT) in a phase 2 trial." | 2.78 | A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. ( Adkins, D; Dehdashti, F; Gay, H; Lewis, J; Ley, J; Mehan, P; Nussenbaum, B; Siegel, BA; Thorstad, W; Trinkaus, K; Wildes, T, 2013) |
| "Squamous cell carcinoma is the main histological subtype of esophageal cancer in the east Asia." | 2.78 | A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus. ( Chang, J; Ji, D; Li, W; Peng, W; Wang, H; Wang, J; Wu, X; Yu, H, 2013) |
| "Sixty-four patients with squamous cell carcinoma of the glottic larynx underwent treatment of the primary tumor using induction chemotherapy with two cycles of intra-arterial docetaxel and cisplatin, plus continuous intravenous infusion of 5-fluorouracil for 120 h starting on day 2; followed by two cycles of concurrent chemoradiation therapy." | 2.78 | Superselective intra-arterial chemoradiation therapy for functional laryngeal preservation in advanced squamous cell carcinoma of the glottic larynx. ( Furusaka, T; Ikeda, M; Matsuda, A; Matsuda, H; Tanaka, A, 2013) |
| "This Phase Ib trial assessed the maximum tolerated dose (MTD) and safety of the Toll-like receptor 9 agonist IMO-2055 combined with 5-fluorouracil, cisplatin, and cetuximab (PFE) as first-line palliative treatment in patients with relapsed and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)." | 2.78 | Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. ( Brümmendorf, TH; Delord, JP; Forssmann, U; Goddemeier, T; Kaminsky, MC; Keller, U; Machiels, JP, 2013) |
| "Acute Grade 3 (G3) dysphagia was higher in DL2 (87% DL2 vs." | 2.77 | Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. ( A'hern, R; Barbachano, Y; Bhide, SA; Bidmead, AM; Clark, C; Guerrero-Urbano, MT; Harrington, KJ; Hickey, J; Miah, AB; Newbold, KL; Nicol, R; Nutting, CM; St Rose, S; Tanay, M, 2012) |
| "pCR was achieved in 67% of squamous cell carcinoma." | 2.77 | Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. ( Balagué, C; Bellmunt, J; Conill, C; Gallego, R; Iglesias, M; Martín-Richard, M; Maurel, J; Momblan, D; Montagut, C; Pera, M; Pétriz, L; Reig, A, 2012) |
| "Patients with stage III-IV HNSCC received hyperfractionated radiation (72-74." | 2.77 | Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck. ( Adelstein, DJ; Ives, DI; Lorenz, RR; Rodriguez, CP; Rybicki, LA; Saxton, JP; Scharpf, J; Wood, BG, 2012) |
| "We performed a prospective phase II trial to investigate the safety and efficacy of radiotherapy combined with capecitabine in patients suffering from a recurrence of a squamous cell carcinoma of the head and neck (SCCHN) within a previously irradiated field." | 2.77 | Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial. ( Kornek, G; Lemaire, C; Radonjic, D; Selzer, E; Vormittag, L, 2012) |
| "Patients with stage II and III esophageal cancer were enrolled." | 2.77 | Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. ( Chak, A; Chang, KJ; Hanna, N; Pinto, H; Reid, T; Senzer, N; Soetikno, R; Swisher, S, 2012) |
| "The numbers of circulating tumor cells (CTCs) and their expression/activation of epidermal growth factor receptor (EGFR) during the course of combined chemo- or bioradiotherapy regimens as potential biomarkers of treatment efficacy in squamous cell carcinoma of the head and neck (SCCHN) were determined." | 2.77 | Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck. ( Budach, V; Hristozova, T; Keilhoiz, U; Stromberger, C; Tinhofer, I, 2012) |
| " Maintenance chemotherapy started 4-8 weeks later, three courses repeated every 21 days, using 5-FU/CDDP doses above, with MMC reduced to 7 mg/m(2) and administered with the first and third cycles." | 2.77 | Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. ( Cunningham, D; Davidson, N; Glynne-Jones, R; Grieve, R; Hurman, DC; Levine, E; Meadows, HM; Plowman, PN; Sebag-Montefiore, D, 2012) |
| "Locally advanced head and neck squamous cell carcinoma (HNSCC) has a high rate of recurrence." | 2.77 | Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma. ( Abgral, R; Gouders, D; Keromnes, N; Le Roux, PY; Leleu, C; Mollon, D; Nowak, E; Querellou, S; Rousset, J; Salaün, PY; Valette, G, 2012) |
| "The objective of this study was to review the outcomes of recombinant human endostatin combined with chemoradiotherapy (CRT) as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma (SCC) of the oesophagus." | 2.77 | Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus. ( Dai, N; Gu, X; Li, M; Qing, Y; Wang, D; Zhang, Z; Zhong, Z, 2012) |
| "Forty cases of resectable HNSCC were treated with nimotuzumab (400 mg on day 1) combined with PF regimens (cisplatin 75 mg/m² on days 1 and 5-Fu 750 mg/m² on days 1-5 q3wks)." | 2.77 | [Clinical analysis of nimotuzumab plus cisplatin and fluorouracil regimen as induction treatment in resectable head and neck squamous cell carcinoma]. ( Guo, Y; Hu, CS; Ji, QH; Wang, Y; Zhao, XY; Zhu, GP; Zhu, YX, 2012) |
| "Objectives were to assess maximum tolerated dose, dose-limiting toxicity (DLT) and to recommend a safe dose of LAP when administered with 4 cycles of TPF followed by CRT." | 2.77 | EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma. ( Andry, G; Awada, A; Bogaerts, J; El-Hariry, I; Fortpied, C; Lacombe, D; Lalami, Y; Langendijk, JA; Liberatoscioli, C; Specenier, PM; Vermorken, JB, 2012) |
| "Outcome of the patients with oral cancer is poor." | 2.77 | Survival following non surgical treatments for oral cancer: a single institutional result. ( Larizadeh, MH; Shabani, M, 2012) |
| "To evaluate the efficacy and safety of weekly paclitaxel combined with S-1 or fluorouracil in the first line treatment of advanced gastric carcinoma." | 2.77 | [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma]. ( Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX, 2012) |
| "Eligible patients had newly diagnosed HNSCC." | 2.76 | A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. ( Blair, EA; Cohen, EE; Haraf, DJ; Kunnavakkam, R; Salama, JK; Seiwert, T; Stenson, KM; Vokes, EE; Williams, R; Witt, ME, 2011) |
| "Advanced esophageal cancer with widespread metastasis to lymph nodes or other organs is difficult to treat and has an extremely poor prognosis." | 2.76 | Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. ( Aoki, T; Hoshino, S; Ogata, T; Osaka, Y; Shinohara, M; Takagi, Y; Tsuchida, A, 2011) |
| "Esophageal squamous cell carcinoma (ESCC) is refractory to current therapeutic regimens and more effective therapies are imperative." | 2.76 | Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. ( Doki, Y; Miyata, H; Mori, M; Motoori, M; Peng, YF; Shiozaki, H; Shiraishi, O; Tanaka, K; Yamasaki, M; Yano, M; Yasuda, T, 2011) |
| "To evaluate the efficacy of late accelerated hyperfractionated conformal radiotherapy (LACF) combined with capecitabine on esophageal carcinoma." | 2.76 | [Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma]. ( Feng, XZ; Han, JQ; Sheng, W, 2011) |
| "In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5-fluorouracil (5-FU) and cisplatin has increased acute toxicities as well as survival." | 2.75 | Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. ( Cho, BC; Choi, EC; Choi, HJ; Kim, GE; Kim, JH; Lee, CG; Lee, YJ; Sohn, JH, 2010) |
| "Patients with locally advanced head and neck cancer, and who had not previously undergone surgery, were randomly assigned to one of four groups in a 3:2:2:2 ratio, stratified by centre and chemotherapy regimen: radical radiotherapy alone (n=233); radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy (SIM alone; n=166); or 14 and 28 days after completing radiotherapy (SUB alone, n=160); or both (SIM+SUB; n=154)." | 2.75 | Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. ( Glaholm, J; Gupta, N; Hackshaw, A; Hutchison, I; Kadalayil, L; Macdougall, H; Monson, K; Tobias, JS, 2010) |
| "For patients with advanced laryngeal cancer, a trial was designed to determine if chemotherapy alone, in patients achieving a complete histologic complete response after a single neoadjuvant cycle, was an effective treatment with less morbidity than concurrent chemoradiotherapy." | 2.75 | Chemotherapy alone for organ preservation in advanced laryngeal cancer. ( Bradford, CR; Chepeha, DB; Divi, V; Eisbruch, A; Hogikyan, ND; Lee, JS; Moyer, JS; Prince, ME; Teknos, TN; Tsien, CI; Urba, SG; Wolf, GT; Worden, FP, 2010) |
| "Capecitabine seems to be an active, feasible and well-tolerated mode of palliative treatment for advanced HNC patients who have previously received PBT schedules." | 2.75 | Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. ( Adansa, JC; Cruz, JJ; Gil-Arnaiz, I; Hitt, R; Irigoyen, A; Isla, D; Lambea, J; Lecumberri, MJ; Martinez-Trufero, J, 2010) |
| "Grade 3 neutropenia was seen in seven patients and grade 4 in one patient." | 2.75 | Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. ( Egashira, H; Fujiwara, J; Honda, M; Izumi, Y; Kato, T; Miura, A; Monma, K; Nemoto, T; Ryotokuji, T, 2010) |
| "The peak prevalence of grade 3 dysphagia was higher and the recovery was slower in patients with lower OTT (median 38 days vs." | 2.75 | Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy. ( Bhide, SA; Fowler, J; Gulliford, S; Harrington, KJ; Newbold, K; Nutting, CM; Rosenfelder, N, 2010) |
| "To investigate the therapeutical effect and side-effect of docetaxel combined with cisplatin (DDP) on the treatment of local advanced esophageal cancer with concomitant radiation therapy." | 2.75 | [Efficacy and side-effects of docetaxel combined with cisplatin on the treatment of local advanced esophageal cancer with concomitant radiation therapy]. ( Gu, XW; Pan, YK; Xu, X; Zhang, TR; Zhao, T, 2010) |
| "Patients with resectable advanced squamous cell carcinoma of the larynx (tumor stage T3-T4) or hypopharynx (T2-T4), with regional lymph nodes in the neck staged as N0-N2 and with no metastasis, were randomly assigned to treatment in the sequential (or control) or the alternating (or experimental) arm." | 2.74 | Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. ( Bardet, E; Barzan, L; Bernier, J; Bogaerts, J; Chevalier, D; de Raucourt, D; Geoffrois, L; Horiot, JC; Hupperets, P; Lacombe, D; Leemans, CR; Lefebvre, JL; Licitra, L; Lunghi, F; Rolland, F; Stupp, R; Tesselaar, M; Vermorken, JB, 2009) |
| "Gefitinib was continued while patients received concurrent weekly docetaxel and radiation therapy." | 2.74 | Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. ( Burris, HA; Greco, FA; Hainsworth, JD; Kuzur, M; Lunin, S; Markus, TM; Shipley, D; Spigel, DR, 2009) |
| "To assess the feasibility and activity of radio-chemotherapy with mitomycin C (MMC) and cisplatin (CDDP) in locally advanced squamous cell anal carcinoma with reference to radiotherapy (RT) combined with MMC and fluorouracil (5-FU)." | 2.74 | Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). ( Bosset, JF; Collette, L; Haustermans, K; Koswig, S; Maingon, P; Matzinger, O; Mineur, L; Mueller, RP; Radosevic-Jelic, L; Roelofsen, F; Van Der Steen-Banasik, EM; Van Houtte, P, 2009) |
| "Protracted low-dose concurrent chemotherapy combined with radiation has been proposed for enhanced treatment results for esophageal cancer." | 2.74 | Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma. ( Furuta, T; Hamaya, Y; Ikuma, M; Iwaizumi, M; Kanaoka, S; Kodaira, C; Kosugi, T; Nishino, M; Osawa, S; Sugimoto, K; Takagaki, K; Takayanagi, Y; Terai, T; Yamada, T; Yamade, M; Yoshida, K, 2009) |
| "Patients with advanced esophageal squamous cell carcinoma receive neoadjuvant chemotherapy or chemoradiotherapy to improve survival, but benefits are observed only in those with histologic response." | 2.73 | Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma. ( Doki, Y; Fujiwara, Y; Fukunaga, H; Hatazawa, J; Higuchi, I; Miyata, H; Monden, M; Takiguchi, S; Tatsumi, M; Yano, M; Yasuda, T, 2008) |
| " However, their optimal dosage and efficacy when combined with concurrent radiotherapy as neoadjuvant treatment are unknown." | 2.73 | Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. ( Brücher, B; Geinitz, H; Höfler, H; Lordick, F; Lorenzen, S; Molls, M; Ott, K; Peschel, C; Riera, J; Roethling, N; Schuster, T; Siewert, JR; Zimmermann, F, 2008) |
| "2004, 285 patients with stage IIB-IIIB cervical cancer treated in Maternal and Child Health Hospital of Jiangxi Province were randomly assigned to receive radiotherapy alone or concurrent chemoradiotherapy." | 2.73 | [Concurrent chemoradiotherapy versus radiotherapy in advanced cervical carcinoma]. ( Li, HP; Li, LY; Luo, B; Pan, M; Shu, KY; Zeng, SY, 2008) |
| "Forty-four patients with esophageal squamous cell carcinoma (ESCC) were randomized into two groups." | 2.73 | [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer]. ( Chen, K; Gao, XS; Lin, Q; Qiao, XY; Wang, YD; Zhou, ZG, 2008) |
| "Full-dose reirradiation combined with chemotherapy has been shown to be feasible after salvage surgery with acceptable toxicity." | 2.73 | Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. ( Bardet, E; Benhamou, E; Bensadoun, RJ; Bourhis, J; Castaing, M; de Raucourt, D; Dolivet, G; Ferron, C; Géry, B; Grégoire, V; Hamoir, M; Janot, F; Julieron, M, 2008) |
| "This concurrent chemoradiotherapy with PFML was safe and well tolerated." | 2.73 | Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. ( Katori, H; Taguchi, T; Tsukuda, M, 2007) |
| "Celecoxib was prescribed at 400 mg twice daily beginning on day 1 for 1 year." | 2.73 | A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Winter, K, 2007) |
| " The dosage of chemotherapy was as follows: DOC 60 mg/m(2) on day 1 by infusion over 2 hours; CDGP 20-30 mg/m(2)/day on day 1 to 5 by infusion over 1 hour, and 5-FU 600 mg/m(2)/day on day 1 to 5 by 5 days continuous infusion." | 2.73 | [Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck]. ( Iwabuchi, H; Nakayama, S; Uchiyama, K, 2007) |
| "First-line chemotherapy for 32 advanced squamous cell carcinomas of the esophagus is not effective, and early recurrences after chemotherapy were examined." | 2.73 | [Evaluation of docetaxel, CDDP and 5-FU combined therapy as second-line chemotherapy for esophagus cancer]. ( Aoyama, N; Minamide, J; Oota, Y; Takada, K, 2007) |
| "Grade III mucositis was more frequently observed in test group than in control group (75." | 2.73 | [Concurrent chemoradiotherapy followed by adjuvant chemotherapy for stage III-IVa nasopharyngeal carcinoma]. ( Fu, ZF; Hu, QY; Liu, P; Wang, L, 2007) |
| "Seventy patients with advanced head and neck cancer were treated with vinorelbine and continuous 5-FU administered in a central venous catheter." | 2.73 | A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer. ( Adimi, P; Andersen, LJ; Bastholt, L; Larsen, S; Lindeløv, B; McCulloch, T; Serup-Hansen, E, 2007) |
| "Celecoxib was prescribed at a dose of 400 mg twice daily for 1 year beginning on the first day of radiotherapy." | 2.73 | Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Small, W; Winter, K, 2007) |
| "Patients with local/regional oesophageal cancer with adequate functional status should not be excluded from potentially curative treatment based on age alone." | 2.73 | Combined modality chemoradiation in elderly oesophageal cancer patients. ( Anderson, SE; Bains, M; Hummer, A; Ilson, DH; Kelsen, D; Minsky, BD, 2007) |
| "For patients with localized esophageal cancer, whether or not preoperative chemotherapy is administered, only an R0 resection results in substantial long-term survival." | 2.73 | Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. ( Ajani, JA; Estes, NC; Gunderson, LL; Haller, DG; Kelsen, DP; Kocha, W; Minsky, BD; Mortimer, J; Roth, JA; Willett, CG; Winter, KA, 2007) |
| "This study assessed the clinical activity and safety of twice-weekly paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin (TP-HDFL) in patients with recurrent or metastatic esophageal squamous cell carcinoma." | 2.73 | Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. ( Cheng, AL; Hsu, C; Hsu, CH; Hsu, WL; Lin, CC; Tsai, YC; Yang, CH; Yeh, KH, 2007) |
| "Eight patients had esophageal cancer and 9 had gastric cancer." | 2.73 | A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer. ( Akerman, P; Evans, D; Jean, M; Kennedy, T; Millis, R; Miner, T; Safran, H, 2007) |
| "All patients had histologically proven squamous cell carcinoma of the esophagus." | 2.73 | A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. ( Cho, EY; Hong, YS; Im, YH; Kang, WK; Kim, HS; Kim, K; Kim, MJ; Lee, HR; Lee, J; Park, K; Shim, YM, 2008) |
| "Patients with recurrent squamous cell carcinoma or a second primary arising in a previously irradiated field were eligible." | 2.73 | Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. ( Ang, KK; Harris, J; Machtay, M; Meredith, R; Rotman, M; Schultz, C; Spanos, W; Spencer, SA; Wheeler, RH, 2008) |
"These specimens were evaluated for DNA aneuploidy (DI | 2.73 | Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trial. ( Crook, W; Eifel, PJ; Gaffney, DK; Grigsby, PW; Krishan, A; Lucci, JA; Markoe, AM; Morris, M; Winter, K; Wolfson, AH, 2008) | |
| "Imiquimod treatment of AK resulted in superior sustained clearance and cosmetic outcomes compared with cryosurgery and 5-FU." | 2.73 | A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. ( Krawtchenko, N; Mann, I; Roewert-Huber, J; Sterry, W; Stockfleth, E; Ulrich, M, 2007) |
| "50 patients with squamous cell carcinoma (90%) or adenocarcinoma and mostly advanced tumor stage were treated (82% T3/T4 and 70% N1)." | 2.73 | Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost. ( Brunner, TB; Grabenbauer, GG; Melzner, W; Rupp, A; Sauer, R, 2008) |
| "To test the efficacy and safety of pharmacokinetic modulating chemotherapy combined with cisplatin (PMC-cisplatin) as induction chemotherapy (ICT) before definitive treatment in patients with respectable locally advanced head and neck squamous cell carcinoma (HNSCC)." | 2.73 | Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. ( Chang, PM; Chang, SY; Chen, PM; Chu, PY; Huang, JL; Tai, SK; Tsai, TL; Wang, LW; Wang, YF; Yang, MH, 2008) |
| "Acute mucositis is a dose-limiting toxicity of concurrent chemoradiotherapy regimens for locally advanced head and neck cancer." | 2.73 | Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. ( Berger, D; Brizel, DM; Brizel, HE; Chen, MG; Glück, S; Mendenhall, W; Meredith, RF; Murphy, BA; Pandya, KJ; Rosenthal, DI, 2008) |
| "These tumours are assessed as rectal cancer using immunohistochemical and radiological tests, and certain criteria (localisation, relationship with neighbouring structures) have to be fulfilled to make the diagnosis." | 2.72 | Squamous rectal carcinoma: a rare malignancy, literature review and management recommendations. ( Astaras, C; Bornand, A; Koessler, T, 2021) |
| "Treatment comprised cetuximab (initial dose 400 mg/m2 with subsequent weekly doses of 250 mg/m2) in combination with 3-week cycles of either cisplatin (100 mg/m2) or carboplatin (area under the curve, 5), each in combination with a 5-day infusion of fluorouracil (FU) at escalating doses of 600, 800, and 1,000 mg/m2/d." | 2.72 | Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. ( Amellal, N; Awada, A; Borel, C; Bourhis, J; Duck, L; Geoffrois, L; Harstrick, A; Hitt, R; Humblet, Y; Lopez-Pousa, A; Mesia, R; Rivera, F; Rosine, D; Schueler, A; Vega Villegas, ME, 2006) |
| "Fluorouracil was applied for 4 weeks." | 2.72 | Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. ( Bedane, C; Horn, M; Ibbotson, S; Khemis, A; Leman, J; Morton, C; Tack, B; Tjioe, M; Wolf, P, 2006) |
| "Patients with intermediate-stage squamous cell carcinoma of the head and neck traditionally have been treated with initial surgical resection followed by radiotherapy (RT) alone or chemoradiotherapy." | 2.72 | High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. ( Brockstein, B; Cohen, EE; Haraf, DJ; Kies, MS; Kocherginsky, M; List, MA; Mittal, BB; Rosen, F; Stenson, KM; Vokes, EE; Williams, R; Witt, ME, 2006) |
| "Treatment with fluorouracil, trichloroacetic acid, or carbon dioxide laser resulted in an 83% to 92% reduction in AKs (P< or =." | 2.72 | Facial resurfacing for nonmelanoma skin cancer prophylaxis. ( Cooper, ZA; Hantash, BM; Koch, RJ; Rehmus, WE; Stewart, DB; Swetter, SM, 2006) |
| "Twenty patients with squamous cell carcinoma (SCC) of the head and neck were included in the study." | 2.71 | FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. ( Kitagawa, Y; Nakamura, M; Nishizawa, S; Ogasawara, T; Sadato, N; Sano, K; Yonekura, Y, 2003) |
| "Eleven patients with oral cancer were treated with the new platinum agent, nedaplatin, and 5-fluorouracil and simultaneous radiation therapy." | 2.71 | Concurrent chemoradiotherapy with new platinum compound nedaplatin in oral cancer. ( Fukuda, K; Hanakita, T; Hayatsu, Y; Ita, M; Mitsuoka, K; Okafuji, M, 2003) |
| "Multimodal treatment of esophageal cancer showed promising results, although not significant, in terms of survival and disease progression for patients achieving a complete pathologic response." | 2.71 | Preoperative chemoradiotherapy in cancer of the thoracic esophagus. ( Baccarani, U; Bresadola, F; Bresadola, V; Buffoli, A; Cartei, G; Cedolini, C; Fongione, S; Iop, A; Sacco, C; Signor, M; Terrosu, G; Uzzau, A; Vigevani, E, 2003) |
| "Treatment of locoregionally advanced nasopharyngeal cancer with induction chemotherapy followed by concomitant chemoradiotherapy resulted in excellent overall survival with acceptable toxicity." | 2.71 | Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. ( Haraf, DJ; Kies, MS; Mittal, BB; Oh, JL; Vokes, EE; Weichselbaum, RR; Witt, ME, 2003) |
| "Thirteen patients with previously untreated squamous cell carcinoma of the hypopharynx, T3 or T4, were included." | 2.71 | Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome. ( Agostini, D; Babin, E; Bequignon, A; Chesnay, E; Constans, JM; Moreau, S; Regeasse, A; Sobrio, F, 2003) |
| "Ninety-two patients with esophageal cancer (65 with adenocarcinoma and 27 with squamous cell carcinoma) were treated in two sequential protocols of preoperative chemoradiotherapy." | 2.71 | Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. ( Burtness, B; Forastiere, AA; Heath, EI; Heitmiller, R; Kleinberg, L; Knisely, JP; Salem, R; Zahurak, M, 2003) |
| "Ten patients with advanced or recurrent cancer of the cervix with no prior chemotherapy were entered in a phase II trial from October 2000 to November 2001." | 2.71 | First-line chemotherapy with 5-FU and platinum for advanced and recurrent cancer of the cervix: a phase II study. ( Behtash, N; Ghaemmaghami, F; Khanafshar, N; Modares, M; Moosavi, A; Toogeh, G; Yarandi, F, 2003) |
| " The purpose of this study was to evaluate the efficacy and toxicity of a modified TPFL regimen (m-TPFL) for locally advanced SCCHN, consisting of a modified dosage with docetaxel, cisplatin, 5-FU and l-leucovorin (l-LV) designed for Japanese patients." | 2.71 | Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients. ( Sasaki, S; Taniguchi, M; Watanabe, A, 2003) |
| "122 patients with primary squamous cell carcinoma of the lip, the oral cavity and the oropharynx have been treated with 100 mg/m2 cisplatin bolus infusion and 120-h continuous infusion of 1000 mg/m2 5-fluorouracil following radical surgery; 99 patients completed all 3 cycles." | 2.71 | Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx--long-term results. ( Bitter, K; Ghahremani, MT; Kovács, AF; Stefenelli, U, 2003) |
| "Treatment was given until disease progression or unacceptable toxicity." | 2.71 | A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. ( Han, JY; Ju, SY; Kim, EA; Kim, HY; Lee, DH; Lee, JJ; Lee, JS; Shin, EH, 2003) |
| "5-FU/irinotecan is a valuable regimen for second-line treatment in 5-FU/platinum-resistant O-G carcinoma." | 2.71 | Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. ( Assersohn, L; Brown, G; Cunningham, D; Hill, ME; Norman, AR; Oates, J; Ward, C; Waters, JS, 2004) |
| " A study was conducted of a novel treatment, EMR combined with CRT, for patients with superficial esophageal carcinoma." | 2.71 | EMR combined with chemoradiotherapy: a novel treatment for superficial esophageal squamous-cell carcinoma. ( Asaka, M; Fujita, M; Hosokawa, M; Kato, M; Nakagawa, S; Shimizu, Y; Tsukagoshi, H; Yamamoto, J, 2004) |
| "Four hundred three women with cervical cancer were randomly assigned to receive either EFRT or CTRT." | 2.71 | Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. ( Cooper, J; Eifel, PJ; Gershenson, D; Grigsby, PW; Levenback, C; Morris, M; Mutch, DG; Rotman, M; Winter, K, 2004) |
| "Capecitabine was given twice daily, 7 days a week at a dose starting at 350 mg/m(2) bid." | 2.71 | Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. ( Ironside, JA; MacDougall, RH; Mais, KL; Slevin, NJ; Sykes, AJ, 2004) |
| "Patients with stage III or IV squamous carcinoma of the oral cavity, oropharynx, or hypopharynx were eligible." | 2.71 | Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. ( Cooper, JS; Demas, W; Forastiere, AA; Garden, AS; Glisson, BS; Gore, E; Harris, J; Horwitz, EM; Jones, C; Nabell, L; Ridge, JA; Vokes, EE, 2004) |
| "Grade 4 neutropenia was observed in one patient." | 2.71 | Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. ( Castellano, D; Cortés-Funes, H; Hitt, R; Jimeno, A; Millán, JM, 2004) |
| "The paclitaxel dose was started at 75 mg/m(2) (n = 7) and escalated to 125 mg/m(2) (n = 5), at which point, dose-limiting toxicities occurred." | 2.71 | Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. ( Ancukiewicz, M; Choi, N; Donahue, D; Lynch, T; Mathisen, D; Park, SD; Wain, J; Wright, C, 2004) |
| "Patients with previously untreated esophageal cancer were eligible if they had performance status 0-1, were 75 years or younger and had adequate organ function." | 2.71 | Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer. ( Fujitani, K; Hirao, M; Tsujinaka, T, 2004) |
| "Patients with locally advanced squamous cell carcinoma of the esophagus, who respond to preoperative neoadjuvant combined radiochemotherapy, seem to have more benefit from subsequent resection than non-responding patients." | 2.71 | Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. ( Brücher, BL; Busch, R; Dittler, HJ; Fink, U; Molls, M; Sarbia, M; Siewert, JR; Stein, HJ; Werner, M; Zimmermann, F, 2004) |
| "Stage IIIB cervical cancer patients with bilateral parametrial involvement have a poor prognosis with low survival rates." | 2.71 | Concurrent chemotherapy and hypofractionated twice-daily radiotherapy in cervical cancer patients with stage IIIB disease and bilateral parametrial involvement: a phase I-II study. ( Araujo, CM; Dantas, MA; Froimtchuk, M; Marchiori, E; Oliveira, JA; Souhami, L; Viegas, CM, 2004) |
| " This study was to compare effects and toxicities of intratumoral H101 injection combined with cisplatin plus 5-fluorouracil (PF) regimen or adriamycin plus 5-fluorouracil (AF) regimen versus PF or AF regimen alone in treating patients with head and neck or esophagus squamous cell cancer." | 2.71 | [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. ( Chang, JH; Chen, JC; Chen, ZC; Fan, QX; Guan, ZZ; Hu, XH; Huang, JJ; Jiang, WQ; Liu, JW; Lu, JW; Wang, HQ; Wu, GH; Xia, ZJ; Zhang, L; Zhang, Y; Zheng, X; Zhou, QH, 2004) |
| "Esophageal cancer has a poor prognosis." | 2.71 | [Phase I study of the combination of nedaplatin (NED), adriamycin (ADM), and 5-fluorouracil (5-FU) (NAF) for treatment of unresectable advanced esophageal cancer]. ( Fujitani, K; Hirao, M; Tsujinaka, T, 2005) |
| "Celecoxib (Celebrex) was administered at 200 mg orally twice daily beginning on day 1 until surgery and then at 400 mg orally twice daily until disease progression or unexpected toxicities, or for a maximum of 5 years." | 2.71 | Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. ( Ansari, R; Fineberg, N; Fox, E; Govindan, R; Hanna, N; Helft, P; Kesler, K; Mantravadi, P; McLeod, H; Stoner, C, 2004) |
| "In all, 16 patients with biopsy-proven squamous cell carcinoma of the anal canal or margin and performance status or co-morbidity precluding the use of full-dose CRT were included in this protocol." | 2.71 | Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy. ( Charnley, N; Chesser, P; Choudhury, A; Cooper, RA; Sebag-Montefiore, D, 2005) |
| "Patients with locally advanced squamous cell carcinoma (SCC) of the esophagus were randomly allocated to either induction chemotherapy followed by chemoradiotherapy (40 Gy) followed by surgery (arm A), or the same induction chemotherapy followed by chemoradiotherapy (at least 65 Gy) without surgery (arm B)." | 2.71 | Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. ( Budach, W; Franke, C; Klump, B; Lehmann, N; Meyer, HJ; Schmitt, G; Schmitt, M; Seeber, S; Stahl, M; Stuschke, M; Teichmann, R; Walz, MK; Wilke, H, 2005) |
| "To define the maximum-tolerated dose of oxaliplatin given with cisplatin, protacted 96-h infusion of fluorouracil, and radiotherapy for patients with advanced esophageal cancer." | 2.71 | Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma. ( Cervantes, A; Chirivella, I; Conill, C; Gallego, R; Manzano, H; Marfa, X; Martin-Richard, M; Maurel, J; Pera, M; Salazar, R, 2005) |
| "In a phase II IRB approved trial, capecitabine was given at a dosage of 2000 mg/m2/day orally in a divided dose daily for 14 days followed by a 7-day rest period." | 2.71 | Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. ( Atkinson, EN; Bodurka, DC; Brown, J; Jenkins, AD; Johnston, T; Levenback, C; Ramondetta, LM; Sun, C; Wolf, JK, 2005) |
| "Forty-three patients with a T4 esophageal cancer were enrolled in a prospective study in which each patient decided for themselves a treatment arm, CRT-followed-by-esophagectomy or esophagectomy-followed-by-CRT." | 2.71 | Prospective non-randomized trial comparing esophagectomy-followed-by-chemoradiotherapy versus chemoradiotherapy-followed-by-esophagectomy for T4 esophageal cancers. ( Fujita, H; Hayabuchi, N; Inutsuka, H; Sasahara, H; Shirouzu, K; Sueyoshi, S; Suzuki, G; Tanaka, T; Tanaka, Y, 2005) |
| "Patients with either adenocarcinoma or squamous cell carcinoma of the esophagus could enroll; however, patients could not have received prior chemotherapy for metastatic disease." | 2.71 | A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. ( Ahuja, H; Bailey, H; Berlin, JD; Hansen, R; Jumonville, A; Kim, K; McFarland, T; Morgan-Meadows, S; Mulkerin, D; Saphner, T; Thomas, JP, 2005) |
| "This study analyzed the impact on long-term results of an increase in the dosage of an induction chemoradiotherapy protocol for squamous cell carcinoma (SCC) of the thoracic esophagus." | 2.71 | Induction chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus: impact of increased dosage on long-term results. ( Bernini, M; Cordiano, C; de Manzoni, G; Grandinetti, A; Laterza, E; Pasini, F; Pedrazzani, C; Ruzzenente, A; Tomezzoli, A; Zerman, G, 2005) |
| " This regimen is under way in which chemotherapy with 5-FU 500 mg/day on days 1 to 5 and superselective intra-arterial infusion of CDGP on day 6 combined with radiation therapy is being evaluated for locally advanced oral cancer." | 2.71 | [Clinical trial of chemotherapy by superselective intra-arterial infusion of nedaplatin combined with radiotherapy for advanced oral cancer]. ( Goto, M; Shikimori, M; Yamshita, Y, 2005) |
| "Thirty patients with squamous cell carcinoma of the esophagus received CRT followed by surgery." | 2.71 | Chemoradiotherapy for T3 and T4 squamous cell carcinoma of the esophagus using low-dose FP and radiation: a preliminary report. ( Fujiwara, M; Fujiwara, Y; Inoue, T; Kamikonya, N; Koishi, K; Kojima, S; Nakagawa, K; Nakao, K; Nishiwaki, M; Yagyu, R; Yamamura, T; Yoshikawa, R, 2005) |
| "To evaluate the effect and acute toxicity of late course conformal radiotherapy combined with chemotherapy for stage III and IV a nasopharyngeal carcinoma (NPC)." | 2.71 | [Late course conformal radiotherapy combined with chemotherapy for stage III and IV a nasopharyngeal carcinoma]. ( Feng, LP; Lin, Q; Wu, H; Yang, ZX; Yu, ZH, 2005) |
| "3 mg of ramosetron (RAM) combined with 8 mg of dexamethasone (DEX) and 0." | 2.71 | [A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone]. ( Horiuchi, C; Ikeda, Y; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Tanigaki, Y; Tsukuda, M; Yoshida, T, 2005) |
| " Patients in arm B were given cisplatin and 5-FU in the same dosage and schedule as in arm A." | 2.70 | Use of high-dose cytarabine to enhance cisplatin cytotoxicity-effects on the response and overall survival rates of advanced head and neck cancer patients. ( Babović, N; Gavrilović, D; Jelić, S; Jovanović, N; Kreacić, M; Mikić, A; Petrović, Z; Stamatović, Lj; Vucićević, S, 2002) |
| "From 1991 to 1997, 83 consecutive esophageal cancer patients underwent surgical exploration after completion of two cycles of cisplatin and 5-fluorouracil chemotherapy regimens, either in pulse or in continuous infusion cycles." | 2.70 | The clinical efficacy of neoadjuvant chemotherapy in squamous esophageal cancer: a prospective nonrandomized study of pulse and continuous-infusion regimens with Cisplatin and 5-Fluorouracil. ( Chan, AC; Chung, SC; Griffith, JF; Lam, CC; Lam, YH; Lau, JY; Lee, DW; Leung, SF; Ng, EK, 2002) |
| "33 had squamous carcinoma and 7 adenocarcinoma; 15 were male; the locoregional metastatic ratio was 1:39; median ECOG performance status was 2 (range 1-3)." | 2.70 | A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma. ( Ajarim, D; Al Fadda, M; Bazarbashi, S; El Weshi, A; Ezzat, A; Memon, M; Pai, C; Rahal, M; Raja, MA, 2002) |
| "Raltitrexed has been shown to be devoid of clinical activity against SCCHN when used alone; however, both preclinical and early clinical data regarding the combination raltitrexed-CDDP hold promise." | 2.70 | Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study. ( Avallone, A; Caponigro, F; Comella, G; Comella, P; De Lucia, L; De Rosa, P; De Rosa, V; Rosati, G, 2002) |
| "Sixty-five patients with advanced head and neck cancer underwent a definitive (53 patients) or a postoperative adjuvant (12 patients) chemoradiation treatment." | 2.70 | Accelerated hyperfractionated radiotherapy and concurrent protracted venous infusion chemotherapy in locally advanced head and neck cancer. ( Arcangeli, G; Arcangeli, S; Carlini, P; Cognetti, F; Danesi, DT; De Campora, E; Giovinazzo, G; Mecozzi, A; Saracino, B, 2002) |
| " This phase I study was designed to find the maximum tolerated dose (MTD) of weekly cisplatin in combination with standard doses of gemcitabine (1,000 mg/m(2), 30 min) and 5-FU (750 mg/m(2), 24 h)/folinic acid (200 mg/m(2), 30 min)." | 2.70 | Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer. ( Arnold, D; Hoepffner, N; Kern, M; Neuhaus, P; Oettle, H; Riess, H; Settmacher, U, 2002) |
| "All had squamous cell carcinomas of the oral cavity in stage III or in nonmetastatic stage IV and were selected for surgery or radiation therapy (if located in the tonsils or in the base of the tongue)." | 2.70 | Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study. ( Alós, L; Blanch, JL; Castro, V; Domingo, J; Estapé, J; Grau, JJ; Nadal, A; Verger, E, 2002) |
| "Patients with locally advanced bladder cancer or who are not medically fit for surgery are a therapeutic dilemma." | 2.70 | Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. ( Al-Sarraf, M; Balcerzak, SP; Crawford, ED; Forman, J; Glass, TR; Grossman, HB; Hussain, MH; Jones, J; Sakr, W; Smith, DC, 2001) |
| "The purpose of this study was to analyze the tolerance and efficacy of full dose reirradiation combined with chemotherapy in patients with head and neck carcinoma (HNC) with a high risk of recurrence after salvage surgery." | 2.70 | Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. ( Bobin, S; Bourhis, J; De Crevoisier, R; Domenge, C; Eschwege, F; Janot, F; Koscielny, S; Luboinski, B; Lusinchi, A; Wibault, P, 2001) |
| "Complete responses were observed in squamous carcinomas from various primary sites including head and neck, esophagus, cervix, vagina, anus, and unknown primary." | 2.70 | Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial. ( Baker, MN; Burris, HA; Greco, FA; Hainsworth, JD; Meluch, AA; Morrissey, LH, 2001) |
| "The subjects were 8 patients with squamous cell carcinoma (5 males and 3 females aged 33-65 years)." | 2.70 | [Evaluation of a combination chemotherapy with nedaplatin and 5-FU for oral cancers]. ( Iba, T; Ishida, Y; Nakata, T; Nishida, T; Ohtsuki, T; Shimada, T; Takigami, K; Tanaka, A; Tsuda, Y; Yamaguchi, Y; Yamamoto, G; Yoshitake, K, 2001) |
| "Distant metastases remain the main cause of treatment failure in NPC." | 2.70 | Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfractionation in stage III and IV nasopharyngeal carcinoma--a phase II study. ( Allam, A; El-Badawi, S; El-Serafi, M; El-Weshi, A; Ibrahim, E; Khafaga, Y; Mosseri, V, 2001) |
| "Patients with recurrent squamous cell cancer of the head and neck (SCH&N) are generally treated with systemic chemotherapy." | 2.70 | RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. ( Harris, J; Machtay, M; Meredith, R; Rotman, M; Schultz, C; Spanos, W; Spencer, SA; Wheeler, RH, 2001) |
| "Gemcitabine has shown in vitro and in vivo radiosensitizing properties, synergistic activity with cisplatin, and cytotoxic activity against SCC-HN." | 2.70 | Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study. ( Benasso, M; Corvò, R; Marchetti, G; Merlano, M; Numico, G; Pallestrini, E; Ricci, I; Rosso, R; Sanguineti, G; Santelli, A; Vitale, V, 2001) |
| "We evaluated the clinical effect of 5-FU and low-dose Cisplatin (LFP) therapy alone and LFP therapy combined with radiation therapy in patients with advanced or recurrent esophageal cancer." | 2.70 | [Preliminary clinical evaluation of continuous infusion of 5-FU and low-dose Cisplatin (LFP) therapy alone and combined with radiation therapy for treatment of advanced or recurrent esophageal cancer]. ( Horimi, T; Itoh, S; Morita, S; Ohnishi, T; Takamatsu, M; Tsuji, A, 2002) |
| "Thirty-seven patients with cT4 squamous cell carcinoma of the thoracic esophagus were enrolled in this study." | 2.70 | Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. ( Aoki, K; Iijima, S; Ikeda, K; Ishida, K; Iwaya, T; Kimura, Y; Koeda, K; Maesawa, C; Nakamura, R; Ogasawara, S; Saito, K; Sato, N; Uesugi, N, 2001) |
| "The subjects were patients with squamous cell carcinoma of the oral cavity who had not received any therapy, comprising 7 patients with carcinoma of the tongue, 2 with buccal carcinoma, 2 with maxillary gingival carcinoma, and 1 with carcinoma of the oral floor." | 2.70 | [Combination chemotherapy with nedaplatin (CDGP) and 5-FU for oral cancer]. ( Ando, T; Fukada, K; Hoshino, M; Kuwazawa, T; Maruoka, Y; Nishihara, N; Ogiuchi, H; Ogiuchi, Y; Okamoto, T, 2002) |
| "Weight gain was observed in 48% of patients, and dysphagia improved in 76%." | 2.70 | Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer. ( Artru, P; Baujat, B; Carola, E; de Gramont, A; Krulik, M; Louvet, C; Mabro, M; Maindrault, F; Taïeb, J; Tournigand, C, 2002) |
| "To identify a dose and schedule of oxaliplatin (OXP) to be safely administered in combination with protracted-infusion (PI) fluorouracil (5-FU) and external-beam radiation therapy (XRT) for patients with primary esophageal carcinoma (EC)." | 2.70 | Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. ( Berdzik, J; Bodnar, L; Douglass, H; Greco, W; Khushalani, NI; Klippenstein, D; Leichman, CG; Leichman, L; Litwin, A; Nava, E; Nava, H; Pendyala, L; Proulx, G; Smith, J; Smith, P, 2002) |
| "The first-line chemotherapy for head and neck cancer is reported to be the combination of CDDP and 5-FU." | 2.69 | [Combination chemotherapy with nedaplatin and 5-FU for head and neck cancer]. ( Fujii, M; Imanishi, Y; Kanke, M; Kanzaki, J; Ohno, Y; Tokumaru, Y, 1998) |
| "Patients with locoregionally advanced head and neck cancer were treated either with RT alone (arm A) or simultaneous RT plus CT (RCT; arm B)." | 2.69 | Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. ( Aydin, H; Grabenbauer, GG; Iro, H; Popella, C; Rödel, CM; Rohloff, R; Schalhorn, A; Thiel, HJ; Wendt, TG; Wustrow, TP, 1998) |
| "Paclitaxel is an important new agent in the treatment of esophageal carcinoma, and further evaluation of this agent in combination chemotherapy is warranted." | 2.69 | Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. ( Ajani, J; Bhalla, K; Donegan, J; Forastiere, A; Huang, Y; Ilson, DH; Kelsen, DP; Martin, L; Patel, P; Pazdur, R; Reed, C, 1998) |
| "For patients with squamous cell carcinoma of the head and neck (HNSCC), persistence of cervical adenopathy following organ-preservation therapy is a strong predictor of locoregional failure." | 2.69 | Squamous cell granulomas of the neck: histologic regression of metastatic squamous cell carcinoma following chemotherapy and/or radiotherapy. ( Eisele, DW; Forastiere, AA; Lee, DJ; Westra, WH, 1998) |
| "Squamous cell cancer of the esophagus is the most common cancer among black South African males, and 60% of patients present with localized inoperable disease." | 2.69 | A randomized study of radiotherapy alone versus radiotherapy plus 5-fluorouracil and platinum in patients with inoperable, locally advanced squamous cancer of the esophagus. ( Burger, W; Falkson, CI; Falkson, G; Nel, JS; Schoeman, L; Slabber, CF, 1998) |
| "Since the prognosis of patients with T4 squamous cell carcinoma (SCC) of the esophagus is extremely poor, an effective multimodal treatment needs to be established." | 2.69 | Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus. ( Doki, Y; Inoue, M; Inoue, T; Monden, M; Shiozaki, H; Tanaka, E; Tsujinaka, T; Yamamoto, M; Yano, M, 1999) |
| "Ifosfamide was given initially to 12 patients in combination with standard fixed doses of cisplatin and 5-fluorouracil, at 1,000 mg/m2 daily on days 2, 3, and 4." | 2.69 | Phase II clinical trial of cisplatin, 5-fluorouracil, and ifosfamide as treatment for advanced locoregional head and neck carcinoma. ( Abad, T; Alvárez, I; Churruca, C; Egana, L; Guimón, E; Lacasta, A; López de Argumedo, G; Paredes, A; Piera, JM; Sánchez Parra, M, 1999) |
| "Patients with previously untreated squamous cell carcinoma of the oral cavity were eligible for this trial." | 2.69 | High rate of clinical complete response to weekly outpatient neoadjuvant chemotherapy in oral carcinoma patients using a new regimen of cisplatin, 5-fluorouracil, and bleomycin alternating with methotrexate and epirubicin. ( Hsu, CY; Jan, JS; Lin, JC; Wong, DY, 1999) |
| "Two of 13 patients with squamous cell carcinoma (SCC) had a complete response (CR), but one died of pneumonia after 9 months while still in CR, and the other still in CR after more than 5 years." | 2.69 | Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma. ( Bjarnason, GA; Cripps, C; Fields, AL; Goel, R; Hrincu, A; Jensen, JL; Kerr, IA; Khoo, KE; Warner, E, 1999) |
| "All patients had biopsy-proven invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix." | 2.69 | Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. ( Bundy, BN; Clarke-Pearson, DL; Fowler, WC; Hannigan, EV; Liao, SY; Malfetano, JH; Sause, W; Whitney, CW, 1999) |
| "In head-and-neck cancer, chemosensitivity is inconstant, and no marker is available to predict response to treatment." | 2.69 | Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma. ( Beaune, P; Blons, H; Brasnu, D; Cabelguenne, A; Carnot, F; de Waziers, I; Hamelin, R; Laccourreye, O; Laurent-Puig, P, 1999) |
| "Paclitaxel has exhibited single-agent activity in patients with this disease." | 2.69 | Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. ( Du, W; Ensley, J; Gadgeel, S; Hussain, M; Kucuk, O; Salwen, W, 1999) |
| "Six of 40 patients with metastatic colorectal cancer obtained an objective response (15%; 95% confidence interval, 6-30%)." | 2.69 | Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. ( Avallone, A; Blackie, R; Budillon, A; Caponigro, F; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lucia, L; De Vita, F; Gravina, A; McLeod, H; Morsman, J, 1999) |
| "For locally unresectable recurrent squamous cell carcinoma of the head and neck, we investigated two salvage chemotherapy regimens as second-line chemotherapy." | 2.69 | Prognosis after salvage chemotherapy for locally unresectable recurrent squamous cell carcinoma of the head and neck. ( Kawaida, M; Kitahara, S; Kohno, N; Ohmuma, T, 1999) |
| "Paclitaxel and cisplatin were administered as postoperative adjuvant therapy." | 2.69 | Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. ( Burtness, BA; Canto, MI; Forastiere, AA; Heath, EI; Heitmiller, RF; Kaufman, HS; Kleinberg, L; Knisely, JP; Olukayode, K; Salem, R; Talamini, MA; Topazian, M; Wu, TT; Yang, SC, 2000) |
| "From 1992 to 1998, 34 of 131 total esophageal cancer patients were designated stage III (16 T3N1, 9 T4N0, 9 T4N1) and medically fit to enter a combined modality protocol with continuous infusion 5-fluorouracil (CIS-FU, 300 to 600 mg/m2/day), high-dose external beam irradiation (60 Gy), and interval esophagectomy." | 2.69 | Aggressive multimodality therapy for stage III esophageal cancer: a phase I/II study. ( Alexander, EP; Harmon, J; Lipman, T; Wadleigh, R, 2000) |
| "Febrile neutropenia was recorded in 15% of courses." | 2.69 | Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. ( Boukis, H; Janinis, J; Lefantzis, D; Panagos, G; Papadakou, M; Poulis, A; Xidakis, E, 2000) |
| "All patients had advanced but operable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx." | 2.69 | The influence of beam energy on the outcome of postoperative radiotherapy in head and neck cancer patients: secondary analysis of RTOG 85-03. ( Aref, A; Berkey, BA; Ensley, J; Ervin, TJ; Haselow, RE; Laramore, GE; Schuller, DE; Schwade, JG, 2000) |
| "To improve survival rate in advanced head and neck cancer, we scheduled 90 patients to receive low dose cisplatin plus 5-fluorouracil regimen as neoadjuvant(NAC), concurrent(CC), adjuvant(AC), and second line chemotherapy (SC) setting." | 2.69 | The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck. ( Kawada, M; Kitahara, S; Kohno, N; Nakanoboh, M; Shirasaka, T; Tamura, E; Tanabe, T, 2000) |
| "Patients with a squamous cell carcinoma of the oropharynx for whom curative radiotherapy or surgery was considered feasible were entered in a multicentric randomized trial comparing neoadjuvant chemotherapy followed by loco-regional treatment to the same loco-regional treatment without chemotherapy." | 2.69 | Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC). ( Coche-Dequeant, B; De Raucourt, D; Domenge, C; Hill, C; Lefebvre, JL; Luboinski, B; Marandas, P; Rhein, B; Sancho-Garnier, H; Stromboni-Luboinski, M; Wibault, P, 2000) |
| " However, in combination with radiation therapy, this regimen is tolerable when the primary goal is palliation of dysphagia near the end of life." | 2.68 | Split-course accelerated radiation therapy combined with carboplatin and 5-fluorouracil for palliation of metastatic or unresectable carcinoma of the esophagus. ( Turrisi, AT; Urba, SG, 1995) |
| "Recurrent squamous cell carcinoma of the head and neck is poorly responsive to most chemotherapy regimens." | 2.68 | Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancer. ( Baez, L; Benner, SE; Brooks, J; Dimery, IW; Earley, CL; Hong, WK; Huber, MH; Lippman, SM; Shirinian, M; Winn, RJ, 1995) |
| "Completed clinical trials in laryngeal cancer indicate that such an approach is feasible, but progress thus far has been limited by our inability to predict which patients are likely to respond to chemotherapy and preserve their larynx." | 2.68 | Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group. ( Beals, T; Bradford, CR; Carey, TE; Fisher, SG; McClatchey, KD; Poore, J; Wolf, GT; Zhu, S, 1995) |
| "Conventional treatment of esophageal cancer with surgery or radiation alone has afforded few long-term survivors." | 2.68 | Preoperative chemoradiotherapy for locoregional esophageal cancer: preliminary report. ( Chang, HS; Choi, EK; Kim, SB; Kim, SH; Kim, SW; Lee, JS; Lee, JW; Lee, KH; Song, HY; Suh, CW, 1995) |
| "The histology was squamous cell carcinoma in 44 patients and adenocarcinoma in 3 patients with esophagus cancer." | 2.68 | Chemotherapy rapidly alternating with twice-a-day accelerated radiation therapy in carcinomas involving the hypopharynx or esophagus: an update. ( Beattie, E; Malamud, S; Nussbaum, M; Vikram, B; Yu, L; Yudelman, I, 1995) |
| "Twenty patients with stage IV squamous cell carcinoma of head and neck were studied." | 2.68 | Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. ( Chan, WK; Chang, CY; Chao, JY; Chen, CH; Chen, KY; Chen, SY; Chi, KH; Chow, KC; Yen, SH, 1995) |
| "To analyze clinical and pharmacokinetic data of cisplatin (CP)/fluorouracil (FU)/l folinic acid (l FA) chemotherapy administered as first-line treatment to locally advanced head and neck cancer patients." | 2.68 | Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ( Dassonville, O; Demard, F; Etienne, MC; Guillot, T; Milano, G; Mobayen, H; Otto, J; Saudes, L; Schneider, M; Thyss, A, 1995) |
| "N&V and leukopenia were the major side effects." | 2.68 | Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer. ( Ichikawa, G; Inuyama, Y; Kawaida, M; Kohno, N; Ohnuma, T; Shirasaka, T, 1995) |
| " The Kaplan-Meier overall and cancer specific survival analysis estimates that the chronic administration of antimetabolites did not improve the cumulative 5-year survival in the SCC group." | 2.68 | [Usefulness of adjuvant chemotherapy with antimetabolites for cervical invasive cancer]. ( Hirota, Y; Hongo, J; Iijima, Y; Inagaki, M; Koyama, M; Ozaki, M; Wada, K, 1995) |
| "Chemotherapy for squamous cell carcinoma with unknown primary (SCUP) has not been prospectively studied." | 2.68 | Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary. ( Allred, C; Anand, V; Khansur, T; Little, D, 1995) |
| "Six patients (21%) had residual cancer in the resected specimen, either at the primary site or--more often--in adjacent lymph nodes." | 2.68 | Treating esophageal cancer with a combination of chemotherapy, radiation, and excision. ( Bates, DM; Clyde, JC; Garcia, JM; Girvin, GW; Lin, PH; Matsumoto, GH, 1995) |
| "Thirty-one patients with squamous cell carcinoma of the vulva were treated with two courses of combination chemotherapy mitomycin C, 15 mg/m2 intravenously (i." | 2.68 | Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study. ( di Re, F; Fontanelli, R; Kenda, R; Lupi, G; Paladini, D; Raspagliesi, F; Zucali, R, 1996) |
| "Recurrent cancer of the head and neck after primary therapy is almost always fatal." | 2.68 | Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. ( Benedetti, J; Ensley, J; Hussain, M; Rodriguez, GI; Schuller, D; Smith, RE, 1995) |
| "Stage IV inoperable head and neck cancer has a 2-year mortality rate of greater than 70% when treated with conventional radiotherapy." | 2.68 | Accelerated fractionation radiotherapy and concomitant chemotherapy in patients with stage IV inoperable head and neck cancer. ( Benninger, MS; Boyd, SB; Carlson, ER; Doyle, TJ; Dragovic, J; Jacobsen, GR; Nichols, RD; Tilchen, EJ, 1995) |
| "Sixty-three patients developed distant metastases or local relapse, 30 in the CT + RT group and 33 in the RT group." | 2.68 | Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. ( Bertelsen, K; Högberg, T; Koern, J; Onsrud, M; Simonsen, E; Sundfør, K; Tropé, CG; Westberg, R, 1996) |
| "8%)." | 2.68 | Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and neck cancer. ( Bishop, JF; Hughes, PG; Narayan, K; Olver, IN; Smith, JG, 1996) |
| "Patients with advanced laryngeal cancer received two cycles of cisplatin 100 mg/m2 and fluorouracil (5-Fu) 1,000 mg/m2/d for 5 days." | 2.68 | Chemotherapy followed by accelerated fractionated radiation for larynx preservation in patients with advanced laryngeal cancer. ( Bradford, CR; Carroll, WR; Eisbruch, A; Esclamado, RM; Hazuka, MB; Littles, FJ; Strawderman, M; Thornton, AF; Urba, S; Wolf, GT, 1996) |
| "Patients with residual tumor on posttreatment biopsy were treated with a salvage regimen that consisted of additional pelvic RT (9 Gy), 5-FU, and cisplatin (100 mg/m2)." | 2.68 | Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. ( Coia, L; Doggett, S; Flam, M; John, M; Kerman, H; Murray, K; Myerson, R; Pajak, TF; Petrelli, N; Quivey, J; Rotman, M, 1996) |
| "Since 1984, 373 patients with oesophageal cancer have been treated on three prospective, but unrandomised, protocols involving radiation with concurrent cisplatin and infusional fluorouracil." | 2.68 | Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG) ( Burmeister, BH; Denham, JW; Hamilton, CS; Joseph, DJ; Lamb, DS; O'Brien, P; Spry, NA; Walker, QJ; Yeoh, E, 1996) |
| "Eighty patients with advanced squamous carcinoma of the head and neck were entered into a study using a 2-day, inpatient, intravenous regimen." | 2.68 | Carboplatin, 5-fluorouracil and folinic acid: a 48-hour chemotherapy regimen in advanced and recurrent squamous carcinoma of the head and neck. ( Canney, PA; Hatton, MQ; Junor, EJ; McGurk, FM; Paul, J; Robertson, AG; Symonds, RP; Yosef, H, 1996) |
| "Twenty-five patients with esophageal cancer were treated in a phase I pilot protocol consisting of initial esophagectomy with gastroesophagostomy and subsequent combined chemotherapy and radiation." | 2.68 | Integration of surgery in multimodality therapy for esophageal cancer. ( Doolas, A; Ebie, N; Griem, K; Hartsell, W; Kang, HJ; Millikan, K; Murthy, AK; Recine, DC; Taylor, S, 1997) |
| "Eligible patients had Stage III or IV squamous cell carcinoma of the head and neck with no distant metastases." | 2.68 | Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center. ( Athanasiadis, I; Blough, R; Ganzenko, N; Kies, MS; Lester, EP; Mittal, BB; Pelzer, HJ; Rademaker, A; Taylor, S; Vokes, EE, 1997) |
| "25 horses with 27 T2-stage periocular squamous cell carcinomas." | 2.68 | Comparison of intratumoral administration of cisplatin versus bleomycin for treatment of periocular squamous cell carcinomas in horses. ( Carlson, G; Madigan, JE; Metzger, L; Pascoe, JR; Théon, AP, 1997) |
| "Thirteen patients with advanced squamous cell carcinoma of the esophagus were treated with 1,000 mg/m2/day 5-fluorouracil days 1-5 continuously and 100 mg/m2 cisplatin on day 1." | 2.68 | Sequential chemotherapy and radiotherapy for squamous cell esophageal carcinoma. ( Davis, EB; Hussain, MA; Krasnow, SH; Lunzer, S; Sharma, D; Wadleigh, RG, 1997) |
| "Forty patients with esophageal cancer were treated in a phase I and II trial of induction chemotherapy (cisplatin, 5-fluorouracil, and paclitaxel) at three dosage levels (75, 125, and 100 mg/m2) and concurrent hyperfractionated radiotherapy (45 Gy to the mediastinum, 58." | 2.68 | Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. ( Carey, RW; Choi, NC; Grillo, HC; Grossbard, ML; Lynch, TJ; Mathisen, DJ; Moncure, AC; Wain, JC; Wright, CD, 1997) |
| "Locally advanced esophageal cancer is rarely operable and has a dismal prognosis." | 2.68 | First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up. ( Ancona, E; Bonavina, L; Castoro, C; Chiarion-Sileni, V; Merigliano, S; Peracchia, A; Ruol, A; Santi, S, 1997) |
| "Patients with localized esophageal cancer also received radiation therapy beginning on day 1 (1." | 2.68 | Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial. ( Greco, FA; Hainsworth, JD; Meluch, AA, 1997) |
| "The paclitaxel dose levels were 25 mg/m2 in four patients, 40 mg/m2 in five patients, 60 mg/m2 in nine patients, and paclitaxel 50 mg/m2 with 5-FU reduced to 200 mg/m2 in nine patients." | 2.68 | Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy. ( Coia, LR; Colarusso, P; Dresler, C; Goldberg, M; Weiner, LM, 1997) |
| "The EORTC Head and Neck Cancer Cooperative Group conducted a randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in chemotherapy naive patients with recurrent or metastatic squamous cell carcinoma of the head and neck." | 2.67 | Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head a ( Cappelaere, P; Clavel, M; Clerico, M; Cognetti, F; de Mulder, PH; Schornagel, JH; Tueni, EA; Vermorken, JB; Verweij, J; Wildiers, J, 1994) |
| "Leukopenia was more frequent in the simultaneous than in the sequential arm (p = 0." | 2.67 | A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck. ( Carlini, P; Cercato, MC; Cognetti, F; Del Vecchio, MR; Giannarelli, D; Impiombato, FA; Marzetti, F; Milella, M; Pinnarò, P, 1994) |
| "The maximum tolerated 5-fluorouracil dosage was 300 mg/m2 i." | 2.67 | Intensified chemotherapy with granulocyte-monocyte colony stimulating factor protection in advanced, relapsed squamous cell carcinoma of the head and neck. A phase I study. ( Benasso, M; Blengio, F; Cavallari, M; Merlano, M; Rosso, M; Rosso, R; Sguotti, C, 1994) |
| "In the first study by the "Kinki Head and Neck Tumor Study Group," we performed a comparative study to investigate intergroup difference between a control group consisting of patients given radical treatment only, and a HCFU group consisting of patients receiving long-term administration of HCFU after radical treatment." | 2.67 | [A comparative clinical study on the treatment of head and neck tumors by adjuvant chemotherapy with HCFU--Second Study by Kinki Head and Neck Tumor Study Group]. ( Kozuka, T; Matsunaga, T; Matsuoka, H; Miyaguchi, M; Nakai, Y; Nishimura, T; Sakai, S; Sato, T; Tanabe, M; Yoshino, K, 1994) |
| "FLEP is an active combination for oesophageal cancer, especially when used preoperatively in LAD." | 2.67 | 5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus. ( Achterrath, W; Berger, M; Berns, T; Fink, U; Harstrick, A; Knipp, H; Meyer, HJ; Preusser, P; Stahl, M; Wilke, H, 1994) |
| " The radiation therapy dosage planned to the whole neck, nasopharynx, and supraclavicular area was 45 Gy in 24 daily fractions in 5 weeks, increasing to 60-70 Gy to the metastatic site." | 2.67 | Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study. ( Jeremic, B; Marinkovic, J; Matovic, M; Zivic, DJ, 1993) |
| "Clinical response to chemotherapy and observed toxic effects during chemotherapy." | 2.67 | Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer. ( Bajorin, D; Bosl, G; Harrison, L; Louison, C; Motzer, R; Pfister, DG; Scher, H; Shah, J; Strong, E, 1994) |
| "Patients with head and neck cancer who continue to smoke during radiation therapy have lower rates of response and survival than patients who do not smoke during radiation therapy." | 2.67 | Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. ( Browman, GP; Hodson, I; Levine, MN; McAlpine, L; Russell, R; Sathya, J; Skingley, P; Wong, G, 1993) |
| "Thirteen patients had squamous cell carcinoma and 8 adenocarcinoma." | 2.67 | Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon. ( Fell, S; Haynes, H; Kaleya, R; Katz, HJ; Rozenblit, A; Wadler, S; Wiernik, PH, 1993) |
| "IL 2 in advanced head and neck squamous cell carcinoma (HNSCC)." | 2.67 | Neo-adjuvant chemotherapy +/- immunotherapy with s.c. IL 2 in advanced squamous cell carcinoma of the head and neck: a pilot study. ( Bianchi, A; Curreli, L; Ghiani, M; Mantovani, G; Proto, E; Puxeddu, P; Santona, MC, 1994) |
| "The majority of patients with head and neck cancer die of locoregional recurrence of disease following surgery and/or radiotherapy." | 2.67 | Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. ( Haraf, DJ; McEvilly, JM; Mick, R; Panje, WR; Vokes, EE; Weichselbaum, RR, 1992) |
| "Twenty-eight patients with recurrent squamous carcinoma of the cervix not amenable to cure by further surgery or radiation therapy were entered into a Phase II trial utilizing i." | 2.67 | 5-fluorouracil and low-dose leucovorin in the treatment of recurrent squamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group. ( Blessing, JA; Look, KY; Malfetano, JH; Muss, HB; Partridge, EE, 1992) |
| "Forty Stage IV head and neck cancer patients were entered on a multimodality trial of induction chemotherapy (cisplatin + infusional 5-fluorouracil), surgery, and radiation." | 2.67 | Induction chemotherapy for advanced head and neck cancer: modification of response to chemotherapy by antiemetics. ( Ashayeri, E; Gumbs, RV; Myers, EM; Pressoir, R; White, RM, 1992) |
| "Twenty-eight patients with previously untreated Stage IV squamous cell carcinoma of the head and neck received 2 cycles of cisplatin 100 mg/m2 on day 1 followed by a 5-day continuous infusion of 5-FU at 800 mg/m2/day and 100 mg of leucovorin administered orally every 4 hours." | 2.67 | Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach. ( Clendeninn, NJ; Collier, MA; Goldman, MD; Haraf, DJ; Kozloff, MF; McEvilly, JM; Mick, R; Moran, WJ; Vokes, EE; Weichselbaum, RR, 1992) |
| "Thirty-nine patients with head and neck cancer were entered into Phase I-II study of simultaneous radiation therapy with continuous infusion fluorouracil at 800 mg/m2/day and escalating doses of hydroxyurea." | 2.67 | Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1991) |
| "Histology was squamous cell carcinoma in 6 patients and undifferentiated carcinoma in the remaining 33 patients." | 2.67 | Platinum-based chemotherapy followed by radiation therapy of locally advanced nasopharyngeal cancer. A retrospective analysis of 39 cases. ( Banis, K; Daniilidis, J; Dimitriadis, A; Fountzilas, G; Kalogera-Fountzila, A; Kosmidis, P; Makrantonakis, P; Nicolaou, A; Sombolos, K; Sridhar, KS, 1991) |
| "A prospective randomized trial in 64 esophageal cancer patients was conducted from 1986 to 1989." | 2.67 | [Randomized trial of combined chemotherapy including high dose cisplatin and radiotherapy for esophageal cancer]. ( Zhou, JC, 1991) |
| "59 patients with histological verified squamous cell carcinoma of the head and neck, 39 with primary disease and 20 with relapse were given carboplatin and 5-fluorouracil (5-FU) in escalated carboplatin doses." | 2.67 | Phase I/II study of carboplatin and 5-fluorouracil in patients with advanced head and neck carcinoma. ( Evensen, JF; Gundersen, S; Høst, H; Kaasa, S; Tausjø, J; Thorud, E; Wist, E, 1991) |
| "Eight patients with untreated squamous cell carcinoma of the esophagus accompanying distant metastases who were treated by one to five cycles of chemotherapy consisting of Cisplatin and 120 hour infusion of 5-Fluorouracil were reported." | 2.67 | [Combined radiotherapy and pre-radiation chemotherapy with cisplatin and 5-fluorouracil for advanced esophageal carcinoma. I. Clinical evaluation in cases with distant metastases]. ( Sueyama, H, 1990) |
| "AKs must be considered an early squamous cell carcinoma (SCC) for their probable progression into invasive SCC." | 2.66 | Current therapies for actinic keratosis. ( Conforti, C; Corneli, P; di Meo, N; Dianzani, C; Farinazzo, E; Giuffrida, R; Magaton Rizzi, G; Moret, A; Zalaudek, I, 2020) |
| "By histology, 22 cases were squamous cell carcinoma, 1 adenocarcinoma and 2 squamous adenocarcinoma." | 2.66 | [Preoperative chemotherapy of esophageal cancer]. ( Wang, ZY, 1986) |
| "The patients all had previously untreated squamous cell carcinoma of the head and neck (SCCHN)." | 2.66 | Sequential versus alternating chemotherapy and radiotherapy in stage III-IV squamous cell carcinoma of the head and neck: a phase III study. ( Benasso, M; Bonelli, L; Corvó, R; Gardin, G; Grimaldi, A; Margarino, G; Merlano, M; Rosso, R; Scarpati, D; Sertoli, MR, 1988) |
| "The histopathology of 54 squamous carcinomas of the head and neck was evaluated by qualitative grading and morphometry in order to identify those features which predicted a good response to cisplatinum chemotherapy." | 2.66 | Morphometric analysis, ploidy and response to chemotherapy in squamous carcinomas of the head and neck. ( Atkinson, MW; Cooke, LD; Cooke, TG; Helliwell, TR; Stell, PM, 1989) |
| " The dosage schedule was cisplatinum 100 mg/m2 D1 and 5-FU 1 g/m2 D1 to D5 every 3 weeks for 3 courses before evaluation." | 2.66 | [Results of a phase II study of the combination of cis-platinum and 5-FU in epidermoid or undifferentiated large cell bronchial cancer]. ( Abouz, D; Ayela, P; Berthaud, P; Frenay, M; Lagrange, JL; Le Chevalier, T; Pujol, JL; Rivière, A; Robillard, J, 1989) |
| " During the past eleven years, we have used postoperative chemotherapy in three ways over three different periods: in the earliest period, short-term combined chemotherapy (STCC) was used, in the middle period, intermittent long-term combined chemotherapy (ILTCC) was used in combination with immunotherapy for a randomized group, and in the latest period, when continuous long-term combined chemotherapy (CLTCC) with immunotherapy was employed." | 2.66 | [Clinical value of postoperative chemotherapy for non-small cell lung cancer--with special reference to long-term combined chemotherapy combined with immunotherapy]. ( Hashizume, Y; Ichihashi, T; Iida, S; Kimoto, H; Kobayashi, H; Sato, H; Shimizu, J; Tsunamura, Y; Watanabe, Y; Yamada, T, 1985) |
| "The eligible patients with an advanced head and neck cancer were paired off successively on the basis of the tumour site and the UICC stage." | 2.66 | Sequential trial of initial chemotherapy for advanced cancer of the head and neck. DDP versus DDP + 5-fluorouracil. ( Coninx, P; Garbe, E; Lebrun, D; Legros, M; Lucas, P; Nasca, S; Panis, X, 1988) |
| "In patients with Stage I-II squamous cell carcinoma of the lung without regional lymph node metastases the used regimen of combined therapy had no significant effect." | 2.66 | Combined treatment including postoperative chemotherapy in lung cancer patients. ( Amiraliev, MA; Barchuk, AS; Glagolev, AN; Grigoryeva, SP; Kovalev, VN; Malay, EF; Trakhtenberg, AKh; Vidyak, IV; Zakharchenkov, AV; Zhiglov, MA, 1988) |
| "Stomatitis was more frequent on the infusion arm but it was mild and reversible." | 2.66 | A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. ( Al-Sarraf, M; Cummings, G; Ensley, JF; Jacobs, J; Kish, JA; Weaver, A, 1985) |
| "Thirty-nine patients with previously untreated squamous cell carcinoma of the buccal mucosa were treated by two polychemotherapeutic regimens." | 2.65 | Polychemotherapy in squamous cell carcinoma of the buccal mucosa. ( Bannerjee, A; Dhawan, IK; Madan, NC; Sahoo, BK; Thakur, NS, 1983) |
| " day 1, 2, 23 and 24) was applied with the same schedule and dosage of radiation." | 2.65 | The value of two combined chemoradiotherapy approaches in the treatment of inoperable esophageal cancer. ( Dujmović, I; Kolarić, K; Roth, A, 1984) |
| "Among patients with primary head and neck cancer, the stage of the disease influenced the response rate." | 2.65 | Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer. ( Archibald, SD; Browman, GP; Hryniuk, WM; Kiehl, K; Levine, MN; Russell, R; Young, JE, 1983) |
| "In well differentiated squamous cell carcinoma, a marked positive effect was obtained in 48." | 2.65 | [Cooperative trials of the Council of Mutual Economic Aid countries on chemoradiotherapy of lung cancer]. ( Bidiak, IP; Kiseleva, ES; Pitskhelauri, VG; Trakhtenberg, AKh; Zholkiver, KI, 1984) |
| "Thirty patients with recurrent squamous cell carcinoma of the head and neck were treated with methotrexate (250 mg/m2) followed 1 hour later by 5-FU (600 mg/m2)." | 2.65 | Use of methotrexate and 5-FU for recurrent head and neck cancer. ( Jacobs, C, 1982) |
| " The polychemotherapy was given as a high dosage intermittent stosstherapy with 3 infusions at intervals of a week for 3 years." | 2.64 | [The combined treatment of bronchial carcinoma (author's transl)]. ( Karrer, K; Pridun, N, 1975) |
| "Cutaneous squamous cell carcinoma (SCC) is the second most common skin cancer." | 2.61 | Present and future perspectives of photodynamic therapy for cutaneous squamous cell carcinoma. ( Bhatta, AK; Keyal, U; Wang, XL; Zhang, G, 2019) |
| "Chemoprevention of nonmelanoma skin cancer should be considered in patients likely to develop numerous, invasive, or metastatic nonmelanoma skin cancers." | 2.61 | Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer. ( Council, ML; Nemer, KM, 2019) |
| "Differentiating a KA from a squamous cell carcinoma (SCC) is important for treatment implications but is often challenging." | 2.61 | Treatment of Solitary Keratoacanthoma of the Nose With Intralesional Methotrexate and Review of the Literature ( Doerfler, L; Hanke, CW, 2019) |
| "The predominant histological types of esophageal cancer are adenocarcinoma and squamous cell carcinoma." | 2.55 | Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma. ( Baba, H; Baba, Y; Maehara, Y; Nakashima, Y; Oki, E; Saeki, H; Shigaki, H; Watanabe, M; Yoshida, N, 2017) |
| " Management of these adverse effects is reviewed, as are future directions in anal cancer treatment and their impact on toxicity." | 2.55 | Evolution and Management of Treatment-Related Toxicity in Anal Cancer. ( Czito, BG; Kachnic, LA; Ludmir, EB, 2017) |
| "Nonmelanoma skin cancer (NMSC) is the most common cancer in patients and includes basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)." | 2.53 | Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies. ( Cherpelis, B; Rudnick, EW; Thareja, S, 2016) |
| "The incidence of cutaneous squamous cell carcinomas (SCCs) in immunosuppressed solid organ transplant recipients (SOTRs) is 65- to 250-fold greater than in the general population." | 2.53 | Cutaneous squamous cell carcinomas in solid organ transplant recipients: emerging strategies for surveillance, staging, and treatment. ( Cheng, J; Colegio, OR; Kim, C, 2016) |
| "Rectal squamous cell carcinoma is a rare tumour; it management should be based on anal curative and conservative intent chemoradiation." | 2.53 | [Rectal squamous cell carcinoma treatment: Retrospective experience in two French university hospitals, review and proposals]. ( Bosset, JF; Huguet, F; Loganadane, G; Schernberg, A; Servagi-Vernat, S; Touboul, E, 2016) |
| "In the UK, the standard of care for esophageal cancer has generally combined surgery with neoadjuvant chemotherapy, with definitive chemoradiotherapy (dCRT) being reserved for certain subgroups." | 2.52 | Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature. ( Cook, N; Gilligan, D; Hategan, M; Hindmarsh, A; Prewett, S; Qian, W, 2015) |
| "The majority of anal cancers are squamous cell carcinomas, and they are treated according to stage." | 2.52 | Anal cancer treatment: current status and future perspectives. ( Abdayem, P; Antoun, J; Ghosn, M; Kourie, HR; Nasr, D, 2015) |
| "When paclitaxel plus platinum was compared with platinum plus 5-fluorouracil, the hazard ratios (95% CrI) in the entire, squamous cell carcinoma, and adenocarcinoma population were 0." | 2.52 | Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer. ( Hsu, CH; Huang, TC; Lin, CC; Tu, YK, 2015) |
| "One of them was well differentiated tubular adenocarcinoma which occupied in mucosal layer." | 2.52 | Resection of a Submucosal Tumor-Like Superficial Carcinoma in Middle Thoracic Esophagus Concomitant with Mucosal Adenocarcinoma and Submucosal Squamous Cell Carcinoma: A Case Report and Review of Literature. ( Chino, O; Kazuno, A; Kumaki, N; Makuuchi, H; Ozawa, S; Sakai, I; Shimada, H; Tamayama, T; Yamamoto, S; Yasuda, S, 2015) |
| "Primary squamous cell carcinoma of the rectum is a rare malignancy." | 2.49 | Concurrent chemoradiotherapy for squamous cell carcinoma of the rectum. ( Jeong, BG; Kim, DY; Kim, SY, 2013) |
| "The treatment for esophageal squamous cell carcinoma (SCC) depends on its etiology." | 2.49 | Treatment options for esophageal squamous cell carcinoma. ( Kato, H; Nakajima, M, 2013) |
| "In head and neck squamous cell carcinoma (HNSCC), the inhibition of epidermal growth factor receptor (EGFR) signaling as a central step in carcinogenesis, progression, and metastasis is the predominant approach." | 2.49 | Molecular targeting agents in the context of primary chemoradiation strategies. ( Knecht, R; Laban, S; Münscher, A; Schafhausen, P; Tribius, S; Wang, CJ, 2013) |
| "Vulvar cancer is a relatively rare gynecological malignancy afflicting elderly women." | 2.48 | Radiation in vulvar cancer. ( Sharma, DN, 2012) |
| "Head and neck squamous cell carcinoma is now the 8th most common cancer affecting men in the United States largely due to a rising epidemic of oropharynx cancer (tonsil and tongue base) associated with the human papillomavirus (HPV)." | 2.48 | Current treatment options for metastatic head and neck cancer. ( Cohen, EE; Price, KA, 2012) |
| "The majority of patients with a squamous cell carcinoma of the head and neck present with locally advanced tumors." | 2.48 | Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature. ( Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N, 2012) |
| "Nonmelanoma skin cancer, which encompasses basal cell and squamous cell carcinoma, is the most common cancer in the United States." | 2.48 | Diagnosis and treatment of Basal cell and squamous cell carcinoma. ( Firnhaber, JM, 2012) |
| "With regard to squamous cell carcinoma, treatment with 5-fluorouracil, methotrexate, interferon, and bleomycin are reviewed." | 2.47 | Intralesional agents in the management of cutaneous malignancy: a review. ( Good, LM; High, WA; Miller, MD, 2011) |
| "The majority of the head and neck cancers are squamous cell carcinomas, which commonly overexpress the EGF receptor (EGFR)." | 2.47 | Cetuximab in the treatment of squamous cell carcinoma of the head and neck. ( Specenier, P; Vermorken, JB, 2011) |
| "Although anal canal squamous cell carcinoma is rare, the general practitioner should consider this diagnosis in a patient with persistent lower abdominal symptoms." | 2.47 | [Management of anal canal carcinoma]. ( Betz, M; Cochet, S; George, AC; Roth, A; Thang, NN, 2011) |
| "The management of low risk squamous cell carcinoma with topical therapies, photodynamic therapy, systemic retinoids, and capecitabine is reviewed." | 2.47 | Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. ( Brown, M; O'Reilly Zwald, F, 2011) |
| " A number of orally bioavailable tyrosine kinase inhibitors have been tested or are undergoing trials in SCCHN." | 2.47 | Management of recurrent head and neck cancer: recent progress and future directions. ( Brockstein, BE, 2011) |
| "We report a case with perianal squamous cell carcinoma, which showed a complete response more than five years after chemoradiotherapy." | 2.47 | [A case of perianal squamous cell carcinoma attaining a complete response over five years with chemoradiotherapy]. ( Imada, S; Ishikawa, O; Kishi, K; Miyashiro, I; Motoori, M; Nishiyama, K; Noura, S; Ohue, M; Shingai, T; Yano, M, 2011) |
| "The role of cisplatin in anal cancer is not completely clear, although an ongoing randomized trial (Anal Cancer Trial II) may help clarify the role of cisplatin." | 2.44 | Current treatment for localized anal carcinoma. ( Ajani, JA; Crane, CH; Das, P, 2007) |
| "Induction chemotherapy for squamous cell carcinoma of the head and neck has long been known to be highly active with tumor responses observed in a high percentage of patients." | 2.44 | Induction chemotherapy for head and neck squamous cell carcinomas (SCCHN). ( Kies, MS, 2007) |
| "Recurrent and metastatic squamous cell carcinoma of the head and neck still carries a poor prognosis." | 2.44 | Recurrent head and neck cancer: current treatment and future prospects. ( Specenier, PM; Vermorken, JB, 2008) |
| "Advanced squamous cell carcinomas of the oral cavity, oro-, hypopharynx and larynx often have to be categorised as non resectable disease." | 2.43 | [Decision making in non resectable head and neck tumours]. ( Dietz, A; Dollner, R; Hildebrandt, G; Weber, A, 2005) |
| "Patients with locally recurrent head and neck cancer previously treated with radiation have a poor prognosis." | 2.43 | Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? ( Li, Y; Machtay, M; Wong, SJ, 2006) |
| "Actinic keratosis is a precancerous lesion that is commonly seen in the elderly patient and requires treatment." | 2.43 | [Actinic keratosis]. ( Dissemond, J; Grabbe, S, 2006) |
| " The administration of the conventional dose of S-1 including dihydropyrimidine dehydrogenase (DPD), an metabolic inhibitor of 5-FU, results in exceeding the critical plasma concentration of 5-FU, and the long-term administration with high plasma concentration of 5-FU is considered to show clinical effectiveness in head and neck cancer." | 2.43 | [Clinical efficacy of administration with S-1 alone for head and neck carcinoma]. ( Horiuchi, C; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Toth, G; Tsukuda, M; Yoshida, T, 2006) |
| "Patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) are often treated with induction chemotherapy or chemoradiotherapy, but to date without major impact on survival." | 2.42 | Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. ( Lefebvre, JL; Posner, MR, 2003) |
| "The systemic therapy of head and neck cancer has gained momentum in recent years." | 2.42 | Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. ( Argiris, A; Haraf, DJ; Kies, MS; Vokes, EE, 2003) |
| "No case of epidermoid (squamous cell) cancer of the colon has been previously described in a pregnant woman." | 2.42 | [Colon cancer in pregnancy]. ( Fermeaux, V; Mathonnet, M, 2003) |
| "Actinic keratosis is currently believed to be an early stage in the evolution of squamous cell carcinoma." | 2.42 | Topical and light-based treatments for actinic keratoses. ( Alam, M; Goldberg, LH; Silapunt, S, 2003) |
| "Case 2: A 74-year-old female with anal squamous cell carcinoma Stage II was treated by chemoradiotherapy with tegafur/uracil, external irradiation (30 Gy) and interstitial irradiation (24 Gy)." | 2.42 | [Effectiveness of chemoradiotherapy for three cases of squamous cell anal carcinoma]. ( Fujitani, K; Hirao, M; Ikenaga, M; Kashiwazaki, M; Masuda, N; Mishima, H; Sawamura, T; Takeda, Y; Takeno, A; Tsujinaka, T, 2004) |
| "During the past two decades, anal cancer has served as a paradigm for the successful application of chemoradiation to solid tumours; so far, it remains one of the few carcinomas of the gastrointestinal tract which are curable without the need for definitive surgery." | 2.42 | Chemotherapeutic options in the management of anal cancer. ( Allal, AS; Gervaz, P; Morel, P; Roth, A, 2004) |
| "Actinic keratoses are superficial squamous cell carcinomas." | 2.42 | Optimum treatment strategies for actinic keratosis (intraepidermal squamous cell carcinoma). ( Fenske, NA; Lober, BA, 2004) |
| "Standard treatment for squamous cell carcinomas in the head and neck consists of surgery and/or radiotherapy." | 2.41 | [Recent regimen of chemotherapy for advanced head and neck carcinomas]. ( Tsukuda, M, 2000) |
| "Mitomycin C and 5 FU were delivered on weeks 1 and 5 of the irradiation." | 2.41 | [Radiochemotherapy in anal canal epidermoid cancer]. ( Peiffert, D, 2000) |
| "For head and neck cancer, a recent meta-analysis of published randomized trial results showed that concurrent chemoradiotherapy, adjuvant chemotherapy and neoadjuvant chemotherapy may increase absolute survival by 12." | 2.41 | [Role of Chemotherapy in head and neck cancer]. ( Kitahara, S; Kohno, N, 2001) |
| "Cases with head and neck squamous cell carcinoma (HNSCC) have clinically advanced tumors." | 2.41 | [Preoperative chemotherapy for patients with advanced head and neck cancer]. ( Tsukuda, M, 2001) |
| "An integrated program of skin cancer awareness, sun protection, and prophylactic approaches is critical." | 2.41 | Nonmelanoma skin cancer. ( Ho, DQ; Nguyen, TH, 2002) |
| "Traditionally, the most accepted treatment of vulvar cancer has been and continues to be surgery." | 2.41 | Recurrent vulvar cancer. ( Penalver, M; Salom, EM, 2002) |
| "Both protocols are responsive to squamous cell carcinoma of the head and neck." | 2.40 | [Head and neck cancer]. ( Fukuda, S; Inuyama, Y; Satoh, N, 1997) |
| "At diagnosis of head and neck cancer, over half of all patients show advanced stages." | 2.40 | [Chemoradiotherapy for patients with advanced head and neck cancer]. ( Tsukuda, M, 1997) |
| "The majority of these cases were anal cancers with proximal extension into the rectum and were excluded." | 2.40 | Squamous-cell carcinoma of the colon responsive to combination chemotherapy: report of two cases and review of the literature. ( Francis, B; Juturi, JV; Koontz, PW; Wilkes, JD, 1999) |
| "Five-year survival rates were 57% for squamous cell carcinoma, 63% for adenocarcinoma, and 33% for melanoma." | 2.40 | Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. ( Klas, JV; Madoff, RD; Rothenberger, DA; Wong, WD, 1999) |
| "We present an additional case of rectal squamous cell carcinoma (SCC) complicating chronic ulcerative colitis in a 33-year-old woman who had the disease for 15 years." | 2.39 | Squamous cell carcinoma complicating idiopathic inflammatory bowel disease. ( Butler, B; Doerr, R; Kulaylat, MN; Satchidanand, SK; Singh, A, 1995) |
| "The standard chemotherapy of squamous cell carcinomas of the head and neck is cisplatin and 5-FU." | 2.39 | [A critical consideration of the combined radiochemotherapy of head and neck tumors]. ( Hainz, A; Schlappack, O; Springer, B, 1994) |
| "Eighty percent of the patients had squamous cell carcinoma and 20% had adenocarcinoma." | 2.39 | Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. ( Bates, BA; Bernard, SA; Detterbeck, FC; Qaqish, BF; Tepper, JE, 1996) |
| "The implantation of cervical cancer in an episiotomy scar is very rare." | 2.38 | Squamous cell carcinoma of the cervix implanting in the episiotomy site. ( Issa, PY; Khalil, AM; Khatib, RA; Mufarrij, AA; Tawil, AN, 1993) |
| "A patient was diagnosed by biopsy and treated for squamous cell carcinoma in situ of the scrotum." | 2.38 | Paget's disease of the scrotum: a case report and review of current literature. ( Boman, DA; Dudrey, EF; Moliver, CL; Morales, CA; Reedy, MB, 1991) |
| "Among studies in recurrent head and neck cancer, the most effective chemotherapy regimens appear to be variations of the program consisting of cisplatin followed by a 5-day infusion of 5-fluorouracil." | 2.38 | Current chemotherapy of head and neck cancer. ( Amrein, P, 1991) |
| "Dystrophic epidermolysis bullosa is associated with a high incidence of cutaneous squamous cell carcinoma." | 2.38 | Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy. ( Lentz, SR; Marion, JM; Orlowski, EP; Raish, RJ, 1990) |
| "Thirteen patients with previously untreated advanced squamous cell carcinoma of the esophagus were treated with pre-radiation chemotherapy followed by radiation therapy." | 2.38 | [Combined radiotherapy and pre-radiation chemotherapy with cisplatin and 5-fluorouracil for advanced esophageal carcinoma. II. Clinical evaluation in cases with higher than T2 stage]. ( Sueyama, H, 1990) |
| "Oral squamous cell carcinoma in situ has been described as a relatively rare lesion." | 2.38 | Management of oral squamous cell carcinoma in situ with topical 5-fluorouracil and laser surgery. ( Headington, JT; Maxson, BB; Scott, RF, 1989) |
| "This paper presents an overview of studies of therapy of head and neck squamous cell carcinoma in which chemotherapy was combined with other modalities." | 2.35 | Current concepts of chemotherapy combined with other modalities for head and neck cancer. ( DeWys, WD, 1975) |
| " In this study, we report the safety and efficacy of cetuximab (an epidermal growth factor receptor inhibitor) in combination with 5-FU plus irinotecan based chemotherapy." | 1.91 | Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma. ( Boige, V; Boilève, A; Cervantes, B; Ducreux, M; Hollebecque, A; Malka, D; Smolenschi, C; Valery, M, 2023) |
| "Anal cancer is a rare form of gastrointestinal malignancy, and treatment is often confined to specialist centres." | 1.91 | Concurrent Chemo-radiotherapy in Anal Squamous Cell Carcinoma: A Retrospective Review of a Tertiary Centre Experience. ( Elmasry, A; Giridharan, S; Patel, C, 2023) |
| "Anal squamous cell carcinoma (ASCC) is an uncommon tumor." | 1.91 | Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation. ( Fukuya, A; Kagemoto, K; Kawaguchi, T; Mitsui, Y; Miyamoto, H; Noda, K; Okamoto, K; Sato, Y; Takayama, T; Yamasaki, M, 2023) |
| "International guidelines regarding the treatment of squamous cell carcinoma of the anus (SCCA) recommend intensity-modulated radiotherapy (IMRT) combined with mitomycin-based chemotherapy (CT)." | 1.91 | Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE. ( Baba-Hamed, N; Crehange, G; Diaz, O; Drouet, F; Hautefeuille, V; Hummelsberger, M; Larrouy, A; LE Malicot, K; Lemanski, C; Lepage, C; Lievre, A; Menager-Tabourel, E; Minsat, M; Mornex, F; Peiffert, D; Pommier, P; Quero, L; Regnault, P; Rivin Del Campo, E; Ronchin, P; Saint, A; Tougeron, D; Vendrely, V; Zasadny, X, 2023) |
| "The clinical diagnosis was squamous cell carcinoma of the lower rectum, cT4b(bladder and seminal vesicle)N0M0, cStage Ⅱc." | 1.91 | [A Case of Squamous Cell Carcinoma of the Lower Rectum]. ( Doki, Y; Eguchi, H; Hata, T; Miyoshi, N; Ogino, T; Osaki, M; Sakai, D; Satoh, T; Sekido, Y; Takahashi, H; Uemura, M, 2023) |
| "The treatment of oral squamous cell carcinoma (OSCC) includes systemic chemotherapy and is associated with aggressive side effects on patients." | 1.91 | A novel intra-tumoral drug delivery carrier for treatment of oral squamous cell carcinoma. ( Aboushelib, MN; Al-Wakeel, E; Badawi, MF; Elsaady, SA, 2023) |
| "Although rare, the rate of squamous cell carcinoma of the anus (SCCA) is rising globally." | 1.72 | Current treatment and future directions in the management of anal cancer. ( Eng, C; Hong, TS; Kachnic, LA; Ludmir, EB; Messick, CA; Tchelebi, LT; Zaorsky, NG, 2022) |
| "5‑fluorouracil (5‑FU) is a commonly used treatment for OSCC, but cells typically display resistance to the drug." | 1.72 | Propofol induces apoptosis and ameliorates 5‑fluorouracil resistance in OSCC cells by reducing the expression and secretion of amphiregulin. ( Che, PC; Chen, JC; Chen, MS; Hsieh, MJ; Lee, IN; Wu, YP; Yang, KS, 2022) |
| "Our results suggest IMRT-based CRT with concurrent fluoropyrimidine and cisplatin is a safe and feasible option for patient with SCCA and may cause less acute toxicity." | 1.72 | Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. ( Bednarski, BK; Chang, GJ; Das, P; Delclos, ME; Eng, C; Holliday, EB; Jennings, K; Johnson, B; Koay, EJ; Koong, AC; Ludmir, EB; Messick, CA; Minsky, BD; Morris, VK; Rodriguez-Bigas, MA; Skibber, JM; Smith, GL; Taniguchi, C; Tillman, MM; You, YN, 2022) |
| "Non-melanoma skin cancer (NMSC) is the most common malignancy worldwide, with rising incidence in the recent years." | 1.72 | In vitro 5-Fluorouracil resistance produces enhanced photodynamic therapy damage in SCC and tumor resistance in BCC. ( Gilaberte, Y; González, S; Gutiérrez-Pérez, M; Juarranz, Á; Nicolás-Morala, J; Portillo-Esnaola, M; Terrén, S, 2022) |
| "Primary squamous cell carcinoma (SCC) of the liver is a rare disease that is difficult to diagnose until the pathology is confirmed." | 1.72 | Primary Squamous Cell Carcinoma of the Liver with Good Response to Carboplatin and 5-Flurouracil: A Case Report. ( Chen, LM; Chien, LY; Fu, CK; Lee, HL, 2022) |
| "Twenty-five patients with squamous cell carcinoma of the anal canal were treated at our centre from 2012 to 2019 using IMRT based chemoradiation." | 1.72 | Outcomes of Squamous Cell Carcinoma Anal Canal treated with IMRT-VMAT-based Concurrent Chemoradiation: a Single Institutional Experience. ( Ram, TS; Ramireddy, JK; Sathyamurthy, A; Singh, K, 2022) |
| "Anal cancer is a rare disease that has doubled in incidence over the last four decades." | 1.62 | Molecular and genomic characterisation of a panel of human anal cancer cell lines. ( Behrenbruch, CC; Bernardi, MP; Chittleborough, TJ; Di Costanzo, N; Guerra, GR; Hawkes, D; Haynes, NM; Heriot, AG; Kong, JC; Liu, DS; Lupat, R; Millen, RM; Mitchell, C; Ngan, SY; Phillips, WA; Ramsay, RG; Read, M; Roth, S; Sampurno, S; Sia, J; Teh, J; Tothill, RW; Xu, H; Yu, J, 2021) |
| "To evaluate the efficacy and safety of ultrasound hyperthermia combined with TPF chemotherapy for advanced oral squamous cell carcinoma in the elderly." | 1.62 | [Analysis of curative effect of ultrasonic hyperthermia combined with TPF chemotherapy on 19 elderly with advanced oral squamous cell carcinoma]. ( Ge, LY; Gu, QP; Li, L; Li, XD; Li, ZP; Meng, J; Zhuang, QW, 2021) |
| " Fifty percent of patients reported Common Terminology Criteria for Adverse Events v5." | 1.62 | Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity. ( Aydin, AM; Chahoud, J; Cheryian, SK; Hajiran, A; Pow-Sang, JM; Spiess, PE; Zemp, L, 2021) |
| "Anal squamous cell carcinoma has rarely been reported in the setting of ulcerative colitis." | 1.62 | Anal Squamous Cell Carcinoma in Ulcerative Colitis: Can Pouches Withstand Traditional Treatment Protocols? ( Click, B; Hull, TL; Lightner, AL; McMichael, J; Regueiro, M; Steele, SR; Vaidya, P, 2021) |
| "Currently, no disease recurrence, dysphagia, or respiratory symptoms have been reported at 13 months after initiating chemoradiotherapy." | 1.56 | Adaptive radiotherapy in locally advanced esophageal cancer with atelectasis: a case report. ( Fujii, K; Mizowaki, T; Sakanaka, K, 2020) |
| "The objectives of this study were to evaluate survival in 141 patients with stage II-IV oral squamous cell carcinoma (OSCC) treated with preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil (IADCPIVF) via the superficial temporal artery, and to clarify the prognostic factors." | 1.56 | Preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil for oral squamous cell carcinoma. ( Endo, M; Hasegawa, H; Kaneko, T; Kanno, C; Kano, M; Kitabatake, T; Monma, T; Sato, E; Takeishi, E; Yamazaki, M, 2020) |
| "Introduction: Standard of care for squamous cell carcinoma (SCC) is usually surgical, with either excision or Mohs micrographic surgery." | 1.56 | Combination Topical Chemotherapy for the Treatment of an Invasive Cutaneous Squamous Cell Carcinoma ( Fayne, R; Nanda, S; Nichols, A; Shen, J, 2020) |
| "We demonstrated in this study that dose escalation using IMRT in combination with platin-based chemotherapy as a definitive treatment for esophageal carcinoma is safe and results in higher loco-regional and control survival when compared to previously reported data." | 1.56 | Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients. ( Carrère, N; Dalmasso, C; Guimbaud, R; Izar, F; Lusque, A; Modesto, A; Moyal, E; Rives, M; Vieillevigne, L, 2020) |
| "Laryngeal squamous cell carcinoma (LSCC) is a common head and neck cancer that is unresponsive to chemotherapy; therefore, understanding the causes of chemotherapy resistance is important." | 1.56 | ( Chen, B; Ding, Y; Fan, J; Gao, W; Nan, X; Wang, B; Wang, J; Wen, S; Wu, Y; Zhao, Q, 2020) |
| "Patients with esophageal cancer treated with dCRT between January 2004 and November 2016 were included in this retrospective analysis." | 1.56 | Definitive chemoradiotherapy for squamous cell carcinoma of the esophagus: outcomes for borderline-resectable disease. ( Ishikura, S; Kondo, T; Miyakawa, A; Murai, T; Ozawa, Y; Shibamoto, Y; Sugie, C; Yanagi, T, 2020) |
| "Definitive chemoradiation for anal cancer is effective but may be associated with toxic effects, and some patients may not be able to complete the planned treatment." | 1.56 | Factors Associated With Chemoradiation Therapy Interruption and Noncompletion Among Patients With Squamous Cell Anal Carcinoma. ( Booth, CM; Brogly, SB; Hanna, TP; Kalyvas, M; Ko, G; Li, W; Patel, SV; Raphael, MJ, 2020) |
| "Resistance of laryngeal squamous cell carcinoma cells to traditional therapeutic regimens still remains to be a major reason for therapeutic failure in patients." | 1.56 | Expression profile of stem cell markers and ABC transporters in 5-fluorouracil resistant Hep-2 cells. ( Duz, MB; Karatas, OF, 2020) |
| "Acute hematotoxicity (G3, 4, 5 according to Common Terminology Criteria for Adverse Events - CTCAE) was significantly associated with the concomitant chemoradiotherapy (P = 0." | 1.56 | Haematotoxicity in IMRT/VMAT curatively treated anal cancer. ( Drbohlavová, T; Jirkovská, M; Lohynská, R; Malinová, B; Mazaná, E; Nýdlová, A; Stankušová, H; Veselský, T, 2020) |
| "Definitive chemoradiotherapy(CRT)for esophageal cancer is the standard treatment and alternative to surgery." | 1.56 | [Tolerability of Definitive Chemoradiotherapy in Elderly Patients with Esophageal Cancer]. ( Asagi, A; Hamamoto, Y; Hasebe, A; Hino, K; Hori, S; Inoue, T; Kajiwara, T; Kataoka, M; Nadano, S; Nakasya, A; Nishide, N; Nishina, T; Sakaguchi, C; Tanimizu, M; Terao, T; Yoshimatsu, M, 2020) |
| "Subconjunctival/perilesional 5-fluorouracil injections are an effective and safe treatment for OSSN." | 1.56 | Long-Term Efficacy and Safety of Subconjunctival/Perilesional 5-Fluorouracil Injections for Ocular Surface Squamous Neoplasia. ( Hua, R; Sun, Y, 2020) |
| "Metastatic squamous cell carcinomas (SCC) of the anal canal are rare and there is no international consensus on their second-line management." | 1.51 | Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal. ( Benezery, K; Cavaglione, G; Evesque, L; Falk, AT; Francois, E; Montagne, L; Saint, A, 2019) |
| "For 70 women with anal cancer treated at our department, acute and chronic side effects and quality of life (QoL) were evaluated with questionnaires using the Common Terminology Criteria for Adverse Events (CTCAE v." | 1.51 | Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects. ( Adeberg, S; Debus, J; Haefner, MF; Herfarth, K; Koerber, SA; Krug, D; Liermann, J; Seither, B; Slynko, A; Sterzing, F, 2019) |
| "Oropharyngeal and esophageal squamous cell carcinomas, especially the latter, are a lethal disease, featuring intratumoral cancer cell heterogeneity and therapy resistance." | 1.51 | Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells. ( Arigami, T; Avadhani, NG; Bass, AJ; Basu, D; Chandramouleeswaran, PM; Diehl, JA; Doki, Y; Ginsberg, GG; Giroux, V; Hara, T; Kasagi, Y; Kijima, T; Kikuchi, O; Kita, Y; Klein-Szanto, AJ; Mori, M; Muir, AB; Muto, M; Naganuma, S; Nakagawa, H; Natsugoe, S; Ohashi, S; Omoto, I; Rustgi, AK; Sahu, V; Sasaki, K; Shimonosono, M; Shinden, Y; Tanaka, K; Uchikado, Y; Whelan, KA, 2019) |
| "Distant metastases (DM) are a leading cause of death for patients with oropharyngeal cancer (OPSCC)." | 1.51 | The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting. ( Griffiths, RJ; Hall, SF; Liu, FF; O'Sullivan, B, 2019) |
| "Actinic keratoses (AKs) and squamous cell carcinoma in situ (SCCIS) are precursor lesions for cutaneous squamous cell carcinoma (cSCC), the second most common form of cancer." | 1.51 | Topical kinase inhibitors induce regression of cutaneous squamous cell carcinoma. ( Beer, J; D'Armas, S; Daifallah, AEM; Dentchev, T; Farag, AM; Hahn, J; Lee, V; Marshall, C; Sabry, HH; Seykora, F; Seykora, JT; Shankar, S; Yang, X, 2019) |
| "Long-term outcomes of older esophageal cancer patients (70 y and above) selected for treatment with neoadjuvant chemoradiotherapy followed by surgery or definitive chemoradiotherapy were comparable with the outcomes of their younger counterparts." | 1.48 | Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer. ( Aleman, BMP; Grootscholten, C; Sikorska, K; Snaebjornsson, P; van der Kaaij, RT; van Dieren, JM; van Sandick, JW; van Werkhoven, E; Voncken, FEM, 2018) |
| "Patients with oral squamous cell carcinoma were enrolled." | 1.48 | Influence of a dosing-time on toxicities induced by docetaxel, cisplatin and 5-fluorouracil in patients with oral squamous cell carcinoma; a cross-over pilot study. ( Ando, H; Fujimura, A; Hayasaka, JI; Jinbu, Y; Kusama, M; Mori, Y; Noguchi, T; Okada, N; Tsuchiya, Y; Ushijima, K, 2018) |
| "Ninety-seven patients with oral squamous cell carcinoma, treated preoperatively with radiotherapy in combination with chemotherapy or cetuximab, were included in this retrospective analysis." | 1.48 | P16 positivity and regression grade predict survival after neoadjuvant radiotherapy of OSCC. ( Eder-Czembirek, C; Fuereder, T; Selzer, E; Sulzbacher, I, 2018) |
| "Myocardial metastasis for esophageal squamous cell carcinoma(ESCC)is relatively rare and it is diagnosed as a part of widespread metastasis in the terminal stage." | 1.48 | [A Case of Myocardial Metastasis of Esophageal Squamous Cell Carcinoma]. ( Akaishi, T; Hakamada, K; Mitsuhashi, Y; Muroya, T; Sato, K; Suzuki, T; Tsuruta, S; Umemura, K; Umetsu, S; Wajima, N; Wakasa, Y; Yachi, T; Yoshida, T, 2018) |
| "In the present study, human primary oral squamous carcinoma cells treated with cisplatin and 5-fluorouracil were analyzed, for the first time, by in vitro FTIR Microspectroscopy (FTIRM), to improve the knowledge on the biochemical pathways activated by these two chemotherapy drugs." | 1.48 | In vitro FTIR microspectroscopy analysis of primary oral squamous carcinoma cells treated with cisplatin and 5-fluorouracil: a new spectroscopic approach for studying the drug-cell interaction. ( Bedolla, DE; Conti, C; Giorgini, E; Mitri, E; Notarstefano, V; Orilisi, G; Rocchetti, R; Rubini, C; Sabbatini, S; Vaccari, L, 2018) |
| "Human papillomavirus-associated oropharyngeal cancer was associated with a significant improved overall survival, locoregional, distant and overall tumor control rates in multivariate analysis." | 1.48 | Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer". ( Baumeister, P; Belka, C; Ganswindt, U; Hess, J; Kirchner, T; Macht, C; Maihoefer, C; Pflugradt, U; Schneider, L; Schüttrumpf, L; Walch, A; Woischke, C; Zitzelsberger, H, 2018) |
| " Patient acute gastrointestinal toxicity was recorded using Common Terminology Criteria of Adverse Events (CTCAE) diarrhoea grading." | 1.48 | Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes. ( Amor, H; Blakey, D; Chao, M; Guerrieri, M; Guiney, M; Ho, H; Macleod, C; Melven, L; Ng, M; Skelton, J; Subramanian, B, 2018) |
| "The change in the dysphagia score from before to after treatment was assessed, and NSFS was evaluated." | 1.48 | Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia. ( Karasawa, K; Kawamoto, T; Nihei, K; Sasai, K, 2018) |
| "Esophageal squamous cell carcinoma (ESCC) exhibits good reactivity to chemoradiation therapy (CRT)." | 1.48 | Correlation between high FBXW7 expression in pretreatment biopsy specimens and good response to chemoradiation therapy in patients with locally advanced esophageal cancer: A retrospective study. ( Baatar, S; Gombodorj, N; Kumakura, Y; Kuriyama, K; Kuwano, H; Miyazaki, T; Nishiyama, M; Sakai, M; Shirabe, K; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T; Yoshida, T, 2018) |
| "Non-melanoma skin cancer (NMSC) is the most commonly diagnosed cancer in the United States." | 1.48 | Intralesional 5-Fluorouracil in the Treatment of Lower Leg Squamous Cell Carcinoma ( Mackey, M; Mackey, VT; Shahsavari, A, 2018) |
| "Esophageal squamous cell carcinoma (ESCC) is the second common cancer in Henan province and is well-known for aggressiveness and dismal prognosis." | 1.46 | All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma. ( Cui, H; Li, D; Li, N; Li, S; Lian, J; Lu, T; Lu, Y; Sang, L; Wang, Y; Yu, JJ; Zhang, L; Zheng, X, 2017) |
| "Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers in the world." | 1.46 | Ectopic overexpression of CD133 in HNSCC makes it resistant to commonly used chemotherapeutics. ( Hyun, H; Kim, B; Kim, D; Kim, O; Ko, Y; Lee, J; Lim, W; Moon, YL; Park, M; Sohn, H, 2017) |
| "Esophageal squamous cell carcinoma (ESCC) accounts for 80% of all esophageal cancers worldwide." | 1.46 | EGFR Expression in Patients with Esophageal Squamous Cell Carcinoma and its Association with Pathologic Response to Preoperative Chemoradiotherapy: A Study in Northeastern Iran. ( Abdollahi, A; Aledavoud, SA; Anvari, A; Anvari, K; Forghani, MN; Ghaffarzadegan, K; Memar, B; Seilanian Toussi, M; Shahidsales, S; Sima, HR, 2017) |
| "The responsiveness of head and neck squamous cell carcinoma (HNSCC) to chemotherapy widely affects prognosis." | 1.46 | Livin enhances chemoresistance in head and neck squamous cell carcinoma. ( Chung, IJ; Joo, YE; Kim, SA; Lee, DH; Lee, JK; Lee, KH; Lim, SC; Park, YL; Yoon, TM, 2017) |
| "Esophageal cancer is the eighth most common cancer worldwide." | 1.46 | Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience. ( Chen, Y; Hao, D; He, C; Liu, J; Wang, J; Wang, W; Wu, X; Xing, W; Yang, Y, 2017) |
| "Grade 3-4 neutropenia was seen in 10/23 patients (43%)." | 1.46 | PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. ( Beer, J; Bodis, S; Oehler, C; Vlachopoulou, V; von Moos, R; Zimmermann, M; Zwahlen, DR, 2017) |
| "Stage IV squamous cell carcinoma of the anus outcomes are poor, but first-line chemotherapy can enable good response rates." | 1.46 | Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience. ( Benezery, K; Cavaglione, G; Doyen, J; Evesque, L; Follana, P; François, E; Reure, J; Tuan Falk, A, 2017) |
| "We report a case of perianal squamous cell carcinoma and left inguinal lymph node metastasis that showed a complete response more than 5 years after chemotherapy and concomitant proton beam therapy." | 1.46 | [A Case of Perianal Squamous Cell Carcinoma with Left Inguinal Lymph Node Metastasis That Showed a Complete Response More Than Five Years after Chemotherapy and Concomitant Proton Beam Therapy]. ( Abe, T; Azami, A; Honda, M; Nakamura, T; Sato, A; Suzuki, N; Tada, T; Takano, Y; Teranishi, Y; Todate, Y; Waragai, M, 2017) |
| "The wool hydrolysates decreased squamous cell carcinoma cells viability by up to 67% comparing to untreated cells." | 1.46 | The effect of wool hydrolysates on squamous cell carcinoma cells in vitro. Possible implications for cancer treatment. ( Borkowska, JK; Czuwara, J; Damps, T; Konop, M; Kowalkowski, T; Laskowska, AK; Misicka, A; Prokopowicz, M; Puszko, AK; Różycki, K; Rudnicka, L; Sosnowski, P, 2017) |
| "Of 216 stage IIIB cervical cancer patients, 114 of them had no LTI and 72 had LTI." | 1.46 | Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion. ( Katanyoo, K, 2017) |
| "The FBXW7 expression patterns in oral squamous cell carcinoma and adjacent normal tissues from 15 patients who underwent radical resection were evaluated using quantitative real-time polymerase chain reaction and immunohistochemical staining." | 1.46 | FBXW7 expression affects the response to chemoradiotherapy and overall survival among patients with oral squamous cell carcinoma: A single-center retrospective study. ( Arita, H; Hiraki, A; Hirosue, A; Kawahara, K; Kojima, T; Matsuoka, Y; Murakami, R; Nagata, M; Nakashima, H; Nakayama, H; Sakata, J; Shinohara, M; Toya, R; Yoshida, R, 2017) |
| "Penile squamous cell carcinoma (pSCC) is a relatively rare disease in Western world but is a significant health problem in developing countries like India." | 1.46 | Successful downstaging of locally recurrent penile squamous cell carcinoma with neoadjuvant nanosomal docetaxel lipid suspension (NDLS) based regimen followed by curative surgery. ( Bunger, D; Gupta, S; Pawar, SS, 2017) |
| "Esophageal squamous cell carcinoma is a highly aggressive neoplasm and the sixth leading cause of global cancer-related death; the 5-year survival rate for esophageal cancer is only about 20%-25% for all stages." | 1.46 | Low-dose hyperthermia enhances the antitumor effects of chemotherapy in squamous cell carcinoma. ( Akutsu, Y; Hanari, N; Hu, X; Kano, M; Matsubara, H; Matsumoto, Y; Murakam, K; Otsuta, R; Qin, W; Suganami, A; Suito, H; Takahashi, M; Tamura, Y; Usui, A, 2017) |
| "Topical chemotherapy of skin cancers is a promising strategy for reduction of side effects and for improvement of patient compliance." | 1.46 | Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells. ( Eloy, JO; Lee, RJ; Lopez, RF; Petrilli, R, 2017) |
| "5-Fluorouracil (5-FU) is an essential chemotherapeutic agent for oral squamous cell carcinoma (OSCC)." | 1.46 | Synergistic effect of honokiol and 5-fluorouracil on apoptosis of oral squamous cell carcinoma cells. ( Chen, F; Chen, Q; Deng, P; Feng, M; Ji, N; Jiang, L; Li, J; Li, L; Liao, G; Lin, Y; Liu, J; Xu, H; Zeng, X, 2017) |
| "The involvement of S-1 chemotherapy in ATLL development suggests that a test for HTLV-1 antibody should be performed before treatment and that S-1 should not be administered in HTLV-1 positive patients with head and neck carcinoma." | 1.46 | Adult T-cell leukemia/lymphoma in patients with head and neck cancer after S-1 chemotherapy. ( Kurono, Y; Matushita, K; Nagano, H, 2017) |
| "Cotreatment with celecoxib and 5-FU partially blocked AKT phosphorylation, although no significant changes in total AKT protein levels were detected." | 1.46 | Celecoxib enhances the inhibitory effect of 5-FU on human squamous cell carcinoma proliferation by ROS production. ( Ahn, SH; Choi, JJ; Kim, YH; Kwon, SK; Lee, DY; Oh, SM; Park, SW; Shin, ES; Sung, MW, 2017) |
| "We analyzed data of mspHNSCC patients collected from the Taiwan Cancer Registry database." | 1.46 | Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma. ( Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS, 2017) |
| "Twenty esophageal cancer patients receiving chemotherapy with 5-fluorouracil plus cisplatin were assigned randomly to one of the following two groups: (1) receiving elemental diet with Elental (one pack per day) for 14 days and (2) not receiving Elental during chemotherapy." | 1.46 | A prospective study of nutritional supplementation for preventing oral mucositis in cancer patients receiving chemotherapy. ( Hoshino, A; Kawada, K; Kawano, T; Miyawaki, Y; Nagai, K; Nakajima, Y; Nishikage, T; Okada, T; Ryotokuji, T; Tokairin, Y, 2017) |
| "Advanced stage squamous cell carcinoma of the head and neck carries an overall poor prognosis, and survivorship gains have remained relatively stagnant compared to other malignancies due to its complex tumor biology and lack of proven effective targeting agents." | 1.46 | Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma. ( Bhandari, M; Jones, RG; Kang, SY; Seim, NB; Teknos, TN, 2017) |
| "50 patients with advanced esophageal cancer were treated with a continuous infusion of CF, 5-FU, and CDDP, and the short-term effects, adverse reactions, and survival periods after treatment were analyzed." | 1.46 | Continuous infusion of a large dose of CF (folinic acid) and 5-FU combined with CDDP in the treatment of advanced esophageal cancer. ( Cai, HX; Zhu, ZA; Zhu, ZQ, 2017) |
| "Type of esophageal cancer was adenocarcinoma in 213 patients (80%) and squamous cell carcinoma in 46 patients (17%)." | 1.43 | Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience. ( Bhatia, S; Martenson, JA; Miller, RC; Quevedo, JF; Schomas, DA; Sio, TT; Stauder, MC; Wilson, ZC, 2016) |
| "In recurrent head and neck squamous cell carcinoma ineligible for resection or irradiation, treatment aims primarily at symptom control and quality of life enhancement with an expected outcome of 6-12 months." | 1.43 | Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab. ( Carp, L; Corthouts, B; Specenier, P; Szturz, P; Van Den Weyngaert, D; Van Laer, C; Van Marck, E; Vanderveken, O; Vermorken, JB, 2016) |
| "Globally, head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer and represents approximately 6% of all diagnosed cancers." | 1.43 | Combinatorial Effects of Curcumin with an Anti-Neoplastic Agent on Head and Neck Squamous Cell Carcinoma Through the Regulation of EGFR-ERK1/2 and Apoptotic Signaling Pathways. ( Krishnan, UM; Sethuraman, S; Sivanantham, B, 2016) |
| "Esophageal squamous cell carcinoma (ESCC) contains genomic alterations of undefined clinical significance." | 1.43 | Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China. ( Bi, Y; Chen, X; Chen, Y; Cheng, C; Cheng, X; Cui, H; Cui, Y; Guo, J; Guo, S; Hu, X; Jia, J; Jia, Z; Kong, P; Li, G; Li, H; Li, Q; Li, Y; Liang, J; Liu, H; Liu, J; Qian, Y; Shi, R; Song, B; Wang, C; Wang, F; Wang, J; Wang, T; Xi, Y; Xu, E; Yan, T; Yang, B; Yang, J; Zhan, Q; Zhang, L; Zhang, Y; Zhao, Z; Zhou, Y, 2016) |
| "Patients with early and advanced esophageal cancer and relapsed esophageal cancer after radical surgery were included." | 1.43 | Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer. ( Haga, A; Kiritoshi, T; Nakagawa, K; Ohtomo, K; Okuma, K; Takenaka, R; Yamashita, H, 2016) |
| "Although squamous cell carcinoma (SCC) is the second most common nonmelanoma skin cancer, clinicians have difficulty diagnosing SCC of the toe because its clinical features can mimic other less serious diseases." | 1.43 | A Digital Squamous Cell Carcinoma Mimicking a Diabetic Foot Ulcer, With Early Inguinal Metastasis and Cancer-Related Lymphedema. ( Kim, HW; Kim, JE; Ko, JY; Kwon, HI; Park, HC; Ro, YS, 2016) |
| "However, anal cancers are rare in patients with HIV in Japan." | 1.43 | [Squamous cell carcinoma of the anal canal treated with chemoradiotherapy in a patient with HIV]. ( Ishida, H; Mita, E; Mori, K; Nakazuru, S; Nishio, K; Sakakibara, Y; Sugimoto, A; Uehira, T; Yajima, K; Yamada, T, 2016) |
| "Differentially expressed in squamous cell carcinoma 1 (DESC1), which belongs to the Type II transmembrane serine protease family, was frequently downregulated in ESCC." | 1.43 | DESC1, a novel tumor suppressor, sensitizes cells to apoptosis by downregulating the EGFR/AKT pathway in esophageal squamous cell carcinoma. ( Cal, S; Dai, W; Ip, JC; Ko, JM; Lung, ML; Ng, HY; Yu, VZ, 2016) |
| "We reviewed 21 patients diagnosed with HNSCC of the PNSNC who were treated with IC." | 1.43 | Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. ( Hah, JH; Han, DH; Heo, DS; Keam, B; Kim, DW; Kim, DY; Kim, TM; Kwon, TK; Lee, SH; Ock, CY; Rhee, CS; Sung, MW; Won, TB; Wu, HG, 2016) |
| "Information about 406 consecutive esophageal cancer patients with resectable disease who underwent surgery with neoadjuvant chemotherapy consisting of cisplatin plus 5-fluorouracil or who underwent definitive CRT was reviewed." | 1.43 | Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis. ( Abe, T; Andoh, M; Kadowaki, S; Kodaira, T; Komori, A; Masuishi, T; Muro, K; Muto, M; Narita, Y; Niwa, Y; Nomura, M; Oze, I; Tachibana, H; Tajika, M; Taniguchi, H; Uemura, N; Ura, T, 2016) |
| "Oesophageal cancer is a highly aggressive disease with about 50% of patients presenting with advanced or metastatic disease at initial diagnosis." | 1.43 | Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review. ( Bai, L; Cheng, Z; Dai, G; Han, Z; Liang, P; Liu, F; Tan, S; Yu, J; Yu, X; Zhou, F, 2016) |
| "Toxicity was acceptable, with grade 3 renal failure (n=1) and grade 3 or 4 myelotoxicity (n=2)." | 1.43 | Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer. ( Dietrich, PY; Espeli, V; Hottinger, AF; Modarressi, A; Ruegg, E, 2016) |
| "Metformin was reported to be effective against various cancers as it inhibits cell proliferation by activating AMPK, and inhibiting mTOR and HIF-1α." | 1.43 | Metformin in combination with 5-fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinoma. ( Ferdous, T; Harada, K; Harada, T; Ueyama, Y, 2016) |
| "Achalasia is a recognized risk factor for esophageal SCC." | 1.43 | [A Case of Squamous Cell Carcinoma of the Esophagus with Achalasia -- Conversion from Chemoradiotherapy to Surgery]. ( Hanaki, K; Higashide, S; Kanda, Y; Mise, M; Morimoto, T; Nio, M; Noda, H; Yata, Y; Yonenaga, Y, 2016) |
| "Radiotherapy is a common approach for treating squamous cell carcinoma (SCC) of the oropharynx." | 1.43 | Treatment: Outcome and Toxicity of Volumetric Modulated Arc Therapy in Oropharyngeal Carcinoma. ( Clerici, E; Cozzi, L; D'Agostino, G; Fogliata, A; Franceschini, D; Franzese, C; Mancosu, P; Navarria, P; Scorsetti, M; Tomatis, S, 2016) |
| "Many patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) receive cisplatin-based radiochemotherapy." | 1.43 | Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks. ( Bajrovic, A; Hakim, SG; Janssen, S; Kazic, N; Rades, D; Schild, SE; Seidl, D; Strojan, P; Wollenberg, B, 2016) |
| "Oral squamous cell carcinoma (OSCC), one of the most deadliest malignancies in the world, is caused primarily by areca nut chewing in Southeast Asia." | 1.43 | Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline. ( Chang, YC; Chou, MY; Lee, SS; Peng, CY; Wang, TY; Yu, CC, 2016) |
| "Anal cancer was diagnosed in a 36-year-old nulliparous woman." | 1.43 | Successful Delivery in a 39-Year-Old Patient with Anal Cancer after Fertility-Preserving Surgery Followed by Primary Chemoradiation and Low Anti-Mullerian Hormone Level. ( Biel, P; Cordes, T; Köhler, C; Marnitz, S, 2016) |
| "Head and neck squamous cell carcinomas from 81 patients were analyzed; clinical factors, histologic parameters, and expression of p16 and p53 were correlated with response to chemotherapy and prognosis." | 1.43 | Clinical and Histologic Predictive Factors of Response to Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma. ( Dumollard, JM; Forest, F; Fournel, P; Froudarakis, M; Gavid, M; Giroult, JB; Karpathiou, G; Monaya, A; Peoc'h, M; Prades, JM, 2016) |
| "Oesophageal squamous cell carcinoma (ESCC) is the sixth most common cause of cancer-associated death in the world and novel therapeutic alternatives are urgently warranted." | 1.43 | Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway. ( Bai, L; Chen, DL; Chen, LZ; Ju, HQ; Lu, YX; Mo, HY; Sheng, H; Wang, DS; Wang, F; Wu, QN; Xie, D; Xu, RH; Yu, HE; Yun, JP; Zeng, ZL, 2016) |
| "Indications for surgery for esophageal cancer often do not include cases with SCLN metastasis because the latter is considered distant metastasis." | 1.42 | Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. ( Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M, 2015) |
| "Since the prognosis of head and neck squamous cell carcinoma (HNSCC) still remains poor, identifying novel chemotherapeutic agents is of outmost importance." | 1.42 | Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines. ( Brunner, M; Enzenhofer, E; Haymerle, G; Heiduschka, G; Kadletz, L; Kotowski, U; Stanisz, I; Thurnher, D, 2015) |
| "We aimed to identify esophageal squamous cell carcinoma (ESCC) stem-like cells, the epigenetic mechanism and identify novel biomarkers for targeting ESCC CSCs." | 1.42 | Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity. ( Chen, X; Gao, Q; Huang, L; Li, F; Li, J; Li, S; Ping, Y; Wang, D; Wang, L; Yang, L; Yue, D; Zhang, T; Zhang, Y, 2015) |
| "The treatment of head and neck squamous cell carcinoma (HNSCC) with N3 (>6cm) lymph nodes remains difficult, and the best treatment strategy has not been elucidated." | 1.42 | Role of induction chemotherapy for N3 head and neck squamous cell carcinoma. ( Hanai, N; Hasegawa, Y; Hirakawa, H; Nakashima, T; Nishikawa, D; Ozawa, T; Suzuki, H, 2015) |
| "Sarcopenia is a significant predictor of DLT in oesophago-gastric cancer patients undergoing neo-adjuvant chemotherapy." | 1.42 | Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. ( Brammer, K; Catton, JA; James, EJ; Parsons, SL; Randhawa, N; Tan, BH; Welch, NT, 2015) |
| "The incidence of non-melanoma skin cancer (NMSC), including actinic keratosis (AK), squamous cell carcinoma (SCC), Bowen's Disease (BD) and basal cell carcinoma (BCC), is increasing." | 1.42 | Field cancerization: from molecular basis to selective field-directed management of actinic keratosis. ( Philipp-Dormston, WG, 2015) |
| " Most adverse events were mild (grade 1-2) (Common Terminology Criteria for Adverse Events, version 3." | 1.42 | Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer. ( Kumita, S; Mine, T; Murata, S; Onozawa, S; Sakamoto, A; Sugihara, F; Ueda, T; Yamaguchi, H; Yasui, D, 2015) |
| "Anal cancer is uncommon." | 1.42 | Review of anal cancer patients at the Ottawa hospital. ( Abunassar, M; Asmis, T; Jonker, DJ; Reinders, J, 2015) |
| "All patients had squamous cell carcinoma." | 1.42 | Long-term results of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer (T1bN0M0). ( Doi, Y; Kenjo, M; Kimura, T; Murakami, Y; Nagata, Y; Nishibuchi, I; Okabe, T; Takahashi, I, 2015) |
| "025) in the toxic group (n = 12) compared to the non-toxic group (n = 19)." | 1.42 | Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study. ( Bowen, JM; Game, PA; Hussey, DJ; Irvine, T; Karapetis, CS; Keefe, DM; Kristaly, K; Smith, L; Tan, H; Thompson, SK; Tsykin, A; Watson, DI; White, I, 2015) |
| "Using two head and neck squamous cell carcinoma cell lines, Hep-2 (larynx) and CAL-27 (oral cavity), the present study sequentially exposed these cells to increasing concentrations of the combination of docetaxel, cisplatin and 5-FU (TPF) to generate triple drug-resistant cells, termed Hep-2 TPF resistant (TPFR) and CAL-27 TPFR." | 1.42 | Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines. ( Das, D; Govindan, SV; Hicks, W; Kulsum, S; Kuriakose, MA; Pandian, RS; Seshadri, M; Suresh, A, 2015) |
| "Oral squamous cell carcinoma (OSCC) comprises a subset of head and neck squamous cell carcinoma (HNSCC) with poor therapeutic outcomes and high glycolytic dependency." | 1.42 | Lactate dehydrogenase B is associated with the response to neoadjuvant chemotherapy in oral squamous cell carcinoma. ( Ding, X; Geng, M; Huang, M; Li, H; Sun, W; Wu, H; Xie, Z; Zhang, X, 2015) |
| "TomoTherapy for locally advanced anal cancer is feasible." | 1.42 | French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients. ( Belhomme, S; Benech, J; Doussau, A; Frison, E; Henriques de Figueiredo, B; Kantor, G; Lisbona, A; Mahé, MA; Maire, JP; Nomikossoff, N; Rio, E; Vendrely, V, 2015) |
| "Esophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancies of the digestive tract in East Asian countries." | 1.42 | Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma. ( Ban, X; Guan, XY; Li, L; Li, XD; Li, Y; Xie, D; Yang, H; Yun, J; Zeng, TT; Zhang, BZ; Zhou, Y, 2015) |
| "In mouse xenograft model of oral squamous cell carcinoma (OSCC), SNNP loaded with 5-fluoro-uracile (5-FU-SNNP) remarkably retarded the tumor growth compared with free 5-FU, albeit SNNP alone showed no antitumor effect." | 1.42 | Self-Assembling Monomeric Nucleoside Molecular Nanoparticles Loaded with 5-FU Enhancing Therapeutic Efficacy against Oral Cancer. ( Chen, F; Chen, Q; Chu, L; Dan, H; Feng, H; He, Y; Ji, N; Jiang, L; Ju, X; Li, J; Li, L; Liang, X; Liu, D; Liu, J; Luo, X; Meng, J; Sun, C; Yang, H; Zeng, X; Zhao, H; Zhou, M; Zhou, Y, 2015) |
| "Lobaplatin plus 5-Fu combined with concurrent radiotherapy is safe and effective in treating patients with middle-advanced stage esophageal cancer." | 1.42 | Clinical Study on Lobaplatin Combined with 5-Fu and Concurrent Radiotherapy in Treating Patients with Inoperable Esophageal Cancer. ( Huang, JZ; Jia, XJ, 2015) |
| "A PPC was defined as pneumonia or acute respiratory distress syndrome within 30 days after surgery." | 1.42 | Serum Transforming Growth Factor-β1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy. ( Chang, DT; Cheng, JC; Hsu, CH; Hsu, FM; Huang, PM; Koong, AC; Lee, JM; Lu, SL; Tsai, CL; Wu, JK, 2015) |
| "Head and neck squamous cell carcinomas (HNSCCs) are characterized by marked heterogeneity in their biological behavior and response to treatment." | 1.40 | p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. ( Fresno, MF; García-Pedrero, JM; Hermsen, M; Moreno-Galindo, C; Rodrigo, JP; Suárez, C, 2014) |
| "Case 1 was a 61-year-old man with squamous cell carcinoma of the urethra that directly invaded into the perineal skin." | 1.40 | Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma. ( Arai, Y; Itoh, J; Kaiho, Y; Kimura, S; Mitsuzuka, K; Saito, H; Tanaka, T; Yamada, S; Yamamuro, T; Yamashita, S, 2014) |
| "After 4 weeks, dysphagia scores improved by at least 1 point in 67% of patients in group 1 versus 93% in group 2 (p=0." | 1.40 | Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer. ( Archambeaud, I; Landi, B; Lepère, C; Lièvre, A; Mitry, E; Rougier, P; Touchefeu, Y, 2014) |
| "Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most common cancer worldwide." | 1.40 | The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines. ( Bailly, C; Bal-Mahieu, C; Bertheau, C; Chevalier, D; Gros, A; Horn, S; Lansiaux, A; Lartigau, E; Meignan, S; Mouawad, F; Rysman, B; Sarrazin, T, 2014) |
| "Between 1998 and 2012, 56 patients with squamous cell carcinoma were treated at our institution and included in the analysis." | 1.40 | [Results of definitive radiotherapy for squamous cell carcinomas of the larynx patients with subglottic extension]. ( Blanchard, P; Bourhis, J; Daly-Schveitzer, N; Janot, F; Lévy, A; Tao, Y; Temam, S, 2014) |
| "Oral squamous cell carcinoma specimens were obtained from 61 patients who underwent surgery following 5-fluorouracil-based chemoradiotherapy at Kumamoto University Hospital between October 2003 and January 2009." | 1.40 | A low Dicer expression is associated with resistance to 5-FU-based chemoradiotherapy and a shorter overall survival in patients with oral squamous cell carcinoma. ( Hiraki, A; Hirosue, A; Kawahara, K; Kojima, T; Matsuoka, Y; Nagata, M; Nakagawa, Y; Nakayama, H; Shinohara, M; Takamune, Y; Tanaka, T; Yoshida, R; Yoshitake, Y, 2014) |
| "5-Fluorouracil (5-FU) has been used for oral squamous cell carcinoma (OSCC) treatments, and the acquisition of resistance is the major problem to successful OSCC treatment." | 1.40 | Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes. ( Ferdous, T; Harada, K; Ueyama, Y, 2014) |
| "Basaloid squamous cell carcinoma (BSCC) is a high-grade variant of squamous cell carcinoma usually localized in the aerodigestive tract, with a poor prognosis." | 1.40 | Basaloid squamous cell carcinoma: a rare tumor at the esophagogastric junction and an unexpected durable complete response to FOLFOX-4. ( Attademo, L; Camera, L; Carlomagno, C; Cella, CA; D'Armiento, M; De Stefano, A; Feliciano, S; Guadagno, E; Lordick, F; Matano, E; Moretto, R; Raimondo, L, 2014) |
| "DCF has strong antitumor activity for esophageal cancer and may confer survival benefits when used as preoperative chemotherapy." | 1.40 | Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer. ( Baba, H; Baba, Y; Ishimoto, T; Iwagami, S; Iwatsuki, M; Nagai, Y; Watanabe, M; Yoshida, N, 2014) |
| "Distant metastasis accounted for the predominant cause of death." | 1.40 | [Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment]. ( Guo, Y; Ji, Q; Qian, W; Wang, Y; Zhu, G, 2014) |
| "Postoperative complications were graded according to the Clavien-Dindo classification." | 1.40 | Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy. ( Baba, H; Baba, Y; Ida, S; Imamura, Y; Ishimoto, T; Iwagami, S; Karashima, R; Miyamoto, Y; Sakamoto, Y; Watanabe, M; Yoshida, N, 2014) |
| "Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide." | 1.40 | INF-γ sensitizes head and neck squamous cell carcinoma cells to chemotherapy-induced apoptosis and necroptosis through up-regulation of Egr-1. ( Liu, P; Shu, Y; Xu, B, 2014) |
| "Head and neck squamous cell carcinoma (HNSCC) is the sixth most common type of cancer worldwide." | 1.40 | Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro. ( Aderhold, C; Faber, A; Hoermann, K; Hofheinz, RD; Sauter, A; Schultz, JD; Stern-Straeter, J; Umbreit, C, 2014) |
| "Esophageal squamous cell carcinoma (ESCC) patients with regional lymph node metastases have poor prognosis after surgery." | 1.40 | Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma? ( Feng, Q; Gao, S; He, J; Huang, J; Jiang, Y; Liu, Y; Lyu, X; Mao, Y; Shao, K; Wang, J, 2014) |
| "Locally recurrent rate of advanced head and neck squamous cell carcinoma (HNSCC) still remains high and the treatment is controversial." | 1.40 | Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma. ( Chen, CH; Lin, SF; Liu, YC; Sun, Y; Tang, JY; Wu, CF; Yang, WC, 2014) |
| "Grade 2 anorexia was the most frequent chemotherapy-related toxicity and no toxic death was noted." | 1.40 | Intraarterial chemotherapy as the first-line therapy in penile cancer. ( Chen, CH; Chiang, PH; Shen, YC, 2014) |
| "Lung cancer is one of the leading causes of cancer-related death in developed countries." | 1.40 | SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer. ( Feng, Y; Lu, W; Zhang, M; Zuo, Y, 2014) |
| "However, the esophageal cancer recurred, and subtotal esophagectomy was performed in January 2011." | 1.40 | [A case of esophageal squamous cell carcinoma with an adenocarcinoma component that dedifferentiated after chemotherapy]. ( Kigawa, G; Matsubara, T; Matsumiya, A; Mizukami, H; Nemoto, H; Saito, M; Tanaka, J; Tate, G; Umemoto, T, 2014) |
| "Capecitabine is an established treatment alternative to intravenous 5-fluorouracil (5-FU) for patients with rectal cancer receiving chemoradiotherapy." | 1.40 | Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. ( Beijnen, JH; Cats, A; Dewit, L; Meulendijks, D; Schellens, JH; Tomasoa, NB; van Tinteren, H, 2014) |
| "Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the world." | 1.40 | Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro. ( Aderhold, C; Birk, R; Faber, A; Hörmann, K; Schultz, JD; Sommer, JU; Umbreit, C, 2014) |
| "Metastatic squamous cell carcinoma (SCCA) of the anal canal is a rare malignancy for which no standard treatment algorithm exists." | 1.40 | The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. ( Chang, GJ; Crane, CH; Das, P; Eng, C; Ohinata, A; Pathak, P; Phillips, JK; Rodriguez-Bigas, M; Rogers, JE; Sethi, S; Vauthey, JN; Wolff, RA; Xing, Y; You, YN, 2014) |
| "Esophageal carcinosarcoma is a rare malignant esophageal neoplasm consisting of both carcinomatous and sarcomatous elements, with an incidence of 0." | 1.40 | A case of metachronous development of esophageal squamous cell carcinoma in the patient with esophageal carcinosarcoma. ( Cha, RR; Ha, CY; Jung, WT; Kim, HJ; Kim, TH; Ko, GH; Oh, HW, 2014) |
| "Esophageal obstruction prior to CCRT, residual tumor according to the first follow-up endoscopy, and poor follow-up computed tomography responses were significantly associated with locoregional failure." | 1.40 | Local control may be the key in improving treatment outcomes of esophageal squamous cell carcinoma undergoing concurrent chemoradiation. ( Kim, HW; Kim, JH; Kim, JW; Lee, CG; Lee, IJ; Lee, YC; Park, H; Park, JJ; Youn, YH, 2014) |
| "He had squamous cell carcinoma diagnosed by biopsy specimens, found in the esophagogastric junction by esophagogastroduodenoscopy." | 1.39 | [A case of squamous cell carcinoma of the esophagogastric junction with bulky no.7-metastatic node successfully treatedby chemoradiation followed by surgery]. ( Koide, N; Miyagawa, S; Shinoda, A; Suzuki, A; Takeuchi, D; Yoshizawa, J, 2013) |
| "Ninety-five patients with esophageal cancer were retrospectively analyzed." | 1.39 | Endoscopic ultrasound in staging esophageal cancer after neoadjuvant chemotherapy--results of a multicenter cohort analysis. ( Domagk, D; Domschke, W; Heinzow, HS; Kucharzik, T; Meister, T; Seifert, H; Tsepetonidis, S; Wolters, H, 2013) |
| " Food and Drug Administration approved cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer." | 1.39 | Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. ( Chen, H; Cohen, MH; Fuchs, C; He, K; Keegan, P; Pazdur, R; Shord, S; Sickafuse, S; Zhao, H, 2013) |
| "We retrospectively analyzed esophageal squamous cell carcinoma (SCC) patients with e-CR after nCRT between 1999 and 2006." | 1.39 | Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy. ( Chang, HK; Chang, WC; Chao, YK; Chiu, CT; Liu, YH; Tseng, CK; Wan, YL; Wen, YW, 2013) |
| "Oral squamous cell carcinoma (OSCC) is a common malignant tumor of the head and neck, and recurrence is an important prognostic factor in patients with OSCC." | 1.39 | The recurrence and survival of oral squamous cell carcinoma: a report of 275 cases. ( Wang, B; Wang, XD; Yue, K; Zhang, S, 2013) |
| "Head and neck squamous cell carcinoma (HNSCC) is the most common malignant epithelial tumor in the upper aerodigestive tract." | 1.39 | Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro. ( Aderhold, C; Birk, R; Erben, P; Faber, A; Hofheinz, RD; Hörmann, K; Sauter, A; Schultz, JD; Sommer, JU; Stern-Straeter, J; Umbreit, C, 2013) |
| "The survival rates of esophageal cancer treated with DCRT in North West of Iran is poor; therefore, early detection and improved treatment methods, with clinical trials are a high priority." | 1.39 | Survival in patients treated with definitive chemo- radiotherapy for non-metastatic esophageal cancer in north- west iran. ( Ghojazadeh, M; Jangjoo, AG; Mirinezhad, SK; Mohammadzadeh, M; Naseri, AR; Nasiri, B; Seyednezhad, F; Somi, MH, 2013) |
| "Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2) tyrosine kinase domains." | 1.39 | Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models. ( Bachman, KE; Fei, M; Greshock, J; Hou, W; Liu, L; Liu, P; Moon, H; Qin, X; Wang, H; Ye, BC; Zang, CY; Zhang, P; Zhu, X, 2013) |
| "Patients with advanced gastric cancer receiving chemotherapy were retrospectively collected, and divided into two groups." | 1.39 | Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer. ( Huang, XE; Qian, YD; Wang, L; Xiang, J; Xu, HQ; Xu, X, 2013) |
| "Head and neck squamous cell carcinoma (HNSCC) is the sixth most common type of cancer worldwide." | 1.39 | Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro. ( Aderhold, C; Faber, A; Hoermann, K; Hofheinz, RD; Sauter, A; Schultz, JD; Sommer, JU; Stern-Sträter, J; Umbreit, C, 2013) |
| "Eighty-one patients with oral squamous cell carcinoma (OSCC) received oral fluoropyrimidine UFT and radiotherapy (RT) with or without an immunotherapeutic agent OK-432." | 1.39 | Immunochemoradiotherapy for patients with oral squamous cell carcinoma: augmentation of OK-432-induced helper T cell 1 response by 5-FU and X-ray irradiation. ( Bando, T; Fujita, T; Goda, H; Hamakawa, H; Homma, S; Kan, S; Kawakami, Y; Koido, S; Nakashiro, K; Okamoto, M; Sato, M; Shimodaira, S; Tano, T; Yamashita, N, 2013) |
| " The aim of the study was to assess the benefit of ICT with docetaxel, cisplatin and 5-fluorouracil (5-FU) (TPF) when combined with concurrent cisplatin chemoradiotherapy (CRT) for HNSCC." | 1.39 | The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis. ( Coyle, C; Dyker, KE; Karakaya, E; Prestwich, RJ; Sen, M; Teo, M; Young, CA, 2013) |
| "We retrospectively studied 276 esophageal cancer patients treated with nCRT and surgery between 2002 and 2008." | 1.39 | Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome? ( Chan, SC; Chang, HK; Chao, YK; Chen, WH; Chiu, CH; Liu, YH; Tseng, CK, 2013) |
| "DNA from 143 esophageal cancer patients, 63 receiving neoadjuvant therapy and 80 receiving primary surgery, was analyzed for the following polymorphisms: the GSTM1 null, GSTT1 null, and GSTP1 Ile105Val (rs16953) in glutathione S-transferase (GST) family, 2 in thymidylate synthase (TS) gene, and the ERCC1 Asn118Asn (rs11615), ERCC1 C8092A (rs3212986), XPD/ERCC2 Asp312Asn (rs1799793), and XPD/ERCC2 Lys751Gln (rs13181) of the nucleotide excision repair pathway." | 1.39 | ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy. ( Alfieri, R; Amadori, A; Ancona, E; Basso, D; Boldrin, E; Cagol, M; Castoro, C; Cavallin, F; Rumiato, E; Ruol, A; Saggioro, D, 2013) |
| "The treatment of anal cancer is based on concomitant radiotherapy and chemotherapy and is associated with a nonnegligible rate of local severe toxicities that can strongly impair the quality of life." | 1.39 | Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy. ( Benezery, K; Doyen, J; Follana, P; Francois, E; Gal, J; Gérard, JP; Hannoun-Levi, JM; Ortholan, C, 2013) |
| "A total of 96 patients with penile cancer were included, the expression of TS and DPD in tumor tissues were examined by immunohistochemistry method, the relationship of TS and DPD expressions with the clinical characters were also analyzed." | 1.39 | [Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in penile cancer]. ( Chen, X; Chen, Y; Cheng, K; Ding, J; Dong, H; Gou, HF; Li, LH; Liu, JY; Men, HT; Tang, J; Zhao, F, 2013) |
| "To investigate the inhibitory effects of sinomenine (SIN) combined with 5-fluorouracil (5-FU) on esophageal carcinoma in vitro and in vivo." | 1.39 | Cooperative inhibitory effect of sinomenine combined with 5-fluorouracil on esophageal carcinoma. ( Dong, WG; Guo, XF; Qiu, S; Song, J; Wang, J; Yang, ZR; Zhang, JX, 2013) |
| "Although squamous cell carcinoma was diagnosed by biopsy of the SMT-like tumor in the gastric cardia, gastric involvement was suspected via metastasis to the perigastric lymph nodes or direct invasion of the gastric wall by the ESCC, because the primary lesion of ESCC could not be identified during the examinations." | 1.39 | [A case of esophageal squamous cell carcinoma with submucosal tumor-like tumor due to direct invasion of the gastric wall]. ( Fujiwara, H; Ichikawa, D; Ikoma, H; Komatsu, S; Konishi, H; Kubota, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Nako, Y; Okamoto, K; Otsuji, E; Sakakura, C; Shiozaki, A, 2013) |
| "Induction chemotherapy in head and neck squamous cell carcinoma does not compromise delivery of definitive radiotherapy with or without concurrent chemotherapy." | 1.39 | Feasibility and tolerance of sequential chemoradiotherapy in squamous cell carcinoma of the head and neck. ( Geropantas, K; Loo, SW; Martin, C; Roques, TW; Tasigiannopoulos, Z, 2013) |
| "By this stage of esophageal cancer, surgery, although very invasive, is the standard radical therapy for the patients." | 1.39 | Clinical outcome of endoscopic mucosal resection for esophageal squamous cell cancer invading muscularis mucosa and submucosal layer. ( Kameda, Y; Ohkawa, S; Tamai, S; Yoshii, T, 2013) |
| "A 57-year-old male with lower esophageal cancer underwent subtotal esophagectomy with lymphadenectomy." | 1.39 | Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case. ( Fujiwara, H; Ichikawa, D; Iitaka, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Sonoyama, T, 2013) |
| "All patients had histologically proven squamous cell carcinoma." | 1.39 | Results of chemoradiotherapy for stage I esophageal cancer in medically inoperable patients compared with results in operable patients. ( Ariga, H; Jingu, K; Matsushita, H; Miyata, G; Narazaki, K; Nemoto, K; Onodera, K; Sugawara, T; Takeda, K; Umezawa, R; Yamada, S, 2013) |
| " CRT combined with 5-fluorouracil (5-FU) and cisplatin (CDDP) was administered to all patients." | 1.39 | Treatment strategy for superficial pharyngeal squamous cell carcinoma synchronously combined with esophageal cancer. ( Hayashi, R; Ikematsu, H; Ito, M; Kaneko, K; Kojima, T; Minashi, K; Ohtsu, A; Onozawa, M; Oono, Y; Satake, H; Yajima, Y; Yano, T; Yoda, Y, 2013) |
| "Twenty patients with esophageal cancer were treated with trimodal therapy (CRT plus surgery) and underwent [(18)F]FDG-PET/CT scans both before (pre-CRT) and after (post-CRT) CRT." | 1.39 | Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. ( Chen, W; D'Souza, WD; Feigenberg, S; Kim, G; Kligerman, S; Lu, M; Lu, W; Suntharalingam, M; Tan, S, 2013) |
| "To assess the outcome of esophageal cancer according to therapeutic strategy." | 1.39 | [Esophageal cancer: outcome according to therapeutic strategy]. ( Capitain, O; Cellier, P; Denis, F; Girault, S; Hamy, A; Mahé, MA; Mesgouez-Nebout, N; Paumier, A; Poirier, AL; Rousseau, D, 2013) |
| "Patients who had squamous cell carcinoma (SCC) or adenocarcinoma (AC) were treated in four referral centers in the north-east Netherlands with definitive chemoradiotherapy (dCRT) or radiotherapy (dRT) between 1996 and 2008." | 1.39 | Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands. ( Beukema, JC; Burgerhof, JG; Hospers, GA; Langendijk, JA; Muijs, CT; Mul, VE; Muller, K; Paardekooper, G; Plukker, JT; Smit, JK; Timmer, PR; van Dijk, BA; Woutersen, D, 2013) |
| "Head and neck squamous cell carcinoma (HNSCC) represents more than 5% of all cancers diagnosed annually in United States and around the world." | 1.39 | Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells. ( Bi, ZG; Cheng, L; Gu, B; Ji, C; Lu, CC; Wang, R; Yang, YL, 2013) |
| "TE13 human esophageal squamous cell carcinoma cells were transfected with a COX-2 constitutive expression vector, and stable transfectants overexpressing COX-2 were established." | 1.39 | COX-2 overexpression Induced by gene transfer reduces sensitivity of TE13 esophageal carcinoma cells to 5-fluorouracil and cisplatin. ( Fujiwara, H; Furutani, A; Ichikawa, D; Komatsu, S; Kubota, T; Ochiai, T; Okamoto, K; Okamura, H; Okamura, S; Otsuji, E; Sakakura, C; Shiozaki, A; Takahashi, Y; Todo, M; Umehara, S; Yoneda, M; Yoshimoto, T, 2013) |
| "Chemoradiation for anal cancer yields effective tumor control, but is associated with significant acute toxicity." | 1.38 | Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. ( Blaszkowsky, LS; Coen, JJ; Hartshorn, K; Hong, TS; Kachnic, LA; Kwak, EL; Ryan, DP; Tsai, HK; Willins, JD, 2012) |
| " SERMS are a safe and effective intervention in dysphagic patients undergoing neoadjuvant chemotherapy for esophageal cancer." | 1.38 | Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer. ( Gilani, SQ; Jain, PK; Pellen, MG; Razack, A; Sabri, S, 2012) |
| "Eighteen patients with esophageal squamous cell carcinoma with and without neoadjuvant chemotherapy were analyzed using immunohistochemical methods for human leukocyte antigen (HLA) class I heavy chain, CD4-, CD8-, and Foxp3-positive cell infiltration." | 1.38 | The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma. ( Hirano, S; Kondo, S; Miyamoto, M; Shichinohe, T; Tsuchikawa, T; Yamamura, Y, 2012) |
| "CRT is a highly effective approach in anal cancer." | 1.38 | Twenty-five-year experience with radical chemoradiation for anal cancer. ( Chander, S; Chu, J; Foo, M; Heriot, A; Lee, MT; Leong, T; Link, E; Lynch, CA; Mackay, J; Michael, M; Ngan, SY; Tomaszewski, JM; Tran, P; Vazquez, M, 2012) |
| "In the majority of cases, HNSCC overexpress the epidermal growth factor receptor (EGFR), and its presence is associated with a poor outcome." | 1.38 | Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus. ( Bossow, S; Grossardt, C; Kalle, Cv; Leber, MF; Plinkert, PK; Springfeld, C; Ungerechts, G; Zaoui, K, 2012) |
| "To study the efficacy of low-dose-rate californium-252 ((252)Cf) neutron intracavitary afterloading radiotherapy (RT) combined with external pelvic RT for treatment of cervical cancer." | 1.38 | Low-dose-rate californium-252 neutron intracavitary afterloading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer. ( Lin, S; Liu, JR; Pan, SD; Xu, HD; Yue, JH; Zhang, M, 2012) |
| "The prognosis of stage IVB cervical cancer is generally poor." | 1.38 | Outcomes and toxicities for the treatment of stage IVB cervical cancer. ( Hwang, JH; Kang, S; Kim, JY; Lim, MC; Park, SY; Seo, SS, 2012) |
| "The optimal dosage and frequency of platinum-based chemoradiotherapy (CRT) regimen for treating advanced head and neck squamous cell carcinoma remains unresolved." | 1.38 | Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma. ( Best, SR; Blanco, RG; Califano, JA; Fan, KY; Gogineni, H; Ha, PK; Lake, S; Levine, MA; Messing, B; Pai, SI; Saunders, JR; Tang, M; Zaboli, D; Zahurak, ML; Zinreich, ES, 2012) |
| "ACA in locally advanced cervical cancer had poorer response rate from treatment and also used longer time to achieve CR than SCC." | 1.38 | Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. ( Katanyoo, K; Manusirivithaya, S; Sanguanrungsirikul, S, 2012) |
| "Concurrent radiochemotherapy of oral squamous cell carcinoma was shown to drive the composition of inflammatory cells in a direction which is supposed to be prognostically favourable." | 1.38 | Radiochemotherapy induces a favourable tumour infiltrating inflammatory cell profile in head and neck cancer. ( Büttner, M; Distel, LV; Fietkau, R; Grabenbauer, GG; Lubgan, D; Nkenke, E; Tabachnyk, M, 2012) |
| "The optimal management of oropharyngeal squamous cell carcinoma (OPSCC) is controversial." | 1.38 | Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. ( Annino, DJ; Balboni, TA; Goguen, LA; Haddad, RI; Lorch, J; Norris, CM; Posner, MR; Sher, DJ; Thotakura, V; Tishler, RB, 2012) |
| "In case of Head and Neck Squamous Cell Carcinoma, chromosomal changes are detectable at all stages of tumor development providing excellent opportunity for chromosomal prognosis and therapy." | 1.38 | Chromosomal rearrangements in lymphocytes of head and neck squamous cell carcinoma treated with chemotherapeutic agents. ( Desai, B; Gadhia, P, 2012) |
| "Curcumin was more effective than p65 siRNA in vitro and in vivo." | 1.38 | Comparison of the effect of p65 siRNA and curcumin in promoting apoptosis in esophageal squamous cell carcinoma cells and in nude mice. ( Jiang, Y; Tian, F; Tian, W; Zhang, C; Zhang, X, 2012) |
| "Apigenin has an antioxidant capacity as well as the ability to inhibit lipid peroxidation." | 1.38 | Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin. ( Chan, LP; Chen, PR; Chiang, FY; Chou, TH; Ding, HY; Kuo, PL; Liang, CH, 2012) |
| "Tegafur is a 5-fluorouracil (5-FU) prodrug widely used outside the United States to treat colorectal cancer as well as cancers of the head and neck." | 1.38 | Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. ( Hurwitz, HI; McManus, TJ; Peer, CJ; Petros, WP, 2012) |
| "Pre- and post-treatment staging of anal cancer are often inaccurate." | 1.38 | Role of positron emission tomography-computed tomography in the management of anal cancer. ( Baccega, M; Bellò, M; Cassoni, P; Cravero, F; Filippini, C; Fora, G; Lesca, A; Milanesi, E; Mistrangelo, M; Morino, M; Munoz, FH; Pelosi, E; Racca, P; Ricardi, U; Skanjeti, A, 2012) |
| " Boosted high dosing to metastatic lymph nodes can increase the relapse-free survival rate." | 1.38 | Efficacy analysis of simplified intensity-modulated radiotherapy with high or conventional dose and concurrent chemotherapy for patients with neck and upper thoracic esophageal carcinoma. ( Chen, XF; Han, JH; Li, T; Yu, CH; Zhou, K; Zhu, WG, 2012) |
| "Oral squamous cell carcinoma (OSCC) is responsible for about 90% of oral malignancies and its incidence is increasing." | 1.38 | The effects of 5-fluorouracil alone and in combination with 13-cis retinoic acid and vitamin D3 on human oral squamous cell carcinoma lines. ( Dalirsani, Z; Farajnia, S; Javadzadeh, Y; Koozegari, S; Mehdipour, M, 2012) |
| "Capecitabine seems to be an active and well-tolerated regimen, even in heavily pretreated, frail patients." | 1.38 | Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma. ( Ceruse, P; Fayette, J; Girodet, D; Péron, J; Poupart, M; Ramade, A; Zrounba, P, 2012) |
| "A total of 45 patients with primary squamous cell carcinoma of the tongue were included in the study." | 1.38 | Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer. ( Asakawa, T; Furusaka, T; Ikeda, M; Matsuda, H; Tanaka, A, 2012) |
| "In patients with cervical oesophageal cancer 35 of 55 (64%) underwent oesophageal resection or pharyngo-laryngectomy." | 1.38 | [The role of neoadjuvant therapy in the treatment of locally advanced squamous cell cancer of the cervical oesophagus]. ( Bellyei, S; Cseke, L; Farkas, R; Horváth, OP; Márton, S; Papp, A; Pavlovics, G; Potó, L; Varga, G, 2012) |
| "Between 1997 and 2007, 94 patients with esophageal cancer were treated with chemoradiation in our institute." | 1.37 | Chemoradiation for esophageal cancer: institutional experience with three different regimens. ( Aleman, BM; Boot, H; Cats, A; Courrech Staal, EF; Jansen, EP; van Coevorden, F; van Sandick, JW; van Velthuysen, ML, 2011) |
| "Paclitaxel was identified as a potent inducer of numerous drug transporters and phenotypic MDR in HNSCC." | 1.37 | Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. ( Bertholet, V; Dyckhoff, G; Efferth, T; Haefeli, WE; Herold-Mende, C; Ketabi-Kiyanvash, N; Theile, D; Weiss, J, 2011) |
| "Fatigue was a prominent long-lasting symptom in these patients." | 1.37 | Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer. ( Aarstad, AK; Aarstad, HJ; Hjermstad, MJ; Hurmuzlu, M; Viste, A, 2011) |
| "To update our experience in treating squamous cell carcinoma of the anal margin with definitive radiotherapy (RT)." | 1.37 | Squamous cell carcinoma of the anal margin: the university of Florida experience. ( Balamucki, CJ; George, TJ; Kirwan, JM; Mendenhall, WM; Morris, CG; Newlin, HE; Rout, WR; Zlotecki, RA, 2011) |
| "All of the patients had squamous cell carcinoma." | 1.37 | Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. ( Ahn, SD; Choi, EK; Kim, JH; Kim, SB; Lee, SW; Lee, YS; Park, JW; Park, SI; Song, SY; Yoon, SM, 2011) |
| "To compare outcomes in patients with squamous cell carcinoma (SCC) of the vulva treated with radiation (RT) and concurrent weekly platinum-based or every-3-4-week regimens containing 5-fluorouracil (5-FU)." | 1.37 | Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3-4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva. ( Ancukiewicz, M; Halasz, LM; Mak, RH; Russell, AH; Schultz, DJ; Tanaka, CK; Viswanathan, AN, 2011) |
| "Chemoradiotherapy (CRT) for esophageal cancer is disadvantageous because of a high locoregional failure rate." | 1.37 | Submucosal tumor appearance is a useful endoscopic predictor of early primary-site recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma. ( Horimatsu, T; Ishikura, S; Minashi, K; Muto, M; Nihei, K; Ohtsu, A; Onozawa, M; Taku, K; Tu, CH; Yano, T; Yoshida, S, 2011) |
| "Furthermore, HNSCC-driven squamospheres appeared to be chemoresistant to cisplatin, 5-fluorouracil (FU), paclitaxel and doxetaxel, and showed increased levels of ABCG2, one of the ATP-binding cassette (ABC) transporters." | 1.37 | Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas. ( Cha, YY; Jin, X; Kim, H; Kim, SH; Lim, YC; Oh, SY, 2011) |
| "Head and neck squamous cell carcinoma (HNSCC) is one prevalent human cancer worldwide." | 1.37 | Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma. ( Chang, SY; Chang, YC; Chu, PY; Hsieh, SL; Li, WY; Tai, SK; Tsai, TL; Wang, YF; Yang, MH, 2011) |
| "Major forms of oral candidiasis are pseudomembranous and atrophic form, but chronic hyperplastic candidiasis (CHC) is rarely seen." | 1.37 | Oral candidiasis mimicking tongue cancer. ( Hasegawa, S; Hashikawa, K; Nibu, K; Otsuki, N; Saito, M; Shibata, T; Tahara, S; Yamashita, D, 2011) |
| "Strictures were associated with tumor location (tonsil vs base of tongue; p = ." | 1.37 | Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma. ( Best, SR; Blanco, RG; Califano, JA; Ha, PK; Levine, MA; Messing, BP; Murakami, P; Pai, SI; Saunders, JR; Thompson, R; Trachta, J; Ulmer, K; Walker, M; Zinreich, ES, 2011) |
| "A cohort of 148 patients with esophageal cancer received cisplatin-based CCRT (concurrently combined with 40 Gy irradiation) and subsequent esophagectomy." | 1.37 | Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery. ( Chen, JS; Cheng, JC; Chuang, TH; Hsu, CH; Hsu, HH; Huang, PM; Kuo, SW; Lee, JM; Lee, YC; Lin, CC; Shun, CT; Wang, YH; Wu, MT; Yang, PW; Yang, SY, 2011) |
| "Honokiol (HNK) is a small organic molecule purified from magnolia species and has demonstrated anticancer activities in a variety of cancer cell lines; however, its effect on oral squamous cell carcinoma (OSCC) cells is unknown." | 1.37 | Honokiol: a promising small molecular weight natural agent for the growth inhibition of oral squamous cell carcinoma cells. ( Chen, XR; Dan, HX; Ji, N; Li, XY; Liao, G; Lu, R; Zhou, M, 2011) |
| " Despite widespread concern about the successful performance of this procedure following neoadjuvant chemoradiotherapy (NACR) treatment, we hypothesized that safe and effective MIE could be performed in this setting." | 1.37 | Minimally invasive esophagectomy is safe and effective following neoadjuvant chemoradiation therapy. ( Ben-David, K; Cendan, JC; Grobmyer, SR; Hochwald, SN; Rossidis, G; Sarosi, GA; Zlotecki, RA, 2011) |
| "Histological examinations revealed squamous cell carcinoma." | 1.37 | [A case of advanced esophageal cancer with multiple liver metastases accompanying poorly general conditions and serious liver dysfunctions, successfully treated using concurrent radiotherapy and chemotherapy with low-dose nedaplatin and 5-fluorouracil]. ( Fukui, T; Itoh, Y; Kawada, S; Takeda, H; Yoshioka, T, 2011) |
| "Tumour histology was squamous cell carcinoma in 74% of the cases." | 1.37 | [Radiotherapy for cutaneous cancers with xeroderma pigmentosum]. ( Abdelmoula, M; Bahri, M; Ben Salah, H; Daoud, J; Frikha, M; Turki, H, 2011) |
| "However, oral squamous carcinoma cells (OSCCs) are resistant to these drugs, so finding a way to enhance the sensitivity of these cells to anticancer drugs is important." | 1.37 | The bacterial protein azurin enhances sensitivity of oral squamous carcinoma cells to anticancer drugs. ( Cho, JH; Cho, YJ; Kim, GC; Kim, S; Lee, MH; Park, BS, 2011) |
| " The most common side effect of this medication is localized irritant dermatitis." | 1.37 | Metallic taste as a side effect of topical fluorouracil use. ( Han, SY; Youker, S, 2011) |
| "Here, Japanese patients with esophageal squamous cell carcinoma (ESCC) were followed up for 5 years after treatment with a definitive 5-FU/cisplatin (CDDP)-based chemoradiotherapy (CRT), and the association between prognosis and the plasma concentration of 5-FU was evaluated." | 1.37 | Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Kadoyama, K; Kuwahara, A; Miki, I; Nakamura, T; Nishiguchi, K; Okuno, T; Omatsu, H; Sakaeda, T; Tamura, T; Yamamori, M, 2011) |
| "Squamous cell cancer of the anal canal (anal cancer) is a rare disease but with worldwide increasing incidence." | 1.37 | Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. ( Abbas, A; Fakih, M; Nehme, E, 2011) |
| "Patients who had clinical Stage I-IVA esophageal cancer and received definitive CRT between 2001 and 2007 were retrospectively analyzed." | 1.36 | Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. ( Higashino, K; Iishi, H; Imai, A; Ishihara, R; Nishiyama, K; Sugimoto, N; Takeuchi, Y; Tatsuta, M; Uedo, N; Yamamoto, S; Yano, M, 2010) |
| "Mucositis was the major acute toxicity, but this was well tolerated in most subjects." | 1.36 | Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study. ( Fujii, M; Fukada, J; Kawaguchi, O; Kubo, A; Kunieda, E; Ohashi, T; Shigematsu, N; Shiotani, A; Takeda, A; Tomita, T, 2010) |
| "Esophageal squamous cell carcinoma (ESCC) exhibits abnormalities in epidermal growth factor receptor (EGFR) gene." | 1.36 | EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. ( Hirayama, Y; Imawari, M; Kagawa, N; Kaneko, K; Katagiri, A; Kogo, M; Konishi, K; Kubota, Y; Kumekawa, Y; Kushima, M; Makino, R; Muramoto, T; Nozawa, H; Ohmori, T; Ohtsu, A; Oyama, T, 2010) |
| "Using a comprehensive esophageal cancer database, we identified patients who underwent esophagectomy between 1994 and 2008." | 1.36 | Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. ( Hoffe, S; Karl, R; Kelley, S; Marcovalerio, M; McLoughlin, J; Meredith, KL; Shah, N; Siegel, EM; Turaga, KK; Weber, JM, 2010) |
| "Patients with deeply invading (T3-T4) oesophageal cancers usually receive chemoradiotherapy with or without surgery." | 1.36 | Pre- and post-therapy nodal status equally affects survival of patients with oesophageal squamous cell carcinoma receiving preoperative chemoradiation. ( Doki, Y; Fujiwara, Y; Miyata, H; Mori, M; Nakajima, K; Takiguchi, S; Yamasaki, M, 2010) |
| " However, the optimal dosage of chemoradiotherapy and the treatment strategy for esophageal cancer in patients with Fanconi anemia remain unclear, and outcomes are generally extremely poor." | 1.36 | Successful treatment of esophageal squamous cell carcinoma in a patient with Fanconi anemia. ( Hirashima, Y; Hosoya, Y; Jinbu, Y; Lefor, A; Muroi, K; Nakazawa, M; Nokubi, M; Yamaguti, T; Yasuda, Y, 2010) |
| "Eighty-four patients with invasive anal cancer treated with definitive external beam radiotherapy (RT) with a mandatory split of 12 days (52 patients, Montreal, Canada) or without an intended split (32 patients, Zurich, Switzerland) were reviewed." | 1.36 | Chemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature. ( Bahary, JP; Ciernik, IF; Donath, D; Lütolf, UM; Oehler, C; Provencher, S, 2010) |
| "From 1991 to 2005, 58 patients with anal cancer were curatively treated with CRT." | 1.36 | Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. ( Donath, D; Fortin, B; Jolicoeur, M; Lavertu, S; Oehler, C; Provencher, S, 2010) |
| "298 patients with inoperable cancer of the esophagus were identified (16." | 1.36 | Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. ( Belka, C; Ganswindt, U; Haimerl, W; Hölzel, D; Niyazi, M; Schmidt, M; Wolf, M; Zehentmayr, F, 2010) |
| "For an improved treatment of actinic keratosis and squamous cell carcinoma, inhibitors of human DNA polymerase alpha (pol alpha) are developed by docking nucleoside phosphonate diphosphates into the active site of pol alpha." | 1.36 | Antitumor effects of guanosine-analog phosphonates identified by molecular modelling. ( Höltje, HD; Höltje, M; Korting, HC; Murruzzu, C; Natek, M; Reissig, HU; Schäfer-Korting, M; Schwanke, A; Zdrazil, B; Zuhse, R, 2010) |
| " In this study, the response of human OSCC cells to Lentinan alone and in combination with S-1 was examined using nude mouse xenograft models." | 1.36 | Effects of lentinan alone and in combination with fluoropyrimidine anticancer agent on growth of human oral squamous cell carcinoma in vitro and in vivo. ( Harada, K; Itashiki, Y; Takenawa, T; Ueyama, Y, 2010) |
| "Non-melanoma skin cancers, such as squamous cell carcinoma and basal cell carcinoma, also represent sun-related conditions that require early and aggressive treatment." | 1.36 | Case-based considerations in the treatment of actinic keratoses: utilizing combination or sequential therapy with 5-fluorouracil cream and destructive treatments. ( Goldsmith, A; Han, A; Marmur, ES; Penrose, C, 2010) |
| "Squamous cell carcinoma was an adverse factor related to increased postoperative pulmonary complications." | 1.36 | High-dose preoperative chemoradiotherapy in esophageal cancer patients does not increase postoperative pulmonary complications: correlation with dose-volume histogram parameters. ( Hurmuzlu, M; Muren, LP; Smaaland, R; Viste, A; Wentzel-Larsen, T; Øvrebø, K, 2010) |
| "To improve the prognosis of advanced esophageal cancer, neoadjuvant chemotherapy (NACT) followed by surgery is a promising treatment strategy." | 1.36 | Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples. ( Doki, Y; Fujiwara, Y; Komori, T; Matsubara, K; Matsuura, N; Miyata, H; Monden, M; Mori, M; Motoori, M; Takemasa, I; Takeno, A; Takiguchi, S; Yamasaki, M; Yano, M; Yasuda, T, 2010) |
| "HIV-positive patients with squamous cell carcinoma of the canal treated at Continuum Cancer Centers-affiliated hospitals were identified from tumor registries." | 1.36 | Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer. ( Ennis, RD; Evans, A; Grossbard, M; Hauerstock, D, 2010) |
| "Records of 632 patients with cervical cancer stage II - IVa proved by pathology in Lanzhou Command General Hospital from January 1st, 1999 to August 31st, 2009 were retrospective analysed." | 1.36 | [Clinical value of the comprehensive treatment in intermediate and advanced cervical cancer with uterine arterial interventional chemoembolization and radiotherapy]. ( Chen, XH; Li, S; Liu, ML; Tian, ZZ; Yue, YJ; Zhao, R; Zhu, XH, 2010) |
| "These activities compared with those in squamous cell carcinoma." | 1.36 | [Four resected cases with basaloid carcinoma of esophagus--comparison of 5-FU-related enzymes (thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT)) between basaloid carcinoma and squamous cell carcin ( Fujiwara, Y; Morimura, K; Takemura, M; Yoshida, K, 2010) |
| "We report three cases of anal canal squamous cell carcinoma treated with radiotherapy combined with S-1 and mitomycin C(MMC)." | 1.36 | [Three cases of radiotherapy combined with S-1 and mitomycin C for anal canal squamous cell carcinomas]. ( Akaike, M; Motohashi, O; Nakayama, N; Nakayama, Y; Nishimura, K; Nonaka, T; Shiozawa, M; Takagi, S; Yoshii, T, 2010) |
| "Fifteen patients with esophageal squamous cell carcinoma underwent CDDP/5-FU chemoradiotherapy." | 1.36 | [ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma]. ( Haga, N; Ishibashi, K; Ishida, H; Kumamoto, K; Sobajima, J, 2010) |
| "We report a case of squamous cell carcinoma of the anus with associated HIV infection." | 1.36 | [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus]. ( Fujitani, K; Hirao, M; Ikenaga, M; Mishima, H; Miyamoto, A; Miyazaki, M; Nakamori, S; Omiya, H; Sueda, K; Takami, K; Tsujie, M; Tsujinaka, T; Yasui, M; Yoshida, K, 2010) |
| "The growing number of patients with head and neck cancer is a reason to search for new effective treatment strategies." | 1.36 | [Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results]. ( Chilimoniuk, M; Maksimowicz, T; Olszewska, E, 2010) |
| "A total of 59 patients with esophageal cancer (clinical tumor stage 2-4, N(x), M(0)) received neoadjuvant chemoradiation followed by transthoracic en bloc esophagectomy." | 1.35 | Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer. ( Baldus, SE; Brabender, J; Drebber, U; Hoelscher, AH; Hoffmann, AC; Kuhn, E; Metzger, R; Schneider, PM; Vallböhmer, D; Warnecke-Eberz, U, 2008) |
| "We investigated the role of squamous cell carcinoma (SCC) at presentation (pre-SCC) and after treatment (post-SCC) as predictor of pathological response and outcome in locally advanced cervical cancer (LACC) patients undergoing preoperative chemoradiation." | 1.35 | Squamous cell carcinoma antigen in patients with locally advanced cervical carcinoma undergoing preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome. ( Carone, V; Deodato, F; Digesù, C; Ferrandina, G; Forni, F; Legge, F; Macchia, G; Morganti, AG; Scambia, G, 2008) |
| "In patients with advanced squamous cell head and neck cancer, the haemoglobin level prior to induction chemotherapy is significantly related to outcome including response and survival." | 1.35 | Pre-treatment haemoglobin level predicts response and survival after TPF induction polychemotherapy in advanced head and neck cancer patients. ( Baghi, M; Gstoettner, W; Hambek, M; Knecht, R; Moertel, S; Strebhardt, K; Wagenblast, J, 2008) |
| "Recurrent lymph node metastasis was detected in 68 patients with thoracic esophageal carcinoma after curative esophagectomy (R0, International Union Against Cancer criteria)." | 1.35 | Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. ( Mitsuhashi, N; Nakamura, T; Narumiya, K; Ohki, T; Ota, M; Sato, T; Yamamoto, M, 2008) |
| "Patients with localized esophageal cancer (LEC) have diverse outcomes (post-therapy pathologic response, disease-free survival [DFS], and overall survival [OS]) after preoperative chemoradiation (P-CTRT), dictated also by inherent molecular heterogeneity." | 1.35 | Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. ( Ajani, JA; Arora, R; Bhutani, MS; Correa, AM; Hofstetter, WL; Izzo, JG; Javeri, H; Lee, JH; Liao, Z; Maru, D; McAleer, MF; Swisher, SG, 2008) |
| "To evaluate the therapeutic activity of taxanes (T) in combination with cisplatin-fluorouracil (PF) for salvage of primarily unresectable or relapsed nodal metastases from squamous cell carcinoma (SCC) of the penis." | 1.35 | Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. ( Milani, A; Nicolai, N; Pizzocaro, G, 2009) |
| "Managing patients with diffuse squamous cell carcinoma (SCC) and actinic damage on their extremities is challenging because SCCs may be ill-defined, confluent, and only amenable to radical surgery." | 1.35 | Chemowraps as an adjuvant to surgery for patients with diffuse squamous cell carcinoma of the extremities. ( Berk, DR; Mann, M; Petersen, J, 2008) |
| " The CDDP dosage was reduced to 40% and HD was started 30 minutes after CDDP administration." | 1.35 | [Successful treatment with 5-fluorouracil and cis-dichlorodiammineplatinum combined with 60Gy of radiation in a case of advanced esophageal cancer complicated with chronic renal failure treated with hemodialysis]. ( Arai, Y; Hotta, K; Miyata, Y; Oyama, T; Tomori, A, 2008) |
| "We report two cases of squamous cell carcinoma of upper urinary tract with hypercalcemia." | 1.35 | [Two cases of squamous cell carcinoma of upper urinary tract with hypercalcemia]. ( Kobayashi, Y; Matsuzaki, A; Terauchi, F; Washino, S, 2008) |
| "The basaloid squamous cell carcinoma of the esophagus is highly malignant with poor prognosis." | 1.35 | [Diagnosis and treatment of basaloid squamous cell carcinoma of the esophagus]. ( Chen, JX; Tang, Q; Zheng, YD; Zhu, HN, 2008) |
| "However, few studies examining oral squamous cell carcinomas (OSCCs) have been reported." | 1.35 | Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy. ( Morishita, K; Ohno, S; Tateishi, Y; Tatemoto, Y; Ueta, E; Yamamoto, T, 2009) |
| "5-Fluorouracil (5-FU) is a widely used drug in head and neck squamous cell carcinoma (HNSCC)." | 1.35 | Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma. ( Ayada, T; Fukushima, M; Kogo, R; Komune, S; Masuda, M; Nakashima, T; Uryu, H; Wakasaki, T; Yasumatsu, R, 2009) |
| "Six patients with advanced oral squamous cell carcinoma were treated with preoperative concurrent chemoradiotherapy." | 1.35 | [Clinical effects of concurrent chemoradiotherapy (hyperfractionation and cisplatin/5-fluorouracil) for patients with advanced oral squamous cell carcinoma]. ( Hoshi, K; Ito, H; Jinbu, Y; Kusama, M; Matsumoto, K; Matsumura, T; Noguchi, T; Osano, H; Tsuchiya, Y, 2009) |
| " The toxic grade for leukopenia (grade 0-2/3-4) and pathological effect (grade 3/1-2) were significantly different by univariate analysis (P = 0." | 1.35 | Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer. ( Doki, Y; Eguchi, H; Imaoka, S; Ishikawa, O; Kishi, K; Miyashiro, I; Miyoshi, N; Noura, S; Ohigashi, H; Ohue, M; Sasaki, Y; Takachi, K; Yamada, T; Yano, M, 2009) |
| " Chemotherapy with cisplatin plus 5-FU (PF) is widely used, but the standard dosage, PF (100/1000; cisplatin 100 mg/m(2) day 1 and 5-FU 1000 mg/m(2)/24 h by continuous intravenous infusion on days 1 through 4), is relatively toxic for palliative use, and PF (80/800; cisplatin 80 mg/m(2) day 1 and 5-FU 800 mg/m(2)/24 h by continuous intravenous infusion on days 1 through 5) is more commonly used in Japan, albeit without clear comparative data." | 1.35 | Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan. ( Doi, T; Fuse, N; Kadowaki, S; Kiyota, N; Minami, H; Ohtsu, A; Tahara, M, 2009) |
| "The most common malignancy is squamous cell carcinoma, which consists of about 75% of malignant transformations." | 1.35 | Squamous cell carcinoma arising in an ovarian mature cystic teratoma: a case report. ( Azadbakht, F; Emami-Aleagha, M; Hajarizadeh, B; Keshvari, A; Rosai, J; Sedighi, S; Shariat-Torbaghan, S, 2009) |
| " Five cardiopulmonary toxic events of Grade 3 or greater were observed in 4 patients, Grade 5 heart failure and Grade 3 pericarditis in 1 patient, and Grade 3 myocardial infarction, Grade 3 radiation pneumonitis, and Grade 3 pleural effusion." | 1.35 | Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. ( Chin, K; Gomi, K; Ito, H; Kozuka, T; Matsuura, M; Morota, M; Oguchi, M; Yamashita, T, 2009) |
| "Severe dysphagia (Grade 3-4) was observed in 22 patients (47%) as an acute toxic event." | 1.35 | Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers. ( Kadoya, M; Koiwai, K; Sasaki, S; Shikama, N; Shinoda, A, 2009) |
| "Treatment of base of tongue (BOT) squamous cell carcinoma (SCC) has traditionally been associated with poor prognosis and significant morbidity." | 1.35 | Management of squamous cell carcinoma of the base of tongue with chemoradiation and brachytherapy. ( Cano, ER; Carrau, RL; Caylakli, F; Ferris, RL; Gooding, WE; Johnson, JT; Lai, SY; Myers, EN; Simenthal, AA; Snyderman, CH, 2009) |
| "A xenograft model using SCID mice with esophageal cancer cells would monitor gene changes during treatment and regrowth." | 1.35 | Gene expression changes in a chemoresistant model with human esophageal cancer xenografts using cDNA microarray. ( Miyoshi, T; Seike, J; Takechi, H; Tangoku, A; Yamai, H; Yoshida, T; Yuasa, Y, 2009) |
| "Five patients had less than one-third residual tumor cells in resected specimens histopathologically; eight had more than two-thirds residual tumor cells." | 1.35 | Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer. ( Kusunoki, M; Miki, C; Mohri, Y; Ohi, M; Otake, K; Tanaka, K; Toiyama, Y; Tonouchi, H; Yokoe, T, 2009) |
| "A new animal model of esophageal cancer causing tumor colonization of the peritoneal cavity and producing bloody ascites was made by injecting YES-2 cells into the peritoneal cavity of a severe combined immunodeficiency mouse." | 1.35 | Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. ( Bando, Y; Kenzaki, K; Kondo, K; Miyoshi, T; Ohnishi, Y; Sawada, N; Seike, J; Takizawa, H; Tangoku, A; Yamai, H; Yoshida, T, 2009) |
| "Esophageal adenosquamous carcinoma is a rare esophageal disease and prone to be misdiagnosed as esophageal squamous cell carcinoma." | 1.35 | [Clinical analysis of 22 cases of esophageal adenosquamous carcinoma]. ( Fu, JH; Lin, P; Long, H; Ma, GW; Rong, TH; Su, XD; Zhang, DK; Zhang, LJ, 2009) |
| "Of 99 eligible patients with squamous cell carcinoma registered between January 2001 and December 2005, 51 selected CRT and 48 selected surgery." | 1.35 | Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. ( Ariga, H; Ichikawa, H; Ishioka, C; Jingu, K; Kamei, T; Kato, S; Miyata, G; Miyazaki, S; Nemoto, K; Ogawa, Y; Onodera, K; Sakayauchi, T; Satomi, S; Yamada, S; Yoshioka, T, 2009) |
| "Seven of the 45 had distant metastasis." | 1.35 | [Chemotherapy with MTX, 5-FU and CDGP for treatment of newly diagnosed head and neck cancer]. ( Enomoto, T; Enomoto, Y; Kitano, H; Morizane, R; Nakahara, K; Nosaka, A; Sakoda, T, 2009) |
| "Five months later, diffuse and multiple brain metastases relapsed, and second-line chemotherapy did not respond well, and finally he was died 3 months after palliative care." | 1.35 | [A case of a 14-month survival patient on advanced esophageal cancer with uncontrolled brain metastasis completely responding to nedaplatin, adriamycin, plus 5-FU (NAF) therapy]. ( Doi, T; Hoshi, M; Iijima, S; Kato, A; Kato, T; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Miyo, M; Ooshima, S; Sakamoto, T, 2009) |
| "Unknown primary head and neck cancers often require comprehensive mucosal and bilateral neck irradiation." | 1.35 | Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy. ( Klem, ML; Kraus, D; Lee, NY; Mechalakos, JG; Pfister, DG; Shah, J; Shaha, A; Singh, B; Wolden, SL; Zelefsky, MJ, 2008) |
| "All tumors were squamous cell carcinomas." | 1.35 | Concurrent chemoradiotherapy for esophageal cancer with malignant fistula. ( Kanamori, S; Koike, R; Nakamatsu, K; Nishimura, Y; Shibata, T, 2008) |
| " The pharmacokinetic parameters of 5-FU/PEG-PBLG nanoparticles in rabbit plasma were determined by measuring the 5-FUby high-performance liquid chromatography (HPLC)." | 1.35 | Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. ( Guan, Z; Jiang, W; Li, S; Wang, A, 2008) |
| "Since human head and neck cancer cells highly express the antiapoptotic protein myeloid cell leukemia-1 (Mcl-1), the aim of this study was to explore the efficacy of the Mcl-1 suppression in combination with various cytotoxic agents in the head and neck cancer cell line SCC9." | 1.35 | Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck. ( Erovic, BM; Heiduschka, G; Kloimstein, P; Martinek, H; Selzer, E; Skoda, C; Thurnher, D; Vormittag, L; Wachek, V; Wrba, F, 2008) |
| "Neoadjuvant treatment modalities for esophageal cancer were developed to improve local tumor control as well as to reduce lymph node metastases and distant metastases in patients with locally advanced esophageal cancer." | 1.34 | Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer. ( Baldus, SE; Bollschweiler, E; Dienes, HP; Hölscher, AH; Izbicki, JR; König, A; Mueller, RP; Prenzel, KL; Schneider, PM; Schnickmann, C; Schröder, W, 2007) |
| "Fifty patients with advanced squamous cell carcinoma of the head and neck (SSCHN) who underwent MRI volumetry before and after neoadjuvant chemotherapy consisting of docetaxel, cisplatin, and 5-fluorouracil (TPF) were included in this study." | 1.34 | Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy. ( Baghi, M; Bisdas, S; Gstoettner, W; Hambek, M; Knecht, R; Mack, MG; Muerthel, R; Vogl, T; Wagenblast, J, 2007) |
| "The role of surgery for esophageal squamous cell carcinoma (SCC) with clinical evidence of adjacent organ invasion (cT4) is a debated issue." | 1.34 | Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. ( Bernini, M; Cordiano, C; de Manzoni, G; Giacopuzzi, S; Grandinetti, A; Minicozzi, AM; Pasini, F; Pedrazzani, C, 2007) |
| "A resected case of squamous cell carcinoma associated with ductal carcinoma in the hemilateral breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases is reported with some discussion." | 1.34 | [A resected case of squamous cell carcinoma of the breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases]. ( Akagawa, T; Fujioka, S; Hara, T; Hiramatsu, K; Hirata, A; Ito, T; Kato, K; Kutsuna, Y; Machiki, Y; Matsuba, H; Miyata, T, 2007) |
| "The prognosis of recurrent metastatic cervical cancer is extremely poor." | 1.34 | Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series. ( Abu-Rustum, NR; Aghajanian, C; Bowes, RJ; Jhamb, N; Khoury-Collado, F, 2007) |
| "We herein report on a case of pure squamous cell carcinoma of the prostate approached with combined-modality treatment, with the administration of 3 courses of cisplatin 75 mg/m(2) on day 1 and continuous infusion 5-fluorouracil 750 mg/m2 on day 1 to 5 and, subsequently, radiotherapy, with the delivery of a total dose of 46 Gy to the whole pelvis, with additional boost doses of 20 Gy to the prostatic bed and adjunctive 6 Gy to the prostate gland (72 Gy in total)." | 1.34 | Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation. ( Ciammella, P; Clerico, M; Filippi, AR; Franco, P; Giudici, M; Munoz, F; Ricardi, U, 2007) |
| "The sensitivity of fresh human cervical cancer cells from 32 patients to 9 cytotoxic drugs was tested using in vitro MTT assay." | 1.34 | [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer]. ( Feng, YL; Li, JD; Li, MD; Liu, JH; Shi, HL; Xiao, Y, 2007) |
| "In cases of esophageal cancer, a different pattern of tumor shrinkage is often observed between primary tumors and metastatic lymph nodes (MLNs)." | 1.34 | Reduction rate of lymph node metastasis as a significant prognostic factor in esophageal cancer patients treated with neoadjuvant chemoradiation therapy. ( Aiko, S; Ishizuka, T; Kumano, I; Maehara, T; Sakano, T; Sugiura, Y; Yoshizumi, Y, 2007) |
| "Head and neck cancer patients are treated with various therapeutic regimens, including chemotherapy with 5-FU at a dose of 600 mg m(-2) day(-1) with radiotherapy." | 1.34 | Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy. ( Beneton, M; Blasco, H; Boisdron-Celle, M; Calais, G; Chapet, S; Denis, F; Deporte-Fety, R; Giraudeau, B; Le Guellec, C; Narcisso, B, 2007) |
| "Thoracic esophageal cancers frequently metastasize to the right recurrent nerve nodes (RRNNs)." | 1.34 | Salvage lymphadenectomy of the right recurrent nerve node with tracheal involvement after definitive chemoradiation therapy for esophageal squamous cell carcinoma: report of two cases. ( Doki, Y; Fujiwara, Y; Makari, Y; Masuoka, T; Matsuyama, J; Miyata, H; Monden, M; Takiguchi, S; Yamasaki, M; Yasuda, T, 2007) |
| "Ninety-nine per cent had squamous cell carcinoma and 56% had the main lesion in the middle thoracic esophagus." | 1.34 | Results of the 1999 2001 Japanese patterns of care study for patients receiving definitive radiation therapy without surgery for esophageal cancer. ( Kenjo, M; Murakami, Y; Oguchi, M; Shimada, M; Teshima, T; Uno, T, 2007) |
| "Basaloid squamous cell carcinoma (BSC) of the esophagus is a rare malignant disease." | 1.34 | Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin. ( Arita, S; Ariyama, H; Baba, E; Kusaba, H; Miki, R; Mitsugi, K; Nakano, S; Noshiro, H; Ogami, N; Qin, B; Shibata, Y; Yao, T, 2007) |
| "101 patients with cervical cancer FIGO IB1-IVB underwent chemoradiation after transperitoneal laparoscopic staging." | 1.34 | Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging. ( Bischoff, A; Budach, V; Füller, J; Köhler, C; Marnitz, S; Roth, C; Schneider, A; Wendt, T, 2007) |
| "Herein, we report two cases of female urethral cancer." | 1.34 | [Two cases of primary female urethral cancer]. ( Bando, S; Inai, T; Kanda, K; Koizumi, T, 2007) |
| " The adverse effect included grade 3 or grade 4 leukopenia in 12." | 1.34 | [Efficiency and side effects of concurrent radiotherapy and chemotherapy for advanced cervical cancers]. ( Bai, P; Li, XG; Ma, SK; Wu, LY; Zhang, R; Zhang, WH, 2007) |
| "Totally 197 patients with primary cervical cancer in our hospital from 2000 to 2006 were studied." | 1.34 | [Retrospective study of chemoradiotherapy based on cisplatin compared with radiotherapy alone for cervical cancer]. ( Han, C; Kong, WM, 2007) |
| "Recent studies on polychemotherapy of head and neck cancer showed an improved remission rate on adding taxanes to the standard cytotoxic drugs cisplatin and 5-fluorouracil (5-FU)." | 1.33 | EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment. ( Baghi, M; Gstöttner, W; Hambek, M; Knecht, R; Peters, S; Solbach, C, 2005) |
| "Most patients (95%) had histology of squamous cell carcinoma." | 1.33 | Radiotherapy for uterine cervical cancer: results of the 1995-1997 patterns of care process survey in Japan. ( Inoue, T; Kawaguchi, A; Kodaira, T; Maebayashi, K; Mitsuhashi, N; Nakamura, K; Ogawa, K; Shinoda, A; Teshima, T; Toita, T; Uno, T, 2005) |
| "Treatment of non operable esophageal cancer still remains debatable." | 1.33 | [Role of an exclusive concomitant radio-chemotherapy treatment in non operable esophageal cancer: results of a 10-year experience in Antoine-Lacassagne Center]. ( François, E; Lagrange, JL; Magné, N; Marcy, PY; Touati, L; Van Houtte, P, 2005) |
| "Ocular metastasis in patients with esophageal cancer is quite rare." | 1.33 | Iris metastasis of esophageal cancer. ( Hirose, N; Ichiki, Y; Morita, M; Sugio, K; Yano, K; Yasumoto, K, 2005) |
| " CM-Na was given 1 h before radiotherapy at Monday, Wednesday, and Friday every week, combined with 2 circles of continuous 5-day chemotherapy of 500 mg x (m(2) x d)(-1) of 5-fluoruracil (5-FU) and 20 mg x (m(2) x d)(-1) of cisplatin (DDP) at the first and the fifth week." | 1.33 | [Phase I study of CM-Na combined with concurrent radiochemotherapy for advanced esophageal carcinoma]. ( Cai, L; Chen, EC; Cui, NJ; Gu, MF; Hu, YH; Huang, Y; Li, QQ; Lin, HX; Liu, H; Liu, MZ; Rong, TH; Wang, HY, 2005) |
| "We present the first reported case of a squamous cell carcinoma recurrence on a reconstructed flap in the pharynx treated successfully with topical chemotherapy." | 1.33 | Recurrent squamous cell carcinoma in the neopharynx treated successfully with topical 5-fluorouracil. ( Banga, R; Cox, G; Ramsden, J, 2005) |
| "190 patients suffering from T3 squamous carcinoma of lower thoracic esophagus who underwent radical surgery from January 1990 to January 1999, 158 males and 32 females, aged 62." | 1.33 | [The value of postoperative arterial infusion chemotherapy in patients with T3 esophageal squamous carcinoma after radical surgery]. ( Liu, BD; Xu, QS; Zhi, XY, 2005) |
| "Based on laboratory data, we diagnosed acute renal failure caused by MTX and added the infusion of Ringer and LV." | 1.33 | [A case of head and neck squamous cell carcinoma suffering from acute renal failure after methotrexate administrator]. ( Matsuda, H; Mikami, Y; Nagao, J; Sakuma, N; Tsukuda, M; Yoshida, T, 2005) |
| "The esophageal cancer was found by endoscopy to have diminished significantly after completion of neoadjuvant therapy, An endoscopic biopsy specimen was found to contain no malignant cells." | 1.33 | [Pathologic complete response of thoracic esophageal cancer developing after gastrectomy to neoadjuvant low-dose nedaplatin (CDGP), 5-fluorouracil and radiotherapy]. ( Fukuhara, K; Iwasaki, H; Lee, S; Nishikawa, T; Osugi, H; Takemura, M, 2005) |
| "Fifty-eight patients with advanced laryngeal cancer (T3/T4N0/N + M0) were treated with curative intent with accelerated RT during the period 1990-1998." | 1.33 | Accelerated radiotherapy for advanced laryngeal cancer. ( Edström, S; Ejnell, H; Haugen, H; Johansson, KA; Mercke, C, 2005) |
| "Unknown primary squamous cell carcinoma in the neck has been treated by combination therapy consisting of chemotherapy, radiation therapy and surgery." | 1.33 | [A case of unknown primary squamous cell carcinoma in the neck showing a high response with combined chemotherapy including nedaplatin, adriamycin and 5-fluorouracil]. ( Fujitani, K; Hirao, M; Ikenaga, M; Kashiwazaki, M; Masuda, N; Mishima, H; Nakamori, S; Sawamura, T; Tsujinaka, T; Yamashita, S, 2005) |
| "Twenty-two patients with localized esophageal cancer suitable for curative chemoradiation therapy and 24 patients suitable for palliative therapy were enrolled." | 1.33 | Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin. ( Burmeister, BH; Burmeister, EA; Gotley, DC; Harvey, JA; Mark Smithers, B; Thomas, J; Thomson, DB; Walpole, ET, 2005) |
| "Moderately differentiated squamous cell carcinoma diagnosed by pre-operative endoscopic biopsy." | 1.33 | [A case of complete response after neoadjuvant chemotherapy for advanced esophageal cancer with low-dose FP therapy]. ( Endoh, H; Koyama, K; Miyazawa, M; Muto, A; Ohtani, S; Satoh, M; Tsukada, M, 2005) |
| "HDRBT is safe and beneficial for local control in the radical treatment of patients with esophageal cancer." | 1.33 | The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy. ( Burtin, P; Corns, R; David, M; Devic, S; Evans, M; Faria, S; Mayrand, S; Parent, J; Szego, P; Vuong, T, 2005) |
| "Ten patients (77%) had undifferentiated carcinoma (WHO type III) and three patients (23%) had nonkeratinizing carcinoma (WHO type II)." | 1.33 | Nasopharyngeal carcinoma in the pediatric age group: the northern Israel (Rambam) medical center experience, 1989-2004. ( Arush, MW; Bar-Sela, G; Barak, AB; Bernstein, Z; Gez, E; Haimi, M; Kuten, A; Postovsky, S, 2005) |
| "In 140 patients with primary squamous cell carcinoma (SCC) of the tongue, intratumoural TS expression was evaluated by immunohistochemistry." | 1.33 | Intratumoural expression of thymidylate synthase is an independent predictor of prognosis in patients with squamous cell carcinoma of the tongue: results from a retrospective study. ( Fukuda, J; Goto, H; Goto, M; Ikemura, K; Inokuchi, T; Kawano, K; Kusukawa, J; Mimura, T; Oishi, M; Shiba, R; Shinohara, M; Sugihara, K; Sunagawa, H; Takahashi, T; Yanagisawa, S, 2006) |
| "Fifty-two patients with resectable esophageal cancers (cT2-4, Nx, and M0) received neoadjuvant radiochemotherapy (cisplatin, 5-5-fluorouracil, 36 Gy) followed by transthoracic en bloc esophagectomy." | 1.33 | High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. ( Baldus, SE; Bollschweiler, E; Brabender, J; Dienes, HP; Hoelscher, AH; Ling, FC; Metzger, R; Moenig, S; Mueller, RP; Neiss, S; Schneider, PM; Warnecke-Eberz, U; Xi, H, 2005) |
| "As patients with oesophageal cancer have a high incidence of co-morbidities including cardiac problems, the aim of this paper was to quantify the extent of cardiac radiation and discuss the influence of beam arrangement to reduce this." | 1.33 | Quantification and reduction of cardiac dose in radical radiotherapy for oesophageal cancer. ( Cominos, M; Cornes, P; Henrys, A; Mosleh-Shirazi, MA; Tait, D, 2005) |
| "Twenty-five squamous cell carcinomas, 1 melanoma, 2 basocellular carcinomas and 2 adenoid cystic carcinomas were treated." | 1.33 | [The outcome of treatments for carcinoma of the external auditory canal]. ( Delalande, C; Dumas, G; Lavieille, JP; Reyt, E; Righini, Ch; Schmerber, S; Soriano, E, 2005) |
| "This study is the first to evaluate esophageal cancer treatment with a pharmacogenetic paradigm and its application of pharmacogenetic analysis to multiple genes in each drug action pathway as a means of developing a more accurate and consistent risk prediction model." | 1.33 | Pharmacogenetics in esophageal cancer. ( Ajani, JA; Chiang, SS; Lu, C; Wu, X, 2005) |
| "Laryngeal squamous cell carcinoma (LSCC) is a common malignancy of the head and neck." | 1.33 | [Treatment and prognosis of stage III-IV laryngeal squamous cell carcinoma]. ( Chen, FJ; Guo, ZM; Tian, WD; Wu, GH; Zeng, ZY; Zhang, Q, 2006) |
| " We conclude that tumor ablation by ethanol injection for palliation combined with chemoradiation may be a low-cost alternative for advanced unresectable esophageal cancer." | 1.33 | Palliative ethanol injections of unresectable advanced esophageal carcinoma combined with chemoradiation. ( Abbasi, S; Korman, L; Wadleigh, RG, 2006) |
| "Most patients with anal cancer can expect to retain a functional sphincter after chemoradiation/radiation." | 1.33 | The bottom line: outcomes after conservation treatment in anal cancer. ( Dwyer, MK; Gebski, VJ; Jayamohan, J, 2006) |
| " Univariate analysis showed that gender, age, educational level, monthly income, economic status, religion, and the number of complications had influences on QOL; the patients in earlier T and N stages, irradiated by linear accelerator, with lower total dose and weekly dosage to the nasopharynx and neck, and those who had anterior nasal field radiation reported better QOL." | 1.33 | [Quality of life of 192 disease-freely survival nasopharyngeal carcinoma patients after radiotherapy]. ( Cui, NJ; Hu, WH; Liu, MZ; Ma, J; Wu, Y; Xia, YF, 2005) |
| "Most of the head and neck tumors are squamous cell carcinomas (SCCs), which are relatively sensitive to chemotherapeutic agents." | 1.33 | [Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer]. ( Horiuchi, C; Kawakami, M; Kondo, N; Masuda, Y; Matsuda, H; Mikami, Y; Nagao, J; Nishimura, G; Taguchi, T; Tsukuda, M; Yabuki, K; Yoshida, T, 2006) |
| " An eight-compartment pharmacokinetic model was used to describe the observed trends in concentrations of LNPs and total 5-FU and to estimate the released 5-FU concentration in the above tissues." | 1.33 | Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. ( Hitzman, CJ; Wattenberg, LW; Wiedmann, TS, 2006) |
| "In esophageal squamous cell carcinoma (ESCC), chemoradiotherapy (CRT) has a curative potential even in cases of locally advanced carcinoma." | 1.33 | Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications. ( Aoyagi, K; Ashida, A; Boku, N; Minashi, K; Muto, M; Ochiai, A; Ohtsu, A; Sasaki, H; Sato, H; Tsubosa, Y; Yoshida, S; Yoshida, T, 2006) |
| " To optimize radiotherapy, dosage was reduced by 10% or daily single target dose of intracavitary and distant irradiation split per 24 hrs, indications for preoperative radiotherapy variants were extended, and local dosage escalation in areas of lymphocyst or hematoma renounced." | 1.33 | [Improvement of postoperative radiotherapy in the complex treatment of stage II-III cervical cancer]. ( Kreĭnina, IuM; Povarova, EV; Shevchenko, LN; Shipilova, AN; Titova, VA, 2006) |
| "The radiosensitive human cervical squamous cell carcinoma cell line ME180 was examined to investigate the effects of 5FU on radiosensitivity and the effects of irradiation on 5FU-sensitivity." | 1.33 | Effective chemoradiotherapy protocol with 5-fluorouracil for cervical squamous cell carcinoma in vitro. ( Tanaka, T; Umesaki, N; Yukawa, K, 2006) |
| "In order to cure head and neck cancer without resection, chemotherapy (superselective intra-arterial infusion therapy with DCF) was conducted by anterograde, superselective intra-arterial infusion of 50-60 mg/m(2) of DOC and 50-60 mg/m(2) of CDDP via the femoral artery on day 1 followed by continuous intravenous instillation of 600-750 mg/m(2)/day of 5-FU for 5 days from day 2." | 1.33 | [Superselective intra-arterial infusion therapy with docetaxel, cisplatin and 5-fluorouracil for head and neck cancer--for tongue cancer patients in comparison patients with other therapies]. ( Furusaka, T, 2006) |
| "The most common sites of distant recurrence are represented by lung, liver and bone while brain and breast metastases are rare." | 1.33 | Successful outcome after combined chemotherapeutic and surgical management in a case of esophageal cancer with breast and brain relapse. ( Cossu Rocca, P; Costantino, S; Fadda, GM; Farris, A; Pinna, MA; Piredda, G; Putzu, C; Sanna, G; Santeufemia, DA; Sarobba, MG, 2006) |
| "The prognosis of esophageal cancer is not only affected by TNM stage but also by the level of serum vascular endothelial growth factor (S-VEGF)." | 1.33 | [Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squamous cell carcinoma patients--a report of 43 cases]. ( Cai, L; Cui, NJ; Liu, MZ; Wang, XS; Zhang, CQ, 2006) |
| "Docetaxel and nedaplatin are active for esophageal cancer." | 1.33 | Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. ( Chiba, N; Ishioka, C; Kakudo, Y; Kato, S; Miyazaki, S; Nemoto, K; Ohtsuka, K; Sakata, Y; Sakayori, M; Shibata, H; Shimodaira, H; Yoshioka, T, 2006) |
| "From January 1999 to November 2000, a total of 24 esophageal cancer patients (17 untreated and 7 recurrent cases) were treated with radiation therapy (60-70 Gy) combined with cis-diammine-glycolatoplatinum (Nedaplatin) (80-120 mg/body) and 5-fluorouracil (5-FU) (500-1,000 mg/body/24 h, continuous infusion for 5 days)." | 1.32 | Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer. ( Britton, KR; Matsushita, H; Miyata, T; Miyazaki, S; Nemoto, K; Ogawa, Y; Takahashi, C; Takai, Y; Takeda, K; Yamada, S, 2003) |
| "Two hundred and eleven patients with a squamous cell carcinoma in the thoracic esophagus who underwent transthoracic curative (R0) esophagectomy with radical lymphadenectomy, such as 3-field lymphadenectomy or total 2-field lymphadenectomy, between 1988 and 2000, were retrospectively reviewed." | 1.32 | Adjuvant chemotherapy after radical resection of squamous cell carcinoma in the thoracic esophagus: who benefits? A retrospective study. ( Fujita, H; Heroor, A; Matono, S; Mine, T; Sasahara, H; Shirouzu, K; Sudo, T; Sueyoshi, S; Tanaka, T; Toh, U; Yamana, H, 2003) |
| "Basaloid squamous carcinoma (BSC) of the esophagus has been associated with a poor outcome after surgery." | 1.32 | Basaloid-squamous carcinoma of the esophagus treated by preoperative chemotherapy: report of two cases. ( Adachi, W; Amano, J; Hanazaki, K; Igarashi, J; Kishimoto, K; Koide, N; Maezawa, T; Nakamura, T, 2003) |
| "Six patients had recurrent head and neck cancer, and 13 had newly diagnosed disease." | 1.32 | [Combined MTX.5-FU.CDGP for the treatment of head and neck cancer]. ( Dake, Y; Enomoto, T; Ikeda, H; Kawano, A; Kitano, H; Saitoh, Y; Sakoda, T; Seno, S, 2003) |
| " One course of nedaplatin, 5-FU and LV combined with radiation was performed alternatively." | 1.32 | [Effect of nedaplatin, 5-FU, and leucovorin combined with radiation therapy in unresectable esophageal carcinoma]. ( Futami, R; Makino, H; Maruyama, H; Miyashita, M; Miyashita, T; Nomura, T; Sasajima, K; Tajiri, T; Tateno, A, 2003) |
| "102 cases with oral squamous cell carcinoma(OSCC) were included in the study (63 males and 39 females, aged 22 to 67 years)." | 1.32 | [The clinical application and evaluation of combined chemotherapy in comprehensive treatment for oral squamous cell carcinoma]. ( Liao, C; Liu, S; Wang, D, 2003) |
| "We conducted a pilot study of nedaplatin + 5-fluorouracil (5-FU) combined with radiotherapy for 29 patients with primary advanced (stage IV) esophageal cancer." | 1.32 | [Nedaplatin and 5-fluorouracil combined with radiotherapy for advanced esophageal cancer]. ( Eguchi, R; Hayashi, K; Ide, H; Mitsuhashi, M; Nakamura, T; Narumiya, K; Ota, M; Takasaki, K, 2003) |
| "Primary hepatic squamous cell carcinoma is rare." | 1.32 | A case report of primary hepatic squamous cell carcinoma that remarkably responded to low dose arterial injection of anti-cancer drugs. ( Kaji, R; Nagata, E; Okabe, Y; Sasaki, N; Sata, M; Tateishi, I; Ueno, T; Yoshida, T, 2003) |
| "The treatment of oral cancer has a strong impact on the quality of life." | 1.32 | [Evaluation of quality of life of patients with oral squamous cell carcinoma. Comparison of two treatment protocols in a prospective study-first results]. ( Bloch-Birkholz, A; Grabenbauer, G; Kessler, P; Leher, A; Neukam, FW; Wiltfang, J, 2003) |
| "The murine AT-84 orthotopic model of oral cancer was assessed to find how similar it is to human oral cancer." | 1.32 | Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer. ( Hutchison, R; Kellman, RM; Lou, E; Shillitoe, EJ, 2003) |
| "5-Fluorouracil (5-FU) has been used topically and intralesionally to treat lesions related to squamous cell carcinoma (SCC) such as actinic keratosis, Bowen's disease, and keratoacanthoma." | 1.32 | Treatment of squamous cell carcinoma with intralesional 5-Fluorouracil. ( Hooper, D; Kendrick, C; Morse, LG; Parry, E; Ward, H, 2003) |
| "We report a case of esophageal cancer infiltrating the left main bronchus in which radical esophagectomy with clear surgical margins could be performed after preoperative radiochemotherapy." | 1.32 | [Resection of esophageal cancer infiltrating the left main bronchus following complete response to preoperative radiochemotherapy--a case report]. ( Fujiwara, Y; Fukuhara, K; Kaneko, M; Kinoshita, H; Lee, S; Nishizawa, S; Osugi, H; Taguchi, S; Takemura, M; Tanaka, Y, 2003) |
| "We used KB cell that an oral floor squamous cell carcinoma, vitamins as all-trans retinoic acid (ATRA), 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), 1alpha,25(OH)(2)D(3) (calcitriol) and 22-oxa-1,25-(OH)(2)D(3) (OCT)." | 1.32 | Anti-tumor effect of vitamin A and D on head and neck squamous cell carcinoma. ( Imagawa, Y; Ishii, A; Kato, Y; Kimura, Y; Satake, K; Takagi, E; Tsukuda, M, 2003) |
| "An analysis of chromosomal abnormalities in 10 head and neck cancer cell lines by comparative genomic hybridization was performed." | 1.32 | Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. ( Aldosari, N; Cullen, KJ; Haddad, BR; Newkirk, KA; Rone, JD; Schumaker, LM, 2003) |
| " We compared the expected AUC (area under the curve) with the actual AUC in primary oral cancer cases to assess the optimal dosage of CDGP for intra-arterial chemotherapy and to study relevance of AUC, effectiveness of independent chemotherapy and side effects." | 1.32 | [Clinical study of the area under the blood concentration-time curve of targeting intra-arterial infusion chemotherapy with nedaplatin for primary oral cancer]. ( Iwasaki, A; Miyake, M; Nagahata, S; Ogawa, T; Ohbayashi, Y; Ohkawa, M; Toyama, Y, 2004) |
| "Fifteen patients with advanced squamous cell carcinoma of the thoracic esophagus were treated with neoadjuvant chemoradiotherapy (NAC) combined with concurrent radiation (30 Gy/12 f) and 3 courses of 5-FU and CDDP (CDDP 5 mg/m2/day + 5-FU 250 mg/m2/day: day 1-5: div)." | 1.32 | [Neoadjuvant chemoradiotherapy for advanced squamous cell carcinoma of thoracic esophagus]. ( Honnma, S; Kohashi, S; Kondo, M; Kudo, T; Maeda, Y; Sato, Y; Shimokuni, T; Shinohara, T; Takahashi, S; Todo, S, 2004) |
| "Patients with locally advanced squamous carcinoma of the head and neck who also presented with nodal disease and underwent hyperfractionated radiotherapy and concurrent cisplatin/5-fluorouracil chemotherapy constituted the study population." | 1.32 | Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. ( Brizel, DM; Clough, RL; Downey, MA; Fisher, SR; Hunter, S; Prosnitz, RG; Scher, RL, 2004) |
| "Of 149 consecutive patients treated for cancer of the bladder, 14 patients met eligibility criteria." | 1.32 | Tolerance of radiotherapy and chemotherapy in elderly patients with bladder cancer. ( Goffin, JR; Rajan, R; Souhami, L, 2004) |
| "Infiltrating squamous cell carcinomas of the URT occurred in 92% of the controls and were reduced by 50% in animals receiving DFMO (P = 0." | 1.32 | Chemoprevention of cancer of the upper respiratory tract of the Syrian golden hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil. ( Estensen, RD; Wattenberg, LW; Wiedmann, TS, 2004) |
| "Treatment of head and neck cancer often associates different therapeutic modalities, including surgery, radiotherapy, and chemotherapy." | 1.32 | Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. ( Beaune, P; Beauregard, J; Blons, H; Brasnu, D; Gad, S; Laccourreye, O; Laurent-Puig, P; Manière, I; Tregouet, D; Zinzindohoué, F, 2004) |
| "To evaluate the efficacy and toxic effects of intensive chemoradiotherapy as a primary modality for organ preservation in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) and to define the patterns of treatment failure associated with this therapy." | 1.32 | Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations. ( Alexiou, M; Badley, J; Breau, R; Fan, CY; Hanna, E; Maddox, AM; Morgan, J; Penagaricano, J; Suen, J, 2004) |
| "Clinical staging of the tongue cancers showed two patients with stage III and four with stage IV disease." | 1.32 | Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for tongue cancer. ( Komori, T; Shibuya, Y; Tanimoto, H; Umeda, M; Yokoo, S, 2004) |
| "This is a report of a case with esophageal cancer in which pathological CR was obtained by neoadjvant chemoradiotherapy using a low-dose of nedaplatin (CDGP)/5-FU." | 1.32 | [A resected case of thoracic esophageal cancer in which pCR was obtained using low-dose of nedaplatin (CDGP)/5-FU and radiotherapy]. ( Fujiwara, Y; Higashino, M; Iwasaki, H; Kaneko, M; Lee, S; Nishizawa, S; Osugi, H; Takemura, M; Tanaka, Y, 2004) |
| "Avascular-differentiated regions in squamous cell carcinoma offer sanctuary to some hypoxic but viable tumor cells (carbonic anhydrase IX and Ki67 positive) that escape therapy because of limited drug delivery." | 1.32 | Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. ( Azrak, R; Bhattacharya, A; Cao, S; Durrani, FA; Mazurchuk, R; Pendyala, L; Rustum, YM; Slocum, HK; Spernyak, JA; Tóth, K, 2004) |
| "We report a patient with esophageal cancer with concomitant liver metastasis in whom complete response was achieved by chemoradiation therapy." | 1.31 | Complete regression of esophageal cancer with concomitant liver metastasis achieved by concurrent chemoradiation therapy. ( Hiramoto, J; Murakami, S; Nagayama, K; Nakada, T; Sakabe, S; Tsuruta, Y, 2002) |
| "In patients with advanced laryngeal cancer, quality of life can be significantly enhanced by treatment regimens that preserve the larynx." | 1.31 | Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. ( Bradford, CR; Devaney, K; Fisher, SG; Johnson, M; Singleton, T; Trask, DK; Wicha, M; Wolf, GT, 2002) |
| "Postoperative complications were anastomosis leakage in 1 patient, and anastomosis stenosis in 2 and esophagobronchial fistula in 1." | 1.31 | [Salvage operation for esophageal cancer after radical chemoradiotherapy]. ( Boku, N; Gotohda, N; Nagai, K; Nishimura, M; Ohtsu, A; Yoshida, J, 2002) |
| "A complete remission of anal cancer was achieved in both patients with minimal acute and late toxicities." | 1.31 | Successful chemoradiotherapy for anal cancer despite previous radical radiotherapy for gynaecological malignancy. ( Arnott, SJ; Leslie, MD; Subramaniam, R, 2002) |
| "Cells derived from human oesophageal squamous cell carcinoma (OSC-1) were grown for 2 days and incubated with cisplatin (CDDP), 5-fluorouracil (5-FU), methotrexate (MTX) or gemcitabine (GEM) for 4 h." | 1.31 | Early changes in [18F]FLT uptake after chemotherapy: an experimental study. ( Bares, R; Bartusek, G; Dittmann, H; Dohmen, BM; Kehlbach, R; Pritzkow, M; Sarbia, M, 2002) |
| "A 77-year-old man with advanced esophageal cancer with tracheal and esophageal obstruction underwent continuous low-dose FP chemotherapy for a total of seven weeks, resulting in a complete response (CR) and disappearance of the esophago-tracheal fistula." | 1.31 | [A trial of continuous and biweekly low-dose cisplatin and 5-FU with UFT chemotherapy for esophageal cancer]. ( Hasebe, K; Sasaki, S; Takamura, H; Urade, M; Yagi, M, 2002) |
| "Advanced esophageal cancer patients with extensive lymph node metastases show extremely poor prognosis and the long-term outcome is poorer with the involvement of more lymph nodes." | 1.31 | A case of advanced esophageal cancer with extensive lymph node metastases successfully treated with multimodal therapy. ( Gunduz, M; Haisa, M; Naomoto, Y; Shigemitsu, K; Shirakawa, Y; Tanaka, N, 2002) |
| " Further study of dosage and schedule is necessary, however, CDGP/5-FU combined with radiation therapy could be used as choices of chemoradiotherapy for esophageal cancer in the future." | 1.31 | [Clinical study of the combination of small amount of nedaplatin (CDGP)/5-FU with radiation for the treatment of esophageal cancer]. ( Endo, T; Hara, T; Hoshikawa, Y; Iino, S; Inaba, H; Kato, N; Kitajima, S; Kobayashi, Y; Koitabashi, Y; Miyazaki, A; Nakagawa, T; Nakaya, S; Ogihara, K; Tsuda, T; Watanabe, Y, 2002) |
| "During the follow-up, an elevated squamous cell carcinoma antigen (SCC Ag) level led to restaging computed tomography scans, which confirmed recurrent metastatic disease in the liver." | 1.31 | Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy. ( Bolton, M; Copur, S; Frankforter, S; Fruehling, RM; Ledakis, P; Mleczko, KL; Muhvic, J; Norvell, M; Novinski, D; VanWie, E, 2001) |
| "Compared with adenocarcinoma, squamous cell carcinoma might be a favorable target for 5-FU-based chemotherapy in the treatment of nonsmall-cell lung cancer." | 1.31 | Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues. ( Koga, T; Ninomiya, S; Takeo, S; Yano, T, 2002) |
| "We encountered a case of extensive squamous cell carcinoma ranging from the tongue to the mouth floor, in which chemotherapy using a combination of nedaplatin and 5-FU was effective." | 1.31 | [A case of large carcinoma of the tongue and mouth floor, in which chemotherapy using a combination of nedaplatin and 5-FU was effective]. ( Inoda, H; Nishida, T; Nishikawa, M; Shimada, T; Takigami, K; Tanaka, A; Tsuda, Y; Yamamoto, G; Yoshitake, K, 2002) |
| "Over forty percent patients with squamous cell carcinoma showed moderate chemosensitivity to VM-26, CDDP and E-ADM, and over forty percent cases with adenoid carcinoma showed moderate chemosensitivity to Vm-26, Taxol and E-ADM." | 1.31 | [Chemosensitivity testing of oral and maxillofacial cancer with biopsy specimens]. ( Chen, W; Guo, W; Lin, L; Xu, Q; Zhou, X, 2002) |
| "Eight patients affected by conjunctival squamous cell carcinoma (three recurrent cases, three incompletely excised, and two untreated cases) were treated with 1% 5-FU eye drops." | 1.31 | Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil. ( Angeli, CD; Boccato, P; de Belvis, V; Midena, E; Valenti, M, 2000) |
| " Radiotherapy was administered twice per day on dosing days 1 through 42 to a total dose of 7200 cGy to the primary tumor and 6000 cGy to the involved lymph nodes." | 1.31 | Nodal volume reduction after concurrent chemo- and radiotherapy: correlation between initial CT and histopathologic findings. ( Labadie, RF; Mukherji, SK; Pillsbury, HC; Weissler, MC; Yarbrough, WG, 2000) |
| "It is possible to cure oesophageal cancer with chemo-radiotherapy and selective oesophagectomy, and achieve organ preservation in the majority of long term survivors." | 1.31 | Primary chemo-radiotherapy and selective oesophagectomy for oesophageal cancer: goal of cure with organ preservation. ( Lim, JT; Wilson, KS, 2000) |
| "Of 69 patients with laryngeal cancer, 14 were treated by partial laryngectomy and 19 by radiation therapy; of 46 patients with piriform sinus cancer, 8 were treated by partial surgery and 12 by radiation therapy; the other patients were treated as was initially planned (total laryngectomy with partial pharyngectomy)." | 1.31 | Conservative surgery in T3-T4 pharyngolaryngeal squamous cell carcinoma: an alternative to radiation therapy and to total laryngectomy for good responders to induction chemotherapy. ( Angelard, B; Lecanu, JB; Monceaux, G; Périé, S; St Guily, JL, 2000) |
| "Chemotherapy is commonly used to treat advanced oral squamous cell carcinoma (SCC) and is known to kill cancer cells through apoptosis." | 1.31 | 5-Fluorouracil-induced apoptosis in cultured oral cancer cells. ( Hu, D; Oda, D; Poot, M; Tong, D, 2000) |
| "225 patients with squamous cell carcinoma of the oesophagus were prospectively studied." | 1.31 | Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis. ( Busch, R; Roder, RJ; Rosenberg, R; Thorban, S, 2000) |
| "5-fluorouracil (5-FU) treatment is also widely utilized." | 1.31 | Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. ( Chiarello, SE, 2000) |
| "In the present study we adapted 4 colon cancer (C26-A, C26-10, C26-G and WiDr) and 3 squamous cell carcinoma of the head and neck (HNSCC) cell lines (11B, 14C and 22B) to culture medium with low folate (LF) levels (2." | 1.31 | Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. ( Backus, HH; Jansen, G; Molders, N; Padrón, JM; Peters, GJ; Pinedo, HM; van Der Wilt, CL; van Groeningen, CJ; Wouters, D, 2000) |
| "Most nonendocrine pancreatic neoplasms are adenocarcinomas of ductal cell or acinar origin." | 1.31 | Squamous cell carcinoma of the pancreas with cystic degeneration. ( Colarian, J; Fowler, D; Poolos, S; Schor, J, 2000) |
| "Squamous cell carcinoma was diagnosed by histologic examination of a biopsy specimen." | 1.31 | Successful treatment of oral squamous cell carcinoma with intralesional fluorouracil in a Malayan tapir (Tapirus indicus). ( Karpinski, L; Miller, CL; Templeton, RS, 2000) |
| "In the patients with squamous cell carcinoma, 100 mg/m2 of cisplatin was infused intravenously, followed immediately by five consecutive daily administrations of 5-fluorouracil, 1,000 mg/m2/day, each infused intravenously over 24 hr." | 1.31 | Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors. ( Kim, GE; Kim, SN; Kim, SW; Park, TK; Suh, CO, 2000) |
| "Occasionally in head and neck cancer patients treated surgically after induction chemotherapy, the histologic analysis of the excised tissue does not show evidence of viable tumor cells, a situation that the authors named "negative specimen." | 1.31 | Histologically negative specimens after induction therapy: frequency and impact on survival. ( de Juan, M; León, X; López-Pousa, A; Orús, C; Quer, M; Sancho, FJ, 2000) |
| "The prognosis of upper thoracic esophageal cancer is poor when compared with middle and lower thoracic esophageal cancer because the tumor easily infiltrates the respiratory tract and surgical en-bloc resection is difficult." | 1.31 | Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy. ( Doki, Y; Fujiwara, Y; Inoue, M; Monden, M; Shiozaki, H; Tsujinaka, T; Yano, M, 2000) |
| "Forty-seven patients with squamous cell carcinomas of the esophagus had undergone radiation therapy, followed by surgical resection." | 1.31 | CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. ( Doki, Y; Fujiwara, Y; Inoue, M; Kishi, K; Miyata, H; Monden, M; Nishioka, K; Shiozaki, H; Yamamoto, H; Yano, M, 2000) |
| "Thirty-four patients with advanced squamous cell carcinoma of the thoracic esophagus (T2-4 N0-1 M0), who underwent one cycle of cisplatin and 5-fluorouracil therapy followed by subtotal esophagectomy, were studied." | 1.31 | Assessment of the predictive value of clinical and histopathological factors as well as the immunoexpression of p53 and bcl-2 proteins in response to preoperative chemotherapy for esophageal squamous cell carcinoma. ( Chibowski, D; D browski, A; Szumilo, J, 2000) |
| "The effect of the treatment of anal cancer by performing a high-dose-rate (HDR) brachytherapy boost during a short split between the external beam radiotherapy series (EBR) +/- chemotherapy was investigated." | 1.31 | Experience with split-course external beam irradiation +/- chemotherapy and integrated Ir-192 high-dose-rate brachytherapy in the treatment of primary carcinomas of the anal canal. ( Berger, A; Gebhart, FH; Geyer, E; Hebenstreit, J; Kapp, KS; Oechs, AC; Stoeger, H, 2001) |
| "We recently treated 2 patients with squamous cell carcinoma in the anal canal with bilateral inguinal nodal metastases using chemoradiotherapy." | 1.31 | [Two cases of squamous cell carcinoma of the anal canal treated with chemoradiotherapy]. ( Furutani, K; Fuwa, N; Kamata, M; Kodaira, T; Matsumoto, A; Sasaoka, M, 2001) |
| "In most new cases of head and neck squamous cell carcinoma, especially in the pharynx and oral cavity, the tumors are advanced." | 1.31 | [Development of new treatment modalities for advanced head and neck carcinomas]. ( Tsukuda, M, 2001) |
| "We report a typical case with a squamous cell carcinoma of the tongue and classical cutaneous symptoms disappearing with the treatment of the tumour." | 1.31 | Bazex syndrome. ( Buxtorf, K; Hübscher, E; Panizzon, R, 2001) |
| "We reviewed the records of 223 patients treated for T3--4 squamous cell carcinoma of the larynx between October 1, 1957, and December 1, 1999." | 1.31 | Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience. ( Fu, KK; Goffinet, DR; Le, QT; Nguyen-Tan, PF; Quivey, JM; Singer, M; Terris, DJ, 2001) |
| "All of them had stage IV, unresectable squamous cell carcinoma of the pharynx and they received continuous bid radiotherapy (two daily fractions of 1." | 1.31 | [Concomitant bifractionated radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in locally progressive, non-resectable epidermoid carcinomas of the pharynx: ten years experience at the Antoine Lacassagne center]. ( Bensadoun, RJ; Chauvel, P; Courdi, A; Dassonville, O; Demard, F; Ettore, F; Falewee, MN; Lagrange, JL; Magné, N; Marcy, PY; Milano, G; Pivot, X; Poissonnet, G; Santini, J; Schneider, M; Vallicioni, J, 2001) |
| "We report a case of advanced esophageal cancer, which was treated by chemoradiotherapy combined with surgical treatment." | 1.31 | [Chemoradiotherapy and salvage surgery in a patient with advanced esophageal cancer]. ( Fukao, K; Kawamoto, T; Koike, N; Kondo, T; Moon, Y; Nakagawa, Y; Ohara, K; Shimizu, W; Todoroki, T; Yamamoto, Y; Yoshida, S, 2001) |
| "A 63-year-old male with advanced esophageal cancer was admitted to our hospital." | 1.31 | [Tissue platinum distribution and the effect following intra-arterial injection of cisplatin to metastatic liver cancer--a case report]. ( Kumada, K; Makuuchi, M; Midorikawa, T; Nemoto, H; Sanada, Y; Sasaya, S; Takeuchi, S; Takizawa, K; Uemichi, O; Yamaguchi, M; Yoshizawa, Y, 2001) |
| "A diagnosis of esophageal cancer with subcutaneous abscess was made based on examination and biopsy results." | 1.31 | [A patient with esophageal cancer with subcutaneal abscess and esophago-tracheal fistula who survived more than 2 years following treatment by drainage and chemoradiation therapy]. ( Furukawa, J; Katsumoto, Y; Maruyama, K; Maruyama, N; Morimoto, T; Nakaguchi, K; Nakamura, M; Okajima, S; Shingai, T; Sue, F, 2001) |
| "Telomerase activity was high in esophageal cancer tissue and showed positive correlation with blood vessel invasion." | 1.31 | Telomerase activity in esophageal squamous cell carcinoma: down-regulation by chemotherapeutic agent. ( Fujii, Y; Iwase, H; Kato, J; Kuwabara, Y; Mitani, M; Mitsui, A; Sato, A; Shinoda, N; Sugiura, M; Suzuki, T; Toyama, T, 2002) |
| "Patients with advanced squamous cell head and neck cancer were treated with hyperfractionated radiation therapy (72 Gy at 1." | 1.31 | Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy. ( Adelstein, DJ; Carroll, MA; Esclamado, RM; Lavertu, P; Rybicki, LA; Saxton, JP; Strome, M; Wood, BG, 2002) |
| "Six head and neck cancer cell lines were used to study the cytotoxic effects of combining ZD1839 ('Iressa'), a new selective epidermal growth factor receptor tyrosine kinase inhibitor, and radiation." | 1.31 | Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. ( Dubreuil, A; Fischel, JL; Formento, P; Lagrange, JL; Magné, N; Marcié, S; Milano, G, 2002) |
| "Patients diagnosed with Chronic Lymphocytic Leukemia (CLL) have an increased risk of developing second primary cancers." | 1.31 | Multiple neoplasms: a case report. ( Pigeaud-Klessens, ML; van der Valk, P, 2002) |
| " Patients in the P+M group who received a 5-fluorouracil (5-FU) dosage of more than 3500 mg had a better 5-year local control rate than patients who received a 5-FU dosage of less than 3500 mg (p = 0." | 1.31 | Trimodal combination therapy for maxillary sinus carcinoma. ( Amagasa, T; Enomoto, S; Kishimoto, S; Miura, M; Ogura, I; Shibuya, H; Yoshimura, R, 2002) |
| "A case of primary squamous cell carcinoma of the ureter is reported." | 1.30 | [A case of primary squamous cell carcinoma of the ureter: biochemical modulation with cisplatin and 5-fluorouracil]. ( Kageyama, S; Ueda, T, 1997) |
| "We report a case of tongue cancer presenting with SSD type brain embolism induced by chemotherapy with CBDCA and 5-FU (CF Therapy) A 35-year-old woman underwent CF therapy for squamous cell carcinoma of the tongue." | 1.30 | [A case report of tongue cancer presenting with SSD type brain embolism induced by chemotherapy with CBDCA and 5-FU]. ( Akasaka, Y; Hanyu, S; Ikeguchi, K; Itoh, H; Numao, A; Osano, H, 1997) |
| "Trimodality treatment for esophageal cancer may provide long-term survival in some patients regardless of their pCR status." | 1.30 | Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus. ( Bernard, SA; Detterbeck, FC; Egan, TM; Jones, DR; Parker, LA; Tepper, JE, 1997) |
| "The subject was a patient who had squamous cell carcinoma in the pudendum and the inguinal region (12." | 1.30 | [A case of FIGO stage IV A vulvar cancer successfully treated by neoadjuvant chemotherapy with continuous intra-arterial infusion (cisplatin, 5-fluorouracil)]. ( Narimatsu, A; Okada, O, 1997) |
| "Most of them (n = 40) were squamous cell carcinomas." | 1.30 | [Therapy pf cervical lymph node metastases of unknown primary tumor]. ( Fietkau, R; Iro, H; Kirschner, MJ; Sauer, R; Waldfahrer, F, 1997) |
| "In this case, there were esophageal cancer in the cervical esophagus, with intramural spreading in whole esophagus." | 1.30 | Esophageal intramural pseudodiverticulosis with esophageal cancer improved by target rotation irradiation: case report. ( Katayama, H; Naoi, Y; Tomiyoshi, H, 1997) |
| "Pretreatment of 5-fluorouracil (5-FU), but not posttreatment, has been shown to augment the cytotoxicity of cisplatin (CDDP) or even circumvent CDDP resistance by inhibiting repair of platinum-DNA interstrand crosslinks as well as by reducing the cellular glutathione (GSH) contents in CDDP-resistant HST-1/CP0." | 1.30 | Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line. ( Esaki, T; Fujishima, H; Kondo, T; Masumoto, N; Nakano, S; Niho, Y; Tatsumoto, T, 1997) |
| "Eighty-eight patients with cancer of the esophagus ineligible for surgery were entered in the study between 1986 and 1993." | 1.30 | Accelerated fractionation in esophageal cancers: a multivariate analysis on 88 patients. ( Auperin, A; Dhermain, F; Ducreux, M; Elias, D; Girinsky, T; Kac, J; Marsiglia, H; Randrianarivelo, H; Rougier, P, 1997) |
| "Hypercalcemia is the most common metabolic disorder associated with malignancies." | 1.30 | Hypercalcemia and carcinoma of the penis. ( Ago, CT; Videtic, GM; Winquist, EW, 1997) |
| "The histopathological diagnosis was squamous cell carcinoma of the ureter, G1 INF beta, pT2, pR0, pV1 and pL0." | 1.30 | [A case of advanced primary ureteral squamous cell carcinoma responding to combination chemotherapy with cisplatin and 5-fluorouracil]. ( Fujita, T; Mori, H; Nakamura, Y; Noguchi, M; Okada, K, 1997) |
| "The most common histologic type is squamous cell carcinoma (82%)." | 1.30 | Squamous cell carcinoma of the vulva in the south of Israel: a study of 50 cases. ( Cohen, Y; Friger, M; Glezerman, M; Piura, B; Rabinovich, A, 1998) |
| "Thrombocytopenia was the major dose-limiting toxicity in this study." | 1.30 | [Importance of AUC of carboplatin in head and neck cancer]. ( Makishima, K; Shimizu, T; Yoshida, M, 1998) |
| "Fifteen patients with squamous cell carcinoma arising in the gingiva (8), tongue (3), floor of the mouth (1), or maxillary sinus (3) were enrolled." | 1.30 | Intranodal injection of anticancer drugs into fixed cervical metastatic lymph nodes. ( Osaki, T; Ueta, E; Yamamoto, T; Yoneda, K, 1997) |
| "5-Fluorouracil is an S-phase-specific, synthetic pyrimidine antimetabolite, which is used as a cytostatic agent for a variety of malignant lesions, either singly or in multidrug regimens." | 1.30 | Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. ( Ahmad, M; Aziz, SA; Iqbal, K; Jalal, S; Mohi-ud-Din, K; Tramboo, NA, 1998) |
| "In group 3, invasive squamous cell carcinoma and adenocarcinoma developed in one rat each." | 1.30 | Effect of 5-fluorouracil on gastrointestinal carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats. ( Mori, M; Muto, T; Nagawa, H; Seto, Y; Tsuruo, T, 1999) |
| " The findings indicate that a method is available to rationally address the design of dosing schedules in concurrent therapy regimens." | 1.30 | Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. ( Bachert, P; Becker, M; Dietz, A; Knopp, MV; Rudat, V; Schlemmer, HP; van Kaick, G; Vanselow, B; Wannenmacher, M; Weidauer, H; Wollensack, P; Zuna, I, 1999) |
| "Metaplastic breast cancer is a rare disease with little information available to guide therapy." | 1.30 | Metaplastic breast cancer: prognosis and response to systemic therapy. ( Adjei, AA; Ingle, JN; Rayson, D; Suman, VJ; Wold, LE, 1999) |
| "8-30 mg/kg of BOF-A2) was orally administered every day to 5 mice in each dosage group for 4 weeks." | 1.30 | The inhibitory action of BOF-A2, a 5-fluorouracil derivative, on squamous cell carcinoma. ( Osaki, T; Ueta, E; Yamamoto, T; Yoneda, K, 1999) |
| "The treatment of upper thoracic esophageal cancer remains challenging, and combined treatment is necessary to improve the outcome." | 1.30 | Role of preoperative chemoradiation in the management of upper third thoracic esophageal squamous cell carcinoma. ( Doki, Y; Inoue, M; Monden, M; Shiozaki, H; Tsujinaka, T; Yamamoto, M; Yano, M, 1999) |
| "Three cases of prominent-type advanced esophageal cancer were treated with chemoradiation therapy using a 5-FU analog and low dose CDDP." | 1.30 | [Chemoradiation therapy for advanced esophageal cancers--report of 3 cases]. ( Fukao, K; Kawai, Y; Kawamoto, T; Koike, N; Maruyama, T; Monoi, H; Ohara, K; Shimizu, W; Todoroki, T; Yamamoto, Y; Yoshida, S, 1999) |
| "A 63-year-old male with an esophageal cancer invading the bronchus was treated with radiation therapy (70 Gy) from November 1995, resulting in the disappearance of the lesion." | 1.30 | [Usefulness of combination therapy with expandable metallic stent replacement and FLEP chemotherapy (consisting of 5-FU, leucovorin, etoposide and cisplatin) for advanced esophageal cancer invading the bronchus: a case report]. ( Hada, T; Kobayashi, I; Kohno, S; Matai, K; Oda, Y; Ohmori, H; Sasaya, K; Yamazaki, Y, 1999) |
| "Fifty-three patients with localized esophageal cancer received concurrent chemoradiotherapy followed by brachytherapy." | 1.30 | High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma. ( Dokiya, T; Oki, Y; Yorozu, A, 1999) |
| "Local control of esophageal cancer is excellent following neoadjuvant chemotherapy and radiation therapy." | 1.30 | Resectable esophageal carcinoma: local control with neoadjuvant chemotherapy and radiation therapy. ( Adelstein, DJ; Becker, M; Chidel, MA; Kupelian, PA; Rice, TW; Suh, JH, 1999) |
| "These guidelines for management of Bowen's disease have been prepared for dermatologists on behalf of the British Association of Dermatologists." | 1.30 | Guidelines for management of Bowen's disease. British Association of Dermatologists. ( Cox, NH; Eedy, DJ; Morton, CA, 1999) |
| "Prognosis for advanced head and neck squamous cell carcinoma remains poor despite advances in treatment, although a small number of patients may benefit from induction therapy leading to increased local control." | 1.30 | p53 expression in locally advanced pharyngeal squamous cell carcinoma. ( Alvarez-Vicent, JJ; Ballestín, C; Benito, A; Brandáriz, JA; Colomer, R; de la Cruz, J; Gómez, C; Hitt, R; Lassaletta, L, 1999) |
| "Distant-metastases-free survival was influenced by the following factors: lymph-node involvement (NO: 82% vs N1 to N3: 68%, p = 0." | 1.30 | [Nasopharyngeal carcinoma: only irradiation or simultaneous radiochemotherapy?]. ( Grabenbauer, GG; Grüner, A; Iro, H; Martus, P; Rödel, C; Sauer, R; Weidenbecher, M, 1999) |
| "Intraarterial drug therapy for head and neck cancer has been used for more than 30 years." | 1.29 | Palliative, intraarterial chemotherapy for advanced head and neck cancer using an implantable port system. ( Eckardt, A; Kelber, A, 1994) |
| "Patients with locally advanced squamous cell carcinoma of the bulbomembranous urethra fare poorly whether they undergo surgery or primary radiotherapy." | 1.29 | Combined chemoradiotherapy for locally advanced squamous cell carcinoma of the bulbomembranous urethra: a case report. ( Huang, DT; Lutz, ST, 1995) |
| "The standard treatment for anal cancer is combination chemo-radiotherapy." | 1.29 | The influence of age on the management of anal cancer. ( Basrur, V; de Gara, CJ; Figueredo, A; Goodyear, M; Knight, P, 1995) |
| "Daily administration of low-dose CDDP and 5-FU combined with radiotherapy was performed in three cases of oral squamous cell carcinoma in aged patients whose general condition was poor." | 1.29 | [Method for daily administration of low-dose CDDP and 5-FU combined with radiotherapy for oral squamous cell carcinoma]. ( Kimura, T; Kishimoto, K; Matsumura, T; Misaki, M; Terakado, N; Yamada, Y, 1995) |
| "Histologically, aneuploidy was detected in 71." | 1.29 | [Flow cytometric DNA analysis and chemosensitivity in squamous cell carcinoma of the head and neck]. ( Miyagi, M; Nakashima, T; Soda, T, 1994) |
| "Cardiotoxicity is a serious but relatively unknown side-effect of treatment with 5-fluorouracil (5-FU)." | 1.29 | Changes of blood viscosity in patients treated with 5-fluorouracil--a link to cardiotoxicity? ( Albertsson, M; Cwikiel, M; Eskilsson, J; Larsson, H; Persson, SU, 1995) |
| "We have treated 17 patients with squamous cell carcinoma of the upper esophagus by alternating chemoradiotherapy and by following the patients for 2 to 5 years, or until their death." | 1.29 | Patterns of failure in carcinoma of the upper esophagus after alternating chemoradiotherapy. ( Chadha, M; Malamud, S; Vikram, B; Yu, L, 1994) |
| "The tegafur suppository was useful because of the high concentration in cancer tissue and metastatic lymph nodes without any obvious side effects in the head and neck region." | 1.29 | [Tissue concentration of tegafur suppository in patients with head and neck cancer--concentration of 5-FU in cancer tissue]. ( Esu, H; Itokazu, T; Kamiya, S; Kanazawa, T; Koja, S; Maeshiro, N; Noda, Y; Simoji, Y; Yamauchi, M, 1994) |
| "Four hundred five patients with anal cancer were identified by computer search, and 204 (51%) were evaluable; 164 of 204 (80%) had squamous cell carcinoma, 137 of whom (84%) were treated with sphincter-preserving procedures, and 27 of whom (16%) were treated by by radical surgery." | 1.29 | Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy. ( Coplin, MA; Johnson, FE; Longo, WE; Vernava, AM; Virgo, KS; Wade, TP, 1994) |
| "Among them, three patients had acquired immunodeficiency syndrome (AIDS)." | 1.29 | Squamous-cell carcinoma of the anus in HIV-positive patients. ( Berson, A; Chadha, M; Malamud, S; Pisch, J; Rosenblatt, EA, 1994) |
| " In a first step, the 5-FU pharmacokinetic and pharmacodynamic analysis of 25 cycles for 14 patients revealed that both the time-concentration product (ASC) for the entire cycle and the half-cycle were predictive of cycle toxicity and a dose adjustment diagram was established." | 1.29 | [Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion]. ( Klein, T; Levêque, D; Velten, M; Wihlm, J, 1993) |
| "The second patient had advanced gastric cancer with carcinomatosis." | 1.29 | [Nocturnal infusion of 5-fluorouracil in advanced digestive tract cancer--two case reports]. ( Furuya, Y; Hamabe, Y; Ku, Y; Nakamura, T; Saitoh, Y; Yamamoto, K, 1994) |
| "Eighty-one laryngeal cancer patients treated at our clinic during the past ten years were studied clinically." | 1.29 | Results of treatment of laryngeal cancer. ( Hasegawa, T; Kim, Y; Sano, R; Suzuki, H, 1994) |
| "A total of 48 patients with squamous cell carcinomas (SCC) of the head and neck were examined with positron emission tomography (PET) and 18Fluor-deoxyglucose (FDG)." | 1.29 | The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors. ( Haberkorn, U; Reisser, C; Strauss, LG, 1993) |
| " Adverse reactions to chemotherapy were documented for all 164 patients included in the study." | 1.29 | Predictive factors of a complete response to and adverse effects of a CDDP-5FU combination as primary therapy for head and neck squamous carcinomas. ( Bachaud, JM; Boussin, G; Daly-Schveitzer, NJ; David, JM; De Forni, M; Perineau, D; Pessey, JJ; Serrano, E; Shubinski, RE, 1993) |
| "An advanced esophageal cancer patient with multiple liver metastases was treated with a combination of CDDP, 5-FU and THP-ADM." | 1.29 | [A case of nonresectable esophageal cancer treated by the combination of cisplatin, 5-fluorouracil and THP-adriamycin]. ( Anai, H; Ichiyoshi, Y; Matsuzaki, K; Minamisono, Y; Miura, O; Nagasaki, S; Toda, T, 1993) |
| "Twenty-six patients with advanced squamous carcinoma of the head and neck or local recurrence after surgery and/or radiotherapy received carboplatin 300 mg/m2 intravenously on day 1 and 5-fluorouracil 1 gm/m2 by continuous intravenous infusion for 4 days." | 1.29 | Carboplatin and 5-fluorouracil in advanced and recurrent squamous carcinoma of the head and neck. ( Canney, P; Junor, E; Yosef, H, 1993) |
| "The conventional surgical treatment of anal squamous cell carcinoma is abdominoperineal resection." | 1.29 | An alternative treatment of anal squamous cell carcinoma: combined radiotherapy and chemotherapy. ( Changchien, CR; Chen, JS; Fan, HA; Hsu, KC; Tang, R; Wang, JY; You, YT, 1993) |
| "Seventy patients with local squamous cell carcinoma of the esophagus were treated between 1981 and 1990 with preoperative chemotherapy, surgical resection, and possible postoperative radiation therapy and/or chemotherapy." | 1.29 | Long-term follow-up of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and possible postoperative radiotherapy and/or chemotherapy in squamous cell carcinoma of the esophagus. ( Bromberg, C; Carey, RW; Choi, NC; Grillo, HC; Hilgenberg, AD; Logan, DL; Mathisen, DJ; Wain, JC; Wilkins, EW, 1993) |
| "From 1972 to 1986, 108 patients with squamous cell carcinoma of the maxillary sinus were treated at the Department of Radiology, University of Tokyo Hospital." | 1.29 | Analysis of the results of combined therapy for maxillary carcinoma. ( Akanuma, A; Aoki, Y; Hasezawa, K; Karasawa, K; Muta, N; Nakagawa, K; Onogi, Y; Sakata, K; Sasaki, Y; Terahara, A, 1993) |
| "However, the presence of a tracheoesophageal fistula has historically been considered a relative contraindication to radiation therapy." | 1.29 | Irradiation of carcinoma of the esophagus containing a tracheoesophageal fistula. ( Arlington, A; Bohorquez, J, 1993) |
| "Because DNA aneuploidy is an indirect measure of the proliferative activity of a cell population, a study was conducted to examine differences in tumor response to induction chemotherapy based on aDI values." | 1.29 | DNA content and tumor response to induction chemotherapy in patients with advanced laryngeal squamous cell carcinoma. ( Beals, TE; Fisher, SG; Gregg, CM; McClatchy, KM; Wolf, GT, 1993) |
| "The palliative effects on dysphagia of radiotherapy (RT) and chemotherapy (CT) were evaluated retrospectively and compared with the effect of the self-expanding stent, evaluated in the prospective study." | 1.29 | Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment. ( Albertsson, M; Cwikiel, M; Cwikiel, W, 1996) |
| "The role of cisplatin and alcohol abuse in this neurotoxic episode, can not yet completely be excluded." | 1.29 | [Acute cerebellar syndrome after treatment with 5-fluorouracil]. ( Barbieux, C; Cerf, I; de Parades, V; Patri, B, 1996) |
| "Patients presenting with squamous cell carcinoma of the pyriform sinus, epilarynx or postcricoid area with indication of pharyngolaryngectomy, without previous treatment, distant metastasis, multiple primaries or general contraindications for surgery and chemotherapy were included in the study." | 1.29 | [Perioperative chemotherapy of squamous cell carcinoma of the hypopharynx]. ( Domenge, C; Eschwège, F; Leridant, AM; Luboinski, B; Mamelle, G; Wibault, P, 1996) |
| " In CCR managed with EC, the independent factors of age, tumor classification, exact tumor location, true vocal cord motion, arytenoid cartilage motion, total dosage of drugs delivered, and number of courses received were tested for potential correlation with survival, local recurrence, nodal recurence, and distant metastasis." | 1.29 | Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results. ( Bassot, V; Brasnu, D; Khayat, D; Laccourreye, H; Laccourreye, O; Ménard, M, 1996) |
| "Results of 21 cases of squamous cell carcinoma of anal canal treated by continuous infusion of 5-fluorouracil 1000 mg/sqm for 4 days and mitomycin-C 15 mg/sqm on 1st day by i." | 1.29 | Management of carcinoma anal canal with combination chemotherapy and concurrent radiotherapy. ( Mishra, RC; Sai, PL; Senapati, S, 1996) |
| " Our preliminary data indicate that postradiation adjuvant chemotherapy with a weekly FP regimen at our dosage is not recommended for high-risk NPC." | 1.29 | Preliminary report of outpatient weekly adjuvant chemotherapy for high-risk nasopharyngeal carcinoma. ( Hsu, CY; Jan, JS; Lin, JC, 1996) |
| " Further studies are needed to establish a standard for appropriate dosage and administration of LV." | 1.29 | [Biochemical modulation applied to experimental cancer chemotherapy]. ( Nakamura, Y, 1996) |
| "We conclude that inoperable esophageal cancer can be treated successfully by radiotherapy with a curative intent." | 1.28 | [Radiotherapy of inoperable esophageal cancer. Retrospective analysis apropos of 108 cases]. ( Calais, G; Chauvet, B; Geara, F; Le Floch, O; Reynaud-Bougnoux, A, 1990) |
| "Twenty four patients with advanced cancer of cervix were submitted to sequential chemotherapy 5FU and MTX." | 1.28 | Sequential MTX-5 FU chemotherapy in pallination of advanced cancer cervix. ( Mathur, RK; Mathur, V; Sharma, K; Tripathi, N, 1992) |
| " Radiotherapy is often combined with concurrent chemotherapy although no firm evidence exists that such combinations are more effective than radiotherapy alone." | 1.28 | Induction chemotherapy with carboplatin and 5-fluorouracil in combination with radiotherapy in loco-regionally advanced epidermoid carcinoma of the anus--preliminary results. ( Goldman, S; Kaigas, M; Svensson, C, 1992) |
| "Twenty-two cases of early squamous cell carcinoma of the arytenoid cartilage staged as T1 according to the 1983 American Joint Committee for Cancer Staging Classification system were reviewed." | 1.28 | T1 squamous cell carcinoma of the arytenoid. ( Brasnu, D; Chabardes, E; Housset, M; Laccourreye, H; Laccourreye, O; Weinstein, G, 1992) |
| "Tolerance was good." | 1.28 | Curative non-surgical combined treatment of squamous cell carcinoma of the oesophagus. ( Gerard, JP; Lambert, R; Romestaing, P; Zenone, T, 1992) |
| "A total of 8 patients with advanced squamous cell carcinoma of the penis (Jackson stages III and IV) received chemotherapy with 100 mg." | 1.28 | Cisplatin and 5-fluorouracil in advanced cancer of the penis. ( Fossa, SD; Ous, S; Shammas, FV, 1992) |
| "Ten patients with squamous cell carcinoma of the cervix metastatic to periaortic lymph nodes were treated with external-beam radiation therapy and synchronous infusion of intravenous 5-fluorouracil (5-FU) chemotherapy at doses of 350 mg/m2/day." | 1.28 | Continuous infusion of low-dose 5-fluorouracil and radiation therapy for poor-prognosis squamous cell carcinoma of the uterine cervix. ( Drescher, CW; Hopkins, MP; Perez-Tamayo, C; Reid, GC; Roberts, JA; Schoeppel, SL; Terada, K, 1992) |
| "The records of patients with esophageal cancer who were treated with a combined modality therapy were reviewed to determine the effects of simultaneously administered chemotherapy and radiotherapy (RT) at sites of recurrence and the relationship between treatment outcome and clinicopathologic variables." | 1.28 | Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery . ( Denham, JW; Devitt, PG; Gill, PG; Jamieson, GG; Olweny, C; Yeoh, E, 1992) |
| " Age and sex are among the host factors that have been implicated in the pharmacokinetic variability of drugs." | 1.28 | Influence of sex and age on fluorouracil clearance. ( Cassuto-Viguier, E; Demard, F; Etienne, MC; Frenay, M; Milano, G; Renee, N; Santini, J; Schneider, M; Thyss, A, 1992) |
| "All tumor were squamous cell carcinoma." | 1.28 | [The clinical effect of cisplatin and 5-FU infusion in oral cancer]. ( Hyoudou, I; Ichihara, H; Oka, N; Okuda, T; Okumura, Y; Okutomi, T; Tatematsu, N, 1992) |
| "Hydroxyurea is an active single agent in squamous cell cancer of the head and neck." | 1.28 | Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. ( Haraf, DJ; Panje, WR; Schilsky, RL; Vokes, EE; Weichselbaum, RR, 1992) |
| "Between 1979 and 1988, 33 patients with squamous cell carcinoma of the anal canal were treated with chemoradiation." | 1.28 | Squamous cell carcinoma of the anal canal. ( Fleshman, JW; Fry, RD; Halverson, JD; Kodner, IJ; Lopez, MJ; Monafo, WW; Myerson, RJ; Shapiro, SJ, 1991) |
| "Twelve patients with unresectable squamous cell carcinoma of the esophagus were treated with a combination chemotherapy regimen consisting of cis-diamminedichloroplatinum (CDDP), bleomycin (BLM) or peplomycin (PEP), and 5-fluorouracil (5-FU)." | 1.28 | [Evaluation of multidisciplinary treatment involving chemotherapy with cis-diamminedichloroplatinum, bleomycin (peplomycin) and 5-fluorouracil for advanced esophageal carcinoma]. ( Inoue, Y; Masamune, O; Nakamura, J; Nasu, H, 1990) |
| "Patients with cancer of nasopharynx had a better survival than those with other primaries (P = 0." | 1.28 | Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region. ( Daniilidis, J; Destouni-Salem, E; Fountzilas, G; Kalogera-Fountzila, A; Sombolos, K; Sridhar, KS; Tourkantonis, A; Vritsios, A; Zaramboukas, T, 1990) |
| "Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2." | 1.28 | Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. ( Coia, LR; Engstrom, PF; Hanks, GE; Paul, AR; Stafford, PM, 1991) |
| "We report a case of recurrent squamous cell carcinoma of the renal pelvis." | 1.28 | [Successful treatment of recurrent kidney pelvic squamous cell cancer with chemotherapy and radiotherapy: a case report]. ( Miyagawa, I; Nemoto, R; Yamane, A, 1991) |
| "Therapeutic results in advanced cervical cancer have not been showing any progress for more than 30 years." | 1.28 | [Systemic therapy in recurrent and primary advanced cervix cancer]. ( Bastert, G; Junkermann, H; Kaufmann, M; Schmid, H; Schönig, T; von Fournier, D, 1991) |
| "with metastasis) of whom 3 had recurrent disease." | 1.28 | Cisplatin and 5-FU combined with radiotherapy and surgery in the treatment of squamous cell carcinoma of the esophagus. Palliative effects and tumor response. ( Albertsson, M; Hambraeus, G; Lillo-Gil, R; Mercke, C; Ranstam, J; Samuelsson, L; Tennvall, J; Willén, R, 1991) |
| "Thirty-six patients with advanced squamous cell carcinoma of the head and neck (SCCHN) were treated with a regimen including cisplatinum (CP) 30 mg/m2 i." | 1.28 | 5-fluorouracil + folinic acid with cisplatinum and bleomycin in the treatment of advanced head and neck squamous cell carcinoma. ( Caliceti, U; Dall'Olio, D; Guaraldi, M; Laudadio, P; Martoni, A; Occhiuzzi, L; Pannuti, F; Tononi, A, 1991) |
| "Radiation myelitis is a rare but serious complication of radiation therapy." | 1.28 | Radiation myelitis: a complication of concurrent cisplatin and 5-fluorouracil chemotherapy with extended field radiotherapy for carcinoma of the uterine cervix. ( Berman, ML; Bloss, JD; DiSaia, PJ; Hyden, EC; Manetta, A; Mannel, RS; Walker, JL, 1991) |
| " For both groups, RT technique and dosage were similar." | 1.28 | Nasopharyngeal carcinoma: results of treatment by radiotherapy vs chemotherapy plus radiotherapy. ( Atichartakarn, V; Clongsusuek, P; Isarangkul, W; Kraiphibul, P; Kulapaditharom, B; Ratanatharathorn, V, 1991) |
| "There are few reports about the methods, amounts, and kinds of dosage about intermittent intra-arterial chemotherapy of liver metastases from primal pathological type's squamous cell carcinoma." | 1.28 | [Study of intermittent intra-arterial infusion chemotherapy in liver metastases from squamous cell carcinoma]. ( Aoki, T; Kasuya, K; Kimura, K; Koyanagi, Y; Ozawa, T; Sato, S; Tsuchida, A; Yasuda, D; Yoshimatsu, A, 1991) |
| "Fifty patients of advanced squamous cell carcinoma of head and neck received infusions of cisplatin 50 mg and 5-FU 500 mg weekly for 4 wk." | 1.28 | Cisplatin and 5-FU infusions in therapy of advanced squamous cell carcinoma of head and neck in 50 Indian patients. ( Sharma, AK; Sharma, SC; Singhal, KC, 1990) |
| "Patients with squamous cell carcinoma of the head and neck are treated with cisplatin and fluorouracil according to a schedule based on the findings of clinical studies." | 1.28 | Cisplatin-fluorouracil interaction in a squamous cell carcinoma xenograft. ( Rydell, R; Wennerberg, J, 1990) |
| "Hypercalcemia was previously considered a terminal phenomenon in advanced head and neck squamous-cell carcinoma." | 1.28 | Hypercalcemia in head and neck squamous-cell carcinoma. ( Hussein, AM; Sridhar, KS, 1990) |
| "Neutropenic enterocolitis is a recognized complication of immunosuppression or chemotherapy for leukemia." | 1.28 | Neutropenic enterocolitis. A new complication of head and neck cancer chemotherapy. ( de Vries, EJ; Johnson, JT; Petruzzelli, GJ, 1990) |
| "Thirty-seven patients with oral squamous cell carcinoma, many with advanced disease, were treated initially with a protocol using simultaneous intravenous 5-fluorouracil (5-FU) cis-platinum, and radiation." | 1.28 | Treatment of oral squamous cell carcinoma with simultaneous chemotherapy and radiation: results and surgical implications. ( Adelstein, DJ; Earle, AS; Indresano, AT; Sharan, VM; Vlastou, C, 1990) |
| "Thirty-five patients with nonmetastatic squamous cell carcinoma of the esophagus were treated with chemotherapy (5-fluorouracil, cisplatin) and concomitant split-course radiation therapy." | 1.28 | Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy. ( Carcassonne, Y; Fuentes, P; Gauthier, AP; Giovannini, M; Giudicelli, R; Padaut-Cesana, J; Seitz, JF, 1990) |
| "Over a 2-year period, 17 patients with histologically proven squamous cell carcinoma of the bronchus, assessed as inoperable or incurable on surgical or medical grounds, were treated with palliative radiotherapy and a concurrent 120-h infusion of 5-flurouracil, at a dosage of 1 g/day." | 1.28 | The use of simultaneous radiotherapy and 5-flurouracil in patients with inoperable squamous cell lung cancer. ( Ash, DV; Kelly, SA; MacLeod, PM, 1989) |
| "A 62-year-old female with anal cancer underwent Miles operation in November, 1987." | 1.28 | [Effects of intra-arterial infusion chemotherapy in local recurrence of anal cancer]. ( Amino, K; Mieno, K; Miura, S; Satoi, Y; Shikata, J; Takeda, Y, 1989) |
| "And our data are presented in head and neck cancer with multi-drug chemotherapy containing cisplatin." | 1.28 | [Treatment of squamous cell carcinoma of the head and neck with multi-drug chemotherapy and radiotherapy]. ( Asano, K; Kagami, Y; Narimatsu, N; Nishio, M; Sanbe, S; Somekawa, Y, 1989) |
| "Of 25 patients with squamous cell carcinoma, 13 underwent esophagectomy." | 1.28 | Cisplatin, 5-fluorouracil, mitomycin C, and concurrent radiation therapy with and without esophogectomy for esophageal carcinoma. ( Daniel, TM; Hahn, SS; Harkins, BJ; Stewart, FM, 1989) |
| "He experienced amoebic dysentery during World War II some 40 years ago, thus, this case report suggested that amoebiasis relapsed by depressed cellular immunity and was calculated as one of the opportunistic infections." | 1.28 | [Amoebic dysentery: a relapsing case by cancer chemotherapy]. ( Takenaka, A, 1989) |
| "Seventy patients with squamous cell carcinoma or cloacogenic carcinoma of the anus treated from 1979-1987 were reviewed." | 1.28 | Radiotherapy for anal cancer: experience from 1979-1987. ( Ajani, JA; Delclos, L; Hughes, LL; Martin, RG; Rich, TA, 1989) |
| "A review of 20 patients with postburn scar carcinoma is presented." | 1.28 | Postburn scar carcinoma. ( Aron, NK; Tajuri, S, 1989) |
| " With regard to toxicity, the applied treatment schedule (three courses) is fully acceptable, safe and suitable as neoadjuvant chemotherapy in the complex management of oral cavity carcinoma without the risk of delaying subsequent definitive treatment." | 1.28 | [Toxicity of cisplatin with continuous infusion of 5-fluorouracil in neoadjuvant chemotherapy of carcinoma of the oral cavity]. ( Koza, I; Mracna, J; Nagy, V; Poruban, D; Vasko, J, 1989) |
| "Sixty one aged patients with advanced squamous cell carcinoma of the upper aerodigestive tract were given a chemotherapy Cis DDP-5 FU before any local treatment." | 1.28 | [Induction chemotherapy with Cis DDP-5FU in cancers of the upper respiratory and digestive tract after 70 years of age]. ( Camuzard, JF; Demard, F; Falewee, MN; Santini, J; Schneider, M; Thyss, A; Vallicioni, J, 1989) |
| "Six patients developed distant metastases." | 1.28 | Cisplatin, fluorouracil with leucovorin calcium enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: a phase II study. ( Hartenstein, RC; Lissner, J; Wendt, TG; Wustrow, TP, 1989) |
| "Twenty patients with stage III-IV squamous cell carcinoma of the head and neck were treated with the combination of a multidrug cytotoxic regimen CMF-B (cyclophosphamide, methotrexate, 5-fluorouracil, bleomycin) and radical radiotherapy." | 1.27 | Combined radiotherapy and CMF-B cytotoxic regimen in stage III-IV head and neck squamous cell carcinoma. ( Corvò, L; Merlano, M; Rosso, R; Tatarek, R, 1984) |
| "Twenty-seven patients with squamous cell carcinoma of the head and neck were treated with bleomycin 7." | 1.27 | Bleomycin infusion followed by cyclophosphamide, methotrexate, and 5-fluorouracil in advanced squamous carcinoma of the head and neck. ( Biller, H; Brooks, S; Holland, JF; Ohnuma, T; Plasse, TF; Saponaro, E, 1984) |
| "30 patients with advanced squamous cell carcinoma of the head and neck received initial chemotherapy with Cisplatin (100 mg/m2 i." | 1.27 | [Results of drug therapy with cisplatin and 5-fluorouracil in squamous cell carcinoma of the head and neck region]. ( Nagel, GA; Scherpe, A; Schröder, M; von Heyden, HW, 1984) |
| "Of 55 patients with esophageal squamous cell carcinoma, 30 with localized disease were treated with a combined modality for curative intent." | 1.27 | Combined modality therapy for esophageal squamous cell carcinoma. ( Asfaw, I; Franklin, R; Hoschner, J; Loh, J; Miller, P; Rosenberg, J; Steiger, Z; Vaishampayan, G, 1983) |
| " The following pharmacokinetic results were obtained in comparison with single administration." | 1.27 | [Pharmacokinetics of FT-207 rectum suppository in squamous cell carcinoma of the uterine cervix. (II) Pharmacokinetics in continuous administration at a daily dose of 1 gram]. ( Chin, N; Endoh, S; Fukui, H; Hasegawa, T; Hayashi, Y; Ishii, Y; Kohno, I; Nakagiri, Y; Okazaki, H; Rin, K, 1984) |
| "Twenty-one patients with squamous cell cancer of the esophagus were entered into a pilot clinical trial using preoperative chemotherapy (5-fluorouracil and cis-platinum) and radiation with the intent of improving cure rate and survival." | 1.27 | Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: a potentially curative approach. ( Dindogru, A; Kinzie, J; Leichman, L; MacKenzie, G; Seydel, HG; Shell, J; Steiger, Z; Toben, S, 1984) |
| "Thirty-six patients with squamous cell carcinoma of the head and neck were treated with sequential methotrexate-5-fluorouracil followed by leucovorin rescue." | 1.27 | Sequential methotrexate-5-fluorouracil treatment of squamous cell carcinoma of the head and neck. ( Ewert, G; Kinnman, J; Lundqvist, PG; Ringborg, U; Strander, H, 1983) |
| " The most common treatment was intraarterial chemotherapy using 5-FU combined with external irradiation (15 cases, 31." | 1.27 | [Evaluation of multi-disciplinary treatment combined with intra-arterial chemotherapy for carcinoma of the meso-pharynx]. ( Kurosawa, Y; Maehara, Y; Makino, S; Matsuura, S; Mitomo, O; Nozaki, M; Sakaino, K; Satake, B, 1984) |
| "Thirty-six cases of squamous cell carcinoma of the maxillary sinus were treated between 1974 and 1981, and followed up for more than 2 years." | 1.27 | [Treatment of maxillary cancer]. ( Miyata, M; Morita, M, 1984) |
| "Twenty-eight patients with squamous cell carcinoma of the anal canal were treated by preoperative radiation therapy and chemotherapy." | 1.27 | Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. ( Considine, B; Kinzie, JJ; Leichman, L; Nigro, ND; Seydel, HG; Vaitkevicius, VK, 1983) |
| "A histologically confirmed case of Bowen's disease in multiple nail beds in the hands of a 40-year-old is reported." | 1.27 | Bowen's disease in multiple nail beds--case report. ( Strong, ML, 1983) |
| "All of them were squamous cell carcinoma except a case presenting parotid lesion caused by adenocarcinoma." | 1.27 | [Clinical study of HCFU and radiation therapy for head and neck cancer]. ( Honda, T, 1983) |
| "Average survival for advanced head and neck cancer (AHNC) is 18 months." | 1.27 | Pretreatment with chemotherapy in patients with advanced head and neck cancer. ( Barron, P; Cripps, C; Danjoux, C; de la Bastide, Y; Hardie, J; Nichol, J; Odell, P, 1985) |
| "A series of 344 patients with squamous cell carcinoma (oropharynx, larynx, hypopharynx, or buccal cavity) were treated between November 1982 and January 1985 by chemotherapy." | 1.27 | [Induction chemotherapy in cancers of the respiratory and digestive tracts by continuous infusions combining cisplatinum (C), fluorouracil (F), bleomycin (B) or C and F]. ( Bassot, V; Brasnu, D; Donnadieu, S; Fabre, A; Jacquillat, C; Lacau-St-Guily, J; Laccourreye, H; Menard, M, 1986) |
| "Ninety-one patients with malignant epithelial tumors of the nasopharynx seen in our department from 1970 to 1982 were evaluated." | 1.27 | Carcinoma of the nasopharynx. An analysis of 91 cases and a comparison of differing treatment approaches. ( Barzilay, J; Rahima, M; Rakowsky, E; Sidi, J, 1986) |
| "Forty patients with advanced squamous cell carcinoma of the esophagus were treated with a combination of cisplatin, 5-FU (by continuous 5-day infusion), and allopurinol; 37 are evaluable for response." | 1.27 | Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer. ( Cartei, G; De Besi, P; Fiorentino, M; Fosser, V; Paccagnella, A; Peracchia, A; Salvagno, L; Sileni, VC; Tremolada, C, 1986) |
| "In patients with locally advanced head and neck cancer, the results of standard definitive treatments of surgery, radiotherapy, or both were disappointing." | 1.27 | Combined modality therapy utilizing a cisplatin combination for effective chemotherapy in patients with previously untreated head and neck cancer. ( Ahmad, K; Al-Sarraf, M; Crissman, J; Ensley, JF; Jacobs, JR; Kish, J; Weaver, A, 1986) |
| "Twenty-one consecutive patients with squamous cell carcinoma of the esophagus (EC) were referred, with advanced Stage III disease in nine patients, severe pulmonary/cardiac disease in five patients, and postsurgical recurrences or metastatic disease in seven patients." | 1.27 | Inoperable esophageal carcinoma: results of aggressive synchronous radiotherapy and chemotherapy. A pilot study. ( Flam, M; John, M; Mowry, PA; Wittlinger, P, 1987) |
| "Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2." | 1.27 | Nonsurgical management of esophageal cancer: report of a study of combined radiotherapy and chemotherapy. ( Coia, LR; Engstrom, PF; Paul, A, 1987) |
| "Between 1975 and 1984, 33 patients with squamous cell carcinoma of the nasopharynx received adjuvant chemotherapy before and/or after definitive radiotherapy at UT M." | 1.27 | Acute and late toxicity associated with sequential bleomycin-containing chemotherapy regimens and radiation therapy in the treatment of carcinoma of the nasopharynx. ( Dimery, IW; Fields, R; Goepfert, H; Harrison, ML; Oswald, MJ; Peters, LJ, 1988) |
| "The majority of patients (78%) had squamous cell carcinoma." | 1.27 | Chemotherapy for paranasal sinus carcinoma. A 10-year experience at Wayne State University. ( al-Sarraf, M; Cummings, G; Ensley, JF; Kelly, J; Kish, JA; LoRusso, P; Tapazoglou, E, 1988) |
| "Nine patients had squamous cell carcinoma, two adenocarcinoma, and two large cell carcinoma." | 1.27 | [Postoperative chemotherapy of pathological stage I non-small cell carcinoma of the lung]. ( Kikuchi, K; Ogata, T, 1986) |
| " The drug sensitivity of the cultured cancer cells was investigated with a colony forming assay, and a dose-response curve was obtained for the time-dependent anticancer drug." | 1.27 | [Studies on oral-adjuvant chemotherapy of uterine cervical cancer after surgical treatment]. ( Maeda, T, 1986) |
| "Fifty-seven patients with advanced squamous carcinoma of the larynx and hypopharynx were entered on a pilot study of initial therapy using split course radiation therapy combined with simultaneous chemotherapy using mitomycin-C and 5-fluorouracil." | 1.27 | A pilot study of mitomycin-C/5-fluorouracil infusion combined with split course radiation therapy for carcinomas of the larynx and hypopharynx. ( Beale, FA; Cummings, BJ; Elhakim, T; Harwood, AR; Keane, TJ; Payne, DG; Rawlinson, E, 1986) |
| " During the first week of radiotherapy, 5-fluorouracil (1000 mg/m2 daily for four days by continuous infusion), and mitomycin (10 mg/m2 on day 1) were administered; four weeks later, a second cycle at the same dosage followed." | 1.27 | [Function-preserving treatment of anal cancer using simultaneous radio- and chemotherapy]. ( Dunst, J; Reichard, U; Sauer, R; Wolf, N, 1987) |
| "Of the 77 patients who had squamous cell carcinoma, 62 received definitive treatment for disease confined to the esophagus and regional nodes." | 1.27 | Esophageal carcinoma: modest benefits from combined modality therapy. ( Carlson, RW; Goffinet, DR; Hancock, SL; Mark, JB, 1987) |
| "A synchronous chemoradiotherapy schedule of modest dosage has been used in 36 patients with oesophageal cancer since July 1984 at the Royal Adelaide Hospital." | 1.27 | Preliminary experience with a combined-modality approach to the management of oesophageal cancer. ( Abbott, RL; Britten-Jones, R; Denham, JW; Devitt, P; Fitch, R; Gibson, GE; Gill, PG; Hecker, R; Hetzel, D; Jamieson, GG, 1988) |
| " Compared to a group treated in 1970 bis 1982 with the same dosage of irradiation without the combination of chemotherapy the median survival could be raized from nine to 24 months, the two year survival rate improved from 18% to 42%." | 1.27 | [Simultaneous radio- and chemotherapy of squamous cell carcinoma of the esophagus]. ( Rohloff, R; Tosch, U; Wendt, TG; Willich, N, 1988) |
| "We report a case of cardiac arrest occurring during an infusion of 5-fluorouracil where electrocardiograms suggested coronary artery spasm as the underlying event." | 1.27 | Cardiac arrest--a manifestation of 5-fluorouracil cardiotoxicity. ( Buck, M; Ganju, V; Millward, MJ, 1988) |
| "Esophageal cancer was treated with sequential intravenous cisplatin 100 mg/m2 (day 1) and 5-fluorouracil (5-FU) 40 mg/m2/hour X 120 (days 2-7)." | 1.27 | Respiratory tract fistulae in recurrent aerodigestive cancers after chemotherapy. ( Barreras, L; Manten, H; Saldana, MJ; Sridhar, KS, 1988) |
| " Dose-response curves for cisplatin or fluorouracil on MTS cells closely followed those from monolayer cells, indicating good drug penetration into the MTS core." | 1.27 | Effects of cisplatin plus fluorouracil vs cisplatin plus cytarabine on head and neck squamous multicellular tumor spheroids. ( Biller, HF; Holland, JF; Kohno, N; Ohnuma, T, 1988) |
| "To improve the results, we have treated the squamous cell carcinomas with topical 5-fluorouracil to obtain sensitization and shrinkage of the tumor before resection." | 1.27 | Topical 5-fluorouracil in treatment of carcinoma of nasal floor and nasal alae. ( Marks, MW; Ryan, RF, 1988) |
| "Thirty patients with recurrent squamous cell carcinoma of the head and neck were treated with an outpatient schedule: cisplatin (100 mg/m2) day 1 and an 8-hour infusion of 5-fluorouracil (1000 mg/m2) on days 1-4 every 28 days." | 1.27 | Cisplatin and 5-fluorouracil in recurrent head and neck cancer: results of an outpatient schedule. ( Airoldi, M; Brando, V; Gabriele, P; Giordano, C; Pedani, F, 1988) |
| " Using an intensive adjuvant treatment, the overall toxicity was tolerable allowing the application of the full therapeutic dosage in 95% without any interruptions." | 1.27 | [Principles of the simultaneous radiation and polychemotherapy in advanced head and neck carcinoma]. ( Hartenstein, RC; Wendt, TG; Wustrow, TP, 1987) |
| "We treated 20 patients with squamous cell carcinoma of the esophagus with the following regimen: cisplatin = 100 mg/m2 i." | 1.27 | Cisplatin, high dose folinic acid and 5-fluorouracil in squamous cell carcinoma of the esophagus. A pilot study. ( Farfaglia, R; Lancini, GP; Marini, G; Marpicati, P; Montini, E; Pezzola, D; Simoncini, E; Tonini, G; Zaniboni, A, 1987) |
| " 5-FU dosage was decreased in ten patients (36%) for grade 2 or greater stomatitis or diarrhea." | 1.27 | A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck. ( Forastiere, AA; Goren, MP; Kudla-Hatch, V; Natale, RB; Takasugi, BJ; Vogel, WC, 1987) |
| "Fifty-seven patients with esophageal cancer were treated with curative intent between January 1979 and June 1985." | 1.27 | Comparison of three treatment strategies for esophageal cancer within a single institution. ( Bae, Y; Burdakin, J; Jacobsen, G; Lewis, J; Richmond, J; Seydel, HG, 1987) |
| "Chemotherapeutic response of two squamous cell carcinoma xenograft lines (established from the primary and metastatic lesion of a tongue carcinoma) was studied using SC and SRC assays (as well as immunocompetent and -suppressed recipients in the latter assay)." | 1.27 | Chemotherapeutic response of squamous cell carcinoma xenografts (subcutaneous and subrenal capsule assay). ( Kopper, L; Lapis, K; Rajnay, J, 1987) |
| "Among 30 patients with squamous cell carcinoma, five achieved complete response (CR) (17%) and 13 achieved partial response (PR) (43%)." | 1.27 | Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study. ( DeConti, RC; Marsh, JC; Milner, LM; O'Donnell, MR; Rowland, KM; Showel, J; Spiers, AS; Stott, PB; Taylor, SG, 1986) |
| "Thirty-two patients with squamous cell carcinomas of the head and neck and three patients with parotid gland carcinomas were treated with methotrexate 40 mg/m2 followed 1 h later by 5-fluorouracil 600 mg/m2." | 1.27 | Methotrexate and 5-fluorouracil in the treatment of squamous and other carcinomas of the head and neck. ( Cripps, C; Gerin-Lajoie, J; Laframboise, G; Maroun, JA; Stewart, DJ; Young, V, 1986) |
| "Twenty-four patients with squamous cell cancer of the esophagus were entered into a treatment protocol consisting of preoperative chemotherapy (CT), surgical resection (SR), and possible postoperative CT or radiation therapy (RT) beginning August 1981." | 1.27 | Preoperative chemotherapy followed by surgery with possible postoperative radiotherapy in squamous cell carcinoma of the esophagus: evaluation of the chemotherapy component. ( Carey, RW; Choi, NC; Grillo, H; Hilgenberg, AD; Mathisen, DJ; Wilkins, EW, 1986) |
| "Allopurinol has been shown to ameliorate the myelotoxicity of 5-fluorouracil (5-FU) given as an infusion." | 1.27 | Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule. ( Ahmann, FR; Garewal, H, 1986) |
| "9 g carmofur (HCFU) in combination with a mean total dose of 49." | 1.27 | [Clinical study of HCFU in combination with irradiation therapy in squamous cell carcinoma of the head and neck]. ( Fukukita, K; Harada, T; Ito, Y; Kubo, M; Sakakura, Y; Yamagiwa, M, 1986) |
| "One hundred and eight patients with squamous cell carcinoma of the upper aerodigestive tract (UADT) (T3, T4, NO-N3; 17% stage II, 54% stage III, 27% stage IV) were given three courses of chemotherapy before any local treatment." | 1.27 | Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. ( Caldani, C; Chauvel, P; Demard, F; Santini, J; Schneider, M; Thyss, A; Vallicioni, J, 1986) |
| "As far as squamous cell carcinoma is concerned, the post-therapeutic courses of our combination therapy have been satisfactory." | 1.27 | Analysis of the long-term results of our combination therapy for maxillary cancer, with particular reference to treatment of T4 and N1-3 maxillary cancer. ( Hanazawa, S; Konno, A; Okamoto, Y; Togawa, K, 1985) |
| "Eight patients with deeply invasive bladder cancer were treated with cis-DDP alone or in combination with other drugs following radical cystectomy." | 1.27 | [Chemotherapy for advanced bladder cancer: clinical evaluation of chemotherapy for locally advanced or metastatic bladder cancer and adjuvant chemotherapy for deeply invasive bladder cancer following radical cystectomy]. ( Hirano, A; Ogawa, T; Ohkawa, T; Shinka, T; Uekado, Y; Watanabe, T; Yamamoto, S; Yoshida, T, 1985) |
| "Thermotherapy combined with tegafur (FT-207) and Picibanil was performed in 13 patients with cancer of the urinary bladder." | 1.27 | [Thermotherapy for cancer of the urinary bladder in combination with tegafur suppository and picibanil--concentrations of tegafur in the serum and tissues in bladder carcinoma]. ( Arai, T; Honda, M; Kanbe, K; Kaneko, K; Maeda, S; Mukae, K; Murahashi, I; Sakuma, H; Tabata, Y; Takasaki, E, 1985) |
| "For many years surgery has been the treatment of choice for squamous cell carcinoma of the anus, but it is now becoming apparent that well-planned definitive radiation therapy combined with chemotherapy may obviate the need for an abdomino-perineal resection." | 1.27 | The use of radiation therapy combined with chemotherapy in the management of squamous cell carcinoma of the anus and marginally resectable adenocarcinoma of the rectum. ( Sischy, B, 1985) |
| "Thyroid cancer, nasal cancer and paranasal sinus cancer gave the best results." | 1.27 | [Chemotherapy with FT-207 suppository (Futraful Supo) in head and neck cancer--cooperative studies by six medical schools in Kanagawa Prefecture]. ( Hattori, Y; Horiuchi, M; Miyake, H; Murakami, T; Otake, H; Sawaki, S; Takahashi, H; Takeyama, I; Tamamushi, N; Yao, K, 1985) |
| "Surgical management of squamous cell carcinoma of the esophagus continues to be a controversial area in thoracic surgery." | 1.27 | Combined treatment approach in surgical management of carcinoma of the esophagus: a preliminary report. ( Hatcher, CR; McIntyre, B; Miller, JI, 1985) |
| "Histologic characteristics of squamous cell carcinoma include loss of cell organization and orientation, loss of intercellular bridges, presence of nuclear atypia and mitotic figures, and premature cell keratinization." | 1.27 | Skin lesions from sun exposure: a treatment guide. ( Gibson, LE; Perry, HO, 1985) |
| " This study demonstrates that sequential MTX and 5-FU in this dosage and schedule is ineffective in NSCCL." | 1.27 | Sequential methotrexate and 5-fluorouracil in the treatment of non-small cell carcinoma of the lung. ( Ponder, BA; Slevin, ML; Wood, CD; Wrigley, PF, 1985) |
| " The mean half-life of 5-FU in the isolated circuit was 18." | 1.27 | Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion. ( Abramson, IS; Andrews, PA; Howell, SB; Murphy, MP; Stemmer, EA; Wile, AG, 1985) |
| "Squamous cell carcinoma was found in 4 horses and appears to be the most common bladder tumor in the horse." | 1.27 | Neoplasia of the equine urinary bladder as a cause of hematuria. ( Carlson, GP; Fischer, AT; Hackett, RP; Spier, S, 1985) |
| "Thirty patients with squamous cell carcinoma of the head and neck were treated with a combination of cisplatin (20 mg/m2) and 5-FU (400-200 mg/m2) by iv push on Days 1-5 every 21 days." | 1.27 | Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule. ( Grimaldi, A; Margarino, G; Merlano, M; Rosso, R; Tatarek, R, 1985) |
| " They received 5FU and cisplatin in the same dosage every 28 days for either recurrent or metastatic disease." | 1.27 | A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck. ( Citrin, P; Dasmahapatra, KS; Hill, GJ; Mohit-Tabatabai, MA; Rush, BF; Yee, R, 1985) |
| "Patients with squamous cell carcinoma or good performance status were somewhat more likely to respond." | 1.27 | Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer. ( Einstein, AB; Rudolph, RH; Weiden, PL, 1985) |
| "Fifteen patients with advanced squamous cell carcinoma of the head and neck were treated with the six-drug Price-Hill regimen (vincristine, bleomycin, methotrexate, hydrocortisone, 5-fluorouracil, and leucovorin)." | 1.26 | Combination chemotherapy for advanced squamous cell carcinoma of the head and neck. ( Oster, MW; Raafat, J, 1980) |
| "Twenty-five patients with advanced squamous cell carcinoma of the head and neck were entered into this study." | 1.26 | Advanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with adriamycin, bleomycin, 5-fluorouracil, methotrextate, and vitamin A. ( Blackledge, G; Crowther, D; Thatcher, N, 1980) |
| "Phosphorylating activity in squamous cell carcinoma of the lung was similar to that in adenocarcinomas." | 1.26 | Metabolism of 5-fluorouracil in various human normal and tumor tissues. ( Fujii, S; Maehara, Y; Nagayama, S; Nakamura, H; Okazaki, H; Shirasaka, T, 1981) |
| "In the total 70 cases including those of undifferentiated carcinoma and adenocarcinoma, the 3-year and 5-year actual survival rates were 75." | 1.26 | Analysis of the results of our combined therapy for maxillary cancer. ( Inoue, S; Konno, A; Togawa, K, 1980) |
| "Thirty-one patients with advanced stage squamous cell carcinoma of the cervix were treated with the four-drug combination fluorouracil, doxorubicin, cyclophosphamide, and vincristine." | 1.26 | Four-drug combination chemotherapy for advanced cervical carcinoma. ( Aroney, RS; Chan, WK; Fox, RM; Levi, JA; Tattersall, MH; Woods, RL, 1982) |
| "In white persons, most skin cancer occurs in sites that have been exposed to sunlight for long periods." | 1.26 | Dysplastic epidermal keratosis in a black woman. ( Kelly, AP; Lopansri, S; Weaver, SM, 1981) |
| " Treatment was combined with cobalt 60 irradiation at 4,000 rads (200 rads X 20 doses over a one month period) and concurrent arterial infusion of 5-fluorouracil (5-FU) with a total dosage of 5,000 mg (250 mg X 20 doses)." | 1.26 | Use of phytohemagglutinin in the treatment of maxillary cancer. ( Okuda, M; Sakaguchi, K; Takahashi, M; Tomiyama, S, 1980) |
| "A case of an exquisitely painful squamous cell carcinoma of the bladder is reported." | 1.26 | Dramatic palliation for painful, fixed bladder squamous cell carcinoma with 5-fluorouracil infusion. ( Confer, DJ; Gillespie, L; Smith, RB, 1977) |
| "Palliation of unresectable head and neck cancer remains a difficult problem." | 1.26 | Palliation of inoperable head and heck cancer: combined intra-arterial infusion chemotherapy and irradiation. ( Armstrong, AL; Meeker, WR, 1978) |
| "A total of 77 patients with cancer of the head and neck area were treated with five different drug combination regimens." | 1.26 | Combination chemotherapy of head and neck cancer. ( Byers, RM; Gard, DA; Goepfert, H; Guillamondegui, OM; Holoye, PY; Jesse, RH, 1978) |
| "The increased incidence of skin cancer and its possible cause is briefly discussed and the role of immunobiologic factors in the development of squamous cell carcinomas is mentioned." | 1.26 | Squamous cell carcinoma. Case report of an unusually aggressive skin cancer. ( Biro, L; Price, E, 1979) |
| "Eight patients with squamous cell carcinoma in situ of the vagina were treated with monthly 5 day courses of 20% 5-fluorouracil cream applied to the vagina." | 1.26 | Postirradiation squamous cell carcinoma in situ of the vagina: treatment by topical 20 percent 5-fluorouracil cream. ( Barlow, JJ; Gamarra, M; Piver, MS; Sandecki, A; Tsukada, Y, 1979) |
| "Sixty-six confirmed cases of Bowen's disease (intraepidermal squamous cell carcinoma) were seen from 1965 through 1976: twenty-four cases were treated surgically-four by excision (two recurrences) and twenty by desiccation and curettage (four recurrences); one was treated with x-ray radiation; and forty-one were treated with topical 5-fluorouracil (5-FU) (three recurrences)." | 1.26 | Bowen's disease and 5-fluorouracil. ( Sturm, HM, 1979) |
| "A case of extensive Bowen's disease of the skin treated successfully with topical 5-fluor-uracil is described." | 1.26 | [Therapy of morbus Bowen with 5-fluoro-uracil ointment (author's transl)]. ( Grussendorf, EI; Krause, H, 1979) |
| "The 12th case of Bowen's disease, presented here, offers an alternative method of treatment using 5-fluorouracil combined with a keratolytic ointment." | 1.26 | Bowen's disease of the nail bed: a case presentation and review of the literature. ( Defiebre, BK, 1978) |
| "Four cases of Bowen's disease of the finger have been treated, three during the past two years." | 1.26 | Bowen's Disease of the Finger. ( Kern, AB; Schiff, BL, 1977) |
| "An ususual case of Bowen's disease of the skin of the penile shaft treated successfully with topical 5-fluorouracil is presented along with a review of different modes of treatment." | 1.26 | Bowen's disease of shaft of penis. Successful treatment with 5-fluorouracil. ( Castro, VL; Mouded, IM; Newman, HR; Tolia, BM, 1976) |
| "A fourth patient with previously treated epidermoid carcinoma of the anus presented with biopsy-proven pulmonary metastasis and was placed on the chemotherapeutic regimen alone." | 1.26 | Multi-modality therapy for epidermoid carcinoma of the anus. ( Newman, HK; Quan, SH, 1976) |
| ""Bowen's disease" is a clinical and histologic diagnosis describing the lesions (single or multiple) of cutaneous in situ squamous cell carcinoma." | 1.26 | Treatment of Bowen's disease with topical dinitrochlorobenzene and 5-fluorouracil. ( Cunningham-Rundles, W; Krown, SE; Oettgen, HF; Pinsky, CM; Raaf, JH; Safai, B, 1976) |
| "A therapeutical method of inoperable squamous cell carcinomas based on cell kinetics has been applied since 1969 by using 5-fluorine-uracil." | 1.25 | [Radiotherapy of inoperable orofacial squamous epithelial carcinomas following pharmacologically induced partial synchronization]. ( Esser, E; Schumann, J; Wannenmacher, M, 1975) |
| "The relation between the induction of delayed hypersensitivity reactions to 5-FU following treatment with topical 5-FU and the cure rate for cutaneous neoplasms showed a trend toward correlation." | 1.25 | Delayed hypersensitivity to 5-fluorouracil following topical chemotherapy of cutaneous cancers. ( Ichinose, H; Krementz, ET; Litwin, MS; Mansell, PW, 1975) |
| " The 5-fluoro-uracil was given intravenously at a relatively nontoxic dosage level." | 1.24 | The potentiation of radiation effects with 5-fluoro-uracil. ( FOYE, LV; HALL, B; ROTH, M; WILLETT, FM, 1960) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 627 (19.62) | 18.7374 |
| 1990's | 628 (19.66) | 18.2507 |
| 2000's | 841 (26.32) | 29.6817 |
| 2010's | 977 (30.58) | 24.3611 |
| 2020's | 122 (3.82) | 2.80 |
| Authors | Studies |
|---|---|
| Cristalli, G | 1 |
| Franchetti, P | 1 |
| Grifantini, M | 1 |
| Vittori, S | 1 |
| Bordoni, T | 1 |
| Geroni, C | 1 |
| Liu, XH | 1 |
| Lv, PC | 1 |
| Xue, JY | 1 |
| Song, BA | 1 |
| Zhu, HL | 1 |
| Neale, H | 1 |
| Michelon, M | 1 |
| Jacob, S | 1 |
| Pinkston, M | 1 |
| Ukaegbu, R | 1 |
| Zamor, W | 1 |
| Morrison, E | 1 |
| Deng, A | 1 |
| Levin, NA | 1 |
| Almeida, LY | 1 |
| Moreira, FDS | 1 |
| Santos, GASD | 1 |
| Cuadra Zelaya, FJM | 1 |
| Ortiz, CA | 1 |
| Agostini, M | 1 |
| Mariano, FS | 1 |
| Bastos, DC | 1 |
| Daher, URN | 1 |
| Kowalski, LP | 1 |
| Coletta, RD | 1 |
| Graner, E | 1 |
| Hamad, J | 1 |
| Jolly, PS | 1 |
| Mao, G | 1 |
| Mu, Z | 1 |
| Wu, DA | 1 |
| Guerra, GR | 1 |
| Kong, JC | 1 |
| Millen, RM | 1 |
| Read, M | 1 |
| Liu, DS | 1 |
| Roth, S | 2 |
| Sampurno, S | 1 |
| Sia, J | 1 |
| Bernardi, MP | 1 |
| Chittleborough, TJ | 1 |
| Behrenbruch, CC | 1 |
| Teh, J | 1 |
| Xu, H | 5 |
| Haynes, NM | 1 |
| Yu, J | 3 |
| Lupat, R | 1 |
| Hawkes, D | 1 |
| Di Costanzo, N | 1 |
| Tothill, RW | 1 |
| Mitchell, C | 2 |
| Ngan, SY | 4 |
| Heriot, AG | 1 |
| Ramsay, RG | 1 |
| Phillips, WA | 1 |
| Roy, PS | 1 |
| Kumar, G | 1 |
| Mallik, S | 1 |
| Sarangi, SS | 1 |
| Saikia, BJ | 1 |
| Hazarika, M | 1 |
| Talukdar, A | 1 |
| Tchelebi, LT | 1 |
| Eng, C | 5 |
| Messick, CA | 2 |
| Hong, TS | 4 |
| Ludmir, EB | 3 |
| Kachnic, LA | 6 |
| Zaorsky, NG | 1 |
| Yang, KS | 1 |
| Che, PC | 1 |
| Hsieh, MJ | 1 |
| Lee, IN | 1 |
| Wu, YP | 1 |
| Chen, MS | 1 |
| Chen, JC | 2 |
| Li, L | 5 |
| Li, XD | 2 |
| Zhuang, QW | 1 |
| Ge, LY | 1 |
| Li, ZP | 1 |
| Gu, QP | 1 |
| Meng, J | 3 |
| Hasan, ZU | 1 |
| Ahmed, I | 1 |
| Matin, RN | 1 |
| Homer, V | 1 |
| Lear, JT | 1 |
| Ismail, F | 2 |
| Whitmarsh, T | 1 |
| Green, AC | 1 |
| Thomson, J | 1 |
| Milligan, A | 1 |
| Hogan, S | 1 |
| Van-de-Velde, V | 1 |
| Mitchell-Worsford, L | 1 |
| Kentley, J | 1 |
| Gaunt, C | 1 |
| Jefferson-Hulme, Y | 1 |
| Bowden, SJ | 1 |
| Gaunt, P | 1 |
| Wheatley, K | 1 |
| Proby, CM | 2 |
| Harwood, CA | 1 |
| Stouvenot, M | 1 |
| Meurisse, A | 2 |
| Saint, A | 3 |
| Buecher, B | 4 |
| André, T | 3 |
| Samalin, E | 5 |
| Jary, M | 3 |
| El Hajbi, F | 5 |
| Baba-Hamed, N | 4 |
| Pernot, S | 2 |
| Kaminsky, MC | 2 |
| Bouché, O | 4 |
| Desrame, J | 3 |
| Zoubir, M | 2 |
| Smith, D | 3 |
| Ghiringhelli, F | 2 |
| Parzy, A | 3 |
| de la Fouchardiere, C | 3 |
| Almotlak, H | 1 |
| Vienot, A | 2 |
| Jacquin, M | 3 |
| Taieb, J | 3 |
| Nguyen, T | 2 |
| Vernerey, D | 4 |
| Borg, C | 6 |
| Kim, S | 10 |
| Mohney, L | 1 |
| Singh, R | 1 |
| Grada, A | 1 |
| Feldman, S | 1 |
| Radka, L | 1 |
| Zdeňka, P | 1 |
| Holliday, EB | 1 |
| Morris, VK | 1 |
| Johnson, B | 1 |
| Das, P | 4 |
| Minsky, BD | 12 |
| Taniguchi, C | 1 |
| Smith, GL | 1 |
| Koay, EJ | 1 |
| Koong, AC | 5 |
| Delclos, ME | 1 |
| Skibber, JM | 2 |
| Rodriguez-Bigas, MA | 2 |
| You, YN | 2 |
| Bednarski, BK | 1 |
| Tillman, MM | 1 |
| Chang, GJ | 2 |
| Jennings, K | 1 |
| Yakita, M | 1 |
| Chujo, T | 1 |
| Wei, FY | 1 |
| Hirayama, M | 1 |
| Kato, K | 21 |
| Takahashi, N | 5 |
| Naganuma, K | 1 |
| Nagata, M | 8 |
| Kawahara, K | 13 |
| Nakayama, H | 9 |
| Tomizawa, K | 1 |
| Baird, BA | 1 |
| Lyon, TD | 1 |
| Wu, K | 1 |
| Anderson, A | 1 |
| Broderick, GA | 1 |
| Citrin, D | 1 |
| Valle, L | 1 |
| Camphausen, K | 1 |
| Cooley-Zgela, T | 1 |
| Smart, D | 1 |
| Yao, M | 1 |
| Mitchell, JB | 1 |
| Thompson, W | 1 |
| Sereti, I | 1 |
| Uldrick, T | 1 |
| Neelis, KJ | 1 |
| Kip, DM | 1 |
| Speetjens, FM | 1 |
| van der Linden, YM | 1 |
| Ahmady, S | 1 |
| Jansen, MHE | 1 |
| Nelemans, PJ | 1 |
| Kessels, JPHM | 1 |
| Arits, AHMM | 1 |
| de Rooij, MJM | 1 |
| Essers, BAB | 1 |
| Quaedvlieg, PJF | 1 |
| Kelleners-Smeets, NWJ | 1 |
| Mosterd, K | 1 |
| Campoverde, LE | 1 |
| Batalini, F | 1 |
| Bulushi, Y | 1 |
| Bullock, A | 1 |
| Patil, VM | 1 |
| Kolkur, M | 1 |
| Kumar Chinthala, S | 1 |
| Waratkar, G | 1 |
| Menon, N | 1 |
| Noronha, V | 1 |
| Ghosh Laskar, S | 1 |
| Simha, V | 1 |
| Talreja, V | 1 |
| Dhumal, S | 1 |
| Chandrasekharan, A | 1 |
| Prabhash, K | 1 |
| Cheng, B | 1 |
| Veerabagu, S | 1 |
| Miller, CJ | 2 |
| Sobanko, JF | 1 |
| Shin, TM | 1 |
| Higgins, HW | 1 |
| Giordano, CN | 1 |
| Etzkorn, JR | 1 |
| Nicolás-Morala, J | 1 |
| Portillo-Esnaola, M | 1 |
| Terrén, S | 1 |
| Gutiérrez-Pérez, M | 1 |
| Gilaberte, Y | 1 |
| González, S | 1 |
| Juarranz, Á | 1 |
| Lohynská, R | 2 |
| Pechačová, Z | 1 |
| David, P | 1 |
| Baum, S | 1 |
| Shoenfeld, Y | 1 |
| Ito, R | 1 |
| Nakamura, Y | 5 |
| Sunakawa, H | 1 |
| Fujiwara, H | 9 |
| Hojo, H | 2 |
| Nakamura, N | 4 |
| Fujita, T | 6 |
| Yano, T | 7 |
| Daiko, H | 7 |
| Akimoto, T | 4 |
| Yoshino, T | 6 |
| Kojima, T | 16 |
| Kozma, K | 1 |
| Dömötör, ZR | 1 |
| Csutak, A | 1 |
| Szabó, L | 1 |
| Hegyi, P | 1 |
| Erőss, B | 1 |
| Helyes, Z | 1 |
| Molnár, Z | 1 |
| Dembrovszky, F | 1 |
| Szalai, E | 1 |
| Delhiat, AC | 1 |
| Combet-Curt, V | 1 |
| Vendrely, V | 7 |
| Valery, M | 1 |
| Cervantes, B | 1 |
| Smolenschi, C | 1 |
| Boilève, A | 1 |
| Boige, V | 1 |
| Malka, D | 1 |
| Hollebecque, A | 1 |
| Ducreux, M | 4 |
| Hitt, R | 13 |
| Mesía, R | 13 |
| Lozano, A | 3 |
| Iglesias Docampo, L | 1 |
| Grau, JJ | 6 |
| Taberna, M | 3 |
| Rubió-Casadevall, J | 2 |
| Martínez-Trufero, J | 5 |
| Morillo, EDB | 1 |
| García Girón, C | 2 |
| Vázquez Estévez, S | 1 |
| Cirauqui, B | 2 |
| Cruz-Hernández, JJ | 2 |
| Algarin, YA | 1 |
| Jambusaria-Pahlajani, A | 3 |
| Ruiz, E | 1 |
| Patel, VA | 2 |
| Sugase, T | 1 |
| Sugimura, K | 7 |
| Kanemura, T | 1 |
| Takeoka, T | 1 |
| Yamamoto, M | 8 |
| Shinno, N | 1 |
| Hara, H | 4 |
| Omori, T | 2 |
| Fujii, Y | 2 |
| Mukai, Y | 1 |
| Mikamori, M | 1 |
| Hasegawa, S | 3 |
| Haraguchi, N | 1 |
| Akita, H | 4 |
| Nishimura, J | 2 |
| Wada, H | 1 |
| Matsuda, C | 1 |
| Yasui, M | 3 |
| Miyata, H | 24 |
| Patel, C | 1 |
| Elmasry, A | 1 |
| Giridharan, S | 1 |
| Murofushi, KN | 1 |
| Itasaka, S | 4 |
| Shimokawa, M | 2 |
| Murakami, Y | 6 |
| Yamamoto, T | 14 |
| Nishimura, Y | 7 |
| Kudo, S | 1 |
| Sakamoto, T | 4 |
| Ariga, T | 2 |
| Ogo, E | 2 |
| Taguchi, K | 1 |
| Jingu, K | 5 |
| Ogawa, K | 6 |
| Yamasaki, M | 22 |
| Sato, Y | 7 |
| Okamoto, K | 10 |
| Fukuya, A | 3 |
| Kawaguchi, T | 4 |
| Noda, K | 5 |
| Kagemoto, K | 3 |
| Mitsui, Y | 3 |
| Miyamoto, H | 3 |
| Takayama, T | 6 |
| Wylegala, A | 2 |
| Sripawadkul, W | 2 |
| Zein, M | 2 |
| Alvarez, OP | 2 |
| Al Bayyat, G | 2 |
| Galor, A | 7 |
| Karp, CL | 7 |
| Aoyama, S | 2 |
| Motoori, M | 8 |
| Shiraishi, O | 8 |
| Hirao, M | 9 |
| Takeno, A | 5 |
| Makino, T | 8 |
| Tanaka, K | 12 |
| Hamakawa, T | 2 |
| Yamashita, K | 10 |
| Kimura, Y | 14 |
| Fujitani, K | 10 |
| Yasuda, T | 19 |
| Yano, M | 22 |
| Doki, Y | 31 |
| Dhaka, S | 2 |
| Jakhar, SL | 2 |
| Sharma, N | 2 |
| Kumar, HS | 2 |
| Kumar, R | 2 |
| Kumar, V | 2 |
| Bansal, S | 2 |
| Badola, A | 2 |
| Nautiyal, V | 2 |
| Gupta, M | 2 |
| Ahmad, M | 3 |
| Saini, S | 2 |
| Lee, HL | 1 |
| Fu, CK | 1 |
| Chien, LY | 1 |
| Chen, LM | 2 |
| Kato, H | 10 |
| Momose, K | 1 |
| Hiraki, Y | 7 |
| Yasuda, A | 3 |
| Shinkai, M | 3 |
| Imano, M | 3 |
| Matsuki, G | 1 |
| Nakajima, T | 4 |
| Ichise, N | 1 |
| Nomura, K | 1 |
| Fujikawa, M | 1 |
| Kasai, M | 1 |
| Okamoto, R | 2 |
| Ikuta, S | 1 |
| Nakamoto, Y | 1 |
| Aihara, T | 2 |
| Kajimoto, N | 1 |
| Kakuno, A | 1 |
| Yanagi, H | 1 |
| Yamanaka, N | 1 |
| Monroy, D | 1 |
| Serrano, A | 1 |
| Killock, D | 1 |
| Lemanski, C | 5 |
| Pommier, P | 6 |
| LE Malicot, K | 1 |
| Rivin Del Campo, E | 2 |
| Regnault, P | 1 |
| Ronchin, P | 1 |
| Crehange, G | 6 |
| Tougeron, D | 2 |
| Menager-Tabourel, E | 1 |
| Diaz, O | 1 |
| Hummelsberger, M | 1 |
| Minsat, M | 2 |
| Drouet, F | 1 |
| Larrouy, A | 1 |
| Peiffert, D | 8 |
| Lievre, A | 3 |
| Zasadny, X | 1 |
| Hautefeuille, V | 1 |
| Mornex, F | 4 |
| Lepage, C | 1 |
| Quero, L | 2 |
| Schlosser, S | 1 |
| Zalmanov, S | 1 |
| Pfeffer, RM | 1 |
| Lipski, Y | 1 |
| Grinberg, V | 1 |
| Kalmus, Y | 1 |
| Levin, D | 1 |
| Hod, K | 1 |
| Ben David, MA | 1 |
| Ali, A | 1 |
| Madni, A | 1 |
| Shah, H | 1 |
| Jamshaid, T | 1 |
| Jan, N | 1 |
| Khan, S | 1 |
| Khan, MM | 1 |
| Mahmood, MA | 1 |
| Khamaikawin, W | 1 |
| Locharoenrat, K | 1 |
| Osaki, M | 1 |
| Hata, T | 1 |
| Sekido, Y | 1 |
| Ogino, T | 7 |
| Miyoshi, N | 3 |
| Takahashi, H | 5 |
| Sakai, D | 1 |
| Uemura, M | 1 |
| Satoh, T | 2 |
| Eguchi, H | 2 |
| Agarwal, A | 1 |
| Kaliki, S | 2 |
| Murthy, SI | 1 |
| Marka, A | 1 |
| Rodgers, D | 1 |
| Zelaya Castillo, L | 1 |
| Hoyt, B | 1 |
| Chapman, M | 1 |
| Carter, J | 1 |
| Nahm, W | 1 |
| Nichols, A | 2 |
| Rapoport, E | 1 |
| Kirsner, R | 1 |
| Badiavas, E | 1 |
| Wyant, W | 1 |
| Arthur, A | 1 |
| Shen, J | 3 |
| Dietz, MD | 1 |
| Zelmanski, MH | 1 |
| Choueiri, MA | 1 |
| Elsaady, SA | 1 |
| Aboushelib, MN | 1 |
| Al-Wakeel, E | 1 |
| Badawi, MF | 1 |
| Yamada, A | 2 |
| Shinomiya, H | 2 |
| Uehara, N | 1 |
| Iritani, K | 1 |
| Tatehara, S | 1 |
| Furukawa, T | 5 |
| Teshima, M | 1 |
| Miyawaki, D | 1 |
| Kakigi, A | 1 |
| Kiyota, N | 4 |
| Sasaki, R | 2 |
| Nibu, KI | 1 |
| Azin, M | 1 |
| Ameri, AH | 1 |
| Nazarian, RM | 1 |
| Cusack, JC | 1 |
| Tsiaras, WG | 1 |
| Asgari, MM | 2 |
| Demehri, S | 3 |
| Luu, W | 1 |
| McRae, MY | 1 |
| Bhattacharya, S | 1 |
| Shinde, P | 1 |
| Page, A | 1 |
| Sharma, S | 1 |
| Tsukamoto, Y | 2 |
| Kurogi, S | 1 |
| Fujishima, H | 3 |
| Shibata, T | 9 |
| Fumoto, S | 2 |
| Nishiki, K | 1 |
| Suzuki, K | 6 |
| Etoh, T | 1 |
| Shiraishi, N | 1 |
| Fuchino, T | 1 |
| Hirashita, Y | 1 |
| Nakada, C | 1 |
| Uchida, T | 1 |
| Inomata, M | 1 |
| Moriyama, M | 1 |
| Hijiya, N | 1 |
| Ogo, T | 1 |
| Ishihara, K | 1 |
| Nishino, M | 2 |
| Inokuch, M | 1 |
| Sakurai, U | 1 |
| Lai, M | 1 |
| Pampena, R | 1 |
| Cornacchia, L | 1 |
| Pellacani, G | 2 |
| Peris, K | 2 |
| Longo, C | 1 |
| Sunde, B | 1 |
| Klevebro, F | 2 |
| Johar, A | 1 |
| Johnsen, G | 2 |
| Jacobsen, AB | 2 |
| Glenjen, NI | 1 |
| Friesland, S | 2 |
| Lindblad, M | 2 |
| Ajengui, A | 1 |
| Lundell, L | 2 |
| Lagergren, P | 1 |
| Nilsson, M | 2 |
| Zhang, L | 10 |
| Ji, Z | 1 |
| Zhang, J | 7 |
| Yang, S | 1 |
| Rogers, JE | 2 |
| Ajani, JA | 21 |
| Collins, A | 1 |
| Savas, J | 1 |
| Doerfler, L | 2 |
| Evesque, L | 2 |
| Falk, AT | 2 |
| Cavaglione, G | 3 |
| Montagne, L | 1 |
| Benezery, K | 9 |
| Francois, E | 10 |
| Agarwal, MS | 1 |
| Hitchcock, KE | 1 |
| Morris, CG | 5 |
| George, TJ | 2 |
| Mendenhall, WM | 7 |
| Zlotecki, RA | 5 |
| Chapalain, M | 1 |
| Baroudjian, B | 1 |
| Dupont, A | 1 |
| Lhote, R | 1 |
| Lambert, J | 1 |
| Bagot, M | 1 |
| Lebbe, C | 1 |
| Basset-Seguin, N | 1 |
| Navarrete-Dechent, C | 1 |
| Marghoob, AA | 2 |
| Marchetti, MA | 1 |
| Maredia, H | 1 |
| Simkin, D | 1 |
| Soni, A | 1 |
| Loss, MJ | 1 |
| Li, R | 3 |
| Tian, S | 1 |
| Zhu, Y | 3 |
| Zhu, W | 1 |
| Wang, S | 2 |
| de Meric de Bellefon, M | 1 |
| Castan, F | 2 |
| Mazard, T | 1 |
| Lenglet, A | 1 |
| Demontoy, S | 1 |
| Riou, O | 1 |
| Llacer-Moscardo, C | 1 |
| Fenoglietto, P | 2 |
| Aillères, N | 1 |
| Thezenas, S | 1 |
| Debrigode, C | 1 |
| Vieillot, S | 2 |
| Gourgou, S | 2 |
| Azria, D | 2 |
| Li, J | 18 |
| Vangundy, Z | 1 |
| Poi, M | 1 |
| Sakanaka, K | 2 |
| Fujii, K | 1 |
| Mizowaki, T | 2 |
| Morsy, RAA | 1 |
| Abbass, EA | 1 |
| Hager, EAA | 1 |
| Farid, MH | 1 |
| Ellithy, MM | 1 |
| Azmy, A | 1 |
| Wei, B | 1 |
| Xu, L | 3 |
| Hui, H | 1 |
| Sun, Y | 3 |
| Wu, J | 3 |
| Ju, WT | 1 |
| Ma, HL | 1 |
| Zhao, TC | 1 |
| Liang, SY | 1 |
| Zhu, DW | 4 |
| Wang, LZ | 6 |
| Zhang, ZY | 8 |
| Zhou, G | 2 |
| Zhong, LP | 7 |
| Dianzani, C | 1 |
| Conforti, C | 1 |
| Giuffrida, R | 1 |
| Corneli, P | 1 |
| di Meo, N | 1 |
| Farinazzo, E | 1 |
| Moret, A | 1 |
| Magaton Rizzi, G | 1 |
| Zalaudek, I | 1 |
| Hasegawa, H | 1 |
| Kaneko, T | 1 |
| Kanno, C | 1 |
| Endo, M | 3 |
| Yamazaki, M | 1 |
| Kitabatake, T | 1 |
| Monma, T | 1 |
| Takeishi, E | 1 |
| Sato, E | 1 |
| Kano, M | 2 |
| Fayne, R | 1 |
| Nanda, S | 1 |
| Modesto, A | 1 |
| Dalmasso, C | 1 |
| Lusque, A | 1 |
| Vieillevigne, L | 1 |
| Izar, F | 1 |
| Moyal, E | 1 |
| Carrère, N | 1 |
| Guimbaud, R | 1 |
| Rives, M | 2 |
| Iwama, M | 2 |
| Kawakami, H | 4 |
| Okuno, T | 14 |
| Nakagawa, K | 12 |
| Wang, J | 17 |
| Fan, J | 1 |
| Gao, W | 2 |
| Wu, Y | 4 |
| Zhao, Q | 1 |
| Chen, B | 1 |
| Ding, Y | 2 |
| Wen, S | 1 |
| Nan, X | 1 |
| Wang, B | 5 |
| Ishikura, S | 13 |
| Kondo, T | 3 |
| Murai, T | 1 |
| Ozawa, Y | 2 |
| Yanagi, T | 1 |
| Sugie, C | 1 |
| Miyakawa, A | 1 |
| Shibamoto, Y | 4 |
| Fukui, K | 1 |
| Nagasawa, S | 1 |
| Hanasaki, T | 1 |
| Ueda, Y | 3 |
| Aihara, K | 1 |
| Kokura, K | 1 |
| Matsuo, S | 1 |
| Zozumi, M | 1 |
| Raphael, MJ | 1 |
| Ko, G | 1 |
| Booth, CM | 1 |
| Brogly, SB | 1 |
| Li, W | 2 |
| Kalyvas, M | 1 |
| Hanna, TP | 1 |
| Patel, SV | 1 |
| Bidard, FC | 3 |
| Dahan, L | 3 |
| Rebucci-Peixoto, M | 1 |
| Spehner, L | 3 |
| Cornejo, CM | 1 |
| Willenbrink, TJ | 1 |
| Schmults, CD | 3 |
| Arron, ST | 2 |
| Ruiz, ES | 1 |
| Yuan, Y | 2 |
| You, J | 1 |
| Li, X | 8 |
| Wang, W | 5 |
| Saeki, H | 4 |
| Jogo, T | 2 |
| Kawazoe, T | 1 |
| Kamori, T | 1 |
| Nakaji, Y | 1 |
| Zaitsu, Y | 1 |
| Fujiwara, M | 5 |
| Baba, Y | 8 |
| Nakamura, T | 27 |
| Iwata, N | 3 |
| Egashira, A | 1 |
| Nakanoko, T | 1 |
| Morita, M | 5 |
| Tanaka, Y | 13 |
| Nakashima, Y | 3 |
| Emi, Y | 2 |
| Makiyama, A | 1 |
| Oki, E | 4 |
| Tokunaga, S | 1 |
| Mori, M | 19 |
| Wen, J | 2 |
| Liu, R | 1 |
| Chen, Q | 3 |
| Dai, Y | 1 |
| Xu, Y | 2 |
| Kanda, M | 2 |
| Koike, M | 2 |
| Shimizu, D | 1 |
| Tanaka, C | 2 |
| Hattori, N | 1 |
| Hayashi, M | 2 |
| Yamada, S | 8 |
| Omae, K | 1 |
| Nakayama, G | 2 |
| Kodera, Y | 2 |
| Beatson, M | 4 |
| Leader, N | 1 |
| Shaw, FM | 3 |
| Weinstock, MA | 8 |
| Landow, SM | 1 |
| Glynne-Jones, R | 11 |
| Meadows, HM | 4 |
| Lopes, A | 2 |
| Muirhead, R | 2 |
| Sebag-Montefiore, D | 8 |
| Adams, R | 3 |
| Cao, C | 1 |
| Parikh, P | 2 |
| Moezardalan, K | 1 |
| Anantharaman, A | 1 |
| Azarm, A | 1 |
| Lai, J | 1 |
| Duz, MB | 1 |
| Karatas, OF | 1 |
| Leiker, AJ | 1 |
| Wang, CJ | 2 |
| Sanford, NN | 2 |
| Aguilera, TA | 1 |
| Karri, S | 1 |
| Beg, MS | 1 |
| Kazmi, SA | 1 |
| Olson, C | 1 |
| Matthews, JA | 1 |
| Abdelnaby, A | 1 |
| Meyer, JJ | 1 |
| Folkert, MR | 1 |
| Bußmann, L | 1 |
| Laban, S | 4 |
| Wittekindt, C | 2 |
| Stromberger, C | 4 |
| Tribius, S | 5 |
| Möckelmann, N | 2 |
| Böttcher, A | 1 |
| Betz, CS | 1 |
| Klussmann, JP | 1 |
| Budach, V | 9 |
| Muenscher, A | 1 |
| Busch, CJ | 2 |
| Hӧllhumer, R | 2 |
| Williams, S | 2 |
| Michelow, P | 2 |
| Bahig, H | 1 |
| Lambert, L | 1 |
| Filion, E | 2 |
| Soulières, D | 6 |
| Guertin, L | 5 |
| Ayad, T | 1 |
| Christopoulos, A | 1 |
| Bissada, E | 1 |
| Alizadeh, M | 1 |
| Bélair, M | 3 |
| Nguyen-Tan, PF | 6 |
| Nýdlová, A | 1 |
| Drbohlavová, T | 1 |
| Mazaná, E | 1 |
| Jirkovská, M | 1 |
| Veselský, T | 1 |
| Malinová, B | 1 |
| Stankušová, H | 1 |
| Gilchrest, BA | 1 |
| Adotevi, O | 1 |
| Abdeljaoued, S | 1 |
| Hajiran, A | 1 |
| Zemp, L | 1 |
| Aydin, AM | 1 |
| Cheryian, SK | 1 |
| Pow-Sang, JM | 1 |
| Chahoud, J | 1 |
| Spiess, PE | 1 |
| Hino, K | 1 |
| Kajiwara, T | 2 |
| Nishina, T | 2 |
| Inoue, T | 7 |
| Yoshimatsu, M | 1 |
| Sakaguchi, C | 1 |
| Nakasya, A | 1 |
| Nishide, N | 1 |
| Asagi, A | 1 |
| Hasebe, A | 1 |
| Terao, T | 1 |
| Hori, S | 3 |
| Nadano, S | 1 |
| Hamamoto, Y | 5 |
| Kataoka, M | 2 |
| Tanimizu, M | 1 |
| Hua, R | 1 |
| Maxfield, L | 1 |
| Shah, M | 1 |
| Schwartz, C | 1 |
| Tanner, LS | 1 |
| Appel, J | 1 |
| Singh, K | 1 |
| Sathyamurthy, A | 1 |
| Ramireddy, JK | 1 |
| Ram, TS | 1 |
| Heron, CE | 1 |
| Feldman, SR | 2 |
| Lai, KC | 1 |
| Chia, YT | 1 |
| Yih, LH | 1 |
| Lu, YL | 1 |
| Chang, ST | 1 |
| Hong, ZX | 1 |
| Chen, TL | 1 |
| Hour, MJ | 1 |
| Cabel, L | 1 |
| Ombredane, AS | 1 |
| de Andrade, LR | 1 |
| Bonadio, RS | 1 |
| Pinheiro, WO | 1 |
| de Azevedo, RB | 1 |
| Joanitti, GA | 1 |
| Maghfour, J | 1 |
| Kuraitis, D | 1 |
| Murina, A | 1 |
| Zou, J | 1 |
| Wang, X | 8 |
| Li, Z | 1 |
| Shen, Y | 1 |
| Nahm, WJ | 1 |
| Zito, PM | 1 |
| Gonzalez, AM | 1 |
| Nagrani, N | 1 |
| Moore, K | 1 |
| Badiavas, EV | 1 |
| Kirsner, RS | 1 |
| Nichols, AJ | 1 |
| Means, AD | 3 |
| Leader, NF | 3 |
| Siegel, JA | 3 |
| Walker, JL | 2 |
| Pomerantz, H | 2 |
| Zeng, H | 1 |
| Zhao, X | 1 |
| Tang, C | 1 |
| Ferriol, A | 1 |
| Morán, MDC | 1 |
| Lightner, AL | 1 |
| Vaidya, P | 1 |
| McMichael, J | 1 |
| Click, B | 1 |
| Regueiro, M | 1 |
| Steele, SR | 1 |
| Hull, TL | 1 |
| Larizadeh, MH | 2 |
| Mohammadi, F | 1 |
| Shabani, M | 2 |
| Damghani, MA | 1 |
| Astaras, C | 1 |
| Bornand, A | 1 |
| Koessler, T | 2 |
| Ren, G | 2 |
| Ju, H | 1 |
| Song, H | 1 |
| Ma, X | 1 |
| Ge, M | 1 |
| Qiu, W | 1 |
| Chen, Y | 7 |
| He, Y | 5 |
| Zhuang, Q | 1 |
| Guo, W | 5 |
| Sun, W | 4 |
| Zhao, T | 3 |
| Aladelusi, TO | 1 |
| Ju, W | 1 |
| Zhang, Z | 7 |
| Zhong, L | 1 |
| Zhu, D | 1 |
| Meirovitz, A | 1 |
| Bergerson, S | 1 |
| Hirshoren, N | 1 |
| Weinberger, JM | 1 |
| Bersudski, E | 1 |
| Daniel, S | 1 |
| Sheva, K | 1 |
| Perez, CA | 1 |
| Bennardo, L | 1 |
| Bennardo, F | 1 |
| Giudice, A | 1 |
| Passante, M | 1 |
| Dastoli, S | 1 |
| Morrone, P | 1 |
| Provenzano, E | 1 |
| Patruno, C | 1 |
| Nisticò, SP | 1 |
| Echanique, KA | 1 |
| Evans, LK | 1 |
| Han, AY | 1 |
| Chhetri, DK | 1 |
| St John, MA | 1 |
| Stewart, JR | 2 |
| Lang, ME | 1 |
| Brewer, JD | 1 |
| Yang, M | 1 |
| Luo, Q | 2 |
| Chen, X | 6 |
| Chen, F | 4 |
| Anand, S | 1 |
| Rollakanti, KR | 1 |
| Brankov, N | 1 |
| Brash, DE | 1 |
| Hasan, T | 1 |
| Maytin, EV | 1 |
| Li, N | 2 |
| Lu, Y | 1 |
| Li, D | 5 |
| Zheng, X | 3 |
| Lian, J | 1 |
| Li, S | 4 |
| Cui, H | 2 |
| Sang, L | 1 |
| Wang, Y | 12 |
| Yu, JJ | 1 |
| Lu, T | 1 |
| Chang, PM | 3 |
| Lu, HJ | 1 |
| Wang, LW | 5 |
| Tai, SK | 6 |
| Chen, MH | 1 |
| Chu, PY | 8 |
| Yang, MH | 6 |
| Lee, J | 4 |
| Park, M | 1 |
| Ko, Y | 1 |
| Kim, B | 1 |
| Kim, O | 1 |
| Hyun, H | 1 |
| Kim, D | 1 |
| Sohn, H | 1 |
| Moon, YL | 1 |
| Lim, W | 1 |
| Zhang, C | 3 |
| Ma, Q | 1 |
| Shi, Y | 2 |
| Wang, M | 1 |
| Ge, J | 1 |
| Chen, Z | 3 |
| Wang, Z | 5 |
| Jiang, H | 1 |
| Anvari, K | 1 |
| Sima, HR | 1 |
| Seilanian Toussi, M | 1 |
| Anvari, A | 1 |
| Shahidsales, S | 1 |
| Memar, B | 1 |
| Aledavoud, SA | 1 |
| Forghani, MN | 1 |
| Abdollahi, A | 1 |
| Ghaffarzadegan, K | 1 |
| Fang, M | 1 |
| Song, T | 1 |
| Liang, X | 2 |
| Lv, S | 1 |
| Luo, L | 1 |
| Jia, Y | 1 |
| Burgy, M | 1 |
| Barthélémy, P | 1 |
| Lefevre, F | 1 |
| Dupret-Bories, A | 2 |
| Truntzer, P | 1 |
| Korenbaum, C | 1 |
| Flesch, H | 1 |
| Bronner, G | 1 |
| Borel, C | 4 |
| Yamashita, H | 8 |
| Abe, O | 2 |
| Zhang, Y | 12 |
| Liu, J | 7 |
| Zhang, W | 5 |
| Deng, W | 1 |
| Yue, J | 1 |
| Yoon, TM | 3 |
| Kim, SA | 2 |
| Lee, DH | 4 |
| Lee, JK | 5 |
| Park, YL | 2 |
| Lee, KH | 5 |
| Chung, IJ | 4 |
| Joo, YE | 3 |
| Lim, SC | 4 |
| Xi, M | 5 |
| Zhang, P | 7 |
| Yang, YD | 2 |
| Liu, SL | 5 |
| Li, Y | 11 |
| Fu, JH | 5 |
| Liu, MZ | 11 |
| Olsen, JR | 1 |
| Moughan, J | 3 |
| Myerson, R | 2 |
| Abitbol, A | 4 |
| Doncals, DE | 1 |
| Johnson, D | 2 |
| Schefter, TE | 1 |
| Fisher, B | 1 |
| Michalski, J | 1 |
| Narayan, S | 1 |
| Chang, A | 2 |
| Crane, CH | 6 |
| Kachnic, L | 2 |
| Hao, D | 1 |
| Wu, X | 5 |
| Xing, W | 1 |
| Yang, Y | 2 |
| He, C | 1 |
| Catalano, PJ | 1 |
| Enzinger, PC | 2 |
| King, BL | 1 |
| Bueno, R | 1 |
| Martin, NE | 1 |
| Wo, JY | 2 |
| Mamon, HJ | 1 |
| Seto, Y | 2 |
| Takenaka, R | 3 |
| Okuma, K | 4 |
| Kiritooshi, T | 1 |
| Mori, K | 3 |
| Yamada, K | 2 |
| Fukuda, T | 1 |
| Kaminishi, M | 2 |
| Hung, CC | 1 |
| Chien, CY | 4 |
| Wu, YJ | 2 |
| Lin, CS | 1 |
| Huang, CJ | 1 |
| Chan, LP | 2 |
| Wang, YY | 1 |
| Yuan, SF | 1 |
| Hour, TC | 1 |
| Chen, JY | 1 |
| Inhestern, J | 1 |
| Schmalenberg, H | 2 |
| Dietz, A | 7 |
| Rotter, N | 1 |
| Maschmeyer, G | 2 |
| Jungehülsing, M | 1 |
| Grosse-Thie, C | 1 |
| Kuhnt, T | 2 |
| Görner, M | 1 |
| Sudhoff, H | 2 |
| Guntinas-Lichius, O | 3 |
| Fujiwara, Y | 23 |
| Yanagimoto, Y | 1 |
| Ohue, M | 4 |
| Tomokuni, A | 1 |
| Kobayashi, S | 1 |
| Nakajima, Y | 4 |
| Kawada, K | 3 |
| Tokairin, Y | 3 |
| Hoshino, A | 2 |
| Okada, T | 3 |
| Kawano, T | 8 |
| Zimmermann, M | 1 |
| Beer, J | 2 |
| Bodis, S | 1 |
| von Moos, R | 1 |
| Vlachopoulou, V | 1 |
| Zwahlen, DR | 1 |
| Oehler, C | 3 |
| Chen, CC | 2 |
| Lin, JC | 4 |
| Chen, KW | 1 |
| Klinghammer, K | 1 |
| Otto, R | 1 |
| Raguse, JD | 2 |
| Albers, AE | 1 |
| Tinhofer, I | 2 |
| Fichtner, I | 1 |
| Leser, U | 1 |
| Keilholz, U | 4 |
| Hoffmann, J | 1 |
| Coen, M | 1 |
| Rigamonti, F | 1 |
| Roth, A | 4 |
| Feng, X | 1 |
| Zhang, H | 4 |
| Wang, H | 5 |
| Chen, W | 4 |
| Meng, G | 1 |
| Psyrri, A | 2 |
| Fortpied, C | 4 |
| Koutsodontis, G | 1 |
| Avgeris, M | 1 |
| Kroupis, C | 1 |
| Goutas, N | 1 |
| Menis, J | 3 |
| Herman, L | 1 |
| Giurgea, L | 2 |
| Remenár, É | 8 |
| Degardin, M | 3 |
| Pateras, IS | 1 |
| Langendijk, JA | 3 |
| van Herpen, CML | 1 |
| Awada, A | 6 |
| Germà-Lluch, JR | 1 |
| Kienzer, HR | 3 |
| Licitra, L | 10 |
| Vermorken, JB | 22 |
| Baggio, R | 1 |
| Chavel, P | 1 |
| Tisseau, L | 1 |
| Darrieux, L | 1 |
| Safa, G | 1 |
| Follana, P | 3 |
| Tuan Falk, A | 1 |
| Doyen, J | 3 |
| Reure, J | 1 |
| Tao, Y | 2 |
| Aupérin, A | 2 |
| Graff, P | 1 |
| Lapeyre, M | 1 |
| Grégoire, V | 4 |
| Maingon, P | 5 |
| Geoffrois, L | 4 |
| Verrelle, P | 2 |
| Calais, G | 15 |
| Gery, B | 3 |
| Martin, L | 3 |
| Alfonsi, M | 4 |
| Deprez, P | 1 |
| Bardet, E | 5 |
| Pignon, T | 1 |
| Sire, C | 4 |
| Bourhis, J | 7 |
| Suzuki, N | 3 |
| Azami, A | 1 |
| Todate, Y | 1 |
| Tada, T | 1 |
| Waragai, M | 1 |
| Honda, M | 3 |
| Sato, A | 4 |
| Takano, Y | 1 |
| Abe, T | 4 |
| Teranishi, Y | 1 |
| Wakabayashi, M | 1 |
| Shinoda, M | 10 |
| Katayama, H | 5 |
| Igaki, H | 10 |
| Tsubosa, Y | 7 |
| Okabe, H | 2 |
| Kosugi, S | 5 |
| Toh, Y | 3 |
| Nakamura, K | 13 |
| Fukuda, H | 12 |
| Ando, N | 16 |
| Kitagawa, Y | 12 |
| Mynhardt, C | 1 |
| Damelin, LH | 1 |
| Jivan, R | 1 |
| Peres, J | 1 |
| Prince, S | 1 |
| Veale, RB | 1 |
| Mavri-Damelin, D | 1 |
| Voncken, FEM | 1 |
| van der Kaaij, RT | 1 |
| Sikorska, K | 1 |
| van Werkhoven, E | 1 |
| van Dieren, JM | 1 |
| Grootscholten, C | 1 |
| Snaebjornsson, P | 1 |
| van Sandick, JW | 2 |
| Aleman, BMP | 1 |
| Davuluri, R | 1 |
| Jiang, W | 3 |
| Fang, P | 1 |
| Xu, C | 1 |
| Komaki, R | 7 |
| Gomez, DR | 1 |
| Welsh, J | 1 |
| Cox, JD | 5 |
| Hsu, CC | 1 |
| Lin, SH | 1 |
| Vellayappan, BA | 1 |
| Soon, YY | 1 |
| Ku, GY | 1 |
| Leong, CN | 1 |
| Lu, JJ | 2 |
| Tey, JC | 1 |
| Bascoul-Mollevi, C | 1 |
| Galais, MP | 3 |
| Raoul, JL | 6 |
| Douillard, JY | 1 |
| Adenis, A | 7 |
| Etienne, PL | 5 |
| Juzyna, B | 1 |
| Bedenne, L | 5 |
| Conroy, T | 7 |
| Dumont, S | 1 |
| Louvet, C | 3 |
| Bachet, JB | 1 |
| Abdelghani, MB | 1 |
| Aparicio, T | 1 |
| Bennouna, J | 3 |
| Gornet, JM | 2 |
| Bonnetain, F | 3 |
| Bollo, J | 1 |
| Balla, A | 1 |
| Rodriguez Luppi, C | 1 |
| Martinez, C | 1 |
| Quaresima, S | 1 |
| Targarona, EM | 1 |
| Damps, T | 1 |
| Laskowska, AK | 1 |
| Kowalkowski, T | 1 |
| Prokopowicz, M | 1 |
| Puszko, AK | 1 |
| Sosnowski, P | 1 |
| Czuwara, J | 1 |
| Konop, M | 1 |
| Różycki, K | 1 |
| Borkowska, JK | 1 |
| Misicka, A | 1 |
| Rudnicka, L | 1 |
| Tsang, JS | 1 |
| Tong, DKH | 1 |
| Lam, KO | 1 |
| Law, BTT | 1 |
| Wong, IYH | 1 |
| Chan, DKK | 1 |
| Chan, FSY | 1 |
| Kwong, D | 1 |
| Law, S | 5 |
| Okamura, A | 1 |
| Watanabe, M | 13 |
| Mine, S | 1 |
| Kurogochi, T | 1 |
| Hayami, M | 1 |
| Imamura, Y | 3 |
| Ogura, M | 1 |
| Ichimura, T | 1 |
| Takahari, D | 3 |
| Chin, K | 6 |
| Francis, SR | 1 |
| Orton, A | 1 |
| Thorpe, C | 1 |
| Stoddard, G | 1 |
| Lloyd, S | 1 |
| Anker, CJ | 1 |
| Kumabe, A | 2 |
| Zenda, S | 5 |
| Motegi, A | 2 |
| Onozawa, M | 5 |
| Shigematsu, N | 3 |
| Otowa, Y | 1 |
| Kanaji, S | 1 |
| Matsuda, Y | 2 |
| Matsuda, T | 3 |
| Oshikiri, T | 1 |
| Sumi, Y | 1 |
| Suzuki, S | 6 |
| Kakeji, Y | 1 |
| Specenier, PM | 4 |
| Buter, J | 1 |
| Schrijvers, DL | 1 |
| Bergamini, C | 2 |
| Licitra, LF | 1 |
| Clement, PM | 2 |
| Ghi, MG | 4 |
| Paccagnella, A | 9 |
| Ferrari, D | 1 |
| Foa, P | 2 |
| Alterio, D | 1 |
| Codecà, C | 1 |
| Nolè, F | 2 |
| Verri, E | 1 |
| Orecchia, R | 4 |
| Morelli, F | 1 |
| Parisi, S | 1 |
| Mastromauro, C | 3 |
| Mione, CA | 3 |
| Rossetto, C | 1 |
| Polsinelli, M | 1 |
| Koussis, H | 3 |
| Loreggian, L | 3 |
| Bonetti, A | 2 |
| Campostrini, F | 2 |
| Azzarello, G | 1 |
| D'Ambrosio, C | 1 |
| Bertoni, F | 1 |
| Casanova, C | 1 |
| Emiliani, E | 1 |
| Guaraldi, M | 4 |
| Bunkheila, F | 1 |
| Bidoli, P | 1 |
| Niespolo, RM | 1 |
| Gava, A | 6 |
| Massa, E | 2 |
| Frattegiani, A | 1 |
| Valduga, F | 1 |
| Pieri, G | 1 |
| Cipani, T | 1 |
| Da Corte, D | 1 |
| Chiappa, F | 1 |
| Rulli, E | 1 |
| Monfort, JB | 1 |
| Mathian, A | 1 |
| Amoura, Z | 1 |
| Francès, C | 1 |
| Barbaud, A | 1 |
| Senet, P | 1 |
| Smith, CA | 1 |
| Fujimoto, Y | 3 |
| Sasaki, S | 5 |
| Hirose, K | 2 |
| Edahiro, K | 1 |
| Korehisa, S | 1 |
| Taniguchi, D | 1 |
| Kudou, K | 1 |
| Nakaji, YU | 1 |
| Nakanishi, R | 1 |
| Ando, K | 3 |
| Oda, Y | 3 |
| Maehara, Y | 7 |
| Hirakawa, H | 4 |
| Hanai, N | 6 |
| Suzuki, H | 8 |
| Nishikawa, D | 3 |
| Matayoshi, S | 2 |
| Hasegawa, Y | 9 |
| Suzuki, M | 6 |
| Katanyoo, K | 2 |
| Arita, H | 4 |
| Yoshida, R | 8 |
| Matsuoka, Y | 6 |
| Hirosue, A | 6 |
| Sakata, J | 4 |
| Nakashima, H | 3 |
| Toya, R | 2 |
| Murakami, R | 4 |
| Hiraki, A | 8 |
| Shinohara, M | 9 |
| Gupta, S | 4 |
| Pawar, SS | 1 |
| Bunger, D | 1 |
| Tsuchiya, Y | 5 |
| Ushijima, K | 1 |
| Noguchi, T | 5 |
| Okada, N | 2 |
| Hayasaka, JI | 1 |
| Jinbu, Y | 3 |
| Ando, H | 1 |
| Mori, Y | 1 |
| Kusama, M | 3 |
| Fujimura, A | 1 |
| Miyazaki, Y | 3 |
| Wada, N | 1 |
| Takahashi, T | 8 |
| Kurokawa, Y | 5 |
| Nakajima, K | 8 |
| Takiguchi, S | 17 |
| Eder-Czembirek, C | 2 |
| Sulzbacher, I | 3 |
| Fuereder, T | 1 |
| Selzer, E | 9 |
| Fukada, J | 2 |
| Kota, R | 1 |
| Koike, N | 3 |
| Shiraishi, Y | 1 |
| Seki, S | 4 |
| Yoshida, K | 10 |
| Chaugule, SS | 1 |
| Park, J | 1 |
| Finger, PT | 1 |
| Thwin, SS | 1 |
| Marcolivio, K | 1 |
| Hogan, D | 1 |
| Eilers, D | 1 |
| Swetter, SM | 2 |
| Chen, SC | 1 |
| Jacob, SE | 1 |
| Warshaw, EM | 1 |
| Stricklin, GP | 1 |
| Dellavalle, RP | 1 |
| Sidhu-Malik, N | 1 |
| Konnikov, N | 3 |
| Werth, VP | 1 |
| Keri, JE | 1 |
| Robinson-Bostom, L | 2 |
| Ringer, RJ | 1 |
| Lew, RA | 2 |
| Ferguson, R | 1 |
| DiGiovanna, JJ | 1 |
| Huang, GD | 1 |
| Huang, KJ | 1 |
| Kuo, CH | 1 |
| Chen, SH | 2 |
| Lin, CY | 1 |
| Lee, YR | 1 |
| Lobato-Berezo, A | 1 |
| Fernández-Figueras, MT | 1 |
| Campoy, A | 1 |
| Pujol, RM | 1 |
| Moya-Horno, I | 1 |
| Konishi, H | 4 |
| Shiozaki, A | 7 |
| Shoda, K | 2 |
| Kosuga, T | 1 |
| Kubota, T | 3 |
| Otsuji, E | 7 |
| Liang, L | 1 |
| Luo, H | 1 |
| He, Q | 1 |
| You, Y | 1 |
| Fan, Y | 1 |
| Liang, J | 5 |
| Kurniadi, I | 1 |
| Yamada, D | 1 |
| Wirya, AY | 1 |
| Norimatsu, Y | 1 |
| Kuzumi, A | 1 |
| Ogaki, J | 1 |
| Sato, S | 2 |
| Muroya, T | 2 |
| Wajima, N | 2 |
| Yachi, T | 1 |
| Akaishi, T | 1 |
| Umetsu, S | 2 |
| Yoshida, T | 21 |
| Wakasa, Y | 2 |
| Sato, K | 5 |
| Mitsuhashi, Y | 1 |
| Umemura, K | 1 |
| Suzuki, T | 5 |
| Tsuruta, S | 1 |
| Hakamada, K | 2 |
| Yoon, J | 1 |
| Phibbs, CS | 1 |
| Chow, A | 1 |
| Zhang, JZ | 1 |
| Liu, JF | 4 |
| Li, HY | 1 |
| Li, AW | 1 |
| Lalor, LE | 1 |
| Bellodi Schmidt, F | 1 |
| Luu, M | 1 |
| Colombo, AF | 1 |
| Boito, R | 1 |
| Bova, F | 1 |
| Greco, S | 1 |
| Lucà, R | 1 |
| Sellaro, A | 1 |
| Rizzuto, G | 1 |
| Lowe, NM | 1 |
| Kershaw, LE | 1 |
| Bernstein, JM | 1 |
| Withey, SB | 1 |
| Mais, K | 3 |
| Homer, JJ | 1 |
| Slevin, NJ | 3 |
| Bonington, SC | 1 |
| Carrington, BM | 1 |
| West, CM | 1 |
| Huang, X | 2 |
| Huang, H | 2 |
| Liu, Y | 10 |
| Yu, M | 1 |
| Hsieh, HY | 1 |
| Hsu, CP | 1 |
| Yeh, HL | 1 |
| Chuang, CY | 1 |
| Lin, JF | 2 |
| Chang, CF | 1 |
| Franco, P | 6 |
| Montagnani, F | 1 |
| Arcadipane, F | 4 |
| Casadei, C | 1 |
| Andrikou, K | 1 |
| Martini, S | 1 |
| Iorio, GC | 1 |
| Scartozzi, M | 1 |
| Mistrangelo, M | 5 |
| Fornaro, L | 1 |
| Cassoni, P | 5 |
| Cascinu, S | 2 |
| Ricardi, U | 8 |
| Casadei Gardini, A | 2 |
| Jones, CM | 1 |
| Downing, A | 2 |
| Harrison, M | 1 |
| Hawkins, M | 1 |
| Gilbert, DC | 1 |
| Doosti-Irani, A | 1 |
| Holakouie-Naieni, K | 1 |
| Rahimi-Foroushani, A | 1 |
| Mansournia, MA | 1 |
| Haddad, P | 1 |
| Katz, KA | 1 |
| Giorgini, E | 1 |
| Sabbatini, S | 1 |
| Rocchetti, R | 1 |
| Notarstefano, V | 1 |
| Rubini, C | 1 |
| Conti, C | 1 |
| Orilisi, G | 1 |
| Mitri, E | 1 |
| Bedolla, DE | 1 |
| Vaccari, L | 1 |
| Akiyama, Y | 1 |
| Sasaki, A | 2 |
| Endo, F | 1 |
| Nikai, H | 1 |
| Amano, S | 1 |
| Umemura, A | 1 |
| Baba, S | 1 |
| Chiba, T | 1 |
| Kimura, T | 4 |
| Takahara, T | 1 |
| Nitta, H | 1 |
| Otsuka, K | 1 |
| Mizuno, M | 2 |
| Koeda, K | 3 |
| Iwaya, T | 3 |
| Maihoefer, C | 1 |
| Schüttrumpf, L | 1 |
| Macht, C | 1 |
| Pflugradt, U | 1 |
| Hess, J | 1 |
| Schneider, L | 1 |
| Woischke, C | 1 |
| Walch, A | 1 |
| Baumeister, P | 1 |
| Kirchner, T | 1 |
| Zitzelsberger, H | 1 |
| Belka, C | 4 |
| Ganswindt, U | 2 |
| Abate, D | 1 |
| Giusti, G | 1 |
| Caria, N | 1 |
| De Vita, G | 1 |
| Lucci Chiarissi, M | 1 |
| De Lisa, A | 1 |
| Tamura, T | 11 |
| Taniguchi, N | 1 |
| Otsuki, K | 1 |
| Narai, T | 1 |
| Kawasaki, M | 1 |
| Fujii, N | 1 |
| Doi, R | 2 |
| Kodani, I | 1 |
| Sclafani, F | 1 |
| Ng, M | 1 |
| Ho, H | 1 |
| Skelton, J | 1 |
| Guerrieri, M | 1 |
| Guiney, M | 1 |
| Chao, M | 1 |
| Blakey, D | 1 |
| Macleod, C | 2 |
| Amor, H | 1 |
| Subramanian, B | 1 |
| Melven, L | 1 |
| Hu, X | 4 |
| Akutsu, Y | 4 |
| Suganami, A | 1 |
| Qin, W | 2 |
| Hanari, N | 3 |
| Murakam, K | 1 |
| Usui, A | 1 |
| Suito, H | 1 |
| Takahashi, M | 7 |
| Matsumoto, Y | 2 |
| Otsuta, R | 1 |
| Tamura, Y | 2 |
| Matsubara, H | 9 |
| Kawamoto, T | 3 |
| Nihei, K | 5 |
| Sasai, K | 2 |
| Karasawa, K | 4 |
| Elkashty, OA | 1 |
| Ashry, R | 1 |
| Elghanam, GA | 1 |
| Pham, HM | 1 |
| Su, X | 2 |
| Stegen, C | 1 |
| Tran, SD | 1 |
| Gombodorj, N | 1 |
| Yokobori, T | 3 |
| Tanaka, N | 8 |
| Kuriyama, K | 1 |
| Kumakura, Y | 1 |
| Sakai, M | 3 |
| Sohda, M | 3 |
| Baatar, S | 1 |
| Miyazaki, T | 8 |
| Nishiyama, M | 2 |
| Shirabe, K | 1 |
| Kuwano, H | 4 |
| Hashimoto, J | 1 |
| Ito, Y | 8 |
| Matsushita, H | 5 |
| Katano, S | 1 |
| Saito, Y | 1 |
| Nagashima, K | 3 |
| Chen, YH | 2 |
| Lu, HI | 2 |
| Lo, CM | 1 |
| Wang, YM | 2 |
| Chou, SY | 1 |
| Hsiao, CC | 1 |
| Huang, CC | 1 |
| Shih, LH | 1 |
| Chen, SW | 1 |
| Li, SH | 4 |
| Polski, A | 1 |
| Sibug Saber, M | 1 |
| Kim, JW | 3 |
| Berry, JL | 1 |
| Faivre, JC | 1 |
| Hannoun-Levi, JM | 6 |
| Mirabel, X | 6 |
| Stanbury, T | 1 |
| Salleron, J | 1 |
| Guillemin, F | 1 |
| Celentano, A | 1 |
| McCullough, M | 1 |
| Cirillo, N | 1 |
| Esin, E | 1 |
| Yıldız, F | 1 |
| Laçin, Ş | 1 |
| Karakaş, Y | 1 |
| Gültekin, M | 1 |
| Dizdar, Ö | 1 |
| Yalçın, Ş | 2 |
| Athauda, A | 1 |
| Watkins, D | 1 |
| Mohammed, K | 1 |
| Chau, I | 2 |
| Starling, N | 1 |
| Rao, S | 2 |
| Tait, D | 6 |
| Aitken, K | 1 |
| Cunningham, D | 9 |
| Mondaca, S | 1 |
| Chatila, WK | 1 |
| Bates, D | 1 |
| Hechtman, JF | 1 |
| Cercek, A | 1 |
| Segal, NH | 1 |
| Stadler, ZK | 1 |
| Varghese, AM | 1 |
| Kundra, R | 1 |
| Capanu, M | 1 |
| Shia, J | 2 |
| Schultz, N | 1 |
| Saltz, L | 4 |
| Yaeger, R | 1 |
| Kina, S | 1 |
| Nakasone, T | 1 |
| Kinjo, T | 1 |
| Nimura, F | 1 |
| Sunagawa, N | 1 |
| Arasaki, A | 1 |
| Elson, JK | 1 |
| Kharofa, JR | 1 |
| Rechinger, S | 1 |
| Kornek, G | 4 |
| Seemann, R | 2 |
| Ott, OJ | 1 |
| Schmidt, M | 2 |
| Semrau, S | 1 |
| Strnad, V | 1 |
| Matzel, KE | 2 |
| Schneider, I | 2 |
| Raptis, D | 1 |
| Uter, W | 1 |
| Grützmann, R | 1 |
| Fietkau, R | 4 |
| Keyal, U | 1 |
| Bhatta, AK | 1 |
| Zhang, G | 1 |
| Wang, XL | 1 |
| Neugebauer, R | 1 |
| Su, KA | 1 |
| Zhu, Z | 2 |
| Sokil, M | 1 |
| Chren, MM | 2 |
| Friedman, GD | 1 |
| Venkateswaran, N | 1 |
| Mercado, C | 2 |
| Lyu, J | 2 |
| Li, T | 4 |
| Wang, Q | 2 |
| Li, F | 2 |
| Diao, P | 1 |
| Liu, L | 4 |
| Li, C | 3 |
| Lang, J | 2 |
| Koerber, SA | 1 |
| Seither, B | 1 |
| Slynko, A | 1 |
| Haefner, MF | 1 |
| Krug, D | 1 |
| Liermann, J | 1 |
| Adeberg, S | 1 |
| Herfarth, K | 1 |
| Debus, J | 5 |
| Sterzing, F | 1 |
| Mackey, M | 1 |
| Shahsavari, A | 1 |
| Mackey, VT | 1 |
| Kijima, T | 1 |
| Nakagawa, H | 2 |
| Shimonosono, M | 1 |
| Chandramouleeswaran, PM | 1 |
| Hara, T | 3 |
| Sahu, V | 1 |
| Kasagi, Y | 2 |
| Kikuchi, O | 1 |
| Giroux, V | 1 |
| Muir, AB | 1 |
| Whelan, KA | 1 |
| Ohashi, S | 1 |
| Naganuma, S | 1 |
| Klein-Szanto, AJ | 1 |
| Shinden, Y | 1 |
| Sasaki, K | 7 |
| Omoto, I | 4 |
| Kita, Y | 5 |
| Muto, M | 9 |
| Bass, AJ | 1 |
| Diehl, JA | 1 |
| Ginsberg, GG | 1 |
| Uchikado, Y | 5 |
| Arigami, T | 2 |
| Avadhani, NG | 1 |
| Basu, D | 1 |
| Rustgi, AK | 1 |
| Natsugoe, S | 9 |
| Kim, TH | 2 |
| Lee, IJ | 2 |
| Kim, JH | 15 |
| Lee, CG | 6 |
| Lee, YC | 6 |
| Dando, EE | 1 |
| Lim, GFS | 1 |
| Lim, SJM | 1 |
| Kim, C | 2 |
| Pugliano-Mauro, M | 1 |
| Dohmae, T | 1 |
| Hotta, K | 2 |
| Kageyama, SI | 1 |
| Baba, H | 6 |
| Kohno, R | 1 |
| Tsuchihara, K | 1 |
| Ueda, H | 2 |
| Chikugo, T | 1 |
| Imamoto, H | 1 |
| Sato, H | 7 |
| Koide, Y | 2 |
| Shiota, M | 2 |
| Morise, Z | 1 |
| Uyama, I | 1 |
| Laccourreye, O | 11 |
| Marret, G | 1 |
| Rubin, F | 1 |
| Fabre, E | 1 |
| Badoual, C | 1 |
| Oudard, S | 1 |
| Bonfils, P | 1 |
| Lisan, Q | 1 |
| Yang, LY | 1 |
| Shan, YM | 1 |
| Zhou, EH | 1 |
| Chen, XP | 1 |
| Hall, SF | 1 |
| Griffiths, RJ | 1 |
| O'Sullivan, B | 3 |
| Liu, FF | 2 |
| Shah, MA | 1 |
| Enzinger, P | 1 |
| Shen, L | 1 |
| Sun, JM | 2 |
| Cho, BC | 4 |
| Özgüroğlu, M | 1 |
| Kostorov, V | 1 |
| Hierro, C | 1 |
| McLean, LA | 1 |
| Shah, S | 1 |
| Doi, T | 6 |
| Chen, L | 5 |
| Huang, JQ | 2 |
| Zhu, XL | 1 |
| Wen, YH | 1 |
| Wen, WP | 1 |
| Yang, X | 3 |
| Daifallah, AEM | 1 |
| Shankar, S | 1 |
| Marshall, C | 1 |
| Dentchev, T | 1 |
| Seykora, F | 1 |
| D'Armas, S | 1 |
| Hahn, J | 1 |
| Lee, V | 1 |
| Sabry, HH | 1 |
| Farag, AM | 1 |
| Seykora, JT | 1 |
| Huang, WC | 1 |
| Jang, TH | 1 |
| Tung, SL | 1 |
| Yen, TC | 1 |
| Chan, SH | 1 |
| Wang, LH | 1 |
| Akhter, K | 1 |
| Enamur Rashid, M | 1 |
| Maebayashi, T | 1 |
| Ishibashi, N | 2 |
| Aizawa, T | 1 |
| Sakaguchi, M | 1 |
| Ikeda, A | 1 |
| Hirai, R | 1 |
| Furusaka, T | 8 |
| Homma, T | 1 |
| Kiss, N | 1 |
| Avci, P | 1 |
| Bánvölgyi, A | 1 |
| Lőrincz, K | 1 |
| Szakonyi, J | 1 |
| Gyöngyösi, N | 1 |
| Fésűs, L | 1 |
| Lee, G | 1 |
| Wikonkál, N | 1 |
| Ito, T | 6 |
| Kuwahara, Y | 1 |
| Rosenberg, AR | 1 |
| Tabacchi, M | 2 |
| Ngo, KH | 1 |
| Wallendorf, M | 2 |
| Rosman, IS | 1 |
| Cornelius, LA | 2 |
| Ye, J | 1 |
| Zhao, W | 2 |
| Zhou, J | 1 |
| Wu, C | 1 |
| Tang, H | 1 |
| Fan, M | 1 |
| Lin, Q | 4 |
| Xia, Y | 1 |
| Jia, H | 1 |
| Lu, S | 1 |
| Zhao, K | 3 |
| Martin, D | 2 |
| Rödel, C | 6 |
| Fokas, E | 4 |
| Vazquez-Romo, KA | 1 |
| García de Oteyza, G | 1 |
| Sebastian-Arellano, C | 1 |
| Ramos-Betancourt, N | 1 |
| Hernandez-Quintela, E | 1 |
| Lu, B | 1 |
| Lu, C | 2 |
| Sun, Z | 1 |
| Qu, C | 1 |
| Chen, J | 3 |
| Hua, Z | 1 |
| Tong, R | 1 |
| Han, C | 2 |
| Wang, P | 3 |
| Pang, Q | 1 |
| Sun, X | 2 |
| Wang, L | 6 |
| Lin, Y | 5 |
| Ge, X | 1 |
| Zhou, Z | 2 |
| Ni, W | 1 |
| Chang, X | 1 |
| Deng, L | 1 |
| Zhao, Y | 3 |
| Xiao, Z | 1 |
| Maskell, D | 1 |
| Buckley, H | 1 |
| Sission, K | 1 |
| Roques, T | 1 |
| Geropantas, K | 3 |
| Nemer, KM | 1 |
| Council, ML | 1 |
| Kobayashi, T | 4 |
| Que, SKT | 1 |
| Compton, LA | 1 |
| Plastaras, JP | 1 |
| Metz, JM | 1 |
| Yeap, BY | 1 |
| Drapek, LC | 1 |
| Adams, J | 1 |
| Baglini, C | 1 |
| Ryan, DP | 2 |
| Murphy, JE | 1 |
| Parikh, AR | 1 |
| Allen, JN | 1 |
| Clark, JW | 1 |
| Blaszkowsky, LS | 2 |
| DeLaney, TF | 1 |
| Ben-Josef, E | 2 |
| Oguma, J | 1 |
| Ozawa, S | 5 |
| Koyanagi, K | 1 |
| Kazuno, A | 2 |
| Ninomiya, Y | 1 |
| Yatabe, K | 1 |
| Monma, S | 1 |
| Shouji, H | 1 |
| Okita, N | 2 |
| Takashima, A | 2 |
| Honma, Y | 3 |
| Iwasa, S | 3 |
| Hamaguchi, T | 1 |
| Yamada, Y | 5 |
| Shimada, Y | 3 |
| Boku, N | 13 |
| Itami, J | 1 |
| Boustani, J | 2 |
| Blanc, J | 1 |
| Pereira, R | 1 |
| Rio, E | 2 |
| Le Prisé, E | 5 |
| Huguet, F | 5 |
| Giuliani, A | 1 |
| Romanzi, F | 1 |
| Di Sibio, A | 1 |
| Calvisi, G | 1 |
| Lombardi, L | 1 |
| Marchese, M | 1 |
| Di Staso, M | 1 |
| Schietroma, M | 1 |
| Carlei, F | 1 |
| Romano, L | 1 |
| Hanke, CW | 1 |
| Nishizawa, Y | 1 |
| Ikeda, R | 1 |
| Shinsato, Y | 1 |
| Minami, K | 1 |
| Nitta, M | 1 |
| Terazono, H | 1 |
| Akiyama, SI | 1 |
| Takeda, Y | 6 |
| Nakano, K | 1 |
| Seto, A | 1 |
| Sasaki, T | 7 |
| Shimbashi, W | 1 |
| Fukushima, H | 1 |
| Yonekawa, H | 1 |
| Mitani, H | 1 |
| Takahashi, S | 4 |
| Fan, H | 1 |
| Ma, Y | 1 |
| Liang, D | 1 |
| Huang, R | 2 |
| Zhou, F | 2 |
| Kan, Q | 1 |
| Ming, L | 1 |
| Li, H | 4 |
| Giercksky, KE | 1 |
| Nesland, JM | 1 |
| Suo, Z | 1 |
| Perri, F | 1 |
| Muto, P | 1 |
| Argenone, A | 1 |
| Ionna, F | 2 |
| Longo, F | 1 |
| Fulciniti, F | 1 |
| Sandomenico, F | 1 |
| Daponte, A | 1 |
| Caponigro, F | 5 |
| Gebhardt, BJ | 1 |
| Mendenhall, CM | 1 |
| Kirwan, J | 1 |
| McAfee, WJ | 1 |
| Rigalli, JP | 2 |
| Reuter, T | 1 |
| Herold-Mende, C | 3 |
| Dyckhoff, G | 3 |
| Haefeli, WE | 2 |
| Weiss, J | 3 |
| Theile, D | 3 |
| Monden, N | 2 |
| Homma, A | 3 |
| Okami, K | 1 |
| Onozawa, Y | 5 |
| Fujii, M | 13 |
| Taguchi, T | 15 |
| de Blas, B | 1 |
| Beier, F | 1 |
| Tahara, M | 11 |
| Mukaida, H | 1 |
| Kobayashi, Y | 5 |
| Nozaki, I | 1 |
| Hato, S | 1 |
| Kobatake, T | 1 |
| Ohta, K | 1 |
| Kubo, Y | 1 |
| Tanada, M | 1 |
| Kurita, A | 2 |
| Yoshizawa, J | 1 |
| Koide, N | 2 |
| Takeuchi, D | 1 |
| Suzuki, A | 2 |
| Shinoda, A | 3 |
| Miyagawa, S | 1 |
| William, WN | 3 |
| Ma, J | 4 |
| Yang, CZ | 2 |
| Myers, JN | 5 |
| Lee, JJ | 6 |
| Zhang, CP | 4 |
| Deenen, MJ | 1 |
| Dewit, L | 3 |
| Boot, H | 2 |
| Beijnen, JH | 2 |
| Schellens, JH | 2 |
| Cats, A | 4 |
| Khan, H | 2 |
| Barik, S | 1 |
| Negi, MP | 3 |
| Fayette, J | 7 |
| Bonnin, N | 1 |
| Ferlay, C | 1 |
| Lallemant, B | 3 |
| Ramade, A | 6 |
| Favrel, V | 3 |
| Zrounba, P | 5 |
| Chabaud, S | 2 |
| Poupart, M | 5 |
| Céruse, P | 7 |
| Heinzow, HS | 1 |
| Seifert, H | 1 |
| Tsepetonidis, S | 1 |
| Wolters, H | 1 |
| Kucharzik, T | 1 |
| Domschke, W | 1 |
| Domagk, D | 1 |
| Meister, T | 1 |
| Mayahara, H | 1 |
| Tanaka, T | 11 |
| Kobayashi, R | 2 |
| Shiraishi, K | 3 |
| Ohtomo, K | 5 |
| Wang, CQ | 1 |
| Li, YJ | 1 |
| Wei, ZM | 1 |
| Zhu, CJ | 1 |
| Qu, X | 1 |
| Wei, FC | 1 |
| Xing, XM | 1 |
| Yu, WJ | 1 |
| Cohen, MH | 2 |
| Chen, H | 2 |
| Shord, S | 1 |
| Fuchs, C | 1 |
| He, K | 1 |
| Zhao, H | 2 |
| Sickafuse, S | 1 |
| Keegan, P | 1 |
| Pazdur, R | 4 |
| James, RD | 1 |
| Myint, AS | 1 |
| Saunders, MP | 1 |
| Maughan, T | 2 |
| McDonald, A | 2 |
| Essapen, S | 1 |
| Leslie, M | 2 |
| Falk, S | 3 |
| Wilson, C | 2 |
| Gollins, S | 4 |
| Begum, R | 1 |
| Ledermann, J | 1 |
| Kadalayil, L | 2 |
| Malet, C | 1 |
| Gérard, JP | 8 |
| Box, C | 1 |
| Mendiola, M | 1 |
| Gowan, S | 1 |
| Box, GM | 1 |
| Valenti, M | 2 |
| Brandon, Ade H | 1 |
| Al-Lazikani, B | 1 |
| Rogers, SJ | 1 |
| Wilkins, A | 1 |
| Harrington, KJ | 4 |
| Eccles, SA | 1 |
| Chao, YK | 4 |
| Tseng, CK | 4 |
| Wen, YW | 3 |
| Liu, YH | 5 |
| Wan, YL | 1 |
| Chiu, CT | 1 |
| Chang, WC | 1 |
| Chang, HK | 5 |
| Nakajima, TE | 4 |
| Katada, C | 5 |
| Ishiyama, H | 3 |
| Tokunaga, SY | 1 |
| Tanaka, M | 2 |
| Hironaka, S | 6 |
| Hashimoto, T | 1 |
| Ura, T | 5 |
| Kodaira, T | 13 |
| Yoshimura, K | 1 |
| Zhang, S | 5 |
| Yue, K | 1 |
| Wang, XD | 1 |
| Zilli, T | 1 |
| Betz, M | 2 |
| Bieri, S | 2 |
| Ris, F | 1 |
| Roche, B | 1 |
| Roth, AD | 2 |
| Allal, AS | 6 |
| Zhang, SS | 1 |
| Yang, H | 7 |
| Xie, X | 2 |
| Luo, KJ | 1 |
| Bella, AE | 1 |
| Hu, Y | 3 |
| Yang, F | 1 |
| Kua, VF | 1 |
| Chee Ee Phua, V | 1 |
| Aslan, NM | 1 |
| Crosby, T | 2 |
| Hurt, CN | 1 |
| Mukherjee, S | 1 |
| Staffurth, J | 1 |
| Ray, R | 1 |
| Bashir, N | 1 |
| Bridgewater, JA | 1 |
| Geh, JI | 1 |
| Blazeby, J | 1 |
| Roy, R | 1 |
| Griffiths, G | 1 |
| Shridhar, R | 2 |
| Hoffe, SE | 2 |
| Almhanna, K | 2 |
| Weber, JM | 2 |
| Chuong, MD | 1 |
| Karl, RC | 2 |
| Meredith, K | 2 |
| Jeong, BG | 1 |
| Kim, DY | 3 |
| Kim, SY | 2 |
| McPartlin, AJ | 1 |
| Barker, C | 1 |
| Swindell, R | 1 |
| Mitchell, K | 1 |
| Sykes, A | 2 |
| Lee, L | 2 |
| Yap, B | 2 |
| Motoyama, S | 2 |
| Nanjo, H | 1 |
| Ito, S | 1 |
| Yoshino, K | 3 |
| Kuribayashi, K | 1 |
| Nagaki, Y | 1 |
| Imai, K | 3 |
| Saito, H | 7 |
| Minamiya, Y | 2 |
| Ogawa, J | 2 |
| Aderhold, C | 4 |
| Umbreit, C | 4 |
| Faber, A | 5 |
| Sauter, A | 4 |
| Sommer, JU | 3 |
| Birk, R | 2 |
| Erben, P | 1 |
| Hofheinz, RD | 5 |
| Stern-Straeter, J | 2 |
| Hörmann, K | 3 |
| Schultz, JD | 5 |
| Khanna, A | 1 |
| Reece-Smith, AM | 1 |
| Cunnell, M | 1 |
| Madhusudan, S | 1 |
| Thomas, A | 1 |
| Bowrey, DJ | 1 |
| Parsons, SL | 2 |
| Tallon, B | 1 |
| Turnbull, N | 1 |
| Goto, Y | 1 |
| Furutani, K | 6 |
| Tachibana, H | 8 |
| Tomita, N | 1 |
| Ito, J | 1 |
| Ozawa, T | 3 |
| Nakajima, M | 2 |
| Mirinezhad, SK | 2 |
| Somi, MH | 2 |
| Seyednezhad, F | 1 |
| Jangjoo, AG | 2 |
| Ghojazadeh, M | 2 |
| Mohammadzadeh, M | 2 |
| Naseri, AR | 2 |
| Nasiri, B | 2 |
| Hou, W | 1 |
| Qin, X | 1 |
| Zhu, X | 3 |
| Fei, M | 1 |
| Liu, P | 3 |
| Moon, H | 1 |
| Greshock, J | 1 |
| Bachman, KE | 1 |
| Ye, BC | 1 |
| Zang, CY | 1 |
| Xu, X | 2 |
| Xu, HQ | 1 |
| Huang, XE | 2 |
| Qian, YD | 1 |
| Xiang, J | 1 |
| Stöhlmacher-Williams, J | 1 |
| Davidenko, I | 1 |
| Winquist, E | 3 |
| Villanueva, C | 1 |
| Rottey, S | 4 |
| Skladowski, K | 1 |
| Pai, VR | 1 |
| Faivre, S | 3 |
| Blajman, CR | 3 |
| Forastiere, AA | 16 |
| Stein, BN | 1 |
| Oliner, KS | 1 |
| Pan, Z | 1 |
| Bach, BA | 1 |
| Stern-Sträter, J | 1 |
| Hoermann, K | 2 |
| Cutilli, T | 3 |
| Leocata, P | 1 |
| Dolo, V | 1 |
| Altobelli, E | 1 |
| Yen, CY | 1 |
| Chiang, WF | 1 |
| Liu, SY | 2 |
| Cheng, PC | 1 |
| Lee, SY | 2 |
| Hong, WZ | 1 |
| Lin, PY | 1 |
| Lin, MH | 2 |
| Liu, YC | 3 |
| Castoro, C | 4 |
| Scarpa, M | 2 |
| Cagol, M | 3 |
| Alfieri, R | 3 |
| Ruol, A | 7 |
| Cavallin, F | 3 |
| Michieletto, S | 1 |
| Zanchettin, G | 2 |
| Chiarion-Sileni, V | 6 |
| Corti, L | 3 |
| Ancona, E | 7 |
| Tano, T | 1 |
| Okamoto, M | 1 |
| Kan, S | 1 |
| Bando, T | 1 |
| Goda, H | 1 |
| Nakashiro, K | 1 |
| Shimodaira, S | 1 |
| Koido, S | 1 |
| Homma, S | 1 |
| Sato, M | 7 |
| Yamashita, N | 1 |
| Hamakawa, H | 2 |
| Kawakami, Y | 1 |
| Yamamoto, Y | 7 |
| Ichikawa, D | 6 |
| Arita, T | 2 |
| Komatsu, S | 5 |
| Ikoma, H | 3 |
| Ochiai, T | 9 |
| Inoue, J | 1 |
| Inazawa, J | 1 |
| Imanishi, S | 1 |
| Shuto, K | 4 |
| Aoyagi, T | 1 |
| Kono, T | 2 |
| Lee, DW | 3 |
| Lee, JW | 3 |
| Park, ST | 1 |
| Park, JS | 3 |
| Lee, HN | 2 |
| Saba, NF | 1 |
| Magliocca, KR | 1 |
| Muller, S | 1 |
| Owonikoko, TK | 1 |
| Sarlis, NJ | 3 |
| Eggers, C | 1 |
| Phelan, V | 1 |
| Grist, WJ | 1 |
| Chen, AY | 1 |
| Ramalingam, SS | 1 |
| Chen, ZG | 1 |
| Beitler, JJ | 3 |
| Shin, DM | 6 |
| Khuri, FR | 3 |
| Marcus, AI | 1 |
| Shirmohamadi, M | 1 |
| Seyednejad, F | 1 |
| Graham, CM | 1 |
| Elci, O | 1 |
| Griswold, ME | 1 |
| Zhang, X | 8 |
| Khan, MA | 1 |
| Pitman, K | 1 |
| Caudell, JJ | 1 |
| Hamilton, RD | 1 |
| Ganeshan, B | 1 |
| Smith, AD | 1 |
| Chitwood, K | 1 |
| Etzkorn, J | 1 |
| Cohen, G | 1 |
| Tsuda, Y | 3 |
| Hidaka, G | 1 |
| Kawano, H | 1 |
| Otsu, H | 1 |
| Kusumoto, T | 2 |
| Teo, M | 1 |
| Karakaya, E | 2 |
| Young, CA | 1 |
| Dyker, KE | 2 |
| Coyle, C | 3 |
| Sen, M | 3 |
| Prestwich, RJ | 3 |
| Lupinacci, RM | 1 |
| Simon, JM | 1 |
| Spano, JP | 1 |
| Menegaux, F | 1 |
| Huddart, RA | 1 |
| Hall, E | 2 |
| Hussain, SA | 1 |
| Jenkins, P | 1 |
| Rawlings, C | 1 |
| Tremlett, J | 1 |
| Crundwell, M | 1 |
| Adab, FA | 1 |
| Sheehan, D | 1 |
| Syndikus, I | 1 |
| Hendron, C | 1 |
| Lewis, R | 1 |
| Waters, R | 2 |
| James, ND | 1 |
| Chiu, CH | 2 |
| Chan, SC | 2 |
| Chen, WH | 2 |
| Rumiato, E | 1 |
| Boldrin, E | 1 |
| Basso, D | 1 |
| Amadori, A | 1 |
| Saggioro, D | 1 |
| Kadowaki, S | 3 |
| Nagase, M | 1 |
| Hosoya, Y | 3 |
| Peserico, A | 1 |
| Neri, L | 1 |
| Calzavara Pinton, P | 1 |
| Catricalà, C | 1 |
| Pimpinelli, N | 1 |
| Bao, Q | 1 |
| Schwarz, B | 2 |
| Zhao, L | 5 |
| Mysliwietz, J | 1 |
| Ellwart, J | 1 |
| Renner, A | 1 |
| Hirner, H | 1 |
| Niess, H | 1 |
| Camaj, P | 1 |
| Angele, M | 1 |
| Gros, S | 1 |
| Izbicki, J | 1 |
| Jauch, KW | 1 |
| Nelson, PJ | 1 |
| Bruns, CJ | 1 |
| Donnelly, ED | 1 |
| Refaat, T | 2 |
| Gentile, M | 1 |
| Herskovic, A | 9 |
| Boyle, J | 1 |
| Helenowski, I | 1 |
| Rademaker, A | 3 |
| Lurain, J | 1 |
| Schink, J | 1 |
| Singh, D | 1 |
| Strauss, JB | 1 |
| Small, W | 2 |
| Ortholan, C | 2 |
| Gal, J | 1 |
| Chen, WW | 1 |
| Lin, CC | 6 |
| Huang, TC | 2 |
| Cheng, AL | 4 |
| Yeh, KH | 3 |
| Hsu, CH | 8 |
| Hayashi, R | 5 |
| Ebihara, M | 1 |
| Miyazaki, M | 4 |
| Shinozaki, T | 1 |
| Sakuraba, M | 2 |
| Fujii, S | 4 |
| Sakogawa, K | 1 |
| Aoki, Y | 4 |
| Misumi, K | 1 |
| Hamai, Y | 1 |
| Emi, M | 1 |
| Hihara, J | 2 |
| Shi, L | 1 |
| Kono, K | 4 |
| Horikoshi, Y | 1 |
| Sun, J | 3 |
| Ikura, T | 1 |
| Okada, M | 1 |
| Tashiro, S | 1 |
| Keller, M | 1 |
| Gunderson, LL | 3 |
| Pedersen, JE | 1 |
| Winter, KA | 3 |
| Benson, AB | 4 |
| Thomas, CR | 4 |
| Mayer, RJ | 3 |
| Haddock, MG | 2 |
| Rich, TA | 5 |
| Willett, CG | 7 |
| Denaro, N | 2 |
| Russi, EG | 2 |
| Merlano, MC | 1 |
| Oh, D | 1 |
| Lee, JE | 2 |
| Huh, SJ | 2 |
| Park, W | 2 |
| Nam, H | 1 |
| Choi, JY | 1 |
| Kim, BT | 1 |
| Fradley, MG | 1 |
| Barrett, CD | 1 |
| Clark, JR | 4 |
| Francis, SA | 1 |
| Oranratanaphan, S | 1 |
| Khemapech, N | 1 |
| Lin, W | 2 |
| Lin, S | 2 |
| Lee, YY | 2 |
| Yoon, A | 1 |
| Park, JY | 1 |
| Choi, CH | 1 |
| Kim, TJ | 1 |
| Kim, BG | 1 |
| Bae, DS | 1 |
| Scardina, GA | 1 |
| Cacioppo, A | 1 |
| Messina, P | 1 |
| Strojan, P | 4 |
| Grašič Kuhar, C | 1 |
| Žumer, B | 1 |
| Kadivec, M | 1 |
| Karner, K | 1 |
| Fajdiga, I | 1 |
| Jančar, B | 1 |
| Gale, N | 1 |
| Poljak, M | 1 |
| Kocjan, BJ | 1 |
| Zakotnik, B | 1 |
| Roberts, OA | 1 |
| Owonikoko, KM | 1 |
| Abdus-Salam, AA | 1 |
| Ogun, O | 1 |
| Omatsu, H | 4 |
| Kuwahara, A | 9 |
| Yamamori, M | 10 |
| Fujita, M | 4 |
| Miki, I | 9 |
| Nishiguchi, K | 7 |
| Okamura, N | 4 |
| Azuma, T | 5 |
| Hirano, T | 1 |
| Ozawa, K | 1 |
| Hirai, M | 3 |
| Nicholson, S | 1 |
| Harland, SJ | 1 |
| Chester, JD | 1 |
| Pickering, L | 1 |
| Barber, J | 1 |
| Elliott, T | 1 |
| Thomson, A | 1 |
| Burnett, S | 1 |
| Cruickshank, C | 1 |
| Carrington, B | 1 |
| Bahl, A | 1 |
| Moreno-Galindo, C | 1 |
| Hermsen, M | 1 |
| García-Pedrero, JM | 1 |
| Fresno, MF | 1 |
| Suárez, C | 1 |
| Rodrigo, JP | 1 |
| Itoh, J | 1 |
| Mitsuzuka, K | 1 |
| Kimura, S | 1 |
| Yamamuro, T | 1 |
| Yamashita, S | 3 |
| Kaiho, Y | 1 |
| Arai, Y | 6 |
| López-Pousa, A | 7 |
| Berrocal, A | 3 |
| García-Girón, C | 1 |
| Irigoyen, A | 3 |
| Sastre, J | 2 |
| Brandariz Castelo, JA | 1 |
| Verger, E | 2 |
| Touchefeu, Y | 1 |
| Archambeaud, I | 1 |
| Landi, B | 1 |
| Lepère, C | 1 |
| Rougier, P | 4 |
| Mitry, E | 2 |
| Sunpaweravong, S | 1 |
| Puttawibul, P | 1 |
| Ruangsin, S | 1 |
| Laohawiriyakamol, S | 1 |
| Sunpaweravong, P | 1 |
| Sangthawan, D | 1 |
| Pradutkanchana, J | 1 |
| Raungkhajorn, P | 1 |
| Geater, A | 1 |
| Bejarano, PA | 1 |
| Boutros, M | 1 |
| Berho, M | 1 |
| Mouawad, F | 1 |
| Gros, A | 1 |
| Rysman, B | 1 |
| Bal-Mahieu, C | 1 |
| Bertheau, C | 1 |
| Horn, S | 1 |
| Sarrazin, T | 1 |
| Lartigau, E | 1 |
| Chevalier, D | 2 |
| Bailly, C | 1 |
| Lansiaux, A | 1 |
| Meignan, S | 1 |
| Lévy, A | 2 |
| Blanchard, P | 1 |
| Janot, F | 7 |
| Temam, S | 5 |
| Daly-Schveitzer, N | 1 |
| Kajiura, S | 1 |
| Hosokawa, A | 1 |
| Yoshita, H | 1 |
| Ueda, A | 1 |
| Mihara, H | 1 |
| Ando, T | 4 |
| Fujinami, H | 1 |
| Nishikawa, J | 1 |
| Minemura, M | 1 |
| Sugiyama, T | 2 |
| Becker, ET | 1 |
| Boehmer, D | 1 |
| Badakhshi, H | 1 |
| Jahn, U | 1 |
| Wernecke, KD | 2 |
| Zhao, F | 3 |
| Tang, J | 1 |
| Gou, HF | 1 |
| Li, LH | 1 |
| Dong, H | 1 |
| Cheng, K | 1 |
| Ding, J | 1 |
| Men, HT | 1 |
| Liu, JY | 1 |
| Nakagawa, Y | 6 |
| Takamune, Y | 1 |
| Yoshitake, Y | 3 |
| Wang, R | 4 |
| Yang, ZR | 1 |
| Dong, WG | 1 |
| Zhang, JX | 1 |
| Guo, XF | 1 |
| Song, J | 2 |
| Qiu, S | 1 |
| Schulze Schwering, M | 1 |
| Schwering, MS | 1 |
| Chagaluka, G | 1 |
| Molyneux, E | 1 |
| Olgun, DC | 1 |
| Bakan, S | 1 |
| Samanci, C | 1 |
| Tutar, O | 1 |
| Demiryas, S | 1 |
| Korkmazer, B | 1 |
| Kantarci, F | 1 |
| Nako, Y | 1 |
| Morimura, R | 1 |
| Murayama, Y | 2 |
| Kuriu, Y | 2 |
| Nakanishi, M | 2 |
| Sakakura, C | 2 |
| Kubo, N | 2 |
| Lee, T | 1 |
| Shinto, O | 1 |
| Sakurai, K | 2 |
| Toyokawa, T | 1 |
| Tanaka, H | 5 |
| Muguruma, K | 2 |
| Shibutani, M | 1 |
| Yamazoe, S | 1 |
| Nagahara, H | 1 |
| Kimura, K | 2 |
| Amano, R | 2 |
| Ohtani, H | 1 |
| Yashiro, M | 2 |
| Maeda, K | 3 |
| Ohira, M | 2 |
| Hirakawa, K | 2 |
| Iwasaki, K | 1 |
| Ogata, T | 3 |
| Fujikawa, H | 1 |
| Shirai, J | 1 |
| Cho, H | 2 |
| Yoshikawa, T | 1 |
| Ohta, Y | 1 |
| Tachibana, S | 1 |
| Oosaka, Y | 1 |
| Tsuchida, A | 3 |
| Call, JA | 1 |
| Prendergast, BM | 1 |
| Jensen, LG | 1 |
| Ord, CB | 1 |
| Goodman, KA | 4 |
| Jacob, R | 1 |
| Mell, LK | 3 |
| Jabbour, SK | 1 |
| Miller, RC | 3 |
| Bossi, P | 3 |
| Lo Vullo, S | 3 |
| Guzzo, M | 2 |
| Mariani, L | 4 |
| Granata, R | 2 |
| Orlandi, E | 2 |
| Locati, L | 3 |
| Scaramellini, G | 1 |
| Fallai, C | 1 |
| Téllez-Gabriel, M | 1 |
| Arroyo-Solera, I | 1 |
| León, X | 5 |
| Gallardo, A | 1 |
| López, M | 3 |
| Céspedes, MV | 1 |
| Casanova, I | 1 |
| Quer, M | 5 |
| Mangues, MA | 1 |
| Barnadas, A | 1 |
| Mangues, R | 1 |
| Pavón, MA | 1 |
| Suzuki, G | 2 |
| Yamazaki, H | 1 |
| Hayabuchi, N | 4 |
| Umeno, H | 2 |
| Nakashima, T | 12 |
| Nakamura, S | 7 |
| Mochinaga, K | 1 |
| Tsuchiya, T | 2 |
| Nagasaki, T | 2 |
| Arai, J | 1 |
| Tominaga, T | 1 |
| Yamasaki, N | 2 |
| Matsumoto, K | 2 |
| Nanashima, A | 1 |
| Hayashi, T | 2 |
| Tsukamoto, K | 1 |
| Nagayasu, T | 2 |
| Li, XF | 1 |
| Li, YH | 2 |
| Gao, YN | 1 |
| Li, CL | 1 |
| Yue, HZ | 1 |
| Xu, G | 1 |
| Li, DM | 1 |
| Ferrandina, G | 3 |
| Ercoli, A | 1 |
| Fagotti, A | 2 |
| Fanfani, F | 2 |
| Gallotta, V | 2 |
| Margariti, AP | 1 |
| Salerno, MG | 1 |
| Chiantera, V | 1 |
| Legge, F | 2 |
| Macchia, G | 2 |
| Morganti, AG | 3 |
| Valentini, V | 3 |
| Scambia, G | 4 |
| Shen, ZT | 1 |
| Wu, XH | 1 |
| Li, B | 4 |
| Shen, JS | 1 |
| Zhu, XX | 1 |
| Balermpas, P | 3 |
| Bauer, C | 1 |
| Fraunholz, I | 2 |
| Ottinger, A | 1 |
| Wagenblast, J | 3 |
| Stöver, T | 1 |
| Seitz, O | 1 |
| Weiss, C | 2 |
| Gal, Z | 1 |
| Warta, R | 1 |
| Lahrmann, B | 1 |
| Grabe, N | 1 |
| Yuno, A | 1 |
| Harada, K | 5 |
| Ferdous, T | 2 |
| Ueyama, Y | 3 |
| Foo, M | 2 |
| Link, E | 2 |
| Leong, T | 4 |
| Chu, J | 2 |
| Lee, MT | 2 |
| Chander, S | 3 |
| Tran, PK | 1 |
| Tomaszewski, JM | 2 |
| Michael, M | 2 |
| Heriot, A | 3 |
| Maggiore, RJ | 1 |
| Curran, EK | 1 |
| Witt, ME | 14 |
| Haraf, DJ | 25 |
| Vokes, EE | 37 |
| Cohen, EE | 9 |
| Kim, GJ | 1 |
| Koshy, M | 1 |
| Hanlon, AL | 1 |
| Horiba, MN | 1 |
| Edelman, MJ | 1 |
| Burrows, WM | 1 |
| Battafarano, RJ | 1 |
| Suntharalingam, M | 3 |
| de Mello, RA | 1 |
| Gerós, S | 1 |
| Alves, MP | 1 |
| Moreira, F | 1 |
| Avezedo, I | 1 |
| Dinis, J | 1 |
| Yusup, G | 2 |
| Mutallip, M | 1 |
| Komatsu-Akimoto, A | 2 |
| Hoshino, I | 2 |
| Akanuma, N | 2 |
| Isozaki, Y | 2 |
| Claren, A | 1 |
| Frin, AC | 1 |
| Mari, V | 1 |
| Peyrade, F | 7 |
| Krauss, J | 3 |
| Gauler, TC | 1 |
| Delord, JP | 3 |
| Schafhausen, P | 2 |
| Erfán, J | 3 |
| Brümmendorf, TH | 3 |
| Iglesias, L | 1 |
| Bethe, U | 2 |
| Hicking, C | 1 |
| Jamshed, A | 1 |
| Hussain, R | 1 |
| Iqbal, H | 1 |
| Xing, L | 1 |
| Liang, Y | 1 |
| Wu, P | 1 |
| Xu, D | 1 |
| Liu, F | 2 |
| Yu, X | 2 |
| Jiang, Z | 1 |
| Song, X | 2 |
| Zang, Q | 1 |
| Minegaki, T | 1 |
| Sakaeda, T | 9 |
| Kawasaki, Y | 1 |
| Okumura, H | 8 |
| Owaki, T | 5 |
| Ishigami, S | 7 |
| Fraunholz, IB | 2 |
| Haberl, A | 1 |
| Klauke, S | 1 |
| Gute, P | 1 |
| Rödel, CM | 2 |
| Cella, CA | 1 |
| Carlomagno, C | 1 |
| Lordick, F | 5 |
| Moretto, R | 1 |
| De Stefano, A | 1 |
| Raimondo, L | 1 |
| D'Armiento, M | 1 |
| Camera, L | 1 |
| Guadagno, E | 1 |
| Attademo, L | 1 |
| Feliciano, S | 1 |
| Matano, E | 1 |
| Cheng, JC | 4 |
| Graber, MS | 1 |
| Hsu, FM | 3 |
| Tsai, CL | 2 |
| Castaneda, L | 1 |
| Lee, JM | 6 |
| Chang, DT | 5 |
| Capelli, L | 1 |
| Ulivi, P | 1 |
| Giannini, M | 1 |
| Freier, E | 1 |
| Tamberi, S | 1 |
| Scarpi, E | 1 |
| Passardi, A | 1 |
| Zoli, W | 1 |
| Ragazzini, A | 1 |
| Amadori, D | 2 |
| Frassineti, GL | 1 |
| Mak, MP | 1 |
| Glisson, BS | 4 |
| Do, N | 1 |
| Weindl, G | 1 |
| Grohmann, L | 1 |
| Salwiczek, M | 1 |
| Koksch, B | 1 |
| Korting, HC | 2 |
| Schäfer-Korting, M | 2 |
| Montgomery, B | 1 |
| Komatsu, M | 4 |
| Shiono, O | 2 |
| Sakuma, Y | 5 |
| Nishimura, G | 9 |
| Sano, D | 2 |
| Sakuma, N | 2 |
| Yabuki, K | 2 |
| Isitoya, J | 1 |
| Oridate, N | 1 |
| Ferreira, AO | 1 |
| Loureiro, AL | 1 |
| Marques, V | 1 |
| Sousa, HT | 1 |
| Guo, Y | 4 |
| Shi, M | 1 |
| Yang, A | 1 |
| Feng, J | 1 |
| Choi, YJ | 1 |
| Hu, G | 2 |
| Pan, J | 2 |
| Hu, C | 1 |
| Luo, R | 1 |
| Zhou, L | 3 |
| Cheng, Y | 1 |
| Lüpfert, C | 1 |
| Cai, J | 1 |
| Dorth, JA | 1 |
| Pura, JA | 1 |
| Palta, M | 1 |
| Uronis, HE | 1 |
| D'Amico, TA | 3 |
| Czito, BG | 3 |
| Yoshida, N | 5 |
| Ishimoto, T | 3 |
| Nagai, Y | 1 |
| Iwatsuki, M | 1 |
| Iwagami, S | 3 |
| Uenosono, Y | 1 |
| Matsushita, D | 2 |
| Takamoto, D | 1 |
| Kasuga, J | 1 |
| Yumura, Y | 1 |
| Koizumi, M | 1 |
| Hanai, T | 1 |
| Ishida, H | 3 |
| Hattori, Y | 2 |
| Teranishi, J | 1 |
| Miyoshi, Y | 1 |
| Kondo, K | 4 |
| Noguchi, K | 1 |
| Li, MY | 1 |
| Liu, JQ | 1 |
| Chen, DP | 1 |
| Qi, B | 1 |
| Liang, YY | 1 |
| Yin, WJ | 1 |
| Liu, H | 8 |
| Jia, X | 2 |
| Liu, B | 3 |
| Wan, X | 1 |
| Qian, W | 2 |
| Zhu, G | 1 |
| Ji, Q | 1 |
| Ida, S | 3 |
| Karashima, R | 1 |
| Sakamoto, Y | 3 |
| Miyamoto, Y | 3 |
| Fujii, H | 2 |
| Yana, I | 1 |
| Otani, S | 1 |
| Rödel, F | 2 |
| Wieland, U | 2 |
| Kitz, J | 2 |
| Rave-Fränk, M | 2 |
| Wolff, HA | 2 |
| Wirtz, R | 1 |
| Xu, B | 1 |
| Shu, Y | 1 |
| Cosmidis, A | 1 |
| Belot, A | 1 |
| Rabilloud, M | 1 |
| Fuchsmann, C | 1 |
| Tartas, S | 2 |
| Furutani, A | 2 |
| Sowa, Y | 1 |
| Sakai, T | 1 |
| Freilich, J | 1 |
| Fulp, WJ | 1 |
| Yue, B | 1 |
| Zhao, M | 1 |
| Xie, TX | 1 |
| Patel, AA | 1 |
| Ward, AM | 1 |
| Sandulache, VC | 1 |
| Jasser, SA | 1 |
| Skinner, HD | 1 |
| Fitzgerald, AL | 1 |
| Osman, AA | 1 |
| Wei, Y | 1 |
| Xia, X | 1 |
| Songyang, Z | 1 |
| Mills, GB | 1 |
| Hung, MC | 1 |
| Caulin, C | 1 |
| da Costa, AA | 1 |
| D'Almeida Costa, F | 1 |
| Ribeiro, AR | 1 |
| Guimarães, AP | 1 |
| Chinen, LT | 1 |
| Lopes, CA | 1 |
| de Lima, VC | 1 |
| Hategan, M | 1 |
| Cook, N | 1 |
| Prewett, S | 1 |
| Hindmarsh, A | 1 |
| Gilligan, D | 1 |
| Higuchi, K | 2 |
| Komori, S | 2 |
| Tanabe, S | 2 |
| Azuma, M | 2 |
| Ishido, K | 1 |
| Katada, N | 3 |
| Hayakawa, K | 2 |
| Koizumi, W | 3 |
| Sio, TT | 1 |
| Wilson, ZC | 1 |
| Stauder, MC | 1 |
| Bhatia, S | 1 |
| Martenson, JA | 1 |
| Quevedo, JF | 1 |
| Schomas, DA | 2 |
| Huang, RW | 1 |
| Thind, G | 1 |
| Johal, B | 1 |
| Follwell, M | 1 |
| Kennecke, HF | 1 |
| Blazeby, JM | 2 |
| Strong, S | 1 |
| Donovan, JL | 1 |
| Hollingworth, W | 1 |
| Nicklin, J | 1 |
| Falk, SJ | 1 |
| Barham, CP | 2 |
| Hollowood, AD | 2 |
| Streets, CG | 2 |
| Titcomb, D | 1 |
| Krysztopik, R | 2 |
| Griffin, SM | 1 |
| Brookes, ST | 1 |
| Ijichi, K | 5 |
| Adachi, M | 2 |
| Ogawa, T | 7 |
| Murakami, S | 2 |
| Konda, S | 1 |
| O'Bryan, KW | 1 |
| Ratner, D | 1 |
| Jin, J | 2 |
| Ye, MC | 1 |
| Wang, LP | 1 |
| Li, RX | 1 |
| Zhou, Y | 4 |
| Zhu, WZ | 1 |
| Zuo, Y | 2 |
| Liu, SH | 1 |
| Kubota, A | 10 |
| Furukawa, M | 7 |
| Kitani, Y | 1 |
| Nakayama, Y | 2 |
| Nonaka, T | 2 |
| Mizoguchi, N | 1 |
| Shiomi, M | 1 |
| Shimomura, H | 1 |
| Sasahira, T | 1 |
| Yamanaka, Y | 1 |
| Kurihara, M | 1 |
| Imai, Y | 2 |
| Tamaki, S | 1 |
| Yamakawa, N | 2 |
| Shirone, N | 1 |
| Hasegawa, M | 3 |
| Kuniyasu, H | 1 |
| Kirita, T | 2 |
| Pierson, JC | 1 |
| Loong, HH | 1 |
| Waldron, J | 2 |
| Chen, EX | 2 |
| Kim, J | 2 |
| Palma, D | 1 |
| Read, N | 1 |
| Razak, AR | 1 |
| Diaz-Padilla, I | 1 |
| Chan, K | 1 |
| Bayley, A | 2 |
| Hossain, M | 1 |
| Chin, S | 2 |
| Siu, LL | 1 |
| Hope, A | 1 |
| Maeda, H | 1 |
| Deng, Z | 1 |
| Kiyuna, A | 1 |
| Ganaha, A | 1 |
| Yamashita, Y | 3 |
| Agena, S | 1 |
| Toita, T | 4 |
| Uehara, T | 1 |
| Lyu, X | 1 |
| Huang, J | 1 |
| Mao, Y | 1 |
| Feng, Q | 1 |
| Shao, K | 1 |
| Gao, S | 1 |
| Jiang, Y | 5 |
| He, J | 1 |
| Yang, WC | 1 |
| Chen, CH | 5 |
| Tang, JY | 1 |
| Wu, CF | 1 |
| Lin, SF | 1 |
| Mizumachi, T | 2 |
| Kakizaki, T | 1 |
| Sakashita, T | 2 |
| Kano, S | 2 |
| Hatakeyama, H | 2 |
| Tsuchiya, K | 2 |
| Yasuda, K | 2 |
| Onimaru, R | 2 |
| Shirato, H | 3 |
| Taguchi, J | 1 |
| Shimizu, Y | 3 |
| Kinoshita, I | 1 |
| Fukuda, S | 3 |
| Siegel, EM | 2 |
| Eschrich, S | 1 |
| Winter, K | 7 |
| Riggs, B | 1 |
| Berglund, A | 1 |
| Ajidahun, A | 1 |
| Simko, J | 1 |
| Ajani, J | 4 |
| Magliocco, A | 1 |
| Elahi, A | 1 |
| Hoffe, S | 2 |
| Shibata, D | 1 |
| Péron, J | 3 |
| Polivka, V | 1 |
| Girodet, D | 2 |
| Chen, YK | 1 |
| Huang, AH | 1 |
| Lin, LM | 1 |
| Fakhrian, K | 3 |
| Ordu, AD | 3 |
| Theisen, J | 1 |
| Haller, B | 1 |
| Omrčen, T | 1 |
| Molls, M | 5 |
| Nieder, C | 3 |
| Geinitz, H | 4 |
| Sudarshan, M | 1 |
| Alcindor, T | 1 |
| Ades, S | 1 |
| Aloraini, A | 1 |
| van Huyse, M | 1 |
| Asselah, J | 1 |
| David, M | 2 |
| Frechette, D | 1 |
| Brisson, S | 1 |
| Thirlwell, M | 1 |
| Ferri, L | 1 |
| Nishimura, K | 4 |
| Okamoto, H | 2 |
| Gosho, M | 1 |
| Fukayama, M | 1 |
| Yoshikawa, K | 2 |
| Bradford, CR | 11 |
| Carey, TE | 4 |
| Mizusawa, J | 5 |
| Kii, T | 3 |
| Tsushima, T | 5 |
| Tomori, A | 2 |
| Taniki, T | 1 |
| Kusaba, H | 3 |
| Taira, K | 1 |
| Chan, JY | 1 |
| Wong, TS | 1 |
| Karrison, TG | 1 |
| Kocherginsky, M | 2 |
| Mueller, J | 1 |
| Egan, R | 1 |
| Huang, CH | 1 |
| Brockstein, BE | 7 |
| Agulnik, MB | 1 |
| Mittal, BB | 10 |
| Yunus, F | 1 |
| Samant, S | 1 |
| Raez, LE | 3 |
| Mehra, R | 1 |
| Kumar, P | 1 |
| Ondrey, F | 1 |
| Marchand, P | 1 |
| Braegas, B | 1 |
| Seiwert, TY | 3 |
| Villaflor, VM | 2 |
| Chiang, PH | 1 |
| Shen, YC | 1 |
| Alomar, A | 1 |
| Lu, W | 2 |
| Feng, Y | 1 |
| Zhang, M | 2 |
| Ishikawa, K | 4 |
| Nakamatsu, K | 3 |
| O'Callaghan, C | 1 |
| Fanning, LJ | 1 |
| Barry, OP | 1 |
| Mohan, A | 1 |
| Narayanan, S | 1 |
| Sethuraman, S | 2 |
| Krishnan, UM | 2 |
| Nemoto, H | 2 |
| Tate, G | 1 |
| Umemoto, T | 1 |
| Matsubara, T | 1 |
| Mizukami, H | 1 |
| Saito, M | 4 |
| Kigawa, G | 1 |
| Matsumiya, A | 1 |
| Tanaka, J | 3 |
| Shapiro, LQ | 1 |
| Sherman, EJ | 1 |
| Riaz, N | 1 |
| Setton, J | 1 |
| Koutcher, L | 1 |
| Shi, W | 1 |
| Fury, MG | 2 |
| Wolden, SL | 2 |
| Pfister, DG | 4 |
| Morris, L | 1 |
| Lee, N | 2 |
| Shen, JX | 1 |
| Li, QQ | 5 |
| He, LR | 3 |
| Kandioler, D | 1 |
| Schoppmann, SF | 1 |
| Zwrtek, R | 1 |
| Kappel, S | 1 |
| Wolf, B | 1 |
| Mittlböck, M | 2 |
| Kührer, I | 1 |
| Hejna, M | 1 |
| Pluschnig, U | 1 |
| Ba-Ssalamah, A | 1 |
| Wrba, F | 2 |
| Zacherl, J | 1 |
| Rose, PG | 1 |
| Java, JJ | 1 |
| Whitney, CW | 2 |
| Stehman, FB | 1 |
| Lanciano, R | 1 |
| Thomas, GM | 5 |
| Meulendijks, D | 2 |
| Tomasoa, NB | 2 |
| van Tinteren, H | 1 |
| Ma, W | 1 |
| Zhang, T | 3 |
| Shi, N | 1 |
| Fan, Q | 2 |
| Lu, SH | 1 |
| Lindner, K | 1 |
| Borchardt, C | 1 |
| Schöpp, M | 1 |
| Bürgers, A | 1 |
| Stock, C | 1 |
| Hussey, DJ | 5 |
| Haier, J | 4 |
| Hummel, R | 4 |
| Schwameis, M | 1 |
| Thaler, J | 1 |
| Schober, A | 1 |
| Schörgenhofer, C | 1 |
| Kulinna-Cosentini, C | 1 |
| Laggner, A | 1 |
| Röggla, M | 1 |
| Jilma, B | 1 |
| Sinha, R | 1 |
| Larkin, J | 1 |
| Fearfield, L | 1 |
| Izawa, N | 1 |
| Hikosaka, T | 1 |
| Hamauchi, S | 2 |
| Todaka, A | 1 |
| Machida, N | 1 |
| Haraguchi, Y | 1 |
| Ogawa, H | 1 |
| Nishimura, T | 3 |
| Nakagawa, M | 1 |
| Fuke, T | 1 |
| Iida, Y | 2 |
| Kamijo, T | 1 |
| Onitsuka, T | 1 |
| Yasui, H | 4 |
| Yokota, T | 5 |
| Hayashi, Y | 3 |
| Nishida, T | 8 |
| Tsujii, M | 1 |
| Tsutsui, S | 1 |
| Yamamoto, K | 7 |
| Isohashi, F | 2 |
| Kato, M | 2 |
| Yamada, T | 8 |
| Shinzaki, S | 1 |
| Iijima, H | 1 |
| Takehara, T | 1 |
| Wu, W | 1 |
| Ma, L | 2 |
| Liu, M | 3 |
| Huang, D | 1 |
| Overton, TL | 1 |
| Allbaugh, RA | 1 |
| Whitley, D | 1 |
| Ben-Shlomo, G | 1 |
| Griggs, A | 1 |
| Tofflemire, KL | 1 |
| Whitley, EM | 1 |
| Yamahsita, S | 1 |
| Kishino, T | 1 |
| Kushima, R | 2 |
| Tachimori, Y | 3 |
| Osugi, H | 4 |
| Nagino, M | 1 |
| Ushijima, T | 1 |
| Syed, N | 2 |
| Chavan, S | 1 |
| Sahasrabuddhe, NA | 1 |
| Renuse, S | 1 |
| Sathe, G | 1 |
| Nanjappa, V | 1 |
| Radhakrishnan, A | 1 |
| Raja, R | 1 |
| Pinto, SM | 1 |
| Srinivasan, A | 1 |
| Prasad, TS | 1 |
| Srikumar, K | 1 |
| Gowda, H | 1 |
| Santosh, V | 1 |
| Sidransky, D | 1 |
| Califano, JA | 3 |
| Pandey, A | 1 |
| Chatterjee, A | 1 |
| Zheng, K | 1 |
| Yan, H | 1 |
| Liu, Q | 3 |
| Lynggaard, CD | 1 |
| Therkildsen, MH | 1 |
| Kristensen, CA | 1 |
| Specht, L | 1 |
| Haymerle, G | 1 |
| Thurnher, D | 2 |
| Kadletz, L | 1 |
| Stanisz, I | 1 |
| Brunner, M | 1 |
| Kotowski, U | 1 |
| Enzenhofer, E | 1 |
| Heiduschka, G | 2 |
| Yue, D | 1 |
| Ping, Y | 1 |
| Gao, Q | 1 |
| Wang, D | 4 |
| Yang, L | 1 |
| Huang, L | 2 |
| Sie, C | 1 |
| Watson, DI | 5 |
| Wang, T | 4 |
| Ansar, A | 1 |
| Michael, MZ | 3 |
| Van der Hoek, M | 2 |
| Rodriguez-Bigas, M | 1 |
| Xing, Y | 1 |
| Vauthey, JN | 1 |
| Ohinata, A | 1 |
| Pathak, P | 2 |
| Sethi, S | 1 |
| Phillips, JK | 1 |
| Wolff, RA | 2 |
| Kenawy, N | 1 |
| Garrick, A | 1 |
| Heimann, H | 1 |
| Coupland, SE | 1 |
| Damato, BE | 1 |
| Kup, PG | 2 |
| Deymann, LF | 1 |
| Scherer, V | 2 |
| Combs, SE | 2 |
| Hagiwara, K | 2 |
| Kochi, M | 2 |
| Song, K | 2 |
| Tamegai, H | 2 |
| Takayama, Y | 2 |
| Suda, H | 2 |
| Teshima, Y | 1 |
| Yuan, YX | 1 |
| Qiao, JK | 1 |
| Yu, C | 1 |
| Agüero, A | 1 |
| García, J | 1 |
| Farré, N | 1 |
| Omori, M | 1 |
| Hoover, WD | 1 |
| Jorizzo, JL | 1 |
| Clark, AR | 1 |
| Holbrook, J | 1 |
| Huang, KE | 1 |
| Shinriki, S | 1 |
| Jono, H | 1 |
| Ueda, M | 5 |
| Guo, J | 3 |
| Ota, T | 1 |
| Ota, K | 3 |
| Ando, Y | 1 |
| Tan, BH | 1 |
| Brammer, K | 1 |
| Randhawa, N | 1 |
| Welch, NT | 1 |
| James, EJ | 1 |
| Catton, JA | 1 |
| Schuster, T | 3 |
| Cha, RR | 1 |
| Jung, WT | 1 |
| Oh, HW | 1 |
| Kim, HJ | 3 |
| Ha, CY | 1 |
| Ko, GH | 1 |
| Kim, HW | 2 |
| Park, JJ | 1 |
| Youn, YH | 1 |
| Park, H | 1 |
| Atanaskova Mesinkovska, N | 1 |
| Conic, RZ | 1 |
| Kiracofe, EA | 1 |
| Vidimos, AT | 1 |
| Derouet, MF | 1 |
| Liu, G | 1 |
| Darling, GE | 1 |
| Philipp-Dormston, WG | 1 |
| Gambacorta, A | 1 |
| Smaniotto, D | 2 |
| Tagliaferri, L | 1 |
| Foti, E | 1 |
| Autorino, R | 1 |
| Yu, W | 1 |
| Cai, XW | 1 |
| Zhu, ZF | 1 |
| Feng, W | 1 |
| Zhang, Q | 4 |
| Zhang, YJ | 1 |
| Yao, ZF | 1 |
| Fu, XL | 1 |
| Yossi, S | 2 |
| El Alouani, C | 1 |
| Pointreau, Y | 4 |
| Laccourreye, L | 2 |
| Capitain, O | 3 |
| Gustin, P | 2 |
| Peyraga, G | 2 |
| Septans, AL | 2 |
| Jadaud, É | 2 |
| Vinchon-Petit, S | 1 |
| Cellier, P | 2 |
| Autret, D | 1 |
| Tuchais, C | 2 |
| Zhang, WW | 1 |
| Zhu, YJ | 1 |
| Wang, QX | 1 |
| Wang, XH | 2 |
| Xiao, WW | 1 |
| Hu, YH | 4 |
| Poulalhon, N | 1 |
| Dalle, S | 1 |
| Balme, B | 1 |
| Thomas, L | 1 |
| Iyer, NG | 1 |
| Tan, DS | 1 |
| Tan, VK | 1 |
| Hwang, J | 1 |
| Tan, NC | 1 |
| Sivanandan, R | 1 |
| Tan, HK | 1 |
| Lim, WT | 1 |
| Ang, MK | 1 |
| Wee, J | 3 |
| Soo, KC | 2 |
| Tan, EH | 4 |
| Minashi, K | 8 |
| Poettgen, C | 1 |
| Baumann, M | 1 |
| Budach, W | 6 |
| Grabenbauer, G | 3 |
| Marnitz, S | 3 |
| Olze, H | 1 |
| Ghadjar, P | 1 |
| Chibaudel, B | 1 |
| Lacave, R | 1 |
| Lefevre, M | 1 |
| Soussan, P | 1 |
| Antoine, M | 1 |
| Périé, S | 3 |
| Belloc, JB | 1 |
| Banal, A | 2 |
| Albert, S | 1 |
| Chabolle, F | 1 |
| Baril, P | 1 |
| Gatineau, M | 2 |
| Housset, M | 2 |
| Moukoko, R | 1 |
| Benetkiewicz, M | 1 |
| de Gramont, A | 3 |
| Lacau St Guily, J | 2 |
| Li, MH | 1 |
| Shang, DP | 1 |
| Chen, C | 1 |
| Huang, Y | 6 |
| Kong, L | 1 |
| Yu, JM | 3 |
| Nguyen, BT | 2 |
| Gan, SD | 2 |
| Liang, CA | 2 |
| Ojima, H | 1 |
| Fukuchi, M | 1 |
| Ieta, K | 1 |
| Saito, K | 4 |
| Sano, A | 1 |
| Inose, T | 1 |
| Chen, YS | 1 |
| Aubee, J | 1 |
| DiVito, KA | 1 |
| Zhou, H | 2 |
| Chou, FP | 1 |
| Simbulan-Rosenthal, CM | 1 |
| Rosenthal, DS | 1 |
| Reigneau, M | 1 |
| Robert, C | 1 |
| Routier, E | 1 |
| Mamelle, G | 4 |
| Moya-Plana, A | 1 |
| Tomasic, G | 1 |
| Mateus, C | 1 |
| Yamashita, M | 2 |
| Takenaka, HY | 1 |
| Nishiike, S | 1 |
| Takenaka, Y | 2 |
| Nakahara, S | 4 |
| Yasui, T | 2 |
| Hanamoto, A | 2 |
| Inohara, H | 2 |
| Zhao, B | 1 |
| Shang, D | 1 |
| Zhong, M | 1 |
| Deng, C | 1 |
| Ghosn, M | 1 |
| Kourie, HR | 1 |
| Abdayem, P | 1 |
| Antoun, J | 1 |
| Nasr, D | 1 |
| Zhao, LJ | 1 |
| Liu, NB | 1 |
| Zhang, WC | 1 |
| Pang, QS | 1 |
| Yuan, ZY | 1 |
| Nakamaru, Y | 1 |
| Terasaka, S | 1 |
| Yoshida, D | 1 |
| Furusawa, J | 1 |
| Ji, YH | 1 |
| Yang, XY | 1 |
| Wu, JQ | 1 |
| Huo, XQ | 1 |
| Li, WW | 1 |
| Li, GJ | 1 |
| Mu, YL | 1 |
| Lu, P | 2 |
| Kushwaha, VS | 1 |
| Husain, N | 1 |
| Jamal, N | 1 |
| Ghatak, A | 1 |
| Murata, S | 1 |
| Onozawa, S | 1 |
| Sugihara, F | 1 |
| Sakamoto, A | 1 |
| Ueda, T | 3 |
| Yamaguchi, H | 2 |
| Yasui, D | 1 |
| Mine, T | 2 |
| Kumita, S | 1 |
| Troussier, I | 1 |
| Servagi-Vernat, S | 2 |
| Benahim, C | 1 |
| Khalifa, J | 1 |
| Darmon, I | 1 |
| Krebs, L | 1 |
| Dejean, C | 1 |
| Bensadoun, RJ | 6 |
| Thariat, J | 1 |
| Abunassar, M | 1 |
| Reinders, J | 1 |
| Jonker, DJ | 1 |
| Asmis, T | 1 |
| Takácsi-Nagy, Z | 1 |
| Hitre, E | 1 |
| Oberna, F | 1 |
| Polgár, C | 1 |
| Major, T | 1 |
| Gödény, M | 1 |
| Fodor, J | 1 |
| Kásler, M | 1 |
| Takahashi, I | 1 |
| Nishibuchi, I | 1 |
| Doi, Y | 1 |
| Okabe, T | 1 |
| Kenjo, M | 2 |
| Nagata, Y | 2 |
| El-Hadaad, HA | 1 |
| Wahba, HA | 1 |
| Roshdy, S | 1 |
| Bowen, JM | 1 |
| White, I | 1 |
| Smith, L | 1 |
| Tsykin, A | 1 |
| Kristaly, K | 1 |
| Thompson, SK | 2 |
| Karapetis, CS | 2 |
| Tan, H | 1 |
| Game, PA | 1 |
| Irvine, T | 1 |
| Keefe, DM | 1 |
| Yang, JS | 1 |
| Qiu, MQ | 1 |
| Li, QL | 1 |
| Ma, SR | 3 |
| Wang, WM | 1 |
| Huang, CF | 3 |
| Zhang, WF | 3 |
| Sun, ZJ | 3 |
| Sachdev, S | 1 |
| Bacchus, ID | 1 |
| Sathiaseelan, V | 1 |
| Johnson, E | 1 |
| Viste, A | 4 |
| Myrnäs, T | 1 |
| Szabo, E | 1 |
| Tsai, JA | 1 |
| Persson, S | 1 |
| Xie, Q | 1 |
| Rao, Q | 1 |
| Han, J | 1 |
| Yao, T | 2 |
| Lin, Z | 1 |
| Lin, WC | 3 |
| Huang, TL | 3 |
| Chiu, TJ | 4 |
| Fang, FM | 3 |
| Huang, WT | 1 |
| Hsu, CM | 2 |
| Luo, SD | 3 |
| Lai, CC | 2 |
| Su, YY | 2 |
| Chuang, HC | 1 |
| Munoz, F | 3 |
| Sciacero, P | 1 |
| Spadi, R | 1 |
| Migliaccio, F | 1 |
| Angelini, V | 1 |
| Bombaci, S | 1 |
| Rondi, N | 3 |
| Numico, G | 8 |
| Ragona, R | 6 |
| Morino, M | 4 |
| Racca, P | 4 |
| Govindan, SV | 1 |
| Kulsum, S | 1 |
| Pandian, RS | 1 |
| Das, D | 1 |
| Seshadri, M | 1 |
| Hicks, W | 1 |
| Kuriakose, MA | 1 |
| Suresh, A | 1 |
| Oyanagi, H | 1 |
| Ichikawa, H | 3 |
| Banba, T | 1 |
| Hanyu, T | 1 |
| Hirashima, K | 1 |
| Ishikawa, T | 1 |
| Kameyama, H | 1 |
| Minagawa, M | 1 |
| Koyama, Y | 2 |
| Wakai, T | 1 |
| Tamura, S | 2 |
| Taniguchi, H | 3 |
| Katsura, Y | 2 |
| Ohmura, Y | 1 |
| Kagawa, Y | 1 |
| Sakisaka, H | 1 |
| Kato, T | 7 |
| Gakis, G | 1 |
| Morgan, TM | 1 |
| Daneshmand, S | 1 |
| Keegan, KA | 1 |
| Todenhöfer, T | 1 |
| Mischinger, J | 1 |
| Schubert, T | 1 |
| Zaid, HB | 1 |
| Hrbacek, J | 1 |
| Ali-El-Dein, B | 1 |
| Clayman, RH | 1 |
| Galland, S | 1 |
| Olugbade, K | 1 |
| Rink, M | 1 |
| Fritsche, HM | 1 |
| Burger, M | 1 |
| Chang, SS | 1 |
| Babjuk, M | 1 |
| Thalmann, GN | 1 |
| Stenzl, A | 1 |
| Efstathiou, JA | 1 |
| Ding, X | 2 |
| Geng, M | 1 |
| Xie, Z | 1 |
| Wu, H | 4 |
| Huang, M | 3 |
| Julie, DA | 1 |
| Oh, JH | 1 |
| Apte, AP | 1 |
| Deasy, JO | 1 |
| Tom, A | 1 |
| Wu, AJ | 1 |
| Yamashita, D | 2 |
| Ejima, Y | 1 |
| Kenji, Y | 1 |
| Otsuki, N | 2 |
| Sakakibara, S | 1 |
| Nomura, T | 5 |
| Hashikawa, K | 2 |
| Kohmura, E | 1 |
| Nibu, K | 4 |
| Luc, G | 1 |
| Gronnier, C | 1 |
| Lebreton, G | 1 |
| Brigand, C | 1 |
| Mabrut, JY | 1 |
| Bail, JP | 1 |
| Meunier, B | 5 |
| Collet, D | 1 |
| Mariette, C | 6 |
| Sonoda, K | 1 |
| Yahata, H | 1 |
| Ichinoe, A | 1 |
| Okugawa, K | 1 |
| Kaneki, E | 1 |
| Kawano, Y | 2 |
| Kenjo, H | 1 |
| Ohgami, T | 1 |
| Yagi, H | 2 |
| Ohga, S | 2 |
| Asai, K | 1 |
| Honda, H | 2 |
| Zheng, W | 1 |
| Xu, YJ | 1 |
| Qiu, SF | 1 |
| Zong, JF | 1 |
| Huang, LL | 1 |
| Huang, CB | 1 |
| Lin, SJ | 1 |
| Pan, JJ | 1 |
| de Souza Viana, L | 1 |
| de Aguiar Silva, FC | 1 |
| Andrade Dos Anjos Jacome, A | 1 |
| Calheiros Campelo Maia, D | 1 |
| Duarte de Mattos, M | 1 |
| Arthur Jacinto, A | 1 |
| Elias Mamere, A | 1 |
| Boldrini Junior, D | 1 |
| de Castro Capuzzo, R | 1 |
| Roberto Santos, C | 1 |
| Lopes Carvalho, A | 1 |
| Szturz, P | 1 |
| Specenier, P | 3 |
| Van Laer, C | 1 |
| Van Den Weyngaert, D | 3 |
| Corthouts, B | 1 |
| Carp, L | 1 |
| Van Marck, E | 1 |
| Vanderveken, O | 1 |
| Sadighi, S | 1 |
| Keyhani, A | 1 |
| Harirchi, I | 1 |
| Garajei, A | 1 |
| Aghili, M | 1 |
| Kazemian, A | 1 |
| Motiee Langroudi, M | 1 |
| Zendehdel, K | 1 |
| Nikparto, N | 1 |
| Van De Voorde, L | 1 |
| Janssen, L | 1 |
| Larue, R | 1 |
| Houben, R | 1 |
| Buijsen, J | 1 |
| Sosef, M | 1 |
| Vanneste, B | 1 |
| Schraepen, MC | 1 |
| Berbée, M | 1 |
| Lambin, P | 1 |
| Kataoka, K | 3 |
| Hayashi, K | 5 |
| Ryoo, I | 1 |
| Choi, SH | 1 |
| Sohn, CH | 1 |
| Kim, SC | 1 |
| Ren, GX | 2 |
| Hong, CS | 1 |
| Zhu, HG | 2 |
| Tu, WY | 2 |
| Cai, YL | 2 |
| Yin, QM | 1 |
| Wang, ZH | 2 |
| Hu, YJ | 2 |
| Ji, T | 2 |
| Yang, WJ | 2 |
| Ye, WM | 2 |
| Wang, YA | 2 |
| Xu, LQ | 2 |
| Zhuang, Z | 1 |
| Yeh, CJ | 1 |
| Takekuma, M | 1 |
| Kasamatsu, Y | 1 |
| Kado, N | 1 |
| Kuji, S | 1 |
| Tanaka, A | 6 |
| Abe, M | 2 |
| Hirashima, Y | 3 |
| Negoro, Y | 2 |
| Kawaguchi, G | 1 |
| Kobayashi, M | 2 |
| Itoh, Y | 4 |
| Morris, EJ | 1 |
| Aravani, A | 1 |
| Finan, PJ | 1 |
| Lawton, S | 1 |
| Thomas, JD | 1 |
| Kun, M | 1 |
| Xinxin, Z | 1 |
| Feifan, Z | 1 |
| Lin, M | 1 |
| Luo, LL | 3 |
| Ruffier-Loubière, A | 1 |
| Janoray, G | 2 |
| Chapet, S | 6 |
| de Calan, L | 1 |
| Dumont, P | 1 |
| Dorval, É | 1 |
| Orain, I | 1 |
| Tu, YK | 1 |
| Haxel, BR | 1 |
| Berg, S | 1 |
| Boessert, P | 1 |
| Mann, WJ | 1 |
| Fruth, K | 1 |
| Henriques de Figueiredo, B | 2 |
| Benech, J | 1 |
| Belhomme, S | 1 |
| Lisbona, A | 1 |
| Frison, E | 1 |
| Doussau, A | 1 |
| Nomikossoff, N | 1 |
| Mahé, MA | 2 |
| Kantor, G | 1 |
| Maire, JP | 1 |
| Lépinoy, A | 1 |
| Lescut, N | 1 |
| Puyraveau, M | 1 |
| Caubet, M | 1 |
| Lakkis, Z | 1 |
| Fantoli, M | 1 |
| Buffet-Miny, J | 1 |
| Bednarek, C | 1 |
| Bosset, JF | 4 |
| Piro, G | 1 |
| Giacopuzzi, S | 5 |
| Bencivenga, M | 1 |
| Carbone, C | 1 |
| Verlato, G | 3 |
| Frizziero, M | 1 |
| Zanotto, M | 1 |
| Mina, MM | 1 |
| Merz, V | 1 |
| Santoro, R | 1 |
| Zanoni, A | 3 |
| De Manzoni, G | 6 |
| Tortora, G | 1 |
| Melisi, D | 1 |
| Joseph, K | 2 |
| Nijjar, Y | 1 |
| Warkentin, H | 2 |
| Schiller, D | 2 |
| Tankel, K | 2 |
| Usmani, N | 2 |
| Severin, D | 2 |
| Ghosh, S | 2 |
| Syme, A | 1 |
| Nijjar, T | 2 |
| Mulder, K | 2 |
| Doll, C | 1 |
| Wong, C | 2 |
| Field, C | 2 |
| Ye, D | 1 |
| Ban, X | 1 |
| Zeng, TT | 1 |
| Zhang, BZ | 1 |
| Yun, J | 1 |
| Xie, D | 4 |
| Guan, XY | 4 |
| Tian, J | 2 |
| Shang, M | 1 |
| Shi, SB | 1 |
| Han, Y | 2 |
| Xu, J | 2 |
| Kitamura, K | 3 |
| Honma, K | 2 |
| Morii, E | 1 |
| Niwa, Y | 2 |
| Oya, H | 1 |
| Nishio, N | 1 |
| Hiramatsu, M | 2 |
| Kobayashi, D | 1 |
| Fujii, T | 4 |
| Sugimoto, H | 1 |
| Nomoto, S | 1 |
| Nicolai, N | 4 |
| Sangalli, LM | 1 |
| Necchi, A | 3 |
| Giannatempo, P | 2 |
| Paganoni, AM | 1 |
| Colecchia, M | 3 |
| Piva, L | 3 |
| Catanzaro, MA | 1 |
| Biasoni, D | 2 |
| Stagni, S | 2 |
| Torelli, T | 3 |
| Raggi, D | 2 |
| Faré, E | 1 |
| Pizzocaro, G | 3 |
| Salvioni, R | 3 |
| White, EC | 1 |
| Goldman, K | 1 |
| Aleshin, A | 1 |
| Lien, WW | 1 |
| Rao, AR | 3 |
| Feng, H | 1 |
| Liu, D | 1 |
| Ji, N | 3 |
| Luo, X | 1 |
| Dan, H | 1 |
| Zeng, X | 2 |
| Sun, C | 2 |
| Ju, X | 1 |
| Zhou, M | 2 |
| Chu, L | 1 |
| Jiang, L | 2 |
| Najafzadeh, N | 1 |
| Mazani, M | 1 |
| Abbasi, A | 1 |
| Farassati, F | 1 |
| Amani, M | 1 |
| Yamamoto, S | 7 |
| Kumaki, N | 1 |
| Makuuchi, H | 3 |
| Shimada, H | 8 |
| Chino, O | 1 |
| Yasuda, S | 2 |
| Tamayama, T | 1 |
| Sakai, I | 1 |
| Yates, A | 1 |
| Carroll, S | 1 |
| Kneebone, A | 1 |
| Tse, R | 1 |
| Horvath, L | 1 |
| Byrne, C | 1 |
| Solomon, M | 1 |
| Hruby, G | 1 |
| Kanamori, J | 1 |
| Bozec, A | 3 |
| Chamorey, E | 4 |
| Ettaiche, M | 2 |
| Vandersteen, C | 2 |
| Dassonville, O | 8 |
| Poissonnet, G | 5 |
| Riss, JC | 2 |
| Chand, ME | 2 |
| Leysalle, A | 2 |
| Saada, E | 3 |
| Sudaka, A | 3 |
| Haudebourg, J | 1 |
| Hebert, C | 2 |
| Falewee, MN | 4 |
| Demard, F | 14 |
| Santini, J | 11 |
| Jia, XJ | 1 |
| Huang, JZ | 1 |
| Belgioia, L | 1 |
| Vagge, S | 1 |
| Agnese, D | 1 |
| Garelli, S | 1 |
| Murialdo, R | 1 |
| Fornarini, G | 1 |
| Chiara, S | 1 |
| Gallo, F | 1 |
| Bacigalupo, A | 10 |
| Corvò, R | 14 |
| Glenn, CJ | 1 |
| Parlette, EC | 1 |
| Otter, S | 1 |
| Schick, U | 1 |
| Gulliford, S | 2 |
| Lal, P | 2 |
| Franceschini, D | 2 |
| Newbold, K | 3 |
| Nutting, C | 1 |
| Harrington, K | 1 |
| Bhide, S | 1 |
| Lu, SL | 1 |
| Wu, JK | 1 |
| Huang, PM | 4 |
| Xu, WW | 2 |
| Qin, YR | 2 |
| Lee, NP | 3 |
| Chan, KT | 3 |
| Tam, PY | 1 |
| Li, YY | 1 |
| Chan, KW | 2 |
| Yuen, HF | 1 |
| Tsao, SW | 3 |
| He, QY | 1 |
| Cheung, AL | 2 |
| Chen, YJ | 4 |
| Liu, CT | 1 |
| Rau, KM | 3 |
| Chen, YC | 1 |
| Tsai, HT | 1 |
| Potenza, I | 1 |
| Schena, M | 3 |
| Riva, G | 1 |
| Pecorari, G | 1 |
| Garzino Demo, P | 1 |
| Fasolis, M | 1 |
| Moretto, F | 1 |
| Garzaro, M | 1 |
| Di Muzio, J | 1 |
| Melano, M | 1 |
| Airoldi, M | 8 |
| Rampino, M | 2 |
| Sivanantham, B | 1 |
| Song, B | 2 |
| Cheng, C | 1 |
| Yang, B | 2 |
| Wang, F | 2 |
| Kong, P | 1 |
| Jia, Z | 1 |
| Bi, Y | 1 |
| Zhao, Z | 1 |
| Shi, R | 1 |
| Yang, J | 1 |
| Yan, T | 1 |
| Xu, E | 1 |
| Qian, Y | 1 |
| Xi, Y | 1 |
| Guo, S | 1 |
| Li, G | 2 |
| Jia, J | 1 |
| Li, Q | 3 |
| Wang, C | 1 |
| Cheng, X | 1 |
| Zhan, Q | 1 |
| Cui, Y | 1 |
| Mai, S | 2 |
| Welzel, G | 1 |
| Ottstadt, M | 1 |
| Lohr, F | 1 |
| Severa, S | 1 |
| Prigge, ES | 1 |
| Wentzensen, N | 1 |
| Trunk, MJ | 1 |
| Wenz, F | 3 |
| von Knebel-Doeberitz, M | 1 |
| Reuschenbach, M | 1 |
| Choi, MY | 1 |
| Lam, HY | 1 |
| Tung, LN | 1 |
| Tzang, FC | 1 |
| Han, H | 1 |
| Lam, IP | 1 |
| Kwok, SY | 1 |
| Lau, SH | 1 |
| Man, C | 1 |
| Tong, DK | 1 |
| Wong, BL | 1 |
| Bu, LL | 2 |
| Zhao, ZL | 2 |
| Rudnick, EW | 1 |
| Thareja, S | 1 |
| Cherpelis, B | 1 |
| Glebovskaya, VV | 1 |
| Tkachev, SI | 3 |
| Rasulov, AO | 1 |
| Tsaryuk, VF | 1 |
| Gordeev, SS | 1 |
| Fedyanin, MY | 1 |
| Aliev, VA | 1 |
| Mamedly, ZZ | 1 |
| Kuzmichev, DV | 1 |
| Trofimova, OP | 1 |
| Borisova, TN | 1 |
| Yazhgunovich, IP | 1 |
| Kim, R | 2 |
| Hahn, S | 1 |
| Shin, J | 1 |
| Ock, CY | 2 |
| Kim, M | 1 |
| Keam, B | 2 |
| Kim, TM | 3 |
| Kim, DW | 6 |
| Heo, DS | 7 |
| Bölke, E | 1 |
| Kammers, K | 1 |
| Gerber, PA | 1 |
| Orth, K | 1 |
| Gripp, S | 1 |
| Matuschek, C | 1 |
| Ebran, N | 1 |
| Radosevic-Robin, N | 1 |
| Monteverde, M | 2 |
| Toussan, N | 1 |
| Etienne-Grimaldi, MC | 1 |
| Nigro, CL | 1 |
| Merlano, M | 24 |
| Penault-Llorca, F | 1 |
| Milano, G | 11 |
| Leon, O | 1 |
| Guren, MG | 2 |
| Radu, C | 1 |
| Gunnlaugsson, A | 1 |
| Johnsson, A | 1 |
| Izumi, D | 1 |
| Shiraishi, S | 1 |
| Kosumi, K | 1 |
| Tokunaga, R | 1 |
| Taki, K | 1 |
| Higashi, T | 1 |
| Miyata, T | 3 |
| Vázquez, S | 3 |
| García-Sáenz, JA | 2 |
| García, C | 1 |
| Carles, J | 2 |
| Mañós, M | 2 |
| García-Paredes, B | 1 |
| del Barco, E | 2 |
| Escobar, Y | 1 |
| Cruz, JJ | 5 |
| Bay, C | 1 |
| Togsverd-Bo, K | 1 |
| Lerche, CM | 1 |
| Haedersdal, M | 1 |
| Garaud, P | 3 |
| Oliveira, SC | 1 |
| Moniz, CM | 1 |
| Riechelmann, R | 1 |
| Alex, AK | 1 |
| Braghirolli, MI | 1 |
| Bariani, G | 1 |
| Nahas, C | 1 |
| Hoff, PM | 1 |
| Ojima, T | 3 |
| Nakamori, M | 4 |
| Nakamura, M | 10 |
| Katsuda, M | 3 |
| Hayata, K | 3 |
| Matsumura, S | 1 |
| Iwahashi, M | 3 |
| Yamaue, H | 4 |
| Ortman, S | 1 |
| Liang, C | 1 |
| Masloub, SM | 1 |
| Elmalahy, MH | 1 |
| Sabry, D | 1 |
| Mohamed, WS | 1 |
| Ahmed, SH | 1 |
| Aguilar, JL | 1 |
| Chen, E | 1 |
| Misiukiewicz, K | 1 |
| Ernst, S | 1 |
| Lee, HJ | 1 |
| Bryant, K | 1 |
| He, S | 1 |
| Obasaju, CK | 1 |
| Chang, SC | 1 |
| Adkins, D | 3 |
| Chang, S | 1 |
| Koo, PJ | 1 |
| Kwak, JJ | 1 |
| Kim, SJ | 2 |
| Haga, A | 1 |
| Kiritoshi, T | 1 |
| Kotecki, N | 1 |
| Hiret, S | 1 |
| Penel, N | 2 |
| Tresch, E | 2 |
| Ben Abdelghani, M | 2 |
| Michel, P | 4 |
| Ghiringelli, F | 1 |
| Piessen, G | 4 |
| Peugniez, C | 1 |
| Clisant, S | 2 |
| Kramar, A | 2 |
| Dhawan, A | 2 |
| Ruwali, M | 1 |
| Pant, MC | 5 |
| Rahman, Q | 1 |
| Parmar, D | 1 |
| Akasaka, H | 1 |
| Ichinohe, D | 1 |
| Park, HC | 1 |
| Kwon, HI | 1 |
| Kim, JE | 1 |
| Ro, YS | 1 |
| Ko, JY | 1 |
| Kitadani, J | 1 |
| Tabata, H | 1 |
| Takeuchi, A | 1 |
| Sugimoto, A | 1 |
| Nakazuru, S | 1 |
| Sakakibara, Y | 1 |
| Nishio, K | 1 |
| Yajima, K | 1 |
| Uehira, T | 1 |
| Mita, E | 1 |
| Ng, HY | 1 |
| Ko, JM | 1 |
| Yu, VZ | 1 |
| Ip, JC | 1 |
| Dai, W | 1 |
| Cal, S | 1 |
| Lung, ML | 1 |
| Guigay, J | 3 |
| Veloz-Martínez, MG | 1 |
| Quintana-Romero, V | 1 |
| Contreras-Morales, Mdel R | 1 |
| Jiménez-Vieyra, CR | 1 |
| Nair, AG | 1 |
| Mishra, DK | 1 |
| Reddy, VA | 1 |
| Naik, MN | 1 |
| Tebbutt, NC | 1 |
| Price, TJ | 1 |
| Ferraro, DA | 1 |
| Wong, N | 1 |
| Veillard, AS | 1 |
| Hall, M | 1 |
| Sjoquist, KM | 1 |
| Pavlakis, N | 2 |
| Strickland, A | 1 |
| Varma, SC | 1 |
| Cooray, P | 1 |
| Young, R | 1 |
| Underhill, C | 1 |
| Shannon, JA | 1 |
| Ganju, V | 2 |
| Gebski, V | 3 |
| Moriya, H | 2 |
| Hosoda, K | 2 |
| Mieno, H | 2 |
| Hoshi, K | 2 |
| Nijkamp, J | 1 |
| Kim, HR | 1 |
| Choi, EC | 3 |
| Koh, YW | 1 |
| Tanahashi, T | 1 |
| Okumura, N | 1 |
| Matsuhashi, N | 1 |
| Yamaguchi, K | 3 |
| Honjo, H | 1 |
| Hara, K | 1 |
| Ozawa, D | 1 |
| Koca, D | 1 |
| Ozdemir, O | 1 |
| Demir, D | 1 |
| Akdeniz, H | 1 |
| Kurt, M | 1 |
| Matsuda, S | 2 |
| Takebayashi, K | 1 |
| Kawamorita, K | 1 |
| Niihara, M | 1 |
| Takeuchi, H | 2 |
| Ahn, D | 1 |
| Sohn, JH | 4 |
| Park, SH | 2 |
| Kim, JC | 2 |
| Ishida, Y | 2 |
| Ezoe, Y | 1 |
| Aoyama, I | 1 |
| Miyamoto, S | 2 |
| Horimatsu, T | 2 |
| Hiraoka, M | 2 |
| Han, DH | 1 |
| Won, TB | 1 |
| Lee, SH | 2 |
| Hah, JH | 4 |
| Kwon, TK | 3 |
| Rhee, CS | 3 |
| Wu, HG | 5 |
| Sung, MW | 7 |
| Nomura, M | 2 |
| Oze, I | 1 |
| Komori, A | 1 |
| Narita, Y | 2 |
| Masuishi, T | 1 |
| Andoh, M | 1 |
| Uemura, N | 1 |
| Tajika, M | 1 |
| Muro, K | 7 |
| Miyawaki, Y | 2 |
| Joag, MG | 1 |
| Sise, A | 1 |
| Murillo, JC | 1 |
| Sayed-Ahmed, IO | 1 |
| Wong, JR | 1 |
| Boupaijit, K | 1 |
| Suprasert, P | 1 |
| Catanzaro, M | 2 |
| Tryakin, A | 1 |
| Pokataev, I | 1 |
| Kononets, P | 1 |
| Fedyanin, M | 1 |
| Bokhyan, V | 1 |
| Malikhova, O | 1 |
| Minin, K | 1 |
| Shogenov, M | 1 |
| Stilidi, I | 1 |
| Vybarava, A | 1 |
| Davydov, M | 1 |
| Tjulandin, S | 2 |
| Liang, P | 1 |
| Cheng, Z | 1 |
| Han, Z | 1 |
| Tan, S | 2 |
| Dai, G | 1 |
| Bai, L | 2 |
| Dang, RP | 1 |
| LE, VH | 1 |
| Miles, BA | 1 |
| Teng, MS | 1 |
| Genden, EM | 2 |
| Bakst, RL | 1 |
| Gupta, V | 2 |
| Zhang, DY | 1 |
| Demicco, EG | 1 |
| Posner, MR | 21 |
| Misiukiewicz, KJ | 1 |
| Laliscia, C | 1 |
| Fabrini, MG | 1 |
| Delishaj, D | 1 |
| Coraggio, G | 1 |
| Morganti, R | 1 |
| Tana, R | 1 |
| Paiar, F | 1 |
| Gadducci, A | 1 |
| Schmaltz, H | 1 |
| Ciftci, S | 1 |
| Takeda-Raguin, C | 1 |
| Debry, C | 1 |
| Schultz, P | 1 |
| Hatogai, K | 1 |
| Kadota, T | 1 |
| Takiguchi, Y | 1 |
| Ohtsu, A | 19 |
| Yasumatsu, R | 4 |
| Nakano, T | 3 |
| Kogo, R | 2 |
| Hashimoto, K | 1 |
| Sawatsubashi, M | 1 |
| Nakagawa, T | 2 |
| Stojanović, N | 1 |
| Brozovic, A | 1 |
| Majhen, D | 1 |
| Bosnar, MH | 1 |
| Fritz, G | 1 |
| Osmak, M | 1 |
| Ambriović-Ristov, A | 1 |
| Yu, GT | 1 |
| Gutkind, JS | 2 |
| Kulkarni, AB | 1 |
| Fontaine-Delaruelle, C | 1 |
| Ambrun, A | 1 |
| Daveau, C | 1 |
| Neidhardt, EM | 1 |
| Diallo, A | 1 |
| Braig, F | 1 |
| Voigtlaender, M | 1 |
| Schieferdecker, A | 1 |
| Grob, T | 1 |
| Kriegs, M | 1 |
| Knecht, R | 7 |
| Bokemeyer, C | 3 |
| Binder, M | 1 |
| Espeli, V | 1 |
| Ruegg, E | 1 |
| Hottinger, AF | 1 |
| Modarressi, A | 1 |
| Dietrich, PY | 1 |
| Seidl, D | 4 |
| Janssen, S | 4 |
| Hakim, SG | 4 |
| Wollenberg, B | 3 |
| Schild, SE | 7 |
| Rades, D | 7 |
| Bajrovic, A | 3 |
| Amraotkar, AR | 1 |
| Pachika, A | 1 |
| Grubb, KJ | 1 |
| DeFilippis, AP | 1 |
| Cheng, J | 1 |
| Colegio, OR | 1 |
| Guo, X | 3 |
| Satake, H | 3 |
| Mochizuki, S | 1 |
| Bando, H | 2 |
| Yamazaki, T | 1 |
| Messager, M | 1 |
| Paumier, A | 2 |
| Glehen, O | 1 |
| Vasseur, F | 1 |
| Lacornerie, T | 1 |
| Robb, WB | 2 |
| Sudo, K | 1 |
| Korgavkar, K | 1 |
| Lee, KC | 1 |
| Lew, R | 1 |
| Harada, T | 3 |
| Morimoto, T | 2 |
| Yata, Y | 1 |
| Nio, M | 1 |
| Yonenaga, Y | 1 |
| Hanaki, K | 1 |
| Mise, M | 1 |
| Higashide, S | 1 |
| Kanda, Y | 1 |
| Noda, H | 1 |
| Petrilli, R | 1 |
| Eloy, JO | 1 |
| Lopez, RF | 1 |
| Lee, RJ | 1 |
| Sakakura, K | 1 |
| Mito, I | 1 |
| Chikamatsu, K | 1 |
| Gil, S | 1 |
| Yébenes, M | 1 |
| Luelmo, J | 1 |
| Alsina, M | 1 |
| Sabés, M | 1 |
| Franzese, C | 1 |
| Fogliata, A | 1 |
| Clerici, E | 1 |
| D'Agostino, G | 1 |
| Navarria, P | 1 |
| Mancosu, P | 1 |
| Tomatis, S | 1 |
| Cozzi, L | 1 |
| Scorsetti, M | 1 |
| Hsu, SH | 1 |
| Peng, HY | 1 |
| Cheng, YC | 1 |
| Hsu, YM | 1 |
| Wu, GH | 4 |
| Kuo, CC | 1 |
| Liou, JP | 1 |
| Chang, JY | 1 |
| Jin, SL | 1 |
| Shiah, SG | 1 |
| Burtness, BA | 3 |
| Niedzwiecki, D | 3 |
| Ye, X | 1 |
| Douglas, K | 1 |
| Ilson, DH | 5 |
| Cohen, SJ | 1 |
| Venook, A | 1 |
| Goldberg, RM | 2 |
| Kawakubo, H | 1 |
| Ahn, PH | 1 |
| Machtay, M | 6 |
| Anne, PR | 1 |
| Cognetti, D | 1 |
| Keane, WM | 1 |
| Wuthrick, E | 1 |
| Dicker, AP | 3 |
| Axelrod, RS | 1 |
| Vos, LJ | 1 |
| Paulson, K | 1 |
| Polkosnik, LA | 1 |
| Rusz, O | 1 |
| Pál, M | 1 |
| Szilágyi, É | 1 |
| Rovó, L | 1 |
| Varga, Z | 1 |
| Tomisa, B | 1 |
| Fábián, G | 1 |
| Kovács, L | 1 |
| Nagy, O | 1 |
| Mózes, P | 1 |
| Reisz, Z | 1 |
| Tiszlavicz, L | 1 |
| Deák, P | 1 |
| Kahán, Z | 1 |
| Nakata, Y | 1 |
| Shimizu, T | 2 |
| Tang, N | 1 |
| Han, X | 1 |
| Helmke, C | 1 |
| Matthess, Y | 1 |
| Raab, M | 1 |
| Strebhardt, K | 2 |
| Deng, P | 1 |
| Liao, G | 2 |
| Feng, M | 1 |
| Meeks, NM | 1 |
| Burden, JG | 1 |
| Carroll, BT | 1 |
| Chen, NX | 1 |
| Zhang, XX | 1 |
| Wang, JL | 1 |
| Yan, F | 1 |
| Shi, Q | 1 |
| Lian, M | 1 |
| Fang, JG | 1 |
| Liu, HG | 1 |
| Meng, LZ | 1 |
| Ma, HZ | 1 |
| Feng, L | 1 |
| Motton, M | 1 |
| Casella, F | 2 |
| Weindelmayer, J | 2 |
| Ambrosi, E | 1 |
| Di Leo, A | 1 |
| Vassiliadis, A | 1 |
| Ricci, F | 1 |
| Rice, TW | 7 |
| Lefebvre, JL | 9 |
| Barzan, L | 5 |
| de Raucourt, D | 6 |
| Hupperets, P | 2 |
| Leemans, CR | 2 |
| Rolland, F | 5 |
| Tesselaar, M | 2 |
| Kazic, N | 2 |
| Xiao, D | 1 |
| Xu, T | 1 |
| Nagano, H | 3 |
| Kurono, Y | 1 |
| Matushita, K | 1 |
| Popovtzer, A | 1 |
| Burnstein, H | 1 |
| Stemmer, S | 1 |
| Limon, D | 1 |
| Hili, O | 1 |
| Bachar, G | 1 |
| Sopov, V | 1 |
| Feinmesser, R | 1 |
| Groshar, D | 1 |
| Shvero, J | 1 |
| Wang, TY | 2 |
| Peng, CY | 1 |
| Lee, SS | 1 |
| Chou, MY | 1 |
| Yu, CC | 2 |
| Chang, YC | 2 |
| Takeshita, H | 1 |
| Miyamae, M | 1 |
| Ohashi, T | 2 |
| Okajima, W | 1 |
| Imamura, T | 1 |
| Kiuchi, J | 1 |
| Huang, T | 1 |
| Ma, S | 1 |
| Zhang, K | 1 |
| Guan, F | 1 |
| Hiyoshi, Y | 1 |
| Kurashige, J | 1 |
| Lee, DY | 2 |
| Park, SW | 1 |
| Oh, SM | 1 |
| Choi, JJ | 1 |
| Shin, ES | 1 |
| Kwon, SK | 1 |
| Ahn, SH | 1 |
| Kim, YH | 3 |
| Linot, B | 1 |
| Rousseau, D | 2 |
| Breheret, R | 1 |
| Rives, P | 1 |
| Köhler, C | 2 |
| Biel, P | 1 |
| Cordes, T | 1 |
| Kobayashi, K | 1 |
| Ley, J | 2 |
| Michel, L | 1 |
| Wildes, TM | 1 |
| Thorstad, W | 3 |
| Gay, HA | 1 |
| Daly, M | 1 |
| Rich, J | 1 |
| Paniello, R | 1 |
| Uppaluri, R | 1 |
| Jackson, R | 1 |
| Trinkaus, K | 2 |
| Nussenbaum, B | 2 |
| Karpathiou, G | 1 |
| Giroult, JB | 1 |
| Forest, F | 1 |
| Fournel, P | 1 |
| Monaya, A | 1 |
| Froudarakis, M | 1 |
| Dumollard, JM | 1 |
| Prades, JM | 4 |
| Gavid, M | 1 |
| Peoc'h, M | 1 |
| Gemici, C | 1 |
| Yaprak, G | 1 |
| Batirel, HF | 1 |
| Ilhan, M | 1 |
| Mayadagli, A | 1 |
| Miceli, R | 1 |
| Cova, A | 1 |
| Resteghini, C | 1 |
| Alfieri, S | 1 |
| Imbimbo, M | 1 |
| Iacovelli, NA | 1 |
| Huber, V | 1 |
| Cavallo, A | 1 |
| Rivoltini, L | 1 |
| Li, CY | 1 |
| Chen, PM | 3 |
| Lin, MW | 1 |
| Kuo, SW | 2 |
| Lu, YX | 1 |
| Chen, DL | 1 |
| Wang, DS | 1 |
| Chen, LZ | 1 |
| Mo, HY | 1 |
| Sheng, H | 1 |
| Wu, QN | 1 |
| Yu, HE | 1 |
| Yun, JP | 1 |
| Zeng, ZL | 1 |
| Ju, HQ | 1 |
| Xu, RH | 2 |
| Schernberg, A | 1 |
| Loganadane, G | 1 |
| Touboul, E | 6 |
| Lim, SH | 1 |
| Shim, YM | 4 |
| Kim, HK | 2 |
| Choi, YS | 1 |
| Ahn, MJ | 2 |
| Park, K | 5 |
| Zo, JI | 1 |
| Shigaki, H | 1 |
| Cunningham, TJ | 1 |
| Eliane, JP | 1 |
| Tuchayi, SM | 1 |
| Manivasagam, S | 1 |
| Mirzaalian, H | 1 |
| Turkoz, A | 1 |
| Kopan, R | 1 |
| Schaffer, A | 1 |
| Saavedra, AP | 1 |
| DeWitt, JM | 1 |
| Murthy, SK | 1 |
| Ardhanari, R | 1 |
| DuVall, GA | 1 |
| Wallner, G | 1 |
| Litka, P | 1 |
| Daugherty, C | 1 |
| Fowers, K | 1 |
| Sparano, JA | 2 |
| Lee, JY | 2 |
| Palefsky, J | 2 |
| Henry, DH | 1 |
| Wachsman, W | 1 |
| Rajdev, L | 1 |
| Aboulafia, D | 1 |
| Ratner, L | 1 |
| Fitzgerald, TJ | 3 |
| Mitsuyasu, R | 1 |
| Parrozzani, R | 1 |
| Frizziero, L | 1 |
| Trainiti, S | 1 |
| Testi, I | 1 |
| Miglionico, G | 1 |
| Pilotto, E | 1 |
| Blandamura, S | 1 |
| Fassina, A | 1 |
| Midena, E | 3 |
| Chen, JH | 1 |
| Yen, YC | 1 |
| Chen, TM | 1 |
| Yuan, KS | 1 |
| Lee, FP | 1 |
| Lin, KC | 1 |
| Lai, MT | 1 |
| Wu, CC | 1 |
| Chang, CL | 1 |
| Wu, SY | 1 |
| Pastor, M | 2 |
| Lambeaz, J | 1 |
| Martínez-Galán, J | 1 |
| Mel, JR | 1 |
| González, B | 1 |
| Casado, E | 1 |
| Rodríguez-Jaráiz, A | 1 |
| Su, J | 2 |
| Zhu, S | 2 |
| Liu, Z | 1 |
| Song, C | 1 |
| Nishikage, T | 1 |
| Ryotokuji, T | 3 |
| Nagai, K | 7 |
| Seim, NB | 1 |
| Kang, SY | 1 |
| Bhandari, M | 1 |
| Jones, RG | 1 |
| Teknos, TN | 6 |
| Garg, MK | 1 |
| Whittington, R | 1 |
| Mitchell, EP | 1 |
| Mulcahy, MF | 1 |
| Armstrong, KI | 1 |
| Nabbout, NH | 1 |
| Kalnicki, S | 1 |
| El-Rayes, BF | 1 |
| Onitilo, AA | 1 |
| Moriarty, DJ | 1 |
| Lee, AY | 1 |
| Golden, DW | 1 |
| Bazan, JG | 3 |
| Kopec, M | 1 |
| Pelizzari, CA | 1 |
| Aggarwal, S | 1 |
| Liauw, SL | 2 |
| Sugawara, M | 1 |
| Ashkenazy, N | 1 |
| Wang, G | 1 |
| Acosta, CM | 1 |
| Kawai, T | 1 |
| Matsuno, Y | 1 |
| Fujisaki, S | 1 |
| Takashina, M | 1 |
| Tomita, R | 1 |
| Byer, J | 1 |
| Kothari, N | 1 |
| Mahipal, A | 1 |
| Chang, YD | 1 |
| Kim, RD | 1 |
| Katsumi, C | 1 |
| Bamba, T | 1 |
| Nakagawa, S | 4 |
| Aizawa, M | 1 |
| Matsuki, A | 2 |
| Yabusaki, H | 2 |
| Homma, K | 1 |
| Zhu, ZQ | 1 |
| Zhu, ZA | 1 |
| Cai, HX | 1 |
| McDowell, LJ | 1 |
| Huang, SH | 1 |
| Xu, W | 1 |
| Che, J | 1 |
| Wong, RKS | 1 |
| Brierley, J | 2 |
| Cummings, B | 3 |
| Hansen, A | 1 |
| Witterick, I | 1 |
| Ringash, J | 2 |
| Hui, L | 1 |
| Jiang, X | 1 |
| Vallböhmer, D | 5 |
| Kuhn, E | 1 |
| Warnecke-Eberz, U | 3 |
| Brabender, J | 5 |
| Hoffmann, AC | 1 |
| Metzger, R | 6 |
| Baldus, SE | 6 |
| Drebber, U | 3 |
| Hoelscher, AH | 4 |
| Schneider, PM | 6 |
| Salama, JK | 8 |
| Stenson, KM | 7 |
| Kistner, EO | 1 |
| Argiris, A | 6 |
| Rosen, F | 4 |
| Deodato, F | 1 |
| Forni, F | 1 |
| Digesù, C | 1 |
| Carone, V | 1 |
| Baghi, M | 3 |
| Hambek, M | 4 |
| Moertel, S | 1 |
| Gstoettner, W | 2 |
| Bhide, SA | 3 |
| Ahmed, M | 1 |
| Barbachano, Y | 2 |
| Nutting, CM | 3 |
| Tian, F | 5 |
| Song, M | 1 |
| Xu, PR | 1 |
| Liu, HT | 1 |
| Xue, LX | 1 |
| Ota, M | 2 |
| Narumiya, K | 2 |
| Sato, T | 4 |
| Ohki, T | 1 |
| Mitsuhashi, N | 2 |
| Higuchi, I | 2 |
| Tatsumi, M | 1 |
| Fukunaga, H | 1 |
| Hatazawa, J | 1 |
| Monden, M | 13 |
| Uryu, H | 2 |
| Masuda, M | 5 |
| Hirakawa, N | 2 |
| Shiratsuchi, H | 1 |
| Tomita, K | 2 |
| Fukushima, M | 4 |
| Komune, S | 4 |
| Javeri, H | 1 |
| Arora, R | 1 |
| Correa, AM | 4 |
| Hofstetter, WL | 2 |
| Lee, JH | 1 |
| Liao, Z | 3 |
| McAleer, MF | 1 |
| Maru, D | 1 |
| Bhutani, MS | 1 |
| Swisher, SG | 7 |
| Izzo, JG | 2 |
| Hiroe, S | 1 |
| Okumura, K | 2 |
| Chayahara, N | 4 |
| Milani, A | 1 |
| Teng, HW | 1 |
| Chang, SY | 5 |
| Tsai, TL | 5 |
| Wang, YF | 5 |
| Huang, JL | 3 |
| Mann, M | 1 |
| Berk, DR | 1 |
| Petersen, J | 1 |
| Mohri, Y | 3 |
| Ohi, M | 3 |
| Yokoe, T | 2 |
| Koike, Y | 1 |
| Morimoto, Y | 1 |
| Miki, C | 2 |
| Tonouchi, H | 2 |
| Kusunoki, M | 4 |
| Okoshi, A | 1 |
| Shiga, K | 1 |
| Asada, Y | 1 |
| Nishikawa, H | 2 |
| Bazarbashi, S | 2 |
| Abdelsalam, M | 1 |
| Amin, T | 1 |
| El-Bassiouni, M | 1 |
| Soudy, H | 1 |
| Elweshi, A | 1 |
| Alhusseiny, H | 1 |
| Rehman, K | 1 |
| Memon, M | 2 |
| Ajarim, D | 2 |
| Yoshiba, S | 1 |
| Ito, D | 1 |
| Nagumo, T | 1 |
| Shirota, T | 1 |
| Hatori, M | 1 |
| Shintani, S | 2 |
| Button, MR | 1 |
| Morgan, CA | 1 |
| Croydon, ES | 1 |
| Roberts, SA | 2 |
| Crosby, TD | 2 |
| Hattori, S | 1 |
| Yoshida, S | 11 |
| Rivera, F | 6 |
| Kawecki, A | 3 |
| Zabolotnyy, D | 2 |
| Cupissol, D | 5 |
| Benasso, M | 22 |
| Vynnychenko, I | 1 |
| Schueler, A | 2 |
| Amellal, N | 2 |
| Kikuchi, M | 1 |
| Kamei, S | 1 |
| Morirama, Y | 1 |
| Tuchiya, T | 1 |
| Miwa, K | 1 |
| Yokoi, S | 1 |
| Nakano, M | 1 |
| Ehara, H | 1 |
| Deguchi, T | 1 |
| Hirose, Y | 1 |
| Huang, HQ | 1 |
| Cai, QQ | 1 |
| Lin, XB | 1 |
| Wang, AL | 1 |
| Bu, Q | 1 |
| Hu, XH | 3 |
| Pan, ZH | 1 |
| Shuang, YR | 1 |
| Guan, ZZ | 4 |
| Lorenzen, S | 3 |
| Brücher, B | 1 |
| Zimmermann, F | 2 |
| Riera, J | 1 |
| Roethling, N | 1 |
| Höfler, H | 1 |
| Ott, K | 1 |
| Peschel, C | 3 |
| Siewert, JR | 3 |
| Zeng, SY | 1 |
| Li, LY | 1 |
| Shu, KY | 1 |
| Pan, M | 1 |
| Li, HP | 1 |
| Luo, B | 1 |
| Innocente, R | 3 |
| Cavina, R | 1 |
| Pigozzo, J | 2 |
| Del Bianco, P | 2 |
| Fumagalli, U | 1 |
| Santoro, A | 1 |
| Shinohara, F | 2 |
| Sugazaki, M | 1 |
| Echigo, S | 2 |
| Rikiishi, H | 2 |
| Bollschweiler, E | 6 |
| Baldus, S | 1 |
| Kocher, M | 2 |
| Hölscher, AH | 5 |
| Fujita, Y | 3 |
| Kawai, M | 1 |
| Sumiyoshi, K | 1 |
| Nishimura, H | 1 |
| Tanigawa, N | 1 |
| Oyama, T | 3 |
| Miyata, Y | 4 |
| Gao, XS | 2 |
| Qiao, XY | 2 |
| Chen, K | 2 |
| Wang, YD | 1 |
| Zhou, ZG | 2 |
| Finnegan, V | 1 |
| Parsons, JT | 2 |
| Greene, BD | 1 |
| Sharma, V | 3 |
| Benhamou, E | 1 |
| Ferron, C | 1 |
| Dolivet, G | 1 |
| Hamoir, M | 2 |
| Julieron, M | 2 |
| Castaing, M | 1 |
| Washino, S | 1 |
| Terauchi, F | 1 |
| Matsuzaki, A | 1 |
| Chen, JX | 1 |
| Tang, Q | 1 |
| Zhu, HN | 1 |
| Zheng, YD | 1 |
| Tateishi, Y | 1 |
| Tatemoto, Y | 2 |
| Ohno, S | 1 |
| Morishita, K | 1 |
| Ueta, E | 6 |
| Le Tourneau, C | 1 |
| Kamnerdsupaphon, P | 2 |
| Chitapanarux, I | 2 |
| Lorvidhaya, V | 6 |
| Sumitsawan, Y | 2 |
| Tharavichitkul, E | 2 |
| Sukthomya, V | 1 |
| Ishihama, H | 1 |
| Chida, M | 1 |
| Araki, O | 1 |
| Karube, Y | 1 |
| Seki, N | 1 |
| Tamura, M | 1 |
| Umezu, H | 1 |
| Masawa, N | 1 |
| Miyoshi, S | 3 |
| Ayada, T | 1 |
| Wakasaki, T | 2 |
| Koyota, S | 1 |
| Koizumi, Y | 1 |
| Takasawa, S | 1 |
| Itaya-Hironaka, A | 1 |
| Sakuramoto-Tsuchida, S | 1 |
| Maruyama, K | 3 |
| Kim, L | 1 |
| Karas, M | 1 |
| Wong, SC | 1 |
| Hakenberg, OW | 1 |
| Su, YX | 1 |
| Zheng, JW | 1 |
| Zheng, GS | 1 |
| Liao, GQ | 1 |
| Kuang, YH | 1 |
| Wu, LS | 1 |
| Liao, LQ | 1 |
| Chen, ZS | 1 |
| Kanekura, T | 1 |
| Tsukuda, M | 31 |
| Mikami, Y | 12 |
| Matsuda, H | 15 |
| Horiuchi, C | 11 |
| Satake, K | 4 |
| Kawakami, M | 4 |
| Hanamura, H | 3 |
| Utsumi, A | 1 |
| Kagami, Y | 3 |
| Khan, K | 1 |
| Yu, SZ | 1 |
| Ronson, S | 1 |
| Rhee, J | 1 |
| Van Echo, D | 1 |
| O'Malley, BW | 1 |
| Wolff, K | 1 |
| Wein, A | 1 |
| Reulbach, U | 1 |
| Männlein, G | 1 |
| Brückl, V | 1 |
| Meier, C | 1 |
| Ostermeier, N | 1 |
| Schwab, SA | 1 |
| Horbach, T | 1 |
| Hohenberger, W | 3 |
| Hahn, EG | 1 |
| Boxberger, F | 1 |
| Cao, DY | 1 |
| Yang, JX | 2 |
| Shen, K | 2 |
| Xiang, Y | 2 |
| Pan, LY | 1 |
| Lang, JH | 1 |
| Wu, M | 2 |
| Huang, HF | 2 |
| Fujisawa, Y | 3 |
| Ishitsuka, Y | 1 |
| Kawachi, Y | 2 |
| Otsuka, F | 2 |
| Matsumura, T | 2 |
| Ito, H | 7 |
| Osano, H | 3 |
| Takachi, K | 2 |
| Kishi, K | 6 |
| Noura, S | 3 |
| Miyashiro, I | 4 |
| Ohigashi, H | 3 |
| Sasaki, Y | 3 |
| Ishikawa, O | 4 |
| Imaoka, S | 2 |
| Zhang, GQ | 1 |
| Han, F | 1 |
| Pang, ZL | 1 |
| SiKanDaer, AB | 1 |
| Wang, HJ | 1 |
| Lunghi, F | 1 |
| Stupp, R | 1 |
| Lacombe, D | 2 |
| Bogaerts, J | 2 |
| Horiot, JC | 1 |
| Bernier, J | 4 |
| Trotti, AM | 1 |
| Norris, CM | 15 |
| Wirth, LJ | 2 |
| Cullen, KJ | 5 |
| Winquist, EW | 2 |
| Mickiewicz, EA | 1 |
| Frenette, GP | 1 |
| Plinar, LF | 1 |
| Cohen, RB | 2 |
| Steinbrenner, LM | 1 |
| Freue, JM | 1 |
| Gorbunova, VA | 2 |
| Tjulandin, SA | 1 |
| Adkins, DR | 1 |
| Tishler, RB | 13 |
| Roessner, MR | 1 |
| Haddad, RI | 9 |
| Takagawa, R | 1 |
| Kunisaki, C | 1 |
| Makino, H | 4 |
| Kosaka, T | 1 |
| Ono, HA | 1 |
| Akiyama, H | 1 |
| Seo, Y | 1 |
| Kinsella, MT | 1 |
| Reynolds, HL | 1 |
| Chipman, G | 1 |
| Remick, SC | 2 |
| Kinsella, TJ | 1 |
| Fuse, N | 3 |
| Minami, H | 1 |
| Qin, TJ | 1 |
| An, GL | 1 |
| Zhao, XH | 1 |
| Li, XH | 1 |
| Lian, JW | 1 |
| Pan, BR | 1 |
| Gu, SZ | 1 |
| Kim, YS | 2 |
| Ahn, SD | 2 |
| Lee, SW | 3 |
| Shin, SS | 1 |
| Nam, JH | 1 |
| Kim, YT | 1 |
| Kim, YM | 1 |
| Choi, EK | 3 |
| Oblak, I | 1 |
| Petric, P | 1 |
| Anderluh, F | 1 |
| Velenik, V | 1 |
| Hudej, R | 1 |
| Fras, AP | 1 |
| Jamieson, GG | 8 |
| Wu, TC | 1 |
| Zhu, GJ | 1 |
| Drew, PA | 1 |
| Shariat-Torbaghan, S | 1 |
| Emami-Aleagha, M | 1 |
| Sedighi, S | 1 |
| Azadbakht, F | 1 |
| Keshvari, A | 1 |
| Hajarizadeh, B | 1 |
| Rosai, J | 1 |
| Myerson, RJ | 4 |
| Outlaw, ED | 1 |
| Birnbaum, EH | 1 |
| Fleshman, JW | 2 |
| Grigsby, PW | 5 |
| Kodner, IJ | 2 |
| Malayapa, RS | 1 |
| Mutch, MG | 1 |
| Picus, J | 1 |
| Tan, BR | 1 |
| Kim, MK | 1 |
| Cho, KJ | 3 |
| Park, SI | 5 |
| Song, HY | 5 |
| Shin, JH | 2 |
| Jung, HY | 4 |
| Lee, GH | 3 |
| Choi, KD | 2 |
| Song, HJ | 2 |
| Ryu, JS | 1 |
| Kim, SB | 6 |
| Gupta, D | 2 |
| Shukla, P | 1 |
| Bisht, SS | 1 |
| Bhatt, ML | 3 |
| Gupta, R | 1 |
| Hainsworth, JD | 4 |
| Spigel, DR | 2 |
| Burris, HA | 3 |
| Markus, TM | 1 |
| Shipley, D | 1 |
| Kuzur, M | 1 |
| Lunin, S | 1 |
| Greco, FA | 4 |
| Hyodo, I | 3 |
| Moriwaki, T | 1 |
| Endo, S | 2 |
| Nasu, J | 1 |
| Matsuura, B | 1 |
| Hiasa, Y | 1 |
| Onji, M | 1 |
| Tortochaux, J | 3 |
| Guerrif, S | 1 |
| Morota, M | 1 |
| Gomi, K | 1 |
| Kozuka, T | 3 |
| Matsuura, M | 1 |
| Oguchi, M | 2 |
| Yamashita, T | 2 |
| Im, SA | 1 |
| Kim, KH | 6 |
| Koiwai, K | 1 |
| Shikama, N | 2 |
| Kadoya, M | 1 |
| Ishihara, R | 2 |
| Iishi, H | 1 |
| Takeuchi, Y | 1 |
| Sugimoto, N | 1 |
| Higashino, K | 2 |
| Uedo, N | 1 |
| Tatsuta, M | 1 |
| Imai, A | 2 |
| Nishiyama, K | 4 |
| Sasamoto, R | 2 |
| Kanda, T | 3 |
| Hatakeyama, K | 2 |
| Rashid, A | 1 |
| Cano, ER | 1 |
| Lai, SY | 1 |
| Caylakli, F | 1 |
| Johnson, JT | 8 |
| Ferris, RL | 1 |
| Carrau, RL | 1 |
| Snyderman, CH | 2 |
| Gooding, WE | 2 |
| Simenthal, AA | 1 |
| Myers, EN | 7 |
| Takeda, A | 2 |
| Tomita, T | 3 |
| Shiotani, A | 1 |
| Kunieda, E | 1 |
| Kawaguchi, O | 1 |
| Kubo, A | 1 |
| Kim, DH | 3 |
| Wang-Chesebro, A | 1 |
| Weinberg, V | 1 |
| Pouliot, J | 1 |
| Speight, J | 1 |
| Littell, R | 1 |
| Hsu, IC | 1 |
| Miyoshi, T | 2 |
| Seike, J | 4 |
| Yamai, H | 4 |
| Takechi, H | 3 |
| Yuasa, Y | 2 |
| Tangoku, A | 5 |
| Stockfleth, E | 3 |
| Ulrich, C | 1 |
| Otake, K | 1 |
| Toiyama, Y | 2 |
| Barkati, M | 1 |
| Fortin, B | 5 |
| Clavel, S | 4 |
| Després, P | 4 |
| Charpentier, D | 2 |
| Tabet, JC | 1 |
| Olivier, MJ | 1 |
| Coulombe, G | 1 |
| Donath, D | 5 |
| Kovács, AF | 4 |
| Eberlein, K | 1 |
| Hülsmann, T | 1 |
| Garrel, R | 1 |
| Reyt, E | 5 |
| Righini, C | 1 |
| Schmitt, T | 1 |
| Remini, N | 1 |
| Saban-Roche, L | 1 |
| Timoshenko, AP | 2 |
| Trombert, B | 1 |
| Guerrier, B | 1 |
| Yoshioka, A | 1 |
| Nushijima, Y | 1 |
| Mano, M | 3 |
| Sawada, N | 1 |
| Takizawa, H | 1 |
| Kenzaki, K | 1 |
| Bando, Y | 3 |
| Ohnishi, Y | 1 |
| Koh, Y | 1 |
| Jeon, YK | 1 |
| Kim, CW | 1 |
| Xie, L | 1 |
| Wei, L | 2 |
| Lv, L | 1 |
| Hogg, ME | 1 |
| Popowich, DA | 1 |
| Wang, EC | 1 |
| Kiel, KD | 1 |
| Stryker, SJ | 1 |
| Halverson, AL | 1 |
| Worden, FP | 5 |
| Moyer, J | 1 |
| Lee, JS | 11 |
| Taylor, JM | 2 |
| Urba, SG | 11 |
| Eisbruch, A | 6 |
| Chepeha, DB | 5 |
| Prince, ME | 4 |
| Hogikyan, N | 1 |
| Lassig, AA | 1 |
| Emerick, K | 1 |
| Mukherji, S | 1 |
| Hadjiski, L | 1 |
| Tsien, CI | 3 |
| Miller, TH | 2 |
| Wallace, NE | 2 |
| Mason, HL | 2 |
| Wolf, GT | 16 |
| Rogers, LJ | 1 |
| Howard, B | 1 |
| Van Wijk, L | 1 |
| Wei, W | 1 |
| Dehaeck, K | 1 |
| Soeters, R | 1 |
| Denny, LA | 1 |
| Lindel, K | 1 |
| Helmke, B | 1 |
| Simon, C | 3 |
| Weber, KJ | 1 |
| de Villiers, EM | 1 |
| Zemanova, M | 1 |
| Petruzelka, L | 1 |
| Pazdro, A | 1 |
| Kralova, D | 1 |
| Smejkal, M | 1 |
| Pazdrova, G | 1 |
| Honova, H | 1 |
| Klug, C | 4 |
| Berzaczy, D | 1 |
| Voracek, M | 3 |
| Nell, C | 1 |
| Ploder, O | 2 |
| Millesi, W | 5 |
| Ewers, R | 5 |
| Porschen, R | 1 |
| Al-Batran, SE | 1 |
| Hofheinz, R | 1 |
| Thuss-Patience, P | 1 |
| Moehler, M | 1 |
| Grabowski, P | 1 |
| Arnold, D | 2 |
| Greten, T | 1 |
| Müller, L | 1 |
| Röthling, N | 1 |
| Langer, R | 1 |
| Udagawa, H | 1 |
| Togo, A | 1 |
| Tanaka, O | 3 |
| Yamana, H | 5 |
| Holsinger, FC | 1 |
| Lin, HY | 1 |
| Bassot, V | 7 |
| Li, BK | 1 |
| Rao, HL | 1 |
| Deng, HX | 1 |
| Zeng, YX | 2 |
| Adelstein, DJ | 23 |
| Moon, J | 2 |
| Hanna, E | 2 |
| Giri, PG | 2 |
| Mills, GM | 1 |
| Lee, YJ | 1 |
| Kim, GE | 4 |
| Choi, HJ | 1 |
| Iovieno, A | 1 |
| Lambiase, A | 1 |
| Moretti, C | 1 |
| Perrella, E | 1 |
| Bonini, S | 1 |
| Matsutani, T | 3 |
| Sasajima, K | 6 |
| Maruyama, H | 5 |
| Miyamoto, M | 2 |
| Yokoyama, T | 2 |
| Yanagi, K | 1 |
| Matsushita, A | 2 |
| Matsuda, A | 3 |
| Tajiri, T | 3 |
| Zhang, DK | 1 |
| Su, XD | 1 |
| Lin, P | 1 |
| Long, H | 1 |
| Zhang, LJ | 1 |
| Ma, GW | 1 |
| Rong, TH | 3 |
| Takeda, M | 1 |
| Tsujinaka, T | 11 |
| Peñagarícano, JA | 1 |
| Moros, EG | 1 |
| Ratanatharathorn, V | 2 |
| Yan, Y | 1 |
| Corry, P | 1 |
| Toida, M | 1 |
| Long, NK | 1 |
| Asaka, Y | 1 |
| Hatakeyama, D | 1 |
| Yonemoto, K | 1 |
| Makita, H | 1 |
| Kato, Y | 4 |
| Matzinger, O | 1 |
| Roelofsen, F | 1 |
| Mineur, L | 1 |
| Koswig, S | 1 |
| Van Der Steen-Banasik, EM | 1 |
| Van Houtte, P | 3 |
| Haustermans, K | 1 |
| Radosevic-Jelic, L | 1 |
| Mueller, RP | 4 |
| Collette, L | 2 |
| Quinlan, JF | 1 |
| North, J | 1 |
| Clarke, DA | 1 |
| Gwynne-Jones, DP | 1 |
| Grimminger, P | 1 |
| Hoffmann, A | 1 |
| Schulte, C | 1 |
| Kersting, S | 1 |
| Konopke, R | 1 |
| Dittert, D | 1 |
| Distler, M | 1 |
| Rückert, F | 1 |
| Gastmeier, J | 1 |
| Baretton, GB | 1 |
| Saeger, HD | 1 |
| Domingo, E | 1 |
| de Los Reyes, R | 1 |
| Syortin, T | 1 |
| Lertbutsayanukul, C | 1 |
| Vito-Cruz, E | 1 |
| Jin, K | 1 |
| Yoshihara, M | 1 |
| Cupino, N | 1 |
| Lertsanguansinchai, P | 2 |
| Rybicki, LA | 7 |
| Saxton, JP | 12 |
| Videtic, GM | 4 |
| Murthy, SC | 3 |
| Mason, DP | 2 |
| Rodriguez, CP | 4 |
| Ives, DI | 4 |
| Dähn, D | 1 |
| Martell, J | 1 |
| Vorwerk, H | 1 |
| Hess, CF | 2 |
| Becker, H | 1 |
| Jung, K | 1 |
| Hilgers, R | 1 |
| Hermann, RM | 1 |
| Christiansen, H | 1 |
| Eliason, M | 1 |
| Bowen, G | 1 |
| Bowen, A | 1 |
| Hazard, L | 1 |
| Samlowski, W | 2 |
| Norris, C | 1 |
| Goguen, L | 4 |
| Balboni, TA | 2 |
| Costello, R | 9 |
| Wirth, L | 3 |
| Lorch, J | 2 |
| Andreozzi, B | 1 |
| Annino, D | 1 |
| Parthan, A | 1 |
| Brammer, C | 1 |
| Beltran, P | 1 |
| Jansen, JP | 1 |
| Li, BS | 1 |
| Zhou, T | 2 |
| Wang, ZT | 2 |
| Li, HS | 1 |
| Sun, HF | 1 |
| Zhang, ZC | 1 |
| Lin, HQ | 1 |
| Wei, YM | 1 |
| Gong, HY | 1 |
| Huang, W | 2 |
| Yi, Y | 2 |
| Wang, LY | 1 |
| Oikawa, H | 1 |
| Nakamura, R | 2 |
| Nakasato, T | 2 |
| Ehara, S | 2 |
| Ariga, H | 2 |
| Nemoto, K | 4 |
| Miyazaki, S | 4 |
| Yoshioka, T | 4 |
| Ogawa, Y | 2 |
| Sakayauchi, T | 2 |
| Miyata, G | 2 |
| Onodera, K | 2 |
| Kamei, T | 1 |
| Kato, S | 3 |
| Ishioka, C | 2 |
| Satomi, S | 1 |
| Cals, L | 1 |
| Hans, S | 2 |
| Saint-Guily, JL | 1 |
| Lagarde, F | 1 |
| Soto Iglesias, S | 1 |
| Baltar Arias, R | 1 |
| Vázquez Rodríguez, S | 1 |
| Alvarez, M | 1 |
| Gómez Martínez, P | 1 |
| Alvarez Sánchez, MV | 1 |
| Vázquez Astray, E | 1 |
| Sakoda, T | 2 |
| Morizane, R | 1 |
| Nakahara, K | 1 |
| Enomoto, Y | 1 |
| Nosaka, A | 1 |
| Enomoto, T | 2 |
| Kitano, H | 2 |
| Hadley, JC | 1 |
| Tristani-Firouzi, P | 1 |
| Florell, SF | 1 |
| Bowen, GM | 1 |
| Hadley, ML | 1 |
| Allum, WH | 1 |
| Stenning, SP | 1 |
| Bancewicz, J | 1 |
| Clark, PI | 1 |
| Langley, RE | 1 |
| Buiret, G | 1 |
| Combe, C | 1 |
| Ecochard, R | 1 |
| Kogashiwa, Y | 2 |
| Yamauchi, K | 2 |
| Nagafuji, H | 2 |
| Tsubosaka, T | 2 |
| Tsutsumi, T | 1 |
| Karaho, T | 2 |
| Kohno, N | 13 |
| Kronemann, S | 2 |
| Kilic, Y | 1 |
| Schroeder, U | 2 |
| Hakim, S | 1 |
| García-Castaño, A | 1 |
| Vega, N | 1 |
| Vega-Villegas, ME | 2 |
| Gutiérrez-Sanz, L | 1 |
| Inokuma, T | 2 |
| Takemoto, Y | 2 |
| Tobias, JS | 1 |
| Monson, K | 1 |
| Gupta, N | 1 |
| Macdougall, H | 1 |
| Glaholm, J | 1 |
| Hutchison, I | 1 |
| Hackshaw, A | 1 |
| Shueng, PW | 2 |
| Wu, LJ | 1 |
| Chen, SY | 3 |
| Hsiao, CH | 1 |
| Tien, HJ | 1 |
| Cheng, PW | 1 |
| Kuo, YS | 1 |
| Chen, CA | 1 |
| Hsieh, PY | 1 |
| Hsieh, CH | 1 |
| Yoshioka, S | 1 |
| Azad, A | 1 |
| Chionh, F | 1 |
| Jayarajan, J | 1 |
| Arimura, Y | 1 |
| Okahara, S | 1 |
| Tanuma, T | 1 |
| Kodaira, J | 1 |
| Hokari, K | 1 |
| Tsukagoshi, H | 2 |
| Shinomura, Y | 1 |
| Hosokawa, M | 2 |
| Schumaker, L | 1 |
| Nikitakis, N | 1 |
| Goloubeva, O | 2 |
| Tan, M | 2 |
| Osawa, S | 1 |
| Furuta, T | 1 |
| Sugimoto, K | 1 |
| Kosugi, T | 1 |
| Terai, T | 1 |
| Yamade, M | 1 |
| Takayanagi, Y | 1 |
| Hamaya, Y | 1 |
| Kodaira, C | 1 |
| Iwaizumi, M | 1 |
| Takagaki, K | 1 |
| Kanaoka, S | 1 |
| Ikuma, M | 1 |
| Hillel, AT | 1 |
| Fakhry, C | 1 |
| Pai, SI | 3 |
| Williams, MF | 1 |
| Blanco, RG | 3 |
| Zinreich, ES | 3 |
| Levine, MA | 3 |
| Westra, WH | 2 |
| Saunders, JR | 3 |
| Ha, PK | 3 |
| Matsuyama, J | 3 |
| Divi, V | 1 |
| Hogikyan, ND | 1 |
| Moyer, JS | 1 |
| Moore, AY | 1 |
| Zhu, WG | 2 |
| Yu, CH | 2 |
| Han, JH | 2 |
| Zhou, XL | 1 |
| Tao, GZ | 1 |
| Li, M | 2 |
| Hong, L | 1 |
| Gong, T | 1 |
| Sun, L | 1 |
| Wang, ML | 2 |
| Uchida, N | 3 |
| Ishiguro, K | 1 |
| Suda, T | 1 |
| Nishimura, M | 5 |
| Love, WE | 1 |
| Bernhard, JD | 1 |
| Bordeaux, JS | 1 |
| Buffoli, A | 2 |
| Gardani, G | 1 |
| Ardizzoia, A | 1 |
| Dondi, D | 1 |
| Cavallo, R | 1 |
| Tomio, L | 3 |
| Ishitoya, J | 6 |
| Niho, T | 1 |
| Ikeda, Y | 7 |
| Kaneko, K | 9 |
| Kumekawa, Y | 2 |
| Makino, R | 1 |
| Nozawa, H | 2 |
| Hirayama, Y | 1 |
| Kogo, M | 3 |
| Konishi, K | 2 |
| Katagiri, A | 2 |
| Kubota, Y | 3 |
| Muramoto, T | 2 |
| Kushima, M | 1 |
| Ohmori, T | 1 |
| Kagawa, N | 1 |
| Imawari, M | 4 |
| Morimoto, J | 1 |
| Noda, E | 1 |
| Yamada, N | 2 |
| Sawada, T | 1 |
| Iijima, S | 3 |
| Makari, Y | 3 |
| Ooshima, S | 1 |
| Hoshi, M | 1 |
| Miyake, Y | 1 |
| Kato, A | 1 |
| Miyo, M | 1 |
| Kurokawa, E | 1 |
| Kikkawa, N | 1 |
| Mroz, EA | 1 |
| Rocco, JW | 1 |
| Perrone, F | 1 |
| Cortelazzi, B | 1 |
| Quattrone, P | 2 |
| Pierotti, MA | 1 |
| Pilotti, S | 1 |
| Fayaz, S | 1 |
| Vasishta, S | 2 |
| Motawy, M | 1 |
| Rabinowits, G | 1 |
| Bhupalam, L | 1 |
| Miller, DM | 1 |
| Kloecker, GH | 1 |
| Laber, DA | 1 |
| Meredith, KL | 1 |
| Turaga, KK | 1 |
| McLoughlin, J | 1 |
| Marcovalerio, M | 1 |
| Shah, N | 1 |
| Kelley, S | 1 |
| Karl, R | 2 |
| Shim, HJ | 1 |
| Cho, SH | 2 |
| Hwang, JE | 1 |
| Bae, WK | 1 |
| Song, SY | 2 |
| Cho, SB | 1 |
| Lee, WS | 1 |
| Na, KJ | 1 |
| Shimakawa, T | 1 |
| Naritaka, Y | 1 |
| Asaka, S | 1 |
| Isohata, N | 1 |
| Murayama, M | 1 |
| Konno, S | 1 |
| Katsube, T | 1 |
| Ide, H | 8 |
| Kadoyama, K | 3 |
| Yanagisawa, S | 2 |
| Tsuchiya, S | 1 |
| Kaiho, T | 1 |
| Togawa, A | 1 |
| Shinmura, K | 1 |
| Nomura, S | 1 |
| Nobumoto, D | 1 |
| Giannola, LI | 2 |
| De Caro, V | 2 |
| Giandalia, G | 2 |
| Siragusa, MG | 2 |
| Paderni, C | 2 |
| Campisi, G | 2 |
| Florena, AM | 1 |
| Lu, JC | 1 |
| Kong, C | 1 |
| Tao, H | 1 |
| Palmero, R | 1 |
| Cos, M | 1 |
| Vilajosana, E | 1 |
| Pederson, AW | 2 |
| Blair, EA | 5 |
| Guo, JF | 1 |
| Zhang, B | 2 |
| Wu, F | 1 |
| Xing, H | 1 |
| Zhu, GY | 1 |
| Nie, XY | 1 |
| Peng, J | 1 |
| Cho, JS | 1 |
| Chung, WK | 3 |
| Liu, WS | 1 |
| Hsin, CH | 1 |
| Chou, YH | 1 |
| Liu, JT | 1 |
| Wu, MF | 1 |
| Tseng, SW | 1 |
| Tseng, HC | 1 |
| Wang, TH | 1 |
| Su, MC | 1 |
| Lee, H | 1 |
| Good, LM | 1 |
| Miller, MD | 1 |
| High, WA | 1 |
| Kienzer, H | 1 |
| Koralewski, P | 1 |
| Curran, D | 1 |
| Gross, A | 1 |
| Wright, JL | 1 |
| Patil, SM | 1 |
| Temple, LK | 2 |
| Saltz, LB | 1 |
| Meluch, AA | 3 |
| Lane, CM | 1 |
| Farley, C | 1 |
| Gray, JR | 1 |
| Clark, BL | 1 |
| Thanasai, J | 1 |
| Limpaiboon, T | 1 |
| Jearanaikoon, P | 1 |
| Sripa, B | 1 |
| Pairojkul, C | 1 |
| Tantimavanich, S | 1 |
| Miwa, M | 1 |
| Lefor, A | 1 |
| Nokubi, M | 1 |
| Yamaguti, T | 1 |
| Muroi, K | 1 |
| Nakazawa, M | 1 |
| Yasuda, Y | 1 |
| Arikawa, S | 1 |
| Uchida, M | 1 |
| Ogoh, E | 1 |
| Uozumi, J | 1 |
| Watanabe, Y | 3 |
| Kaida, H | 1 |
| Shirouzu, K | 4 |
| Rughani, AI | 1 |
| Lin, C | 1 |
| Tranmer, BI | 1 |
| Wilson, JT | 1 |
| Provencher, S | 2 |
| Bahary, JP | 1 |
| Lütolf, UM | 1 |
| Ciernik, IF | 1 |
| Abbas, A | 2 |
| Yang, G | 1 |
| Fakih, M | 2 |
| Isla, D | 3 |
| Adansa, JC | 1 |
| Gil-Arnaiz, I | 1 |
| Lambea, J | 1 |
| Lecumberri, MJ | 1 |
| Sun, H | 1 |
| Gong, H | 1 |
| Lavertu, S | 1 |
| Jolicoeur, M | 1 |
| Ciocca, O | 1 |
| Vassallo, C | 1 |
| Brazzelli, V | 1 |
| Fiandrino, G | 1 |
| Rosso, R | 17 |
| Borroni, G | 1 |
| Shoimer, I | 1 |
| Rosen, N | 1 |
| Muhn, C | 1 |
| Khaouam, N | 2 |
| Hurmuzlu, M | 3 |
| Øvrebø, K | 2 |
| Monge, OR | 1 |
| Smaaland, R | 2 |
| Wentzel-Larsen, T | 2 |
| Fenske, NA | 2 |
| Spencer, J | 1 |
| Adam, F | 1 |
| Miura, A | 2 |
| Izumi, Y | 2 |
| Monma, K | 2 |
| Fujiwara, J | 1 |
| Egashira, H | 1 |
| Nemoto, T | 1 |
| Courrech Staal, EF | 1 |
| Aleman, BM | 1 |
| van Velthuysen, ML | 1 |
| Jansen, EP | 1 |
| van Coevorden, F | 1 |
| Wolf, M | 1 |
| Zehentmayr, F | 1 |
| Niyazi, M | 1 |
| Haimerl, W | 1 |
| Hölzel, D | 1 |
| Besch, S | 1 |
| Schröder, W | 2 |
| Mönig, SP | 1 |
| Davies, L | 1 |
| Lewis, WG | 1 |
| Arnold, DT | 1 |
| Escofet, X | 1 |
| Blackshaw, G | 1 |
| Gwynne, S | 1 |
| Evans, M | 2 |
| Appadurai, I | 1 |
| Schwanke, A | 1 |
| Murruzzu, C | 1 |
| Zdrazil, B | 1 |
| Zuhse, R | 1 |
| Natek, M | 1 |
| Höltje, M | 1 |
| Reissig, HU | 1 |
| Höltje, HD | 1 |
| Kirby, JS | 1 |
| Meyners, T | 1 |
| Bohlen, G | 1 |
| Dunst, J | 3 |
| Itashiki, Y | 1 |
| Takenawa, T | 1 |
| Han, A | 1 |
| Penrose, C | 1 |
| Goldsmith, A | 1 |
| Marmur, ES | 1 |
| Shinoto, M | 1 |
| Shioyama, Y | 2 |
| Ohura, H | 1 |
| Higaki, Y | 1 |
| Yamaguchi, T | 2 |
| Ohnishi, K | 1 |
| Atsumi, K | 1 |
| Hirata, H | 1 |
| Ma, G | 1 |
| Kawamura, K | 2 |
| Okamoto, S | 1 |
| Kobayashi, H | 4 |
| Liang, M | 1 |
| Tada, Y | 1 |
| Tatsumi, K | 1 |
| Hiroshima, K | 1 |
| Tagawa, M | 1 |
| Won, YW | 1 |
| Park, YH | 2 |
| Do, IG | 1 |
| Ko, YH | 1 |
| Terushkin, V | 1 |
| Braga, JC | 1 |
| Dusza, SW | 1 |
| Scope, A | 1 |
| Busam, K | 1 |
| Gill, M | 1 |
| Halpern, AC | 1 |
| Lee, S | 4 |
| Cho, EY | 2 |
| Ahn, YC | 1 |
| Kim, K | 4 |
| Ahn, JS | 1 |
| Im, YH | 3 |
| Muren, LP | 1 |
| Bartholomeusz, D | 1 |
| Devitt, PG | 4 |
| Lamb, PJ | 1 |
| Ruszkiewicz, AR | 1 |
| Ketabi-Kiyanvash, N | 1 |
| Efferth, T | 1 |
| Bertholet, V | 1 |
| Savva-Bordalo, J | 1 |
| Ramalho-Carvalho, J | 1 |
| Pinheiro, M | 1 |
| Costa, VL | 1 |
| Rodrigues, A | 1 |
| Dias, PC | 1 |
| Veiga, I | 1 |
| Machado, M | 1 |
| Teixeira, MR | 1 |
| Henrique, R | 1 |
| Jerónimo, C | 1 |
| Aarstad, HJ | 1 |
| Aarstad, AK | 1 |
| Hjermstad, MJ | 1 |
| Fowler, J | 1 |
| Rosenfelder, N | 1 |
| Kao, J | 2 |
| Policarpio, EL | 1 |
| Burri, RJ | 1 |
| Rivera, M | 1 |
| Gurudutt, V | 1 |
| Som, PM | 1 |
| Teng, M | 1 |
| Packer, SH | 1 |
| van Herpen, CM | 1 |
| Mauer, ME | 1 |
| Jelic, S | 4 |
| Coens, C | 1 |
| Betka, J | 2 |
| Stewart, JS | 2 |
| Preiss, JH | 2 |
| Bottomley, A | 1 |
| Boscolo-Rizzo, P | 4 |
| Baggio, V | 3 |
| Marchiori, C | 3 |
| Stellin, M | 2 |
| Fuson, R | 1 |
| Lamon, S | 1 |
| Da Mosto, MC | 4 |
| Su, L | 1 |
| Xiao, M | 1 |
| Yu, L | 3 |
| Takemasa, I | 1 |
| Komori, T | 4 |
| Matsuura, N | 3 |
| Matsubara, K | 1 |
| Bran, G | 1 |
| Anders, C | 1 |
| Sadick, H | 1 |
| Sanada, Y | 2 |
| Osada, S | 1 |
| Balamucki, CJ | 1 |
| Rout, WR | 1 |
| Newlin, HE | 2 |
| Kirwan, JM | 1 |
| Park, JW | 1 |
| Yoon, SM | 2 |
| Lee, YS | 2 |
| Hauerstock, D | 1 |
| Ennis, RD | 1 |
| Grossbard, M | 1 |
| Evans, A | 1 |
| Takiuchi, H | 2 |
| Komatsu, Y | 1 |
| James, R | 1 |
| Northover, JM | 1 |
| Jitlal, M | 1 |
| Mak, RH | 1 |
| Halasz, LM | 1 |
| Tanaka, CK | 1 |
| Ancukiewicz, M | 2 |
| Schultz, DJ | 1 |
| Russell, AH | 4 |
| Viswanathan, AN | 1 |
| Jegannathen, A | 1 |
| Birzgalis, A | 1 |
| Homer, J | 1 |
| Ryder, WD | 1 |
| Slevin, N | 1 |
| Mumme, AM | 1 |
| Reitmeier, F | 1 |
| Shah, AY | 1 |
| Doherty, SD | 1 |
| Rosen, T | 2 |
| Tian, ZZ | 1 |
| Liu, ML | 1 |
| Zhu, XH | 1 |
| Zhao, R | 1 |
| Yue, YJ | 1 |
| Chen, XH | 1 |
| Yamauchi, M | 2 |
| D'Amanzo, P | 2 |
| Störkel, S | 1 |
| Senger, S | 1 |
| Stroh, C | 1 |
| Tagawa, T | 1 |
| Honda, S | 1 |
| Hidaka, S | 1 |
| Pantling, AZ | 1 |
| Gossage, JA | 3 |
| Mamidanna, R | 1 |
| Newman, G | 1 |
| Robinson, A | 1 |
| Manifold, DK | 1 |
| Hale, PC | 1 |
| Takemura, M | 4 |
| Morimura, K | 1 |
| Tu, CH | 1 |
| Taku, K | 1 |
| Maruyama, T | 2 |
| Tsai, HK | 1 |
| Coen, JJ | 1 |
| Hartshorn, K | 1 |
| Kwak, EL | 1 |
| Willins, JD | 1 |
| Habl, G | 1 |
| Jensen, AD | 3 |
| Potthoff, K | 2 |
| Uhl, M | 1 |
| Hof, H | 1 |
| Hajda, J | 1 |
| Krempien, R | 1 |
| Münter, MW | 3 |
| Lu, TY | 1 |
| Li, WB | 1 |
| Wang, LX | 1 |
| Gao, DL | 1 |
| Wang, RL | 1 |
| Lu, SX | 1 |
| Fan, QX | 2 |
| Alieva, SB | 1 |
| Romanov, IS | 1 |
| Zaderenko, IA | 1 |
| Tiuliandin, SA | 2 |
| Shiozawa, M | 1 |
| Yoshii, T | 2 |
| Nakayama, N | 1 |
| Motohashi, O | 1 |
| Takagi, S | 1 |
| Akaike, M | 1 |
| Zhang, TR | 1 |
| Gu, XW | 1 |
| Pan, YK | 1 |
| Lim, YC | 1 |
| Oh, SY | 1 |
| Cha, YY | 1 |
| Kim, SH | 3 |
| Jin, X | 1 |
| Kim, H | 2 |
| Balukrishna, S | 1 |
| Jennifer, P | 1 |
| Viswanathan, PN | 1 |
| Nagai, M | 1 |
| Masuzawa, T | 1 |
| Hirst, J | 1 |
| Smithers, BM | 3 |
| Gotley, DC | 2 |
| Thomas, J | 2 |
| Barbour, A | 1 |
| Li, WY | 1 |
| Hsieh, SL | 1 |
| Okumura, Y | 2 |
| Tomemori, T | 1 |
| Mitsuhashi, T | 1 |
| Sobajima, J | 1 |
| Haga, N | 1 |
| Kumamoto, K | 1 |
| Ishibashi, K | 1 |
| Matsuoka, H | 3 |
| Noro, T | 1 |
| Honda, K | 1 |
| Endo, T | 4 |
| Ozeki, S | 1 |
| Fukuda, M | 2 |
| Sueda, K | 1 |
| Ikenaga, M | 3 |
| Mishima, H | 3 |
| Tsujie, M | 1 |
| Omiya, H | 1 |
| Miyamoto, A | 1 |
| Takami, K | 1 |
| Nakamori, S | 3 |
| Tahara, S | 1 |
| Lorch, JH | 1 |
| Cullen, K | 2 |
| Sarlis, N | 1 |
| Tishler, R | 4 |
| Fasciano, J | 1 |
| Sammartino, DE | 1 |
| Jansen, JF | 1 |
| Schöder, H | 1 |
| Lee, NY | 3 |
| Stambuk, HE | 1 |
| Patel, SG | 1 |
| Shah, JP | 1 |
| Koutcher, JA | 1 |
| Shukla-Dave, A | 1 |
| Miah, AB | 1 |
| Guerrero-Urbano, MT | 1 |
| Clark, C | 1 |
| Bidmead, AM | 1 |
| St Rose, S | 1 |
| A'hern, R | 1 |
| Tanay, M | 1 |
| Hickey, J | 1 |
| Nicol, R | 1 |
| Newbold, KL | 1 |
| Moureau-Zabotto, L | 2 |
| Viret, F | 1 |
| Giovaninni, M | 1 |
| Lelong, B | 1 |
| Bories, E | 1 |
| Delpero, JR | 2 |
| Pesenti, C | 1 |
| Caillol, F | 1 |
| de Chaisemartin, C | 1 |
| Monges, G | 1 |
| Sarran, A | 1 |
| Resbeut, M | 2 |
| Smith, C | 1 |
| Kist, J | 1 |
| Best, SR | 2 |
| Walker, M | 1 |
| Trachta, J | 1 |
| Ulmer, K | 1 |
| Murakami, P | 1 |
| Thompson, R | 1 |
| Messing, BP | 1 |
| Muzzi, E | 1 |
| Trabalzini, F | 1 |
| Nguyen, DH | 1 |
| Hu, B | 1 |
| Ji, C | 2 |
| Hara, W | 1 |
| Hsu, A | 1 |
| Kunz, PA | 1 |
| Ford, J | 1 |
| Fisher, GA | 2 |
| Welton, ML | 1 |
| Shelton, A | 1 |
| Kapp, DS | 2 |
| Zampino, MG | 1 |
| Magni, E | 1 |
| Leonardi, MC | 1 |
| Santoro, L | 1 |
| Petazzi, E | 1 |
| Fodor, C | 1 |
| Petralia, G | 1 |
| Trovato, C | 1 |
| Luo, Z | 1 |
| Chang, J | 2 |
| Yu, H | 2 |
| Lu, F | 1 |
| Yang, SY | 2 |
| Yang, PW | 1 |
| Shun, CT | 1 |
| Wu, MT | 1 |
| Wang, YH | 1 |
| Chuang, TH | 1 |
| Chen, JS | 4 |
| Hsu, HH | 1 |
| Chilimoniuk, M | 1 |
| Olszewska, E | 1 |
| Maksimowicz, T | 1 |
| Sher, DJ | 2 |
| Holupka, EJ | 1 |
| Devlin, PM | 2 |
| Charron, MP | 1 |
| Delouya, G | 1 |
| O'Donovan, TR | 1 |
| O'Sullivan, GC | 1 |
| McKenna, SL | 1 |
| Williams, R | 2 |
| Kunnavakkam, R | 1 |
| Seiwert, T | 1 |
| Park, EK | 1 |
| Tabor, MH | 1 |
| Clay, MR | 1 |
| Owen, JH | 1 |
| Shitara, K | 1 |
| Hatooka, S | 1 |
| Mizota, A | 1 |
| Kondoh, C | 1 |
| Kusumoto, M | 1 |
| Toyoda, S | 1 |
| Ishikawa, N | 1 |
| Matsumoto, T | 1 |
| Kusumoto, C | 1 |
| Doi, F | 1 |
| Osaka, Y | 1 |
| Hoshino, S | 1 |
| Takagi, Y | 1 |
| Aoki, T | 4 |
| Mücke, T | 1 |
| Konen, M | 1 |
| Wagenpfeil, S | 1 |
| Kesting, MR | 1 |
| Wolff, KD | 1 |
| Hölzle, F | 1 |
| McCaffrey, R | 1 |
| Bahtiyar, M | 1 |
| Kohorn, EI | 1 |
| Chambers, JT | 1 |
| Schwartz, PE | 2 |
| Chambers, SK | 1 |
| Ikeda, N | 1 |
| Yoneyama, Y | 1 |
| Miyazawa, Y | 2 |
| Shien, K | 1 |
| Okazaki, M | 1 |
| Suehisa, H | 1 |
| Sawada, S | 1 |
| Chen, XR | 1 |
| Lu, R | 1 |
| Dan, HX | 1 |
| Li, XY | 1 |
| Yoon, MS | 2 |
| Nam, TK | 2 |
| Song, JY | 2 |
| Ahn, SJ | 2 |
| Jeong, JU | 1 |
| Nah, BS | 2 |
| Ben-David, K | 1 |
| Rossidis, G | 1 |
| Grobmyer, SR | 1 |
| Cendan, JC | 1 |
| Sarosi, GA | 1 |
| Hochwald, SN | 2 |
| Komaki, RU | 1 |
| Wu, TT | 5 |
| Konski, AA | 1 |
| Wood, J | 1 |
| Pring, M | 1 |
| Eveson, JW | 1 |
| Price, N | 1 |
| Hague, A | 1 |
| Devisetty, K | 2 |
| Wong, SJ | 2 |
| Atean, I | 1 |
| Zheng, M | 1 |
| Liu, JH | 2 |
| Xiong, Y | 1 |
| Li, JD | 2 |
| He, L | 1 |
| Ren, YF | 1 |
| Wang, HY | 3 |
| Brightman, L | 1 |
| Warycha, M | 1 |
| Anolik, R | 1 |
| Geronemus, R | 1 |
| Trigo, JM | 1 |
| Kerber, A | 1 |
| Picard, M | 1 |
| Lone, GN | 1 |
| Sheikh, AA | 1 |
| Sheikh, ZA | 1 |
| Baba, KM | 1 |
| Qurieshi, MA | 1 |
| Mufti, GN | 1 |
| Naikoo, ZA | 1 |
| Syed, AA | 1 |
| Ahangar, AG | 1 |
| Lone, RA | 1 |
| Sharma, ML | 1 |
| Singh, S | 1 |
| Bhat, MA | 1 |
| Dar, AM | 1 |
| Rugge, M | 1 |
| Fukui, T | 1 |
| Takeda, H | 4 |
| Kawada, S | 1 |
| Shigeishi, H | 1 |
| Higashikawa, K | 1 |
| Hatano, H | 1 |
| Okui, G | 1 |
| Tanaka, F | 1 |
| Tran, TT | 1 |
| Rizqiawan, A | 1 |
| Ono, S | 1 |
| Tobiume, K | 1 |
| Kamata, N | 1 |
| Pellen, MG | 1 |
| Sabri, S | 1 |
| Razack, A | 1 |
| Gilani, SQ | 1 |
| Jain, PK | 1 |
| Koike, R | 2 |
| Tamamoto, T | 1 |
| Farkas, R | 2 |
| Pozsgai, E | 1 |
| Bellyei, S | 2 |
| Cseke, L | 2 |
| Szigeti, A | 1 |
| Vereczkei, A | 1 |
| Marton, S | 2 |
| Mangel, L | 1 |
| Horvath, OP | 2 |
| Papp, A | 2 |
| Hatata, T | 1 |
| Higaki, K | 1 |
| Nanba, E | 1 |
| Tatebe, S | 1 |
| Ikeguchi, M | 1 |
| Lu, L | 1 |
| Zhu, Q | 1 |
| Hao, Y | 1 |
| Mo, Y | 1 |
| Cui, N | 1 |
| Rong, T | 1 |
| Öksüz, DÇ | 2 |
| Dyker, K | 1 |
| Pera, M | 2 |
| Gallego, R | 2 |
| Montagut, C | 1 |
| Martín-Richard, M | 2 |
| Iglesias, M | 1 |
| Conill, C | 2 |
| Reig, A | 1 |
| Balagué, C | 1 |
| Pétriz, L | 1 |
| Momblan, D | 1 |
| Bellmunt, J | 2 |
| Maurel, J | 2 |
| Tsai, YC | 2 |
| Chia-Hsien Cheng, J | 1 |
| Ben Salah, H | 2 |
| Bahri, M | 1 |
| Turki, H | 1 |
| Abdelmoula, M | 1 |
| Frikha, M | 2 |
| Daoud, J | 2 |
| Kawaguchi, Y | 2 |
| Miyagi, K | 1 |
| Suzuki, O | 1 |
| Reisinger, DM | 1 |
| Cognetta, AB | 1 |
| Pynes, LT | 1 |
| Paredes, AA | 1 |
| Sweeney, TJ | 1 |
| Dolson, DJ | 1 |
| Woolery-Lloyd, H | 1 |
| Elsaie, ML | 1 |
| Avashia, N | 1 |
| Matsumoto, M | 7 |
| Uchicado, Y | 1 |
| Setoyama, T | 3 |
| Sakurai, T | 3 |
| Shimada, M | 2 |
| Sakamoto, F | 1 |
| Yoshinaka, H | 1 |
| Ueno, S | 1 |
| Ma, JB | 1 |
| Song, YP | 1 |
| Zhou, W | 1 |
| Cheng, EC | 1 |
| Zhang, XQ | 2 |
| Thang, NN | 1 |
| Cochet, S | 1 |
| George, AC | 1 |
| Ikeda, E | 1 |
| Yanamoto, S | 2 |
| Kawasaki, G | 2 |
| Yoshitomi, I | 2 |
| Yonezawa, H | 1 |
| Rokutanda, S | 1 |
| Naruse, T | 1 |
| Umeda, M | 3 |
| O'Reilly Zwald, F | 1 |
| Brown, M | 1 |
| Kawaguchi, K | 1 |
| Yamada, H | 1 |
| Horie, A | 1 |
| Iketani, S | 1 |
| Kanai, I | 1 |
| Nakatani, Y | 1 |
| Hamada, Y | 1 |
| Chen, SZ | 1 |
| Chen, XM | 1 |
| Wang, XC | 2 |
| Zhang, F | 1 |
| Mo, KL | 1 |
| Peng, YF | 1 |
| Shiozaki, H | 7 |
| Cho, JH | 2 |
| Lee, MH | 1 |
| Cho, YJ | 1 |
| Park, BS | 1 |
| Kim, GC | 1 |
| Saigusa, S | 1 |
| Ishino, Y | 1 |
| Okugawa, Y | 1 |
| Inoue, Y | 3 |
| Tsuchikawa, T | 1 |
| Yamamura, Y | 1 |
| Shichinohe, T | 1 |
| Hirano, S | 1 |
| Kondo, S | 1 |
| Gujral, DM | 1 |
| Hawkins, MA | 2 |
| Leonulli, BG | 1 |
| Ashley, S | 2 |
| Lirng, JF | 1 |
| Chen, EL | 1 |
| Weng, XR | 1 |
| Shimizu, H | 1 |
| Aoyama, N | 5 |
| Ikeda, K | 3 |
| Yun, T | 1 |
| Han, JY | 3 |
| Choi, HL | 1 |
| Kim, HY | 3 |
| Nam, BH | 1 |
| Kim, HT | 1 |
| Ceschia, A | 1 |
| Weichert, W | 1 |
| Bergmann, ZP | 1 |
| Freier, K | 1 |
| Furukita, Y | 2 |
| Kajiura, K | 1 |
| Minato, T | 2 |
| Huang, CE | 1 |
| Lu, CH | 1 |
| Chen, PT | 1 |
| Chan, CH | 1 |
| Chen, WC | 1 |
| Wang, WH | 1 |
| Wu, JY | 1 |
| Kuan, FC | 1 |
| Lee, KD | 1 |
| Fukuma, D | 1 |
| Han, SY | 1 |
| Youker, S | 1 |
| Koo, DH | 1 |
| Yoon, DH | 1 |
| Kokubu, A | 1 |
| Saito, S | 4 |
| Narisawa-Saito, M | 1 |
| Sasaki, H | 2 |
| Aoyagi, K | 2 |
| Yoshimatsu, Y | 1 |
| Kiyono, T | 1 |
| Hattersley, SM | 1 |
| Sylvester, DC | 1 |
| Dyer, CE | 1 |
| Stafford, ND | 1 |
| Haswell, SJ | 1 |
| Greenman, J | 1 |
| Su, NW | 1 |
| Leu, YS | 1 |
| Lee, JC | 2 |
| Chen, HW | 1 |
| Liu, CJ | 1 |
| Chang, YF | 1 |
| Vazquez, M | 1 |
| Lynch, CA | 1 |
| Mackay, J | 1 |
| Tran, P | 1 |
| Michal, SA | 1 |
| Wood, BG | 8 |
| Scharpf, J | 2 |
| Yoshida, H | 5 |
| Okamoto, N | 1 |
| Shimoda, T | 1 |
| Masutomi, K | 1 |
| Dalmases, M | 1 |
| Lucena, CM | 1 |
| Cano-Jiménez, E | 1 |
| Xaubet, A | 1 |
| Agustí, C | 1 |
| Paterson, C | 1 |
| Robertson, AG | 2 |
| Grose, D | 1 |
| Correa, PD | 1 |
| Rizwanullah, M | 1 |
| Zaoui, K | 1 |
| Bossow, S | 1 |
| Grossardt, C | 1 |
| Leber, MF | 1 |
| Springfeld, C | 1 |
| Plinkert, PK | 1 |
| Kalle, Cv | 1 |
| Ungerechts, G | 1 |
| Kawashima, M | 2 |
| Arahira, S | 2 |
| Xiang, Q | 1 |
| Zhou, D | 1 |
| Jin, Y | 1 |
| Liberato, NL | 1 |
| Rognoni, C | 1 |
| Rubrichi, S | 1 |
| Quaglini, S | 1 |
| Marchetti, M | 1 |
| Gorlia, T | 2 |
| Schroeder, P | 1 |
| Lindemann, C | 1 |
| Dettmar, K | 1 |
| Brieger, J | 1 |
| Gosepath, J | 1 |
| Pogorzelski, B | 1 |
| Seimetz, D | 1 |
| Atz, J | 1 |
| Semrau, R | 1 |
| Herzog, SL | 1 |
| Müller, RP | 2 |
| Soltys, SG | 1 |
| Choi, CY | 1 |
| Fee, WE | 3 |
| Pinto, HA | 3 |
| Le, QT | 4 |
| Xu, HD | 1 |
| Pan, SD | 1 |
| Yue, JH | 1 |
| Liu, JR | 1 |
| Sharma, DN | 2 |
| Hwang, JH | 2 |
| Lim, MC | 1 |
| Seo, SS | 1 |
| Kang, S | 1 |
| Park, SY | 1 |
| Kim, JY | 1 |
| Lorenz, RR | 2 |
| Fan, T | 2 |
| De Bari, B | 1 |
| Lestrade, L | 1 |
| Chekrine, T | 1 |
| Shakir Shakir, I | 1 |
| Ardiet, JM | 3 |
| Chapet, O | 1 |
| Nehme, E | 1 |
| Imada, S | 1 |
| Shingai, T | 3 |
| Russi, E | 2 |
| Lastrucci, L | 1 |
| Iotti, C | 1 |
| Reali, A | 1 |
| Musu, A | 1 |
| Balcet, V | 1 |
| Piva, C | 1 |
| Bustreo, S | 1 |
| Chitose, S | 1 |
| Chijiwa, H | 1 |
| Maeda, A | 1 |
| Kiyokawa, K | 1 |
| Fujita, H | 3 |
| Jadotte, YT | 1 |
| Schwartz, RA | 1 |
| Price, KA | 1 |
| Gong, L | 1 |
| Lou, JY | 1 |
| Zhang, JW | 1 |
| Peng, ZL | 1 |
| Münscher, A | 1 |
| Berger, B | 1 |
| Stahlberg, K | 1 |
| Lemminger, A | 1 |
| Bleif, M | 1 |
| Bamberg, M | 2 |
| Fan, KY | 1 |
| Gogineni, H | 1 |
| Zaboli, D | 1 |
| Lake, S | 1 |
| Zahurak, ML | 1 |
| Tang, M | 1 |
| Messing, B | 1 |
| Sanguanrungsirikul, S | 1 |
| Manusirivithaya, S | 1 |
| Tian, LL | 1 |
| Zheng, H | 1 |
| Meng, AM | 1 |
| Wang, PL | 1 |
| Cheng, YB | 1 |
| Kuerban, G | 1 |
| Vormittag, L | 2 |
| Lemaire, C | 1 |
| Radonjic, D | 1 |
| Uesato, M | 1 |
| Shiratori, T | 3 |
| Myklebust, MP | 1 |
| Fluge, Ø | 1 |
| Immervoll, H | 1 |
| Skarstein, A | 1 |
| Balteskard, L | 2 |
| Bruland, O | 1 |
| Dahl, O | 2 |
| Sheng, W | 1 |
| Feng, XZ | 1 |
| Han, JQ | 1 |
| Nabeki, B | 1 |
| Nakajo, M | 3 |
| Tabachnyk, M | 1 |
| Distel, LV | 1 |
| Büttner, M | 1 |
| Grabenbauer, GG | 8 |
| Nkenke, E | 1 |
| Lubgan, D | 1 |
| Vivenza, D | 1 |
| Gasco, M | 2 |
| Lattanzio, L | 1 |
| Colantonio, I | 3 |
| Natoli, G | 1 |
| Comino, A | 1 |
| Crook, T | 1 |
| Lo Nigro, C | 1 |
| Peng, B | 1 |
| Yi, S | 1 |
| Gu, Y | 2 |
| Zheng, G | 1 |
| He, Z | 1 |
| Luxton, G | 1 |
| Mok, EC | 1 |
| Thotakura, V | 1 |
| Goguen, LA | 3 |
| Annino, DJ | 1 |
| Bentzen, AG | 1 |
| Wanderås, EH | 1 |
| Frykholm, G | 1 |
| Tveit, KM | 2 |
| Wilsgaard, T | 1 |
| Kurzweg, T | 1 |
| Baudin, F | 1 |
| Guillot, P | 1 |
| Bedock, B | 1 |
| Blanc, PL | 1 |
| Tien, WY | 1 |
| Liang, JL | 1 |
| Nikoghosyan, AV | 1 |
| Lossner, K | 1 |
| Hasegawa, K | 3 |
| Kato, R | 2 |
| Sekiya, T | 1 |
| Udagawa, Y | 1 |
| Desai, B | 1 |
| Gadhia, P | 1 |
| Zhang, HQ | 1 |
| Wang, RB | 1 |
| Yan, HJ | 1 |
| Zhu, KL | 1 |
| Jiang, SM | 1 |
| Hu, XG | 1 |
| Hirakata, A | 1 |
| Takao, Y | 1 |
| Umakoshi, M | 1 |
| Hayakawa, T | 1 |
| Hosone, M | 1 |
| Uchida, E | 1 |
| Loo, SW | 2 |
| Tasigiannopoulos, Z | 1 |
| Martin, C | 3 |
| Roques, TW | 2 |
| Chang, KJ | 1 |
| Reid, T | 1 |
| Senzer, N | 1 |
| Swisher, S | 3 |
| Pinto, H | 1 |
| Hanna, N | 2 |
| Chak, A | 1 |
| Soetikno, R | 1 |
| Tian, W | 1 |
| Chou, TH | 1 |
| Ding, HY | 1 |
| Chen, PR | 1 |
| Chiang, FY | 1 |
| Kuo, PL | 1 |
| Liang, CH | 1 |
| Peer, CJ | 1 |
| McManus, TJ | 1 |
| Hurwitz, HI | 2 |
| Petros, WP | 1 |
| Hristozova, T | 1 |
| Keilhoiz, U | 1 |
| Pelosi, E | 1 |
| Bellò, M | 1 |
| Milanesi, E | 1 |
| Baccega, M | 1 |
| Filippini, C | 1 |
| Lesca, A | 1 |
| Munoz, FH | 1 |
| Fora, G | 1 |
| Skanjeti, A | 1 |
| Cravero, F | 1 |
| Kim, TE | 1 |
| Park, BJ | 1 |
| Kwack, HS | 1 |
| Kwon, JY | 1 |
| Yoon, SC | 1 |
| Zhou, K | 1 |
| Chen, XF | 1 |
| Fucarino, A | 1 |
| Marino Gammazza, A | 1 |
| Pitruzzella, A | 1 |
| Marciano, V | 1 |
| Compilato, D | 1 |
| Holgate, ST | 1 |
| Davies, DE | 1 |
| Farina, F | 1 |
| Zummo, G | 1 |
| Bucchieri, F | 1 |
| Robertson, B | 1 |
| Shepherd, L | 1 |
| Abratt, RP | 1 |
| Hunter, A | 1 |
| Goldberg, P | 1 |
| Ohkawa, S | 1 |
| Tamai, S | 2 |
| Kameda, Y | 2 |
| Oellers, P | 1 |
| Kao, AA | 1 |
| Abdelaziz, A | 1 |
| Feuer, W | 1 |
| Dubovy, SR | 1 |
| Tomita, M | 1 |
| Matsuyama, H | 1 |
| Yamazaki, K | 2 |
| Yeh, J | 1 |
| Hastings, J | 1 |
| Rao, A | 1 |
| Abbas, MA | 1 |
| Peng, F | 1 |
| Zhu, J | 1 |
| Gong, Y | 1 |
| Yoda, Y | 2 |
| Ikematsu, H | 2 |
| Iitaka, D | 1 |
| Kokuba, Y | 1 |
| Sonoyama, T | 2 |
| Huang, XL | 1 |
| Neskey, DM | 1 |
| Sullivan, TJ | 1 |
| Lupato, V | 1 |
| Romeo, S | 1 |
| Spinato, G | 1 |
| Addonisio, G | 1 |
| Goto, M | 6 |
| Schneider, BJ | 1 |
| Hayman, JA | 1 |
| Chang, AC | 1 |
| Orringer, MB | 4 |
| Pickens, A | 1 |
| Pan, CC | 1 |
| Merajver, SD | 1 |
| Masterson, L | 1 |
| Tanweer, F | 1 |
| Hirasawa, N | 1 |
| Naganawa, S | 1 |
| Ishihara, S | 1 |
| Koyama, K | 2 |
| Murao, T | 1 |
| Asano, A | 1 |
| Nomoto, Y | 1 |
| Horikawa, Y | 1 |
| Sasaoka, M | 2 |
| Obata, Y | 1 |
| Plowman, PN | 1 |
| Hurman, DC | 1 |
| Davidson, N | 1 |
| Grieve, R | 1 |
| Levine, E | 2 |
| Yetmen, O | 1 |
| Margolin, DA | 1 |
| Mukherjee, KK | 1 |
| Bose, A | 1 |
| Ghosh, D | 1 |
| Sarkar, K | 1 |
| Goswami, S | 1 |
| Pal, S | 1 |
| Biswas, J | 1 |
| Baral, R | 1 |
| Wang, CC | 1 |
| Lai, CH | 1 |
| Huang, YT | 1 |
| Chao, A | 1 |
| Chou, HH | 1 |
| Hong, JH | 1 |
| Viros, A | 1 |
| Hayward, R | 1 |
| Martin, M | 4 |
| Yashar, S | 1 |
| Sanchez-Laorden, B | 1 |
| Zambon, A | 1 |
| Niculescu-Duvaz, D | 1 |
| Springer, C | 1 |
| Lo, RS | 1 |
| Marais, R | 1 |
| Abgral, R | 1 |
| Le Roux, PY | 1 |
| Keromnes, N | 1 |
| Rousset, J | 1 |
| Valette, G | 1 |
| Gouders, D | 1 |
| Leleu, C | 1 |
| Mollon, D | 1 |
| Nowak, E | 1 |
| Querellou, S | 1 |
| Salaün, PY | 1 |
| Zhong, Z | 1 |
| Gu, X | 1 |
| Qing, Y | 1 |
| Dai, N | 1 |
| Wilson, P | 1 |
| Martin, WM | 1 |
| Shi, X | 1 |
| Yao, W | 1 |
| Jiang, GL | 1 |
| Dalirsani, Z | 1 |
| Farajnia, S | 1 |
| Javadzadeh, Y | 1 |
| Mehdipour, M | 1 |
| Koozegari, S | 1 |
| Takeda, K | 2 |
| Narazaki, K | 1 |
| Umezawa, R | 1 |
| Sugawara, T | 1 |
| Zhao, XY | 1 |
| Zhu, YX | 1 |
| Zhu, GP | 1 |
| Hu, CS | 1 |
| Ji, QH | 1 |
| Izumisawa, M | 1 |
| Akahane, A | 1 |
| Kikuchi, K | 4 |
| Shoji, S | 1 |
| Kogi, S | 1 |
| Mizuki, H | 1 |
| Sugiyama, Y | 1 |
| Perisanidis, C | 1 |
| Mitchell, D | 1 |
| Czembirek, C | 1 |
| Schopper, C | 1 |
| Ambrosy, AP | 1 |
| Kunz, PL | 1 |
| Witteles, RM | 1 |
| Di Lorenzo, G | 1 |
| Buonerba, C | 1 |
| Federico, P | 1 |
| Perdonà, S | 1 |
| Aieta, M | 1 |
| Rescigno, P | 1 |
| D'Aniello, C | 1 |
| Puglia, L | 1 |
| Petremolo, A | 1 |
| Ferro, M | 1 |
| Marinelli, A | 1 |
| Palmieri, G | 1 |
| Sonpavde, G | 1 |
| Mirone, V | 1 |
| De Placido, S | 1 |
| Firnhaber, JM | 1 |
| Stoff, BK | 1 |
| Seidler, A | 1 |
| Kinlaw, K | 1 |
| Keil, F | 1 |
| Berghold, A | 1 |
| Reinisch, S | 1 |
| Kapp, KS | 3 |
| De Vries, A | 2 |
| Greil, R | 1 |
| Bachtiary, B | 1 |
| Tinchon, C | 1 |
| Anderhuber, W | 1 |
| Burian, M | 1 |
| Kasparek, AK | 1 |
| Elsäßer, W | 1 |
| Kainz, H | 1 |
| Riedl, R | 1 |
| Kopp, M | 1 |
| Lalami, Y | 2 |
| Liberatoscioli, C | 1 |
| El-Hariry, I | 1 |
| Andry, G | 2 |
| Lewis, J | 2 |
| Wildes, T | 1 |
| Siegel, BA | 1 |
| Dehdashti, F | 1 |
| Gay, H | 1 |
| Mehan, P | 1 |
| Asakawa, T | 2 |
| Ikeda, M | 6 |
| Shah, SM | 1 |
| Drage, MG | 1 |
| Lichtman, AH | 1 |
| Aguilar-Ponce, JL | 1 |
| Granados-García, M | 1 |
| Cruz López, JC | 1 |
| Maldonado-Magos, F | 1 |
| Alvarez-Avitia, MA | 1 |
| Arrieta, O | 1 |
| González-Ramírez, I | 1 |
| Lara-Cruz, G | 1 |
| Martinez-Juárez, I | 1 |
| Medina-Santillan, R | 1 |
| Castillo-Hernández, C | 1 |
| De la Garza-Salazar, J | 1 |
| Yoshikawa, R | 2 |
| Tsujimura, T | 1 |
| Tao, L | 1 |
| Kamikonya, N | 2 |
| Nagashima, T | 2 |
| Niiro, M | 1 |
| Hirayama, K | 1 |
| Date, S | 1 |
| Okihara, K | 1 |
| Mukaisho, K | 1 |
| Pijaume, CP | 1 |
| Saigí, E | 1 |
| Oertel, K | 1 |
| Spiegel, K | 1 |
| Wendt, TG | 9 |
| Varga, G | 1 |
| Pavlovics, G | 1 |
| Potó, L | 1 |
| Darga, T | 1 |
| Haraf, D | 2 |
| Stenson, K | 7 |
| Villaflor, V | 1 |
| Lingen, MW | 1 |
| Weichselbaum, RR | 19 |
| Susaki, Y | 1 |
| Saito, T | 2 |
| Clavier, JB | 1 |
| Antoni, D | 1 |
| Atlani, D | 1 |
| Schumacher, C | 1 |
| Dufour, P | 1 |
| Kurtz, JE | 1 |
| Noel, G | 1 |
| Ito, M | 1 |
| Yajima, Y | 1 |
| Oono, Y | 1 |
| Fan, XD | 1 |
| Wang, BS | 1 |
| Kies, MS | 14 |
| Mizuno, S | 2 |
| Ren, T | 1 |
| Wan, XR | 1 |
| Feng, FZ | 1 |
| Choi, IJ | 1 |
| Lee, CH | 1 |
| Goodyear, MD | 2 |
| Willins, J | 1 |
| Esthappan, J | 1 |
| Rotman, M | 6 |
| Parikh, PJ | 1 |
| Safran, H | 3 |
| Manabe, Y | 1 |
| Bi, LW | 1 |
| Zhang, LZ | 1 |
| Zhao, HF | 1 |
| Weber, RS | 4 |
| Maor, MH | 1 |
| Goepfert, H | 9 |
| Pajak, TF | 8 |
| Morrison, W | 1 |
| Glisson, B | 2 |
| Trotti, A | 1 |
| Ridge, JA | 4 |
| Wagner, H | 2 |
| Ensley, JF | 8 |
| Cooper, JS | 2 |
| Dewas, CV | 1 |
| Dalban, C | 1 |
| Petitfils, A | 1 |
| Peignaux, K | 2 |
| Truc, G | 1 |
| Martin, E | 1 |
| Khoury, C | 1 |
| Dewas, S | 1 |
| Kligerman, S | 1 |
| Lu, M | 1 |
| Kim, G | 1 |
| Feigenberg, S | 1 |
| D'Souza, WD | 1 |
| Fathi, R | 1 |
| Kamalpour, L | 1 |
| Gammon, B | 1 |
| Tung, R | 1 |
| Clark, JI | 2 |
| Greene, JB | 1 |
| Lau Clark, A | 1 |
| Dalal, JS | 1 |
| Hofmeister, CC | 1 |
| Nishigaki, T | 1 |
| Okada, K | 4 |
| Ebisui, C | 1 |
| Wada, Y | 2 |
| Makino, S | 4 |
| Owada, Y | 1 |
| Murakami, M | 5 |
| Yanagisawa, T | 2 |
| Okamura, S | 4 |
| Murata, K | 2 |
| Yokouchi, H | 2 |
| Kinuta, M | 3 |
| Duchemann, B | 1 |
| Duchemain, B | 1 |
| Wong, S | 1 |
| Baruch-Hennequin, V | 1 |
| Rivera, S | 1 |
| Hennequin, C | 3 |
| Denis, F | 3 |
| Girault, S | 1 |
| Poirier, AL | 1 |
| Hamy, A | 1 |
| Mesgouez-Nebout, N | 1 |
| Beriwal, S | 2 |
| Shukla, G | 1 |
| Shinde, A | 1 |
| Heron, DE | 2 |
| Kelley, JL | 1 |
| Edwards, RP | 2 |
| Sukumvanich, P | 1 |
| Richards, S | 1 |
| Olawaiye, AB | 1 |
| Krivak, TC | 1 |
| Smit, JK | 1 |
| Muijs, CT | 1 |
| Burgerhof, JG | 1 |
| Paardekooper, G | 1 |
| Timmer, PR | 1 |
| Muller, K | 1 |
| Woutersen, D | 1 |
| Mul, VE | 1 |
| Beukema, JC | 1 |
| Hospers, GA | 1 |
| van Dijk, BA | 1 |
| Plukker, JT | 1 |
| Pasini, F | 4 |
| Zhao, E | 1 |
| Huang, DZ | 1 |
| Xiong, JP | 1 |
| Xu, N | 1 |
| Yan, Z | 1 |
| Zhuang, ZX | 1 |
| Yu, Z | 1 |
| Wan, HP | 1 |
| Deng, T | 1 |
| Zheng, RS | 1 |
| Guo, ZQ | 1 |
| Hu, CH | 1 |
| Yu, ZH | 2 |
| Yao, Y | 1 |
| Meng, JC | 1 |
| Ba, Y | 1 |
| Wu, S | 1 |
| Chen, MY | 1 |
| Luo, JC | 1 |
| Parameswaran, R | 1 |
| Titcomb, DR | 1 |
| Blencowe, NS | 1 |
| Berrisford, RG | 1 |
| Wajed, SA | 1 |
| Gu, M | 1 |
| Li, SY | 1 |
| Cheng, HY | 1 |
| Peerawong, T | 1 |
| Phungrassami, T | 1 |
| Pruegsanusak, K | 1 |
| Sangthong, R | 1 |
| Qian, D | 1 |
| Cai, MY | 1 |
| Mai, SJ | 1 |
| Liao, YJ | 1 |
| Lin, MC | 1 |
| Bian, XW | 1 |
| Huang, JJ | 2 |
| Kung, HF | 1 |
| Corry, J | 5 |
| Peters, L | 2 |
| Kleid, S | 1 |
| Rischin, D | 5 |
| Bourmèche, M | 1 |
| Kallel, M | 1 |
| Beyrouti, MI | 1 |
| Makni, S | 1 |
| Boudawara, T | 1 |
| Monnier, L | 1 |
| Durdux, C | 2 |
| Lang, P | 1 |
| St Guily, JL | 3 |
| Wood, MD | 1 |
| Zaki, BI | 1 |
| Gordon, SR | 1 |
| Sutton, JE | 1 |
| Lisovsky, M | 1 |
| Gui, J | 1 |
| Bubis, JA | 1 |
| Dragnev, KH | 1 |
| Rigas, JR | 1 |
| Ji, D | 1 |
| Peng, W | 1 |
| Yang, YL | 1 |
| Bi, ZG | 1 |
| Lu, CC | 1 |
| Gu, B | 1 |
| Cheng, L | 1 |
| Okamura, H | 1 |
| Umehara, S | 1 |
| Todo, M | 1 |
| Yoneda, M | 1 |
| Takahashi, Y | 3 |
| Yoshimoto, T | 1 |
| Misak, H | 1 |
| Zacharias, N | 1 |
| Song, Z | 1 |
| Hwang, S | 1 |
| Man, KP | 1 |
| Asmatulu, R | 1 |
| Machiels, JP | 1 |
| Keller, U | 1 |
| Goddemeier, T | 1 |
| Forssmann, U | 1 |
| Nakada, T | 2 |
| Nagayama, K | 1 |
| Hiramoto, J | 1 |
| Tsuruta, Y | 1 |
| Sakabe, S | 1 |
| Bayne, MC | 1 |
| Stamatović, Lj | 1 |
| Vucićević, S | 1 |
| Petrović, Z | 1 |
| Kreacić, M | 1 |
| Babović, N | 1 |
| Jovanović, N | 1 |
| Mikić, A | 1 |
| Gavrilović, D | 1 |
| Chen, CL | 1 |
| Hong, RL | 1 |
| Chen, KL | 1 |
| Trask, DK | 1 |
| Fisher, SG | 6 |
| Devaney, K | 1 |
| Johnson, M | 1 |
| Singleton, T | 1 |
| Wicha, M | 1 |
| Cox, C | 1 |
| Barrios, MA | 1 |
| Hehr, T | 2 |
| Classen, J | 1 |
| Schreck, U | 1 |
| Glocker, S | 1 |
| Koitschev, A | 1 |
| Chan, AC | 2 |
| Griffith, JF | 2 |
| Leung, SF | 3 |
| Lam, YH | 1 |
| Lam, CC | 1 |
| Lau, JY | 1 |
| Ng, EK | 3 |
| Chung, SC | 1 |
| Gotohda, N | 1 |
| Yoshida, J | 1 |
| Subramaniam, R | 1 |
| Arnott, SJ | 1 |
| Leslie, MD | 1 |
| Toba, T | 1 |
| Kimura, M | 2 |
| Urashima, Y | 1 |
| Terashima, H | 1 |
| Masuda, K | 1 |
| Rahal, M | 2 |
| Raja, MA | 1 |
| El Weshi, A | 1 |
| Pai, C | 1 |
| Ezzat, A | 1 |
| Al Fadda, M | 1 |
| Colevas, AD | 11 |
| Lamb, CC | 2 |
| Karp, D | 1 |
| Busse, PM | 7 |
| Nixon, A | 2 |
| Frankenthaler, R | 1 |
| Lake-Willcutt, B | 2 |
| Case, M | 1 |
| Magois, K | 1 |
| Robert, V | 1 |
| Chiron, A | 1 |
| Lepessot, F | 1 |
| Bodenant, C | 1 |
| Roque, I | 1 |
| Seng, SK | 1 |
| Frebourg, T | 1 |
| Paillot, B | 3 |
| Leonard, GD | 2 |
| Zhuang, SH | 1 |
| Grem, JL | 1 |
| Isogai, K | 2 |
| Suzuki, C | 2 |
| Yabana, T | 2 |
| Senoda, A | 1 |
| Ban, T | 2 |
| De Vita, F | 2 |
| Di Martino, N | 1 |
| Orditura, M | 1 |
| Cosenza, A | 1 |
| Galizia, G | 1 |
| Del Genio, A | 1 |
| Catalano, G | 3 |
| Kitahara, S | 4 |
| Tamura, E | 2 |
| Tanabe, T | 2 |
| Rosati, G | 1 |
| De Rosa, P | 1 |
| Avallone, A | 5 |
| De Rosa, V | 2 |
| De Lucia, L | 3 |
| Comella, P | 5 |
| Comella, G | 5 |
| Mercier, M | 1 |
| Triboulet, JP | 4 |
| Seitz, JF | 5 |
| Rath, GK | 1 |
| Shukla, NK | 1 |
| Maraveyas, A | 1 |
| O'Boyle, C | 1 |
| Cowen, M | 1 |
| Arcangeli, G | 1 |
| Saracino, B | 1 |
| Danesi, DT | 1 |
| De Campora, E | 1 |
| Giovinazzo, G | 1 |
| Cognetti, F | 8 |
| Carlini, P | 4 |
| Arcangeli, S | 1 |
| Mecozzi, A | 1 |
| Oettle, H | 2 |
| Kern, M | 1 |
| Hoepffner, N | 1 |
| Settmacher, U | 1 |
| Neuhaus, P | 1 |
| Riess, H | 2 |
| Dittmann, H | 1 |
| Dohmen, BM | 1 |
| Kehlbach, R | 1 |
| Bartusek, G | 1 |
| Pritzkow, M | 1 |
| Sarbia, M | 5 |
| Bares, R | 1 |
| Takamura, H | 1 |
| Hasebe, K | 1 |
| Urade, M | 2 |
| Yagi, M | 1 |
| Watanabe, A | 5 |
| Taniguchi, M | 3 |
| Kawabori, S | 1 |
| Shigemitsu, K | 1 |
| Naomoto, Y | 1 |
| Shirakawa, Y | 1 |
| Haisa, M | 1 |
| Gunduz, M | 1 |
| Inaba, H | 1 |
| Tsuda, T | 1 |
| Miyazaki, A | 3 |
| Nakaya, S | 1 |
| Koitabashi, Y | 1 |
| Ogihara, K | 1 |
| Kato, N | 1 |
| Kitajima, S | 1 |
| Iino, S | 1 |
| Hoshikawa, Y | 1 |
| Domingo, J | 1 |
| Blanch, JL | 1 |
| Castro, V | 1 |
| Nadal, A | 1 |
| Alós, L | 1 |
| Estapé, J | 1 |
| Waters, JS | 2 |
| Padhani, AR | 2 |
| Hill, ME | 2 |
| Lofts, F | 1 |
| Norman, A | 1 |
| Oates, J | 3 |
| Hill, A | 1 |
| Brown, TA | 1 |
| Goldberg, M | 3 |
| Onda, M | 2 |
| Hagiwara, N | 2 |
| Takubo, K | 2 |
| Miyashita, M | 4 |
| Copur, S | 1 |
| Ledakis, P | 1 |
| Novinski, D | 1 |
| Mleczko, KL | 1 |
| Frankforter, S | 1 |
| Bolton, M | 1 |
| Fruehling, RM | 1 |
| VanWie, E | 1 |
| Norvell, M | 1 |
| Muhvic, J | 1 |
| Fouret, P | 2 |
| Charlotte, F | 1 |
| Lacau-St-Guily, J | 2 |
| Sano, K | 3 |
| Nishizawa, S | 4 |
| Ogasawara, T | 2 |
| Sadato, N | 2 |
| Yonekura, Y | 2 |
| Koga, T | 1 |
| Ninomiya, S | 1 |
| Takeo, S | 1 |
| Yamamoto, G | 3 |
| Shimada, T | 2 |
| Nishikawa, M | 2 |
| Inoda, H | 1 |
| Takigami, K | 2 |
| Yoshitake, K | 2 |
| Ita, M | 1 |
| Okafuji, M | 1 |
| Fukuda, K | 3 |
| Mitsuoka, K | 1 |
| Hanakita, T | 1 |
| Hayatsu, Y | 1 |
| Haddad, R | 3 |
| Busse, P | 2 |
| Sullivan, C | 2 |
| Case, MA | 2 |
| Posner, M | 3 |
| Neuburg, J | 1 |
| Glaser, C | 2 |
| Kermer, C | 3 |
| Rosen, FR | 3 |
| Rademaker, AW | 4 |
| List, MA | 4 |
| Fung, BB | 1 |
| Portugal, L | 4 |
| Pelzer, H | 6 |
| Grandi, C | 1 |
| Valvo, F | 1 |
| Valagussa, P | 1 |
| Bonadonna, G | 2 |
| Molinari, R | 1 |
| Cantù, G | 1 |
| Taussky, D | 2 |
| Rousson, V | 1 |
| Pescia, R | 1 |
| Yoshida, M | 3 |
| Papagikos, M | 1 |
| Skibber, J | 2 |
| Janjan, NA | 1 |
| Feig, B | 2 |
| Hung, A | 2 |
| Delclos, M | 2 |
| Lin, E | 2 |
| Cleary, K | 1 |
| Takahashi, C | 1 |
| Britton, KR | 1 |
| Takai, Y | 1 |
| Terrosu, G | 1 |
| Cedolini, C | 1 |
| Bresadola, V | 1 |
| Baccarani, U | 1 |
| Uzzau, A | 1 |
| Signor, M | 1 |
| Fongione, S | 1 |
| Iop, A | 3 |
| Vigevani, E | 2 |
| Sacco, C | 1 |
| Cartei, G | 5 |
| Bresadola, F | 1 |
| Crane, C | 1 |
| Ballo, M | 1 |
| Janjan, N | 1 |
| Erol, MK | 1 |
| Acikel, M | 1 |
| Senocak, H | 1 |
| Mahadevan, A | 1 |
| Sullivan, CA | 2 |
| Fuchs, S | 1 |
| Brunner, T | 1 |
| Iro, H | 5 |
| Niedobitek, G | 1 |
| Sauer, R | 9 |
| Davis, R | 1 |
| Peterson, AC | 1 |
| Lance, R | 1 |
| Zhou, X | 2 |
| Xu, Q | 1 |
| Lin, L | 1 |
| Oh, JL | 1 |
| Sangruchi, S | 1 |
| Kongthanarat, Y | 1 |
| Tangkaratt, S | 1 |
| Visetsiri, E | 1 |
| Iguchi, H | 3 |
| Kusuki, M | 3 |
| Nakamura, A | 4 |
| Nishiura, H | 2 |
| Kanazawa, A | 3 |
| Yamane, H | 3 |
| Andreadis, C | 1 |
| Vahtsevanos, K | 1 |
| Sidiras, T | 1 |
| Thomaidis, I | 1 |
| Antoniadis, K | 1 |
| Mouratidou, D | 2 |
| Chesnay, E | 1 |
| Babin, E | 1 |
| Constans, JM | 1 |
| Agostini, D | 1 |
| Bequignon, A | 1 |
| Regeasse, A | 1 |
| Sobrio, F | 1 |
| Moreau, S | 1 |
| Kleinberg, L | 2 |
| Knisely, JP | 2 |
| Heitmiller, R | 1 |
| Zahurak, M | 2 |
| Salem, R | 2 |
| Burtness, B | 1 |
| Heath, EI | 3 |
| Kovacs, MS | 1 |
| Dorie, MJ | 1 |
| Koong, A | 2 |
| Terris, DJ | 2 |
| Goffinet, DR | 6 |
| Nowels, K | 1 |
| Bloch, D | 2 |
| Brown, JM | 2 |
| Heroor, A | 1 |
| Sueyoshi, S | 2 |
| Toh, U | 1 |
| Sasahara, H | 2 |
| Sudo, T | 1 |
| Matono, S | 1 |
| Pulcini, C | 1 |
| Vandenbos, F | 1 |
| Bernard, E | 2 |
| Elbeze, JP | 1 |
| Dunais, B | 1 |
| Dellamonica, P | 1 |
| Kishimoto, K | 3 |
| Igarashi, J | 1 |
| Maezawa, T | 1 |
| Hanazaki, K | 1 |
| Adachi, W | 1 |
| Amano, J | 1 |
| Weisser, A | 1 |
| Willer, A | 1 |
| Hehlmann, R | 2 |
| Hochhaus, A | 2 |
| Vuong, T | 3 |
| Devic, S | 2 |
| Belliveau, P | 1 |
| Muanza, T | 1 |
| Hegyi, G | 1 |
| Saitoh, Y | 2 |
| Seno, S | 1 |
| Ikeda, H | 2 |
| Dake, Y | 1 |
| Kawano, A | 1 |
| Futami, R | 2 |
| Tateno, A | 1 |
| Miyashita, T | 1 |
| Denham, JW | 5 |
| Steigler, A | 1 |
| Kilmurray, J | 1 |
| Wratten, C | 1 |
| Burmeister, B | 1 |
| Lamb, DS | 3 |
| Joseph, D | 1 |
| Delaney, G | 1 |
| Christie, D | 1 |
| Jamieson, G | 1 |
| Ackland, S | 1 |
| Walpole, E | 1 |
| Amdur, RJ | 1 |
| Hinerman, RW | 1 |
| Mancuso, AA | 2 |
| Jessner, W | 1 |
| Vogelsang, H | 1 |
| Püspök, A | 1 |
| Ferenci, P | 1 |
| Gangl, A | 1 |
| Novacek, G | 1 |
| Bodisch, A | 1 |
| Wenzl, E | 1 |
| Graf, R | 1 |
| Wust, P | 1 |
| Hildebrandt, B | 1 |
| Gögler, H | 1 |
| Ullrich, R | 1 |
| Herrmann, R | 2 |
| Felix, R | 1 |
| Liu, S | 1 |
| Liao, C | 1 |
| Loré, JM | 3 |
| Kaufman, S | 2 |
| Sundquist, N | 4 |
| Chary, KK | 1 |
| Nahon, P | 1 |
| Artru, P | 2 |
| Tournigand, C | 2 |
| Krulik, M | 2 |
| Iwase, M | 1 |
| Watanabe, H | 6 |
| Kondo, G | 1 |
| Ohashi, M | 2 |
| Nagumo, M | 1 |
| Eguchi, R | 2 |
| Takasaki, K | 1 |
| Mitsuhashi, M | 1 |
| Lee, JL | 2 |
| Kim, DK | 1 |
| Kim, WK | 2 |
| Min, YI | 2 |
| Chan, SW | 1 |
| Mukesh, BN | 2 |
| Sizeland, A | 2 |
| Ghaemmaghami, F | 1 |
| Behtash, N | 1 |
| Yarandi, F | 1 |
| Moosavi, A | 1 |
| Modares, M | 1 |
| Toogeh, G | 1 |
| Khanafshar, N | 1 |
| Yamaoka, K | 1 |
| Kuwajima, S | 1 |
| Hagiwara, H | 1 |
| Toshima, S | 1 |
| Matsuoka, A | 1 |
| Ohnuki, T | 1 |
| Seki, H | 1 |
| Nagai, H | 2 |
| Iino, M | 1 |
| Sageshima, M | 1 |
| Yusa, H | 1 |
| Noguchi, M | 4 |
| Ohara, K | 3 |
| Nesbitt, JC | 1 |
| Lahoti, S | 2 |
| Martin, F | 1 |
| Putnam, JB | 5 |
| Smythe, WR | 2 |
| Vaporciyan, AA | 3 |
| Walsh, GL | 3 |
| Roth, JA | 10 |
| Deniaud-Alexandre, E | 3 |
| Tiret, E | 4 |
| Sezeur, A | 3 |
| Houry, S | 3 |
| Gallot, D | 3 |
| Parc, R | 4 |
| Qu, SH | 1 |
| Pène, F | 4 |
| Schlienger, M | 5 |
| An, FS | 1 |
| Xie, YT | 1 |
| Nagashima, F | 2 |
| Haruno, M | 1 |
| Ochiai, A | 2 |
| Clayton, AS | 1 |
| Stasko, T | 1 |
| Kashima, N | 1 |
| Kanazawa, J | 1 |
| Kaji, R | 1 |
| Sasaki, N | 1 |
| Tateishi, I | 1 |
| Nagata, E | 1 |
| Okabe, Y | 1 |
| Sata, M | 1 |
| Ueno, T | 1 |
| Mathonnet, M | 1 |
| Fermeaux, V | 1 |
| FOYE, LV | 1 |
| WILLETT, FM | 1 |
| HALL, B | 1 |
| ROTH, M | 1 |
| FLETCHER, GH | 1 |
| SUIT, HD | 1 |
| HOWE, CD | 1 |
| SAMUELS, M | 1 |
| JESSE, RH | 4 |
| VILLAREAL, RU | 1 |
| JOHNSON, RO | 6 |
| KISKEN, WA | 2 |
| CURRERI, AR | 2 |
| REITEMEIER, RJ | 1 |
| MOERTEL, CG | 3 |
| BLACKBURN, CM | 1 |
| CHAN, DP | 1 |
| HO, JH | 1 |
| WOO, AW | 1 |
| GOLLIN, FF | 4 |
| ANSFIELD, FJ | 3 |
| VERMUND, H | 5 |
| GASTPAR, H | 1 |
| SCHREINER, L | 1 |
| HELSPER, JT | 1 |
| DEMOSS, EV | 1 |
| RIEHL, JL | 1 |
| BROWN, WJ | 1 |
| HAKIM, P | 1 |
| CRESSY, NL | 2 |
| SCHELL, HW | 2 |
| BAKER, RR | 1 |
| GAERTNER, RA | 1 |
| Schmook, T | 1 |
| Moriuchi, R | 1 |
| Tarasawa, I | 1 |
| Senota, A | 1 |
| Tanguay, JS | 1 |
| Shrihari, N | 1 |
| Warren, RE | 1 |
| Dummer, R | 1 |
| Beyeler, M | 1 |
| Morcinek, J | 1 |
| Burg, G | 1 |
| Farma, J | 1 |
| Lampert, C | 1 |
| Colarusso, P | 2 |
| Coia, L | 2 |
| Frucht, H | 1 |
| Goosenberg, E | 1 |
| Beard, M | 1 |
| Weiner, LM | 2 |
| Wiltfang, J | 1 |
| Bloch-Birkholz, A | 1 |
| Leher, A | 1 |
| Neukam, FW | 1 |
| Kessler, P | 1 |
| Ghahremani, MT | 2 |
| Stefenelli, U | 1 |
| Bitter, K | 1 |
| Balart, J | 1 |
| Balmaña, J | 1 |
| Rius, X | 1 |
| Salazar, R | 2 |
| Gallen, M | 1 |
| Navarro, S | 1 |
| Arcusa, A | 1 |
| Gallardo, E | 1 |
| Brunet, J | 2 |
| Lou, E | 1 |
| Kellman, RM | 1 |
| Hutchison, R | 1 |
| Shillitoe, EJ | 1 |
| Lim, JT | 2 |
| Truong, PT | 1 |
| Berthelet, E | 1 |
| Pai, H | 1 |
| Joe, H | 1 |
| Wai, E | 1 |
| Larsson, S | 1 |
| Kader, HA | 1 |
| Weinerman, B | 1 |
| Wilson, K | 1 |
| Olivotto, IA | 1 |
| Morse, LG | 1 |
| Kendrick, C | 1 |
| Hooper, D | 1 |
| Ward, H | 1 |
| Parry, E | 1 |
| Silapunt, S | 1 |
| Goldberg, LH | 1 |
| Alam, M | 1 |
| Taguchi, S | 1 |
| Kaneko, M | 2 |
| Fukuhara, K | 2 |
| Kinoshita, H | 1 |
| O'Riordan, A | 1 |
| Ong, C | 1 |
| Veitch, P | 1 |
| Takagi, E | 1 |
| Ishii, A | 1 |
| Imagawa, Y | 1 |
| Germain, T | 1 |
| Bergerot, P | 2 |
| Rhein, B | 2 |
| Shibata, K | 1 |
| Kikkawa, F | 1 |
| Suzuki, Y | 2 |
| Terauchi, M | 1 |
| Kajiyama, H | 1 |
| Ino, K | 1 |
| Mizutani, S | 1 |
| Iizuka, T | 4 |
| Ishida, K | 7 |
| Nishimaki, T | 2 |
| Takiyama, W | 2 |
| Isono, K | 3 |
| Ikeuchi, S | 2 |
| Kabuto, T | 3 |
| Kinjo, Y | 1 |
| Kim, EA | 1 |
| Ju, SY | 1 |
| Shin, EH | 1 |
| Newkirk, KA | 1 |
| Schumaker, LM | 1 |
| Aldosari, N | 1 |
| Rone, JD | 1 |
| Haddad, BR | 1 |
| Assersohn, L | 1 |
| Brown, G | 2 |
| Ward, C | 1 |
| Norman, AR | 3 |
| Khandpur, S | 1 |
| Sharma, VK | 2 |
| Tanigaki, Y | 5 |
| Mochimatsu, I | 7 |
| Murphy, BA | 3 |
| Langer, CJ | 2 |
| Katori, H | 10 |
| Mochimatu, I | 1 |
| Kawai, S | 3 |
| Ono, M | 3 |
| Hirose, S | 2 |
| Yamamoto, J | 1 |
| Asaka, M | 1 |
| Ohbayashi, Y | 2 |
| Miyake, M | 3 |
| Iwasaki, A | 2 |
| Nagahata, S | 2 |
| Toyama, Y | 1 |
| Ohkawa, M | 1 |
| Kondo, M | 1 |
| Kudo, T | 1 |
| Shimokuni, T | 2 |
| Maeda, Y | 1 |
| Honnma, S | 1 |
| Shinohara, T | 1 |
| Kohashi, S | 1 |
| Todo, S | 1 |
| Azrak, RG | 1 |
| Cao, S | 2 |
| Slocum, HK | 3 |
| Tóth, K | 3 |
| Durrani, FA | 2 |
| Yin, MB | 1 |
| Pendyala, L | 4 |
| McLeod, HL | 1 |
| Rustum, YM | 3 |
| Maguire, PD | 1 |
| Meyerson, MB | 1 |
| Neal, CR | 1 |
| Hamann, MS | 1 |
| Bost, AL | 1 |
| Anagnost, JW | 1 |
| Ungaro, PC | 1 |
| Pollock, HD | 1 |
| McMurray, JE | 1 |
| Wilson, EP | 1 |
| Kotwall, CA | 1 |
| Eifel, PJ | 9 |
| Morris, M | 4 |
| Levenback, C | 3 |
| Cooper, J | 4 |
| Gershenson, D | 1 |
| Mutch, DG | 3 |
| Mulligan, ED | 1 |
| Dunne, B | 1 |
| Griffin, M | 1 |
| Keeling, N | 1 |
| Reynolds, JV | 1 |
| Ozyar, E | 2 |
| Cengiz, M | 2 |
| Berkey, BA | 2 |
| Gaspar, LE | 5 |
| Brizel, DM | 5 |
| Prosnitz, RG | 2 |
| Hunter, S | 1 |
| Fisher, SR | 2 |
| Clough, RL | 1 |
| Downey, MA | 1 |
| Scher, RL | 1 |
| Mach, N | 1 |
| Becker, M | 5 |
| Dulguerov, P | 1 |
| Goffin, JR | 1 |
| Rajan, R | 1 |
| Souhami, L | 4 |
| Wattenberg, LW | 2 |
| Wiedmann, TS | 2 |
| Estensen, RD | 1 |
| Sykes, AJ | 1 |
| MacDougall, RH | 2 |
| Ironside, JA | 1 |
| Mais, KL | 1 |
| Rosenthal, DI | 3 |
| Chalian, AA | 1 |
| Lustig, R | 1 |
| Hershock, D | 1 |
| Miller, L | 1 |
| Weinstein, GS | 1 |
| Blons, H | 4 |
| Gad, S | 1 |
| Zinzindohoué, F | 1 |
| Manière, I | 1 |
| Beauregard, J | 1 |
| Tregouet, D | 1 |
| Brasnu, D | 11 |
| Beaune, P | 4 |
| Laurent-Puig, P | 4 |
| Riggs, CE | 2 |
| Lerouge, D | 1 |
| Laugier, A | 2 |
| Tamatani, T | 1 |
| Motegi, K | 1 |
| Ashida, Y | 1 |
| Wang, SS | 1 |
| Jiang, WQ | 3 |
| Lin, TY | 1 |
| Fasan, S | 1 |
| Paro, S | 1 |
| Carnuccio, R | 1 |
| Turcato, G | 1 |
| Gatti, C | 1 |
| Pallini, A | 1 |
| Nascimben, O | 1 |
| Biason, R | 1 |
| Oniga, F | 1 |
| Medici, M | 1 |
| Rossi, F | 1 |
| Fila, G | 2 |
| Walsh, G | 2 |
| Morris, J | 1 |
| Lynch, PM | 2 |
| Smythe, R | 3 |
| Vaporciyan, A | 2 |
| Faust, J | 1 |
| Cohen, DS | 1 |
| Nivers, R | 1 |
| Martone, T | 1 |
| Bellone, G | 1 |
| Pagano, M | 1 |
| Beatrice, F | 1 |
| Palonta, F | 1 |
| Emanuelli, G | 1 |
| Cortesina, G | 2 |
| Mulayim, N | 1 |
| Foster Silver, D | 1 |
| Higgins, S | 1 |
| Sai, H | 1 |
| Mitsumori, M | 1 |
| Yamauchi, C | 1 |
| Araki, N | 1 |
| Okumura, S | 1 |
| Aikoh, K | 1 |
| Ross, K | 1 |
| Piacentino, V | 1 |
| Stepnowski, D | 1 |
| McClurken, JB | 1 |
| Furukawa, S | 5 |
| Dempsey, DT | 1 |
| Reilly, EM | 1 |
| Garden, AS | 3 |
| Harris, J | 3 |
| Jones, C | 1 |
| Horwitz, EM | 1 |
| Nabell, L | 1 |
| Demas, W | 1 |
| Gore, E | 1 |
| Alexiou, M | 1 |
| Morgan, J | 1 |
| Badley, J | 1 |
| Maddox, AM | 1 |
| Penagaricano, J | 1 |
| Fan, CY | 1 |
| Breau, R | 1 |
| Suen, J | 1 |
| Kwong, M | 1 |
| DiStasio, S | 1 |
| Lekakis, L | 1 |
| Kassar, M | 1 |
| Sasaki, C | 1 |
| Wilson, LD | 1 |
| Haffty, BG | 1 |
| Son, YH | 2 |
| Ross, DA | 1 |
| Weinberger, PM | 1 |
| Chung, GG | 1 |
| Zelterman, D | 1 |
| Cooper, DL | 2 |
| Hara, I | 1 |
| Hikosaka, S | 1 |
| Eto, H | 1 |
| Miyake, H | 3 |
| Soejima, T | 1 |
| Kamidono, S | 1 |
| Kazakin, J | 1 |
| Adak, S | 5 |
| Jimeno, A | 2 |
| Millán, JM | 2 |
| Castellano, D | 1 |
| Cortés-Funes, H | 4 |
| Choi, N | 1 |
| Park, SD | 1 |
| Lynch, T | 1 |
| Wright, C | 2 |
| Wain, J | 1 |
| Donahue, D | 1 |
| Mathisen, D | 1 |
| Shibuya, Y | 2 |
| Tanimoto, H | 1 |
| Yokoo, S | 2 |
| Morimatsu, M | 1 |
| Tsuzaki, Y | 1 |
| Maoka, K | 1 |
| Sakamoto, K | 1 |
| Iwasaki, H | 2 |
| Higashino, M | 1 |
| Maish, M | 1 |
| Erasmus, JJ | 1 |
| Bresalier, R | 1 |
| Macapinlac, H | 1 |
| Munden, RF | 1 |
| Rice, D | 1 |
| Taillier, G | 1 |
| Van Seuningen, I | 1 |
| Evans, TK | 1 |
| Phillips, HA | 1 |
| Huang, GC | 1 |
| Kuo, YY | 1 |
| Tsuji, T | 1 |
| Imdahl, A | 1 |
| Schöffel, U | 1 |
| Ruf, G | 1 |
| Hopf, UT | 1 |
| Naughton, P | 1 |
| Walsh, TN | 2 |
| Brücher, BL | 2 |
| Stein, HJ | 1 |
| Werner, M | 1 |
| Busch, R | 2 |
| Dittler, HJ | 1 |
| Fink, U | 4 |
| Tanimoto, K | 1 |
| Ukon, K | 1 |
| Tsujimoto, H | 1 |
| Hiyama, K | 1 |
| Takayama, M | 1 |
| Sunami, K | 1 |
| Altundag, O | 1 |
| Gullu, I | 1 |
| Altundag, K | 1 |
| Akyol, F | 1 |
| Yucel, T | 1 |
| Hosal, S | 1 |
| Sozeri, B | 1 |
| Viegas, CM | 1 |
| Araujo, CM | 2 |
| Dantas, MA | 1 |
| Froimtchuk, M | 1 |
| Oliveira, JA | 1 |
| Marchiori, E | 1 |
| Masuda, N | 2 |
| Kashiwazaki, M | 2 |
| Sawamura, T | 2 |
| Gervaz, P | 1 |
| Morel, P | 1 |
| Akst, LM | 1 |
| Chan, J | 1 |
| Elson, P | 1 |
| Saxton, J | 1 |
| Strome, M | 6 |
| Adelstein, D | 1 |
| Bhattacharya, A | 1 |
| Mazurchuk, R | 1 |
| Spernyak, JA | 1 |
| Azrak, R | 1 |
| Raab, B | 1 |
| Willeke, F | 1 |
| Emig, M | 1 |
| Buchheidt, D | 1 |
| Stevens, CW | 1 |
| Ho, L | 1 |
| Yao, JC | 2 |
| Allen, PK | 1 |
| Barone, C | 1 |
| Birocco, N | 1 |
| Dongiovanni, D | 1 |
| Bertetto, O | 2 |
| Genet, D | 1 |
| Bontemps, P | 1 |
| Bourgeois, H | 1 |
| Dutin, JP | 1 |
| Philippi, MH | 1 |
| Bendahmane, B | 1 |
| Mallard-Carre, M | 1 |
| Tubiana-Mathieu, N | 2 |
| Rodríguez-Pinilla, M | 2 |
| Rodríguez-Peralto, JL | 2 |
| López-Martín, A | 1 |
| Brandariz, A | 1 |
| Peña, C | 1 |
| Koike, T | 2 |
| Nakatsuka, A | 1 |
| Kurita, H | 2 |
| Sagara, J | 1 |
| Taniguchi, S | 1 |
| Kurashina, K | 2 |
| Xia, ZJ | 1 |
| Chang, JH | 1 |
| Liu, JW | 1 |
| Wang, HQ | 1 |
| Chen, ZC | 1 |
| Zhou, QH | 1 |
| Lu, JW | 1 |
| Peters, S | 1 |
| Solbach, C | 1 |
| Gstöttner, W | 1 |
| Wollina, U | 1 |
| Hansel, G | 1 |
| Koch, A | 1 |
| Köstler, E | 1 |
| Sanchez, JJ | 2 |
| Ballestin, C | 3 |
| Diez, A | 1 |
| Sanchez-Verde, L | 1 |
| Alameda, F | 1 |
| Sanchez-Cespedes, M | 1 |
| Fisher, R | 1 |
| Macann, A | 1 |
| Denham, J | 1 |
| Poulsen, M | 2 |
| Jackson, M | 2 |
| Kenny, L | 1 |
| Penniment, M | 1 |
| Lamb, D | 1 |
| McClure, B | 1 |
| Takemura, K | 2 |
| Ogi, K | 1 |
| Tokino, T | 1 |
| Kubota, H | 1 |
| Kohama, G | 1 |
| Hiratsuka, H | 2 |
| Davis, GE | 1 |
| Schwartz, SR | 1 |
| Veenstra, DL | 1 |
| Yueh, B | 1 |
| Lober, BA | 1 |
| Lusinchi, A | 3 |
| Wibault, P | 10 |
| Pignon, JP | 1 |
| Govindan, R | 1 |
| McLeod, H | 2 |
| Mantravadi, P | 1 |
| Fineberg, N | 1 |
| Helft, P | 1 |
| Kesler, K | 1 |
| Stoner, C | 1 |
| Ansari, R | 1 |
| Fox, E | 1 |
| Ciruelos, E | 1 |
| Amador, ML | 1 |
| Benito, A | 2 |
| Wutzl, A | 2 |
| Poeschl, PW | 1 |
| Marti, A | 1 |
| Rixe, O | 1 |
| Armand, JP | 10 |
| Domenge, C | 11 |
| Luboinski, B | 7 |
| Raymond, E | 1 |
| Schneider, S | 1 |
| Uchida, K | 1 |
| Yochim, J | 1 |
| Danenberg, KD | 2 |
| Salonga, D | 1 |
| Chen, P | 2 |
| Tsao-Wei, D | 1 |
| Groshen, S | 1 |
| Danenberg, PV | 2 |
| Oeckher, M | 1 |
| Uno, T | 6 |
| Maebayashi, K | 1 |
| Kawaguchi, A | 1 |
| Teshima, T | 3 |
| Borowsky, ME | 1 |
| Elliott, KS | 1 |
| Pezzullo, JC | 1 |
| Santoso, P | 1 |
| Choi, W | 1 |
| Choi, K | 2 |
| Abulafia, O | 1 |
| Magné, N | 5 |
| Touati, L | 1 |
| Marcy, PY | 6 |
| Lagrange, JL | 5 |
| Yao, B | 1 |
| Farrell, CL | 1 |
| Clough, R | 1 |
| Ferrigno, R | 1 |
| Nakamura, RA | 1 |
| Dos Santos Novaes, PE | 1 |
| Pellizzon, AC | 1 |
| Maia, MA | 1 |
| Fogarolli, RC | 1 |
| Salvajoli, JV | 1 |
| Filho, WJ | 1 |
| Vorob'ëv, GI | 1 |
| Odariuk, TS | 1 |
| Orlova, LP | 1 |
| Nechushkin, MI | 1 |
| Rybakov, EG | 1 |
| Yamagishi, H | 1 |
| Itoi, H | 1 |
| Kikuchi, S | 1 |
| Fuji, N | 1 |
| Takatori, H | 2 |
| Aikou, T | 4 |
| Sato, N | 3 |
| Weber, A | 1 |
| Dollner, R | 1 |
| Hildebrandt, G | 1 |
| Chan, L | 1 |
| Yeo, W | 1 |
| Griffith, J | 1 |
| Chan, AT | 2 |
| Joshi, MB | 1 |
| Shirota, Y | 1 |
| Conlon, DH | 1 |
| Salonga, DS | 1 |
| Herndon, JE | 2 |
| Harpole, DH | 3 |
| Charnley, N | 1 |
| Choudhury, A | 1 |
| Chesser, P | 1 |
| Cooper, RA | 1 |
| Stahl, M | 6 |
| Stuschke, M | 6 |
| Lehmann, N | 1 |
| Meyer, HJ | 2 |
| Walz, MK | 3 |
| Seeber, S | 4 |
| Klump, B | 1 |
| Teichmann, R | 1 |
| Schmitt, M | 1 |
| Schmitt, G | 1 |
| Franke, C | 1 |
| Wilke, H | 5 |
| Porceddu, S | 1 |
| Peters, LJ | 7 |
| Cervantes, A | 2 |
| Manzano, H | 1 |
| Chirivella, I | 1 |
| Marfa, X | 1 |
| Ichiki, Y | 1 |
| Yano, K | 1 |
| Sugio, K | 1 |
| Yasumoto, K | 1 |
| Hirose, N | 1 |
| Tamura, N | 1 |
| Fujita, K | 2 |
| Hokita, S | 1 |
| Xi, H | 2 |
| Higashi, H | 1 |
| Dienes, HP | 3 |
| Franchin, G | 1 |
| Vaccher, E | 1 |
| Gobitti, C | 1 |
| Minatel, E | 1 |
| Politi, D | 1 |
| Talamini, R | 1 |
| Di Gennaro, G | 1 |
| Savignano, G | 1 |
| Trovò, MG | 2 |
| Tirelli, U | 3 |
| Ruggeri, EM | 2 |
| Pollera, CF | 1 |
| De Marco, S | 1 |
| Ruscito, P | 1 |
| Pinnarò, P | 3 |
| Nardi, M | 1 |
| Giannarelli, D | 3 |
| Jenkins, AD | 1 |
| Ramondetta, LM | 2 |
| Johnston, T | 1 |
| Wolf, JK | 1 |
| Bodurka, DC | 2 |
| Brown, J | 1 |
| Atkinson, EN | 1 |
| Lee, BJ | 2 |
| Chon, KM | 1 |
| An, WG | 1 |
| Roh, HJ | 2 |
| Goh, EK | 2 |
| Wang, SG | 2 |
| Cai, L | 3 |
| Gu, MF | 1 |
| Chen, EC | 2 |
| Lin, HX | 2 |
| Cui, NJ | 4 |
| Stokes, Z | 1 |
| Symonds, P | 1 |
| Habeshaw, T | 1 |
| Reed, N | 1 |
| Curto, J | 1 |
| Joynson, C | 1 |
| Chan, S | 1 |
| Pedrazzani, C | 3 |
| Laterza, E | 3 |
| Grandinetti, A | 3 |
| Bernini, M | 3 |
| Zerman, G | 2 |
| Tasselli, S | 1 |
| Ruzzenente, A | 2 |
| Blazy, A | 1 |
| Furco, A | 1 |
| Gérard, L | 1 |
| Lémann, M | 1 |
| Maylin, C | 2 |
| Inutsuka, H | 1 |
| Fonseca, E | 2 |
| García-Gómez, JM | 1 |
| Rueda, A | 2 |
| Lara, MA | 1 |
| Navalón, M | 1 |
| Tisaire, JL | 1 |
| Gibson, MK | 2 |
| Murphy, B | 1 |
| Hussain, MH | 3 |
| DeConti, RC | 4 |
| Ensley, J | 10 |
| Naoi, Y | 2 |
| Yokoyama, S | 1 |
| Yoneda, K | 7 |
| Katsumoto, Y | 2 |
| Mauer, AM | 1 |
| Kraut, EH | 1 |
| Krauss, SA | 1 |
| Ansari, RH | 1 |
| Kasza, K | 1 |
| Szeto, L | 1 |
| de Arruda, FF | 1 |
| Puri, DR | 2 |
| Zhung, J | 1 |
| Narayana, A | 1 |
| Wolden, S | 1 |
| Hunt, M | 1 |
| Stambuk, H | 1 |
| Pfister, D | 2 |
| Kraus, D | 2 |
| Shaha, A | 2 |
| Shah, J | 4 |
| Duyster, J | 1 |
| Lersch, C | 1 |
| von Delius, S | 1 |
| Hennig, M | 1 |
| Bredenkamp, R | 1 |
| Ramnath, N | 1 |
| Khushalani, N | 1 |
| Litwin, AM | 1 |
| Intengan, ME | 1 |
| Smith, PF | 1 |
| Stewart, CC | 1 |
| Hoffman, JL | 1 |
| Javle, MM | 1 |
| Berdzik, J | 2 |
| Creaven, PJ | 1 |
| Banga, R | 1 |
| Ramsden, J | 1 |
| Cox, G | 1 |
| Liu, BD | 1 |
| Zhi, XY | 1 |
| Xu, QS | 1 |
| Jayaram, P | 2 |
| Pichardo, D | 2 |
| Kuratomi, Y | 2 |
| Umezaki, T | 1 |
| Nagao, J | 3 |
| Kessler, H | 1 |
| Schneider, IH | 3 |
| Nozawa, A | 1 |
| Yokomakura, N | 1 |
| Takao, S | 2 |
| Herbst, RS | 1 |
| Arquette, M | 1 |
| Dicke, K | 1 |
| Azarnia, N | 1 |
| Hong, WK | 11 |
| Lim, D | 1 |
| Tai, BC | 1 |
| Khoo, ML | 1 |
| Goh, C | 1 |
| Leong, SS | 1 |
| Tan, T | 1 |
| Fong, KW | 2 |
| See, A | 1 |
| Machin, D | 1 |
| Nishikawa, T | 1 |
| Okur, A | 1 |
| Kantarci, M | 1 |
| Akgun, M | 1 |
| Alper, F | 1 |
| Cayir, K | 1 |
| Koc, M | 1 |
| Onbas, O | 1 |
| Bessell, JR | 2 |
| Tsai, JY | 1 |
| Iannitti, D | 1 |
| Berkenblit, A | 1 |
| Akerman, P | 2 |
| Nadeem, A | 1 |
| Rathore, R | 1 |
| Harrington, D | 1 |
| Roye, D | 1 |
| Miner, T | 2 |
| Barnett, JM | 1 |
| Maia, C | 1 |
| Stuart, K | 1 |
| Abdel-Wahab, M | 3 |
| Lewin, A | 3 |
| Troner, M | 3 |
| Hamilton, K | 1 |
| Markoe, A | 3 |
| Guadagnolo, BA | 1 |
| Weeks, L | 1 |
| Yom, SS | 1 |
| Biel, MA | 1 |
| Sinard, RJ | 1 |
| El-Naggar, AK | 1 |
| Chou, W | 1 |
| Garrone, O | 1 |
| Pelissero, A | 1 |
| Granetto, C | 1 |
| Di Costanzo, G | 1 |
| Heouaine, A | 1 |
| Vigna Taglianti, R | 1 |
| Cipolat, M | 1 |
| Kumar, S | 1 |
| Dimri, K | 1 |
| Balachandran, P | 1 |
| Kumar, A | 1 |
| Sikora, SS | 1 |
| Rastogi, N | 1 |
| Saxena, R | 1 |
| Datta, NR | 1 |
| Ayyagari, S | 1 |
| Kapoor, VK | 1 |
| Tóvári, J | 1 |
| Gilly, R | 1 |
| Rásó, E | 1 |
| Paku, S | 1 |
| Bereczky, B | 1 |
| Varga, N | 1 |
| Vágó, A | 1 |
| Tímár, J | 1 |
| Komatsubara, H | 1 |
| Ojima, Y | 1 |
| Minamikawa, T | 1 |
| Shigeta, T | 1 |
| Fountzilas, G | 8 |
| Tolis, C | 1 |
| Kalogera-Fountzila, A | 5 |
| Misailidou, D | 1 |
| Tsekeris, P | 1 |
| Karina, M | 1 |
| Nikolaou, A | 2 |
| Samantas, E | 1 |
| Makatsoris, T | 1 |
| Athanassiou, E | 1 |
| Skarlos, D | 2 |
| Bamias, A | 1 |
| Zamboglou, N | 1 |
| Economopoulos, T | 1 |
| Karanastassi, S | 1 |
| Pavlidis, N | 1 |
| Daniilidis, J | 5 |
| Haugen, H | 1 |
| Johansson, KA | 1 |
| Ejnell, H | 1 |
| Edström, S | 1 |
| Mercke, C | 5 |
| Morgan-Meadows, S | 1 |
| Mulkerin, D | 1 |
| Berlin, JD | 1 |
| Bailey, H | 1 |
| Saphner, T | 1 |
| Jumonville, A | 1 |
| Hansen, R | 1 |
| Ahuja, H | 1 |
| McFarland, T | 1 |
| Thomas, JP | 1 |
| Mitsuyama, S | 1 |
| Anan, K | 1 |
| Burmeister, BH | 4 |
| Walpole, ET | 1 |
| Burmeister, EA | 1 |
| Thomson, DB | 1 |
| Harvey, JA | 1 |
| Mark Smithers, B | 1 |
| Milano, MT | 2 |
| Jani, AB | 2 |
| Farrey, KJ | 1 |
| Rash, C | 1 |
| Heimann, R | 1 |
| Chmura, SJ | 3 |
| Gerszten, K | 2 |
| Selvaraj, RN | 1 |
| Kelley, J | 2 |
| Faul, C | 1 |
| Shimizu, K | 1 |
| Toge, T | 1 |
| Lee, KE | 1 |
| Kang, WK | 2 |
| Piehler, JM | 1 |
| Tomezzoli, A | 1 |
| Cordiano, C | 3 |
| Yamshita, Y | 1 |
| Shikimori, M | 1 |
| Muto, A | 1 |
| Miyazawa, M | 1 |
| Tsukada, M | 1 |
| Ohtani, S | 1 |
| Endoh, H | 1 |
| Satoh, M | 1 |
| Rastogi, M | 3 |
| Srivastava, M | 3 |
| Chufal, KS | 3 |
| Srivastava, K | 2 |
| Bhatt, MB | 1 |
| Szego, P | 1 |
| Parent, J | 1 |
| Mayrand, S | 1 |
| Corns, R | 1 |
| Burtin, P | 2 |
| Faria, S | 1 |
| Harvey, M | 1 |
| Hamilton-Nelson, K | 1 |
| Koishi, K | 1 |
| Nakao, K | 2 |
| Yagyu, R | 1 |
| Nishiwaki, M | 1 |
| Kojima, S | 1 |
| Yamamura, T | 1 |
| Haimi, M | 1 |
| Arush, MW | 1 |
| Bar-Sela, G | 1 |
| Gez, E | 1 |
| Bernstein, Z | 2 |
| Postovsky, S | 1 |
| Barak, AB | 1 |
| Kuten, A | 4 |
| M'barek, B | 1 |
| Gargouri, W | 1 |
| Maalej, M | 1 |
| Kim, JG | 1 |
| Sohn, SK | 1 |
| Baek, JH | 1 |
| Jeon, SB | 1 |
| Chae, YS | 1 |
| Lee, KB | 1 |
| Park, IK | 1 |
| Yang, ZX | 1 |
| Feng, LP | 1 |
| Isobe, K | 2 |
| Hanazawa, T | 1 |
| Ueno, N | 3 |
| Okamoto, Y | 7 |
| Escrig, V | 1 |
| Rizo, A | 1 |
| Vega, ME | 1 |
| Martí, JL | 1 |
| Lobo, F | 1 |
| Pastor, P | 1 |
| Valentí, V | 1 |
| Belón, J | 1 |
| Sánchez, MA | 1 |
| Chaib, C | 1 |
| Pallarés, C | 1 |
| Antón, A | 1 |
| Paz-Ares, L | 1 |
| Kharatishvili, TK | 1 |
| Khatyrëv, SA | 1 |
| Sobolevskiĭ, VA | 1 |
| Ivanov, SI | 1 |
| Vishnevskaia, IaV | 1 |
| Karapetian, RM | 1 |
| Kovalevskiĭ, EE | 1 |
| Kawano, K | 1 |
| Kusukawa, J | 1 |
| Sunagawa, H | 1 |
| Shiba, R | 1 |
| Fukuda, J | 1 |
| Oishi, M | 1 |
| Ikemura, K | 1 |
| Sugihara, K | 1 |
| Inokuchi, T | 2 |
| Mimura, T | 1 |
| Goto, H | 2 |
| Tago, M | 2 |
| Sasano, N | 1 |
| Cavanna, L | 1 |
| Lazzaro, A | 1 |
| Trabacchi, E | 1 |
| Anselmi, E | 1 |
| Vallisa, D | 1 |
| Foroni, RP | 1 |
| Dobelbower, MC | 1 |
| Russo, SM | 1 |
| Raisch, KP | 1 |
| Seay, LL | 1 |
| Clemons, LK | 1 |
| Suter, S | 1 |
| Posey, J | 1 |
| Bonner, JA | 1 |
| Neiss, S | 1 |
| Ling, FC | 1 |
| Moenig, S | 1 |
| Gurfinkel, R | 1 |
| Walfisch, S | 1 |
| Nabeya, Y | 4 |
| Okazumi, S | 4 |
| Gunji, Y | 2 |
| Cominos, M | 1 |
| Mosleh-Shirazi, MA | 1 |
| Henrys, A | 1 |
| Cornes, P | 1 |
| Schmerber, S | 2 |
| Righini, Ch | 1 |
| Soriano, E | 1 |
| Delalande, C | 1 |
| Dumas, G | 1 |
| Lavieille, JP | 3 |
| Canning, CA | 1 |
| Gubbels, S | 1 |
| Chinn, C | 1 |
| Wax, M | 1 |
| Holland, JM | 1 |
| Ramaïoli, A | 2 |
| Bourdin, S | 3 |
| Vallicioni, J | 5 |
| Seng, H | 1 |
| Alzieu, C | 1 |
| Chauvel, P | 4 |
| Schneider, M | 13 |
| Chiang, SS | 2 |
| Tian, WD | 1 |
| Zeng, ZY | 2 |
| Chen, FJ | 1 |
| Guo, ZM | 2 |
| Hachiya, K | 1 |
| King, G | 1 |
| Shogan, J | 1 |
| Bahri, S | 1 |
| Dietz, K | 1 |
| Wadleigh, RG | 3 |
| Abbasi, S | 1 |
| Korman, L | 1 |
| Gath, HJ | 1 |
| Bier, J | 1 |
| Houllier, AM | 2 |
| Dwyer, MK | 1 |
| Gebski, VJ | 1 |
| Jayamohan, J | 1 |
| Okuno, Y | 1 |
| Kusumi, F | 4 |
| Takakuwa, H | 1 |
| Matsusue, S | 3 |
| Esclamado, RM | 4 |
| Lavertu, P | 6 |
| Carroll, MA | 3 |
| Kitabayashi, H | 1 |
| Kamata, T | 1 |
| Tsujii, H | 2 |
| Bai, T | 1 |
| Yukawa, K | 2 |
| Umesaki, N | 2 |
| Shakuto, S | 1 |
| Fujita, F | 1 |
| Taira, A | 2 |
| Budenz, S | 1 |
| Jo Dorie, M | 1 |
| Goode, R | 1 |
| Martin Brown, J | 1 |
| Ponzanelli, A | 3 |
| Ricci, I | 3 |
| Vigo, V | 3 |
| Grossi, F | 1 |
| Cavallo, G | 1 |
| Capaccetti, B | 1 |
| Taveggia, P | 1 |
| Boni, L | 1 |
| Qin, B | 2 |
| Tanaka, R | 1 |
| Ariyama, H | 2 |
| Shibata, Y | 2 |
| Arita, S | 2 |
| Baba, E | 2 |
| Harada, M | 1 |
| Nakano, S | 7 |
| Hirao, T | 1 |
| Gelbard, A | 1 |
| Garnett, CT | 1 |
| Abrams, SI | 1 |
| Patel, V | 1 |
| Palena, C | 1 |
| Tsang, KY | 1 |
| Schlom, J | 1 |
| Hodge, JW | 1 |
| Hu, WH | 2 |
| Xia, YF | 1 |
| Islam, S | 1 |
| Cole, CV | 1 |
| Hoffman, GR | 1 |
| Brennan, PA | 1 |
| Lambert, T | 1 |
| Mullinax, K | 1 |
| Smith, J | 2 |
| Yekebas, EF | 1 |
| Bahrehmand, R | 1 |
| Wildfang, I | 1 |
| Kilic, E | 1 |
| Muellerleile, U | 1 |
| Gross, E | 1 |
| Alberti, W | 1 |
| Kondo, N | 2 |
| Masuda, Y | 1 |
| Sugiyama, M | 2 |
| Forshaw, MJ | 2 |
| Chrystal, K | 2 |
| Cheong, K | 2 |
| Atkinson, S | 1 |
| Botha, A | 1 |
| Harper, PG | 3 |
| Mason, RC | 2 |
| Valencia Julve, J | 1 |
| Alonso Orduña, V | 1 |
| Escó Barón, R | 1 |
| López-Mata, M | 1 |
| Méndez Villamón, A | 1 |
| Hitzman, CJ | 1 |
| Li, QS | 1 |
| Li, DP | 1 |
| Sheng, XG | 1 |
| Du, XL | 1 |
| Song, QQ | 1 |
| Berman, B | 1 |
| Bienstock, L | 1 |
| Kuritzky, L | 1 |
| Mayeaux, EJ | 1 |
| Tyring, SK | 1 |
| Wong, AS | 1 |
| Soo, RA | 1 |
| Loh, KS | 1 |
| Tan, KS | 1 |
| Hsieh, WS | 1 |
| Shakespeare, TP | 1 |
| Chua, ET | 1 |
| Lim, HL | 1 |
| Goh, BC | 1 |
| Ashida, A | 1 |
| Mafune, K | 1 |
| Kreĭnina, IuM | 1 |
| Titova, VA | 1 |
| Shipilova, AN | 1 |
| Povarova, EV | 1 |
| Shevchenko, LN | 1 |
| Humblet, Y | 2 |
| Vega Villegas, ME | 1 |
| Duck, L | 1 |
| Rosine, D | 1 |
| Harstrick, A | 2 |
| Kaneda, Y | 1 |
| Shimamoto, H | 1 |
| Matsumura, K | 1 |
| Arvind, R | 1 |
| Sakai, E | 1 |
| Omura, K | 1 |
| Tsuchida, N | 1 |
| Roof, KS | 1 |
| Coen, J | 1 |
| Lynch, TJ | 2 |
| Fidias, P | 1 |
| Choi, NC | 6 |
| Rapidis, AD | 1 |
| Trichas, M | 1 |
| Stavrinidis, E | 1 |
| Roupakia, A | 1 |
| Ioannidou, G | 1 |
| Kritselis, G | 1 |
| Liossi, P | 1 |
| Giannakouras, G | 1 |
| Douzinas, EE | 1 |
| Katsilieris, I | 1 |
| Mizuno, A | 1 |
| Dakhil, SR | 1 |
| Williamson, S | 1 |
| Lamblin, A | 1 |
| Lu, JI | 1 |
| Carhart, RL | 1 |
| Graziano, SL | 1 |
| Gajra, A | 1 |
| Morton, C | 1 |
| Horn, M | 1 |
| Leman, J | 1 |
| Tack, B | 1 |
| Bedane, C | 1 |
| Tjioe, M | 1 |
| Ibbotson, S | 1 |
| Khemis, A | 1 |
| Wolf, P | 1 |
| O'Donnell, L | 1 |
| Gu, J | 1 |
| Etzel, CJ | 1 |
| Amos, CI | 1 |
| Milas, L | 1 |
| Hittelman, WN | 1 |
| Kurahashi, T | 1 |
| Kuwahara, M | 1 |
| Mizutani, Y | 1 |
| Di Fiore, F | 1 |
| Lecleire, S | 1 |
| Rigal, O | 1 |
| Ben Soussan, E | 1 |
| David, I | 1 |
| Jacob, JH | 3 |
| Miyazawa, H | 1 |
| Uehara, S | 2 |
| Brockstein, B | 2 |
| Dissemond, J | 1 |
| Grabbe, S | 1 |
| Lucato, LT | 1 |
| McKinney, AM | 1 |
| Short, J | 1 |
| Teksam, M | 1 |
| Truwit, CL | 1 |
| Toth, G | 1 |
| Edelman, S | 1 |
| Johnstone, PA | 1 |
| Kim, YB | 1 |
| Keum, KC | 2 |
| Seong, J | 2 |
| Suh, CO | 3 |
| Hantash, BM | 1 |
| Stewart, DB | 1 |
| Cooper, ZA | 1 |
| Rehmus, WE | 1 |
| Koch, RJ | 1 |
| Qiu, XH | 1 |
| Yang, YX | 1 |
| Zhang, SQ | 1 |
| Chen, ZM | 1 |
| Chujo, M | 1 |
| Miura, T | 1 |
| Miyawaki, M | 1 |
| Imakiire, T | 1 |
| Hayashita, Y | 1 |
| Sroa, N | 1 |
| Bartholomew, DA | 1 |
| Magro, CM | 1 |
| Konstantinopoulos, PA | 1 |
| Schlecht, HP | 1 |
| Bryan, B | 1 |
| Pantanowitz, L | 1 |
| Dezube, BJ | 1 |
| Tadakuma, T | 1 |
| Ono, T | 2 |
| Hiroi, S | 1 |
| Masumoto, K | 1 |
| Yip, KW | 1 |
| Ito, E | 1 |
| Mao, X | 1 |
| Au, PY | 1 |
| Hedley, DW | 1 |
| Mocanu, JD | 1 |
| Bastianutto, C | 1 |
| Schimmer, A | 1 |
| Santeufemia, DA | 1 |
| Piredda, G | 1 |
| Fadda, GM | 1 |
| Cossu Rocca, P | 1 |
| Costantino, S | 1 |
| Sanna, G | 1 |
| Sarobba, MG | 1 |
| Pinna, MA | 1 |
| Putzu, C | 1 |
| Farris, A | 3 |
| Wang, HP | 1 |
| Yang, CH | 3 |
| Lin, JT | 1 |
| Kong, W | 1 |
| Chun, JH | 1 |
| Lee, HG | 1 |
| Garcia, AA | 1 |
| Blessing, JA | 3 |
| Darcy, KM | 1 |
| Lenz, HJ | 1 |
| Hannigan, E | 1 |
| Moore, DH | 3 |
| Dequanter, D | 1 |
| Lothaire, P | 1 |
| Hien Nguyen, T | 1 |
| Lemort, M | 1 |
| Vandevelde, L | 1 |
| Umebayashi, Y | 1 |
| Ichikawa, E | 1 |
| Huang, WZ | 1 |
| Sasabe, E | 1 |
| Oku, N | 1 |
| Osaki, T | 8 |
| Schwentner, I | 1 |
| Schmutzhard, J | 1 |
| Andrle, J | 1 |
| Haidenberger, A | 1 |
| Thumfart, WF | 1 |
| Sprinzl, GM | 1 |
| Gaffney, DK | 3 |
| Miller, B | 2 |
| Ryu, J | 2 |
| Avizonis, V | 2 |
| Fromm, M | 2 |
| Greven, K | 2 |
| Wang, XS | 1 |
| Zhang, CQ | 1 |
| Watai, K | 1 |
| Ondo, AL | 1 |
| Mings, SM | 1 |
| Pestak, RM | 1 |
| Shanler, SD | 1 |
| Blanke, CD | 1 |
| Shyr, Y | 1 |
| Berlin, J | 1 |
| Beauchamp, RD | 1 |
| Chakravarthy, B | 1 |
| Prenzel, KL | 1 |
| König, A | 1 |
| Schnickmann, C | 1 |
| Izbicki, JR | 1 |
| Hannoun, L | 1 |
| Allen, AM | 1 |
| Elshaikh, M | 1 |
| Tsien, C | 1 |
| Dawson, LA | 1 |
| Urba, S | 3 |
| Normolle, D | 1 |
| Mack, MG | 1 |
| Bisdas, S | 1 |
| Muerthel, R | 1 |
| Vogl, T | 1 |
| Terada, A | 2 |
| Tytherleigh, MG | 1 |
| Birtle, AJ | 1 |
| Cohen, CE | 1 |
| Livingstone, J | 1 |
| Gilbert, J | 1 |
| Tulunay, OE | 1 |
| Enamorado, II | 1 |
| Kucuk, O | 3 |
| Heilbrun, LK | 1 |
| Otero, JE | 1 |
| Korkmaz, H | 1 |
| Blumberg, R | 1 |
| Jacobs, JR | 9 |
| Shi, YX | 1 |
| Ma, ZY | 1 |
| Wang, JH | 1 |
| Xie, WM | 1 |
| Li, XG | 2 |
| Liu, YL | 1 |
| Pan, LX | 1 |
| Dai, AD | 1 |
| Zhuang, W | 1 |
| Spencker, S | 1 |
| Schmittel, A | 1 |
| Westermann, D | 1 |
| Marek, A | 1 |
| Schultheiss, HP | 1 |
| Witzenbichler, B | 1 |
| Sakayori, M | 1 |
| Chiba, N | 1 |
| Shibata, H | 1 |
| Shimodaira, H | 1 |
| Ohtsuka, K | 2 |
| Kakudo, Y | 1 |
| Sakata, Y | 1 |
| González-González, JJ | 1 |
| Sanz-Alvarez, L | 1 |
| Marqués-Alvarez, L | 1 |
| Navarrete-Guijosa, F | 1 |
| Martínez-Rodríguez, E | 1 |
| Kelsey, CR | 1 |
| Morse, MA | 1 |
| Blobe, GC | 1 |
| Fernando, NH | 1 |
| Honeycutt, W | 1 |
| Yu, D | 1 |
| Bendell, JC | 1 |
| Takenobu, T | 1 |
| Kokubo, M | 1 |
| Taniike, N | 1 |
| Nagano, M | 1 |
| Furutani, M | 1 |
| Ohnishi, M | 2 |
| Uchiyama, K | 1 |
| Iwabuchi, H | 2 |
| Nakayama, S | 1 |
| Minamide, J | 2 |
| Takada, K | 4 |
| Oota, Y | 1 |
| Kawata, T | 1 |
| Boso, C | 1 |
| Mazzarotto, R | 1 |
| Tomassi, O | 1 |
| Fuwa, N | 7 |
| Hayashi, N | 1 |
| Matsuzuka, T | 1 |
| Yuta, A | 1 |
| Oonishi, H | 1 |
| Daimon, T | 4 |
| Poligone, B | 1 |
| Christensen, SR | 1 |
| Lazova, R | 1 |
| Heald, PW | 1 |
| Wang, CT | 1 |
| Cao, KJ | 1 |
| Xie, GF | 1 |
| Huang, PY | 1 |
| Leijte, JA | 1 |
| Kerst, JM | 1 |
| Bais, E | 1 |
| Antonini, N | 1 |
| Horenblas, S | 1 |
| Minicozzi, AM | 1 |
| Kaur, MR | 1 |
| Marsden, JR | 1 |
| Nelson, HM | 1 |
| Hiramatsu, K | 1 |
| Hirata, A | 1 |
| Matsuba, H | 1 |
| Akagawa, T | 1 |
| Kutsuna, Y | 1 |
| Machiki, Y | 1 |
| Fujioka, S | 1 |
| Khoury-Collado, F | 1 |
| Bowes, RJ | 1 |
| Jhamb, N | 1 |
| Aghajanian, C | 1 |
| Abu-Rustum, NR | 1 |
| Ijuin, T | 1 |
| Doi, K | 1 |
| Inoue, H | 2 |
| Saitoh, M | 1 |
| Ohtsuki, N | 1 |
| Makino, K | 1 |
| Amatsu, M | 1 |
| Ciammella, P | 1 |
| Clerico, M | 3 |
| Giudici, M | 1 |
| Filippi, AR | 1 |
| Zuccaro, G | 3 |
| Vargo, JJ | 1 |
| Dumot, JA | 1 |
| Dubois, MD | 1 |
| Crevier-Buchman, L | 1 |
| Vikhlianov, IV | 2 |
| Shoĭket, IaN | 1 |
| Lazarev, AF | 2 |
| Xiao, Y | 1 |
| Shi, HL | 1 |
| Feng, YL | 1 |
| Li, MD | 1 |
| Hu, QY | 1 |
| Fu, ZF | 1 |
| Tsukamoto, G | 1 |
| Ibaragi, S | 1 |
| Shimo, T | 1 |
| Oyama, K | 2 |
| Mese, H | 1 |
| Aoe, M | 1 |
| Kiura, K | 2 |
| Aiko, S | 1 |
| Yoshizumi, Y | 1 |
| Ishizuka, T | 1 |
| Sakano, T | 1 |
| Kumano, I | 1 |
| Sugiura, Y | 1 |
| Maehara, T | 1 |
| Larsen, S | 1 |
| Serup-Hansen, E | 1 |
| Andersen, LJ | 1 |
| Lindeløv, B | 1 |
| McCulloch, T | 1 |
| Adimi, P | 1 |
| Bastholt, L | 1 |
| Briez, N | 1 |
| Chen, YW | 1 |
| Yen, SH | 3 |
| Huang, PI | 1 |
| Shiau, CY | 1 |
| Liu, YM | 1 |
| Lin, JK | 1 |
| Anderson, SE | 1 |
| Bains, M | 1 |
| Hummer, A | 1 |
| Kelsen, D | 3 |
| Kadowaki, Y | 1 |
| Shirasaka, D | 1 |
| Kasuga, M | 1 |
| Beneton, M | 1 |
| Blasco, H | 1 |
| Giraudeau, B | 1 |
| Boisdron-Celle, M | 1 |
| Deporte-Fety, R | 1 |
| Narcisso, B | 1 |
| Le Guellec, C | 1 |
| Di Gennaro, E | 2 |
| Bruzzese, F | 1 |
| Laus, G | 1 |
| Delrio, P | 1 |
| Caraglia, M | 1 |
| Pepe, S | 1 |
| Budillon, A | 3 |
| Masuoka, T | 1 |
| Geisler, JP | 1 |
| Manahan, KJ | 1 |
| Rippy, JK | 1 |
| Takeno, S | 1 |
| Watanabe, S | 3 |
| Miki, R | 1 |
| Ogami, N | 1 |
| Mitsugi, K | 4 |
| Noshiro, H | 1 |
| Nahas, CS | 1 |
| Joseph, R | 1 |
| Schrag, D | 1 |
| Weiser, MR | 1 |
| Guillem, JG | 1 |
| Paty, PB | 2 |
| Klimstra, DS | 1 |
| Tang, LH | 1 |
| Wong, WD | 2 |
| Nasu, K | 1 |
| Hanazono, K | 1 |
| Oowaki, T | 1 |
| Arimura, K | 1 |
| Nakamura, F | 1 |
| Xie, FY | 1 |
| Qi, SN | 1 |
| Zou, GR | 1 |
| Peng, M | 1 |
| Li, JS | 1 |
| Kelsen, DP | 7 |
| Mortimer, J | 2 |
| Estes, NC | 1 |
| Haller, DG | 3 |
| Kocha, W | 2 |
| Kawabe, S | 1 |
| Gotoh, M | 1 |
| Ohta, S | 1 |
| Kuwakado, S | 1 |
| Nishitani, H | 1 |
| Katsu, K | 1 |
| Hsu, C | 1 |
| Hsu, WL | 2 |
| Evans, D | 1 |
| Millis, R | 1 |
| Jean, M | 1 |
| Kennedy, T | 1 |
| Roth, C | 1 |
| Füller, J | 1 |
| Bischoff, A | 1 |
| Wendt, T | 1 |
| Schneider, A | 2 |
| Hong, YS | 1 |
| Lee, HR | 1 |
| Kim, HS | 1 |
| Kim, MJ | 1 |
| Spencer, SA | 4 |
| Wheeler, RH | 4 |
| Schultz, C | 2 |
| Spanos, W | 2 |
| Meredith, R | 2 |
| Ang, KK | 3 |
| Hayano, K | 1 |
| Kazama, T | 1 |
| Yanagawa, N | 1 |
| Kobayashi, J | 2 |
| Kido, Y | 2 |
| Tomihara, K | 1 |
| Dehari, H | 1 |
| Nakamori, K | 1 |
| Nagai, I | 1 |
| Kikuta, S | 1 |
| Asakage, T | 1 |
| Sugasawa, M | 2 |
| Lee, MS | 4 |
| Ho, HC | 1 |
| Hsiao, SH | 1 |
| Lee, CC | 1 |
| Hung, SK | 1 |
| Torres, MA | 1 |
| Jhingran, A | 1 |
| Thames, HD | 1 |
| Levenback, CF | 1 |
| Jeong, WJ | 1 |
| Jung, EJ | 1 |
| Mauer, A | 1 |
| Dekker, A | 1 |
| van de Schoot, L | 1 |
| Romme, EA | 1 |
| van der Sangen, MJ | 1 |
| Creemers, GJ | 1 |
| van Lijnschoten, G | 1 |
| van Driel, OJ | 1 |
| Rutten, HJ | 1 |
| Nieuwenhuijzen, GA | 1 |
| López-Brea, M | 1 |
| Mayorga, M | 1 |
| Galdós, P | 1 |
| Rubio, A | 1 |
| Del Valle, A | 1 |
| García-Reija, F | 1 |
| García-Montesinos, B | 1 |
| Rodríguez-Iglesias, J | 1 |
| Mayordomo, J | 1 |
| Rama, J | 1 |
| Saiz-Bustillo, R | 1 |
| Sanz-Ortiz, J | 1 |
| Wolfson, AH | 1 |
| Crook, W | 1 |
| Krishan, A | 1 |
| Markoe, AM | 3 |
| Lucci, JA | 1 |
| Lee, BH | 1 |
| Kim, CM | 1 |
| Jun, ES | 1 |
| Mundt, AJ | 1 |
| Roeske, JC | 1 |
| Koizumi, T | 1 |
| Bando, S | 1 |
| Kanda, K | 1 |
| Inai, T | 1 |
| Ott, N | 1 |
| Pühringer-Oppermann, F | 1 |
| Sujendran, V | 1 |
| Wheeler, J | 1 |
| Baron, R | 1 |
| Warren, BF | 1 |
| Maynard, N | 1 |
| Ohara, T | 1 |
| Okuda, Y | 1 |
| Kiguchi, K | 1 |
| Ishizuka, B | 1 |
| van Herpen, C | 1 |
| Rey, A | 1 |
| Desaunois, I | 1 |
| Hershock, DM | 1 |
| Mickiewicz, E | 1 |
| Gorbounova, V | 1 |
| Ervin, TJ | 3 |
| Spaulding, M | 4 |
| Roth, B | 1 |
| Viroglio, Rdel C | 1 |
| Venkatesan, V | 1 |
| Romanov, I | 1 |
| Agarwala, S | 1 |
| Harter, KW | 1 |
| Dugan, M | 1 |
| Cmelak, A | 1 |
| Read, PW | 1 |
| Steinbrenner, L | 1 |
| N'guyen, TD | 1 |
| Marchal, C | 1 |
| Roullet, B | 1 |
| Bai, P | 1 |
| Zhang, R | 1 |
| Ma, SK | 1 |
| Wu, LY | 1 |
| Zhang, WH | 1 |
| Klem, ML | 1 |
| Mechalakos, JG | 1 |
| Zelefsky, MJ | 1 |
| Singh, B | 2 |
| Aoki, K | 3 |
| Tatebayashi, S | 1 |
| Yagyuu, T | 1 |
| Kajihara, A | 1 |
| Wong, SK | 1 |
| Chiu, PW | 1 |
| Cheung, KY | 1 |
| Au-Yeung, AC | 1 |
| Chung, SS | 1 |
| Marcenaro, M | 2 |
| Gatteschi, B | 1 |
| Ravetti, JL | 1 |
| Krawtchenko, N | 1 |
| Roewert-Huber, J | 1 |
| Ulrich, M | 1 |
| Mann, I | 1 |
| Sterry, W | 1 |
| Lin, D | 1 |
| Glastonbury, CM | 1 |
| Rafaelian, O | 1 |
| Eisele, DW | 2 |
| Wang, SJ | 1 |
| Shoĭkhet, IaN | 1 |
| Brunner, TB | 1 |
| Rupp, A | 1 |
| Melzner, W | 1 |
| Char, DH | 1 |
| Crawford, JB | 1 |
| Ahn, JB | 1 |
| Roh, JK | 2 |
| Chung, HC | 1 |
| Kim, NK | 1 |
| Song, CH | 1 |
| Park, CI | 2 |
| Bootz, F | 1 |
| Kanamori, S | 2 |
| Koh, DM | 1 |
| Dzik-Jurasz, A | 1 |
| O'Neill, B | 1 |
| Husband, JE | 1 |
| Borghesi, S | 1 |
| Yoneyama, K | 1 |
| Kiuchi, Y | 1 |
| Nakahara, R | 1 |
| Tomoda, T | 1 |
| Inokuchi, H | 1 |
| Kong, WM | 1 |
| Tepper, J | 2 |
| Krasna, MJ | 1 |
| Hollis, D | 1 |
| Reed, CE | 1 |
| Goldberg, R | 1 |
| Kiel, K | 1 |
| Willett, C | 1 |
| Sugarbaker, D | 1 |
| Mayer, R | 1 |
| Zhao, YN | 1 |
| Asaumi, J | 1 |
| Sakata, K | 3 |
| Sakurai, H | 1 |
| Katoh, S | 1 |
| Ohno, T | 1 |
| Tanaka, E | 2 |
| Kaneyasu, Y | 2 |
| Harima, Y | 1 |
| Werner, J | 1 |
| Hagen, R | 1 |
| Flentje, M | 3 |
| Huerva, V | 1 |
| Mangues, I | 1 |
| Higano, CS | 1 |
| Tangen, CM | 1 |
| Sakr, WA | 2 |
| Faulkner, J | 1 |
| Rivkin, SE | 1 |
| Meyers, FJ | 1 |
| Hussain, M | 5 |
| Baker, LH | 1 |
| Russell, KJ | 2 |
| Crawford, ED | 2 |
| Wang, A | 1 |
| Guan, Z | 1 |
| Margarino, G | 9 |
| Seung, SK | 1 |
| Smith, JW | 1 |
| Ross, HJ | 1 |
| Shirao, K | 1 |
| Akatsuka, S | 1 |
| Matsubara, J | 1 |
| Hamguchi, T | 1 |
| Rasheed, S | 1 |
| Yap, T | 1 |
| Zia, A | 1 |
| McDonald, PJ | 1 |
| Fukutomi, A | 1 |
| Hasuike, N | 1 |
| Inui, T | 1 |
| Yamaguchi, Y | 4 |
| Ono, H | 1 |
| Knab, BR | 1 |
| Solanki, A | 1 |
| Meadows, H | 1 |
| Wan, S | 1 |
| McDonald, AC | 1 |
| Myint, S | 1 |
| Samuel, L | 1 |
| Kumar, B | 1 |
| Cordell, KG | 1 |
| D'Silva, NJ | 1 |
| Yang, K | 1 |
| Kurnit, DM | 1 |
| Su, YR | 1 |
| Chen, WK | 1 |
| Wei, MW | 1 |
| Chen, YF | 1 |
| Pandya, KJ | 1 |
| Glück, S | 1 |
| Brizel, HE | 1 |
| Meredith, RF | 3 |
| Berger, D | 1 |
| Chen, MG | 1 |
| Mendenhall, W | 1 |
| Meropol, NJ | 1 |
| Shank, B | 1 |
| Colacchio, TA | 1 |
| Ellerton, J | 1 |
| Valone, F | 1 |
| Budinger, S | 1 |
| Day, JM | 1 |
| Hopkins, J | 1 |
| Skoda, C | 1 |
| Erovic, BM | 1 |
| Wachek, V | 1 |
| Martinek, H | 1 |
| Kloimstein, P | 1 |
| Pennathur, A | 1 |
| Luketich, JD | 2 |
| Landreneau, RJ | 1 |
| Ward, J | 1 |
| Christie, NA | 1 |
| Schuchert, M | 1 |
| Cooper, K | 1 |
| Land, SR | 1 |
| Belani, CP | 2 |
| Gorgun, B | 1 |
| Goplerud, DR | 1 |
| Watne, AL | 1 |
| Jansen, GT | 2 |
| Dillaha, CJ | 2 |
| Honeycutt, WM | 2 |
| Brocard, H | 1 |
| Akoun, G | 1 |
| Turpin, G | 1 |
| Gendre, JP | 1 |
| Mackman, S | 1 |
| Lehnert, M | 4 |
| Jakse, R | 5 |
| Seewann, HL | 1 |
| Al-Sarraf, M | 24 |
| Tatarek, R | 3 |
| Corvò, L | 1 |
| Price, LA | 3 |
| Hill, BT | 3 |
| Schouwenburg, PF | 1 |
| Van Putten, LM | 1 |
| Snow, GB | 2 |
| Raafat, J | 1 |
| Oster, MW | 2 |
| Thatcher, N | 1 |
| Blackledge, G | 1 |
| Crowther, D | 1 |
| Smith, BL | 1 |
| Franz, JL | 1 |
| Mira, JG | 1 |
| Gates, GA | 2 |
| Sapp, J | 1 |
| Cruz, AB | 3 |
| Glick, JH | 1 |
| Zehngebot, LM | 1 |
| Taylor, SG | 6 |
| Harada, H | 1 |
| Cortes, EP | 2 |
| Kalra, J | 2 |
| Amin, VC | 1 |
| Attie, J | 1 |
| Eisenbud, L | 1 |
| Khafif, R | 1 |
| Wolk, D | 1 |
| Aral, I | 1 |
| Sciubba, J | 1 |
| Akbiyik, N | 1 |
| Heller, K | 1 |
| Veronesi, A | 3 |
| Magri, MD | 3 |
| Galligioni, E | 2 |
| Tumolo, S | 2 |
| Comoretto, R | 2 |
| Grigoletto, E | 2 |
| Campisi, J | 1 |
| Pardee, AB | 1 |
| Nagayama, S | 1 |
| Okazaki, H | 3 |
| Nakamura, H | 3 |
| Shirasaka, T | 3 |
| Mead, GM | 1 |
| Jacobs, C | 4 |
| Dhawan, IK | 1 |
| Thakur, NS | 1 |
| Madan, NC | 1 |
| Bannerjee, A | 1 |
| Sahoo, BK | 1 |
| Rasenack, U | 1 |
| Caspary, W | 1 |
| Dimitriadis, K | 1 |
| Boutis, L | 1 |
| Tavantzis, J | 1 |
| Bouchoris, N | 1 |
| Koukourikos, S | 1 |
| Hatzigogos, K | 1 |
| Safarini, S | 1 |
| MacRae, K | 1 |
| Frustaci, S | 1 |
| Crivellari, D | 1 |
| Plasse, TF | 1 |
| Ohnuma, T | 4 |
| Brooks, S | 1 |
| Saponaro, E | 1 |
| Holland, JF | 2 |
| Biller, H | 1 |
| Johnston-Early, A | 1 |
| Citron, ML | 1 |
| Krasnow, SH | 2 |
| Fossieck, BE | 1 |
| Kolarić, K | 1 |
| Dujmović, I | 1 |
| Weaver, A | 9 |
| Kinzie, J | 8 |
| Crissman, J | 5 |
| Kish, JA | 7 |
| Cummings, G | 6 |
| Fu, KK | 4 |
| Rayner, PA | 1 |
| Lam, KN | 1 |
| Fleming, S | 1 |
| Jacobs, J | 6 |
| Oberfield, RA | 2 |
| Karrer, K | 2 |
| Pridun, N | 2 |
| Denck, H | 1 |
| Inuyama, Y | 6 |
| Horiuchi, M | 3 |
| Mashino, S | 1 |
| Ozu, R | 1 |
| Asaoka, K | 1 |
| Konno, A | 2 |
| Togawa, K | 2 |
| Inoue, S | 1 |
| Komatubara, S | 1 |
| Sato, G | 1 |
| Teramoto, S | 1 |
| Tatsumura, T | 2 |
| Murakami, A | 1 |
| Tsuda, M | 1 |
| Sugiyama, S | 1 |
| Fujisawa, T | 1 |
| Carter, DM | 2 |
| Balin, AK | 1 |
| Pitman, SW | 1 |
| Kowal, CD | 1 |
| Bertino, JR | 2 |
| Browman, GP | 5 |
| Archibald, SD | 2 |
| Young, JE | 2 |
| Hryniuk, WM | 1 |
| Russell, R | 4 |
| Kiehl, K | 1 |
| Levine, MN | 5 |
| Coates, AS | 1 |
| Tattersall, MH | 4 |
| Swanson, C | 1 |
| Hedley, D | 1 |
| Fox, RM | 2 |
| Raghavan, D | 1 |
| Kiseleva, ES | 1 |
| Pitskhelauri, VG | 1 |
| Trakhtenberg, AKh | 2 |
| Bidiak, IP | 1 |
| Zholkiver, KI | 1 |
| Scherpe, A | 1 |
| Schröder, M | 4 |
| von Heyden, HW | 1 |
| Nagel, GA | 1 |
| Michaelson, RA | 1 |
| Magill, GB | 3 |
| Quan, SH | 4 |
| Leaming, RH | 2 |
| Nikrui, M | 1 |
| Stearns, MW | 1 |
| Franklin, R | 2 |
| Steiger, Z | 7 |
| Vaishampayan, G | 1 |
| Asfaw, I | 3 |
| Rosenberg, J | 2 |
| Loh, J | 2 |
| Hoschner, J | 3 |
| Miller, P | 2 |
| Flam, MS | 3 |
| John, M | 5 |
| Lovalvo, LJ | 2 |
| Mills, RJ | 1 |
| Ramalho, LD | 2 |
| Prather, C | 1 |
| Mowry, PA | 6 |
| Morgan, DR | 1 |
| Lau, BP | 1 |
| Fukuyo, K | 1 |
| Eura, S | 1 |
| Soda, T | 2 |
| Mishina, T | 1 |
| Maegawa, M | 1 |
| Nakao, M | 2 |
| Hasegawa, T | 3 |
| Fujimori, T | 2 |
| Katayama, S | 1 |
| Sakaguchi, K | 2 |
| Nakagiri, Y | 2 |
| Ishii, Y | 3 |
| Fukui, H | 2 |
| Kohno, I | 2 |
| Endoh, S | 1 |
| Chin, N | 1 |
| Rin, K | 1 |
| Leichman, L | 10 |
| Seydel, HG | 7 |
| Vaitkevicius, VK | 5 |
| Tiver, KW | 3 |
| Langlands, AO | 3 |
| Thomas, G | 4 |
| Dembo, A | 2 |
| Beale, F | 1 |
| Bean, H | 1 |
| Bush, R | 1 |
| Herman, J | 1 |
| Pringle, J | 2 |
| Rawlings, G | 1 |
| Sturgeon, J | 1 |
| Fine, S | 2 |
| Keane, T | 2 |
| Harwood, A | 1 |
| Rider, W | 1 |
| Rogers, M | 1 |
| Bean, DJ | 1 |
| Rees, RS | 1 |
| O'Leary, JP | 1 |
| Lynch, JB | 1 |
| Bahadur, S | 1 |
| Tandon, DA | 1 |
| Kacker, SK | 1 |
| Masaki, N | 1 |
| Shigematsu, Y | 1 |
| Fuchihata, H | 1 |
| Dindogru, A | 2 |
| Toben, S | 1 |
| MacKenzie, G | 1 |
| Shell, J | 1 |
| Shields, TW | 2 |
| Rosen, ST | 2 |
| Hellerstein, SM | 1 |
| Tsang, T | 1 |
| Ujiki, GT | 1 |
| Bellamy, AS | 1 |
| Conte, PF | 1 |
| Scarsi, P | 1 |
| Barbieri, A | 1 |
| Benedetti, G | 2 |
| Ringborg, U | 3 |
| Ewert, G | 2 |
| Kinnman, J | 2 |
| Lundquist, PG | 1 |
| Strander, H | 3 |
| Lundqvist, PG | 1 |
| Bradford, AC | 1 |
| Seniukov, MV | 1 |
| Goldobenko, GV | 1 |
| Mardynskiĭ, IuS | 1 |
| Lushnikov, EF | 1 |
| Skoropad, IuD | 1 |
| Shafir, M | 1 |
| Raventos, E | 1 |
| Gerbie, MV | 1 |
| Decker, DA | 1 |
| Drelichman, A | 2 |
| Loh, JJ | 2 |
| Gisselbrecht, C | 2 |
| Calvo, F | 2 |
| Mignot, L | 2 |
| Pujade, E | 2 |
| Bouvry, M | 2 |
| Danne, O | 2 |
| Belpomme, D | 2 |
| Marty, M | 2 |
| Spaulding, MB | 2 |
| Vasquez, J | 1 |
| Khan, A | 2 |
| Gad-el-Mawla, N | 1 |
| Ziegler, JL | 1 |
| Hamza, R | 1 |
| Elserafi, M | 1 |
| Khaled, H | 1 |
| Matsuura, S | 3 |
| Satake, B | 3 |
| Kurosawa, Y | 1 |
| Sakaino, K | 2 |
| Mitomo, O | 1 |
| Nozaki, M | 2 |
| Miyata, M | 4 |
| Albright, SD | 1 |
| Konnak, JW | 1 |
| Petrilli, ES | 1 |
| Townsend, DE | 2 |
| Morrow, CP | 2 |
| Nakao, CY | 1 |
| Yanagawa, T | 1 |
| Yura, Y | 1 |
| Sugi, M | 1 |
| Hamada, S | 1 |
| Taniguchi, K | 1 |
| Furukawa, H | 1 |
| Iwanaga, T | 1 |
| Terasawa, T | 1 |
| Blokhina, NG | 1 |
| Sorokina, GA | 1 |
| Cummings, BJ | 8 |
| Rider, WD | 4 |
| Harwood, AR | 4 |
| Keane, TJ | 6 |
| Erlichman, C | 1 |
| Sischy, B | 5 |
| Remington, JH | 2 |
| Hinson, EJ | 1 |
| Sobel, SH | 2 |
| Woll, JE | 1 |
| Yamada, E | 1 |
| Nigro, ND | 2 |
| Considine, B | 2 |
| Kinzie, JJ | 1 |
| Strong, ML | 1 |
| Honda, T | 2 |
| Flemming, S | 1 |
| Kish, J | 6 |
| Vandenberg, H | 1 |
| Jacob, J | 1 |
| Morvan, F | 1 |
| Logothetis, CJ | 1 |
| Samuels, ML | 2 |
| Wallace, S | 2 |
| Chuang, V | 1 |
| Trindade, A | 1 |
| Grant, C | 1 |
| Haynie, TP | 1 |
| Johnson, DE | 1 |
| Chan, WK | 3 |
| Aroney, RS | 1 |
| Levi, JA | 2 |
| Woods, RL | 1 |
| Matsumura, Y | 1 |
| Nomura, Y | 1 |
| Komiyama, S | 3 |
| Makishima, K | 2 |
| Hiroto, I | 1 |
| Ohyama, W | 1 |
| Tokashiki, T | 1 |
| Hirokawa, T | 1 |
| Konno, T | 1 |
| Takeda, C | 1 |
| Ryan, RF | 10 |
| Litwin, MS | 8 |
| Krementz, ET | 8 |
| Wanebo, HJ | 2 |
| Futrell, W | 1 |
| Constable, W | 1 |
| Kalra, JK | 2 |
| Grossman, AM | 1 |
| Krumholz, BA | 1 |
| Chen, S | 2 |
| Tinker, MA | 1 |
| Flores, GT | 1 |
| Molho, L | 3 |
| Wilson, RF | 1 |
| Seydel, H | 1 |
| Vaishamapayan, G | 1 |
| Knechtges, T | 1 |
| Rosenberg, JC | 2 |
| Buroker, T | 2 |
| Torres, A | 1 |
| Hoschner, D | 1 |
| Pietruk, T | 1 |
| Vaitkevicius, V | 2 |
| Weaver, SM | 1 |
| Kelly, AP | 1 |
| Lopansri, S | 1 |
| Gulati, SC | 1 |
| Sordillo, P | 1 |
| Kempin, S | 1 |
| Reich, L | 1 |
| Scheiner, E | 1 |
| Clarkson, B | 1 |
| Braun, M | 1 |
| Savlov, ED | 1 |
| Hartmann, HR | 1 |
| Bollag, W | 1 |
| Ezdinli, EZ | 1 |
| Gelber, R | 1 |
| Desai, DV | 1 |
| Falkson, G | 5 |
| Hahn, RG | 1 |
| Okuda, M | 2 |
| Tomiyama, S | 1 |
| Diaz-Ordaz, E | 1 |
| Chary, K | 1 |
| Lawrence, W | 1 |
| Hong, F | 1 |
| Gerold, T | 1 |
| Barrali, RA | 1 |
| Jouffre, V | 2 |
| Ménard, M | 5 |
| Laccourreye, H | 7 |
| Hibino, S | 1 |
| Narayanan, K | 1 |
| Liang, MD | 1 |
| Jacobs, SA | 1 |
| Leichman, CG | 3 |
| Cai, HY | 1 |
| Clavel, M | 2 |
| Cappelaere, P | 5 |
| de Mulder, PH | 3 |
| Schornagel, JH | 2 |
| Tueni, EA | 1 |
| Verweij, J | 4 |
| Wildiers, J | 1 |
| Mick, R | 5 |
| McEvilly, JM | 3 |
| Eckardt, A | 1 |
| Kelber, A | 1 |
| Turrisi, AT | 1 |
| Huber, MH | 1 |
| Lippman, SM | 3 |
| Benner, SE | 1 |
| Shirinian, M | 1 |
| Dimery, IW | 9 |
| Earley, CL | 1 |
| Winn, RJ | 1 |
| Brooks, J | 1 |
| Baez, L | 1 |
| Kitajima, M | 1 |
| Hsu, KH | 1 |
| Crowe, JE | 1 |
| Lubeck, MD | 1 |
| Davis, AR | 1 |
| Hung, PP | 1 |
| Chanock, RM | 1 |
| Murphy, BR | 1 |
| Marsh, RW | 1 |
| Agaliotis, D | 1 |
| Killeen, R | 1 |
| Julienne, V | 1 |
| Gosselin, M | 1 |
| Launois, B | 5 |
| Burke, TW | 1 |
| Gershenson, DM | 1 |
| Hsu, KL | 1 |
| Wang, KS | 1 |
| Chou, FF | 1 |
| Austin, JR | 1 |
| Wong, FC | 1 |
| Kim, EE | 1 |
| Poore, J | 1 |
| Beals, T | 1 |
| McClatchey, KD | 1 |
| Lozac'h, P | 3 |
| Reddy, SP | 1 |
| Lad, T | 1 |
| Mullane, M | 1 |
| Carroll, R | 1 |
| Marks, JE | 1 |
| Akiyama, S | 2 |
| Nonami, T | 1 |
| Kasai, Y | 2 |
| Hibi, K | 1 |
| Ito, K | 5 |
| Takagi, H | 2 |
| Kim, SW | 2 |
| Suh, CW | 1 |
| Chang, HS | 1 |
| Codacci-Pisanelli, G | 1 |
| van der Wilt, CL | 4 |
| Pinedo, HM | 3 |
| Franchi, F | 1 |
| Noordhuis, P | 2 |
| Braakhuis, BJ | 2 |
| van Laar, JA | 1 |
| Peters, GJ | 4 |
| Vikram, B | 2 |
| Malamud, S | 3 |
| Yudelman, I | 1 |
| Nussbaum, M | 1 |
| Beattie, E | 1 |
| Munakata, H | 2 |
| Kayada, Y | 2 |
| Kawahara, M | 3 |
| Yoshiga, K | 1 |
| Chi, KH | 3 |
| Chow, KC | 1 |
| Chao, JY | 1 |
| Chang, CY | 1 |
| Chen, KY | 2 |
| Ohwada, S | 1 |
| Izumi, M | 1 |
| Kawashima, Y | 1 |
| Kobayashi, I | 2 |
| Hosomura, Y | 1 |
| Joshita, T | 1 |
| Lino, Y | 1 |
| Morishita, Y | 3 |
| Etienne, MC | 5 |
| Thyss, A | 7 |
| Otto, J | 1 |
| Mobayen, H | 1 |
| Saudes, L | 1 |
| Guillot, T | 4 |
| O'Brien, M | 2 |
| Gill, PG | 5 |
| Devitt, P | 2 |
| Yeoh, E | 3 |
| Hamilton, CS | 2 |
| Ackland, SP | 1 |
| Wang, HM | 2 |
| Wang, CH | 2 |
| Kiu, MC | 1 |
| Liaw, CC | 1 |
| Ng, KT | 1 |
| Lai, GM | 1 |
| de Andrés, L | 1 |
| Burgués, J | 1 |
| Guedea, F | 1 |
| Vega, M | 1 |
| López, JJ | 1 |
| van Triest, B | 1 |
| Telleman, F | 1 |
| Ichikawa, G | 2 |
| Kawaida, M | 3 |
| Tonusin, A | 3 |
| Sukthomya, W | 1 |
| Changwiwit, W | 2 |
| Nimmolrat, A | 1 |
| Kohno, H | 1 |
| Enomoto, H | 4 |
| Yago, T | 1 |
| Ikema, Y | 1 |
| Makino, Y | 1 |
| Turk, PS | 1 |
| Belliveau, JF | 1 |
| Darnowski, JW | 1 |
| Weinberg, MC | 1 |
| Leenen, L | 1 |
| Gebbia, V | 5 |
| Zerillo, G | 2 |
| Restivo, G | 2 |
| Speciale, R | 2 |
| Cupido, G | 1 |
| Lo Bue, P | 1 |
| Ingria, F | 2 |
| Gallina, S | 1 |
| Spatafora, G | 2 |
| Testa, A | 2 |
| Pannuti, F | 2 |
| Martoni, A | 2 |
| Melotti, B | 1 |
| Morritti, MG | 1 |
| Abram, AC | 1 |
| Nabizadeh, S | 1 |
| Feldman, PS | 1 |
| Cantrell, RW | 2 |
| Levine, PA | 1 |
| Kattan, J | 1 |
| Culine, S | 1 |
| Droz, JP | 1 |
| Fadel, E | 1 |
| Court, B | 1 |
| Perrin, JL | 1 |
| Haie-Meder, C | 2 |
| Wada, K | 1 |
| Koyama, M | 1 |
| Iijima, Y | 1 |
| Inagaki, M | 1 |
| Hirota, Y | 1 |
| Hongo, J | 1 |
| Ozaki, M | 3 |
| Sirott, M | 1 |
| Heelan, R | 2 |
| Keresztes, R | 1 |
| Wahlen, SA | 1 |
| Slater, JD | 1 |
| Wagner, RJ | 1 |
| Wang, WA | 1 |
| Keeney, ED | 1 |
| Hocko, JM | 1 |
| King, A | 1 |
| Slater, JM | 1 |
| Volling, P | 5 |
| Lutz, ST | 1 |
| Huang, DT | 1 |
| Ferguson, MK | 1 |
| Reeder, LB | 1 |
| Hoffman, PC | 1 |
| Drinkard, LC | 1 |
| Sacks, PG | 1 |
| Harris, D | 1 |
| Chou, TC | 1 |
| Khansur, T | 2 |
| Allred, C | 1 |
| Little, D | 1 |
| Anand, V | 1 |
| Kulaylat, MN | 1 |
| Doerr, R | 1 |
| Butler, B | 1 |
| Satchidanand, SK | 1 |
| Singh, A | 1 |
| Girvin, GW | 1 |
| Matsumoto, GH | 1 |
| Bates, DM | 1 |
| Garcia, JM | 1 |
| Clyde, JC | 1 |
| Lin, PH | 1 |
| Licht, MR | 1 |
| Klein, EA | 1 |
| Bukowski, R | 1 |
| Montie, JE | 1 |
| Naudo, P | 1 |
| Ellis, PA | 1 |
| Talbot, DC | 1 |
| Nicolson, MC | 1 |
| Priest, K | 1 |
| Smith, IE | 1 |
| de Gara, CJ | 1 |
| Basrur, V | 2 |
| Figueredo, A | 1 |
| Goodyear, M | 1 |
| Knight, P | 1 |
| Le Prise, EA | 1 |
| Meunier, BC | 1 |
| Julienne, VC | 1 |
| Gedouin, DM | 1 |
| Ben Hassel, M | 2 |
| Campion, JP | 3 |
| Goldberg, H | 1 |
| Tsalik, M | 1 |
| Haim, N | 2 |
| Tran, LN | 1 |
| Krieg, RM | 1 |
| Szabo, RJ | 1 |
| Dinges, S | 1 |
| Jahnke, K | 2 |
| Heselmann, I | 1 |
| Unger, A | 1 |
| Stüben, G | 2 |
| Sack, H | 4 |
| Umazume, M | 1 |
| Murata, A | 1 |
| Nishijima, J | 1 |
| Inoue, M | 5 |
| Mori, T | 3 |
| Misaki, M | 1 |
| Terakado, N | 2 |
| Shapiro, SJ | 2 |
| Lacey, D | 1 |
| Birnbaum, E | 1 |
| Fleshman, J | 1 |
| Fry, R | 1 |
| Kodner, I | 1 |
| Sakai, K | 2 |
| Inakoshi, H | 1 |
| Sueyama, H | 5 |
| Oda, J | 1 |
| Tsuchida, E | 2 |
| Sugita, T | 2 |
| Saito, A | 2 |
| Miyagi, M | 2 |
| Cwikiel, M | 3 |
| Persson, SU | 1 |
| Larsson, H | 1 |
| Albertsson, M | 5 |
| Eskilsson, J | 1 |
| Kokatsu, T | 3 |
| Satoh, H | 1 |
| Sakumoto, M | 1 |
| Yuyama, S | 1 |
| Reisser, C | 2 |
| Haberkorn, U | 3 |
| Dimitrakopoulou-Strauss, A | 1 |
| Seifert, E | 2 |
| Strauss, LG | 3 |
| Fortier, LA | 1 |
| Mac Harg, MA | 1 |
| Dzubow, LM | 1 |
| Fanning, J | 1 |
| Ladd, C | 1 |
| Hilgers, RD | 1 |
| Hickey, K | 1 |
| Grehan, D | 1 |
| Reid, IM | 1 |
| O'Briain, S | 1 |
| Hennessy, TP | 1 |
| Nakai, Y | 3 |
| Furuse, K | 1 |
| Ohta, M | 1 |
| Asakawa, M | 1 |
| Fukuoka, M | 1 |
| Niitani, H | 1 |
| Cercato, MC | 1 |
| Del Vecchio, MR | 1 |
| Impiombato, FA | 2 |
| Marzetti, F | 1 |
| Milella, M | 1 |
| King, WW | 1 |
| Lam, PK | 1 |
| Li, AK | 1 |
| Basser, RL | 1 |
| Smith, JG | 3 |
| Worotniuk, V | 1 |
| Guiney, MJ | 2 |
| Schofield, JB | 1 |
| Lorentzos, A | 1 |
| Moore, J | 1 |
| Atkinson, H | 1 |
| Henk, JM | 1 |
| MacLennan, KA | 1 |
| Gore, ME | 1 |
| Sasson, Z | 1 |
| Morgan, CD | 1 |
| MacKenzie, B | 1 |
| Platts, ME | 1 |
| Beck, DE | 1 |
| Karulf, RE | 1 |
| Cavallari, M | 4 |
| Blengio, F | 4 |
| Sguotti, C | 1 |
| Rosso, M | 2 |
| Chadha, M | 2 |
| Cripps, C | 5 |
| Hodson, DI | 2 |
| Eapen, L | 2 |
| Sathya, J | 3 |
| Pomatto, E | 2 |
| Berutto, M | 1 |
| Falco, V | 1 |
| Bocca, M | 1 |
| Vercellino, V | 4 |
| Higuchi, S | 1 |
| Urso, SU | 1 |
| Castaldini, G | 1 |
| Ebeling, O | 2 |
| Eckel, HE | 1 |
| Heitmann, K | 1 |
| Vössing, M | 1 |
| Koja, S | 1 |
| Itokazu, T | 1 |
| Kamiya, S | 1 |
| Maeshiro, N | 1 |
| Esu, H | 1 |
| Simoji, Y | 1 |
| Kanazawa, T | 4 |
| Noda, Y | 1 |
| Buswell, L | 1 |
| Recht, A | 2 |
| Clark, J | 2 |
| Ravikumar, T | 1 |
| Coleman, CN | 2 |
| Gao, Z | 1 |
| Meng, FH | 1 |
| Longo, WE | 1 |
| Vernava, AM | 1 |
| Wade, TP | 1 |
| Coplin, MA | 1 |
| Virgo, KS | 1 |
| Johnson, FE | 2 |
| McLachlan, SA | 1 |
| Millward, MJ | 2 |
| Toner, GC | 1 |
| Bishop, JF | 3 |
| Fischer, SG | 1 |
| Hartsell, WF | 1 |
| Murthy, AK | 3 |
| Haselow, RE | 4 |
| Zöller, J | 1 |
| Maier, H | 1 |
| Born, IA | 1 |
| Osswald, H | 1 |
| Poplin, EA | 2 |
| Khanuja, PS | 1 |
| Kraut, MJ | 1 |
| Herskovic, AM | 1 |
| Lattin, PB | 2 |
| Kinzie, JL | 1 |
| Rosenblatt, EA | 1 |
| Pisch, J | 1 |
| Berson, A | 1 |
| Vorob'eva, LI | 1 |
| Galakhin, KA | 1 |
| Koval'chuk, EN | 1 |
| Leyvraz, S | 2 |
| Pasche, P | 2 |
| Bauer, J | 2 |
| Bernasconi, S | 1 |
| Monnier, P | 1 |
| Teshima, K | 1 |
| Yamagata, S | 1 |
| Sugawa, T | 1 |
| Kubo, H | 1 |
| Sugimoto, O | 2 |
| Nakajima, H | 1 |
| Yamabe, T | 1 |
| Okayasu, T | 1 |
| Sugiyama, K | 1 |
| Miyauchi, S | 2 |
| Trott, KR | 3 |
| Xiao, XH | 1 |
| Khalil, AM | 2 |
| Khatib, RA | 1 |
| Mufarrij, AA | 1 |
| Tawil, AN | 1 |
| Issa, PY | 1 |
| Vannetzel, JM | 1 |
| Colin, P | 1 |
| Dray, M | 1 |
| Caldarelli, DD | 2 |
| Shott, S | 1 |
| Vokes, E | 1 |
| Showel, JL | 1 |
| Hutchinson, JC | 1 |
| Maddern, G | 1 |
| Gedouin, D | 1 |
| Boutin, D | 1 |
| Smith, DE | 4 |
| Shah, KH | 1 |
| Frost, DB | 2 |
| Latino, F | 1 |
| Anderson, PJ | 2 |
| Peddada, AV | 3 |
| Kagan, AR | 4 |
| Buffat, L | 1 |
| Lefkopoulos, D | 1 |
| Malafosse, M | 1 |
| Husseinzadeh, N | 1 |
| Shrake, P | 1 |
| DeEulis, T | 1 |
| Rowley, K | 1 |
| Aron, B | 1 |
| Orlando, A | 1 |
| Zorat, PL | 2 |
| Cavaniglia, G | 2 |
| Sileni, VC | 3 |
| Jirillo, A | 1 |
| Fede, A | 2 |
| Paik, HC | 1 |
| McLaughlin, PW | 1 |
| Thornton, AF | 3 |
| Wihlm, J | 1 |
| Levêque, D | 1 |
| Velten, M | 1 |
| Klein, T | 1 |
| Casiano, RR | 2 |
| Schuller, DE | 5 |
| Laramore, GE | 5 |
| Valente, G | 1 |
| Corradi, L | 1 |
| Tardy, A | 1 |
| Palestro, G | 1 |
| Fuhrman, GM | 1 |
| Ota, DM | 1 |
| Tanabe, M | 2 |
| Matsunaga, T | 2 |
| Sakai, S | 4 |
| Miyaguchi, M | 3 |
| Furuya, Y | 1 |
| Ku, Y | 1 |
| Hamabe, Y | 1 |
| Renée, N | 3 |
| Sano, R | 1 |
| Kim, Y | 1 |
| Preusser, P | 1 |
| Berns, T | 1 |
| Achterrath, W | 2 |
| Knipp, H | 1 |
| Berger, M | 1 |
| Brambilla, E | 1 |
| Barra, Y | 1 |
| Riva, C | 2 |
| Morrison, WH | 3 |
| Ota, D | 1 |
| Levin, B | 2 |
| Lipsett, J | 1 |
| Leong, L | 1 |
| Wagman, LD | 1 |
| Terz, JJ | 1 |
| Nürnberger, HR | 1 |
| Löffler, T | 1 |
| Hausamen, TU | 2 |
| Theophil, B | 1 |
| Löhlein, D | 1 |
| Kalish, LA | 1 |
| Adams, GL | 1 |
| Oken, MM | 1 |
| Mansour, EG | 1 |
| Jeremic, B | 3 |
| Zivic, DJ | 1 |
| Matovic, M | 1 |
| Marinkovic, J | 1 |
| Toma, S | 4 |
| Pedrick, TJ | 1 |
| Wheeler, W | 1 |
| Riemenschneider, H | 1 |
| Jaiyesimi, IA | 1 |
| Koyama, S | 1 |
| Tsujimoto, M | 1 |
| Kitagawa, M | 1 |
| Kagamimori, S | 1 |
| Bachaud, JM | 1 |
| David, JM | 1 |
| Shubinski, RE | 1 |
| Perineau, D | 1 |
| Boussin, G | 1 |
| Serrano, E | 1 |
| De Forni, M | 2 |
| Pessey, JJ | 2 |
| Daly-Schveitzer, NJ | 1 |
| Stuecklschweiger, G | 1 |
| Berger, A | 3 |
| Geyer, E | 2 |
| Leopold, KA | 1 |
| Panella, TJ | 2 |
| Fine, RL | 1 |
| Bedrosian, CL | 1 |
| Kenan, PD | 1 |
| Huang, A | 1 |
| Womack, T | 1 |
| Bjurstrom, T | 1 |
| Bajorin, D | 1 |
| Motzer, R | 1 |
| Scher, H | 1 |
| Louison, C | 1 |
| Harrison, L | 1 |
| Strong, E | 1 |
| Bosl, G | 1 |
| Shamseddine, AI | 1 |
| Wehbeh, MH | 1 |
| Lin, CZ | 1 |
| Fedeli, A | 1 |
| Luzi Fedeli, S | 1 |
| Rustamov, IR | 1 |
| Dzhulbekov, KI | 1 |
| Schlappack, O | 1 |
| Springer, B | 1 |
| Hainz, A | 1 |
| Rosen, A | 1 |
| Scher, N | 1 |
| Panje, WR | 9 |
| Gall, FP | 2 |
| Endoh, M | 1 |
| Anai, H | 1 |
| Toda, T | 1 |
| Ichiyoshi, Y | 1 |
| Miura, O | 1 |
| Matsuzaki, K | 1 |
| Minamisono, Y | 1 |
| Nagasaki, S | 1 |
| Segati, R | 2 |
| Lora, O | 1 |
| Friso, ML | 1 |
| Favaretto, A | 1 |
| Koh, WJ | 1 |
| Wallace, HJ | 1 |
| Greer, BE | 1 |
| Cain, J | 1 |
| Stelzer, KJ | 1 |
| Tamimi, HK | 1 |
| Figge, DC | 1 |
| Griffin, TW | 1 |
| Hoff, SJ | 1 |
| Sawyers, JL | 1 |
| Murray, MJ | 1 |
| Merrill, WH | 1 |
| Adkins, RB | 1 |
| Johnson, DH | 1 |
| Koizumi, H | 1 |
| Fukano, F | 1 |
| Tokunaga, M | 1 |
| Moriwaki, R | 1 |
| Murren, JR | 1 |
| Ganpule, S | 1 |
| Papac, R | 1 |
| Peschel, RE | 1 |
| Durivage, H | 1 |
| Buzaid, AC | 1 |
| Lamb, L | 1 |
| Makuch, R | 1 |
| Hait, WN | 1 |
| Visser, GW | 1 |
| Wedzinga, R | 1 |
| Smid, K | 1 |
| Turner, SL | 2 |
| Byers, RM | 4 |
| Guillory, C | 1 |
| McCarthy, K | 2 |
| Wong, G | 1 |
| Hodson, I | 2 |
| McAlpine, L | 1 |
| Skingley, P | 2 |
| Tanum, G | 2 |
| Karlsen, KO | 2 |
| Junor, E | 1 |
| Canney, P | 1 |
| Yosef, H | 2 |
| Darnton, SJ | 1 |
| Allen, SM | 1 |
| Edwards, CW | 1 |
| Matthews, HR | 1 |
| Sugimori, H | 1 |
| Chifu, Y | 1 |
| Kudo, J | 1 |
| Ishida, T | 1 |
| Niho, Y | 5 |
| You, YT | 1 |
| Wang, JY | 1 |
| Changchien, CR | 1 |
| Hsu, KC | 1 |
| Tang, R | 1 |
| Fan, HA | 1 |
| Harvey, JC | 1 |
| Davidson, W | 1 |
| Wadler, S | 3 |
| Fell, S | 2 |
| Haynes, H | 3 |
| Katz, HJ | 1 |
| Rozenblit, A | 1 |
| Kaleya, R | 1 |
| Wiernik, PH | 2 |
| Jassem, J | 1 |
| Gyergyay, F | 1 |
| Kerpel-Fronius, S | 1 |
| Nagykálnai, T | 1 |
| Baumöhl, J | 1 |
| Vuletic, L | 1 |
| Mechl, Z | 1 |
| Drozd-Lula, M | 1 |
| Payne, D | 1 |
| Rawlinson, E | 2 |
| MacKenzie, R | 1 |
| Danjoux, C | 2 |
| Carey, RW | 5 |
| Hilgenberg, AD | 4 |
| Wilkins, EW | 3 |
| Mathisen, DJ | 5 |
| Grillo, HC | 4 |
| Wain, JC | 3 |
| Logan, DL | 2 |
| Bromberg, C | 2 |
| Hasezawa, K | 1 |
| Muta, N | 1 |
| Terahara, A | 2 |
| Onogi, Y | 1 |
| Akanuma, A | 1 |
| Girard, A | 1 |
| Perez-Tamayo, C | 3 |
| Arlington, A | 1 |
| Bohorquez, J | 1 |
| Cheruku, R | 1 |
| Tyrkus, M | 1 |
| Edelstein, M | 1 |
| Macia, M | 1 |
| Novo, A | 1 |
| Ces, J | 1 |
| Gonzalez, M | 1 |
| Huidobro, C | 1 |
| Yuste, J | 1 |
| Diab, T | 1 |
| Gregg, CM | 1 |
| Beals, TE | 1 |
| McClatchy, KM | 1 |
| Hecquet, B | 2 |
| Meeus, L | 4 |
| Krakowski, I | 2 |
| De Gislain, C | 2 |
| Chauvergne, J | 3 |
| Dufour-Esquerré, F | 2 |
| Carde, P | 1 |
| Roca, E | 1 |
| Milano, MC | 1 |
| Pennella, E | 1 |
| Barugel, M | 1 |
| Gualdrini, U | 1 |
| Lumi, M | 1 |
| Gonzalez, G | 1 |
| Sardi, M | 1 |
| Fleischer, I | 1 |
| Graziano, A | 1 |
| Yagihashi, A | 1 |
| Hirata, K | 1 |
| Yamamitsu, S | 1 |
| Somekawa, Y | 2 |
| Asano, K | 2 |
| Imai, R | 1 |
| Neuberg, D | 2 |
| Pisansky, TM | 2 |
| Ginsberg, R | 2 |
| Benson, A | 1 |
| Bates, BA | 1 |
| Detterbeck, FC | 2 |
| Bernard, SA | 3 |
| Qaqish, BF | 2 |
| Tepper, JE | 3 |
| Kitchell, BK | 1 |
| Orenberg, EK | 2 |
| Brown, DM | 1 |
| Hutson, C | 1 |
| Ray, K | 1 |
| Woods, L | 1 |
| Luck, E | 1 |
| Malhaire, JP | 2 |
| Labat, JP | 2 |
| Simon, H | 2 |
| Lucas, B | 2 |
| Topart, P | 2 |
| Volant, A | 1 |
| Zeng, Z | 1 |
| Pouliquen, X | 2 |
| Levard, H | 2 |
| Hay, JM | 2 |
| McGee, K | 1 |
| Fingerhut, A | 2 |
| Langlois-Zantin, O | 1 |
| Narimatsu, A | 2 |
| Okada, O | 2 |
| Lupi, G | 1 |
| Raspagliesi, F | 1 |
| Zucali, R | 3 |
| Fontanelli, R | 1 |
| Paladini, D | 1 |
| Kenda, R | 2 |
| di Re, F | 1 |
| Vitale, V | 6 |
| Bonelli, L | 3 |
| Santi, L | 1 |
| Hosokawa, K | 2 |
| Hasebe, T | 1 |
| Alba, E | 1 |
| Sanchez-Chaparro, MA | 1 |
| Alonso, L | 1 |
| Ribelles, N | 1 |
| Ramon Delgado, J | 1 |
| Pablo Tenllado, P | 1 |
| Solano, J | 1 |
| Urquiza, R | 1 |
| Goyal, S | 1 |
| Wang, LS | 1 |
| Hu, MH | 1 |
| Fahn, HJ | 1 |
| Huang, MH | 1 |
| Cwikiel, W | 1 |
| Esaki, T | 3 |
| Masumoto, N | 2 |
| Fett, W | 1 |
| Makoski, HB | 1 |
| Breuer, N | 1 |
| Schmidt, U | 1 |
| Niebel, W | 1 |
| Eigler, FW | 1 |
| Ikegami, H | 1 |
| Kawase, T | 1 |
| Yokota, S | 1 |
| Tachibana, T | 1 |
| Igarashi, T | 1 |
| Komuta, K | 1 |
| Ho, ES | 1 |
| Jan, JS | 3 |
| Liu, FS | 1 |
| Kosmidis, P | 2 |
| Sridhar, KS | 8 |
| Banis, K | 2 |
| Dimitriadis, A | 2 |
| Avramidis, V | 1 |
| Zaramboukas, T | 2 |
| Vritsios, A | 4 |
| Daniilidis, I | 1 |
| Benedetti, J | 1 |
| Smith, RE | 1 |
| Rodriguez, GI | 1 |
| Schuller, D | 1 |
| Wagner, RL | 5 |
| Dragovic, J | 1 |
| Doyle, TJ | 1 |
| Tilchen, EJ | 1 |
| Nichols, RD | 1 |
| Benninger, MS | 1 |
| Carlson, ER | 1 |
| Boyd, SB | 1 |
| Jacobsen, GR | 1 |
| Sundfør, K | 1 |
| Tropé, CG | 1 |
| Högberg, T | 1 |
| Onsrud, M | 1 |
| Koern, J | 1 |
| Simonsen, E | 1 |
| Bertelsen, K | 1 |
| Westberg, R | 1 |
| Bensmaine, ME | 1 |
| Azli, N | 4 |
| Cvitkovic, E | 11 |
| Jen, YM | 1 |
| Wu, CJ | 1 |
| Liu, HS | 1 |
| Su, CC | 1 |
| Hwang, JM | 1 |
| Zidan, J | 3 |
| Robinson, E | 2 |
| Camacho, M | 2 |
| Levine, B | 1 |
| Bensmaine, MA | 1 |
| Tellez Bernal, E | 2 |
| Recondo, G | 5 |
| Eschwege, F | 5 |
| Andreyev, HJ | 2 |
| Hill, AS | 1 |
| Ross, PJ | 1 |
| Webb, A | 1 |
| Hareyama, M | 1 |
| Nagakura, H | 1 |
| Tamakawa, M | 1 |
| Hyodo, K | 1 |
| Asakura, K | 1 |
| Horikoshi, T | 1 |
| Tanaka, S | 1 |
| Hattori, A | 1 |
| Oouchi, A | 1 |
| Shido, M | 1 |
| Koshiba, H | 1 |
| Morita, K | 1 |
| Olver, IN | 2 |
| Hughes, PG | 1 |
| Narayan, K | 1 |
| Barbieux, C | 1 |
| Patri, B | 1 |
| Cerf, I | 1 |
| de Parades, V | 1 |
| Bernal, ET | 1 |
| Sigal, R | 1 |
| Kondoh, H | 1 |
| Niwa, K | 1 |
| Itoh, N | 1 |
| Murase, T | 1 |
| Morishita, S | 1 |
| Tamaya, T | 1 |
| Walter, S | 1 |
| Brette, MD | 1 |
| Monteil, JP | 1 |
| Deboise, A | 1 |
| Leridant, AM | 2 |
| Haddad, E | 1 |
| Mazeron, JJ | 3 |
| Vergnes, L | 2 |
| Brun, B | 1 |
| Piedbois, P | 1 |
| Coste, A | 1 |
| Lelievre, G | 2 |
| Peynegre, R | 2 |
| Le Bourgeois, JP | 1 |
| Romestaing, P | 3 |
| Sentenac, I | 1 |
| Mahé, M | 2 |
| Geara, F | 2 |
| Chauvet, B | 1 |
| Reynaud-Bougnoux, A | 4 |
| Le Floch, O | 4 |
| Carroll, WR | 1 |
| Hazuka, MB | 1 |
| Littles, FJ | 1 |
| Strawderman, M | 3 |
| Khayat, D | 1 |
| Nakazawa, E | 1 |
| Nishiya, M | 1 |
| Cai, Y | 1 |
| Berger, C | 2 |
| Garand, G | 3 |
| Christie, DR | 1 |
| Bull, CA | 1 |
| Mantovani, G | 4 |
| Agostara, B | 2 |
| Contu, A | 1 |
| Colucci, G | 1 |
| Ferrero, B | 1 |
| Popik, MP | 1 |
| Podik, OP | 1 |
| Galun, MM | 1 |
| Mishra, RC | 1 |
| Senapati, S | 1 |
| Sai, PL | 1 |
| Flam, M | 5 |
| Petrelli, N | 1 |
| Doggett, S | 1 |
| Quivey, J | 1 |
| Kerman, H | 1 |
| Murray, K | 1 |
| Look, KY | 2 |
| Gallup, DG | 2 |
| Lentz, SS | 1 |
| Spry, NA | 1 |
| Joseph, DJ | 1 |
| O'Brien, P | 1 |
| Walker, QJ | 1 |
| Fournier, C | 2 |
| Pion, JM | 1 |
| Jacobson, J | 1 |
| Valdivieso, M | 1 |
| Hutchins, LF | 2 |
| Macdonald, JS | 1 |
| Bianchi, A | 2 |
| Curreli, L | 3 |
| Ghiani, M | 2 |
| Santona, MC | 1 |
| Proto, E | 2 |
| Puxeddu, P | 1 |
| Feliu, J | 1 |
| González Barón, M | 1 |
| Espinosa, E | 1 |
| Vicent, JM | 1 |
| Gómez Navarro, J | 1 |
| Ordóñez, A | 1 |
| Vilches, Y | 1 |
| de Castro, J | 1 |
| Díaz, J | 1 |
| Hsu, CY | 2 |
| Bottomley, DM | 1 |
| Aqel, N | 1 |
| Selvaratnam, G | 1 |
| Phillips, RH | 1 |
| Ohno, Y | 4 |
| Tokumaru, Y | 3 |
| Imanishi, Y | 3 |
| Kanke, M | 4 |
| Zinman, LN | 1 |
| Leibenhaut, M | 1 |
| Girshovich, L | 1 |
| Silverman, ML | 1 |
| Doci, R | 2 |
| La Monica, G | 1 |
| Meroni, E | 1 |
| Eboli, M | 1 |
| Lozza, L | 1 |
| Murata, R | 1 |
| Hirohashi, M | 1 |
| Takagi, T | 1 |
| Oya, N | 1 |
| Hatton, MQ | 1 |
| Junor, EJ | 1 |
| Paul, J | 1 |
| Canney, PA | 1 |
| McGurk, FM | 1 |
| Symonds, RP | 1 |
| de Crevoisier, R | 3 |
| Ebie, N | 1 |
| Kang, HJ | 1 |
| Millikan, K | 1 |
| Griem, K | 2 |
| Hartsell, W | 1 |
| Recine, DC | 1 |
| Doolas, A | 1 |
| Taylor, S | 4 |
| del Campo, JM | 1 |
| Felip, E | 1 |
| Giralt, J | 1 |
| Raspall, G | 1 |
| Bescos, S | 1 |
| Casado, S | 1 |
| Maldonado, X | 1 |
| Athanasiadis, I | 2 |
| Pelzer, HJ | 1 |
| Ganzenko, N | 1 |
| Blough, R | 1 |
| Lester, EP | 2 |
| Dimpfl, T | 1 |
| Stumpfe, M | 1 |
| Baltzer, J | 1 |
| Genz, T | 1 |
| Kageyama, S | 1 |
| Rudat, V | 3 |
| Nollert, J | 1 |
| Maiei, H | 1 |
| Wannenmacher, M | 6 |
| Weidauer, H | 2 |
| Geara, FB | 1 |
| Sanguineti, G | 6 |
| Tucker, SL | 1 |
| Clayman, GL | 2 |
| Desogus, A | 1 |
| Moschella, F | 1 |
| Di Gregorio, C | 1 |
| Bajetta, E | 2 |
| Gebbia, N | 2 |
| Itoh, H | 1 |
| Akasaka, Y | 1 |
| Ikeguchi, K | 1 |
| Hanyu, S | 1 |
| Numao, A | 2 |
| Miyaji, N | 1 |
| Miki, T | 1 |
| Takeshita, T | 1 |
| Churei, H | 1 |
| Fukumoto, T | 1 |
| Aiko, T | 1 |
| Maenohara, S | 1 |
| Minamimagari, H | 1 |
| Théon, AP | 1 |
| Pascoe, JR | 1 |
| Madigan, JE | 1 |
| Carlson, G | 1 |
| Metzger, L | 1 |
| Qian, C | 1 |
| Kocha, WI | 2 |
| Coia, LR | 6 |
| Graham, M | 3 |
| Sharma, D | 1 |
| Davis, EB | 1 |
| Lunzer, S | 1 |
| Hussain, MA | 2 |
| Nishino, H | 3 |
| Ueyama, N | 1 |
| Adamietz, IA | 1 |
| Lorenz, M | 1 |
| Staib-Sebler, E | 1 |
| Böttcher, HD | 1 |
| Beauvillain, C | 1 |
| Peuvrel, P | 1 |
| Rivière, A | 2 |
| Vignoud, J | 2 |
| Deraucourt, D | 1 |
| Wesoluch, M | 1 |
| Lewin, F | 1 |
| Damber, L | 1 |
| Jonsson, H | 1 |
| Andersson, T | 2 |
| Berthelsen, A | 1 |
| Biörklund, A | 3 |
| Blomqvist, E | 1 |
| Evensen, JF | 2 |
| Hansen, HS | 1 |
| Hansen, O | 1 |
| Jetlund, O | 1 |
| Modig, H | 1 |
| Overgaard, M | 1 |
| Rosengren, B | 1 |
| Tausjö, J | 1 |
| Tanino, H | 2 |
| Bessho, T | 2 |
| Maebeya, S | 2 |
| Suzuma, T | 2 |
| Hirai, I | 2 |
| Arimoto, J | 2 |
| Harada, N | 1 |
| Hoso, T | 1 |
| Naito, Y | 2 |
| Papola, F | 2 |
| Corbacelli, A | 2 |
| Kumagai, K | 2 |
| Ueki, K | 2 |
| Inoki, C | 1 |
| Orino, I | 1 |
| Ueki, M | 3 |
| Moylan, E | 1 |
| Falk, GL | 1 |
| Santa Cruz Ruiz, S | 1 |
| Gómez González, JL | 1 |
| Flores Corral, T | 1 |
| Del Cañizo Alvarez, A | 1 |
| Cheung, AY | 1 |
| Rinehart, J | 1 |
| Ruff, T | 1 |
| ElAttar, TM | 1 |
| Virji, AS | 1 |
| Rodríguez, CA | 1 |
| Gómez-Bernal, A | 1 |
| Martín, G | 1 |
| Sánchez, P | 1 |
| Nieto, A | 1 |
| Soria, P | 1 |
| Vega, MJ | 1 |
| Muñoz, A | 1 |
| Pardal, JL | 1 |
| Rosenblatt, E | 2 |
| Jones, DR | 1 |
| Egan, TM | 1 |
| Parker, LA | 1 |
| Metges, JP | 1 |
| Lamezec, B | 1 |
| Kumagai, S | 1 |
| Sakaki, K | 1 |
| Morikawa, H | 1 |
| Song, ST | 1 |
| Mori, S | 1 |
| Fishman, A | 1 |
| Chiu, JK | 1 |
| Girtanner, RE | 1 |
| Dennis, W | 1 |
| Carpenter, LS | 1 |
| Lu, HH | 1 |
| Woo, SY | 1 |
| Kerley, JM | 1 |
| Kaplan, AL | 1 |
| Cunningham, MJ | 1 |
| Goyer, RP | 1 |
| Gibbons, SK | 1 |
| Kredentser, DC | 1 |
| Malfetano, JH | 3 |
| Keys, H | 1 |
| Kirschner, MJ | 1 |
| Waldfahrer, F | 1 |
| Tomiyoshi, H | 1 |
| Tatsumoto, T | 2 |
| Fok, M | 1 |
| Chow, S | 1 |
| Chu, KM | 1 |
| Wong, J | 2 |
| Rakovitch, E | 1 |
| Fyles, AW | 1 |
| Pintilie, M | 2 |
| Leung, PM | 1 |
| Girinsky, T | 2 |
| Marsiglia, H | 1 |
| Dhermain, F | 1 |
| Randrianarivelo, H | 1 |
| Kac, J | 3 |
| Elias, D | 3 |
| Deleyiannis, FW | 1 |
| Weymuller, EA | 1 |
| Coltrera, MD | 1 |
| Andersen, JW | 2 |
| Dreyfuss, AI | 2 |
| Rossi, RM | 1 |
| Poulin, MD | 1 |
| Lucarini, JW | 2 |
| Lucarini, D | 1 |
| Thornhill, L | 1 |
| Lackey, M | 1 |
| Peters, E | 1 |
| Bleiberg, H | 1 |
| Lacave, AJ | 1 |
| Blijham, G | 1 |
| Namer, M | 2 |
| De Besi, P | 4 |
| Gay, F | 2 |
| Sahmoud, T | 1 |
| Pitman, KT | 1 |
| Larto, MA | 2 |
| Kirby, TJ | 1 |
| Koka, A | 1 |
| Tefft, M | 2 |
| Mertens, R | 1 |
| Granzen, B | 1 |
| Lassay, L | 1 |
| Gademann, G | 1 |
| Heimann, G | 1 |
| Eliachar, I | 4 |
| Van Kirk, MA | 2 |
| Secic, M | 2 |
| Wanamaker, JR | 3 |
| Tuason, L | 1 |
| Ago, CT | 1 |
| Irwin, JF | 1 |
| Waterfield, W | 1 |
| Poussin-Rosillo, H | 1 |
| Sardi, A | 1 |
| Clocchiatti, L | 1 |
| Mansutti, M | 1 |
| Sibau, AM | 1 |
| González-Larriba, JL | 1 |
| Garcia Carbonero, I | 1 |
| Sastre Valera, J | 1 |
| Perez Segura, P | 1 |
| Diaz-Rubio, E | 2 |
| Satoh, N | 1 |
| Fushiki, H | 1 |
| Hidaka, T | 1 |
| Fujimura, M | 1 |
| Yamakawa, Y | 1 |
| Izumi, R | 3 |
| Kuroda, Y | 3 |
| Yoden, E | 2 |
| Takakita, S | 1 |
| Wright, CD | 1 |
| Grossbard, ML | 1 |
| Moncure, AC | 1 |
| Okawa, MK | 1 |
| Kokubo, N | 1 |
| Fukuhara, N | 1 |
| Toda, J | 1 |
| Okawa, T | 1 |
| Konishi, T | 1 |
| Shimoyama, S | 1 |
| Ito, A | 1 |
| Nouchi, T | 1 |
| Sekiguchi, K | 1 |
| Shimizu, S | 1 |
| Hojo, K | 2 |
| Mori, H | 1 |
| Boccato, P | 2 |
| Angeli, CD | 2 |
| Merigliano, S | 2 |
| Santi, S | 2 |
| Bonavina, L | 2 |
| Peracchia, A | 4 |
| Vanselow, B | 2 |
| Wollensack, P | 2 |
| Bettscheider, C | 1 |
| Eble, MJ | 1 |
| Salwen, W | 2 |
| Landreaneau, RJ | 1 |
| Ramanathan, RK | 1 |
| Day, R | 1 |
| Ferson, PF | 1 |
| Keenan, RJ | 1 |
| Seeger, J | 1 |
| Lembersky, B | 1 |
| Dresler, C | 1 |
| Ray-Coquard, I | 1 |
| Bolla, M | 2 |
| Brochon, D | 1 |
| Lebeau, J | 1 |
| Colonna, M | 1 |
| Kolodié, H | 1 |
| Vincent, F | 1 |
| Chinal-Provencal, J | 1 |
| Paterson, S | 1 |
| Kanzaki, J | 2 |
| Maoleekoonpairoj, S | 1 |
| Phromratanapongse, P | 1 |
| Puttanuparp, S | 1 |
| Ogasawara, S | 2 |
| Kraus, S | 1 |
| Miller, BH | 1 |
| Swinehart, JM | 1 |
| Shavin, JS | 1 |
| Georgouras, KE | 1 |
| Jenner, DA | 1 |
| Griffin, E | 1 |
| Korey, A | 1 |
| Piura, B | 1 |
| Rabinovich, A | 1 |
| Cohen, Y | 1 |
| Friger, M | 1 |
| Glezerman, M | 1 |
| Hajiro, K | 2 |
| Acimovic, L | 1 |
| Matovic, Z | 1 |
| Milicic, B | 1 |
| Milisavljevic, S | 1 |
| Nikolic, N | 1 |
| Bonnier, P | 1 |
| Delaby, F | 1 |
| Murraciole, X | 1 |
| Lejeune, C | 1 |
| Hadjadj, DJ | 1 |
| Juin, P | 1 |
| Piana, L | 1 |
| LeBlanc, M | 1 |
| Adams, G | 1 |
| Thiel, HJ | 1 |
| Aydin, H | 1 |
| Rohloff, R | 3 |
| Wustrow, TP | 6 |
| Popella, C | 1 |
| Schalhorn, A | 3 |
| Fried, M | 1 |
| Poulin, M | 1 |
| Fabian, RL | 2 |
| Dreyfuss, A | 1 |
| Peters, ES | 1 |
| Barton, JJ | 2 |
| Isaia, A | 1 |
| Schrader, M | 1 |
| Schipper, J | 1 |
| Ayzac, L | 1 |
| Hun, D | 1 |
| Coquard, R | 1 |
| Bhalla, K | 1 |
| Forastiere, A | 2 |
| Patel, P | 1 |
| Donegan, J | 1 |
| Reed, C | 1 |
| Delouche, D | 1 |
| Haefliger, JM | 1 |
| Bryce, TJ | 1 |
| Dewhirst, MW | 1 |
| Floyd, CE | 1 |
| Hars, V | 1 |
| Bando, K | 1 |
| Takita, M | 1 |
| Okawa, K | 1 |
| Ujihara, Y | 1 |
| Numico, GM | 2 |
| Danova, M | 1 |
| Santelli, A | 4 |
| Ameli, F | 1 |
| Yamaoka, H | 2 |
| Nagahara, T | 2 |
| Kagata, H | 1 |
| Kagesato, Y | 1 |
| Daicho, S | 1 |
| Mizuno, H | 2 |
| Kawakami, K | 1 |
| Lu, JD | 1 |
| Kim, RY | 4 |
| Svensson, C | 2 |
| Goldman, S | 2 |
| Friberg, B | 1 |
| Glimelius, B | 1 |
| Schaebler, D | 1 |
| Sauter, E | 1 |
| DeMaria, D | 1 |
| Johnson, C | 1 |
| Reilly, DM | 1 |
| Leighton, J | 1 |
| Aks, C | 1 |
| Litwin, S | 1 |
| Fujieda, S | 2 |
| Sunaga, H | 2 |
| Tsuzuki, H | 2 |
| Teicher, BA | 1 |
| Ara, G | 1 |
| Chen, YN | 1 |
| Richard, JM | 4 |
| Sancho-Garnier, H | 2 |
| Dehesdin, D | 2 |
| Stromboni-Luboinski, M | 2 |
| Hill, C | 2 |
| Lee, DJ | 1 |
| Hara, S | 1 |
| Itoyanagi, N | 1 |
| Ryu, C | 1 |
| Fukuoka, H | 1 |
| Ayabe, H | 1 |
| Nakao, H | 1 |
| Nogawa, T | 1 |
| Kozloff, M | 1 |
| Mittal, B | 2 |
| Wenig, B | 2 |
| Vanhoefer, U | 1 |
| Müller, C | 1 |
| Teo, PM | 1 |
| Lam, KC | 1 |
| Chan, WY | 1 |
| Chow, JH | 1 |
| Yim, AP | 1 |
| Mok, TS | 1 |
| Kwan, WH | 1 |
| Leung, TW | 1 |
| Johnson, PJ | 1 |
| Khalil, A | 1 |
| Chammas, M | 1 |
| Shamseddine, A | 1 |
| Seoud, M | 1 |
| Heresbach, D | 1 |
| Montana, GS | 1 |
| Saxer, A | 1 |
| Olt, G | 1 |
| Milan, C | 1 |
| Renard, P | 1 |
| Fraisse, J | 1 |
| Lacourt, J | 1 |
| Janoray, P | 1 |
| Faivre, J | 1 |
| Slabber, CF | 1 |
| Nel, JS | 1 |
| Schoeman, L | 3 |
| Burger, W | 3 |
| Falkson, CI | 1 |
| Stadler, P | 1 |
| Feldmann, HJ | 1 |
| Creighton, C | 1 |
| Kau, R | 1 |
| Pivot, X | 3 |
| Prevost, B | 1 |
| Coche-Dequeant, B | 2 |
| Courdi, A | 2 |
| Teissier, E | 1 |
| Smith, TJ | 1 |
| Ryan, LM | 1 |
| Douglass, HO | 1 |
| Dayal, Y | 1 |
| Kirkwood, J | 1 |
| Tormey, DC | 1 |
| Schutt, AJ | 1 |
| Hinson, J | 1 |
| Harrison, LB | 1 |
| Enker, WE | 1 |
| Mychalczak, B | 1 |
| Guillem, J | 1 |
| Anderson, L | 1 |
| White, C | 1 |
| Cohen, AM | 1 |
| Giaretti, W | 1 |
| Geido, E | 1 |
| Preisler, HD | 1 |
| Kotelnikov, VM | 1 |
| LaFollette, S | 1 |
| Mundle, S | 1 |
| Wood, N | 1 |
| Coon, JS | 1 |
| Hutchinson, J | 1 |
| Panje, W | 1 |
| Di Emidio, P | 1 |
| Hyacinthe, M | 1 |
| Coppola, D | 1 |
| Goodgame, T | 1 |
| Redwood, W | 1 |
| Goldenfarb, P | 1 |
| Ohori, NP | 1 |
| Marcet, J | 1 |
| Bumma, C | 2 |
| Contu, P | 1 |
| Dessì, D | 1 |
| Lampis, B | 1 |
| Lai, P | 1 |
| Mulas, C | 1 |
| Cadeddu, G | 1 |
| Tore, G | 1 |
| Lindner, H | 1 |
| Chevallier, P | 1 |
| Ferrero, JM | 1 |
| Rogopoulos, A | 1 |
| Bruneton, JN | 1 |
| Langlois-Zantain, O | 1 |
| Huguier, M | 2 |
| Lozach, P | 1 |
| Testart, J | 1 |
| Sheahan, DG | 1 |
| Gunderson, L | 1 |
| Estes, N | 1 |
| Kasai, H | 1 |
| Wada, T | 1 |
| Nishida, K | 1 |
| Maekawa, R | 1 |
| Sugita, K | 1 |
| Aziz, SA | 1 |
| Tramboo, NA | 1 |
| Mohi-ud-Din, K | 1 |
| Iqbal, K | 1 |
| Jalal, S | 1 |
| Obradovic, M | 1 |
| Laurencet, F | 1 |
| Spada, A | 1 |
| Marti, MC | 1 |
| Kurtz, JM | 2 |
| Akpek, G | 1 |
| Hartshorn, KL | 1 |
| Matzel, K | 1 |
| Nagawa, H | 1 |
| Tsuruo, T | 1 |
| Muto, T | 1 |
| Heep, H | 2 |
| Dutkowski, P | 1 |
| Willers, R | 1 |
| Gabbert, HE | 1 |
| Sánchez Parra, M | 1 |
| Churruca, C | 1 |
| Paredes, A | 1 |
| Lacasta, A | 1 |
| López de Argumedo, G | 1 |
| Alvárez, I | 1 |
| Abad, T | 1 |
| Egana, L | 1 |
| Guimón, E | 1 |
| Piera, JM | 1 |
| Sekiguchi, H | 1 |
| Sakamoto, J | 1 |
| Giatromanolaki, A | 2 |
| Koukourakis, MI | 2 |
| Georgoulias, V | 1 |
| Gatter, KC | 2 |
| Harris, AL | 2 |
| Ginsberg, RJ | 2 |
| Pajak, T | 1 |
| Salter, M | 1 |
| Kies, M | 2 |
| Sulzen, L | 1 |
| Marcolin, P | 1 |
| Russo Spena, F | 1 |
| Biglietto, M | 1 |
| Cartenì, G | 2 |
| Gravina, A | 2 |
| Bonin, SR | 1 |
| Paris, KJ | 1 |
| Sauter, ER | 1 |
| Wong, DY | 1 |
| Goldblum, J | 1 |
| Medendorp, SV | 1 |
| Pimentel, R | 1 |
| Gitlin, L | 1 |
| Sormani, M | 1 |
| Roncallo, F | 1 |
| Mereu, P | 1 |
| Juturi, JV | 1 |
| Francis, B | 1 |
| Koontz, PW | 1 |
| Wilkes, JD | 1 |
| Paulsen, T | 1 |
| Kaern, J | 3 |
| Tropé, C | 4 |
| Klas, JV | 1 |
| Rothenberger, DA | 1 |
| Madoff, RD | 1 |
| Warner, E | 1 |
| Jensen, JL | 1 |
| Khoo, KE | 1 |
| Goel, R | 1 |
| Kerr, IA | 1 |
| Bjarnason, GA | 1 |
| Fields, AL | 1 |
| Hrincu, A | 1 |
| Nathu, RM | 1 |
| Carroll, RR | 2 |
| Sause, W | 1 |
| Bundy, BN | 1 |
| Hannigan, EV | 1 |
| Fowler, WC | 2 |
| Clarke-Pearson, DL | 1 |
| Liao, SY | 1 |
| Kumamoto, Y | 1 |
| Inokuchi, A | 2 |
| Masuda, A | 1 |
| Ohmagari, J | 1 |
| Matsui, K | 1 |
| Kuraoka, A | 1 |
| Schlemmer, HP | 1 |
| Bachert, P | 1 |
| Zuna, I | 1 |
| Knopp, MV | 1 |
| van Kaick, G | 1 |
| Rayson, D | 1 |
| Adjei, AA | 1 |
| Suman, VJ | 1 |
| Wold, LE | 1 |
| Ingle, JN | 1 |
| Noda, I | 1 |
| Sugimoto, C | 1 |
| Cabelguenne, A | 2 |
| Carnot, F | 2 |
| de Waziers, I | 2 |
| Hamelin, R | 1 |
| Marth, C | 1 |
| Sundfor, K | 1 |
| Streeter, OE | 1 |
| Martz, KL | 1 |
| Delrowe, JD | 1 |
| Asbell, SO | 1 |
| Salter, MM | 3 |
| Roach, M | 1 |
| Hafez, N | 1 |
| Ayache, S | 1 |
| Jones, BD | 1 |
| Damle, S | 1 |
| Wolf, E | 1 |
| Saade, M | 1 |
| Debahy, NE | 1 |
| Houjeily, S | 1 |
| Jonker, D | 1 |
| Mehran, R | 1 |
| Maroun, J | 1 |
| Crepeau, A | 1 |
| Chaney, AW | 1 |
| Logsdon, MD | 1 |
| Wharton, JT | 1 |
| Todoroki, T | 2 |
| Fukao, K | 2 |
| Shimizu, W | 2 |
| Monoi, H | 1 |
| Kawai, Y | 1 |
| Kohno, S | 1 |
| Hada, T | 1 |
| Ohmori, H | 1 |
| Sasaya, K | 1 |
| Matai, K | 1 |
| Yamazaki, Y | 1 |
| Shibusawa, H | 1 |
| Ueno, I | 1 |
| Sakuma, K | 1 |
| Kobayashi, N | 1 |
| Kanazawa, K | 1 |
| Yorozu, A | 1 |
| Dokiya, T | 1 |
| Oki, Y | 1 |
| Nishimura, S | 1 |
| Wong, CS | 3 |
| Tsao, MS | 1 |
| Chapman, WB | 1 |
| Iizuka, N | 2 |
| Noma, T | 1 |
| Hazama, S | 2 |
| Hayashi, H | 4 |
| Oka, M | 2 |
| Grogan, M | 1 |
| Melamed, I | 1 |
| Wong, FL | 1 |
| Pearcey, RG | 1 |
| Joseph, PK | 1 |
| Portelance, L | 1 |
| Crook, J | 1 |
| Jones, KD | 1 |
| Chidel, MA | 1 |
| Kupelian, PA | 1 |
| Suh, JH | 1 |
| Gmyrek, R | 1 |
| Beer, R | 1 |
| Elizeri, Y | 1 |
| Silvers, DN | 1 |
| Schneiderman, P | 1 |
| Grossman, ME | 1 |
| Fried, MP | 2 |
| Gomolin, HI | 1 |
| Amrein, P | 2 |
| Lamb, C | 1 |
| Barton, J | 1 |
| Read, R | 2 |
| Eckel, H | 1 |
| Stennert, E | 2 |
| Callender, DL | 1 |
| Satake, M | 2 |
| Ong, YK | 1 |
| Goh, CB | 1 |
| Lee, KS | 1 |
| Chua, EJ | 1 |
| Huang, XY | 1 |
| Sasagawa, I | 1 |
| Ishigooka, M | 1 |
| Hong, S | 1 |
| Chie, EK | 1 |
| Bang, YJ | 1 |
| Faivre, C | 1 |
| Lasser, P | 2 |
| Cox, NH | 1 |
| Eedy, DJ | 1 |
| Morton, CA | 1 |
| Gadgeel, S | 1 |
| Du, W | 2 |
| Taieb, S | 1 |
| Vaillant, E | 1 |
| Bonvoisin, S | 1 |
| Desseigne, F | 1 |
| Morignat, E | 1 |
| Ychou, M | 1 |
| Senesse, P | 1 |
| Dubois, JB | 1 |
| Lassaletta, L | 1 |
| Brandáriz, JA | 1 |
| de la Cruz, J | 1 |
| Gómez, C | 1 |
| Colomer, R | 1 |
| Alvarez-Vicent, JJ | 1 |
| Brown, D | 1 |
| Russell, P | 1 |
| Biswal, BM | 2 |
| Van den Brande, J | 1 |
| Schrijvers, D | 1 |
| Colpaert, C | 1 |
| Casaretti, R | 1 |
| Morsman, J | 1 |
| Blackie, R | 1 |
| Shiga, H | 2 |
| Rasmussen, AA | 2 |
| Trock, B | 1 |
| Johnston, PG | 2 |
| Langmacher, M | 2 |
| Baylor, A | 2 |
| Lee, M | 2 |
| Grüner, A | 1 |
| Weidenbecher, M | 1 |
| Martus, P | 1 |
| Flahault, A | 1 |
| Monceaux, G | 2 |
| Coulet, F | 1 |
| Callard, P | 1 |
| Bernaudin, JF | 1 |
| Ohmuma, T | 1 |
| Monney, M | 1 |
| Rosset, A | 1 |
| Ozsahin, M | 1 |
| Guillemin, C | 1 |
| Heitmiller, RF | 1 |
| Yang, SC | 1 |
| Talamini, MA | 1 |
| Kaufman, HS | 1 |
| Canto, MI | 1 |
| Topazian, M | 1 |
| Olukayode, K | 1 |
| Dickie, G | 1 |
| Hodge, R | 1 |
| Morton, K | 1 |
| de Belvis, V | 1 |
| Sivridis, E | 1 |
| Labadie, RF | 1 |
| Yarbrough, WG | 2 |
| Weissler, MC | 3 |
| Pillsbury, HC | 3 |
| Mukherji, SK | 1 |
| D'Costa, IA | 1 |
| Huges, PG | 1 |
| Sexton, MA | 1 |
| Lyons, B | 1 |
| Wilson, KS | 1 |
| Barroso, A | 1 |
| Nogueira, R | 1 |
| Lencastre, H | 1 |
| Seada, J | 1 |
| Parente, B | 1 |
| Turowski, B | 1 |
| Loitz, M | 1 |
| Lecanu, JB | 1 |
| Angelard, B | 2 |
| Alexander, EP | 1 |
| Lipman, T | 1 |
| Harmon, J | 1 |
| Wadleigh, R | 1 |
| Soussi, T | 1 |
| Tong, D | 1 |
| Poot, M | 1 |
| Hu, D | 1 |
| Oda, D | 1 |
| Janinis, J | 1 |
| Papadakou, M | 1 |
| Xidakis, E | 1 |
| Boukis, H | 1 |
| Poulis, A | 1 |
| Panagos, G | 1 |
| Lefantzis, D | 1 |
| Cartei, F | 1 |
| Interlandi, G | 1 |
| Meneghini, G | 1 |
| Jop, A | 1 |
| Zingone, G | 1 |
| Tabaro, G | 1 |
| Mazzoleni, F | 1 |
| Aref, A | 1 |
| Schwade, JG | 3 |
| Yoshimasu, T | 1 |
| Oura, S | 1 |
| Matsuyama, K | 1 |
| Gory-Delabaere, G | 1 |
| Brès, J | 1 |
| Gau, F | 1 |
| Constans, B | 1 |
| Nouguier-Soulé, J | 1 |
| Walz, M | 1 |
| Oldenburg, A | 1 |
| Chang, SK | 2 |
| Pyo, HR | 1 |
| Thorban, S | 1 |
| Rosenberg, R | 1 |
| Roder, RJ | 1 |
| Han, SC | 1 |
| Higgins, SA | 1 |
| Carcangiu, ML | 1 |
| Kacinski, BM | 1 |
| Liao, WC | 1 |
| Wu, FY | 1 |
| Wu, CW | 1 |
| Serrano-Castro, PJ | 1 |
| Guardado-Santervás, P | 1 |
| Olivares-Romero, J | 1 |
| Nakanoboh, M | 1 |
| Kawada, M | 1 |
| Hirosawa, H | 1 |
| Fukushima, W | 1 |
| Masutani, H | 1 |
| Kadoya, N | 1 |
| Hirono, T | 1 |
| Amrein, PC | 3 |
| Rivellini, F | 1 |
| Mozzillo, N | 1 |
| Manzione, L | 1 |
| Evans, C | 1 |
| Cockerell, CJ | 1 |
| Nemunaitis, J | 2 |
| Ganly, I | 1 |
| Arseneau, J | 1 |
| Tannock, IF | 1 |
| Romel, L | 1 |
| Gore, M | 1 |
| Ironside, J | 1 |
| Heise, C | 1 |
| Randlev, B | 1 |
| Gillenwater, AM | 1 |
| Bruso, P | 1 |
| Kaye, SB | 1 |
| Kirn, DH | 1 |
| Cuisnie, O | 1 |
| Chiarello, SE | 1 |
| Backus, HH | 1 |
| Wouters, D | 1 |
| Padrón, JM | 1 |
| Molders, N | 1 |
| van Groeningen, CJ | 1 |
| Jansen, G | 1 |
| Colarian, J | 1 |
| Fowler, D | 1 |
| Schor, J | 1 |
| Poolos, S | 1 |
| Yanoma, S | 2 |
| Akl, A | 1 |
| Akl, M | 1 |
| Boike, G | 1 |
| Hebert, J | 1 |
| Graham, J | 2 |
| Miller, CL | 1 |
| Templeton, RS | 1 |
| Karpinski, L | 1 |
| Park, TK | 1 |
| Kim, SN | 1 |
| Boronow, RC | 1 |
| Mancuso, S | 1 |
| Benedetti Panici, P | 1 |
| Favale, B | 1 |
| Greggi, S | 1 |
| Manfredi, R | 1 |
| Margariti, PA | 1 |
| Tortoreto, F | 1 |
| Cellini, N | 1 |
| Nakashima, S | 1 |
| Miyazono, F | 1 |
| Kijima, F | 1 |
| Aridome, K | 1 |
| Kusano, C | 1 |
| Baba, M | 1 |
| Lamont, JP | 1 |
| Kuhn, JA | 1 |
| Landers, SA | 1 |
| McCarty, TM | 1 |
| Tsuzuki, Y | 1 |
| Mochida, Y | 1 |
| Yoshikawa, M | 1 |
| Sekihara, M | 1 |
| Ide, M | 1 |
| Schäfer, U | 1 |
| Schüller, P | 1 |
| Micke, O | 1 |
| Willich, N | 2 |
| Siegelmann-Danieli, N | 1 |
| Hokamura, N | 1 |
| Nakanishi, Y | 1 |
| Ichimura, K | 2 |
| Abe, K | 1 |
| Orús, C | 2 |
| Sancho, FJ | 1 |
| de Juan, M | 1 |
| Maruyama, M | 1 |
| Kumagai, Y | 1 |
| Nara, S | 1 |
| Arii, S | 1 |
| Iwai, T | 1 |
| Kitaura, K | 1 |
| Kusada, O | 1 |
| Mochizuki, Y | 1 |
| Terai, Y | 1 |
| Sumi, H | 1 |
| Cheriparambil, KM | 1 |
| Vasireddy, H | 1 |
| Kuruvilla, A | 1 |
| Gambarin, B | 1 |
| Makan, M | 1 |
| Saul, BI | 1 |
| Glass, TR | 1 |
| Forman, J | 1 |
| Sakr, W | 1 |
| Smith, DC | 1 |
| Jones, J | 1 |
| Balcerzak, SP | 1 |
| Grossman, HB | 1 |
| Terrell, JE | 1 |
| Carpenter, V | 1 |
| Miller, T | 1 |
| Tang, G | 1 |
| de Dios, E | 1 |
| Recher, K | 1 |
| Tanizaki, A | 1 |
| Yamamoto, H | 1 |
| Nishioka, K | 1 |
| Hatta, H | 1 |
| Nishimoto, SI | 1 |
| Pehoushek, J | 1 |
| Smith, KJ | 1 |
| Frenette, G | 1 |
| Seroskie, JD | 1 |
| Olivares, R | 1 |
| Garay, CA | 1 |
| Marandas, P | 3 |
| Lhommé, C | 1 |
| Morice, P | 1 |
| Szumilo, J | 1 |
| Chibowski, D | 1 |
| D browski, A | 1 |
| Agarwal, J | 1 |
| Dinshaw, K | 1 |
| Nehru, RM | 1 |
| Mohandas, M | 1 |
| Deshpande, R | 1 |
| Rayabhattnavar, S | 1 |
| Turrisi, A | 1 |
| Iannettoni, M | 1 |
| Schnirer, II | 1 |
| Putnam, J | 1 |
| Pisters, PW | 2 |
| Gebhart, FH | 1 |
| Oechs, AC | 1 |
| Hebenstreit, J | 1 |
| Stoeger, H | 1 |
| Mitchell, SE | 1 |
| Shinners, MJ | 1 |
| Brodner, DC | 1 |
| Amedee, RG | 1 |
| Matsumoto, A | 1 |
| Kamata, M | 1 |
| List, M | 1 |
| Chung, T | 1 |
| Weichselbaum, R | 1 |
| Strickland, AH | 1 |
| Yip, D | 1 |
| Moore, MB | 1 |
| Aloia, T | 1 |
| Sporn, T | 1 |
| Parr, A | 1 |
| Linoila, I | 1 |
| Allegra, C | 2 |
| Delcambre, C | 1 |
| Pottier, D | 1 |
| Gignoux, M | 1 |
| Ollivier, JM | 1 |
| Vie, B | 1 |
| Roussel, A | 1 |
| Segol, P | 1 |
| Giovannini, M | 4 |
| Cvitkovic, F | 1 |
| Luporsi, E | 1 |
| Ng, SH | 1 |
| Liaw, CT | 1 |
| Yang, TS | 1 |
| Chen, IH | 1 |
| Sommer, K | 1 |
| Peters, SO | 1 |
| Robins, IH | 1 |
| Raap, M | 1 |
| Wiedemann, GJ | 1 |
| Remmert, S | 1 |
| Sieg, P | 1 |
| Bittner, C | 1 |
| Feyerabend, T | 1 |
| Hamouda, B | 1 |
| Jamila, Z | 1 |
| Najet, R | 1 |
| Slim, T | 1 |
| Rafiaa, N | 1 |
| Noureddine, B | 1 |
| Ahmed, EM | 1 |
| Mohamed, F | 1 |
| Ridha, KM | 1 |
| Abderrahman, L | 1 |
| Koscielny, S | 1 |
| Bobin, S | 1 |
| Zaninotto, G | 1 |
| Weber, DC | 1 |
| Glaser, CM | 1 |
| Kornek, GV | 1 |
| Lang, S | 1 |
| Schüll, B | 1 |
| Watzinger, F | 1 |
| Lavey, RS | 1 |
| Kovàcs, G | 1 |
| De Stefani, A | 1 |
| Marchionatti, S | 1 |
| Pedani, F | 6 |
| Gabriele, P | 3 |
| Kishimoto, H | 1 |
| Yoshioka, W | 1 |
| Teranobu, O | 1 |
| Shigeta, Y | 1 |
| Shimada, K | 1 |
| Kamiya, Y | 1 |
| Akazawa, N | 1 |
| Oko, T | 1 |
| Adachi, R | 1 |
| Tanigaki, S | 1 |
| Hirata, Y | 1 |
| Yakushiji, N | 1 |
| Kitamura, R | 1 |
| Hashikawa, N | 1 |
| Guardiola, E | 1 |
| Lew, JI | 1 |
| Ribeiro, U | 1 |
| Safatle-Ribeiro, AV | 1 |
| Posner, MC | 1 |
| Buxtorf, K | 1 |
| Hübscher, E | 1 |
| Panizzon, R | 1 |
| Polee, MB | 1 |
| Kok, TC | 1 |
| Siersema, PD | 1 |
| Tilanus, HW | 1 |
| Splinter, TA | 1 |
| Stoter, G | 2 |
| Van der Gaast, A | 1 |
| Nesbitt, J | 1 |
| Raijman, I | 1 |
| Martin, FD | 1 |
| Leprise, E | 1 |
| Quivey, JM | 1 |
| Singer, M | 1 |
| Funami, Y | 1 |
| Akervall, J | 1 |
| Brun, E | 1 |
| Dictor, M | 1 |
| Wennerberg, J | 4 |
| Baker, MN | 1 |
| Morrissey, LH | 1 |
| Yukiiri, K | 1 |
| Mizushige, K | 1 |
| Kohno, M | 1 |
| Ettore, F | 1 |
| Ma, B | 1 |
| Iba, T | 1 |
| Nakata, T | 1 |
| Ohtsuki, T | 1 |
| Moon, Y | 1 |
| Takeuchi, S | 1 |
| Yoshizawa, Y | 1 |
| Uemichi, O | 1 |
| Sasaya, S | 1 |
| Yamaguchi, M | 1 |
| Makuuchi, M | 1 |
| Midorikawa, T | 1 |
| Kumada, K | 1 |
| Takizawa, K | 1 |
| Catton, P | 1 |
| Catton, C | 1 |
| McLean, M | 1 |
| Panzarella, T | 1 |
| Carinci, F | 1 |
| Cassano, L | 1 |
| Farina, A | 1 |
| Pelucchi, S | 1 |
| Calearo, C | 1 |
| Modugno, V | 1 |
| Nielsen, I | 1 |
| Api, P | 1 |
| Pastore, A | 1 |
| Takamori, K | 1 |
| Honma, H | 1 |
| Asanami, S | 1 |
| Hoque, MO | 1 |
| Kawamata, H | 1 |
| Nakashiro, KI | 1 |
| Omotehara, F | 1 |
| Shinagawa, Y | 1 |
| Hino, S | 1 |
| Begum, NM | 1 |
| Uchida, D | 1 |
| Pories, WJ | 1 |
| Hillard, J | 1 |
| Wiley, AL | 3 |
| Youngblood, R | 1 |
| Stockeld, D | 1 |
| Tennvall, J | 3 |
| Wagenius, G | 1 |
| Backman, L | 1 |
| Brodin, O | 1 |
| Granström, L | 1 |
| Gustafsson, G | 1 |
| Gustavsson, S | 1 |
| Hambraeus, G | 2 |
| Lewensohn, R | 1 |
| Sjöstedt, S | 1 |
| Aberg, B | 1 |
| Fagerberg, J | 1 |
| El-Weshi, A | 1 |
| Khafaga, Y | 1 |
| Allam, A | 1 |
| Mosseri, V | 1 |
| Ibrahim, E | 1 |
| El-Serafi, M | 1 |
| El-Badawi, S | 1 |
| Imamura, M | 1 |
| Heydon, K | 1 |
| Eifel, P | 1 |
| Matsui, S | 1 |
| Iwazawa, T | 1 |
| Yano, H | 1 |
| Tono, T | 1 |
| Nakano, Y | 1 |
| Kanoh, T | 1 |
| Monden, T | 1 |
| Sakon, M | 1 |
| Dono, K | 1 |
| Umeshita, K | 1 |
| Okada, A | 1 |
| Murakami, T | 3 |
| Furukawa, J | 1 |
| Maruyama, N | 1 |
| Nakaguchi, K | 1 |
| Okajima, S | 1 |
| Sue, F | 1 |
| Poole, ME | 1 |
| Sailer, SL | 2 |
| Rosenman, JG | 2 |
| Shockley, WW | 1 |
| Schell, MJ | 1 |
| Heise, JW | 1 |
| Frieling, T | 1 |
| Hartmann, KA | 1 |
| Röher, HD | 1 |
| Egreteau, J | 1 |
| Boucher, E | 1 |
| Lesimple, T | 1 |
| Veivers, D | 1 |
| Doi, S | 1 |
| Mitsui, A | 1 |
| Kuwabara, Y | 1 |
| Iwase, H | 1 |
| Mitani, M | 1 |
| Shinoda, N | 1 |
| Toyama, T | 1 |
| Sugiura, M | 1 |
| Kato, J | 1 |
| Liu, X | 1 |
| Fu, X | 1 |
| Pallestrini, E | 2 |
| Marchetti, G | 1 |
| Hathaway, B | 1 |
| Piccirillo, JF | 1 |
| Labriola, S | 1 |
| Amin, R | 1 |
| Itoh, S | 1 |
| Morita, S | 1 |
| Ohnishi, T | 1 |
| Tsuji, A | 1 |
| Takamatsu, M | 1 |
| Horimi, T | 1 |
| Akisada, T | 1 |
| Takemoto, T | 1 |
| Morita, N | 1 |
| Kajihara, Y | 1 |
| Imai, S | 1 |
| Gyoten, M | 1 |
| Imajo, Y | 1 |
| Hiratsuka, J | 1 |
| Uesugi, N | 1 |
| Maesawa, C | 1 |
| Fischel, JL | 2 |
| Dubreuil, A | 1 |
| Formento, P | 2 |
| Marcié, S | 1 |
| Mai, SK | 1 |
| Grieger, J | 1 |
| Lachmann, R | 1 |
| Bohrer, M | 1 |
| Tiefenbacher, U | 1 |
| Liu, SC | 1 |
| Minton, NP | 1 |
| Giaccia, AJ | 1 |
| El Nakadi, I | 1 |
| Van Laethem, JL | 1 |
| Houben, JJ | 1 |
| Closset, J | 1 |
| Danhier, S | 1 |
| Limbosch, JM | 1 |
| Lambilliotte, JP | 1 |
| Gelin, M | 1 |
| Maruoka, Y | 1 |
| Hoshino, M | 1 |
| Ogiuchi, Y | 1 |
| Nishihara, N | 1 |
| Okamoto, T | 1 |
| Fukada, K | 1 |
| Kuwazawa, T | 1 |
| Ogiuchi, H | 1 |
| Baujat, B | 1 |
| Mabro, M | 1 |
| Carola, E | 1 |
| Maindrault, F | 1 |
| Asai, M | 1 |
| Mochiki, M | 1 |
| Kawahara, N | 1 |
| Asato, H | 1 |
| Schmitt, TM | 1 |
| Simon, PG | 1 |
| de Cornulier, J | 1 |
| Durand, M | 1 |
| Guillot, A | 1 |
| Gopal, HV | 1 |
| Morihiro, M | 1 |
| Shih, CH | 1 |
| Poluri, A | 1 |
| Patel, S | 1 |
| Shaha, AR | 1 |
| Sherman, E | 1 |
| Goberdhan, A | 1 |
| Hoffman, RM | 2 |
| Yagyu, Y | 1 |
| Shigeoka, H | 1 |
| Sarini, J | 1 |
| Bocciolini, C | 1 |
| Kara, A | 1 |
| Van, JT | 1 |
| Pigeaud-Klessens, ML | 1 |
| van der Valk, P | 1 |
| Nguyen, TH | 1 |
| Ho, DQ | 1 |
| Salom, EM | 1 |
| Penalver, M | 1 |
| Yoshimura, R | 1 |
| Shibuya, H | 1 |
| Ogura, I | 1 |
| Miura, M | 1 |
| Amagasa, T | 1 |
| Enomoto, S | 2 |
| Kishimoto, S | 1 |
| Vaishampayan, UN | 1 |
| Philip, PA | 1 |
| Levin, KJ | 1 |
| Shields, AF | 1 |
| Khushalani, NI | 1 |
| Proulx, G | 1 |
| Nava, H | 1 |
| Bodnar, L | 1 |
| Klippenstein, D | 1 |
| Litwin, A | 1 |
| Nava, E | 1 |
| Smith, P | 1 |
| Greco, W | 1 |
| Douglass, H | 1 |
| Knegt, PP | 1 |
| Ah-See, KW | 1 |
| Meeuwis, CA | 1 |
| van der Velden, LA | 1 |
| Kerrebijn, JD | 1 |
| De Boer, MF | 1 |
| Kayahara, H | 1 |
| Rodrigues, MA | 1 |
| Hamilton-Nelson, KL | 1 |
| El-Domeiri, AA | 1 |
| Chaudhuri, P | 1 |
| Miki, Y | 1 |
| Kawatsu, T | 1 |
| Kahata, A | 1 |
| DeWys, WD | 2 |
| Esser, E | 4 |
| Schumann, J | 3 |
| Goldsmith, MA | 1 |
| Carter, SK | 2 |
| Forney, JP | 1 |
| DiSaia, PJ | 3 |
| Futoran, RJ | 1 |
| Hull, MG | 4 |
| Bowen-Simpkins, P | 4 |
| Paintin, DB | 2 |
| Starichkov, MS | 2 |
| Nivinskaia, MM | 1 |
| Bychkov, MB | 2 |
| Lichinitser, MR | 1 |
| Chebotareva, LI | 1 |
| Prostman, TJ | 1 |
| Donegan, WL | 3 |
| Harris, P | 1 |
| Stathopoulos, G | 1 |
| Wiltshaw, E | 1 |
| Lanzotti, VJ | 1 |
| Thomas, DR | 1 |
| Holoye, PY | 4 |
| Boyle, LE | 1 |
| Smith, TL | 1 |
| Israel, L | 4 |
| Depierre, A | 3 |
| Confer, DJ | 1 |
| Smith, RB | 1 |
| Gillespie, L | 1 |
| Helpap, B | 1 |
| Herberhold, C | 1 |
| Thelen, M | 1 |
| Stiens, R | 1 |
| Koch, U | 1 |
| Piver, MS | 3 |
| Barlow, JJ | 2 |
| Xynos, FP | 1 |
| Armstrong, AL | 1 |
| Meeker, WR | 1 |
| Gard, DA | 1 |
| Guillamondegui, OM | 2 |
| Black, K | 1 |
| Hanna, SS | 1 |
| Langer, B | 1 |
| Jirsch, DW | 1 |
| Bianco, A | 1 |
| Reich, S | 1 |
| Merrill, JM | 1 |
| Lamy, P | 1 |
| Lamaze, R | 1 |
| Weber, B | 1 |
| Ramirez, G | 3 |
| Brandenburg, JH | 3 |
| Lieberman, LM | 1 |
| Lo, TC | 2 |
| Kaneda, T | 1 |
| Hiraiwa, K | 1 |
| Tsukeda, H | 1 |
| Nitta, K | 1 |
| Livingston, RB | 1 |
| Davis, HL | 1 |
| Kaufman, RH | 1 |
| Reynolds, RD | 1 |
| O'Dell, S | 1 |
| Chavaudra, N | 1 |
| Malaise, EP | 1 |
| Abisatov, KhA | 2 |
| Biro, L | 1 |
| Price, E | 1 |
| Bruckner, HW | 1 |
| Spigelman, MK | 1 |
| Mandel, E | 1 |
| Cohen, C | 1 |
| Deppe, G | 1 |
| Turell, R | 1 |
| Schiavone, J | 1 |
| Kurtis, B | 1 |
| Andrews, JM | 1 |
| Heising, RA | 1 |
| Tsukada, Y | 1 |
| Gamarra, M | 1 |
| Sandecki, A | 1 |
| Mitrov, G | 1 |
| Penchev, P | 1 |
| Khristov, K | 1 |
| Mushmov, M | 1 |
| Pandova, V | 1 |
| Sturm, HM | 1 |
| Krause, H | 1 |
| Grussendorf, EI | 1 |
| Rohwedder, JJ | 1 |
| Sagastume, E | 1 |
| Bohno, K | 1 |
| Muto, J | 1 |
| Nishiyama, A | 1 |
| Osawa, H | 1 |
| Defiebre, BK | 1 |
| Hajdu, SI | 1 |
| Fichardt, T | 1 |
| Sandison, AG | 2 |
| Miyakawa, K | 1 |
| Nevin, JE | 2 |
| Hoffman, AA | 1 |
| Inoguchi, T | 1 |
| Yamasaki, I | 1 |
| Yazuka, K | 1 |
| Kita, T | 1 |
| Kuwano, K | 1 |
| Kern, AB | 1 |
| Schiff, BL | 1 |
| Gartmann, H | 1 |
| Malkasian, GD | 2 |
| Decker, DG | 2 |
| Jorgensen, EO | 1 |
| Montes, LF | 1 |
| Tolia, BM | 1 |
| Castro, VL | 1 |
| Mouded, IM | 1 |
| Newman, HR | 1 |
| Khan, SV | 1 |
| Nakajima, A | 1 |
| Ikehata, S | 1 |
| Goette, DK | 2 |
| Carson, TE | 2 |
| Benson, JW | 1 |
| Cappellano, RS | 1 |
| Cintra, RA | 1 |
| Focan, C | 1 |
| Hoskins, WJ | 1 |
| Wurzel, JF | 1 |
| Dowell, KE | 1 |
| Armstrong, DM | 1 |
| Aust, JB | 2 |
| Salamon, T | 1 |
| Stojaković, M | 1 |
| Bogdanović, B | 1 |
| Mansell, PW | 1 |
| Ichinose, H | 2 |
| Sturm, JT | 1 |
| Christenson, CE | 1 |
| Uecker, JH | 1 |
| Perry, JF | 1 |
| Pouillart, P | 1 |
| Schwarzenberg, L | 1 |
| Amiel, JL | 1 |
| Mathé, G | 1 |
| Huguenin, P | 1 |
| Morin, P | 1 |
| Baron, A | 1 |
| Laparre, Ch | 1 |
| Parrot, R | 1 |
| Kas'ianenko, IV | 1 |
| Melnick, I | 1 |
| Baggerly, JT | 1 |
| Landes, R | 1 |
| Easley, CA | 1 |
| Newman, HK | 1 |
| Raaf, JH | 1 |
| Krown, SE | 1 |
| Pinsky, CM | 1 |
| Cunningham-Rundles, W | 1 |
| Safai, B | 1 |
| Oettgen, HF | 1 |
| Golematis, BC | 1 |
| Delikaris, PG | 1 |
| Haritopoulos, NK | 1 |
| Setakis, NG | 1 |
| Yokomori, T | 1 |
| Taniguchi, T | 1 |
| Iesato, H | 1 |
| Takeyoshi, I | 1 |
| Owada, S | 1 |
| Sharma, K | 1 |
| Tripathi, N | 1 |
| Mathur, RK | 1 |
| Mathur, V | 1 |
| Reck, T | 1 |
| Köckerling, F | 1 |
| Karaseva, VV | 1 |
| Stepanov, VG | 1 |
| Korolev, VV | 1 |
| Badellino, F | 1 |
| Mahé, E | 1 |
| Filleul, A | 1 |
| Sachwald, J | 1 |
| Bertrand, F | 1 |
| Berlie, J | 1 |
| Zojaji, A | 1 |
| Tubiana-Hulin, M | 1 |
| Schlag, PM | 1 |
| Spielmann, M | 2 |
| Tellez-Bernal, E | 3 |
| Munck, JN | 1 |
| Bachouchi, M | 2 |
| Segawa, Y | 1 |
| Ohnoshi, T | 1 |
| Ueoka, H | 1 |
| Horiguchi, T | 1 |
| Kodani, T | 1 |
| Kamei, H | 1 |
| Tabata, M | 1 |
| Shibayama, T | 1 |
| Maeda, T | 3 |
| Sawaki, S | 4 |
| Wheeler, HR | 1 |
| Friedlander, M | 1 |
| Kefford, R | 1 |
| Dalley, D | 2 |
| Schlag, P | 1 |
| Kaigas, M | 1 |
| Norum, J | 1 |
| Wist, E | 2 |
| Björk-Eriksson, T | 1 |
| Petruson, B | 1 |
| Ekholm, S | 1 |
| Sharan, VM | 6 |
| Damm, C | 5 |
| Earle, AS | 6 |
| Shah, AC | 5 |
| Haria, CD | 5 |
| Trey, JE | 1 |
| Carter, SG | 5 |
| Hines, JD | 5 |
| Kuroki-Migita, M | 1 |
| Mesic, JB | 1 |
| Scudder, SA | 1 |
| Rosenberg, PJ | 1 |
| Smith, LH | 1 |
| Kinney, WK | 1 |
| Trelford, JD | 1 |
| Taylor, MH | 1 |
| Zukowski, CL | 1 |
| Kawasaki, K | 2 |
| Peters, GE | 2 |
| Stephens, S | 2 |
| Weppelmann, B | 2 |
| Muss, HB | 1 |
| Partridge, EE | 1 |
| Poruban, D | 2 |
| Koza, I | 2 |
| Mracna, J | 2 |
| Nagy, V | 2 |
| Vasko, J | 2 |
| Marre, P | 1 |
| Bentata, M | 1 |
| Lenormand, Y | 1 |
| Seguier, JC | 1 |
| Sinda, P | 1 |
| Sfedj, D | 1 |
| Houvenaeghel, G | 1 |
| Weinstein, G | 1 |
| Chabardes, E | 1 |
| Zenone, T | 1 |
| Lambert, R | 1 |
| Harker, GJ | 1 |
| Stephens, FO | 1 |
| Kakegawa, T | 1 |
| Takagi, I | 1 |
| Arimori, M | 1 |
| Kikuchi, H | 1 |
| Kanamaru, R | 1 |
| Alberts, AS | 2 |
| Greeff, F | 1 |
| Friediger, D | 1 |
| Nel, J | 1 |
| Steyn, E | 1 |
| Schmid, EU | 1 |
| Ryan, B | 1 |
| McMurtrey, M | 1 |
| DeCaro, L | 1 |
| Mountain, C | 1 |
| Kuroki, M | 1 |
| Ichinose, I | 1 |
| Anzai, K | 1 |
| Nagafuchi, S | 1 |
| Shammas, FV | 1 |
| Ous, S | 1 |
| Fossa, SD | 2 |
| Wils, JA | 1 |
| Drescher, CW | 1 |
| Reid, GC | 1 |
| Terada, K | 1 |
| Roberts, JA | 1 |
| Hopkins, MP | 1 |
| Schoeppel, SL | 1 |
| Bombelli, L | 1 |
| Montalto, F | 1 |
| Lamonica, G | 1 |
| Greef, F | 1 |
| White, RM | 1 |
| Myers, EM | 1 |
| Ashayeri, E | 1 |
| Gumbs, RV | 1 |
| Pressoir, R | 1 |
| Dobrowsky, W | 7 |
| Dobrowsky, E | 5 |
| Rauth, AM | 3 |
| Charlois, T | 1 |
| Ben Bouali, AK | 2 |
| Person, B | 1 |
| Ferrero, P | 1 |
| Delaby, J | 2 |
| Boyer, J | 2 |
| Charneau, J | 1 |
| Chassevent, A | 1 |
| Larra, F | 1 |
| Naunheim, KS | 1 |
| Petruska, P | 1 |
| Roy, TS | 1 |
| Andrus, CH | 1 |
| Schlueter, JM | 1 |
| Baue, AE | 1 |
| Smith, IM | 1 |
| Robinson, D | 1 |
| Thomson, D | 1 |
| Coman, WB | 1 |
| Wong, SW | 1 |
| Schadel, A | 1 |
| Martz, K | 1 |
| Brindle, J | 1 |
| Byhardt, R | 2 |
| Davis, L | 2 |
| Emami, B | 1 |
| Abitbol, AA | 1 |
| Lewin, AA | 1 |
| Sridhar, K | 2 |
| Brandon, AH | 1 |
| Houdek, PV | 1 |
| Serago, C | 1 |
| Miller, DJ | 1 |
| Kozloff, MF | 1 |
| Goldman, MD | 2 |
| Moran, WJ | 3 |
| Clendeninn, NJ | 1 |
| Collier, MA | 1 |
| Olweny, C | 1 |
| Cassuto-Viguier, E | 1 |
| Frenay, M | 3 |
| Welkoborsky, HJ | 1 |
| Bleier, R | 1 |
| Wissen-Siegert, I | 1 |
| Scott, CB | 1 |
| Wheeler, R | 1 |
| Gahbauer, RA | 1 |
| Russo, A | 1 |
| Rausa, L | 1 |
| Cimino, A | 1 |
| Pastorello, T | 1 |
| Ferrara, P | 1 |
| Okutomi, T | 1 |
| Ichihara, H | 1 |
| Okuda, T | 1 |
| Hyoudou, I | 1 |
| Tatematsu, N | 1 |
| Oka, N | 1 |
| Tantranond, P | 1 |
| Balducci, L | 1 |
| Karam, F | 1 |
| Parker, M | 1 |
| Hescock, H | 1 |
| Cherryholmes, D | 1 |
| Metch, B | 1 |
| Triozzi, P | 1 |
| McClure, S | 1 |
| VonFeldt, E | 1 |
| Williamson, SK | 1 |
| Schilsky, RL | 5 |
| Melin, S | 1 |
| Richards, F | 1 |
| Perry, DJ | 2 |
| Goutsou, M | 1 |
| Modeas, C | 1 |
| Muchmore, E | 1 |
| Rege, V | 1 |
| Chahinian, AP | 1 |
| Hirsh, V | 1 |
| Poiesz, B | 1 |
| Green, MR | 1 |
| Reedy, MB | 1 |
| Morales, CA | 1 |
| Moliver, CL | 1 |
| Dudrey, EF | 1 |
| Boman, DA | 1 |
| Lopez, MJ | 1 |
| Fry, RD | 1 |
| Halverson, JD | 1 |
| Monafo, WW | 1 |
| Altermatt, HJ | 1 |
| Gebbers, JO | 1 |
| Laissue, JA | 1 |
| Aliev, BM | 1 |
| Khydyrov, KhB | 1 |
| Kondrat'eva, NF | 1 |
| Beutter, P | 1 |
| Nakamura, J | 2 |
| Nasu, H | 2 |
| Masamune, O | 2 |
| Sombolos, K | 2 |
| Destouni-Salem, E | 1 |
| Tourkantonis, A | 2 |
| Sadek, H | 1 |
| Wendling, JL | 3 |
| Guillaume, JC | 3 |
| Avril, MF | 2 |
| Belehradek, M | 2 |
| Vericel, R | 1 |
| Fargeot, P | 1 |
| Metz, R | 1 |
| Chazard, M | 1 |
| Sunagawa, M | 1 |
| Engstrom, PF | 3 |
| Paul, AR | 1 |
| Stafford, PM | 1 |
| Hanks, GE | 1 |
| Gil, RA | 1 |
| Carvalho, R | 1 |
| Garcia, JA | 1 |
| Froimtchuk, MJ | 1 |
| Pinto, LH | 1 |
| Canary, PC | 1 |
| De Vathaire, F | 2 |
| de Castelbajac, D | 1 |
| Prost, C | 1 |
| Revuz, J | 1 |
| Köhler, AH | 2 |
| Boussen, H | 1 |
| Mahjoubi, R | 1 |
| Kalifa, C | 1 |
| Schwaab, G | 1 |
| Aoki, H | 1 |
| Mieno, K | 2 |
| Amino, K | 2 |
| Miura, S | 3 |
| Ohtaki, K | 1 |
| Satoi, Y | 2 |
| Shikata, J | 2 |
| Yamane, A | 1 |
| Nemoto, R | 1 |
| Miyagawa, I | 1 |
| Kaufmann, M | 1 |
| Schmid, H | 1 |
| Junkermann, H | 1 |
| Schönig, T | 1 |
| von Fournier, D | 1 |
| Bastert, G | 1 |
| Lillo-Gil, R | 1 |
| Samuelsson, L | 1 |
| Willén, R | 1 |
| Ranstam, J | 1 |
| Benahmed, M | 1 |
| Muttini, MP | 1 |
| Tononi, A | 1 |
| Occhiuzzi, L | 1 |
| Caliceti, U | 1 |
| Dall'Olio, D | 1 |
| Laudadio, P | 1 |
| Nogami, A | 1 |
| Hanashi, T | 1 |
| Kubota, N | 1 |
| Hanyu, F | 1 |
| Nicolaou, A | 2 |
| Makrantonakis, P | 1 |
| Zhou, JC | 1 |
| Lyman, G | 1 |
| Velez-García, E | 2 |
| Knight, W | 1 |
| Hochster, H | 1 |
| Goodnough, LT | 1 |
| Mortimer, JE | 1 |
| Einhorn, LH | 2 |
| Schacter, L | 1 |
| Lovett, D | 1 |
| Buckley, M | 1 |
| Murray, P | 1 |
| Lightdale, C | 1 |
| Terazono, T | 1 |
| Oshima, W | 1 |
| Kihira, S | 1 |
| Takegami, E | 1 |
| Kume, T | 1 |
| Takada, A | 1 |
| Szawłowski, AW | 1 |
| Falkowski, S | 1 |
| Morysiński, T | 1 |
| Nasierowska-Guttmejer, A | 1 |
| Karwowski, A | 1 |
| Krawczyk, M | 1 |
| Kułakowski, A | 1 |
| Nguyen, PD | 1 |
| John, B | 1 |
| Munoz, AK | 1 |
| Yazigi, R | 1 |
| Franklin, P | 1 |
| Roberts, WS | 2 |
| Hoffman, MS | 2 |
| Kavanagh, JJ | 2 |
| Fiorica, JV | 1 |
| Greenberg, H | 2 |
| Finan, MA | 1 |
| Cavanagh, D | 2 |
| Bloss, JD | 1 |
| Mannel, RS | 1 |
| Hyden, EC | 1 |
| Manetta, A | 1 |
| Berman, ML | 1 |
| Kraiphibul, P | 1 |
| Atichartakarn, V | 1 |
| Clongsusuek, P | 1 |
| Kulapaditharom, B | 1 |
| Isarangkul, W | 1 |
| Samoun, M | 1 |
| Potocka, AC | 1 |
| Pillière, R | 1 |
| Delorme, G | 1 |
| Prinseau, J | 1 |
| Baglin, A | 1 |
| Kaasa, S | 1 |
| Thorud, E | 1 |
| Tausjø, J | 1 |
| Gundersen, S | 1 |
| Høst, H | 1 |
| Bonomi, P | 4 |
| Gale, M | 1 |
| Rowland, K | 2 |
| Purl, S | 1 |
| Reddy, S | 3 |
| Phillips, A | 2 |
| Kittle, CF | 2 |
| Warren, W | 2 |
| Weiden, PL | 2 |
| Piantadosi, S | 1 |
| Koyanagi, Y | 1 |
| Yoshimatsu, A | 1 |
| Yasuda, D | 1 |
| Kasuya, K | 1 |
| Strassl, H | 5 |
| Braun, O | 3 |
| Gritzmann, N | 2 |
| Scheiber, V | 2 |
| Braun, SD | 1 |
| Gemer, LS | 1 |
| McIntee, RA | 1 |
| Baugh, R | 1 |
| Thomas, JH | 1 |
| Evans, RG | 1 |
| Khoury, GG | 2 |
| Bulman, AS | 1 |
| Joslin, CA | 1 |
| Rothwell, RI | 1 |
| Raber, MN | 1 |
| Faintuch, J | 1 |
| Abbruzzese, JL | 1 |
| Sumrall, C | 1 |
| Frost, P | 1 |
| Kalnins, I | 1 |
| Catton, CN | 1 |
| Donald, PJ | 1 |
| Kemeny, N | 2 |
| Armstrong, JG | 2 |
| Reichman, B | 1 |
| Botet, J | 1 |
| Macmillan, CH | 1 |
| Carrick, K | 1 |
| Bradley, PJ | 1 |
| Morgan, DA | 1 |
| Berek, JS | 1 |
| Heaps, JM | 1 |
| Fu, YS | 1 |
| Juillard, GJ | 1 |
| Hacker, NF | 1 |
| Robbins, KT | 2 |
| Varki, NM | 1 |
| Storniolo, AM | 1 |
| Hoffman, H | 1 |
| Lowry, LD | 1 |
| Scotte Doggett, RL | 1 |
| Bernard, S | 1 |
| Gioanni, J | 1 |
| Kennedy, A | 1 |
| Anderson, H | 1 |
| Elner, A | 1 |
| Perey, L | 1 |
| Capasso, P | 1 |
| Savary, M | 1 |
| Hillman, R | 1 |
| Endicott, JW | 1 |
| McClatchey, K | 1 |
| Henderson, WG | 1 |
| Mori, N | 1 |
| Itoh, M | 1 |
| Vincent, A | 1 |
| Staumont, M | 1 |
| Dupuis, B | 1 |
| Gautier, P | 1 |
| Adenis, L | 1 |
| Migdał, K | 1 |
| Korzeniowski, S | 1 |
| Skołyszewski, J | 1 |
| Beauduin, M | 1 |
| Longueville, J | 1 |
| Majois, F | 1 |
| Remacle, FM | 1 |
| Rousseau, F | 1 |
| Salamon, E | 1 |
| Wambersie, A | 1 |
| Sharma, SC | 1 |
| Sharma, AK | 1 |
| Singhal, KC | 1 |
| Takasugi, BJ | 2 |
| Bromberg, J | 1 |
| Kaminogo, M | 1 |
| Papillon, J | 1 |
| Tomita, Y | 1 |
| Davis, RK | 3 |
| Gibbs, FA | 2 |
| Sapozink, MD | 1 |
| Farver, M | 1 |
| Harker, G | 2 |
| Sebille, A | 1 |
| St-Guily, JL | 1 |
| de Stabenrath, A | 1 |
| Moriguchi, S | 1 |
| Kohnoe, S | 1 |
| Tsujitani, S | 1 |
| Sugimachi, K | 1 |
| Tsai, CM | 1 |
| Gazdar, AF | 1 |
| Perng, RP | 1 |
| Kramer, BS | 1 |
| Ng, TB | 1 |
| Yeung, HW | 1 |
| Lentz, SR | 1 |
| Raish, RJ | 1 |
| Orlowski, EP | 1 |
| Marion, JM | 1 |
| Rydell, R | 1 |
| Hazan, A | 1 |
| Peytral, C | 1 |
| Sénéchaut, JP | 1 |
| Hussein, AM | 2 |
| Vlastou, C | 5 |
| Heaton, D | 1 |
| Yordan, E | 1 |
| Lincoln, S | 1 |
| Dolan, T | 1 |
| Miller, A | 1 |
| Jevremovic, S | 1 |
| Djuric, L | 1 |
| Mijatovic, L | 1 |
| Höring, E | 1 |
| Neef, B | 1 |
| von Gaisberg, U | 1 |
| Planting, AS | 1 |
| van Sichem, CK | 1 |
| Schmitz, PI | 1 |
| Meeuwis, CM | 1 |
| Crumpler, LS | 1 |
| Wright, JE | 1 |
| Fallon, BG | 1 |
| Casey, D | 1 |
| Klein, R | 1 |
| Petruzzelli, GJ | 1 |
| de Vries, EJ | 1 |
| Benedetto, P | 1 |
| Kuzel, T | 1 |
| Esparaz, B | 1 |
| Green, D | 1 |
| Grimaldi, A | 7 |
| Cacace, F | 1 |
| Abeler, V | 1 |
| Iversen, T | 1 |
| Kjørstad, K | 1 |
| Indresano, AT | 1 |
| Gapany, M | 1 |
| Dawson, DE | 1 |
| Schriever, C | 1 |
| Burgess, R | 1 |
| Gipple, JR | 1 |
| Pappagallo, GL | 1 |
| Zorat, P | 1 |
| Fosser, VP | 1 |
| Fornasiero, A | 1 |
| Fiorentino, MV | 2 |
| Mayernik, DG | 3 |
| Nolan, TA | 3 |
| Sigler, BA | 3 |
| Padaut-Cesana, J | 2 |
| Fuentes, P | 2 |
| Giudicelli, R | 2 |
| Gauthier, AP | 1 |
| Carcassonne, Y | 1 |
| Panis, X | 2 |
| Coninx, P | 2 |
| Nguyen, TD | 1 |
| Legros, M | 2 |
| Skotinkova, OI | 1 |
| Sergeeva, NS | 1 |
| Moroz, IA | 1 |
| Sviridova, IK | 1 |
| Pelevina, II | 1 |
| Donnadieu, S | 2 |
| Jacquillat, C | 2 |
| Panasci, L | 1 |
| Gravenor, D | 1 |
| Black, M | 1 |
| Frenkiel, S | 1 |
| Margolese, R | 1 |
| Stolwijk, C | 1 |
| Wagener, DJ | 1 |
| Van den Broek, P | 1 |
| Levendag, PC | 1 |
| Kazem, I | 1 |
| Bruaset, I | 1 |
| Wright, JC | 1 |
| Takaoka, T | 2 |
| Hosoda, H | 2 |
| Yamauchi, T | 1 |
| Hida, S | 1 |
| Ooishi, K | 1 |
| Yoshida, O | 1 |
| Duttenhaver, JR | 1 |
| Zajtchuk, JT | 1 |
| Hauck, KH | 1 |
| Major, WB | 1 |
| Baumann, JC | 1 |
| Paterson, IC | 2 |
| Quilty, PM | 1 |
| Weitzman, SA | 1 |
| Williams, SD | 1 |
| Essessee, I | 1 |
| Ratkin, G | 1 |
| Birch, R | 1 |
| Odell, P | 1 |
| Nichol, J | 1 |
| de la Bastide, Y | 1 |
| Barron, P | 1 |
| Hardie, J | 1 |
| Vogl, SE | 1 |
| Komisar, A | 1 |
| Kaplan, BH | 1 |
| Kasule, OH | 1 |
| Stolbach, L | 1 |
| Lerner, H | 1 |
| Muggia, F | 1 |
| Ziegler, P | 1 |
| Klotch, D | 1 |
| Lee, K | 1 |
| Lore, J | 1 |
| Grossman, TW | 3 |
| Toohill, RJ | 3 |
| Kun, LE | 2 |
| Byhardt, RW | 3 |
| Duncavage, JA | 3 |
| Teplin, RW | 1 |
| Ritch, PS | 2 |
| Hoffman, RG | 1 |
| Malin, TC | 1 |
| Hoffmann, RG | 1 |
| Malin, T | 1 |
| Fabre, A | 1 |
| Rahima, M | 1 |
| Rakowsky, E | 1 |
| Barzilay, J | 1 |
| Sidi, J | 1 |
| Salvagno, L | 2 |
| Tremolada, C | 2 |
| Fosser, V | 2 |
| Fiorentino, M | 1 |
| Navarro Vila, C | 1 |
| Martínez-Alegría, J | 1 |
| Suñer Machado, M | 1 |
| Wang, ZY | 1 |
| Ahmad, K | 2 |
| Kida, A | 2 |
| Tomita, H | 2 |
| Tapazoglou, E | 5 |
| Arbulu, A | 1 |
| Gardin, G | 2 |
| Ganzer, U | 8 |
| Bier, H | 1 |
| Bachert, C | 1 |
| Campbell, JB | 1 |
| Dorman, EB | 1 |
| Helliwell, TR | 2 |
| McCormick, M | 1 |
| Miles, J | 1 |
| Morton, RP | 1 |
| Rugman, F | 1 |
| Stell, PM | 2 |
| Stoney, PJ | 1 |
| Vauhan, ED | 1 |
| Steindorfer, P | 1 |
| Germann, R | 1 |
| Schneider, G | 1 |
| Mischinger, HJ | 1 |
| Rehak, P | 1 |
| Wittlinger, P | 2 |
| Kawabata, M | 1 |
| Hosokawa, H | 1 |
| Katoh, K | 1 |
| Kane, MA | 1 |
| Roth, E | 1 |
| Raptis, G | 1 |
| Schreiber, C | 1 |
| Waxman, S | 1 |
| Paul, A | 1 |
| Inoue, F | 1 |
| Takeda, I | 1 |
| Mimura, H | 1 |
| Orita, K | 1 |
| Harrison, ML | 1 |
| Fields, R | 1 |
| Oswald, MJ | 1 |
| Sertoli, MR | 2 |
| Scarpati, D | 3 |
| LoRusso, P | 1 |
| Kelly, J | 2 |
| Apostolidis, T | 1 |
| Al-Kourainy, K | 1 |
| Foladore, S | 1 |
| Bidoli, E | 1 |
| Caruso, G | 1 |
| Monfardini, S | 1 |
| Shaw, HJ | 1 |
| Van Tassel, P | 1 |
| De Pena, C | 1 |
| Blacklock, JB | 1 |
| Lele, SB | 1 |
| Kramer, AM | 1 |
| Choksi, AJ | 3 |
| Evenou, P | 1 |
| Duvillard, P | 1 |
| Klijanienko, G | 1 |
| Wagner, L | 1 |
| Noble, JP | 1 |
| Perrino, A | 1 |
| Calabresi, F | 1 |
| Chilelli, MG | 1 |
| Schantz, SP | 1 |
| Savage, HE | 1 |
| Racz, T | 1 |
| Liu, FJ | 1 |
| Brown, BW | 1 |
| Rossen, RD | 1 |
| Martin, DS | 1 |
| Colofiore, J | 1 |
| Sawyer, RC | 1 |
| Derby, S | 1 |
| Salvia, B | 1 |
| Kelly, SA | 1 |
| MacLeod, PM | 1 |
| Ash, DV | 1 |
| Görögh, T | 1 |
| Eickbohm, JE | 1 |
| Lippert, B | 1 |
| Holdener, EE | 1 |
| Kawaura, M | 1 |
| Toji, M | 1 |
| Ookuma, A | 1 |
| Nishio, M | 1 |
| Narimatsu, N | 1 |
| Sanbe, S | 1 |
| Scherlacher, A | 3 |
| Haas, J | 2 |
| Tokuhashi, K | 1 |
| Sideras, T | 1 |
| Haritanti, A | 1 |
| Anastasakis, C | 1 |
| Delis, V | 1 |
| Benhamed, M | 1 |
| Mochizuki, F | 1 |
| Yamagata, M | 1 |
| Moriya, Y | 1 |
| Abiko, Y | 1 |
| Sakabe, T | 1 |
| Atkinson, MW | 1 |
| Cooke, TG | 1 |
| Cooke, LD | 1 |
| Hukku, S | 1 |
| Fernandes, P | 1 |
| Chan, A | 1 |
| Wong, A | 1 |
| Arthur, K | 1 |
| Braun, OM | 2 |
| Neumeister, B | 2 |
| Popp, W | 2 |
| Scherrer, R | 1 |
| Rausch, EM | 2 |
| Krisch, K | 1 |
| Holzner, JH | 2 |
| Johnson, DW | 1 |
| Kessler, JF | 1 |
| Ferrigni, RG | 1 |
| Anderson, JD | 1 |
| Yabushita, H | 1 |
| Sawaguchi, K | 1 |
| Hieda, S | 1 |
| Ishihara, M | 1 |
| Mitani, K | 1 |
| Inoue, K | 1 |
| Stetz, J | 1 |
| Davis, LW | 1 |
| Leibel, S | 2 |
| Stewart, FM | 2 |
| Harkins, BJ | 1 |
| Hahn, SS | 2 |
| Daniel, TM | 1 |
| Takenaka, A | 1 |
| Habr-Gama, A | 1 |
| da Silva e Sousa Júnior, AH | 1 |
| Nadalin, W | 1 |
| Gansl, R | 1 |
| da Silva, JH | 1 |
| Pinotti, HW | 1 |
| DePetrillo, A | 1 |
| Ackerman, I | 1 |
| Bryson, P | 1 |
| Balogh, J | 1 |
| Osborne, R | 1 |
| Rosen, B | 1 |
| Fyles, A | 1 |
| Neuhold, N | 1 |
| Siebenhandl, A | 1 |
| Wimmer, M | 1 |
| Glaser, E | 1 |
| Luquel, L | 1 |
| Thomas, O | 1 |
| Larminat, JM | 1 |
| Offenstadt, G | 1 |
| Vukelja, SJ | 1 |
| James, WD | 1 |
| Weiss, RB | 1 |
| Carrasco, CH | 1 |
| Jackson, DE | 1 |
| Misaki, O | 1 |
| Chang, YM | 1 |
| Abouz, D | 1 |
| Ayela, P | 2 |
| Berthaud, P | 1 |
| Pujol, JL | 1 |
| Robillard, J | 1 |
| Le Chevalier, T | 1 |
| Stoker, K | 1 |
| Davis, K | 1 |
| Harnsberger, HR | 1 |
| Stevens, MH | 1 |
| Parkin, JL | 1 |
| Johnson, LP | 1 |
| Sugiura, T | 1 |
| Urata, A | 1 |
| Grant, HR | 1 |
| Clifford, P | 1 |
| Gordon, LI | 1 |
| Hauck, WW | 1 |
| Krespi, Y | 1 |
| Ossoff, RH | 1 |
| Pecaro, BC | 1 |
| Yuska, C | 1 |
| Lamut, CH | 1 |
| Brand, WN | 1 |
| Bitran, JD | 1 |
| Goldman, M | 1 |
| Hughes, LL | 1 |
| Delclos, L | 1 |
| Martin, RG | 1 |
| Wang, QL | 1 |
| Ferro, A | 1 |
| Vitriolo, S | 1 |
| Serra, C | 1 |
| Darcourt, J | 1 |
| Kearsley, JH | 1 |
| Zhang, ZH | 1 |
| Tukuda, M | 1 |
| Ryo, I | 1 |
| Miyata, K | 2 |
| Woods, R | 1 |
| Aroney, R | 1 |
| Hughes, P | 1 |
| Cruickshank, D | 1 |
| Hartenstein, RC | 4 |
| Kastenbauer, ER | 1 |
| Iwai, Y | 1 |
| Someya, K | 1 |
| Moriya, K | 1 |
| Kobayakawa, H | 1 |
| Ohyama, T | 1 |
| Horii, A | 1 |
| Maxson, BB | 1 |
| Scott, RF | 1 |
| Headington, JT | 1 |
| Liubaev, VL | 1 |
| Shatikhin, VA | 1 |
| Brzhezovskiĭ, VZh | 1 |
| Pustynskiĭ, IN | 1 |
| Awan, AM | 1 |
| Tybor, AG | 1 |
| Doggett, RL | 1 |
| Krall, JM | 1 |
| Taylor, DG | 1 |
| Sause, WT | 1 |
| Lipsett, JA | 1 |
| Furió, V | 1 |
| Blázquez, J | 1 |
| Almenarez, J | 1 |
| Fariña, J | 1 |
| Bennett, JA | 2 |
| Parnes, SM | 2 |
| Aron, NK | 1 |
| Tajuri, S | 1 |
| Bryson, SC | 1 |
| LaPolla, JP | 1 |
| Townsend, PA | 1 |
| Hewitt, S | 1 |
| Lackey, VL | 1 |
| Reagan, MT | 2 |
| Smith, RA | 2 |
| Anderson, WJ | 1 |
| Lim, F | 1 |
| Duncan, L | 1 |
| Coates, A | 1 |
| Blessing, J | 1 |
| Ball, H | 1 |
| Hanjani, P | 1 |
| Sagerman, P | 1 |
| Camuzard, JF | 1 |
| Guaspari, A | 1 |
| Guarnieri, CM | 3 |
| Whaling, SM | 2 |
| Lissner, J | 1 |
| Carlson, LS | 1 |
| Stuart, R | 1 |
| Osguthorpe, JD | 1 |
| de Jong, PC | 1 |
| van der Broek, P | 1 |
| Alexieva-Figusch, J | 1 |
| van Putten, WL | 1 |
| Ravasz, LA | 1 |
| Paredes, J | 1 |
| Felder, TB | 1 |
| Newman, RA | 1 |
| Castellanos, AM | 1 |
| Atkinson, N | 1 |
| Pincus, M | 1 |
| Faber, LP | 1 |
| Hendrickson, FR | 1 |
| Choi, KE | 2 |
| Magid, DM | 1 |
| Ratain, MJ | 1 |
| Zilling, TL | 1 |
| Ahrén, B | 1 |
| Viens, P | 1 |
| Yang, CJ | 1 |
| Jin, SW | 1 |
| Iida, S | 1 |
| Kimoto, H | 1 |
| Tsunamura, Y | 1 |
| Ichihashi, T | 1 |
| Shimizu, J | 1 |
| Hashizume, Y | 1 |
| Watson, KJ | 1 |
| Shulkes, A | 1 |
| Smallwood, RA | 1 |
| Douglas, MC | 1 |
| Hurley, R | 1 |
| Kalnins, R | 1 |
| Moran, L | 1 |
| Sillman, FH | 1 |
| Sedlis, A | 1 |
| Boyce, JG | 1 |
| Legha, SS | 2 |
| Iida, H | 1 |
| Yokode, Y | 1 |
| Axelson, JA | 1 |
| Clark, RH | 1 |
| Dimitrov, NV | 1 |
| Nasca, S | 1 |
| Lebrun, D | 1 |
| Lucas, P | 1 |
| Garbe, E | 1 |
| Gauthier, A | 1 |
| Reboud, E | 1 |
| Polin, L | 1 |
| Corbett, TH | 1 |
| Rauschning, W | 1 |
| Nagel, G | 1 |
| Loeffler, TM | 1 |
| Lindemann, J | 1 |
| Luckhaupt, H | 1 |
| Rose, KG | 1 |
| Muff, NS | 1 |
| Shetabi, H | 1 |
| Lafreniere, R | 1 |
| Ketcham, AS | 1 |
| Podolsky, W | 1 |
| Padmanabhan, A | 2 |
| Beale, FA | 1 |
| Payne, DG | 1 |
| Elhakim, T | 2 |
| Flokkmann, A | 1 |
| John, MJ | 2 |
| Lovalvo, L | 1 |
| Secco, GB | 1 |
| Marino, G | 1 |
| Fardelli, R | 1 |
| Nobile, MT | 1 |
| Wade, J | 1 |
| Reichard, U | 1 |
| Wolf, N | 1 |
| Hancock, SL | 1 |
| Carlson, RW | 1 |
| Mark, JB | 1 |
| Cooke, JK | 1 |
| Hetzel, D | 1 |
| Fitch, R | 1 |
| Britten-Jones, R | 1 |
| Gibson, GE | 1 |
| Abbott, RL | 1 |
| Hecker, R | 1 |
| Brickner, TJ | 1 |
| Gilbertson, GF | 1 |
| Stone, WC | 1 |
| Tosch, U | 1 |
| Patterson, JM | 1 |
| Ray, EH | 1 |
| Mendiondo, OA | 1 |
| Medina, WD | 1 |
| Gee, WF | 1 |
| Rabinowits, M | 1 |
| Denecke, H | 1 |
| Roloff, R | 1 |
| Lattin, P | 1 |
| Han, I | 1 |
| Leichman, G | 1 |
| Bendal, C | 1 |
| White, B | 1 |
| Ludgate, SM | 1 |
| Crandon, AJ | 1 |
| Hudson, CN | 1 |
| Walker, Q | 1 |
| Hatano, T | 1 |
| Miyazato, T | 1 |
| Kashiwabara, N | 1 |
| Igarashi, M | 1 |
| Hayakawa, M | 1 |
| Osawa, A | 1 |
| Garaventa, G | 1 |
| Binns, P | 1 |
| Yosida, T | 1 |
| Thongprasert, S | 1 |
| Phandphae, P | 1 |
| Changwaiwit, W | 1 |
| Chaimongkol, B | 1 |
| Buck, M | 1 |
| Jackson, BS | 1 |
| Johanson, C | 1 |
| Atkinson, D | 1 |
| Ahmed, K | 1 |
| Mathog, R | 1 |
| Goffinet, L | 1 |
| Kohler, M | 1 |
| Barreras, L | 1 |
| Saldana, MJ | 1 |
| Manten, H | 1 |
| Libnock, J | 1 |
| Speyer, J | 1 |
| Tschan, J | 1 |
| Biller, HF | 1 |
| James, P | 1 |
| Rotmensch, J | 1 |
| Senekjian, EK | 1 |
| Javaheri, G | 1 |
| Herbst, AL | 1 |
| Marks, MW | 1 |
| Borgel, J | 1 |
| Guenoun, A | 1 |
| Junien-Lavillauroy, C | 1 |
| Dionet, C | 1 |
| Vrousos, C | 1 |
| Bertin, F | 1 |
| Leclercq, B | 1 |
| Nitenberg, G | 1 |
| Kishi, T | 1 |
| Horikoshi, M | 1 |
| Hasumi, K | 1 |
| Okudaira, Y | 1 |
| Masubuchi, K | 1 |
| Brando, V | 3 |
| Giordano, C | 1 |
| Navarro, M | 1 |
| Hidalgo, R | 1 |
| Solé, LA | 1 |
| Zakharchenkov, AV | 1 |
| Zhiglov, MA | 1 |
| Glagolev, AN | 1 |
| Kovalev, VN | 1 |
| Amiraliev, MA | 1 |
| Barchuk, AS | 1 |
| Malay, EF | 1 |
| Vidyak, IV | 1 |
| Grigoryeva, SP | 1 |
| Chang, H | 1 |
| Leone, LA | 1 |
| Nigri, PT | 1 |
| Toso, S | 1 |
| Fujiwara, K | 1 |
| Akiya, K | 2 |
| Tsang, TK | 1 |
| Shetty, R | 1 |
| Schneider, PA | 1 |
| Wallemark, CB | 1 |
| Barten, G | 1 |
| Jin, BL | 1 |
| Zaniboni, A | 1 |
| Simoncini, E | 1 |
| Tonini, G | 1 |
| Pezzola, D | 1 |
| Farfaglia, R | 1 |
| Lancini, GP | 1 |
| Marpicati, P | 1 |
| Montini, E | 1 |
| Marini, G | 1 |
| Hanks, GA | 1 |
| Weigensberg, I | 1 |
| Natale, RB | 1 |
| Goren, MP | 1 |
| Vogel, WC | 1 |
| Kudla-Hatch, V | 1 |
| Schramm, VL | 2 |
| Chevallier, B | 1 |
| Lefur, R | 1 |
| Bastit, P | 1 |
| Seng, SH | 1 |
| Greenberg, B | 1 |
| Ahmann, F | 1 |
| Garewal, H | 2 |
| Koopmann, C | 1 |
| Coulthard, S | 1 |
| Berzes, H | 1 |
| Alberts, D | 1 |
| Shimm, D | 1 |
| Slymen, D | 1 |
| Brunetti, I | 1 |
| Modenesi, M | 1 |
| Scala, M | 1 |
| Scasso, F | 2 |
| Castiglia, G | 1 |
| Anderson, T | 1 |
| Haas, CD | 1 |
| Haas, JS | 1 |
| Hartz, AJ | 1 |
| Libnoch, JA | 1 |
| Wang, SL | 1 |
| Sekiba, K | 1 |
| Yajima, A | 1 |
| Tenjin, Y | 1 |
| Kurihara, S | 1 |
| Cobb, MW | 1 |
| Pellegrini, AE | 1 |
| Theilen, G | 1 |
| Richmond, J | 1 |
| Bae, Y | 1 |
| Burdakin, J | 1 |
| Jacobsen, G | 1 |
| Weinberg, MJ | 2 |
| Arakawa, H | 1 |
| Rajnay, J | 1 |
| Kopper, L | 1 |
| Lapis, K | 1 |
| Mercier, RJ | 1 |
| Neal, GD | 1 |
| Mattox, DE | 1 |
| Pomeroy, TC | 1 |
| Von Hoff, DD | 1 |
| Dobberstein, N | 1 |
| Stoltmann, R | 1 |
| Hinkel, M | 1 |
| Kamada, T | 1 |
| Arimoto, T | 1 |
| Mizoe, J | 1 |
| Irie, G | 1 |
| Rowland, KM | 1 |
| Spiers, AS | 1 |
| O'Donnell, MR | 1 |
| Showel, J | 1 |
| Stott, PB | 1 |
| Milner, LM | 1 |
| Marsh, JC | 1 |
| Stewart, DJ | 1 |
| Maroun, JA | 1 |
| Young, V | 1 |
| Laframboise, G | 1 |
| Gerin-Lajoie, J | 1 |
| Bernstein, G | 1 |
| Forgaard, DM | 1 |
| Miller, JE | 1 |
| Grillo, H | 1 |
| Praest, J | 1 |
| Klem, V | 1 |
| Dodion, P | 1 |
| van Rymenant, M | 2 |
| Dalesio, O | 1 |
| Kirkpatrick, A | 2 |
| Rozencweig, M | 1 |
| Punpae, P | 1 |
| Sumitrasawan, Y | 1 |
| Ahmann, FR | 1 |
| Schmidt, KU | 1 |
| Wiskemann, A | 1 |
| Mensing, H | 1 |
| Yamagiwa, M | 1 |
| Kubo, M | 1 |
| Fukukita, K | 1 |
| Sakakura, Y | 1 |
| Lapointe, TA | 1 |
| Khater, R | 1 |
| Bourry, J | 1 |
| Vermorken, J | 1 |
| Rossi, A | 1 |
| Dalesic, O | 1 |
| Shimizu, R | 1 |
| Caldani, C | 1 |
| Macchia, R | 1 |
| Silverstein, M | 1 |
| Aziz, H | 1 |
| Rosenthal, J | 1 |
| Braverman, A | 1 |
| Laungani, GB | 1 |
| Robertson, D | 1 |
| Godfrey, R | 1 |
| Hanazawa, S | 1 |
| Fazio, M | 3 |
| Gandolfo, S | 3 |
| Ozzello, F | 3 |
| Camoletto, D | 1 |
| Negri, L | 1 |
| Krook, JE | 1 |
| Jett, JR | 1 |
| Fleming, TR | 1 |
| Dalton, RJ | 1 |
| Marschke, RF | 1 |
| Cullinan, SA | 1 |
| Windschitl, HE | 1 |
| Everson, LK | 1 |
| Brunk, FS | 1 |
| Laurie, JA | 1 |
| Uekado, Y | 1 |
| Hirano, A | 1 |
| Watanabe, T | 1 |
| Shinka, T | 1 |
| Ohkawa, T | 1 |
| Srodes, CH | 1 |
| Swierz, J | 1 |
| Aogauchi, R | 1 |
| Tsubota, N | 1 |
| Yamashita, C | 1 |
| Ishii, N | 1 |
| Nigro, N | 1 |
| Bradley, G | 1 |
| Olchowski, S | 1 |
| Leichman, C | 1 |
| Shah, AB | 1 |
| Silber, L | 1 |
| Murahashi, I | 1 |
| Mukae, K | 1 |
| Tabata, Y | 1 |
| Sakuma, H | 1 |
| Kanbe, K | 1 |
| Arai, T | 1 |
| Maeda, S | 1 |
| Takasaki, E | 1 |
| Cortes, E | 1 |
| Krumholz, B | 1 |
| Rovinsky, JJ | 1 |
| Seltzer, V | 1 |
| Papantoniou, P | 1 |
| Parker, EF | 1 |
| Marks, RD | 1 |
| Kratz, JM | 1 |
| Chaikhouni, A | 1 |
| Warren, ET | 1 |
| Bartles, DM | 1 |
| Tamamushi, N | 1 |
| Yao, K | 1 |
| Takeyama, I | 1 |
| Otake, H | 1 |
| Miller, JI | 1 |
| McIntyre, B | 1 |
| Hatcher, CR | 1 |
| Stubblefield, GC | 1 |
| Brock, DT | 1 |
| Sekiguchi, I | 1 |
| Ohwada, M | 1 |
| Tamada, T | 1 |
| Greenall, MJ | 1 |
| Urmacher, C | 1 |
| DeCosse, JJ | 1 |
| Cooper, JC | 1 |
| Truesdale, GL | 1 |
| Kaplan, MJ | 1 |
| Johns, ME | 1 |
| Constable, WC | 1 |
| Gibson, LE | 1 |
| Perry, HO | 1 |
| Wood, CD | 1 |
| Slevin, ML | 1 |
| Ponder, BA | 1 |
| Wrigley, PF | 1 |
| Wile, AG | 1 |
| Stemmer, EA | 1 |
| Andrews, PA | 1 |
| Murphy, MP | 1 |
| Abramson, IS | 1 |
| Howell, SB | 1 |
| Fischer, AT | 1 |
| Spier, S | 1 |
| Carlson, GP | 1 |
| Hackett, RP | 1 |
| Dasmahapatra, KS | 1 |
| Citrin, P | 1 |
| Hill, GJ | 1 |
| Yee, R | 1 |
| Mohit-Tabatabai, MA | 1 |
| Rush, BF | 1 |
| Wayss, K | 1 |
| Mattern, J | 1 |
| Volm, M | 1 |
| Einstein, AB | 1 |
| Rudolph, RH | 1 |
| Leidi, L | 1 |
| Maina, G | 1 |
| Rappelli, F | 1 |
| Cocola, L | 1 |
| Durando, C | 1 |
| Sorokina, EA | 1 |
| Le Bourgeois, J | 1 |
| Harris, HS | 1 |
| Burdette, WJ | 1 |
| Tari, K | 1 |
| So, K | 1 |
| Nosaka, K | 1 |
| Sighart, H | 1 |
| Wrbka, E | 2 |
| Simml, G | 1 |
| Hellriegel, W | 1 |
| Amblard, P | 1 |
| Colomb, L | 1 |
| Pinguet, JP | 1 |
| Martel, J | 1 |
| Southwick, HW | 1 |
| Holsti, LR | 1 |
| Tancini, G | 1 |
| Sancho, H | 1 |
| Simmonds, WP | 1 |
| Sandeman, TF | 1 |
| Bagshaw, MA | 1 |
| Selawry, OS | 1 |
| Fain, WR | 1 |
| Conn, JH | 1 |
| Chavez, CM | 1 |
| Navashin, SM | 1 |
| Fomina, IP | 1 |
| Osokina, LI | 1 |
| Zharikov, AA | 1 |
| Sugiura, K | 1 |
| Perevodchikova, NI | 1 |
| Dogliotti, M | 1 |
| von Koppenfels, R | 1 |
| Dickinson, JT | 1 |
| Rooker, DW | 1 |
| Leonard, JR | 1 |
| Costanzi, JJ | 1 |
| Coltman, CA | 1 |
| Kühböck, J | 1 |
| Pokorny, D | 1 |
| Steinbach, K | 1 |
| Eggerth, G | 1 |
| Earle, E | 1 |
| Butts, D | 1 |
| Hoaglin, LL | 1 |
| Rottenberg, VI | 1 |
| Knysh, VI | 1 |
| Gründer, K | 1 |
| Leyh, F | 1 |
| Nitze, HR | 6 |
| Vosteen, KH | 3 |
| Moskalik, KG | 1 |
| Kozlov, AP | 1 |
| Akimov, AA | 1 |
| Elias, EG | 2 |
| Brugarolas, A | 1 |
| Copeland, EM | 1 |
| McBride, CM | 1 |
| van der Merwe, AM | 1 |
| van Dyk, JJ | 1 |
| Falkson, HC | 1 |
| Kirsch, WM | 1 |
| Schulz, D | 1 |
| Van Buskirk, JJ | 1 |
| Young, HE | 1 |
| McInnis, WD | 1 |
| Lynch, PJ | 1 |
| Hattowska, H | 1 |
| Borowicz, K | 1 |
| Lindberg, RD | 3 |
| Freckman, HA | 1 |
| Westburg, SP | 1 |
| Stone, OJ | 1 |
| Carr, DT | 1 |
| Childs, DS | 1 |
| Lee, RE | 1 |
| Montminy, L | 1 |
| Cerruti, FR | 1 |
| Ammon, J | 1 |
| Hermann, HJ | 1 |
| Janssen, B | 1 |
| Schmidt, L | 1 |
| Günther, W | 1 |
| Zala, L | 1 |
| Valieva, RK | 1 |
| Turganbaev, AT | 1 |
| Balmukhanov, SB | 1 |
| Klein, E | 5 |
| Weintraub, I | 1 |
| Lagasse, LD | 1 |
| Nel, WS | 1 |
| Fourie, ED | 1 |
| Wagers, LT | 1 |
| Shapiro, L | 1 |
| Kroll, JJ | 1 |
| Finley, AG | 1 |
| Omura, GA | 1 |
| Roberts, GA | 1 |
| Priestman, TJ | 1 |
| Leeming, JA | 1 |
| Dana, M | 1 |
| Byfield, JE | 1 |
| Belisario, JC | 1 |
| Reed, RR | 1 |
| Kremetz, ET | 1 |
| Swart-Bruinsma, WA | 1 |
| Herrmann, WA | 1 |
| Dean, RE | 1 |
| Taylor, ES | 1 |
| Weisbrod, DM | 1 |
| Martin, JW | 1 |
| Glupe, J | 1 |
| Mussey, E | 1 |
| Johnson, CE | 1 |
| Anderson, JM | 2 |
| Hutchison, J | 2 |
| Ashton, H | 1 |
| Beveridge, GW | 1 |
| Stevenson, CJ | 1 |
| Ebner, H | 2 |
| Gleason, MC | 1 |
| Chahinian, P | 1 |
| Smith, JP | 2 |
| Rutledge, F | 1 |
| Burns, BC | 1 |
| Soffar, S | 1 |
| Molina, C | 1 |
| Cheminat, JC | 1 |
| Passemard, N | 1 |
| Adam, J | 1 |
| Migueres, J | 1 |
| Jover, A | 1 |
| Mignon, A | 1 |
| Tournant, A | 1 |
| Meyer, A | 1 |
| Tsuya, A | 1 |
| Kaneda, K | 1 |
| Okano, S | 1 |
| Scherer, E | 1 |
| Rassow, J | 1 |
| Shnider, BI | 2 |
| Randall, GE | 1 |
| Castro, JR | 1 |
| Nelson, CS | 1 |
| Jewell, WR | 1 |
| Lawton, RL | 1 |
| Gulesserian, HP | 1 |
| Sharzer, LA | 1 |
| Lleander, VC | 1 |
| Goldstein, G | 1 |
| Horsley, JS | 1 |
| Cavins, JA | 2 |
| Jacobs, EM | 1 |
| Reeves, WJ | 1 |
| Wood, DA | 1 |
| Pugh, R | 1 |
| Braunwald, J | 1 |
| Bateman, JR | 1 |
| Oka, S | 1 |
| Stoll, HL | 1 |
| Milgrom, H | 1 |
| Helm, F | 1 |
| Walker, MJ | 1 |
| Reed, RJ | 2 |
| Guss, SB | 1 |
| Osbourn, RA | 1 |
| Lutzner, MA | 2 |
| Cohen, JL | 1 |
| Krant, MJ | 1 |
| Matias, PI | 1 |
| Horton, J | 1 |
| Baxter, D | 1 |
| Ott, F | 1 |
| Storck, H | 1 |
| Avrach, W | 1 |
| Ziprkowski, L | 1 |
| Richards, RN | 1 |
| Zeligman, I | 1 |
| Scott, CI | 1 |
| Wieme, RJ | 1 |
| Van Hove, WZ | 1 |
| Van der Straeten, ME | 1 |
| Banzet, P | 1 |
| De la Caffinière, JY | 1 |
| Dufourmentel, C | 1 |
| Eller, JJ | 1 |
| Uthida-Tanaka, AM | 1 |
| de Britto-Costa, R | 1 |
| de Tavares Mello, E | 1 |
| Yonemoto, RH | 1 |
| Byron, RL | 1 |
| Riihimaki, DU | 1 |
| Keating, JL | 1 |
| Neyazaki, T | 1 |
| Seki, Y | 1 |
| Egawa, N | 1 |
| Mouriquand, J | 1 |
| Brun, J | 1 |
| Perrin-Fayolle, M | 1 |
| Pison, H | 1 |
| Kofman, J | 1 |
| Glintzer, W | 1 |
| Achten, G | 2 |
| Van Oost, A | 2 |
| Williams, AC | 1 |
| Thivolet, J | 1 |
| Chabanon, M | 1 |
| Perrot, H | 1 |
| Spencer, SK | 1 |
| Kierland, RR | 1 |
| Bergonzini, R | 1 |
| Vaccari, R | 1 |
| Zagnoli, P | 1 |
| Knock, FE | 1 |
| Galt, RM | 1 |
| Oester, YT | 1 |
| Hill, BH | 1 |
| Garcia-Perez, A | 1 |
| Aparicio, M | 1 |
| Carapeto, FJ | 1 |
| King, GM | 1 |
| Ledoux-Corbusier, M | 1 |
| Midana, A | 1 |
| Leigheb, G | 1 |
| Llombart Bosch, M | 1 |
| Espinosa Cabañero, JA | 1 |
| Binazzi, M | 1 |
| Almeida Gonçalves, JC | 1 |
| De Noronha, T | 1 |
| Gottlieb, JA | 1 |
| Serpick, AA | 1 |
| Bettley, FR | 1 |
| Egawa, J | 1 |
| Hayashi, S | 1 |
| Fulton, JE | 1 |
| Hurley, HJ | 1 |
| Von Essen, CF | 1 |
| Joseph, LB | 1 |
| Simon, GT | 1 |
| Singh, AD | 1 |
| Singh, SP | 1 |
| Genevrier, R | 1 |
| Gouletquer, J | 1 |
| Reboul, AR | 1 |
| Lewest, G | 1 |
| Morere, P | 1 |
| Chauvet, MC | 1 |
| Vaudour, P | 1 |
| Maisse, P | 1 |
| Stain, JP | 1 |
| Lenail, C | 1 |
| Carter, VH | 1 |
| Smith, KW | 1 |
| Noojin, RO | 1 |
| Goolsby, CD | 1 |
| Daly, JW | 1 |
| Skinner, OD | 1 |
| Gibbs, CE | 1 |
| Shima, T | 1 |
| Weitgasser, H | 1 |
| Johnson, RH | 1 |
| Kastl, WH | 1 |
| Knoepp, LF | 1 |
| Soosaar, A | 1 |
| Chakravorty, RC | 1 |
| Sarkar, SK | 1 |
| Mukerji, B | 1 |
| Anderson, FE | 1 |
| Johnson, AM | 1 |
| Havyatt, MT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of the Clinical Value of a Docetaxel, Cisplatin and 5-fluorouracil (DCF) Strategy Adapted to Patients for the Management of Metastatic or Locally Advanced Anal Resistant Radiochemotherapy Squamous Cell Anal Carcinoma.[NCT02402842] | Phase 2 | 70 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| The Value of Optical Coherence Tomography in Discrimination Between the Presence and Absence of Invasion in Clinical Actinic Keratosis[NCT06014697] | 75 participants (Anticipated) | Observational | 2023-03-01 | Active, not recruiting | |||
| Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study[NCT02281682] | Phase 4 | 624 participants (Actual) | Interventional | 2014-11-30 | Active, not recruiting | ||
| Adjuvant Treatment of Cancer of the Esophagus or Cardia Before Resection With Curative Intent. Comparative Study Between Chemotherapy and Radiochemotherapy[NCT01362127] | Phase 2 | 181 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Spartalizumab, mDCF (Docetaxel, Cisplatin and 5-fluorouracil) and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma. A Phase IIA Study[NCT04894370] | Phase 2 | 34 participants (Anticipated) | Interventional | 2022-06-09 | Recruiting | ||
| A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma[NCT03519295] | Phase 2 | 99 participants (Anticipated) | Interventional | 2018-07-22 | Active, not recruiting | ||
| Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer[NCT03691441] | Phase 4 | 280 participants (Anticipated) | Interventional | 2018-01-05 | Active, not recruiting | ||
| Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients[NCT05060471] | Phase 2 | 27 participants (Anticipated) | Interventional | 2021-09-08 | Enrolling by invitation | ||
| Prospective Randomized Controlled Trial of Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy[NCT03734952] | 537 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | |||
| Phase I/II Study of Split-dose TPF-Induction Chemotherapy Before Surgery of Oropharyngeal and Cavity of the Mouth Cancer[NCT01108042] | Phase 1/Phase 2 | 71 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Randomized, Multicenter, Phase III Trial Comparing Induction CT With Docetaxel, Cisplatin and 5-FU (TPF) Followed by Concurrent CT-RT to Concurrent CT Alone, in Nasopharyngeal Cancers Staged as T2b, T3, T4 and/or With Lymph Node Involvement (>N1)[NCT00828386] | Phase 3 | 83 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Low accrual) | ||
| Immunomonitoring and Biomarker Research Based on Tumor and Blood Samples in Patients With Squamous Cell Anal Carcinoma[NCT03942900] | 0 participants (Actual) | Observational | 2020-04-01 | Withdrawn (stopped due to Study not submitted to regulatory authorities) | |||
| A Phase II Study of Efficacy and Safety of Induction Modified TPF (mTPF) Followed by Concurrent Chemoradiotherapy (CCRT) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)[NCT05527782] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | ||
| Neoadjuvant Docetaxel+Cisplatin and 5-fluorouracil (TPF) Followed by Radiotherapy+Concomitant Chemo or Cetuximab Versus Radiotherapy+Concomitant Chemo or Cetuximab in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Randomize[NCT01086826] | Phase 3 | 320 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial[NCT00847912] | Phase 4 | 954 participants (Actual) | Interventional | 2009-06-26 | Completed | ||
| Randomized Trial to Evaluate Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy[NCT02369939] | Phase 3 | 118 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| The Third Phase of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence Was Compared With the Clinical Comparison[NCT04404491] | Phase 3 | 240 participants (Anticipated) | Interventional | 2020-06-01 | Not yet recruiting | ||
| A Prospective Single-arm Phase Ⅱ Study of Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma[NCT04844385] | Phase 2 | 83 participants (Anticipated) | Interventional | 2021-02-20 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Ad[NCT03189719] | Phase 3 | 749 participants (Actual) | Interventional | 2017-07-25 | Completed | ||
| Calcipotriol Plus 5-Fluorouracil Immunotherapy for Skin Cancer Prevention in Organ Transplant Recipients[NCT04642287] | Phase 2 | 64 participants (Anticipated) | Interventional | 2026-01-31 | Not yet recruiting | ||
| Calcipotriol Plus 5-Flourouracil Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients[NCT04329221] | Phase 2 | 62 participants (Anticipated) | Interventional | 2026-01-01 | Not yet recruiting | ||
| A Prospective Phase II Study of Prophylactic TPO Combined With Bone Marrow-Sparing Intensity-Modulated Radiotherapy to Reduce Platelet Inhibition in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy[NCT05944809] | Phase 2 | 27 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| A Phase III Randomized Clinical Trial of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma[NCT01591135] | Phase 3 | 436 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| A Phase II/III Study Comparing Simultaneous Integrated Boost (SIB) Intensity Modulated Radiation Therapy (IMRT) With S1 Based SIB-IMRT Followed by Adjuvant Chemotherapy With S1 in Elderly Patients With Esophageal or Esophagogastric Cancer (3JECROG-P01)[NCT02979691] | Phase 2/Phase 3 | 350 participants (Anticipated) | Interventional | 2016-10-31 | Completed | ||
| A Pilot Feasibility Study of Definitive Concurrent Chemoradiation With Pencil Beam Scanning Proton Beam in Combination With 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal[NCT01858025] | Early Phase 1 | 25 participants (Actual) | Interventional | 2013-07-31 | Active, not recruiting | ||
| Open-label, Single-arm, Multicenter, Phase II Study Investigating Cetuximab in Combination With Chemotherapy in the First-line Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) in Japanese Subjects[NCT00971932] | Phase 2 | 33 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent C[NCT04085250] | Phase 2 | 264 participants (Actual) | Interventional | 2019-11-28 | Active, not recruiting | ||
| Concurrent Radiotherapy and Weekly Chemotherapy of 5-fluorouracil and Cisplatin for Postoperative Locoregional Recurrence of Oesophageal Squamous Cell Carcinoma[NCT02325986] | Phase 2 | 46 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT)[NCT03870607] | Phase 2 | 75 participants (Anticipated) | Interventional | 2019-03-13 | Recruiting | ||
| Study of the Association Between Tumor Microenvironment Macrophages and Treatment Response in Squamous Cell Carcinoma of the Anal Canal[NCT05019235] | 154 participants (Actual) | Observational | 2021-08-05 | Active, not recruiting | |||
| Tumor Recurrence After Abdominal-perineal Amputation in Squamous Cell Carcinoma of the Anus[NCT05201105] | 43 participants (Actual) | Observational | 2021-10-15 | Completed | |||
| A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma[NCT05374252] | Phase 3 | 102 participants (Anticipated) | Interventional | 2022-05-07 | Recruiting | ||
| A Randomized, Open-label, Multicenter Trial of the Chemoradiation Versus Standard Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Cancer in Chinese Patients[NCT02972372] | 196 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | |||
| Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer[NCT02607540] | Phase 3 | 210 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer[NCT02025036] | Phase 3 | 249 participants (Actual) | Interventional | 2014-10-31 | Active, not recruiting | ||
| A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)[NCT00460265] | Phase 3 | 658 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Phase II Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Chemotherapy in Squamous Cell Carcinoma of the Oral Cavity With Molecular Endpoints[NCT00400205] | Phase 2 | 14 participants (Actual) | Interventional | 2006-08-31 | Terminated (stopped due to Safety reasons) | ||
| Randomized Phase III Trial Comparing Induction Chemotherapy With Cisplatin/5-fluorouracil (PF) or Docetaxel/Cisplatin/5-fluorouracil (TPF) Plus Chemoradiotherapy (CRT) Versus CRT Alone as First-line Treatment or Unresectable Locally Advanced Head and Neck[NCT00261703] | Phase 2/Phase 3 | 439 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Open-label, Randomized, Controlled Phase I/II Study of Cilengitide to Evaluate the Safety and Efficacy of the Combination of Different Regimens of Cilengitide Added to Cisplatin, 5-FU, and Cetuximab in Subjects With Recurrent/Metastatic Squamous Cell Canc[NCT00705016] | Phase 1/Phase 2 | 184 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial[NCT02604615] | Phase 3 | 60 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma[NCT01542931] | Phase 2/Phase 3 | 256 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With Intensity-modulated Radiotherapy in High Risk Locregionally Advanced Nasopharyngeal Carcinoma: a Phase 2 Randomized Controlled Trial[NCT02610556] | Phase 2 | 130 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety Profile of Cetuximab When Given in Combination With Chemotherapy for the First-line Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the He[NCT01177956] | Phase 3 | 73 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Phase I Trial of ABI-007 (Abraxane) Plus Cisplatin Plus 5-Fluorouracil (APF) as Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With Locally Advanced Squamous Cell Cancers of the Head and Neck (HNSCC)[NCT00731380] | Phase 1 | 12 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH)[NCT05459415] | 54 participants (Anticipated) | Interventional | 2022-06-22 | Active, not recruiting | |||
| A Randomized Trial Comparing Induction Gemcitabine and Cisplatin Plus Intensity-modulated Radiotherapy With Concurrent Cisplatin Plus Intensity-modulated Radiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT02460887] | Phase 3 | 236 participants (Anticipated) | Interventional | 2015-06-30 | Active, not recruiting | ||
| Neoadjuvant Tislelizumab With Afatinib for the Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial (neoCHANCE-1 Trial)[NCT05517330] | Phase 2 | 23 participants (Anticipated) | Interventional | 2022-12-20 | Recruiting | ||
| The Utility of Circulating Tumour Cells and Plasma microRNA Detection to Predict the Response to Treatment in Patients With Esophageal Adenocarcinoma[NCT02812680] | 200 participants (Anticipated) | Observational | 2016-06-30 | Active, not recruiting | |||
| Dose Escalation Using a Simultaneous Integrated Boost Technique Based on 18FDG-PET/CT for Unresectable Thoracic Esophageal Cancer: a Phase I/II Trial[NCT01843049] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| Phase II Study of Optimum Design of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer[NCT02938195] | Phase 2 | 50 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Measurement of the Distance Between the Corresponding Anatomical Landmarks in the Thoracic Cavity and the Incisors[NCT03720405] | 520 participants (Anticipated) | Observational [Patient Registry] | 2018-07-31 | Recruiting | |||
| Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0[NCT01621217] | Phase 1 | 21 participants (Anticipated) | Interventional | 2012-06-30 | Completed | ||
| Induction Chemotherapy and Toripalimab Followed by Surgery or Radiotherapy for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma[NCT04995120] | Phase 2 | 42 participants (Anticipated) | Interventional | 2021-04-07 | Recruiting | ||
| A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally R[NCT01081041] | Phase 2 | 187 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Multicenter Randomized Phase II Study to Evaluate the Benefit of Chemotherapy Plus Best Supportive Care (BSC) Versus BSC in Patients With Metastatic Oesophageal Cancer of Squamous Cell-type Who Have Not Experienced a Disease Progression or Unacceptable [NCT01248299] | Phase 2 | 105 participants (Actual) | Interventional | 2011-01-31 | Terminated | ||
| Sichuan Cancer Hospital & Institute[NCT05604950] | 2 participants (Actual) | Observational [Patient Registry] | 2009-01-01 | Completed | |||
| PReoperative Chemoradiation With Paclitaxel-carboplatin or With Fluorouracil-oxaliplatine-acide Folinique (FOLFOX) for Resectable Esophageal and Junctional Cancer - A Randomized Phase II Trial[NCT02359968] | Phase 2 | 106 participants (Actual) | Interventional | 2015-02-26 | Active, not recruiting | ||
| Induction Chemotherapy for Locally Advanced Esophageal Cancer: A Phase II Study[NCT03110926] | Phase 2 | 40 participants (Anticipated) | Interventional | 2017-06-19 | Active, not recruiting | ||
| A Pilot Study in Gastric Cancer of Assignment to Postoperative Chemoradiation or Chemotherapy Based Upon Surgical Lymph Node Assessment After Preoperative Chemotherapy, With Gene Assay as Correlate of Biologic Response[NCT03515941] | Early Phase 1 | 6 participants (Actual) | Interventional | 2018-06-22 | Terminated (stopped due to The PI has decided to close the study due to the outdated study design.) | ||
| Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer[NCT00381706] | Phase 2 | 245 participants (Actual) | Interventional | 2006-09-15 | Completed | ||
| Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903)[NCT04138212] | Phase 3 | 456 participants (Anticipated) | Interventional | 2019-10-22 | Recruiting | ||
| Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia Induced by Targeted Therapy and Immunotherapy Combination Treatment[NCT04896528] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-06-06 | Recruiting | ||
| Microbiota, Inflammatory Environment, Clinical and Radiomic Features as Predictors of Normal Tissue Response in Radiotherapy for Prostate and Head-and-neck Cancer[NCT03294122] | 400 participants (Anticipated) | Observational | 2017-02-02 | Recruiting | |||
| The Role of Calcipotriol in Treatment of Pre-cancerous Skin Lesions[NCT02019355] | Early Phase 1 | 132 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Combination Topical 5-fluorouracil 5% / Calcipotriene 0.005% Cream for Treatment of in Situ and Superficially Invasive Squamous Cell Carcinoma of the Skin[NCT04839731] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2021-04-14 | Recruiting | ||
| Combination Calcipotriene 0.005% Foam and Fluorouracil 5% Cream for the Treatment of Actinic Keratoses on the Scalp[NCT03996252] | Early Phase 1 | 15 participants (Actual) | Interventional | 2019-07-01 | Terminated (stopped due to The study team was not able to start the study and they never completed the IRB submission, so the study was terminated.) | ||
| A Randomized Study of the Efficacy and Safety of OncoGel™ Treatment as an Adjunctive Therapy to Systemic Chemotherapy and Concurrent External Beam Radiation Prior to Surgery in Subjects With Localized or Loco-regional Esophageal Cancer[NCT00573131] | Phase 2 | 137 participants (Actual) | Interventional | 2008-01-31 | Terminated (stopped due to OncoGel did not show any impact on overall tumor response) | ||
| Phase II Trial of Combined Modality Therapy Plus Cetuximab in HIV-Associated Anal Carcinoma[NCT00324415] | Phase 2 | 45 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)[NCT03943602] | Phase 2 | 37 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | ||
| A Study to Evaluate the Safety and Feasibility of the Combined Use of Nivolumab With Pemetrexed for the Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck[NCT04107103] | Phase 2 | 20 participants (Anticipated) | Interventional | 2020-03-19 | Recruiting | ||
| A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma[NCT02014831] | Phase 2 | 0 participants (Actual) | Interventional | 2016-02-29 | Withdrawn (stopped due to Industry decline to supply study drug) | ||
| TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)[NCT06163534] | 500 participants (Anticipated) | Observational [Patient Registry] | 2024-01-30 | Not yet recruiting | |||
| The Safety and Feasibility of Neoadjuvant Camrelizumab With Dalpiciclib for the Treatment of Resectable Esophageal or Head and Neck Squamous Cell Carcinoma：A Phase 1 Trial[NCT06109207] | Phase 1 | 12 participants (Anticipated) | Interventional | 2023-10-31 | Recruiting | ||
| Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies[NCT06061705] | 100 participants (Anticipated) | Interventional | 2023-12-30 | Not yet recruiting | |||
| 1922GCCC: PHASE 2 STUDY OF PEMBROLIZUMAB AND BAVITUXIMAB FOR PROGRESSIVE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK[NCT04150900] | Phase 2 | 7 participants (Actual) | Interventional | 2020-01-13 | Active, not recruiting | ||
| A Phase II Trial Aiming to Evaluate the Clinical Interest of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion [NCT03356223] | Phase 2 | 25 participants (Actual) | Interventional | 2018-02-05 | Completed | ||
| Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck[NCT00122460] | Phase 3 | 442 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer[NCT01627379] | Phase 3 | 300 participants (Anticipated) | Interventional | 2012-05-31 | Terminated (stopped due to Sponsor decision due to recommendation of the IDMC.) | ||
| Prospective Study to Analyze the Predictive Role of Factors Implicated in the Signaling Pathway of ERCC1 in Response to Treatment With Neoadjuvant Radiochemotherapy in Patients With Esophageal Cancer[NCT00953511] | 80 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| PHASE II STUDY ON LARYNX PRESERVATION COMPARING INDUCTION CHEMOTHERAPY AND RADIOTHERAPY VERSUS ALTERNATING CHEMO-RADIOTHERAPY IN RESECTABLE HYPOPHARYNX AND LARYNX CANCERS[NCT00002839] | Phase 3 | 564 participants (Anticipated) | Interventional | 1996-07-31 | Completed | ||
| [NCT01849107] | 49 participants (Actual) | Interventional | 2013-04-30 | Completed | |||
| A Phase I/II Trial of Induction Chemotherapy Plus Gefitinib (Iressa) Followed by Concurrent Chemotherapy, Radiation Therapy, and Gefitinib (Iressa) For Patients With Locally Advanced Squamous Carcinoma of the Head and Neck[NCT00193284] | Phase 2 | 50 participants | Interventional | 2003-10-31 | Completed | ||
| New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma[NCT03558035] | Phase 2 | 96 participants (Anticipated) | Interventional | 2014-09-30 | Recruiting | ||
| Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative[NCT02797405] | 97 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to Withdrawal of analysis study Partner.) | |||
| Primary Surgery Vs Primary Chemoradiation for Oropharyngeal Cancer (Scope Trial) - A Phase II/III Integrated Design Randomized Control Trial[NCT05144100] | Phase 2/Phase 3 | 498 participants (Anticipated) | Interventional | 2021-12-01 | Not yet recruiting | ||
| Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.[NCT05832593] | 52 participants (Anticipated) | Observational | 2023-05-01 | Not yet recruiting | |||
| Docetaxel (NSC-628503), Cisplatin (NSC-119875), And 5-Fluorouracil (NSC-19893) Induction Chemotherapy Followed By Accelerated Fractionation/Concomitant Boost Radiation And Concurrent Single Agent Cisplatin (NSC-119875), In Patients With Advanced Squamous [NCT00054054] | Phase 2 | 0 participants | Interventional | 2003-04-30 | Completed | ||
| Continuous Fluorouracil Plus Mitomycin C Versus Mitomycin C Plus Cisplatin As Chemotherapy Combination In Combined Radiochemotherapy For Locally Advanced Anal Cancer. A Phase II-III Study[NCT00068744] | Phase 2/Phase 3 | 88 participants (Actual) | Interventional | 2003-07-31 | Terminated (stopped due to low accrual) | ||
| Randomized Controlled Trial of the Efficacy of Adjuvant Chemotherapy in Patients With Residual Lesions After Concurrent Radiochemotherapy for Locally Advanced Cervical Cancer[NCT04409860] | 120 participants (Anticipated) | Interventional | 2020-05-26 | Recruiting | |||
| Impact of Widths After Gastric Tube Reconstruction on Quality of Life for Patients With Esophagogastric Cancers[NCT01911832] | Phase 3 | 60 participants (Anticipated) | Interventional | 2012-03-31 | Recruiting | ||
| Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by Surgery for Thoracic Esophageal Squamous Cell Cancer: A Prospective, Single Arm, Pilot Study[NCT04776590] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-01-28 | Recruiting | ||
| A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma[NCT05213312] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
| Neoadjuvant Chemoradiotherapy VS. Neoadjuvant Chemotherapy Followed by Minimally Invasive Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma（cT3-4aN0-1M0):A Multi-center Prospective Randomized Clinical Trial[NCT03001596] | 264 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| Phase III Randomized Study of Radiotherapy Alone vs With Concurrent Chemotherapy With MTX or VBMF (VCR/BLEO/MTX/5-FU) vs Subsequent Chemotherapy vs Concurrent and Subsequent Chemotherapy in Patients With Advanced Head and Neck Cancer[NCT00002476] | Phase 3 | 0 participants | Interventional | 1990-01-31 | Completed | ||
| Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT01379339] | Phase 1 | 40 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A Phase II Study of Daily Low-Dose of Nedaplatin (CDGP:Cis-Diammine-Glycolatoplatinum) and Continuous Infusion of 5-FU Combined With Radiation for the Treatment of Esophageal Cancer[NCT00197444] | Phase 2 | 33 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Phase I, Dual Arm, Open-Label, Trial of Intralesional 5-Fluorouracil (5FU) and Intralesional 5FU Combined With Topical Imiquimod in Patients With Squamous Cell Carcinoma (SCC) of the Lower Extremities[NCT03370406] | Phase 1 | 30 participants (Anticipated) | Interventional | 2018-08-03 | Recruiting | ||
| Phase II Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies[NCT00266279] | Phase 2 | 17 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer[NCT03234842] | Phase 2 | 0 participants (Actual) | Interventional | 2017-10-30 | Withdrawn (stopped due to non-accrual) | ||
| A Phase I/II Trial of Preoperative Oxaliplatin, Docetaxel, and Capecitabine With Concurrent Radiation Therapy in Localized Carcinoma of the Esophagus or Gastroesophageal Junction[NCT00193128] | Phase 1/Phase 2 | 59 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Observational Study of Functional Outcomes After Chemoradiotherapy for Squamous Cell Cancer of the Anus[NCT01853059] | 176 participants (Anticipated) | Observational | 2013-10-31 | Not yet recruiting | |||
| A Phase Ⅱ Study on Low-expression and High-expression of ERCC1 in Recurrent or Metastastic Esophageal Cancer Patients Treated With Biweekly Paclitaxel and Cisplatin[NCT01444547] | Phase 2 | 92 participants (Anticipated) | Interventional | 2007-01-31 | Recruiting | ||
| Randomized Phase II Trial of Conventional vs IMRT Whole Brain Radiotherapy for Brain Metastases[NCT01890278] | 60 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | |||
| Phase II Study of Concomitant Fluorouracil, Hydroxyurea, Cetuximab and Hyperfractionated Intensity Modulated Radiation Therapy for Locally Advanced Head and Neck Cancer[NCT00462735] | Phase 2 | 33 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere) Plus Cisplatin Plus 5-Fluorouracil Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil in Patients With Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck[NCT00003888] | Phase 3 | 359 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| [NCT02603159] | Phase 3 | 200 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy[NCT02644408] | Phase 3 | 184 participants (Actual) | Interventional | 2014-10-01 | Completed | ||
| Phase II Study Comparing Gemcitabine Plus Cisplatin to Docetaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma[NCT02016417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2014-05-31 | Not yet recruiting | ||
| Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma: A Randomized Phase III Trial[NCT04898374] | Phase 3 | 120 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| Randomized Trial of Comparing One Cycle With Three Cycles Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Locoregionally Advanced Nasopharyngeal Carcinoma[NCT02096380] | 120 participants (Anticipated) | Observational [Patient Registry] | 2014-05-31 | Not yet recruiting | |||
| A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere®) Plus Cisplatin and 5-Fluorouracil (TPF) Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil Followed by Concomitant Chemoradiotherapy to Improve the Overall Survival and Progressio[NCT00273546] | Phase 3 | 500 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| Quarterback 22: A Phase II Clinical Trial of Sequential Therapy and De-Intensified Chemoradiotherapy for Locally Advanced HPV Positive Oropharynx Cancer[NCT02945631] | 43 participants (Actual) | Interventional | 2016-04-25 | Active, not recruiting | |||
| The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer[NCT01706939] | Phase 3 | 23 participants (Actual) | Interventional | 2012-09-01 | Active, not recruiting | ||
| A Phase II Study Of Paclitaxel-Based Chemoradiotherapy Regimen With Selective Surgical Salvage For Resectable Locoregionally Advanced Carcinoma Of The Esophagus[NCT00069953] | Phase 2 | 43 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in Induction Chemotherapy Plus Concurrent Chemoradiotherapy for Locoregionally Advanced NPC： a Phase 3, Multicentre, Non-inferiority, Randomised Factorial Trial[NCT03503136] | Phase 3 | 632 participants (Anticipated) | Interventional | 2018-06-30 | Not yet recruiting | ||
| A Phase II Study of Weekly Paclitaxel and Capecitabine in Patients With Metastatic or Recurrent Esophageal Cancer[NCT00453323] | Phase 2 | 33 participants (Actual) | Interventional | 2006-06-30 | Active, not recruiting | ||
| A Phase II Randomized Trial of Induction Chemotherapy Versus no Induction Chemotherapy Followed by Definitive Chemoradiotherapy in Patients With Inoperable Thoracic Esophageal Cancer[NCT02403531] | Phase 2 | 110 participants (Actual) | Interventional | 2015-05-01 | Completed | ||
| "Study on Indications of Bard PowerPort Isp Implantable Port: Image Accuracy in Resectable Esophageal Cancer Patients"[NCT02887261] | 100 participants (Actual) | Interventional | 2016-05-31 | Completed | |||
| A Single Arm, Phase II Study of TNFerade™ Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer[NCT00051480] | Phase 2 | 0 participants | Interventional | Completed | |||
| Phase I/II Study on Induction Chemotherapy Followed by Chemoradiation With or Without Lapatinib, a Dual EGFR/ErbB2 Kinase Inhibitor, in Patients With Locally Advanced Larynx and Hypopharynx Squamous Cell Carcinoma[NCT00498953] | Phase 1/Phase 2 | 7 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Multicenter and Prospective Clinical Trial of Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma[NCT04522050] | Phase 1 | 65 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| A Prospective, Phase II Study of Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy in Patients With Esophageal Squamous Cell Carcinoma[NCT04380480] | Phase 2 | 63 participants (Actual) | Interventional | 2020-02-01 | Completed | ||
| A Prospective, Single-arm, Phase II Study of Adelbelimab Combined With Carboplatin and Nab-paclitaxel in Neoadjuvant Therapy for Patients With Resectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT06016413] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | ||
| Role of Neo-adjuvant Chemotherapy in Organ Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue[NCT02985255] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-04-30 | Recruiting | ||
| A Phase III Clinical Trial of Docetaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma[NCT02465736] | Phase 3 | 610 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Could Positon Emission Tomography With Radiolabelled 3'-Deoxy-3'-(18)F-Fluoro-L-Thymidine be a Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patients ?[NCT02069418] | Phase 2 | 80 participants (Anticipated) | Interventional | 2014-02-28 | Active, not recruiting | ||
| Phase I Study of Chemoradiation Therapy With Epitope Peptide Vaccine Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer[NCT00632333] | Phase 1 | 9 participants (Anticipated) | Interventional | 2008-02-29 | Recruiting | ||
| A Phase I/II Study of Taxotere, Cisplatin, 5-Fluorouracil and Leucovorin for Squamous Cell Carcinoma of the Head and Neck[NCT00139243] | Phase 1/Phase 2 | 30 participants | Interventional | 1997-10-31 | Completed | ||
| TPLF-4, Compressed TPLF for Locally Advanced Squamous Cell Carcinoma[NCT00139230] | Phase 2 | 30 participants | Interventional | 1997-01-31 | Completed | ||
| Phase I/II Pilot Study of Induction Chemotherapy With Docetaxel in Combination With Cisplatin and 5-Fluorouracil (5-FU) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)[NCT00139269] | Phase 1/Phase 2 | 38 participants | Interventional | 1998-02-28 | Completed | ||
| Randomized Phase II Study of Two Different Regimens of TPF Induction Chemotherapy Regimen Followed by Radiation Therapy Plus Cetuximab (TPF-CET-HART) vs. HART and Cis-platinum, 5-FU (PF-HART) in Patients With Locally Advanced Unresectable Squamous Cell Ca[NCT01181401] | Phase 2 | 94 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients[NCT01349309] | 26 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| A Prospective, Phase Ⅱ Study of S-1 Plus Moderately Hypofractionated Conformal Radiation for Esophageal Squamous Cell Carcinoma[NCT03660449] | Phase 2 | 58 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Research on Current Prototypes of the Digiclamp. Short Term and Long Term Outcomes of Treating Adults With Achrocordons (Skin Tags)[NCT03259295] | 20 participants (Actual) | Interventional | 2017-12-01 | Completed | |||
| A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Oropharyngeal Cancers[NCT00797446] | 10 participants (Actual) | Observational | 2007-09-30 | Terminated (stopped due to Slow enrollment, feasibility issues) | |||
| Multi-center Prospective Randomized Controlled Clinical Trial of Postoperative Adjuvant Chemotherapy, Adjuvant Radiotherapy, or Surgery Alone for High-risk Histological Node Negative Patients With Thoracic Esophageal Squamous Cell Carcinoma[NCT02891083] | Phase 3 | 486 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Phase II Trial of Weekly Carboplatin-Paclitaxel Adjuvant Chemotherapy After Intensity Modulated Extended-field Chemoradiation in the Treatment of Locally Advanced Cervical Cancer With Para-aortic Positive Nodes[NCT04016142] | Phase 2 | 21 participants (Actual) | Interventional | 2020-07-15 | Active, not recruiting | ||
| Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression[NCT02309658] | Phase 2 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A PHASE III INTERGROUP RANDOMIZED COMPARISON OF COMBINED MODALITY THERAPY FOR CARCINOMA OF THE ESOPHAGUS: HIGH-DOSE VS CONVENTIONAL-DOSE RADIATION THERAPY[NCT00002631] | Phase 3 | 298 participants (Anticipated) | Interventional | 1995-06-30 | Completed | ||
| Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study[NCT05028231] | 46 participants (Anticipated) | Observational | 2021-06-05 | Recruiting | |||
| Phase II Randomized Trial Comparing Paclitaxel Combined With DDP Plus Concurrent Chemoradiotherapy With DDP Plus Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT03047265] | Phase 2 | 164 participants (Anticipated) | Interventional | 2017-02-04 | Active, not recruiting | ||
| The Application of Novel Oncolytic Virus in Late Stage Solid Tumors[NCT06080984] | Phase 1 | 24 participants (Anticipated) | Interventional | 2023-10-15 | Recruiting | ||
| A RANDOMIZED PHASE III EVALUATION OF PACLITAXEL + G-CSF + CISPLATIN VERSUS CISPLATIN + 5-FU IN ADVANCED HEAD AND NECK CANCER[NCT00002888] | Phase 3 | 0 participants | Interventional | 1997-03-31 | Completed | ||
| Surgery and Adjuvant Radiotherapy Versus Concurrent Chemo-Radiotherapy for Resectable (Non-Metastatic) Stage III/IV Head and Neck Squamous Cell Cancer[NCT00003576] | Phase 3 | 200 participants (Anticipated) | Interventional | 1997-01-31 | Completed | ||
| Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation[NCT00970502] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Trial to Determine the CR Rate at the Primary Tumor Site After 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head & Neck Carcinoma Treated With Definitive Concurrent Cisplatin & Radiation Therapy[NCT00736944] | Phase 2 | 30 participants (Actual) | Interventional | 2008-12-19 | Completed | ||
| Prospective Registration of Head and Neck Cancer Patients for Clinical Data and Tissue Collection[NCT02546895] | 2,000 participants (Anticipated) | Observational | 2015-09-30 | Recruiting | |||
| Phase III Randomized Study of Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx[NCT00003627] | Phase 3 | 160 participants (Anticipated) | Interventional | 1998-10-31 | Completed | ||
| Randomized Phase 2 Trial of Tirapazamine and the Role of Tumor Hypoxia in Advanced Squamous Head and Neck Cancer[NCT00002774] | Phase 2 | 63 participants (Actual) | Interventional | 1996-06-30 | Completed | ||
| Evaluation of Three Hour Infusion of Paclitaxel Plus Cisplatin and 5-Fluorouracil in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)[NCT00006248] | Phase 2 | 78 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck[NCT00002951] | Phase 2 | 53 participants (Actual) | Interventional | 1996-06-30 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Phase Ib/II Clinical Study of Anti-pd-l1 Monoclonal Antibody Injection (ZKAB001) Combined Albumin Binding Paclitaxel, Cisplatin in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma.[NCT04460066] | Phase 1/Phase 2 | 70 participants (Anticipated) | Interventional | 2020-11-18 | Active, not recruiting | ||
| A Limited Access Phase II Trial Of Capecitabine In Advanced, Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix[NCT00016926] | Phase 2 | 0 participants | Interventional | 2001-04-30 | Completed | ||
| Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer[NCT01561586] | Phase 3 | 374 participants (Anticipated) | Interventional | 2012-03-31 | Recruiting | ||
| A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer[NCT00023660] | Phase 1/Phase 2 | 84 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Prospective Randomized Clinical Trial on Delay Phenomenon Utility in Preventing Oesophagogastric Anastomotic Dehiscence After Ivor-Lewis Esophagectomy. Pilot Study.[NCT02432794] | 44 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| A Randomized Phase III Non-inferiority Study of Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma[NCT01540136] | Phase 3 | 402 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib as Adjuvant Therapy for Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas[NCT01143545] | Phase 1 | 10 participants (Actual) | Interventional | 2010-12-07 | Terminated (stopped due to Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same population.) | ||
| A Phase 3, Open-Label, Randomized Study to Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxaliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer Patients at Stage IIIB and IV (M0) (Based on AJCC Ed. 6) Who Received Radical Resecti[NCT01935778] | Phase 3 | 286 participants (Anticipated) | Interventional | 2013-10-02 | Recruiting | ||
| Prospective, Randomised and Multi-centric Therapy Optimisation Study for Examining the Influence of Surgical Staging on the Oncological Results for Patients With Cervix Carcinoma of the FIGO Stages IIB-IV After Chemoradiation[NCT01049100] | 250 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | |||
| TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma, a Prospective,Parallel, Randomized, Open Labeled, Multicenter Phase III Clinical Trial[NCT02940925] | Phase 3 | 241 participants (Actual) | Interventional | 2016-10-20 | Completed | ||
| Prospective Randomized Trial Comparing Induction Chemotherapy Plus Concurrent Chemoradiotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT01245959] | Phase 3 | 476 participants (Anticipated) | Interventional | 2011-01-31 | Active, not recruiting | ||
| Phase II Trial of Neoadjuvant Chemotherapy for HPV-Associated Squamous Cell Carcinoma of the Oropharynx Followed by Reduced Dose Radiotherapy/Chemoradiotherapy for Responders or Standard Dose Chemoradiotherapy for Non-Responders[NCT01525927] | Phase 2 | 2 participants (Actual) | Interventional | 2010-08-31 | Terminated (stopped due to Principal Investigator left institution. IRB approval lapsed.) | ||
| Phase II Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil Followed by Weekly Docetaxel and Cetuximab in Concurrence With Intensity-modulated Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma (NPC)[NCT01326559] | Phase 2 | 33 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Phase II Non-Randomised Controlled Trial Of Concomitant Immune Check Point Inhibitor With Radiotherapy And Chemotherapy Or Cetuximab In Advanced Non Metastatic Head And Neck Cancer[NCT03532737] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-10-07 | Recruiting | ||
| A Phase II Randomised Controlled Study Assessing the Role of Dose Escalation Using [18F] FMISO PET CT in Head and Neck Cancer: The DE-HyART (Dose Escalation Using Hypoxia-adjusted Radiotherapy) Protocol[NCT06087614] | Phase 2 | 124 participants (Anticipated) | Interventional | 2023-10-31 | Recruiting | ||
| Randomized Study of Adjuvant Radiochemotherapy After Surgery Versus Radiochemotherapy Alone in Patients With Locally Advanced Esophageal Cancer[NCT00416858] | Phase 3 | 40 participants (Anticipated) | Interventional | Completed | |||
| Evaluation of Topical Application of 5% Imiquimod, 0.05% Imiquimod and 0.05% Nanoencapsulated Imiquimod Gel in the Treatment of Actinic Cheilitis: a Randomized Controlled Trial[NCT04219358] | Phase 1 | 49 participants (Actual) | Interventional | 2019-03-23 | Terminated (stopped due to Study terminated because of COVID19 pandemics.) | ||
| Prospective Non-inferior Clinical Trial Comparing Concurrent Chemoradiotherapy or Radiotherapy Alone in Patients With Intermediate Risk Nasopharyngeal Carcinoma in Intensity-modulated Radiotherapy Era[NCT02633202] | Phase 3 | 338 participants (Anticipated) | Interventional | 2015-11-30 | Recruiting | ||
| Prospective Non-inferior Clinical Trial Comparing Concurrent Chemoradiotherapy or Radiotherapy Alone in Patients With Intermediate Risk Nasopharyngeal Carcinoma in Intensity-modulated Radiotherapy Era[NCT02289807] | 0 participants (Actual) | Interventional | 2015-03-31 | Withdrawn | |||
| A Prospective Randomized Phase III Trial Comparing Trimodality Therapy (Cisplatin, 5-FU, Radiotherapy, and Surgery) to Surgery Alone for Esophageal Cancer[NCT00003118] | Phase 3 | 56 participants (Actual) | Interventional | 1997-10-31 | Completed | ||
| Monitoring Efficacy of Radiotherapy Based on Next Generation Sequencing Liquid Biopsy Technique in Lung Cancer and Esophageal Cancer: a Prospective Study[NCT04014465] | 150 participants (Anticipated) | Observational | 2019-02-01 | Recruiting | |||
| Different Radiation Dose of Neoadjuvant Chemoradiation Followed By Surgery in Treating Patients With Locally Advanced, Resectable Thoracic Esophageal Cancer[NCT03381651] | 144 participants (Anticipated) | Interventional | 2018-02-22 | Recruiting | |||
| Clinical Trial Of Safety Of Robot-assisted Thoracic Approach Verus Open Transthoracic Esophagectomy in Esophageal Cancer.[NCT04652180] | 108 participants (Anticipated) | Interventional | 2020-11-06 | Recruiting | |||
| Induction Chemotherapy With Taxotere, Cisplatin and 5-Fluorouracil Followed by Concomitant Cetuximab and Radiation for Locoregionally Advanced Squamous Cell Cancer of the Head and Neck: A Phase II Trial[NCT01467115] | Phase 2 | 1 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| An Open-label Randomized Clinical Trial to Compare the Toxicities and Efficacy of Pharmacokinetically-guided and BSA Fixed Dosing Strategy of Docetaxel and Paclitaxel in Chinese Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, and Breast Cancer Patie[NCT01891123] | 300 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | |||
| Helping Cancer Patients Quit Smoking Using Brief Advice Based on Risk Communication: a Randomized Controlled Trial[NCT01685723] | 528 participants (Actual) | Interventional | 2012-09-30 | Completed | |||
| Validity and Reliability of the Turkish Version of the McMaster University Head and Neck Radiotherapy Questionnaire[NCT04269148] | 90 participants (Anticipated) | Observational | 2020-03-13 | Recruiting | |||
| Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma: a Phase II Randomized Controlled Trial[NCT02969473] | Phase 2 | 120 participants (Anticipated) | Interventional | 2010-10-31 | Active, not recruiting | ||
| Combination Treatment of S-1 With Paclitaxel Versus Paclitaxel+Cisplatin and 5-Fu+Cisplatin as First-line Treatment in Advanced Esophageal Cancer[NCT01704690] | Phase 2/Phase 3 | 4 participants (Actual) | Interventional | 2012-08-31 | Terminated (stopped due to The enrollment of the study is much slower than expected.) | ||
| A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Carcinoma of the Nasopharynx[NCT00797290] | 9 participants (Actual) | Observational | 2008-06-30 | Terminated (stopped due to Slow enrollment, Feasibility issues) | |||
| Randomized, Placebo-controlled, Double-blind Phase II Clinical Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Immunotherapy Combined With Concurrent Chemoradiotherapy for High-risk Nasopharyngeal Carcinoma[NCT03925090] | Phase 2 | 150 participants (Anticipated) | Interventional | 2019-12-08 | Active, not recruiting | ||
| Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma[NCT00379262] | Phase 3 | 803 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation Versus Concurrent Chemoradiation Alone In Patients With Stage N2-3 Nasopharyngeal Carcinoma: A Phase 3 Multicenter Randomised Controlled Trial[NCT02512315] | Phase 3 | 192 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Phase Ⅲ Trial of Induction Chemotherapy（TPF） Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy (PF) in Patients With High Risk Nasopharyngeal Carcinoma[NCT03306121] | Phase 3 | 322 participants (Anticipated) | Interventional | 2017-11-13 | Active, not recruiting | ||
| Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.[NCT03562897] | Phase 2 | 40 participants (Actual) | Interventional | 2018-10-25 | Completed | ||
| An Open-labeled Study to Evaluate Efficacy of Combining Erbitux Plus Concurrent Chemo-radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)[NCT00815308] | Phase 2 | 55 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer[NCT01137123] | Phase 3 | 301 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons[NCT02437851] | Phase 2 | 16 participants (Actual) | Interventional | 2015-04-30 | Active, not recruiting | ||
| CRP on Radiobiological and Clinical Studies on Viral-induced Cancer's Response to Radiotherapy With Comprehensive Morbidity Assessment[NCT00122772] | Phase 3 | 601 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Effect of Neoadjuvant Cisplatin Based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters[NCT00603408] | Phase 2 | 5 participants (Actual) | Interventional | 2007-12-31 | Terminated (stopped due to Study was discontinued due to lack of accrual.) | ||
| Effect of a Low Residue Diet in Comparison to the Dietary Recommendations From the INCan: A Randomized Clinical Trial to Assess Malnutrition, Gastrointestinal Toxicity and Quality of Life of Advanced Cervical Cancer Patients (IB2-IVA)[NCT03100409] | 137 participants (Actual) | Interventional | 2017-02-01 | Terminated (stopped due to The study was closed prematurely because the interim analysis found that subjects in the experimental group had less gastrointestinal toxicity.) | |||
| Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)[NCT05660083] | Phase 2 | 36 participants (Anticipated) | Interventional | 2023-01-12 | Recruiting | ||
| Pharmacogenetic and Pharmacokinetic Aspects of the Response to Chemotherapy Induction Using Docetaxel, Cisplatin and 5-Fluorouracile (TPF)in ORL Cancers[NCT01104714] | 90 participants (Actual) | Observational | 2010-04-30 | Completed | |||
| Phase Ⅲ Trial of Transcatheter Arterial Chemoembolization(TACE) Plus Recombinant Human Adenovirus Type 5 Injection for Unresectable Hepatocellular Carcinoma (HCC)[NCT01869088] | Phase 3 | 266 participants (Anticipated) | Interventional | 2013-01-31 | Active, not recruiting | ||
| RANDOMIZED STUDY OF PREOPERATIVE CHEMOTHERAPY VERSUS SURGERY ALONE IN ESOPHAGUS CANCER[NCT00002897] | Phase 3 | 240 participants (Anticipated) | Interventional | 1992-07-31 | Completed | ||
| Phase I Trial of Dose Escalated IMRT to the Para-aortic Nodes With Concurrent Cisplatin and Amifostine in Locally Advanced Cervical Cancer[NCT00137358] | Phase 1 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to unable to obtain funding to conduct study) | |||
| Phase III Study Comparing Neoadjuvant Chemotherapy With Carboplatin and Paclitaxel Followed by Standard Therapy, With Standard Therapy Alone in Women With Cervical Cancer and Para Aortic Positive Lymph Node.[NCT03534713] | Phase 3 | 310 participants (Anticipated) | Interventional | 2020-07-17 | Recruiting | ||
| Randomized Phase Ⅱ Trial of Induction Chemotherapy Using Gemcitabine and Cisplatin in Concurrence With Intensity-modulated Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma[NCT01417390] | Phase 2 | 80 participants (Anticipated) | Interventional | 2011-11-30 | Recruiting | ||
| Impacts of Oral Supplement With L-Glutamine on the Radiation-induced Toxicity and Nutritional Status of Head and Neck Cancer Patients Under Radiotherapy[NCT03015077] | 59 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| A Phase II Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis[NCT03114254] | Phase 2 | 17 participants (Actual) | Interventional | 2014-12-05 | Completed | ||
| Phase II Study of High-dose （86 Gy）Intensity Modulated Radiotherapy and Concurrent Paclitaxel and Cisplatin in Locoregionally Advanced Esophageal Cancer[NCT03535207] | 50 participants (Anticipated) | Interventional | 2018-04-01 | Recruiting | |||
| Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Cisplatin and Paclitaxel in Patients With Esophageal Cancer[NCT03082586] | 31 participants (Actual) | Interventional | 2016-11-20 | Completed | |||
| A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer[NCT00001442] | Phase 1 | 35 participants | Interventional | 1995-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Chireac tumour regression grade (NCT01362127)
Timeframe: Therapy followed in 14-16 weeks before surgery. After surgery the patients will be followed until 60 weeks after completed therapy.
| Intervention | Participants (Count of Participants) |
|---|---|
| Radiochemotherapy | 22 |
| Chemotherapy | 7 |
Safety profile of carrying out radical surgery after respective neoadjuvant therapy. (NCT01362127)
Timeframe: Five years follow up
| Intervention | Participants (Count of Participants) |
|---|---|
| Radiochemotherapy | 79 |
| Chemotherapy | 81 |
The European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 and disease specific questionnaires (QLQ-OES24/OG25). All items included in the questionnaires are analysed and also separate analysis of dysphagia questionnaires for oesophageal cancer were used, both clinically and psychometrically validated. All questions have four response alternatives (1, not at all; 2:a little, 3: quite a bit, 4: very much), except global scales which comprise seven response alternatives from poor to excellent. Questionnaire responses were transformed lineraly into scores ranging from 0 to 100 according to the EORTC scoring manual. A higher score indicates either more symotoms or better function, depending on the question. (NCT01362127)
Timeframe: Entry study up to Five years follow up
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Mean global QoL | Dysphagia score all | |
| Chemotherapy | 69 | 31 |
| Radiochemotherapy | 67 | 27 |
(NCT00847912)
Timeframe: date of randomization to last visit before end of study follow up (6/30/2013), assessed up to four years
| Intervention | participants (Number) |
|---|---|
| Arm 1: 5-fluorouracil | 182 |
| Arm 2: Placebo, Vehicle Control | 177 |
Diagnosis of the first Primary Basil Cell Carcinoma (BCC) or primary Squamous Cell Carcinoma (SCC) on the face or ears that was removed surgically. (NCT00847912)
Timeframe: From randomization to last visit prior to end of study date (6/30/2013), assessed up to four years
| Intervention | years (Median) |
|---|---|
| Arm 1: 5-fluorouracil | 3.37 |
| Arm 2: Placebo, Vehicle Control | 3.52 |
"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was reported by treatment arm as a pre-specified secondary analysis for all participants who were PD-L1 CPS ≥10." (NCT03189719)
Timeframe: Baseline, Week 18
| Intervention | Score on a Scale (Least Squares Mean) |
|---|---|
| Pembrolizumab + SOC | -1.73 |
| Placebo + SOC | 0.04 |
"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was reported by treatment arm as a pre-specified secondary analysis for all participants who had ESCC." (NCT03189719)
Timeframe: Baseline, Week 18
| Intervention | Score on a Scale (Least Squares Mean) |
|---|---|
| Pembrolizumab + SOC | -2.00 |
| Placebo + SOC | -1.94 |
"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was reported by treatment arm as a pre-specified secondary analysis for all participants who had ESCC and who were PD-L1 CPS ≥10." (NCT03189719)
Timeframe: Baseline, Week 18
| Intervention | Score on a Scale (Least Squares Mean) |
|---|---|
| Pembrolizumab + SOC | -2.36 |
| Placebo + SOC | -0.40 |
"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was reported by treatment arm as a pre-specified secondary analysis for all participants." (NCT03189719)
Timeframe: Baseline, Week 18
| Intervention | Score on a Scale (Least Squares Mean) |
|---|---|
| Pembrolizumab + SOC | -1.74 |
| Placebo + SOC | -1.64 |
For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per protocol, DOR is reported here for all participants of the ITT population (all randomized) who had CR or PR, and were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 10.4 |
| Placebo + SOC | 5.6 |
For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per protocol, DOR is reported here for all participants of the ITT population (all randomized) who had CR or PR, and who had ESCC. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 9.1 |
| Placebo + SOC | 6.1 |
For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per protocol, DOR is reported here for all participants of the ITT population (all randomized) who had CR or PR, and who had ESCC and were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 10.4 |
| Placebo + SOC | 4.4 |
For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per protocol, DOR is reported here for all participants of the ITT population (all randomized) who had CR or PR. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 8.3 |
| Placebo + SOC | 6.0 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that discontinued any study drug due to an AE was reported for each treatment arm. (NCT03189719)
Timeframe: Up to approximately 27 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + SOC | 90 |
| Placebo + SOC | 74 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that experienced at least one AE was reported for each treatment arm. (NCT03189719)
Timeframe: Up to approximately 28 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + SOC | 370 |
| Placebo + SOC | 368 |
ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by the investigator. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, the percentage of participants who experienced CR or PR is reported here as the ORR for all participants of the ITT population (all randomized). (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + SOC | 45.0 |
| Placebo + SOC | 29.3 |
ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by the investigator. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, the percentage of participants who experienced CR or PR is reported here as the ORR for all participants of the ITT population (all randomized) who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + SOC | 51.1 |
| Placebo + SOC | 26.9 |
ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by the investigator. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, the percentage of participants who experienced CR or PR is reported here as the ORR for all participants of the ITT population (all randomized) who had ESCC. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + SOC | 43.8 |
| Placebo + SOC | 31.0 |
ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by the investigator. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, the percentage of participants who experienced CR or PR is reported here as the ORR for all participants of the ITT population (all randomized) who had ESCC and who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + SOC | 51.0 |
| Placebo + SOC | 28.0 |
Overall survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS is reported here for all participants of the ITT population (all randomized). (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 12.4 |
| Placebo + SOC | 9.8 |
Overall survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS is reported here for all participants of the ITT population (all randomized) who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 13.5 |
| Placebo + SOC | 9.4 |
Overall survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS is reported here for all participants of the ITT population (all randomized) who had ESCC. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 12.6 |
| Placebo + SOC | 9.8 |
Overall survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS is reported here for all participants of the Intent-To-Treat (ITT) population (all randomized) who had ESCC and who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 13.9 |
| Placebo + SOC | 8.8 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 as assessed by the investigator, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, PFS is reported here for all participants of the ITT population (all randomized) who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 6.3 |
| Placebo + SOC | 5.8 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 as assessed by the investigator, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, PFS is reported here for all participants of the ITT population (all randomized) who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 7.5 |
| Placebo + SOC | 5.5 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 as assessed by the investigator, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, PFS is reported here for all participants of the ITT population (all randomized) who had ESCC. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 6.3 |
| Placebo + SOC | 5.8 |
"The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer and contains 18 items assessing symptoms of dysphagia, pain, reflux symptoms, eating restrictions, anxiety, dry mouth, taste, body image, and hair loss. For the purposes of this study, the Dysphagia subscale (three items), Pain subscale (three items), and Reflux subscale (two items) were evaluated. All subscale items were scored using a four-point Likert scale with the following response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores for the subscales were standardized into a range of 0 to 100 by linear transformation, with higher symptom scores representing a higher (worse) level of symptoms. Change from baseline to Week 18 in the Dysphagia, Pain, and Reflux subscales was reported for participants who were PD-L1 CPS≥10 in each treatment arm. Negative changes from baseline indicate a decrease in symptom severity." (NCT03189719)
Timeframe: Baseline, Week 18
| Intervention | Score on a Scale (Least Squares Mean) | ||
|---|---|---|---|
| Dysphagia subscale | Pain subscale | Reflux subscale | |
| Pembrolizumab + SOC | -7.18 | -3.51 | -0.52 |
| Placebo + SOC | 1.02 | 0.07 | 4.25 |
"The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer and contains 18 items assessing symptoms of dysphagia, pain, reflux symptoms, eating restrictions, anxiety, dry mouth, taste, body image, and hair loss. For the purposes of this study, the Dysphagia subscale (three items), Pain subscale (three items), and Reflux subscale (two items) were evaluated. All subscale items were scored using a four-point Likert scale with the following response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores for the subscales were standardized into a range of 0 to 100 by linear transformation, with higher symptom scores representing a higher (worse) level of symptoms. Change from baseline to Week 18 in the Dysphagia, Pain, and Reflux subscales was reported for participants with ESCC in each treatment arm. Negative changes from baseline indicate a decrease in symptom severity." (NCT03189719)
Timeframe: Baseline, Week 18
| Intervention | Score on a Scale (Least Squares Mean) | ||
|---|---|---|---|
| Dysphagia subscale | Pain subscale | Reflux subscale | |
| Pembrolizumab + SOC | -1.18 | -4.03 | -0.40 |
| Placebo + SOC | 3.32 | -2.33 | 1.09 |
"The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer and contains 18 items assessing symptoms of dysphagia, pain, reflux symptoms, eating restrictions, anxiety, dry mouth, taste, body image, and hair loss. For the purposes of this study, the Dysphagia subscale (three items), Pain subscale (three items), and Reflux subscale (two items) were evaluated. All subscale items were scored using a four-point Likert scale with the following response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores for the subscales were standardized into a range of 0 to 100 by linear transformation, with higher symptom scores representing a higher (worse) level of symptoms. Change from baseline to Week 18 in the Dysphagia, Pain, and Reflux subscales was reported for participants with ESCC who were PD-L1 CPS≥10 in each treatment arm. Negative changes from baseline indicate a decrease in symptom severity." (NCT03189719)
Timeframe: Baseline, Week 18
| Intervention | Score on a Scale (Least Squares Mean) | ||
|---|---|---|---|
| Dysphagia subscale | Pain subscale | Reflux subscale | |
| Pembrolizumab + SOC | -5.11 | -2.55 | -0.16 |
| Placebo + SOC | 3.57 | -0.42 | 4.94 |
"The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer and contains 18 items assessing symptoms of dysphagia, pain, reflux symptoms, eating restrictions, anxiety, dry mouth, taste, body image, and hair loss. For the purposes of this study, the Dysphagia subscale (three items), Pain subscale (three items), and Reflux subscale (two items) were evaluated. All subscale items were scored using a four-point Likert scale with the following response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores for the subscales were standardized into a range of 0 to 100 by linear transformation, with higher symptom scores represent a higher (worse) level of symptoms. Per protocol, change from baseline to Week 18 in the Dysphagia, Pain, and Reflux subscales was reported for all participants in each treatment arm. Negative changes from baseline indicate a decrease in symptom severity." (NCT03189719)
Timeframe: Baseline, Week 18
| Intervention | Score on a Scale (Least Squares Mean) | ||
|---|---|---|---|
| Dysphagia subscale | Pain subscale | Reflux subscale | |
| Pembrolizumab + SOC | -3.18 | -4.78 | -0.22 |
| Placebo + SOC | 2.36 | -1.85 | 0.71 |
Percentage of participants experiencing a complete response [CR] (complete disappearance of measurable and evaluable disease without new lesions) or partial response [PR] (greater than or equal to 50 percent decrease in the sum of the products of diameters [SOPD] of index lesions compared to the baseline SOPD, with no evidence of PD) confirmed by a subsequent assessment no less than 28 days after criteria for response were first met based on modified WHO criteria as assessed by Independent Review Committee (IRC). (NCT00971932)
Timeframe: Evaluations performed every 6 weeks until progressive disease (PD) reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 36.4 |
Percentage of participants with objective response based assessment of confirmed CR or confirmed PR according to RECIST as assessed by IRC. CR are those that persist on repeat imaging study at least 28 days after initial documentation of response. PR are those with greater than or equal to 30 percent decrease in the SOPD of index lesions compared to the baseline SOPD, with no evidence of PD. (NCT00971932)
Timeframe: Evaluations performed every 6 weeks until PD reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 45.5 |
Percentage of participants experiencing a CR (complete disappearance of measurable and evaluable disease without new lesions) or PR (>=50 percent decrease in sum of the products of diameters [SOPD] of index lesions compared to baseline SOPD, with no evidence of PD) confirmed by subsequent assessment no less than 28 days after criteria for response were first met) or stable disease [SD] (neither sufficient decrease to qualify for PR nor sufficient increase to qualify for PD) at least once no less than 42 days after first dose of trial treatment based on modified WHO criteria as assessed by IRC. (NCT00971932)
Timeframe: Evaluations performed every 6 weeks until PD reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 87.9 |
Duration of response according to modified WHO criteria as assessed by IRC was defined as the time from the first assessment of CR or PR until the date of the first occurrence of PD, or until the date of death when death occurred within 60 days of the last tumor assessment or first administration of trial treatment (whichever was last). (NCT00971932)
Timeframe: Time from first assessment of CR or PR to PD, death or last tumor assessment, reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 2.8 |
Time from first administration of trial treatment to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00971932)
Timeframe: Time from first administration of trial treatment or last day known to be alive, reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 12.8 |
The PFS time according to modified WHO criteria as assessed by IRC was defined as duration from first administration of trial treatment until PD (radiological or clinical, if radiological progression is not available) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment. (NCT00971932)
Timeframe: Time from first administration of trial treatment to PD, death or last tumor assessment, reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 4.1 |
Time to treatment failure according to modified WHO criteria as assessed by IRC was defined as the time from first administration of trial treatment until the date of the first occurrence of one of the events defining treatment failure: PD assessed by the investigator, discontinuation of treatment due to PD, discontinuation of treatment due to an adverse event (AE), start of any new anticancer therapy, or withdrawal of consent or death within 60 days of the last tumor assessment or first administration of trial treatment. (NCT00971932)
Timeframe: Time from first administration of trial treatment to treatment failure or last tumor assessment, reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 4.2 |
Time from the first confirmed objective response of complete or partial response (that is subsequently confirmed at least 28 days later) to disease progression using a modified version of the RECIST v1.0 (see protocol Appendix H). (NCT00460265)
Timeframe: Every 6 weeks until disease progression, up to 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 5.7 |
An objective tumor response of complete or partial response per modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 that was confirmed no less than 28 days after the criteria for response were first met. Complete response = disappearance of all target lesions and partial response = ≥30% reduction in lesion size. (NCT00460265)
Timeframe: Every 6 weeks until disease progression, up to 56 months
| Intervention | subjects (Number) |
|---|---|
| Panitumumab Plus Chemotherapy | 101 |
| Chemotherapy Alone | 73 |
Time from randomization to death (NCT00460265)
Timeframe: Upto 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 11.1 |
| Chemotherapy Alone | 9.0 |
Time from randomization date to date of disease progression using a modified version of the RECIST v1.0 or death. (NCT00460265)
Timeframe: Every 6 weeks until disease progression or deaths, upto 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 5.8 |
| Chemotherapy Alone | 4.6 |
Time from randomization date to date of disease progression using a modified version of the RECIST 1.0 (see protocol Appendix H) (NCT00460265)
Timeframe: Every 6 weeks until disease progression, up to 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 6.8 |
| Chemotherapy Alone | 5.6 |
Time from randomization date to the first confirmed objective response of complete or partial response (that is subsequently confirmed at least 28 days later) using a modified version of the RECIST v1.0. (NCT00460265)
Timeframe: Every 6 weeks until disease progression, upto 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 1.4 |
| Chemotherapy Alone | 1.5 |
Complete remission (complete disappearance of disease), partial remission [more than 30% decrease in tumor measurement by RECIST (Response evaluation criteria in solid tumors)]. (NCT00400205)
Timeframe: every 3 months
| Intervention | participants (Number) |
|---|---|
| Recipients of Docetaxel, Cisplatin, 5-Fluorouracil | 8 |
"Percent change in TNM stage of tumors after three cycles of study treatment was assessed to see if baseline acetylated tubulin (AT) expression predicts treatment success. Decreasing tumor stage change (a negative number) indicates that the tumor is responding to treatment while an increase means that the severity of the tumor is not decreasing. Immunohistochemistry (IHC) analysis of AT expression was performed in formalin-fixed, paraffin-embedded, pre-treatment tissues. The staining was scored based upon intensity according to the following criteria: 0=no staining, 1+=weak tumor staining, 2+=moderate tumor staining, 3+=moderate to high tumor staining, and 4+=high tumor staining.~Data presented are adopted from Saba, NF, et. al. Acetylated Tubulin (AT) as a Prognostic Marker in Squamous Cell Carcinoma of the Head and Neck. Head and Neck Pathology (2014) 8:66-72." (NCT00400205)
Timeframe: Baseline, After 3 cycles of study treatment
| Intervention | percentage of tumor stage change (Mean) | |
|---|---|---|
| AT score less than or equal to 2 | AT score greater than 2 | |
| Recipients of Docetaxel, Cisplatin, 5-Fluorouracil | -0.8 | -0.36 |
The BOR rate is defined as the percentage of the participants having achieved confirmed complete response (CR) or partial response (PR) as the best overall response according to radiological assessments (based on RECIST Version 1.0). (NCT00705016)
Timeframe: Evaluations will be performed every 6 weeks until progression reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | percentage of participants (Number) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 46.8 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 26.7 |
| Cetuximab+5-FU+Cisplatin | 35.5 |
The disease control rate is defined as the percentage of participants having achieved confirmed CR, PR or stable disease (SD) as best overall response according to radiological assessments (based on RECIST Version 1.0). (NCT00705016)
Timeframe: Evaluations will be performed every 6 weeks until progression reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | percentage of participants (Number) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 85.5 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 73.3 |
| Cetuximab+5-FU+Cisplatin | 80.6 |
Duration of response is defined as the time from the first assessment of CR or PR until the date of the first occurrence of progressive disease (PD), or until the date of death. (NCT00705016)
Timeframe: Time from first assessment of CR or PR until PD, death or last tumor assessment, reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | months (Median) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 5.8 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 4.1 |
| Cetuximab+5-FU+Cisplatin | 6.4 |
The OS time is defined as the time from randomization to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier. (NCT00705016)
Timeframe: Time from randomization to death, reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | months (Median) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 12.4 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 10.6 |
| Cetuximab+5-FU+Cisplatin | 11.6 |
The PFS is defined as the duration from randomization until radiological progression (based on response evaluation criteria in solid tumors [RECIST] Version 1.0) or death due to any cause. Only deaths within 84 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment. Investigator read is the assessment of all imaging by the treating physician at the local trial site. (NCT00705016)
Timeframe: Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | months (Median) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 6.4 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 5.6 |
| Cetuximab+5-FU+Cisplatin | 5.7 |
Please refer to Adverse Events section for details of individual serious adverse events and other adverse events (NCT00705016)
Timeframe: Time from first assessment of CR or PR until PD, death or last tumor assessment, reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | participants (Number) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 61 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 59 |
| Cetuximab+5-FU+Cisplatin | 61 |
TTF is defined as the time from randomization to date of the first occurrence of; progression, discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death (within 84 days of last tumor assessment). Participants without event are censored on the date of last tumor assessment. (NCT00705016)
Timeframe: Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | months (Median) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 5.6 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 4.5 |
| Cetuximab+5-FU+Cisplatin | 4.3 |
BOR: Percentage of participants experiencing a CR (complete disappearance of measurable and evaluable disease without new lesions) or PR (greater than or equal to 50 percent decrease of sum of product diameters of measurable disease, evaluable disease not worsening or progressing, no new lesions confirmed by a subsequent assessment no less than 28 days after criteria for response were first met) (based on modified WHO criteria), divided by the number of participants belonging to ITT or safety population. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 55.9 |
BOR: Percentage of participants experiencing a Complete Response (CR) (complete disappearance of measurable and evaluable disease without new lesions) or Partial Response (PR) (greater than or equal to 50 percent decrease of sum of product diameters of measurable disease, evaluable disease not worsening or progressing, no new lesions confirmed by a subsequent assessment no less than 28 days after criteria for response were first met) (based on modified World Health Organization [WHO] criteria), divided by the number of participants belonging to intention to treat (ITT) or safety population. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 54.4 |
Time from first assessment of CR or PR to disease progression or death (within 60 days of last tumor assessment). Participants without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 6.1 |
Time from first assessment of CR or PR to disease progression or death (within 60 days of last tumor assessment). Participants without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 5.7 |
The OS time was defined as the time from first administration of trial treatment to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT01177956)
Timeframe: Time from randomization to death or last day known to be alive, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 12.6 |
Duration from first administration of trial treatment until progression (radiological or clinical, if radiological progression is not available) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 6.6 |
Duration from first administration of trial treatment until progression (radiological or clinical, if radiological progression is not available) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 6.2 |
Time from first administration of trial treatment to disease progression (radiological or clinical, if radiological progression is not available). Participants without event are censored on the date of last tumor assessment. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 7.0 |
Time from first administration of trial treatment to disease progression (radiological or clinical, if radiological progression is not available). Participants without event are censored on the date of last tumor assessment. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 6.8 |
A total of 4 samples were collected during combination therapy, from the first dose of 250 mg/m^2 cetuximab in Cycle 1 (Day 1) through the final dose in Cycle 3 (Week 3) and used to report AUC of cetuximab at steady state during Part 2 of the study. As specified in the protocol, PK samples were not collected during Part 1 of the study, Safety Lead-In, or during Part 2 monotherapy. (NCT01081041)
Timeframe: Part 2: Weekly from Cycle 1, Day 1 through Cycle 3, Week 3: 0 h (immediately postdose), 24 h, 96 h, and 168 h postdose
| Intervention | micrograms*hours/milliliter (μg*h/mL) (Geometric Mean) |
|---|---|
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 21900 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 18800 |
A total of 4 samples were collected at various times during combination therapy, from the third dose of 250 mg/m^2 cetuximab in Cycle 1 (Week 3) through the final dose in Cycle 3 (Week 3) and used to report Cmax of cetuximab at steady state during Part 2 of the study. As specified in the protocol, PK samples were not collected during Part 1 of the study, Safety Lead-In, or during Part 2 monotherapy. (NCT01081041)
Timeframe: Part 2: Weekly from Cycle 1, Week 3 through Cycle 3, Week 3: 0 h (immediately postdose), 24 h, 96 h, and 168 h postdose
| Intervention | micrograms per milliliter (μg/mL) (Geometric Mean) |
|---|---|
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 225 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 199 |
The Cmax of cetuximab following 400 mg/m² cetuximab dosing during Part 2 of the study is reported. As specified in the protocol, pharmacokinetics (PK) samples were not collected during Part 1 of the study, Safety Lead-In or during Part 2 monotherapy. (NCT01081041)
Timeframe: Part 2: Cycle 1, Day 1: 0 hours [(h); immediately postdose], 1 h, 2 h, and 24 h postdose
| Intervention | micrograms per milliliter (μg/mL) (Geometric Mean) |
|---|---|
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 208 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 208 |
January 23, 2013 is the date when the first participant in the BI-manufactured cetuximab treatment arm switched to US commercial cetuximab due to changes in the manufacturing process for the BI-manufactured cetuximab necessitating the need to switch participants to US commercial cetuximab. Each participant who switched treatments received at least 2 cycles of BI-manufactured cetuximab before switching. All other components of their treatment regimen remained unchanged. The number of participants who had TEAEs during combination therapy is reported. Using January 23 cut-off, data is un-confounded by lack of BI-manufactured cetuximab. TEAEs were defined as serious and other non-serious adverse events (AEs) that occurred or worsened after study treatment (regardless of causality). TEAE information for Safety Lead-in group available in Reported Adverse Event module which is summary of serious and other non-serious AEs regardless of causality. (NCT01081041)
Timeframe: Part 2: Baseline to end of combination therapy or date first participant switched to US commercial cetuximab (up to 18 weeks)
| Intervention | participants (Number) |
|---|---|
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 75 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI), | 68 |
September 27, 2013 is the date when data was last collected for the primary endpoint. Prior to this date, the manufacturing process for the BI-manufactured cetuximab was changed necessitating the need to switch participants to US commercial cetuximab. All other components of their treatment regimen remained unchanged and participants stayed in their original reporting group. Therefore, the number of participants in the BI-manufactured cetuximab treatment arm who had TEAEs includes TEAEs while participants received BI-manufactured and US-commercial cetuximab. Using September 27 cut-off, the analysis of TEAEs is confounded by the switch from BI-manufactured to US commercial cetuximab. TEAEs were defined as serious and other non-serious AEs that occurred or worsened after study treatment (regardless of causality). TEAE information for Safety Lead-In group available in Reported Adverse Events module which is summary of serious and other non-serious AEs regardless of causality. (NCT01081041)
Timeframe: Part 2: Baseline to end of combination therapy (up to 18 weeks)
| Intervention | participants (Number) |
|---|---|
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 76 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 68 |
(NCT01081041)
Timeframe: Day 1, Week 1 of Cycles 3 and 5 (postbaseline samples were collected prior to infusion).
| Intervention | participants (Number) |
|---|---|
| All Participants (Cetuximab) | 4 |
OS was defined as duration from the date of randomization to the date of death from any cause. For each participant not known to have died as of the 23 October 2014 data cutoff date for the analysis, OS was censored at the date last known to be alive. In addition, any participants on Arm B who was switched from BI-manufactured cetuximab to ImClone-manufactured cetuximab was censored at the time of the switch. (NCT01081041)
Timeframe: Parts 1 and 2: Randomization to Date of Death from any Cause (Up to 36.3 Months)
| Intervention | Months (Median) |
|---|---|
| Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | 9.13 |
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 9.23 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 9.46 |
Response was defined using RECIST, v1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Progressive Disease (PD) was defined as having at least a 20% increase in the sum of the longest diameter of target lesions. Stable Disease (SD) was defined as small changes that did not meet the above criteria. (NCT01081041)
Timeframe: Parts 1 and 2: Randomization to Progression of Disease (Up to 32.7 Months)
| Intervention | percentage of participants (Number) |
|---|---|
| Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | 69.7 |
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 58.4 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 62.0 |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version [v]1.0) criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Percentage of participants with a confirmed CR or PR=(number of participants whose best overall response was CR or PR)/(number of participants treated)*100. (NCT01081041)
Timeframe: Parts 1 and 2: Randomization to Progression of Disease (Up to 32.7 Months)
| Intervention | percentage of participants (Number) |
|---|---|
| Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | 24.2 |
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 32.5 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 36.6 |
PFS was defined as duration from the date of randomization to the first date of objective progressive disease (PD) or death from any cause. For each participant who was not known to have died or to have had objective PD as of the 23 October 2014 data cutoff date for the analysis, PFS was censored at the date of the participant's last complete tumor assessment prior to that cutoff date. In addition, any participant in Arm B who was switched from BI-manufactured cetuximab to ImClone-manufactured cetuximab was censored at the time of the switch. (NCT01081041)
Timeframe: Parts 1 and 2: Randomization to Progression of Disease or Death from any Cause (Up to 32.7 Months)
| Intervention | Months (Median) |
|---|---|
| Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | 4.57 |
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 4.34 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 5.59 |
Disease recurrence will be defined as radiographic tumor evidence detected by surveillance imaging. Confirmation of recurrence by biopsy will be at the discretion of the treating physician. This study closed early on June 18, 2020. It was earlier than one planned because of the lack of accrual. (NCT03515941)
Timeframe: From the end of completion of assigned therapy, subjects undergo follow-up every 3 months for a total of 36 months(planned) after the date of surgery or until the study closure
| Intervention | months (Median) |
|---|---|
| Arm 1: Adjuvant Chemotherapy | NA |
| Arm 2: Adjuvant Chemoradiation | NA |
The number of patients who complete the recommended therapy will be counted for each arm. (NCT03515941)
Timeframe: From date of assigned therapy up to 17 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1: Adjuvant Chemotherapy | 3 |
| Arm 2: Adjuvant Chemoradiation | 2 |
Overall survival (OS) was defined as the time from study entry to death of any cause. The median OS with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: Adenocarcinoma (ECF + Cetuximab) | 11.6 |
| Arm B: Adenocarcinoma (IC + Cetuximab) | 8.6 |
| Arm C: Adenocarcinoma (FOLFOX + Cetuximab) | 11.8 |
Progression free survival (PFS) was defined as the time from study entry to progression or death of any cause. The median PFS with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: Adenocarcinoma (ECF + Cetuximab) | 7.1 |
| Arm B: Adenocarcinoma (IC + Cetuximab) | 4.9 |
| Arm C: Adenocarcinoma (FOLFOX + Cetuximab) | 6.8 |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): disappearance of all target lesions; Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria. Overall tumor response is the total number of CR and PRs in participants with adenocarcinoma who have received at least one cycle of therapy. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A: Adenocarcinoma (ECF + Cetuximab) | 61 |
| Arm B: Adenocarcinoma (IC + Cetuximab) | 45 |
| Arm C: Adenocarcinoma (FOLFOX + Cetuximab) | 54 |
Time to treatment failure (TTF) was measured from study entry until documented progression, death resulting from any cause, or end of protocol therapy because of unacceptable toxicity. The median TTF with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: Adenocarcinoma (ECF + Cetuximab) | 5.6 |
| Arm B: Adenocarcinoma (IC + Cetuximab) | 4.3 |
| Arm C: Adenocarcinoma (FOLFOX + Cetuximab) | 6.7 |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): disappearance of all target lesions; Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria. Overall tumor response is the total number of CR and PRs in participants with squamous cell carcinoma who have received at least one cycle of therapy. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A: Squamous Cell Carcinoma (ECF + Cetuximab) | 67 |
| Arm B: Squamous Cell Carcinoma (IC + Cetuximab) | 13 |
| Arm C: Squamous Cell Carcinoma (FOLFOX + Cetuximab) | 60 |
"Per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and by Spiral CT assessment:~Complete Response (CR) is the disappearance of all target lesions; Partial Response (PR) is a >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR" (NCT00573131)
Timeframe: Screening and Week 12
| Intervention | percentage of patients (Number) |
|---|---|
| Group 1 | 12.5 |
| Group 2 | 20.0 |
Change in absolute CD4 counts from start of treatment to 1 year after completion of study treatment (NCT00324415)
Timeframe: 1 year following treatment discontinuation
| Intervention | cells/mm3 (Median) |
|---|---|
| Combined Modality Therapy | 102 |
Percentage of participants who are alive and have not had a colostomy (NCT00324415)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Combined Modality Therapy | 92.4 |
Incidence of opportunistic illnesses, including the development of AIDS during and for 1 year after completion of study treatment (NCT00324415)
Timeframe: 1 year following treatment discontinuation
| Intervention | participants (Number) |
|---|---|
| Combined Modality Therapy | 4 |
Patients will be classified into two groups for purposes of primary endpoint analysis: failure or no failure at 3 years (in the primary analysis, patients lost to follow-up prior to 3 years will be considered failures). For the secondary endpoint of objective response, patients will be classified as responders (NCT00324415)
Timeframe: 3 years following treatment discontinuation
| Intervention | participants (Number) |
|---|---|
| Combined Modality Therapy | 23 |
Number of participants with complete and partial responses based on the RECIST criteria (NCT00324415)
Timeframe: 3 years following treatment discontinuation
| Intervention | participants (Number) |
|---|---|
| Combined Modality Therapy | 30 |
Percentage of participants who are alive at one year (NCT00324415)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Combined Modality Therapy | 92.8 |
Progression-free survival at 1 year is the percentage of patients who are alive and have not experienced progressive disease, defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started, or the appearance of one or more new lesions. (NCT00324415)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Combined Modality Therapy | 87.3 |
EORTC QLQ-C30 Global Score at 1 year. The EORTC QLQ-C30 is a validated questionnaire that evaluates quality of life. The global score is an overall score for quality of life that ranges from 0 to 100. Higher scores indicate between quality of life (NCT00324415)
Timeframe: 1 year
| Intervention | units on a scale (Mean) |
|---|---|
| Combined Modality Therapy | 78.9 |
Percentage of participants who are alive and have not experienced progressive disease and have not relapsed (NCT00324415)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Combined Modality Therapy | 83.1 |
Delayed toxicities are defined as toxicities that occur over 90 days following treatment completion (NCT00324415)
Timeframe: 90 days following treatment discontinuation
| Intervention | events (Number) |
|---|---|
| Combined Modality Therapy | 5 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments according to investigator (based on modified WHO criteria). (NCT00122460)
Timeframe: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 35.6 |
| Chemotherapy Alone | 19.5 |
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments according to investigator (based on modified WHO criteria). (NCT00122460)
Timeframe: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 81.1 |
| Chemotherapy Alone | 60.0 |
"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria." (NCT00122460)
Timeframe: time from first assessment of Complete Response or Partial Response to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 4.7 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00122460)
Timeframe: time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 10.1 |
| Chemotherapy Alone | 7.4 |
"Duration from randomization until radiological progression according to investigator (based on modified World Health Organisation (WHO) criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00122460)
Timeframe: time from randomization to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 3.3 |
Please refer to Adverse Events section for further details (NCT00122460)
Timeframe: time from first dose up to 30 after last dose of study treatment, reported between day of first dose of study treatment, 22 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 218 |
| Chemotherapy Alone | 208 |
"Time from randomization to date of the first occurrence of; progression, discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment." (NCT00122460)
Timeframe: Time from randomization to treatment failure or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 4.8 |
| Chemotherapy Alone | 3.0 |
Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL. (NCT00122460)
Timeframe: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| At baseline | At cycle 3 | Month 6 | |
| Cetuximab Plus Chemotherapy | 50.74 | 52.68 | 55.30 |
| Chemotherapy Alone | 45.15 | 45.48 | 42.49 |
Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of social functioning. (NCT00122460)
Timeframe: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| At baseline | At cycle 3 | Month 6 | |
| Cetuximab Plus Chemotherapy | 62.14 | 64.64 | 61.27 |
| Chemotherapy Alone | 62.05 | 60.67 | 65.72 |
Number of patients that developed common side effect of diarrhea. (NCT00266279)
Timeframe: At study enrollment, Every two 28 day treatment cycles, and at end of treatment due to disease progression
| Intervention | participants (Number) |
|---|---|
| Treatment With Study Drugs | 2 |
"Among the 15 patients treated, 2 (13%) achieved partial response (PR), and 5 (33%) achieved stable disease (SD), for a Overall Response Rate (ORR) of 46% measured by RECIST criteria.~Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.~Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.~Overall Response Rate (ORR)=PR+CR." (NCT00266279)
Timeframe: Every two 28 day treatment cycles until subject no longer on treatment due to disease progression
| Intervention | Participants (Number) | |
|---|---|---|
| Partial Response | Stable Disease | |
| Treatment With Study Drugs | 2 | 5 |
Defined as the interval between the start date of treatment and the date of occurrence of progressive disease or death from any cause. (NCT00193128)
Timeframe: 18 months
| Intervention | months (Median) |
|---|---|
| Oxaliplatin/Docetaxel/Capecitabine/Radiation (Cohort 2) | 16.3 |
Length of time, in months, that patients were alive from their first date of protocol treatment until death. (NCT00193128)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Oxaliplatin/Docetaxel/Capecitabine/Radiation (Cohort 2) | 24.1 |
The absence of any residual tumor cells in a histologic evaluation of a tumor specimen following surgery is defined as a complete pathologic response (NCT00193128)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Oxaliplatin/Docetaxel/Capecitabine/Radiation (Cohort 2) | 24 |
Percentage of participants who did not have distant control (NCT00462735)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Advanced Head and Neck Cancer | 21 |
Percentage of Participants with Loco-regional recurrence. (NCT00462735)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Advanced Head and Neck Cancer | 27 |
Grade 3 toxicities events (NCT00462735)
Timeframe: 2 years
| Intervention | events (Number) |
|---|---|
| Advanced Head and Neck Cancer | 32 |
University of Washington Quality of Life (UW-QOLR) questionnaire - covers 12 domains - pain, appearance, activity, recreation, swallowing, chewing, speech, shoulder function, taste, saliva, mood and anxiety. Each domain have between 3 and 6 response options that are scaled evenly from 0 (worst) to 100 (best) according to the hierarchy of response and reported as one composite score from 0 (worst) to 100 (best). (NCT00462735)
Timeframe: 2 years
| Intervention | units on a scale (Mean) |
|---|---|
| Advanced Head and Neck Cancer | 80 |
Overall Survival - Percentage of Participants who survived Disease-Free Survival - measured from the initiation of nonsurgical treatment to either the last follow-up, disease progression, or death using intent-to-treat methodology (NCT00462735)
Timeframe: 2 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Overall Survival | Disease-Free Survival | |
| Advanced Head and Neck Cancer | 86 | 69 |
To determine biomarkers predictive of failure with either reduced or standard dose radiotherapy. (NCT01706939)
Timeframe: at 5 years
| Intervention | biomarkers (Number) |
|---|---|
| Reduced Dose Radiation | 0 |
| Standard Dose Radiation | 0 |
MDADI is a questionnaire of 20 questions and contains a global subscale, and three other categories of questions (emotional, functional, and physical). The scores are summed and a mean score is calculated. This mean score was multiplied by 20 to obtain a score, with a range of 0 (extremely low functioning) to 100 (high functioning). Thus, a higher MDADI score represented better day-to-day functioning and better QOL. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | -8.12 |
| Standard Dose Radiation | -8.93 |
XQ is a nine questions survey developed specifically for xerostomia symptoms. The scores are summed and a mean score is calculated on a scale of 0 (low xerostomia interference) to 10 (high xerostomia interference). A lower or negative score reflects a better quality of life compared to baseline. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | 2.18 |
| Standard Dose Radiation | 4.38 |
Number of participants with acute toxicity treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 3 |
| Standard Dose Radiation | 1 |
Local-regional control (LRC) at 3 years in patients with advanced HPV related oropharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
Overall Survival (OS) 5 years treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
The EORTC Head and Neck module was specifically designed and validated for head and neck cancer patients. This 35-item questionnaire contains 7 symptom scales (pain, swallowing, senses, speech, social eating, social contact, and sexuality), 6 single-item scales (difficulties of teeth, mouth opening, dry mouth, sticky saliva, coughing, and feeling ill), and 5 items about the additional use of pain medicine, nutritional supplements, and feeding tube and changes in body weight. All items were transformed to scales from 0 to 100, and divided into respective sub-scores of global health (GHS), functional (FS), and symptom scale (SS). Subscales from 0-100. A high score on global health and functional scale represents a better level of functioning, whereas a high score on a symptom scale and head and neck module indicates more severe symptoms. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| EORTC GHS | EORTC FS | EORTC SS | EORTC HN | |
| Reduced Dose Radiation | 5.95 | 5.14 | -3.91 | -2.80 |
| Standard Dose Radiation | -30.56 | -6.33 | 14.97 | 8.97 |
"MD Anderson Symptom Inventory Symptom Inventory and Severity (MDASI-HN SI and SS) MDASI Head and Neck is a site-specific MDASI module which includes the core MDASI 13 symptom severity items (SS) and 6 symptom interference items (SI), alongside 9 items relevant to head and neck cancer. The scores are summed and a mean score is calculated on a scale of 0 (low severity or interference) to 10 (high severity or complete interference). In order to calculate the mean score, a majority of the subscale's items must have been completed.~A lower or negative score reflects a better quality of life compared to baseline." (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |
|---|---|---|
| MDASI-HN SI | MDASI-HN SS | |
| Reduced Dose Radiation | 0.64 | 0.52 |
| Standard Dose Radiation | 1.56 | 1.48 |
Progression free survival (PFS) at 5 years in patients with advanced HPV related oropharynx cancer, nasopharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 and 5 years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| at 3 years | at 5 years | |
| Reduced Dose Radiation | 10 | 10 |
| Standard Dose Radiation | 7 | 7 |
One-year survival estimate is reported. Survival time is defined as time from registration to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at date of last contact. This analysis was planned to occur when all patients had been potentially followed for 1 year. On the basis of a 1-year survival rate of 60% from the Radiation Therapy Oncology Group (RTOG) esophageal database, 38 analyzable patients with a 1-year survival rate of 77.5% or better was needed for this trial to be deemed promising enough for development of a Phase III protocol (type I error of 0.05 and type II error of 0.20). (NCT00069953)
Timeframe: From registration to date of death or last follow-up. Analysis occurs after all patients have been potentially followed for 1 year.
| Intervention | percentage of participants (Number) |
|---|---|
| ChemoRT and Selective Surgery | 71 |
Percentage of subjects who develop discoloration at the site of removal (NCT03259295)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Skin Tag Removal Initial Visit Plus Follow-up | 3 |
Percentage of subjects who develop pain/numbness at the site of removal (NCT03259295)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Skin Tag Removal Initial Visit Plus Follow-up | 0 |
Percentage of subjects who develop a scar at the removal site (NCT03259295)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Skin Tag Removal Initial Visit Plus Follow-up | 1 |
Percentage of subjects who develop scar tissue or keloid at the site of removal (NCT03259295)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Skin Tag Removal Initial Visit Plus Follow-up | 0 |
Percentage of subjects who experience a re-occurrence of the skin tag at the removal site. (NCT03259295)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Skin Tag Removal Initial Visit Plus Follow-up | 0 |
Number of participants with acute and late toxicity (NCT00970502)
Timeframe: 30 DAYS
| Intervention | participants (Number) |
|---|---|
| Celecoxib 200mg | 0 |
| Celecoxib 400mg | 1 |
| Celecoxib 600mg | 2 |
Response to Concurrent Erlotinib, Celecoxib, and Reirradiation according to Response Evaluation Criteria in Solid Tumors - Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT00970502)
Timeframe: 20 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response(CR) | Pathologic partial response (pPR) | Progressive disease (PD) | No evidence of disease (NED) | |
| Erlotinib + Celecoxib | 6 | 1 | 5 | 2 |
At a median follow-up of 11 months, the 1 year locoregional control, progression-free survival, and overall survival rates. (NCT00970502)
Timeframe: 1 year
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| locoregional control | progress-free survival | overall survival rates | long term toxicity | |
| Erlotinib + Celecoxib | 60 | 37 | 55 | 0 |
Patients with locoregional and/or distant progression (NCT00970502)
Timeframe: 20 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| free of disease | isolated locoregional progression | isolated distant progression | both locoregional and distant progression | no evidence of disease, died of comorbid illness | |
| Erlotinib + Celecoxib | 4 | 4 | 2 | 1 | 3 |
"Clinical exam included laryngoscopy in office or operating room.~Complete response rate includes complete response (CR) which is defined as 100% decrease in tumor size and it also includes near complete response (near CR) defined as 95-99% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction (approximately 42 days from start of treatment)
| Intervention | participants (Number) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 16 |
"Clinical exam included laryngoscopy in office or operating room.~Partial response rate (PR) defined as 50% to 94% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 14 |
Time from complete response to death from any cause, to disease progression or to last follow-up alive. (NCT00736944)
Timeframe: 10 years from completion of treatment
| Intervention | months (Mean) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 93.529 |
Time from diagnosis to death or to last follow-up alive. (NCT00736944)
Timeframe: 10 years from completion of treatment
| Intervention | months (Mean) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 83.960 |
Time from initiation of induction chemotherapy to death due to disease progression, to disease progression, or to last follow-up alive. (NCT00736944)
Timeframe: 10 years from completion of treatment
| Intervention | months (Mean) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 38.675 |
(NCT00736944)
Timeframe: completion of the first 10 patients induction chemotherapy
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergic reaction/hypersensitivity | Other allergic reaction:cipro | Other allergic reaction:hives | Hypotension | INR | Fatigue | Alopecia | Chelitis | Dry skin | Rash | Rash:acneiform | Rash:penile (unconfirmed HSV) | Anorexia | Colitis | Constipation | Dehydration | Dental:teeth | Diarrhea | Hemorrhoids | Nausea | Taste alteration | Vomiting | Other:soft stools | Hemoglobin | Leukocytes (WBC) | Lymphopenia | Neutrophils (ANC) | Platelets | Hemmorrhage:nose | Alkaline phosphatase | SGPT (ALT) | Infection other:sinus infection | Edema:limb | Albumin, low | Calcium, low | Magnesium, low | Potassium, low | Potassium, high | Sodium, low | Phosphorus | Dizziness | Mood alteration:anger | Neuropathy:sensory (peripheral) | Vision-photophobia | Pain:thigh | Pain:tumor pain | Hiccoughs (hiccups) | Obstruction/stenosis of airway:trachea | Creatinine | GFR | Renal failure | Thrombosis/thrombus/embolism | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 1 | 1 | 1 | 1 | 1 | 10 | 5 | 1 | 1 | 1 | 7 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 9 | 1 | 1 | 1 | 8 | 8 | 8 | 8 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 5 | 4 | 3 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 |
"Clinical exam consisted of physical exam of neck in office.~Complete response rate includes complete response (CR) which is defined as 100% decrease in tumor size and near complete response (near CR) defined as 95-99% decrease in tumor size.~Partial response rate defined as 50% to 94% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 11 | 7 |
"Clinical exam included laryngoscopy in office or operating room.~Clinical exam consisted of physical exam of neck in office.~Complete response rate includes complete response (CR) which is defined as 100% decrease in tumor size and it also includes near complete response (near CR) defined as 95-99% decrease in tumor size.~Partial response rate defined as 50% to 94% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days)
| Intervention | participants (Number) | |
|---|---|---|
| Overall complete response | Overall partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 13 | 17 |
"Complete response rate defined as complete resolution of the metabolically active primary tumor.~Partial response rate defined as 20% or greater decrease in maximum SUV [SUV g/ml) = ROI activity (mCi/ml) / (injected dose (mCi/body weight(g))] from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 9 | 14 |
"Complete response rate defined as complete resolution of the metabolically active primary tumor.~Partial response rate defined as 20% or greater decrease in maximum SUV [SUV g/ml) = ROI activity (mCi/ml) / (injected dose (mCi/body weight(g))] from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 9 | 17 |
In the future, primary tumor site, nodal, and overall tumor response by visual categorical response (CR-x or PR-x = yes or no) will be compared with response based on CT scan (CR-x or PR-x = yes or no) using a test for difference in paired, binary values (e.g., McNemar's test). Median standardized uptake value of FDG measured by PET/CT will be compared among those with or without response (CR-x or PR-x) using nonparametric Wilcoxon-Mann-Whitney tests. At this point, we are releasing results based on comparing actual responses from visual categorical response, CT scan, and FDG-PET/CT scan after 2 cycles of induction. (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease/Progressive Disease | |
| Clinical Examination | 61 | 39 | 0 |
| CT Scan | 30 | 48 | 22 |
| FDG-PET/CT | 36 | 56 | 8 |
In the future, primary tumor site, nodal, and overall tumor response by visual categorical response (CR-x or PR-x = yes or no) will be compared with response based on CT scan (CR-x or PR-x = yes or no) using a test for difference in paired, binary values (e.g., McNemar's test). Median standardized uptake value of FDG measured by PET/CT will be compared among those with or without response (CR-x or PR-x) using nonparametric Wilcoxon-Mann-Whitney tests. At this point, we are releasing results based on comparing actual responses from visual categorical response, CT scan, and FDG-PET/CT scan after 2 cycles of induction. (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease/Progressive Disease | |
| Clinical Examination | 43 | 57 | 0 |
| CT Scan | 14 | 50 | 36 |
| FDG-PET/CT | 24 | 66 | 10 |
"In the future, primary tumor site, nodal, and OTR by VCR (CR-x or PR-x = Y or N) will be compared with response based on CT scan (CR-x or PR-x = Y or N) using a test for difference in paired, binary values. Median standardized uptake value of FDG measured by PET/CT will be compared among those with or without response (CR-x or PR-x) using nonparametric Wilcoxon-Mann-Whitney tests.~We are releasing results based on comparing actual responses from visual categorical response, CT scan, and FDG-PET/CT scan after 2 cycles." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease/Progressive Disease | |
| Clinical Examination | 53 | 47 | 0 |
| CT Scan | 33 | 41 | 26 |
| FDG-PET/CT | 32 | 61 | 7 |
SPARC expression = intensity of SPARC staining in tumor (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Negative staining | 1+ staining (weak) | 2+ staining (moderate) | 3+ staining (strong) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 14 | 0 | 1 | 0 |
SPARC expression = intensity of SPARC staining in tumor (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Negative staining | 1+ staining (weak) | 2+ staining (moderate) | 3+ staining (strong) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 6 | 2 | 4 | 1 |
SPARC expression = Proportion of tumor cells SPARC-positive in 10 high-power fields (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Negative staining | 1+ staining (0%-24%) | 2+ staining (25%-49%) | 3+ staining (50%-74%) | 4+ staining (75%-100%) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 14 | 0 | 1 | 0 | 0 |
SPARC expression = Proportion of tumor cells SPARC-positive in 10 high-power fields (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Negative staining | 1+ staining (0%-24%) | 2+ staining (25%-49%) | 3+ staining (50%-74%) | 4+ staining (75%-100%) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 6 | 4 | 1 | 2 | 0 |
"Complete response rate defined as complete resolution of the metabolically active primary tumor.~Partial response rate defined as 20% or greater decrease in maximum SUV [SUV g/ml) = ROI activity (mCi/ml) / (injected dose (mCi/body weight(g))] from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Overall complete response | Overall partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 7 | 19 |
"Complete response rate per RECIST criteria is defined as disappearance of all target lesions.~Partial response rate per RECIST criteria is defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 7 | 12 |
"Complete response rate per RECIST criteria is defined as disappearance of all target lesions.~Partial response rate per RECIST criteria is defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 10 | 11 |
"Complete response rate per RECIST criteria is defined as disappearance of all target lesions.~Partial response rate per RECIST criteria is defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Overall complete response | Overall partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 4 | 14 |
DNA was extracted from tumor specimens.Screened for the presence of KRAS codon 12 and 13 mutations using a PCR clamping and melting curve technique. PCR amplification of the wild-type KRAS sequence was suppressed in this process by the incorporation in the reaction mix of a locked nucleic-acid oligomer16 spanning codons 12 and 13 of the KRAS gene. Post-PCR hybridization and melting curve analysis using fluorescently tagged oligonucleotides incorporated in the original PCR reaction permitted the identification and discrimination of distinct KRAS codon 12 and 13 missense mutations. (NCT00815308)
Timeframe: 07/29/2010-09/30/2010
| Intervention | participants (Number) |
|---|---|
| Cetuximab, Concurrent Chemo-radiotherapy | 53 |
The overall response rate was defined as the numbers of patients with a complete response (CR) or partial response (PR). CR was defined as no target lesion at follow-up computed tomography scan and barium swallow examination 3-6 weeks after completion of chemo-radiation. PR was defined at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT00815308)
Timeframe: 1 to 3 month after therapy
| Intervention | participants (Number) |
|---|---|
| Cetuximab, Concurrent Chemo-radiotherapy | 44 |
All patients were regularly monitored for possible adverse events, which were graded according to National Cancer Institute Common Toxicity Criteria version 3.0. (NCT00815308)
Timeframe: Every week during treatment and 1 month after therapy
| Intervention | participants (Number) |
|---|---|
| Cetuximab, Concurrent Chemo-radiotherapy | 55 |
The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 will be utilized for all toxicity reporting. All detailed information regarding serious and other adverse events are listed in the Adverse Event module of these results. (NCT00603408)
Timeframe: 30 days post surgery (week 17-18)
| Intervention | participants (Number) |
|---|---|
| Cisplatin + Radiation + Recommended Surgery | 5 |
(NCT00603408)
Timeframe: 30 days post surgery (week 17-18)
| Intervention | participants (Number) |
|---|---|
| Cisplatin + Radiation + Recommended Surgery | 0 |
OS = Time from registration until death from any cause (NCT00603408)
Timeframe: Until study was terminated (23.5 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Cisplatin + Radiation + Recommended Surgery | 100 |
"Complete response: disappearance of all target lesions, non-target lesions, and normalization of tumor marker level~Partial response: at least a 30% decrease in the sum of the longest diameter (LD) of the target lesions taking as reference the baseline sum LD~Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD since the treatment started,~Progressive disease: at least a 20% increase in the sum of the LD of the target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, appearance of one more new lesions, or unequivocal progression of existing non-target lesions." (NCT00603408)
Timeframe: At the time of surgery (week 13)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | |
| Cisplatin + Radiation + Recommended Surgery | 2 | 3 | 0 | 0 |
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
Local failure will be assessed radiographically using endoscopy with biopsy, CT scan, and a positron emission computed tomography-CT scan. which was defined as persistence /recurrence of the tumor in the radiation therapy field. (NCT03082586)
Timeframe: 15 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1: Radiochemotherapy 1 | 0 |
| Arm 2: Radiochemotherapy 2 | 1 |
| Arm 3: Radiochemotherapy 3 | 1 |
| Arm 4: Radiochemotherapy 4 | 0 |
| Arm 5: Radiochemotherapy 5 | 0 |
| Arm 6: Radiochemotherapy 6 | 0 |
The DLTs were defined as grade >/=4 esophatitis, any other grade >/=3 nonhematological toxicity (except nausea and vomiting), or grade >/=4 hematological toxicity lasting more than 7 days, which are possibly, probably, or definitely associated with protocol treatment occurring during and after completion of the HFRT boost treatment. (NCT03082586)
Timeframe: 15 months
| Intervention | dose limiting toxicity (Number) |
|---|---|
| Arm 1: Radiochemotherapy 1 | 0 |
| Arm 2: Radiochemotherapy 2 | 0 |
| Arm 3：Radiochemotherapy 3 | 0 |
| Arm 4: Radiochemotherapy 4 | 1 |
| Arm 5: Radiochemotherapy 5 | 0 |
| Arm 6: Radiochemotherapy 6 | 2 |
213 reviews available for fluorouracil and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Use of Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis: A Systematic Review.
Topics: Acetamides; Calcitriol; Carcinoma, Squamous Cell; Fluorouracil; Humans; Keratosis, Actinic; Morpholi | 2022 |
Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis.
Topics: Administration, Topical; Carcinoma, Squamous Cell; Conjunctival Neoplasms; Eye Neoplasms; Fluorourac | 2022 |
[Anal cancer: Focus on current treatment and future perspective].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2022 |
Advances in Topical Treatments of Cutaneous Malignancies.
Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Imiqui | 2023 |
Medical treatment for ocular surface squamous neoplasia.
Topics: Carcinoma, Squamous Cell; Conjunctival Neoplasms; Eye Neoplasms; Fluorouracil; Humans; Interferon al | 2023 |
Comparison of intravenous 5-Fluorouracil with Oral Capecitabine in the Treatment of Anal Squamous Cell Carcinoma Using Modern Radiation Techniques.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Ce | 2023 |
Intralesional 5-fluorouracil as a management for cutaneous squamous cell carcinomas: A rural Australian retrospective case series.
Topics: Aged; Aged, 80 and over; Australia; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Mi | 2023 |
Treatments of actinic cheilitis: A systematic review of the literature.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Cheilitis; Combined Modality Therapy; Dermabrasion; D | 2020 |
Nonsurgical Treatments for Nonmelanoma Skin Cancer.
Topics: Administration, Cutaneous; Anilides; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bi | 2019 |
Current therapies for actinic keratosis.
Topics: Aftercare; Carcinoma, Squamous Cell; Chemexfoliation; Cryotherapy; Curettage; Dermoscopy; Diclofenac | 2020 |
Field cancerization: Treatment.
Topics: Administration, Cutaneous; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Carcinogenesi | 2020 |
Actinic Keratoses: Reconciling the Biology of Field Cancerization with Treatment Paradigms.
Topics: Administration, Cutaneous; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Transformation, Neo | 2021 |
[Squamous cell anal carcinoma. What's next ?]
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carboplatin; Ca | 2021 |
Intralesional 5-Fluorouracil for Treatment of Non-Melanoma Skin Cancer: A Systematic Review.
Topics: Biopsy; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Fluorouracil; | 2021 |
Ocular surface squamous neoplasia: management and outcomes.
Topics: Carcinoma, Squamous Cell; Conjunctival Neoplasms; Eye Neoplasms; Fluorouracil; Humans; Neoplasm Recu | 2021 |
Squamous rectal carcinoma: a rare malignancy, literature review and management recommendations.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Fluorouracil; Humans; Rectal Neoplasms | 2021 |
Local Chemotherapy as an Adjuvant Treatment in Unresectable Squamous Cell Carcinoma: What Do We Know So Far?
Topics: Carcinoma, Squamous Cell; Fluorouracil; Humans; Imiquimod; Neoplasm Recurrence, Local; Skin Neoplasm | 2021 |
Cancer of the Larynx and Hypopharynx.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 2021 |
Efficacy of nonexcisional treatment modalities for superficially invasive and in situ squamous cell carcinoma: A systematic review and meta-analysis.
Topics: Carcinoma in Situ; Carcinoma, Squamous Cell; Fluorouracil; Humans; Imiquimod; Skin Neoplasms | 2022 |
Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.
Topics: Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Deglut | 2017 |
Randomized Clinical Trials in Localized Anal Cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcino | 2017 |
Chemoradiotherapy for Solitary Skeletal Muscle Metastasis from Oesophageal Cancer: Case Report and Brief Literature Review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous | 2017 |
A network meta-analysis of the treatments for esophageal squamous cell carcinoma in terms of survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Carcinoma, Squamous Cell | 2018 |
[A Case of Consciousness Disorder Induced by the Syndrome of Inappropriate Antidiuretic Hormone Secretion Following Cisplatin and 5-Fluorouracil Chemotherapy in a Patient with Tongue Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Conscious | 2018 |
Present and future perspectives of photodynamic therapy for cutaneous squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Fluoro | 2019 |
Effectiveness of chemoradiotherapy for radiation-induced bilateral external auditory canal cancer: A case report and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradi | 2019 |
Intralesional therapy for the treatment of keratoacanthoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Dermatologic Agents; Fluorouracil; Humans; Injectio | 2019 |
Chemoradiotherapy for anal cancer: are we as good as we think?
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Combined Modality Thera | 2019 |
Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer.
Topics: Administration, Cutaneous; Administration, Oral; Antineoplastic Agents; Carcinoma, Basal Cell; Carci | 2019 |
Treatment of Solitary Keratoacanthoma of the Nose With Intralesional Methotrexate and Review of the Literature
Topics: Antineoplastic Agents; Biopsy; Bleomycin; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; In | 2019 |
[Brachytherapy for anal cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous C | 2013 |
Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2014 |
Concurrent chemoradiotherapy for squamous cell carcinoma of the rectum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2013 |
Treatment options for esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons.
Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Bleomycin; Carcinoma, Basal Cell; | 2013 |
Outdated dermatologic drug samples and obligations to the patient.
Topics: Administration, Topical; Adult; Carcinoma, Squamous Cell; Dermatology; Fluorouracil; Humans; Liabili | 2013 |
Anal squamous intraepithelial neoplasia.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Antimetabolites, Antineoplastic; A | 2013 |
[Current perspective of treatment for advanced esophageal squamous cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvan | 2014 |
Is there still a role for induction chemotherapy in locally advanced head and neck cancer?
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; | 2014 |
Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Adenosqu | 2015 |
Actinic keratosis: new concepts and therapeutic approaches for an ancestral condition.
Topics: Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Cryotherapy; Electrocoagulation; Fluorour | 2014 |
Anal cancer treatment: current status and future perspectives.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; C | 2015 |
[Three cases of esophageal carcinoma achieved a pathological complete response after neoadjuvant chemotherapy with cisplatin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 2015 |
Unresectable Recurrent Squamous Cell Carcinoma of the Temporal Bone Treated by Induction Chemotherapy Followed by Concurrent Chemo-Reirradiation: A Case Report and Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiothera | 2015 |
Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradio | 2015 |
[A Case of Nasopharyngeal Cancer with Febrile Neutropenia Followed by Death during Adjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carcinoma, Squamous Cell; Chemoradiotherapy | 2015 |
Resection of a Submucosal Tumor-Like Superficial Carcinoma in Middle Thoracic Esophagus Concomitant with Mucosal Adenocarcinoma and Submucosal Squamous Cell Carcinoma: A Case Report and Review of Literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2015 |
Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Topics: Administration, Oral; Anilides; Antineoplastic Agents; Biphenyl Compounds; Capecitabine; Carcinoma, | 2016 |
The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
Cutaneous squamous cell carcinomas in solid organ transplant recipients: emerging strategies for surveillance, staging, and treatment.
Topics: Carcinoma, Squamous Cell; Cryosurgery; Fluorouracil; Humans; Immunosuppressive Agents; Microsurgery; | 2016 |
Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvan | 2016 |
[Rectal squamous cell carcinoma treatment: Retrospective experience in two French university hospitals, review and proposals].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2016 |
Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2017 |
Treatment of the Primary Tumor in Anal Canal Cancers.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2017 |
Evolution and Management of Treatment-Related Toxicity in Anal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2017 |
Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neck.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2008 |
Neoadjuvant chemotherapy of cisplatin and fluorouracil regimen in head and neck squamous cell carcinoma: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2008 |
Actinic keratoses.
Topics: Aged; Aminoquinolines; Carcinoma, Squamous Cell; Cryotherapy; Dermatology; Fluorouracil; Humans; Imi | 2009 |
Topical treatment of field cancerization.
Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Diclofenac; Fluorouraci | 2009 |
[Virchow's node as the form of onset of squamous cell carcinoma of the pancreas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplat | 2009 |
Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders.
Topics: Administration, Cutaneous; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic | 2009 |
Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, S | 2009 |
Intralesional agents in the management of cutaneous malignancy: a review.
Topics: Aminolevulinic Acid; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bleomycin; Carci | 2011 |
Management of anal cancer in 2010. Part 2: current treatment standards and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2010 |
Actinic keratoses: past, present and future.
Topics: Adjuvants, Immunologic; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamou | 2010 |
Intralesional chemotherapy for nonmelanoma skin cancer: a practical review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Basal Cell; Carcinoma, Squamou | 2010 |
[The current value of induction chemotherapy. ASCO Congress 2010].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Actinic cheilitis: a treatment review.
Topics: Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Caustics; Cheilitis; Cryosurgery; | 2010 |
Induction chemotherapy for head and neck cancer: recent data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2010 |
TPF sequential therapy: when and for whom?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2010 |
TPF: a rational choice for larynx preservation?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2010 |
Solitary subcutaneous metastasis from squamous cell carcinoma of the esophagus: a case report and brief review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2011 |
Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2011 |
Do lasers or topicals really work for nonmelanoma skin cancers?
Topics: Administration, Cutaneous; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2011 |
Squamous cell carcinomas of the lower limbs in African American women.
Topics: Administration, Topical; Aged; Aged, 80 and over; Biopsy, Needle; Black or African American; Carcino | 2011 |
[Management of anal canal carcinoma].
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2011 |
Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients.
Topics: Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dermatologic Agent | 2011 |
Management of recurrent head and neck cancer: recent progress and future directions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2011 |
[Induction chemotherapy for head and neck epidermoid carcinomas].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Radiation in vulvar cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, A | 2012 |
[Should the treatment of anal carcinoma be adapted in the elderly? A retrospective analysis of acute toxicities in a French centre and a review of the literature].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachythera | 2012 |
[A case of perianal squamous cell carcinoma attaining a complete response over five years with chemoradiotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Anus Neoplasms; Biopsy; Carcinoma, Squ | 2011 |
Current treatment options for metastatic head and neck cancer.
Topics: Alcohol Drinking; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; | 2012 |
Molecular targeting agents in the context of primary chemoradiation strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineo | 2013 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Car | 2012 |
Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Topical therapies for periorbital cutaneous malignancies: indications and treatment regimens.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, S | 2012 |
Diagnosis and treatment of Basal cell and squamous cell carcinoma.
Topics: Aminoquinolines; Antineoplastic Agents; Biopsy; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cry | 2012 |
[A long survival after the treatment of a squamous cell carcinoma of the gallbladder].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cholecystect | 2013 |
Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 2003 |
Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2003 |
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2003 |
Treatment of nonmelanoma skin cancer in organ transplant recipients: review of responses to a survey.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Combined Modality Therapy; Cryosurgery; Electrosurg | 2003 |
[Colon cancer in pregnancy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cesarean Section; C | 2003 |
Current treatment patterns in non-melanoma skin cancer across Europe.
Topics: Administration, Cutaneous; Aminoquinolines; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cryothe | 2003 |
[Cutaneous neoplasms].
Topics: Adjuvants, Immunologic; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bio | 2003 |
Topical and light-based treatments for actinic keratoses.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminolevulinic Acid; Aminoquinolines; Antineoplasti | 2003 |
[Docetaxel and squamous cell carcinoma of the head and neck].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2004 |
Squamous cell carcinoma of the anal margin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2004 |
Successful treatment for squamous cell carcinoma of the female urethra with combined radio- and chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Th | 2004 |
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplat | 2004 |
Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2004 |
Neoadjuvant treatment of oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 2004 |
[Effectiveness of chemoradiotherapy for three cases of squamous cell anal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2004 |
Chemotherapeutic options in the management of anal cancer.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; HIV Se | 2004 |
Optimum treatment strategies for actinic keratosis (intraepidermal squamous cell carcinoma).
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; | 2004 |
[Larynx preservation: nonsurgical approaches].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2004 |
[Decision making in non resectable head and neck tumours].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
Revisiting induction chemotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cl | 2005 |
[The role of taxanes for head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2005 |
A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 2006 |
Bilateral axillary metastasis from a primary ethmoidal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Carcinoma, Squamous Cell; Cisplatin; Ethmoid | 2006 |
Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel.
Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Consens | 2006 |
Primary combined-modality therapy for esophageal cancer.
Topics: Algorithms; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; | 2006 |
Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; H | 2006 |
Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; H | 2006 |
[Actinic keratosis].
Topics: Adjuvants, Immunologic; Age Factors; Aged; Aminoquinolines; Antimetabolites, Antineoplastic; Antineo | 2006 |
[Clinical efficacy of administration with S-1 alone for head and neck carcinoma].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2006 |
Lipodermatosclerosis as a form of vascular compromise-associated radiation recall dermatitis: case report and a review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2006 |
[Meta-analysis of postoperative adjuvant chemotherapy for localized esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2006 |
[Complications of surgical resection of esophageal cancer].
Topics: Adenocarcinoma; Age Factors; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Endosc | 2006 |
The role of taxanes and targeted therapies in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ci | 2007 |
Current treatment for localized anal carcinoma.
Topics: Antineoplastic Agents; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Humans; Mi | 2007 |
Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2007 |
Induction chemotherapy for head and neck squamous cell carcinomas (SCCHN).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2007 |
[Current role for induction chemotherapy in head and neck tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2008 |
Recurrent head and neck cancer: current treatment and future prospects.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Chemo-radiotherapy: an alternative to surgery for squamous cell carcinoma of the rectum--report of six patients and literature review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2009 |
Chemotherapy strategies in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
Chemotherapy for squamous cell carcinoma of the head and neck: a progress report.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chlorambucil; Clinical Trials as Topic; | 1980 |
Changing role of chemotherapy in treatment of head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Fl | 1982 |
Dermatological aspects of aging.
Topics: Adult; Aged; Aging; Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dermatitis; Female; Fl | 1983 |
Synchronous chemotherapy and radiotherapy for carcinoma of the anal canal--an alternative to abdominoperineal resection.
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous C | 1984 |
Treatment of skin cancer using multiple modalities.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cryosurgery; Electrosurgery; Female; F | 1982 |
Prolonged infusion of fluorinated pyrimidines in gastrointestinal malignancies: a review of recent clinical trials.
Topics: Carcinoma, Squamous Cell; Circadian Rhythm; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasm | 1994 |
[Chemotherapy and multimodality therapy in the treatment of esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A | 1995 |
Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic | 1995 |
[Current perspectives in the treatment of epidermoid cancer of the esophagus].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1995 |
Squamous cell carcinoma complicating idiopathic inflammatory bowel disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transiti | 1995 |
Sequential chemotherapy and radiotherapy for patients with squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Combination therapy for epidermoid carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1994 |
Squamous cell carcinoma of the cervix implanting in the episiotomy site.
Topics: Adult; Carcinoma, Squamous Cell; Cicatrix; Cisplatin; Doxorubicin; Episiotomy; Female; Fluorouracil; | 1993 |
[Role of neoadjuvant chemotherapy for management of resectable head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1994 |
Surgical treatment of stage III lung cancer after chemotherapy and radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Small Cell; Carcinom | 1994 |
Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study.
Topics: Adult; Aged; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; | 1994 |
[A critical consideration of the combined radiochemotherapy of head and neck tumors].
Topics: Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasm | 1994 |
Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1993 |
Myelodysplastic syndrome after cisplatin therapy.
Topics: Anemia, Sideroblastic; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Fluorourac | 1993 |
Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1996 |
Preoperative concomitant radiochemotherapy in squamous cell carcinoma of the esophagus: results of a study of 56 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1996 |
Retropharyngeal abscess after radiation therapy and cis-platinum, 5-fluorouracil treatment for nasopharyngeal carcinoma with collagen disease: report of two patients and a review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Collagen Diseas | 1996 |
[Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1996 |
[Cancer of the anal canal].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 1990 |
[Chemotherapy of head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A | 1996 |
[Concomitant radiochemotherapy with cisplatin (CDDP), 5-fluorouracil (5-FU) and mitomycin C (MMC) in locally advanced carcinoma of the oropharynx. Results of a phase II trial].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
[Predictive value of the hemogram for myelotoxicity induced by the association of carboplatin-fluorouracil on the 4th day of the therapeutic regimen].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carcinom | 1996 |
Anal canal cancer: current treatment and results.
Topics: Anal Canal; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant | 1996 |
Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1997 |
[Head and neck cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1997 |
[Chemoradiotherapy for patients with advanced head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
[Chemoradiation therapy for esophageal carcinoma].
Topics: Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Adminis | 1997 |
[Treatment for recurrent head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Ce | 1998 |
[Treatment of patients with recurrent esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1998 |
Squamous-cell carcinoma of the colon responsive to combination chemotherapy: report of two cases and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisp | 1999 |
Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 1999 |
[Recent regimen of chemotherapy for advanced head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cisplatin; Doce | 2000 |
Neoadjuvant chemotherapy and radiation for inoperable carcinoma of the maxillary antrum: a matched-control study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2000 |
The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2000 |
Preliminary results of chemoradiation as a primary treatment for vulvar carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2000 |
Chemoradiation for carcinoma of the cervix: advances and opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A | 2000 |
[Radiochemotherapy in anal canal epidermoid cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2000 |
[Concomitant radiochemotherapy in cancer of the cervix uteri: modifications of the standards].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2000 |
[Role of Chemotherapy in head and neck cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamou | 2001 |
Combined modality treatment for locally advanced squamous-cell carcinoma of the oropharynx in a woman with Bloom's syndrome: a case report and review of the literature.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bloom Syndro | 2001 |
Neoadjuvant chemoradiation therapy in patients with surgically treated esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
[Preoperative chemotherapy for patients with advanced head and neck cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carci | 2001 |
Sustained complete remission of stage IV carcinoma of the pyriform fossa following chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2002 |
[Chemotherapy for the patients with esophageal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Ce | 2002 |
Nonmelanoma skin cancer.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Diet Therapy; Fluorouracil; Humans; Life Style; Neo | 2002 |
Recurrent vulvar cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluor | 2002 |
Current concepts of chemotherapy combined with other modalities for head and neck cancer.
Topics: Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Head; Head and Neck Neoplasms; | 1975 |
The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Fluoro | 1975 |
Progress report. Cytotoxic therapy for gastrointestinal carcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bleomycin; Carcinoma, | 1976 |
The chemotherapy of head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion | 1977 |
Chemotherapy of solid tumors. Recent advances.
Topics: Adult; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Bronchogenic; Carcinom | 1976 |
Intraepithelial carcinoma of the vulva.
Topics: Carcinoma in Situ; Carcinoma, Squamous Cell; Diagnosis, Differential; Female; Fluorouracil; Humans; | 1977 |
Regional infusion chemotherapy for cancer of the head and neck.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Carcinoma, S | 1975 |
Topical 5-fluorouracil in the treatment of carcinoma in situ of the vulva.
Topics: Administration, Topical; Adult; Carcinoma in Situ; Carcinoma, Squamous Cell; Female; Fluorouracil; H | 1976 |
Alternative management of cutaneous squamous cell carcinoma in an elderly man: report of a case and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Ear, External; | 1992 |
Paget's disease of the scrotum: a case report and review of current literature.
Topics: Carcinoma in Situ; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Genital Neopla | 1991 |
[Chronic lupus erythematosus and epidermoid carcinoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplati | 1990 |
[Role of chemotherapy in squamous cell tumors of the larynx].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 1991 |
Locally advanced (stage III and IV) head and neck cancer: Westmead Hospital experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1991 |
[The status of sequential chemo-/radiotherapy in inoperable head and neck cancers. Personal results and review of the literature].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1991 |
Advanced malignancy in the young marijuana smoker.
Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Ar | 1991 |
Current chemotherapy of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1991 |
Chemotherapy and radiation therapy before transhiatal esophagectomy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1990 |
Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheterization, Ce | 1990 |
[Combined radiotherapy and pre-radiation chemotherapy with cisplatin and 5-fluorouracil for advanced esophageal carcinoma. II. Clinical evaluation in cases with higher than T2 stage].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Eval | 1990 |
Update in cancer chemotherapy, Part III: Lung cancer, Part 1.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Bleomycin; Carcinoma; C | 1985 |
Neoadjuvant chemotherapy and radiotherapy in larynx preservation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fema | 1989 |
[Complete remission (clinical and histologic) of an advanced squamous cell epithelioma treated only by chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1988 |
[A case of bowenoid papulosis of the penis].
Topics: Adult; Bowen's Disease; Carcinoma, Squamous Cell; Fluorouracil; Humans; Male; Ointments; Penis; Skin | 1989 |
Management of oral squamous cell carcinoma in situ with topical 5-fluorouracil and laser surgery.
Topics: Administration, Topical; Brachytherapy; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorou | 1989 |
A review of lower genital intraepithelial neoplasia and the use of topical 5-fluorouracil.
Topics: Acquired Immunodeficiency Syndrome; Administration, Topical; Adult; Anal Canal; Anus Neoplasms; Carc | 1985 |
[Inoperable cancer of the esophagus: preliminary results of combined chemotherapy (5-fluorouracil-cisplatin) and radiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
[Current views of the treatment of non-microcellular carcinoma of the lungs].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyc | 1985 |
Clinical use of radiation sensitizing agents.
Topics: Animals; Antimetabolites, Antineoplastic; Bleomycin; Bromodeoxycytidine; Bromodeoxyuridine; Bromoura | 1974 |
The role of chemotherapy in the treatment of lung cancer.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Bleomycin; Carcinoma, Small Cell; Carcinom | 1974 |
[Use of optical quantum generators (lasers) in oncology].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Basal Cell; Carcinom | 1972 |
Chemotherapy of squamous cell carcinoma of the cervix, vagina, and vulva.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Female; F | 1968 |
Topical treatment of skin tumours with 5-fluorouracil.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Keratosis; Skin Neoplasms | 1970 |
802 trials available for fluorouracil and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).
Topics: Carcinoma, Squamous Cell; Feasibility Studies; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; | 2022 |
Capecitabine in the treatment of anal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Ce | 2022 |
Pilot trial of topical MTS‑01 application to reduce dermatitis in patients receiving chemoradiotherapy for stage I‑III carcinoma of the anal canal.
Topics: Anal Canal; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Dermatitis; Fluorouracil; H | 2022 |
Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; S | 2022 |
Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; S | 2022 |
Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; S | 2022 |
Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; S | 2022 |
Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiothera | 2022 |
A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10-2 trial).
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2023 |
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Health-related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy, Adj | 2019 |
Stathmin guides personalized therapy in oral squamous cell carcinoma.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamou | 2020 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neopla | 2020 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neopla | 2020 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neopla | 2020 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neopla | 2020 |
An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Comb | 2020 |
Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiother | 2020 |
Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC).
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Cause of Death; Chemoradiotherapy, Adjuvant; | 2020 |
Phase II study of de-intensified intensity-modulated radiotherapy and concurrent carboplatin/5-fluorouracil in lateralized p16-associated oropharyngeal carcinoma.
Topics: Carboplatin; Carcinoma, Squamous Cell; Fluorouracil; Humans; Oropharyngeal Neoplasms; Radiotherapy D | 2020 |
Anti-Telomerase CD4
Topics: Adaptive Immunity; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; A | 2020 |
Rate and Proportion of Malignant Skin Biopsies for Basal Cell and Squamous Cell Carcinoma on the Face and Ears After a Single Course of Topical 5-Fluorouracil: The Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Basal Cell; Carci | 2021 |
A multicenter randomized phase II trial of hyperthermia combined with TPF induction chemotherapy compared with TPF induction chemotherapy in locally advanced resectable oral squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2021 |
Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Ch | 2017 |
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patien
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2017 |
The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Move | 2017 |
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; DNA, Viral; Doc | 2017 |
Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiothe | 2017 |
Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Squamous | 2017 |
Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, | 2017 |
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2017 |
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2017 |
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2017 |
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2017 |
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplat | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Carcinoma, Basal Cell; Carcinoma, Squamou | 2018 |
Impact of topical fluorouracil cream on costs of treating keratinocyte carcinoma (nonmelanoma skin cancer) and actinic keratosis.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Basa | 2018 |
Rescue of iCIKs transfer from PD-1/PD-L1 immune inhibition in patients with resectable tongue squamous cell carcinoma (TSCC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Squamous Cell | 2018 |
Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2019 |
Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisp | 2018 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
Skin cancer precursor immunotherapy for squamous cell carcinoma prevention.
Topics: Adaptive Immunity; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitri | 2019 |
Skin cancer precursor immunotherapy for squamous cell carcinoma prevention.
Topics: Adaptive Immunity; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitri | 2019 |
Skin cancer precursor immunotherapy for squamous cell carcinoma prevention.
Topics: Adaptive Immunity; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitri | 2019 |
Skin cancer precursor immunotherapy for squamous cell carcinoma prevention.
Topics: Adaptive Immunity; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitri | 2019 |
Characteristics of Keratinocyte Carcinomas and Patients with Keratinocyte Carcinomas Following a Single 2-4 Week Course of Topical 5-fluorouracil on the Face and Ears.
Topics: Administration, Topical; Aged; Aged, 80 and over; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; D | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, S | 2019 |
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2019 |
Quality Assurance of Dose-Escalated Radiation Therapy in a Randomized Trial for Locally Advanced Oesophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Cancer Care Facilities; Carcinom | 2019 |
Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2013 |
Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2013 |
Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; C | 2013 |
Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous C | 2013 |
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumo | 2013 |
Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2013 |
Evaluation of Outcomes in Patients With Carcinoma of the Cervix Treated With Concurrent Radiation and Cisplatin Versus Cisplatin/5-FU Compared With Radiation Alone.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2015 |
Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squ | 2013 |
Characteristics and treatment outcomes of patients with malignant transformation arising from mature cystic teratoma of the ovary: experience at a single institution.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2013 |
Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2013 |
Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease P | 2013 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
Randomized study of antiinflammatory and immune-modulatory effects of enteral immunonutrition during concurrent chemoradiotherapy for esophageal cancer.
Topics: Adult; Aged; Arginine; C-Reactive Protein; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; E | 2014 |
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2016 |
Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2014 |
Completion surgery after concomitant chemoradiation in locally advanced cervical cancer: a comprehensive analysis of pattern of postoperative complications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Impact of advancing age on treatment and outcomes in anal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Ne | 2014 |
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2014 |
GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinogenesis; Carc | 2014 |
Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Squamous Cell; | 2015 |
Glycididazole sodium combined with radiochemotherapy for locally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control Studies; Chem | 2014 |
Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradioth | 2014 |
Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradioth | 2014 |
[Grade IV myelosuppression after induction chemotherapy of TPF on oral cancer: clinical analysis of 29 cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluo | 2014 |
Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2014 |
Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2014 |
Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Biomarkers, Tumor; Ca | 2014 |
Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of (18)FDG-PET scans: a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2014 |
Efficacy of cryosurgery and 5-fluorouracil cream 0.5% combination therapy for the treatment of actinic keratosis.
Topics: Administration, Cutaneous; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined | 2014 |
Chemoradiation with concomitant boosts followed by radical surgery in locally advanced cervical cancer: long-term results of the ROMA-2 prospective phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma | 2014 |
Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by (18)FDG-PET/CT for esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2015 |
Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Topics: Adult; Aged; Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou | 2015 |
Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2015 |
Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Doce | 2015 |
Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2015 |
Feasibility and efficacy of concurrent chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: a respective study of 116 cases from a single institution.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2015 |
Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluor | 2015 |
Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2015 |
Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2015 |
Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2015 |
Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Area Under Curve; Carcinoma, | 2016 |
Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Neoadjuvant Chemotherapy for Locally Advanced Squamous Carcinoma of Oral Cavity: a Pilot Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adeno | 2015 |
Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2015 |
The Effect of the UK Coordinating Centre for Cancer Research Anal Cancer Trial (ACT1) on Population-based Treatment and Survival for Squamous Cell Cancer of the Anus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2015 |
Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2015 |
Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; China; Cisplatin; D | 2015 |
Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; C | 2015 |
Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2015 |
Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cetu | 2015 |
A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Ci | 2016 |
Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2016 |
Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cape | 2016 |
Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2017 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Ch | 2016 |
First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Bone Neoplasms; C | 2016 |
Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2016 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2016 |
Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Ce | 2016 |
Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2016 |
Preoperative chemotherapy in patients with resectable esophageal carcinoma: a single center Phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2016 |
Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradioth | 2016 |
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer: A Supplementary Analysis of JCOG0303.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Validation of Photograph-Based Toxicity Score for Topical 5-Fluorouracil Cream Application.
Topics: Administration, Cutaneous; Age Factors; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous C | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cel | 2018 |
Patient reported quality of life after helical IMRT based concurrent chemoradiation of locally advanced anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2016 |
Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: A multi-institutional phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Long-term update of the 24954 EORTC phase III trial on larynx preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2017 |
nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot | 2017 |
EUS-guided paclitaxel injection as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation before surgery for localized or locoregional esophageal cancer: a multicenter prospective randomized trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2017 |
Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2017 |
Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2017 |
Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2017 |
EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; | 2017 |
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2008 |
Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2008 |
Phase II trial of neoadjuvant cisplatin, 5-fluorouracil and interferon-alpha in operable squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
[Preliminary result of multi-center clinical trial on the docetaxel, 5-Fu and DDP in the treatment of advanced, recurrent or metastatic nasopharyngeal carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2008 |
Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2008 |
[Concurrent chemoradiotherapy versus radiotherapy in advanced cervical carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherap | 2008 |
Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2009 |
[Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Fem | 2008 |
Taxotere, cisplatin, fluorouracil, and leucovorin (TPFL)as induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2008 |
A phase I trial of 5-fluorouracil with cisplatin and concurrent standard-dose radiotherapy in Japanese patients with stage II/III esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2009 |
Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2009 |
[Impact of different extents of lymph node dissection on the survival in stage III esophageal cancer patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carcinoma, Squamous Cell | 2008 |
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2009 |
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2009 |
A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Carcinoma, Squamous C | 2009 |
A prospective comparision of sequential chemoradiation vs concurrent chemoradiation in locally advanced oropharyngeal carcinomas.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Thera | 2009 |
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2009 |
Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2009 |
Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cause of Death; Cisplatin; | 2010 |
Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2010 |
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2009 |
Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II tria
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2010 |
Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2010 |
Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2009 |
Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2009 |
Capecitabine-based chemoradiotherapy with adjuvant capecitabine for locally advanced squamous carcinoma of the uterine cervix: phase II results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brachytherapy; Capecitabine; Carcinoma, Squamous Cell; | 2009 |
Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2009 |
Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2009 |
Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine, Cisplatin for locally advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Concurrent chemoradiotherapy for organ function preservation in advanced patients with hypopharyngeal and laryngeal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2009 |
Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2010 |
Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2009 |
Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2009 |
Chemotherapy alone for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modal | 2010 |
A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2010 |
Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2010 |
TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, S | 2010 |
Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Drug Admi | 2010 |
Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Confidenc | 2010 |
Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Squamous Cell; Circad | 2010 |
A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2010 |
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fluorouraci | 2010 |
Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2010 |
Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2010 |
A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2011 |
Feasibility study of sentinel lymph node biopsy in esophageal cancer with conservative lymphadenectomy.
Topics: Adenocarcinoma; Aged; Antimony; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2011 |
Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progres | 2010 |
Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2010 |
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2011 |
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2011 |
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2011 |
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2011 |
"Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I).
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2011 |
Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Carcinoma, Squamous Cell; Com | 2011 |
Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2011 |
Phase I study of S-1 plus nedaplatin in patients with advanced/recurrent head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin | 2010 |
Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
[Efficacy and side-effects of docetaxel combined with cisplatin on the treatment of local advanced esophageal cancer with concomitant radiation therapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2010 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers.
Topics: Adult; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2012 |
Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2011 |
Continuous infusion of 5-FU with split-dose cisplatin: an effective treatment for advanced squamous-cell carcinoma of the head and neck.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2011 |
Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2011 |
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2011 |
Neoadjuvant and adjuvant chemotherapy of cervical cancer: mature results of the phase 2 PBM-PFU protocol.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Adenosq | 2011 |
A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2012 |
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2012 |
Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2011 |
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxyc | 2011 |
Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemor | 2012 |
Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemor | 2012 |
Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemor | 2012 |
Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemor | 2012 |
Prospective trial of chemotherapy-enhanced accelerated radiotherapy for larynx preservation in patients with intermediate-volume hypopharyngeal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Chem | 2012 |
Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined | 2012 |
Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combined Modal | 2012 |
A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-F | 2012 |
[Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycyt | 2011 |
Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carboplatin; Carcinoma, Squa | 2012 |
Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2012 |
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2012 |
Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Is neck dissection necessary after induction plus concurrent chemoradiotherapy in complete responder head and neck cancer patients with pretherapy advanced nodal disease?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2013 |
Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2012 |
Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-F | 2012 |
Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradioth | 2012 |
Long-term outcome of irradiation with or without chemotherapy for esophageal squamous cell carcinoma: a final report on a prospective trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2012 |
[Clinical analysis of nimotuzumab plus cisplatin and fluorouracil regimen as induction treatment in resectable head and neck squamous cell carcinoma].
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2013 |
EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2012 |
A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2013 |
Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1)
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2012 |
Survival following non surgical treatments for oral cancer: a single institutional result.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Analysis of Variance; Antineoplastic Combined Chemothera | 2013 |
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; | 2012 |
[Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2012 |
Assessment and comparison of recovery after open and minimally invasive esophagectomy for cancer: an exploratory study in two centers.
Topics: Activities of Daily Living; Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemoth | 2013 |
A phase II study on continuous infusional paclitaxel and 5-Fu as first-line chemotherapy for patients with advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; E | 2012 |
A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
Superselective intra-arterial chemoradiation therapy for functional laryngeal preservation in advanced squamous cell carcinoma of the glottic larynx.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxe | 2013 |
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Use of high-dose cytarabine to enhance cisplatin cytotoxicity-effects on the response and overall survival rates of advanced head and neck cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cy | 2002 |
Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Chemotherapy | 2002 |
Selective lymph node dissection following hyperfractionated accelerated radio-(chemo-)therapy for advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2002 |
The clinical efficacy of neoadjuvant chemotherapy in squamous esophageal cancer: a prospective nonrandomized study of pulse and continuous-infusion regimens with Cisplatin and 5-Fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2002 |
A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2002 |
A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carc | 2002 |
Preoperative chemoradiotherapy for squamous cell carcinoma and adenocarcinoma of the esophagus: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2002 |
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2002 |
Accelerated hyperfractionated radiotherapy and concurrent protracted venous infusion chemotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2002 |
Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2002 |
A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2002 |
FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combine | 2003 |
Concurrent chemoradiotherapy with new platinum compound nedaplatin in oral cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2003 |
Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2003 |
Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 2003 |
Preoperative chemoradiotherapy in cancer of the thoracic esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2003 |
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Ci | 2003 |
Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B | 2003 |
5-Fluorouracil and cisplatin in the treatment of advanced oral cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Di | 2003 |
Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; F | 2003 |
Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2003 |
Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2003 |
Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2003 |
Carcinoma of the head and neck: a 5- to 20-year experience with preoperative chemotherapy, uncompromised surgery, and selective radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2003 |
Efficacy of neoadjuvant chemoradiotherapy in resectable esophageal squamous cell carcinoma--a single institutional study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
First-line chemotherapy with 5-FU and platinum for advanced and recurrent cancer of the cervix: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2003 |
Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2003 |
[Epidermoid carcinomas of the anal canal treated with definitive radiation therapy in a series of 305 patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2003 |
[A prospective study of combined chemoradiotherapy followed by surgery in the treatment of esophageal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2003 |
Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2003 |
Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2003 |
Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx--long-term results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
Treatment of oesophageal cancer with preoperative chemoradiotherapy may increase operative mortality.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2003 |
Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2003 |
Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2004 |
Usefulness of preoperative chemoradiation in locally advanced cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2004 |
Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2003 |
Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2003 |
Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2003 |
Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2003 |
A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2003 |
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2004 |
Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2004 |
Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
EMR combined with chemoradiotherapy: a novel treatment for superficial esophageal squamous-cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach | 2004 |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach | 2004 |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach | 2004 |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach | 2004 |
Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combi | 2004 |
[Rationale and progress of the phase III trial: intensification of the treatment of locally advanced squamous cell carcinoma of the anal canal].
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2003 |
Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Topics: Adult; Aged; Anemia; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 2004 |
A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2004 |
Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2004 |
Post-operative chemotherapy improves disease-free survival, but not overall survival in people with oesophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2004 |
Prospective phase II trial of PFL-induction chemotherapy followed by definitive local treatment for advanced squamous cell carcinoma of the head and neck: 10-year follow-up.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 2004 |
Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2004 |
Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Doxorubici | 2004 |
Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chi-Square Distribution; Eso | 2004 |
Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
Concurrent chemotherapy and hypofractionated twice-daily radiotherapy in cervical cancer patients with stage IIIB disease and bilateral parametrial involvement: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Fe | 2004 |
Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors.
Topics: Adult; Aged; Angiogenesis Inducing Agents; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous | 2004 |
[Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus].
Topics: Adenoviridae; Adenovirus E1B Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2005 |
[Phase I study of the combination of nedaplatin (NED), adriamycin (ADM), and 5-fluorouracil (5-FU) (NAF) for treatment of unresectable advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dose-Response Relati | 2005 |
Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2004 |
Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Anus Neoplasms; Carcinoma, Sq | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2005 |
Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2005 |
Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; | 2005 |
Phase one dose finding study of capecitabine (Xeloda), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2005 |
Prospective non-randomized trial comparing esophagectomy-followed-by-chemoradiotherapy versus chemoradiotherapy-followed-by-esophagectomy for T4 esophageal cancers.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2005 |
Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2005 |
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2005 |
Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2005 |
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squam | 2005 |
S-phase modulation by irinotecan: pilot studies in advanced solid tumors.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2005 |
[Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dru | 2005 |
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2005 |
Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area | 2005 |
Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2005 |
Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2005 |
Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Lack of survival advantage in patients with advanced, resectable squamous cell carcinoma of the oral cavity receiving induction chemotherapy with cisplatin (CDDP), docetaxel (TXT) and 5-fluorouracil (5FU).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2004 |
Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2005 |
Clinical evaluation of low-dose cisplatin and 5-fluorouracil as adjuvant chemoradiotherapy for advanced squamous cell carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2005 |
Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2005 |
Induction chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus: impact of increased dosage on long-term results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2005 |
[Clinical trial of chemotherapy by superselective intra-arterial infusion of nedaplatin combined with radiotherapy for advanced oral cancer].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2005 |
Mitomycin and fluorouracil in combination with concomitant radiotherapy: a potentially curable approach for locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 2005 |
Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Com | 2005 |
Chemoradiotherapy for T3 and T4 squamous cell carcinoma of the esophagus using low-dose FP and radiation: a preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2005 |
Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; | 2005 |
[Late course conformal radiotherapy combined with chemotherapy for stage III and IV a nasopharyngeal carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2006 |
[A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, | 2005 |
French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2006 |
Late chemo-intensification with cisplatin and 5-fluorouracil as an adjunct to radiotherapy: a pragmatic approach for locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2006 |
Oxaliplatin, folinic acid and 5-fluorouracil (OFF) in patients with recurrent advanced head and neck cancer: a phase II feasibility study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Therapy | 2006 |
Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Brach | 2006 |
Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2006 |
Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2006 |
Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study.
Topics: Adenocarcinoma; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2006 |
[Adjuvant chemotherapy (nedaplatin/UFT) after concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2006 |
Paclitaxel, 5-fluorouracil and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 2006 |
Symptomatic responses to neoadjuvant chemotherapy for carcinoma of the oesophagus and oesophagogastric junction: are they worth measuring?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2006 |
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2006 |
Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Topics: Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2006 |
A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2006 |
Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Antimetabolites, Ant | 2006 |
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2006 |
Facial resurfacing for nonmelanoma skin cancer prophylaxis.
Topics: Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Disease-Fr | 2006 |
[Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca | 2006 |
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2007 |
A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma | 2006 |
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; | 2007 |
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; | 2007 |
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; | 2007 |
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; | 2007 |
Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Modified radical neck dissection and minimal invasive tumor surgery in the middle of split course of concomitant chemoradiotherapy of advanced HNSCC.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2007 |
A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adeno | 2007 |
Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2007 |
Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy | 2007 |
Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Squamous Cell; | 2007 |
[Phase II clinical trial of home-produced Nedaplatin in treating advanced esophageal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Ne | 2006 |
A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine | 2007 |
[Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
[Evaluation of docetaxel, CDDP and 5-FU combined therapy as second-line chemotherapy for esophagus cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2007 |
Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, | 2007 |
Treatment results of alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil--a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2007 |
Chemoradiation therapy using radiotherapy, systemic chemotherapy with 5-fluorouracil and nedaplatin, and intra-arterial infusion using carboplatin for locally advanced head and neck cancer - Phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carb | 2007 |
Dose escalation study of nedaplatin with 5-fluorouracil in combination with alternating radiotherapy in patients with head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2007 |
A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction: the impact of clinical heterogeneity.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2007 |
[Concurrent chemoradiotherapy followed by adjuvant chemotherapy for stage III-IVa nasopharyngeal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2007 |
A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheterizati | 2007 |
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2007 |
Combined modality chemoradiation in elderly oesophageal cancer patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2007 |
[Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma].
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2007 |
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2007 |
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2007 |
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2007 |
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2007 |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2007 |
A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squam | 2007 |
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2008 |
Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
A single-institute phase I/II trial combining nedaplatin dose escalation with a fixed dose of docetaxel for induction chemotherapy of oral squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Dr | 2008 |
Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, | 2008 |
Preliminary results of pre-radiation neck dissection in head and neck cancer patients undergoing organ preservation treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ch | 2007 |
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Fe | 2007 |
A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2008 |
Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2008 |
Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trial.
Topics: Adenocarcinoma; Adult; Aged; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2008 |
The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus.
Topics: Adult; Aged; Ataxia Telangiectasia Mutated Proteins; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, S | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality | 2007 |
A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up.
Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Cryosurge | 2007 |
[Means of improvement of surgical treatment for oropharyngeal planocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2007 |
Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2008 |
Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase I trial of escalating-dose cisplatin with 5-fluorouracil and concurrent radiotherapy in Chinese patients with esophageal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2008 |
Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2008 |
A phase II trial of low-dose gemcitabine and radiation alternated to cisplatin and 5-fluorouracil: an active and manageable regimen for stage IV squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2008 |
Selective dose escalation of chemoradiotherapy for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2008 |
EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2008 |
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2008 |
Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Chemotherapy strategies in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
Chemotherapy for squamous cell carcinoma of the head and neck: a progress report.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chlorambucil; Clinical Trials as Topic; | 1980 |
Polychemotherapy in squamous cell carcinoma of the buccal mucosa.
Topics: Adult; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cheek; Clinical Trials as Topic; | 1983 |
[Chemotherapy of the non-small cell bronchogenic carcinoma].
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; | 1983 |
Integration of safe initial combination chemotherapy (without cisplatin) with a high response rate and local therapy for untreated stage III and IV epidermoid cancer of the head and neck: 5-year survival data.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials as Topic; D | 1983 |
The value of two combined chemoradiotherapy approaches in the treatment of inoperable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca | 1984 |
Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
Clinical trials with oral Futraful (INN: Tegafur) in cancer of the head and neck.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Car | 1981 |
Methotrexate and 5-fluorouracil in sequence in squamous head and neck cancer.
Topics: Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Administration Schedule; Drug Synergism; Dr | 1983 |
Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Tria | 1983 |
Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical T | 1984 |
[Cooperative trials of the Council of Mutual Economic Aid countries on chemoradiotherapy of lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1984 |
Selective cytotoxic effect of topical 5-fluorouracil.
Topics: Administration, Topical; Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Double-Blind | 1983 |
Use of methotrexate and 5-FU for recurrent head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Diarrhea; Drug Therapy, Combination | 1982 |
Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Female; Fluorouracil; He | 1982 |
Management of pelvic complications of malignant urothelial tumors with combined intra-arterial and iv chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Drug A | 1982 |
Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, Combination; Esophageal | 1980 |
The activity of paclitaxel in gastrointestinal tumors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 1995 |
Improved survival with preoperative chemotherapy followed by resection uncompromised by tumor response for advanced squamous cell carcinoma of the head and neck.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1995 |
Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head a
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1994 |
Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Split-course accelerated radiation therapy combined with carboplatin and 5-fluorouracil for palliation of metastatic or unresectable carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 1995 |
Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squa | 1995 |
Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic | 1995 |
Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1995 |
Preoperative chemoradiotherapy for locoregional esophageal cancer: preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Chemotherapy rapidly alternating with twice-a-day accelerated radiation therapy in carcinomas involving the hypopharynx or esophagus: an update.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1995 |
Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1995 |
Neoadjuvant chemotherapy with etoposide, leucovorin, 5-fluorouracil and cisplatin for advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1995 |
Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1995 |
Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aust | 1995 |
Cisplatin and 5-fluorouracil as neoadjuvant chemotherapy: predicting response in head and neck squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1995 |
Function preservation in stage III squamous laryngeal carcinoma: results with an induction chemotherapy protocol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1995 |
Induction chemotherapy and irradiation in advanced carcinoma of the cervix.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined M | 1995 |
[Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; | 1995 |
Chemotherapeutic treatment of recurrent and/or metastatic nasopharyngeal carcinoma: a retrospective analysis of 40 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamo | 1993 |
[Usefulness of adjuvant chemotherapy with antimetabolites for cervical invasive cancer].
Topics: Adenocarcinoma; Administration, Oral; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Fluo | 1995 |
A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
[Preliminary results of a prospective randomized study of primary chemotherapy in carcinoma of the oral cavity and pharynx].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 1995 |
Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 1995 |
Treating esophageal cancer with a combination of chemotherapy, radiation, and excision.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; | 1995 |
Sequential chemotherapy and radiotherapy for patients with squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy for inoperable squamous cell carcinoma of the esophagus potentially followed by surgery.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1995 |
Concurrent radiotherapy and chemotherapy with protracted continuous infusion of 5-fluorouracil in inoperable esophageal squamous cell carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Feasibility Studies | 1995 |
Modified combination chemotherapy of cisplatin and 5-fluorouracil in squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Fluorouracil; H | 1994 |
Cisplatin, 5-fluorouracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 1994 |
Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Sm | 1994 |
A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi | 1994 |
Conservative management of squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1994 |
The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1994 |
Combination therapy for epidermoid carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1994 |
Intensified chemotherapy with granulocyte-monocyte colony stimulating factor protection in advanced, relapsed squamous cell carcinoma of the head and neck. A phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1994 |
Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Female; Fluorourac | 1994 |
[Cisplatin/5-FU versus carboplatin/5-FU. 5 year follow-up].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoth | 1994 |
Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1994 |
Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1994 |
Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
[Long-term administration of carmofur as a post-operative adjuvant chemotherapy for cervical adenocarcinoma. Cervical Adenocarcinoma Cooperative Research Association].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Chemotherapy and extended-field radiation therapy to para-aortic area in patients with histologically proven metastatic cervical cancer to para-aortic nodes: a phase II pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1994 |
Chemotherapy as predictor of compliance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1994 |
[A comparative clinical study on the treatment of head and neck tumors by adjuvant chemotherapy with HCFU--Second Study by Kinki Head and Neck Tumor Study Group].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Administr | 1994 |
5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1994 |
Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1993 |
Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1993 |
Concomitant alpha-interferon and chemotherapy in advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1993 |
Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical.
Topics: Adenocarcinoma; Administration, Inhalation; Aerosols; Aged; Animals; Bronchial Neoplasms; Carcinoma, | 1993 |
Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study.
Topics: Adult; Aged; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; | 1994 |
A phase I/II trial of twice daily irradiation and concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Animals; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; Follow-Up Stu | 1994 |
Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1994 |
A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil, and leucovorin in nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplat | 1994 |
Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1994 |
Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1993 |
A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1993 |
Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Chi-Square Distribution; Combined Modality Therapy; Female; Fluorour | 1993 |
Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1993 |
Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: a South-East European Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1993 |
A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1993 |
The Head and Neck Radiotherapy Questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer.
Topics: Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Head an | 1993 |
[Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 1995 |
[Medical treatment of 44 patients with anal canal carcinoma. Argentinian Intergroup for the treatment of gastrointestinal tumors (IATTGI)].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1995 |
[Determination of 5-FU tissue concentrations after oral UFT administration in tumors of the head and neck].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1996 |
Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II intergroup trial 0122.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1996 |
Preoperative concomitant radiochemotherapy in squamous cell carcinoma of the esophagus: results of a study of 56 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1996 |
[Adjuvant chemotherapy in advanced squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1995 |
5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1996 |
[Neoadjuvant chemotherapy with continuous intra-arterial infusion (cisplatin, 5-fluorouracil) in the treatment of stage III cervical cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1995 |
Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1996 |
Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1996 |
Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1996 |
Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 1996 |
Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; | 1996 |
A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcino | 1996 |
Cisplatin and continuous infusion of fluorouracil followed by radiation and weekly carboplatin in the treatment of locally advanced head and neck cancer: a Hellenic Cooperative Oncology Group study.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1996 |
Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
A long-term assessment of adjuvant chemotherapy on outcome of patients with extracapsular spread of cervical metastases from squamous carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1996 |
Accelerated fractionation radiotherapy and concomitant chemotherapy in patients with stage IV inoperable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1996 |
Phase I-II trial of recombinant interferon alpha-2b with cisplatin and 5-fluorouracil in recurrent and/or metastatic carcinoma of head and neck.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; | 1996 |
Concurrent 5-fluorouracil, daily low-dose cisplatin, and radiotherapy in stage IIIB cervical cancer. A phase II prospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squa | 1996 |
Intensive short cause chemotherapy followed by radiotherapy of locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1996 |
Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1996 |
Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1996 |
Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and neck cancer.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Mo | 1996 |
[Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1996 |
Chemotherapy followed by accelerated fractionated radiation for larynx preservation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1996 |
[Combination treatment of late nasopharyngeal carcinoma: an analysis of short-term therapeutic results in 200 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ch | 1996 |
[Concomitant radiochemotherapy with cisplatin (CDDP), 5-fluorouracil (5-FU) and mitomycin C (MMC) in locally advanced carcinoma of the oropharynx. Results of a phase II trial].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1995 |
Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 1996 |
A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Topics: Antidotes; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; | 1996 |
Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG)
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1996 |
Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1996 |
Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1996 |
Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1996 |
Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1996 |
Phase II study of chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus: nine Japanese institutions trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1996 |
Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1996 |
Neo-adjuvant chemotherapy +/- immunotherapy with s.c. IL 2 in advanced squamous cell carcinoma of the head and neck: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1994 |
Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. ONCOPAZ Cooperative Group, Spain.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 1996 |
[Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 1996 |
Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1996 |
Carboplatin, 5-fluorouracil and folinic acid: a 48-hour chemotherapy regimen in advanced and recurrent squamous carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; | 1996 |
[Apropos of two recently published randomized trials of induction chemotherapy in nasopharyngeal and piriform sinus carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Comb | 1996 |
Integration of surgery in multimodality therapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1997 |
Preoperative simultaneous chemoradiotherapy in locally advanced cancer of the oral cavity and oropharynx.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1997 |
Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase II multicenter study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1997 |
Comparison of intratumoral administration of cisplatin versus bleomycin for treatment of periocular squamous cell carcinomas in horses.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bleomy | 1997 |
A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 1997 |
Sequential chemotherapy and radiotherapy for squamous cell esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1997 |
Carboplatin and 5-fluorouracil in squamous cell carcinoma of the head and neck previously responding to cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1997 |
Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1997 |
Locally advanced head and neck cancer: combined chemotherapy and radical radiation therapy for organ and function preservation (interim report).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1997 |
Neoadjuvant chemotherapy with continuous infusion of cisplatin and 5-fluorouracil, with or without leucovorin, for locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Ch | 1996 |
[Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease combine (Elase)].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Cryotherapy; Deoxyribonucleases; Drug Combinations | 1997 |
Phase I-II study of combined 5-fluorouracil and cisplatin chemotherapy and altered fractionation radiotherapy for advanced squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1997 |
Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1997 |
Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1997 |
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 1997 |
Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Car | 1997 |
Nasopharyngeal carcinoma in childhood and adolescence: concept and preliminary results of the cooperative GPOH study NPC-91. Gesellschaft für Pädiatrische Onkologie und Hämatologie.
Topics: Adenocarcinoma, Clear Cell; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; C | 1997 |
Concurrent chemoradiotherapy for salvage in relapsed squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combine | 1997 |
A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combine | 1997 |
Treatment with cisplatin and fluorouracil alternating with radiation favourably affects prognosis of inoperable squamous cell carcinoma of the head and neck: results of a multivariate analysis on 273 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 1997 |
Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1997 |
[Clinical evaluation of intra-arterial infusion chemotherapy for advanced or recurrent cervical cancer with or without radiotherapy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 1997 |
First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1997 |
Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1997 |
Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1997 |
[Combination chemotherapy with nedaplatin and 5-FU for head and neck cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration | 1998 |
Phase II study: concurrent chemo-radiotherapy in advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemo | 1997 |
Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1998 |
Accelerated hyperfractionated radiation therapy and concurrent 5-fluorouracil/cisplatin chemotherapy for locoregional squamous cell carcinoma of the thoracic esophagus: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1998 |
Treatment of carcinoma of the uterine cervix with concomitant cisplatin, 5-fluorouracil and split course hyperfractionated radiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brachy | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Ci | 1998 |
Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carc | 1998 |
Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1998 |
[Hyperfractionated accelerated simultaneous radiochemotherapy in advanced hypopharyngeal carcinomas. Survival rate, retained function quality of life in a phase II study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Co | 1998 |
Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1998 |
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1998 |
Artificial neural network model of survival in patients treated with irradiation with and without concurrent chemotherapy for advanced carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1998 |
5-Fluorouracil dose intensification and granulocyte-macrophage colony-stimulating factor in cisplatin-based chemotherapy for relapsed squamous cell carcinoma of the head and neck: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1998 |
Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 1998 |
Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinoma, Squamous Cell | 1998 |
Randomized trial of induction chemotherapy in larynx carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1998 |
Squamous cell granulomas of the neck: histologic regression of metastatic squamous cell carcinoma following chemotherapy and/or radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1998 |
Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplat | 1998 |
Multimodality treatment of primary lymphoepithelioma-like carcinoma of the lung.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, S | 1998 |
Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1998 |
[Cisplatin, 5-FU and preoperative radiotherapy in esophageal epidermoid cancer. Multicenter phase II FFCD 8804 study].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; F | 1998 |
A randomized study of radiotherapy alone versus radiotherapy plus 5-fluorouracil and platinum in patients with inoperable, locally advanced squamous cancer of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1998 |
Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1998 |
Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Comb | 1998 |
Chemoradiotherapy as an alternative to radiotherapy alone in fast proliferating head and neck squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; | 1997 |
Continued malignant cell proliferation in head and neck tumors during cytotoxic therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Carcinoma, Squamous | 1996 |
Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; | 1998 |
5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1999 |
Phase II clinical trial of cisplatin, 5-fluorouracil, and ifosfamide as treatment for advanced locoregional head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fl | 1999 |
Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 1999 |
Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1999 |
Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1999 |
A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Ci | 1999 |
Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04. Radiation Therapy Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Combined M | 1999 |
High rate of clinical complete response to weekly outpatient neoadjuvant chemotherapy in oral carcinoma patients using a new regimen of cisplatin, 5-fluorouracil, and bleomycin alternating with methotrexate and epirubicin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1999 |
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1999 |
Carboplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1998 |
Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
[No improvement of prognosis by neoadjuvant chemotherapy alone in operable esophageal carcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1999 |
Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; C | 1999 |
Long-term follow-up of neoadjuvant cisplatin and 5-fluorouracil chemotherapy in bulky squamous cell carcinoma of the cervix.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease | 1999 |
Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG #85-01?
Topics: Adenocarcinoma; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Black Pe | 1999 |
Simultaneous chemotherapy and radiotherapy with escalating doses of chemotherapy in patients with advanced esophageal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; D | 1999 |
Phase I-II study of 5-fluorouracil, recombinant interferon alpha2a, and cisplatin in combination with external beam radiation therapy followed by surgery in patients with locally advanced carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1999 |
Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
[Results of a prospective randomized trial with induction chemotherapy for cancer of the oral cavity and tonsils].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Moda | 1999 |
[Low-dose CDDP and 5-FU for head and neck cancer patients].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1999 |
Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1999 |
Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 1999 |
[Neoadjuvant treatment of operable esophageal cancers].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1999 |
Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Colorectal Ne | 1999 |
Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 1999 |
Prognosis after salvage chemotherapy for locally unresectable recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1999 |
An original accelerated radiotherapy schedule in stage III to IV head and neck cancers. Results in a multicenter setting.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 2000 |
Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2000 |
Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
Intraarterial chemotherapy as neoadjuvant treatment of oral cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1999 |
Aggressive multimodality therapy for stage III esophageal cancer: a phase I/II study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality T | 2000 |
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2000 |
Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged.
Topics: Administration, Oral; Age Factors; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; | 2000 |
The influence of beam energy on the outcome of postoperative radiotherapy in head and neck cancer patients: secondary analysis of RTOG 85-03.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2000 |
The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, S | 2000 |
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease Progr | 2000 |
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2000 |
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.
Topics: Adenoviruses, Human; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou | 2000 |
Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2000 |
Phase I-II trial of preoperative chemoradiation in locally advanced cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2000 |
Effect of neoadjuvant chemotherapy for lymph node micrometastasis and tumor cell microinvolvement in the patients with esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2000 |
A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).
Topics: Adenoviruses, Human; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2000 |
Simultaneous radiochemotherapy versus concomitant boost radiation for advanced inoperable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2000 |
Preoperative chemotherapy for esophageal carcinoma with intramural metastasis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Sq | 2000 |
Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitio | 2001 |
Neoadjuvant therapy for organ preservation in head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemot | 2000 |
Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2001 |
Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv | 2000 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Comb | 2001 |
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2001 |
Adjuvant chemotherapy for gastro-oesophageal cancer with epirubicin, cisplatin and fluorouracil: a single-centre experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous | 2001 |
High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2001 |
Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2001 |
Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2001 |
Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2001 |
Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2001 |
Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2001 |
[Percutaneous radiotherapy plus brachytherapy and concurrent chemotherapy for patients with localized esophageal carcinoma--Radiation Oncology Group Study 9207].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Brachytherapy; Carcinoma, Squamous Cell; Combined M | 2001 |
Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2001 |
[Multi-institutional cooperative study on combination chemotherapy with THP, CDDP and 5-FU for squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2001 |
Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 2001 |
Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2001 |
A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2001 |
[Evaluation of a combination chemotherapy with nedaplatin and 5-FU for oral cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administ | 2001 |
Unresectable primary tumor of head and neck: does neck dissection combined with chemoradiotherapy improve survival?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2001 |
[Effect of combination chemotherapy with nedaplatin and 5-FU for head and neck squamous cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedu | 2001 |
A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2001 |
Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfractionation in stage III and IV nasopharyngeal carcinoma--a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squam | 2001 |
Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 2001 |
RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality T | 2001 |
Chemoradiation for locally advanced squamous cell carcinoma of the head and neck for organ preservation and palliation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2001 |
Expense and benefit of neoadjuvant treatment in squamous cell carcinoma of the esophagus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2001 |
[Clinical observation on effect of yiqi huoxue decoction in comprehensive treatment on advanced stage of esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2001 |
[Preliminary clinical evaluation of continuous infusion of 5-FU and low-dose Cisplatin (LFP) therapy alone and combined with radiation therapy for treatment of advanced or recurrent esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 2002 |
Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cisp | 2001 |
Squamous cell carcinoma of the esophagus: multimodal therapy in locally advanced disease.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combine | 2002 |
[Combination chemotherapy with nedaplatin (CDGP) and 5-FU for oral cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administ | 2002 |
Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2002 |
Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2002 |
Combination chemotherapy pilot studies in head and neck squamous cell cancer.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyclophosphamide; Drug T | 1979 |
[Chemotherapy of non-microcellular disseminated bronchial cancer (author's transl)].
Topics: Adenocarcinoma; Adult; Aged; Bleomycin; Bronchial Neoplasms; Carcinoma, Small Cell; Carcinoma, Squam | 1979 |
Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study.
Topics: Carcinoma, Squamous Cell; Fluorouracil; Follow-Up Studies; Humans; Mouth Neoplasms; Neoplasm Metasta | 1976 |
[The combined treatment of bronchial carcinoma (author's transl)].
Topics: Adenocarcinoma; Aged; Bronchial Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical | 1975 |
Combination modality therapy in lung cancer: a survival study showing beneficial results of AMCOF (adriamycin, methotrexate, cyclophosphamide, oncovin and 5-fluorouracil).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Small Cell; Carcinoma, S | 1978 |
[Joint radiation and chemotherapy of squamous cell lung cancer].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; | 1979 |
[Sequential chemotherapy based on the hypothesis of a circadian rhythm of tumor proliferation].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Circadian R | 1975 |
Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisp | 1992 |
Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1992 |
[Squamous cell cancer of the esophagus. Treatment concept at the Houston M.D. Anderson Cancer Center].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Carcinoma, Squamous Cell; Ch | 1992 |
[Randomized study of preoperative chemotherapy in squamous cell cancer of the esophagus. CAO Esophageal Cancer Study Group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1992 |
Potential impact on tumor control and organ preservation with cisplatin and 5-fluorouracil for patients with advanced tumors of the paranasal sinuses and nasal fossa. A prospective pilot study.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1992 |
Concurrent radiation therapy, 5-fluorouracil, and cisplatin for stage II, III, and IV, node-negative, squamous cell head and neck cancer. Results and surgical implications.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1992 |
Synchronous radiation and cytotoxic chemotherapy for locally advanced or recurrent squamous cancer of the vulva.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cisplatin; Combined Modality T | 1992 |
A phase I study of high-dose cisplatin, prolonged infusion 5-fluorouracil, and concomitant conventional fraction radiation therapy in patients with inoperable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1992 |
5-fluorouracil and low-dose leucovorin in the treatment of recurrent squamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1992 |
Effectiveness of salvage neck dissection for advanced regional metastases when induction chemotherapy and radiation are used for organ preservation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Severe complications of 5-fluorouracil and cisplatin with concomitant radiotherapy in inoperable non-metastatic squamous cell oesophageal cancer after intubation--early termination of a prospective randomised trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
A phase II study of 5-fluorouracil and leucovorin in advanced carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evaluati | 1992 |
Induction chemotherapy for advanced head and neck cancer: modification of response to chemotherapy by antiemetics.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Hyperfractionated radiation therapy and concurrent 5-fluorouracil, cisplatin and mitomycin-C in head and neck carcinoma. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1992 |
Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 1992 |
Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1992 |
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1992 |
Simultaneous chemoradiation in the treatment of advanced head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Fluorouracil; Head | 1992 |
Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the cancer and leukemia group B.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1991 |
[Palliative chemotherapy of epidermoid carcinoma of the upper respiratory and digestive tracts with a combination of carboplatin and 5-fluorouracil].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1990 |
A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co | 1991 |
Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Ce | 1991 |
Neoadjuvant chemotherapy consisting of cisplatin and continuous infusions of bleomycin and 5-fluorouracil for advanced head and neck cancer. The need for a new stratification for stage IV (M0) disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1991 |
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 1991 |
Platinum-based chemotherapy followed by radiation therapy of locally advanced nasopharyngeal cancer. A retrospective analysis of 39 cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; | 1991 |
[Randomized trial of combined chemotherapy including high dose cisplatin and radiotherapy for esophageal cancer].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carci | 1991 |
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug | 1992 |
[A comparative clinical study of adjuvant chemotherapy of tumors in the head and neck areas by means of HCFU].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Fluoro | 1991 |
Mitomycin-C/5-FU and radiation therapy for locally advanced uterine cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality T | 1991 |
Further experience with radiation therapy and concomitant intravenous chemotherapy in advanced carcinoma of the lower female genital tract.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell | 1991 |
Phase I/II study of carboplatin and 5-fluorouracil in patients with advanced head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1991 |
Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1991 |
Concomitant pelvic irradiation, 5-fluorouracil and mitomycin C in the treatment of advanced cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Flu | 1991 |
Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1991 |
[The status of sequential chemo-/radiotherapy in inoperable head and neck cancers. Personal results and review of the literature].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1991 |
Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva.
Topics: Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Therapy, Combination; Fem | 1991 |
A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Admini | 1991 |
5-year results of cisplatin and fluorouracil infusion in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Syne | 1991 |
Induction chemotherapy (cisplatin + 5-fluorouracil) and radiotherapy in advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
[Preliminary evaluation of the effectiveness of induction chemotherapy with cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the head and neck].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; | 1991 |
A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1991 |
A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; F | 1990 |
Randomized study of 5 fluorouracil and cis platin as neoadjuvant therapy in head and neck cancer: a preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
[The results of simultaneous radio-chemotherapy in advanced head and neck tumors].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1990 |
[Combined radiotherapy and pre-radiation chemotherapy with cisplatin and 5-fluorouracil for advanced esophageal carcinoma. I. Clinical evaluation in cases with distant metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1990 |
Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1990 |
Randomized neo-adjuvant chemotherapy trial for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamo | 1985 |
Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Randomized study of adjuvant chemotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials | 1985 |
A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract.
Topics: Bleomycin; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclophosphamide; Fluorouracil; Head | 1986 |
[Preoperative chemotherapy of esophageal cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Combined | 1986 |
A randomized trial of combined multidrug chemotherapy and radiotherapy in advanced squamous cell carcinoma of the head and neck. An interim report from the SECOG participants. South-East Co-operative Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials | 1986 |
Factors predicting response of end stage squamous cell carcinoma of the head and neck to cisplatinum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1987 |
Sequential versus alternating chemotherapy and radiotherapy in stage III-IV squamous cell carcinoma of the head and neck: a phase III study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials | 1988 |
Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1989 |
Induction chemotherapy with cisplatinum, 5-fluorouracil, bleomycin, mitomycin C and hydroxyurea for previously untreated locally advanced squamous cell carcinomas of the head and neck.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1989 |
Morphometric analysis, ploidy and response to chemotherapy in squamous carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1989 |
Radiation therapy alone and in combination with bleomycin and 5-fluorouracil in advanced carcinoma esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co | 1989 |
Chemotherapy following surgery for head and neck cancer. A Radiation Therapy Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
[Results of a phase II study of the combination of cis-platinum and 5-FU in epidermoid or undifferentiated large cell bronchial cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squam | 1989 |
[Long-term intravenous infusion of 5-fluorouracil combined with platidiam in local spread of squamous cell carcinoma of the oral cavity].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1989 |
Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Attitude to Health; Carcinoma, Squa | 1989 |
[Clinical value of postoperative chemotherapy for non-small cell lung cancer--with special reference to long-term combined chemotherapy combined with immunotherapy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Ca | 1985 |
Sequential trial of initial chemotherapy for advanced cancer of the head and neck. DDP versus DDP + 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
Chemotherapy of advanced and relapsed squamous cell cancer of the head and neck with split-dose cisplatinum (DDP), 5-fluorouracil (Fura) and leucovorin (CF).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1988 |
Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Methotrexate/fluorouracil scheduling influences normal tissue toxicity but not antitumor effects in patients with squamous cell head and neck cancer: results from a randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; | 1988 |
An intensive, five course, alternating combination chemotherapy induction regimen used in patients with advanced, unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer. A report from the Northern California Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1987 |
Combined treatment including postoperative chemotherapy in lung cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality T | 1988 |
Comparison of methotrexate and sequential methotrexate-5-fluorouracil for patients with recurrent squamous cell carcinoma of the oral cavity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluor | 1987 |
Induction chemotherapy in advanced head and neck cancer. A Radiation Therapy Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1987 |
Adjuvant chemotherapy for high-risk squamous-cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; | 1987 |
Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. A preliminary report.
Topics: Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasm | 1987 |
A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1985 |
A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1985 |
Clinical trials on UFT in the treatment of head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Tria | 1985 |
Advanced lung cancer: A clinical trial of radiotherapy plus two drug combination regimens.
Topics: Adenocarcinoma; Amides; Antineoplastic Agents; Carcinoma; Carcinoma, Small Cell; Carcinoma, Squamous | 1973 |
Combined therapy in advanced head and neck cancer: a randomized study.
Topics: Carcinoma, Squamous Cell; Clinical Trials as Topic; Cobalt Isotopes; Fluorouracil; Humans; Laryngeal | 1972 |
[Radiotherapy of malignant neoplasms following synchronisation of cell division rhythm. Experiences following two years of clinical use].
Topics: Animals; Carcinoma; Carcinoma, Squamous Cell; Clinical Trials as Topic; Fluorouracil; Humans; Infusi | 1972 |
Radiotherapy plus 5-FU compared to radiotherapy alone for inoperable and unresectable bronchogenic carcinoma.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Clinical Trials as Top | 1972 |
Sequential analysis of constant and prolonged regional chemotherapy for cancer of the lung.
Topics: Aged; Carcinoma, Squamous Cell; Catheterization; Clinical Trials as Topic; Decision Making; Female; | 1969 |
Treatment of skin epitheliomas with 5-fluorouracil (5-FU) ointment. Influence of therapeutic design on recurrence of lesions.
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinoma, Squamous Cell; Clinical Trials as T | 1970 |
Combination chemotherapy for 418 cases of advanced cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Squamous Cel | 1971 |
Long-term chemotherapy for cancer of the lung.
Topics: Aged; Carcinoma, Squamous Cell; Catheterization; Clinical Trials as Topic; Fluorouracil; Humans; Inj | 1968 |
2192 other studies available for fluorouracil and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Improved synthesis and antitumor activity of 1-deazaadenosine.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line; Female; HeLa Cells; Humans; Leu | 1987 |
Novel 2,4,5-trisubstituted oxazole derivatives: synthesis and antiproliferative activity.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Hu | 2009 |
Topical 5% 5-fluorouracil versus procedural modalities for squamous cell carcinoma in situ and superficial basal cell carcinoma: A retrospective cohort analysis.
Topics: Administration, Topical; Carcinoma in Situ; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorou | 2022 |
FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin B1; Fat | 2023 |
Debulking followed by intralesional 5-fluorouracil for the treatment of cutaneous squamous cell carcinoma and keratoacanthoma: A retrospective analysis.
Topics: Carcinoma, Squamous Cell; Cytoreduction Surgical Procedures; Fluorouracil; Humans; Keratoacanthoma; | 2021 |
Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance.
Topics: A549 Cells; Adenocarcinoma of Lung; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell | 2021 |
Molecular and genomic characterisation of a panel of human anal cancer cell lines.
Topics: Animals; Anus Neoplasms; B7-H1 Antigen; Carcinogenesis; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2021 |
Clinico-epidemiological profile and treatment outcomes in patients with squamous cell carcinoma of the esophagus following docetaxel-based neoadjuvant chemotherapy: experience from a cancer care center in Northeast India.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neop | 2021 |
Current treatment and future directions in the management of anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2022 |
Propofol induces apoptosis and ameliorates 5‑fluorouracil resistance in OSCC cells by reducing the expression and secretion of amphiregulin.
Topics: Amphiregulin; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferati | 2022 |
[Analysis of curative effect of ultrasonic hyperthermia combined with TPF chemotherapy on 19 elderly with advanced oral squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 2021 |
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2022 |
Extracellular
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Fluorouracil; Humans; Isopentenyl | 2022 |
Complete pathologic response of bulbar urethral squamous cell carcinoma in situ to topical 5-fluorouracil with urethral milking.
Topics: Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Urethra; Urethral Stricture; Urologic | 2022 |
Treatment results for patients with squamous-cell carcinoma of the anus, a single institution retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 2022 |
Response in
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Pancreatic | 2022 |
Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
A comparison of invasive squamous cell carcinoma greater than 1 year after treatment with 5-fluorouracil, imiquimod, or photodynamic therapy with aminolevulinic acid.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; | 2022 |
In vitro 5-Fluorouracil resistance produces enhanced photodynamic therapy damage in SCC and tumor resistance in BCC.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; | 2022 |
New approaches in palliative systemic therapy of anal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2022 |
5-Fluoracil Cream Topical Treatment for Squamous Cell Carcinoma of the Skin: Before and After.
Topics: Administration, Topical; Carcinoma, Squamous Cell; Fluorouracil; Humans; Skin; Skin Neoplasms | 2022 |
Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinom | 2022 |
Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma.
Topics: Anal Canal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemo | 2023 |
Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Concurrent Chemo-radiotherapy in Anal Squamous Cell Carcinoma: A Retrospective Review of a Tertiary Centre Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study.
Topics: Carcinoma, Squamous Cell; Conjunctival Neoplasms; Eye Neoplasms; Female; Fluorouracil; Follow-Up Stu | 2023 |
Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study.
Topics: Carcinoma, Squamous Cell; Conjunctival Neoplasms; Eye Neoplasms; Female; Fluorouracil; Follow-Up Stu | 2023 |
Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study.
Topics: Carcinoma, Squamous Cell; Conjunctival Neoplasms; Eye Neoplasms; Female; Fluorouracil; Follow-Up Stu | 2023 |
Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study.
Topics: Carcinoma, Squamous Cell; Conjunctival Neoplasms; Eye Neoplasms; Female; Fluorouracil; Follow-Up Stu | 2023 |
Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal: A single-institution experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal: A single-institution experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal: A single-institution experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal: A single-institution experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Primary Squamous Cell Carcinoma of the Liver with Good Response to Carboplatin and 5-Flurouracil: A Case Report.
Topics: Abdomen; Adolescent; Adult; Aged; Aged, 80 and over; Carboplatin; Carcinoma, Squamous Cell; Female; | 2022 |
Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esop | 2023 |
[A Case of Long-Term Survival with S-1/Cisplatin for Liver Hilum Lymph Node Metastasis of Anal Canal Squamous Cell Carcinoma after Chemoradiotherapy].
Topics: Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamou | 2022 |
Docetaxel-based CRT improves survival in cisplatin-ineligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2023 |
Solid lipid-based nanoparticulate system for sustained release and enhanced in-vitro cytotoxic effect of 5-fluorouracil on skin Melanoma and squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Delayed-Action Preparations; Fluorouracil; | 2023 |
Evaluation of a docetaxel-cisplatin-fluorouracil-Au complex in human oral carcinoma cell line.
Topics: Carcinoma, Squamous Cell; Cell Line; Cisplatin; Docetaxel; Fluorouracil; Gold; Humans; Metal Nanopar | 2023 |
[A Case of Squamous Cell Carcinoma of the Lower Rectum].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Fluorouracil; Humans; Male | 2023 |
Corneal squamous neoplasia: masquerades and management outcomes at a rural eyecare centre.
Topics: Carcinoma, Squamous Cell; Conjunctival Neoplasms; Corneal Diseases; Eye Neoplasms; Fluorouracil; Hum | 2023 |
Dilute Intralesional 5-Fluorouracil for the Treatment of Squamous Cell Carcinomas and Keratoacanthomas: A Case Series.
Topics: Carcinoma, Squamous Cell; Fluorouracil; Humans; Injections, Intralesional; Keratoacanthoma; Retrospe | 2023 |
Keratinocyte Carcinoma Chemoprevention With a Combination of Imiquimod, 5-Fluorouracil, and Tretinoin.
Topics: Carcinoma, Squamous Cell; Chemoprevention; Fluorouracil; Humans; Imiquimod; Keratinocytes; Keratosis | 2023 |
Radical Resection of Locally Advanced Chest Wall cSCC With Muscle Flap Reconstruction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Squamous C | 2023 |
A novel intra-tumoral drug delivery carrier for treatment of oral squamous cell carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fluoroura | 2023 |
Oncological outcomes of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced squamous cell carcinoma of the external auditory canal: A single-center study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Treatment of an Unresectable Cutaneous Squamous Cell Carcinoma With ED&C and 5-FU.
Topics: Carcinoma, Squamous Cell; Fluorouracil; Humans; Skin Neoplasms | 2023 |
5-Fluorouracil and Anti-EGFR antibody scaffold chitosan-stabilized Pickering emulsion: Formulations, physical characterization, in-vitro studies in NCL-H226 cells, and in-vivo investigations in Wistar rats for the augmented therapeutic effects against squ
Topics: Animals; Carcinoma, Squamous Cell; Chitosan; Emulsions; Fluorouracil; Mice; Nanoparticles; Rats; Rat | 2023 |
Association of immune-related expression profile with sensitivity to chemotherapy in esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
[A Case of Esophageal Cancer with Multiple Lung Metastases Resected after Stent Placement and Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 2023 |
Photodynamic therapy enhances skin cancer chemotherapy effects through autophagy regulation.
Topics: Adenine; Aminolevulinic Acid; Autophagy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferat | 2019 |
Taxane- Versus Cisplatin-Based Chemotherapy With Radiation Therapy Is a Better Platform to Refine Esophageal Cancer Therapy.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; | 2019 |
Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; | 2019 |
Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2019 |
Stage IV cutaneous squamous cell carcinoma: treatment outcomes in a series of 42 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy | 2020 |
Contemporary management of actinic keratosis.
Topics: Carcinoma, Squamous Cell; Cryotherapy; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photoche | 2021 |
Eruptive porokeratosis during pembrolizumab treatment of invasive cutaneous squamous cell carcinoma.
Topics: Administration, Cutaneous; Administration, Intravenous; Aged; Antibodies, Monoclonal, Humanized; Bio | 2020 |
Management of orbital invasion in sinonasal squamous cell carcinoma: 15 years' experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2020 |
Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2020 |
Cisplatin Induced the Expression of
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; | 2020 |
Adaptive radiotherapy in locally advanced esophageal cancer with atelectasis: a case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Ci | 2020 |
Assessment of Anti-carcinogenic Effect of Pomegranate in Oral Squamous Cell Carcinoma (Pre-clinical Study).
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Cell Proli | 2019 |
USP9X mRNA expression predicts clinical outcome for esophageal squamous cell carcinoma treated with cisplatin-based therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2020 |
Preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil for oral squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluo | 2020 |
Combination Topical Chemotherapy for the Treatment of an Invasive Cutaneous Squamous Cell Carcinoma
Topics: Administration, Cutaneous; Aged, 80 and over; Carcinoma, Squamous Cell; Combined Modality Therapy; D | 2020 |
Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2020 |
[Neoadjuvant Triplet Combination Chemotherapy(UDON Therapy)in Esophageal Cancer Patients with Impaired Renal Function-A Retrospective Study].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Topics: Animals; Antigens, Ly; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin | 2020 |
Definitive chemoradiotherapy for squamous cell carcinoma of the esophagus: outcomes for borderline-resectable disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carcinoma, Sq | 2020 |
[PRIMARY SQUAMOUS CELL CARCINOMA OF THE PROSTATE: A CASE REPORT].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 2019 |
Factors Associated With Chemoradiation Therapy Interruption and Noncompletion Among Patients With Squamous Cell Anal Carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; | 2020 |
Adjuvant chemotherapy after radiotherapy or concurrent chemoradiotherapy for pelvic lymph node-positive patients with locally advanced cervical cancer: a propensity score matching analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Ch | 2022 |
RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma: A Large-cohort Observational Study (KSCC1307).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Chemoradiother | 2022 |
MiR-92b as a marker for TPF induced chemotherapy response prediction and prognosis evaluation in with advanced oral squamous cell carcinoma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; | 2020 |
Group clinic for chemoprevention of squamous cell carcinoma: a pilot study.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemopreve | 2020 |
Synchronous Primary Pancreatic Ductal Carcinoma and Colonic Adenocarcinoma Present in a Patient With History of Skin Squamous Cell Carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2020 |
Expression profile of stem cell markers and ABC transporters in 5-fluorouracil resistant Hep-2 cells.
Topics: ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neop | 2020 |
Feasibility and Outcome of Routine Use of Concurrent Chemoradiation in HIV-positive Patients With Squamous Cell Anal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2020 |
Observational study of ocular surface squamous neoplasia: Risk factors, diagnosis, management and outcomes at a tertiary eye hospital in South Africa.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Carcinoma, Squamous Cell; Eye Neoplasms; Female; Flu | 2020 |
Haematotoxicity in IMRT/VMAT curatively treated anal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 2020 |
How to Choose the Right Treatment for Patients With Advanced Squamous Cell Carcinoma in the Absence of a Comparative Randomized Clinical Trial.
Topics: Anus Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Humans; Paclitaxel | 2020 |
Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity.
Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Squamous | 2021 |
[Tolerability of Definitive Chemoradiotherapy in Elderly Patients with Esophageal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2020 |
Long-Term Efficacy and Safety of Subconjunctival/Perilesional 5-Fluorouracil Injections for Ocular Surface Squamous Neoplasia.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Conjunctiva; Eye Neoplasms; Female; | 2020 |
Intralesional 5-fluorouracil for the treatment of squamous cell carcinomas.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Fluorou | 2021 |
Outcomes of Squamous Cell Carcinoma Anal Canal treated with IMRT-VMAT-based Concurrent Chemoradiation: a Single Institutional Experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Ingenol Mebutate and the Treatment of Actinic Keratosis.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Clinical Trials as Topic; Diterpenes; Fluorouracil; H | 2021 |
Antitumor Effects of the Novel Quinazolinone Holu-12: Induction of Mitotic Arrest and Apoptosis in Human Oral Squamous Cell Carcinoma CAL27 Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Checkpoi | 2021 |
Melittin sensitizes skin squamous carcinoma cells to 5-fluorouracil by affecting cell proliferation and survival.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Fluorouracil; G2 Phase Cell Cy | 2021 |
Cisplatin/capecitabine with intensity-modulated radiation therapy in anal squamous cell carcinoma: a preliminary study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradioth | 2021 |
A Non-Surgical and Cost-Effective Treatment Approach Employing Topical Imiquimod, 5-Fluorouracil, and Tretinoin for Primary Non-Melanoma Skin Cancers.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2021 |
Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1-NRF2 signaling.
Topics: 3' Untranslated Regions; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Down-Regulation; Dru | 2021 |
Enhanced performance of gelatin 5-fluorouracil-containing nanoparticles against squamous cell carcinoma in simulated chronic wounds conditions.
Topics: Carcinoma, Squamous Cell; Fluorouracil; Gelatin; Humans; Nanoparticles; Wound Healing | 2021 |
Anal Squamous Cell Carcinoma in Ulcerative Colitis: Can Pouches Withstand Traditional Treatment Protocols?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2021 |
Induction Chemotherapy Followed by either Chemoradiotherapy or Bioradiotherapy in Laryngeal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2021 |
Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
Topics: Annexin A1; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doc | 2021 |
Modified bi-weekly cetuximab-cisplatin and 5-FU/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Fluo | 2022 |
Bitter melon derived extracellular vesicles enhance the therapeutic effects and reduce the drug resistance of 5-fluorouracil on oral squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Checkpoi | 2021 |
Fluorouracil Enhances Photodynamic Therapy of Squamous Cell Carcinoma via a p53-Independent Mechanism that Increases Protoporphyrin IX levels and Tumor Cell Death.
Topics: Animals; Biosynthetic Pathways; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Prolife | 2017 |
All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma.
Topics: Angiopoietin-1; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Mov | 2017 |
Ectopic overexpression of CD133 in HNSCC makes it resistant to commonly used chemotherapeutics.
Topics: AC133 Antigen; Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cisplatin; Fluo | 2017 |
A novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cell line Eca-109/5-FU with significant drug resistance-related characteristics.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resista | 2017 |
EGFR Expression in Patients with Esophageal Squamous Cell Carcinoma and its Association with Pathologic Response to Preoperative Chemoradiotherapy: A Study in Northeastern Iran.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; ErbB Receptors; Esophageal | 2017 |
Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; | 2017 |
Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of 18FDG-PET scans: A long follow-up results of phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluo | 2017 |
Treatment of esophageal cancer with radiation therapy -a pan-Chinese survey of radiation oncologists.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvan | 2017 |
Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Pr | 2017 |
Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Co | 2017 |
Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2017 |
A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2017 |
Survival comparison between radical surgery and definitive chemoradiation in 267 esophageal squamous cell carcinomas in a single institution: A propensity-matched study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2017 |
Differential resistance to platinum-based drugs and 5-fluorouracil in p22phox-overexpressing oral squamous cell carcinoma: Implications of alternative treatment strategies.
Topics: Animals; Apoptosis; Carboplatin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Resista | 2017 |
Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Squamous Cell; Ci | 2017 |
A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2018 |
PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2017 |
Comparison cisplatin with cisplatin plus 5FU in head and neck cancer patients received postoperative chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2017 |
Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cetuxi | 2017 |
Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurr | 2017 |
[Subacute cutaneous lupus erythematosus induced by 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Car | 2017 |
Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone | 2017 |
Chemotherapy, "Lighting the Fire" or "Releasing the Brakes" in Metastatic Anal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Catheter A | 2017 |
[A Case of Perianal Squamous Cell Carcinoma with Left Inguinal Lymph Node Metastasis That Showed a Complete Response More Than Five Years after Chemotherapy and Concomitant Proton Beam Therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Che | 2017 |
Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2018 |
Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2018 |
Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Fluorouracil; Hum | 2017 |
HPV-related squamous cell carcinoma in a neovagina after male-to-female gender confirmation surgery.
Topics: Biopsy; Carboplatin; Carcinoma, Squamous Cell; Colostomy; Fatal Outcome; Female; Fluorouracil; Human | 2018 |
The effect of wool hydrolysates on squamous cell carcinoma cells in vitro. Possible implications for cancer treatment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Diclofena | 2017 |
Appropriate timing for surgery after neoadjuvant chemoradiation for esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2017 |
Toxicity and Outcomes in Patients With and Without Esophageal Stents in Locally Advanced Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2017 |
Long-term Clinical Results of Concurrent Chemoradiotherapy for Patients with Cervical Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2017 |
C-reactive protein to albumin ratio is a prognostic factor for patients with cStage II/III esophageal squamous cell cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Squamous Cell; | 2017 |
[Cancers associated with systemic sclerosis involving anti-RNA polymerase III antibodies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoantigens; Carcinoma; Carcinoma, | 2018 |
Prognostic importance of pathological response to neoadjuvant chemotherapy followed by definitive surgery in advanced oral squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carbopla | 2017 |
FBXW7 expression affects the response to chemoradiotherapy and overall survival among patients with oral squamous cell carcinoma: A single-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle Proteins; Ce | 2017 |
Successful downstaging of locally recurrent penile squamous cell carcinoma with neoadjuvant nanosomal docetaxel lipid suspension (NDLS) based regimen followed by curative surgery.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Influence of a dosing-time on toxicities induced by docetaxel, cisplatin and 5-fluorouracil in patients with oral squamous cell carcinoma; a cross-over pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Circadian Rhy | 2018 |
Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2018 |
P16 positivity and regression grade predict survival after neoadjuvant radiotherapy of OSCC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiothera | 2018 |
Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2018 |
Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: Is surgery necessary?
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, | 2018 |
Concurrent chemoradiotherapy alone is feasible for esophageal squamous cell carcinoma patients not suitable for surgery.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Esophageal Neopl | 2018 |
Consolidation chemotherapy after definite concurrent chemoradiation in patients with non-operable esophageal cancer: Is it useful?
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Esophageal Neopl | 2018 |
Honokiol inhibits in vitro and in vivo growth of oral squamous cell carcinoma through induction of apoptosis, cell cycle arrest and autophagy.
Topics: Adenine; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Biphenyl Compounds; Carci | 2018 |
Monocle tumor as tonsillar squamous cell carcinoma metastasis: resolution after chemotherapy treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cetuximab; | 2018 |
Effects of Neoadjuvant 5-Fluorouracil and Cisplatin Therapy in Patients with Clinical Stage II/III Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2018 |
Investigation of cancer-associated fibroblasts and p62 expression in oral cancer before and after chemotherapy.
Topics: Actins; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Female; Fib | 2018 |
Trousseau syndrome associated with cutaneous squamous cell carcinoma.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Atherosclerosis; Carcinoma, Squamous Cell; Carot | 2018 |
[A Case of Myocardial Metastasis of Esophageal Squamous Cell Carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2018 |
[Outcome of postoperative adjuvant chemotherapy and surgery alone for patients with stage pT1b-3N0M0 squamous cell carcinoma of the thoracic esophagus].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Es | 2018 |
A pediatric case of squamous cell cancer in situ in the setting of sclerodermatous graft-versus-host disease and voriconazole treatment.
Topics: Administration, Topical; Antifungal Agents; Bone Marrow Transplantation; Carcinoma, Squamous Cell; D | 2018 |
[Atypical Hemolitic Uremic Syndrome after administration of Docetaxel].
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineo | 2018 |
Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2018 |
Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; | 2018 |
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biom | 2018 |
Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort.
Topics: Adenocarcinoma; Aged; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Coh | 2018 |
Problematic End Points in a Trial of Topical Fluorouracil, 5%, for Chemoprevention of Keratinocyte Carcinoma.
Topics: Carcinoma, Squamous Cell; Chemoprevention; Fluorouracil; Humans; Keratinocytes | 2018 |
Problematic End Points in a Trial of Topical Fluorouracil, 5%, for Chemoprevention of Keratinocyte Carcinoma-Reply.
Topics: Carcinoma, Squamous Cell; Chemoprevention; Fluorouracil; Humans; Keratinocytes | 2018 |
In vitro FTIR microspectroscopy analysis of primary oral squamous carcinoma cells treated with cisplatin and 5-fluorouracil: a new spectroscopic approach for studying the drug-cell interaction.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Humans; Spectro | 2018 |
Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2018 |
Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; | 2018 |
Skin flap squamous cell carcinoma developed after urethroplasty.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; F | 2018 |
Building evidence-based treatment recommendations for advanced anal cancer: the time is now.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Epitopes; Fluorouracil; Humans; Neop | 2018 |
Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Topics: Abdominal Cavity; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; An | 2018 |
Low-dose hyperthermia enhances the antitumor effects of chemotherapy in squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; bcl-2-Ass | 2017 |
Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2018 |
Broccoli extract improves chemotherapeutic drug efficacy against head-neck squamous cell carcinomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line | 2018 |
Correlation between high FBXW7 expression in pretreatment biopsy specimens and good response to chemoradiation therapy in patients with locally advanced esophageal cancer: A retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cell Line, T | 2018 |
The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Mod | 2018 |
Extending far and wide: the role of biopsy and staging in the management of ocular surface squamous neoplasia.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Squamous Cell; Conjunctival Neoplasms; Corneal Disea | 2019 |
Glucocorticoids reduce chemotherapeutic effectiveness on OSCC cells via glucose-dependent mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Doxorubicin; Drug Inte | 2019 |
Real world survival data of a rare malignancy: Anal cancer results in HIV negative patients from Turkey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2018 |
Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamo | 2018 |
FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biom | 2019 |
Outcomes after up-front surgery and metronomic neoadjuvant chemotherapy with S-1 or UFT for early tongue squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 2019 |
Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: A National Cancer Data Base study.
Topics: Aged; Aged, 80 and over; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Databases, Fac | 2018 |
Experience in Intra-arterial Chemotherapy using Two Protocols for the Treatment of OSCC over Two Decades at the University Hospital Vienna.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2018 |
Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Chemoradiot | 2019 |
Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study.
Topics: Administration, Cutaneous; Aged; California; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Compar | 2019 |
Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia.
Topics: Administration, Ophthalmic; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic | 2019 |
Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2018 |
Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2019 |
Intralesional 5-Fluorouracil in the Treatment of Lower Leg Squamous Cell Carcinoma
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Squamous Cell; Female; Fluoro | 2018 |
Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells.
Topics: Animals; Autophagy; Biopsy; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemoradiotherapy; Drug Resi | 2019 |
High-dose versus standard-dose radiation therapy for cervical esophageal cancer: Retrospective single-institution study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2019 |
Intralesional 5-Fluorouracil for the Nonsurgical Management of Low-Risk, Invasive Squamous Cell Carcinoma.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Female; Fluorouracil; | 2020 |
Effect of 5-fluorouracil on cellular response to proton beam in esophageal cancer cell lines according to the position of spread-out Bragg peak.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Survival; Dose-Response Relationship | 2019 |
Effects of new keratinocyte carcinomas on skin-related quality of life: Results from the Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chemoprevention; C | 2019 |
[A Case of Advanced Esophageal Cancer Successfully Treated with Neoadjuvant Chemotherapy Containing 5-FU, Docetaxel. and Nedaplatin Combination Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2018 |
[Outcomes of Anal Squamous Cell Carcinoma Treated with Chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2018 |
Ten-year outcome of curative "exclusive" chemotherapy in N0M0 squamous cell carcinoma of the larynx and pharynx with complete clinical response.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2019 |
Aurora kinase A induces chemotherapy resistance through revival of dormant cells in laryngeal squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Aurora Kinase A; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell M | 2019 |
The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiothe | 2019 |
Dynamic changes in chemosensitivity immune predictors in patients with hypopharyngeal cancer treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CD4-Positive | 2019 |
Topical kinase inhibitors induce regression of cutaneous squamous cell carcinoma.
Topics: Administration, Topical; Animals; Carcinoma, Squamous Cell; Dasatinib; Fluorouracil; Humans; Imidazo | 2019 |
A novel miR-365-3p/EHF/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing β5-integrin/c-met signaling pathway.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Fluor | 2019 |
Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Squamous Cell; Case-Control Studies; | 2019 |
Circulating miRNA-1290 as a potential biomarker for response to chemoradiotherapy and prognosis of patients with advanced oral squamous cell carcinoma: A single-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Differentiation; C | 2019 |
Rapid resolution of squamous cell carcinoma with topical chemotherapy.
Topics: Administration, Topical; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Conjunctival Neoplas | 2019 |
Ipsilateral neck radiotherapy in N2b well-lateralized tonsil cancer - Approach with caution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2019 |
Successful Stenting Followed by Surgery for Perforated Esophageal Cancer Due to Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2019 |
Eruptive squamous atypia (also known as eruptive keratoacanthoma): Definition of the disease entity and successful management via intralesional 5-fluorouracil.
Topics: Adult; Biopsy, Needle; Carcinoma, Squamous Cell; Cohort Studies; Databases, Factual; Diagnosis, Diff | 2019 |
Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study.
Topics: Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamou | 2019 |
Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2019 |
Gastric mucosal injury and hemorrhage after definitive chemoradiotherapy for locally advanced esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2019 |
Hypovolemic shock after pelvic radiotherapy. A rare combination leading to a devastating complication.
Topics: Aged; Anaphylaxis; Anus Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Colon, Si | 2019 |
Reply to A. Adenis et al.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; | 2019 |
Definitive Chemoradiotherapy for Esophageal Squamous Cell Cancer: A Matter of Standard.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; | 2019 |
5-Aza-2-deoxycytidine Enhances the Sensitivity of 5-Fluorouracil by Demethylation of the Thymidine Phosphorylase Promoter.
Topics: Binding Sites; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methy | 2019 |
Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2019 |
Notch1 is a 5-fluorouracil resistant and poor survival marker in human esophagus squamous cell carcinomas.
Topics: Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Transformation, Vi | 2013 |
Radiotherapy alone or combined with chemotherapy for the treatment of squamous cell carcinoma of the base of the tongue.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2014 |
Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Dru | 2013 |
Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer: RECIST or histology?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2013 |
[A case of reversible encephalopathy syndrome caused by hyponatremia during neoadjuvant 5-FU+CDDP therapy for esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
[A case of squamous cell carcinoma of the esophagogastric junction with bulky no.7-metastatic node successfully treatedby chemoradiation followed by surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Chemoradiotherapy; | 2013 |
Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease.
Topics: Aged; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; | 2013 |
Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Endoscopic ultrasound in staging esophageal cancer after neoadjuvant chemotherapy--results of a multicenter cohort analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2013 |
Ring-enhancing lesion associated with radiation-induced liver disease.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2013 |
Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinosarcom | 2014 |
Stable gene-silence of Kif2a synergistic with 5-fluorouracil suppresses oral tongue squamous cell carcinoma growth in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Fluorouracil; | 2013 |
Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
The recurrence and survival of oral squamous cell carcinoma: a report of 275 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2013 |
Cisplatin plus capecitabine as first-line chemotherapy for recurrent or metastatic head and neck squamous cell cancer: experience outside of a trial setting.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine | 2013 |
REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; C | 2013 |
Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, West | 2013 |
Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2014 |
5% fluorouracil chemowraps in the management of widespread lower leg solar keratoses and squamous cell carcinoma.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Bandages; Carcinoma, Squamous Cell; Fluo | 2013 |
Clinical outcome and patterns of recurrence of head and neck squamous cell carcinoma with a limited field of postoperative radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Survival in patients treated with definitive chemo- radiotherapy for non-metastatic esophageal cancer in north- west iran.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2013 |
Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Topics: Antimetabolites; Antineoplastic Agents; beta Catenin; Carcinoma, Squamous Cell; Cell Line, Tumor; Do | 2013 |
Evaluation of p53 protein as a prognostic factor for oral cancer surgery.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined C | 2013 |
Long-term stimulation of areca nut components results in increased chemoresistance through elevated autophagic activity.
Topics: Actins; Adenine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Areca; Autophagy; Autophagy | 2014 |
Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, A | 2013 |
Immunochemoradiotherapy for patients with oral squamous cell carcinoma: augmentation of OK-432-induced helper T cell 1 response by 5-FU and X-ray irradiation.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cytokines; Dendritic Cells; Female; Fluoro | 2013 |
Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2013 |
Significance of GSTP1 for predicting the prognosis and chemotherapeutic efficacy in esophageal squamous cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemotherapy, Adj | 2013 |
Diffusion-weighted magnetic resonance imaging for predicting and detecting the early response to chemoradiotherapy of advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, A | 2013 |
Is neoadjuvant chemotherapy followed by radical surgery more effective than radiation therapy for stage IIB cervical cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2013 |
Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2014 |
Impact of postoperative chemoradiotherapy and chemoradiotherapy alone for esophageal cancer in North-West Iran.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Locally advanced squamous cell carcinoma of the head and neck: CT texture and histogram analysis allow independent prediction of overall survival in patients treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2013 |
Multimodal treatment strategy for clinical T3 thoracic esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case | 2013 |
The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Aggressive strategy for the treatment of synchronous metastatic anal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2013 |
ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Endonuclease | 2013 |
Key Opinion Leader (KOL) Consensus for actinic keratosis management in Italy: the AKTUAL Workshop.
Topics: Aminoquinolines; Carcinoma, Squamous Cell; Case Management; Clinical Trials as Topic; Cryosurgery; D | 2013 |
Stem cell-like side populations in esophageal cancer: a source of chemotherapy resistance and metastases.
Topics: Adenocarcinoma; Animals; Antimetabolites; Antineoplastic Agents; ATP Binding Cassette Transporter, S | 2014 |
Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2013 |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2013 |
The effectiveness of chemoradiation therapy and salvage surgery for hypopharyngeal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell L | 2013 |
Strategies for non-resectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2013 |
Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brachytherapy; Carcinoma, Squ | 2013 |
Ventricular fibrillation cardiac arrest due to 5-fluorouracil cardiotoxicity.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Coronary Angiography; Coronary Vasospasm; Defibrill | 2013 |
Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinom | 2013 |
Changes of oral microcirculation in chemotherapy patients: A possible correlation with mucositis?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fema | 2014 |
TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Advanced carcinoma of the cervix in a 17-year-old girl.
Topics: Adolescent; Antineoplastic Agents; Carcinoma, Squamous Cell; Cervix Uteri; Cisplatin; Fatal Outcome; | 2013 |
TNF-α -857C>T genotype is predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug-Related Side Effects and | 2013 |
p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, S | 2014 |
Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradio | 2014 |
Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Flow Cy | 2014 |
[Results of definitive radiotherapy for squamous cell carcinomas of the larynx patients with subglottic extension].
Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Antibodies, Monoclonal, Humanized; Antineoplasti | 2014 |
[Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in penile cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Dihydrouracil Dehydrogenase (NADP); Fluoro | 2013 |
A low Dicer expression is associated with resistance to 5-FU-based chemoradiotherapy and a shorter overall survival in patients with oral squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Carcinom | 2014 |
Sequential therapy of advanced buccal mucosa squamous cell carcinoma: three-year outcome.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2014 |
Cooperative inhibitory effect of sinomenine combined with 5-fluorouracil on esophageal carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Carc | 2013 |
Treatment of cancer in a child with ocular xeroderma pigmentosa (XP) in Malawi.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Child, Preschool; | 2014 |
Simultaneous thrombosis of superior mesenteric artery and superior mesenteric vein following chemotherapy: MDCT findings.
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil; | 2014 |
[A case of esophageal squamous cell carcinoma with submucosal tumor-like tumor due to direct invasion of the gastric wall].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; E | 2013 |
[Successful treatment of locally advanced squamous cell carcinoma of the esophagus by combination chemotherapy with 5-fluorouracil plus nedaplatin following tracheal stent tube placement-a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms | 2013 |
[A case of primary esophageal carcinoma treated with 5-fluorouracil plus cisplatin and curatively resected after complete response].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 2013 |
Intensity-modulated Radiation Therapy for Anal Cancer: Results From a Multi-Institutional Retrospective Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cape | 2016 |
High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Squam | 2013 |
Multimodal treatment for t1-2 supraglottic cancer: the impact of tumor location.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Sq | 2014 |
[Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ib2 to IVa squamous cell carcinoma of the uterine cervix].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2014 |
Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, | 2014 |
Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Adhesi | 2014 |
Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cadherins; Carcinoma, Squamous Cell; Cell Line, | 2014 |
Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Che | 2013 |
The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.
Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplati | 2016 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2014 |
A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; C | 2014 |
Results of age-dependent anal canal cancer treatment: a single centre retrospective study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Ne | 2014 |
Gemcitabine and Cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Topics: Aged; Asian People; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Esophageal Squamous C | 2014 |
Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2014 |
Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; | 2014 |
Basaloid squamous cell carcinoma: a rare tumor at the esophagogastric junction and an unexpected durable complete response to FOLFOX-4.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophagogastric Junc | 2014 |
High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2014 |
KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Axons; Carcinoma, Squamous Cell; Class I Phosphatidylin | 2014 |
Cationic membrane-active peptides - anticancer and antifungal activity as well as penetration into human skin.
Topics: Amphotericin B; Antifungal Agents; Antimicrobial Cationic Peptides; Antineoplastic Agents; Candida a | 2014 |
Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Primary squamous cell carcinoma of the most distal rectum: a dilemma in origin and management.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradioth | 2014 |
Patterns of recurrence after trimodality therapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Anastomotic Leak; Antineoplastic Agents; Antineoplastic Combined Chemot | 2014 |
Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2014 |
The usefulness of neoadjuvant chemoradiation therapy for locally advanced esophageal cancer with multiple lymph-node metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2014 |
[Neoadjuvant and adjuvant chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for advanced penile cancer: a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2014 |
The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2014 |
[Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Squamous Cell; Ci | 2014 |
Feasibility of cisplatin/5-fluorouracil and panitumumab in Japanese patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; C | 2014 |
Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biomarkers, Tumor; Carcinoma, Squamo | 2015 |
INF-γ sensitizes head and neck squamous cell carcinoma cells to chemotherapy-induced apoptosis and necroptosis through up-regulation of Egr-1.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Synerg | 2014 |
A pyriform sinus cancer organ preservation strategy comprising induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, followed by potentiated radiotherapy: a multicenter, retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2014 |
The novel HDAC inhibitor OBP-801/YM753 enhances the effects of 5-fluorouracil with radiation on esophageal squamous carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Growth Processes; Cel | 2014 |
Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Car | 2014 |
Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2015 |
Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2016 |
Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2014 |
Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2014 |
Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relatio | 2014 |
Cell-cycle distribution and Thymidilate Synthatase (TS) expression correlate with 5-FU resistance in head and neck carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Proli | 2014 |
Fibrohistiocytic tumors in a lung transplant patient taking oral capecitabine for nonmelanoma skin cancer chemoprevention.
Topics: Acitretin; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Sq | 2014 |
Definitive radiotherapy for early-stage hypopharyngeal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Su | 2015 |
[18F]fluoro-2-deoxyglucose-positron emission tomography for the assessment of histopathological response after preoperative chemoradiotherapy in advanced oral squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2015 |
Let's put an expiration date on the current approach to drug expiration dates.
Topics: Carcinoma, Squamous Cell; Fluorouracil; Humans; Male; Medication Therapy Management; Physician-Patie | 2014 |
Prediction of concurrent chemoradiotherapy outcome in advanced oropharyngeal cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Fluorouracil; Human Papillomavirus | 2014 |
Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2014 |
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2014 |
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopla | 2014 |
Sphere-forming-like cells (squamospheres) with cancer stem-like cell traits from VX2 rabbit buccal squamous cell carcinoma.
Topics: AC133 Antigen; Aldehyde Dehydrogenase 1 Family; Animals; Antigens, CD; Antineoplastic Agents; Carcin | 2014 |
Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU: more than 20 years' experience at a single institution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvan | 2014 |
Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2015 |
Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2014 |
Long non-coding RNA deregulation in tongue squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Female; Fluorouracil; Gene Expression Profili | 2014 |
Intraarterial chemotherapy as the first-line therapy in penile cancer.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; | 2014 |
SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Wester | 2014 |
Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2015 |
p38δ MAPK phenotype: an indicator of chemotherapeutic response in oesophageal squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cel | 2015 |
Novel resveratrol and 5-fluorouracil coencapsulated in PEGylated nanoliposomes improve chemotherapeutic efficacy of combination against head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response | 2014 |
[A case of esophageal squamous cell carcinoma with an adenocarcinoma component that dedifferentiated after chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell | 2014 |
Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2014 |
Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma?
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Esophag | 2014 |
Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Car | 2014 |
Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2014 |
Assessment of insulin-like growth factor 1 receptor as an oncogene in esophageal squamous cell carcinoma and its potential implication in chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; C | 2014 |
Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Ce | 2014 |
Tranexamic acid and fibrinogen restore clotting in vitro and in vivo in cardiac thrombus associated hyperfibrinolysis with overt bleedings.
Topics: Adenocarcinoma; Aged; Anemia; Antifibrinolytic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor | 2014 |
Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Doxorub | 2015 |
Clinical resolution of vemurafenib-induced squamous cell carcinoma with topical 5-fluorouracil.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamo | 2015 |
Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2015 |
Lymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2014 |
[Non-surgical combined modality treatments for laryngeal organ preservation in advanced hypopharyngeal carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2014 |
A pulse-dose topical 1% 5-fluorouracil treatment regimen in a young dog with corneal squamous cell carcinoma.
Topics: Administration, Ophthalmic; Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Corn | 2015 |
ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, | 2015 |
Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Cisplatin; Drug Resist | 2015 |
Combination of SNX-2112 with 5-FU exhibits antagonistic effect in esophageal cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Drug Antagonism | 2015 |
The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): treatment outcome in a single institution cohort.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplati | 2015 |
Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival | 2015 |
Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity.
Topics: Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; DNA Methylation; Drug Resi | 2015 |
MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor | 2014 |
The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carb | 2014 |
Conjunctival squamous cell neoplasia: the Liverpool Ocular Oncology Centre experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Brachytherapy; Carcinoma in Situ; C | 2015 |
Radio(chemo)therapy for locally advanced squamous cell carcinoma of the esophagus: long-term outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2015 |
Radiochemotherapy for esophageal squamous cell carcinoma in elderly patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2014 |
Enhanced anticancer activity of a protein phosphatase 2A inhibitor on chemotherapy and radiation in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Bridged Bicyclo Compound | 2015 |
Salvage surgery after local recurrence in patients with head and neck carcinoma treated with chemoradiotherapy or bioradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Osteopontin-integrin α(v)β(3) axis is crucial for 5-fluorouracil resistance in oral squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Animals; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Fluor | 2015 |
Role of induction chemotherapy for N3 head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2015 |
Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Capecitabine | 2015 |
Association between radiation dose and pathological complete response after preoperative radiochemotherapy in esophageal squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2015 |
A case of metachronous development of esophageal squamous cell carcinoma in the patient with esophageal carcinosarcoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Carcinosarcoma; Cisplatin; Drug Therapy, Combinatio | 2014 |
Local control may be the key in improving treatment outcomes of esophageal squamous cell carcinoma undergoing concurrent chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2014 |
Treatment of invasive squamous cell carcinomas in an open Clagett window.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Debride | 2015 |
MiR-145 expression accelerates esophageal adenocarcinoma progression by enhancing cell invasion and anoikis resistance.
Topics: Adenocarcinoma; Anoikis; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cell Proliferati | 2014 |
Field cancerization: from molecular basis to selective field-directed management of actinic keratosis.
Topics: Administration, Topical; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Ag | 2015 |
[Recurrence sites following definitive intensity-modulated conformational radiotherapy of squamous-cell carcinomas of the upper aerodigestive tract].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Concurrent radiotherapy and weekly chemotherapy of 5-fluorouracil and platinum agents for postoperative locoregional recurrence of oesophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Administration | 2015 |
Fast-growing cutaneous squamous cell carcinoma in a patient treated with vismodegib.
Topics: Aged, 80 and over; Anilides; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Basa | 2015 |
The tumour stromal features are associated with resistance to 5-FU-based chemoradiotherapy and a poor prognosis in patients with oral squamous cell carcinoma.
Topics: Actins; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Car | 2015 |
Perfusion computed tomography in predicting treatment response of advanced esophageal squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Treatment of superficial basal cell carcinoma and squamous cell carcinoma in situ on the trunk and extremities with ablative fractional laser-assisted delivery of topical fluorouracil.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, | 2015 |
Id3 induces an Elk-1-caspase-8-dependent apoptotic pathway in squamous carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Caspase 8; Caspase Inhibitors; | 2015 |
Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemother | 2015 |
EGR1 regulates radiation-induced apoptosis in head and neck squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regula | 2015 |
Semi-radical chemoradiotherapy for 53 esophageal squamous cell carcinomas with supraclavicular lymph node metastasis in a single institutional retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; D | 2014 |
Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 2015 |
Dormancy activation mechanism of oral cavity cancer stem cells.
Topics: Base Sequence; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell T | 2015 |
Management for squamous cell carcinoma of the nasal cavity and ethmoid sinus: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2015 |
Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcin | 2015 |
Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2015 |
[Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2015 |
Review of anal cancer patients at the Ottawa hospital.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 2015 |
Long-term results of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer (T1bN0M0).
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherap | 2015 |
Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinom | 2015 |
Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2015 |
Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; C | 2015 |
Age most significant predictor of requiring enteral feeding in head-and-neck cancer patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2015 |
Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
Topics: Adult; Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2016 |
Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell | 2016 |
Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma | 2015 |
Induction Chemotherapy Using FAP for Patients with Stage II/III Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2015 |
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carb | 2015 |
Lactate dehydrogenase B is associated with the response to neoadjuvant chemotherapy in oral squamous cell carcinoma.
Topics: Aged; Apoptosis; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Combinations; Drug Resistance, | 2015 |
Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 2016 |
Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2015 |
Retrospective Analysis of Concurrent Chemoradiation with Triweekly Cisplatin plus 5-Fluorouracil Versus Weekly Cisplatin in Cervical Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Analysis on clinical characteristics and influencing factors of patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2015 |
Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Dise | 2016 |
Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2015 |
Squamous Cell Carcinoma of the Head and Neck: Comparison of Diffusion-weighted MRI at b-values of 1,000 and 2,000 s/mm(2) to Predict Response to Induction Chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2015 |
Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Reconsideration of postoperative concurrent chemoradiotherapy with fluorouracil and cisplatin for uterine cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; | 2015 |
Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
[Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2015 |
Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control | 2015 |
Olfaction in chemotherapy for head and neck malignancies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbopl | 2016 |
French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2015 |
Evaluation of a 36 Gy elective node irradiation dose in anal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2015 |
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Baculoviral IAP Rep | 2015 |
Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Lin | 2015 |
Salvage pharyngolaryngectomy with total esophagectomy following definitive chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2016 |
A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings.
Topics: Adult; Aged; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Co | 2016 |
Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2015 |
Self-Assembling Monomeric Nucleoside Molecular Nanoparticles Loaded with 5-FU Enhancing Therapeutic Efficacy against Oral Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prolifera | 2015 |
Low-dose all-trans retinoic acid enhances cytotoxicity of cisplatin and 5-fluorouracil on CD44(+) cancer stem cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cel | 2015 |
Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Australia; Carcinoma, S | 2015 |
The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Nutritional status and feeding-tube placement in patients with locally advanced hypopharyngeal cancer included in an induction chemotherapy-based larynx preservation program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2016 |
Autophagy in human skin squamous cell carcinoma: Inhibition by 3-MA enhances the effect of 5-FU-induced chemotherapy sensitivity.
Topics: Adenine; Apoptosis; Autophagy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proli | 2015 |
Clinical Study on Lobaplatin Combined with 5-Fu and Concurrent Radiotherapy in Treating Patients with Inoperable Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamous Cell | 2015 |
Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Cyclin- | 2015 |
Fractionated CO₂Laser-Assisted Delivery of Topical 5-Fluorouracil as a Useful Modality for Treating Field Cutaneous Squamous Cell Carcinomas.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; | 2015 |
Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Computer Graphics; De | 2015 |
Serum Transforming Growth Factor-β1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compoun | 2015 |
Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance.
Topics: Binding, Competitive; Carcinoma, Squamous Cell; Cdc20 Proteins; Cell Line, Tumor; Cell Proliferation | 2016 |
Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2015 |
Combinatorial Effects of Curcumin with an Anti-Neoplastic Agent on Head and Neck Squamous Cell Carcinoma Through the Regulation of EGFR-ERK1/2 and Apoptotic Signaling Pathways.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamou | 2016 |
Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Wester | 2016 |
Prognostic Relevance of HPV Infection and p16 Overexpression in Squamous Cell Anal Cancer.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Anus | 2015 |
Oxygen carrier YQ23 can enhance the chemotherapeutic drug responses of chemoresistant esophageal tumor xenografts.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cisplatin | 2015 |
STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
Topics: Aminosalicylic Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Ca | 2015 |
Role of AMPK signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2016 |
[Results of complex treatment of patients with squamous cell carcinoma of the anal canal using advanced radiotherapy technologies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2015 |
Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2016 |
Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2016 |
Skin tumor development after UV irradiation and photodynamic therapy is unaffected by short-term pretreatment with 5-fluorouracil, imiquimod and calcipotriol. An experimental hairless mouse study.
Topics: Aminolevulinic Acid; Aminoquinolines; Animals; Calcitriol; Carcinoma, Squamous Cell; Female; Fluorou | 2016 |
Sequential Curettage, 5-Fluorouracil, and Photodynamic Therapy for Field Cancerization of the Scalp and Face in Solid Organ Transplant Recipients.
Topics: Antimetabolites, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; Combined Modality Ther | 2016 |
Comparative evaluation of PLGA nanoparticle delivery system for 5-fluorouracil and curcumin on squamous cell carcinoma.
Topics: Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug | 2016 |
Changes in Total Lesion Glycolysis Evaluated by Repeated F-18 FDG PET/CT as Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Preoperative Chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell | 2016 |
Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Car | 2016 |
Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control Studies; Cisp | 2017 |
[A Case of Solitary Brain Metastasis from Stage 0 Esophageal Carcinoma after Neoadjuvant Chemotherapy Followed by Surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Cell; Cisplatin | 2015 |
Pre-treatment neutrophil to lymphocyte ratio predicts the chemoradiotherapy outcome and survival in patients with oral squamous cell carcinoma: a retrospective study.
Topics: Adult; Aged; C-Reactive Protein; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Fluorourac | 2016 |
A Digital Squamous Cell Carcinoma Mimicking a Diabetic Foot Ulcer, With Early Inguinal Metastasis and Cancer-Related Lymphedema.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; | 2016 |
Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
[Squamous cell carcinoma of the anal canal treated with chemoradiotherapy in a patient with HIV].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Che | 2016 |
DESC1, a novel tumor suppressor, sensitizes cells to apoptosis by downregulating the EGFR/AKT pathway in esophageal squamous cell carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Dow | 2016 |
Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2016 |
[Treatment results for different categories of vaginal intraepithelial neoplasia with electrocoagulation, 5-fluorouracil and combined treatment].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma in Situ; Carcinoma, Squam | 2015 |
Neoadjuvant chemotherapy for invasive squamous cell carcinoma of the conjunctiva: A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Conjunct | 2015 |
Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2016 |
Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Second-Line Modified FOLFOX6 Regimen in The Patients with Metastatic Esophagus Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 2015 |
Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Admin | 2017 |
Concurrent chemoradiotherapy with capecitabine/cisplatin versus 5-fluorouracil/cisplatin in resectable laryngohypopharyngeal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemor | 2016 |
Identification of a predictive factor for distant metastasis in esophageal squamous cell carcinoma after definitive chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2016 |
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2016 |
Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2016 |
Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2017 |
Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Areca; Biomarkers, Tumor; Carcinoma, Sq | 2016 |
Topical 5-Fluorouracil 1% as Primary Treatment for Ocular Surface Squamous Neoplasia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Conjuncti | 2016 |
Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2017 |
Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Fe | 2016 |
Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma After Regional Lymphadenectomy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 2016 |
Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review.
Topics: Ablation Techniques; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2016 |
Clinical Outcomes in Patients with Recurrent or Metastatic Human Papilloma Virus-positive Head and Neck Cancer.
Topics: Bridged-Ring Compounds; Carcinoma, Squamous Cell; Disease-Free Survival; Fluorouracil; Follow-Up Stu | 2016 |
Concomitant External-beam Irradiation and Chemotherapy Followed by High-dose Rate Brachytherapy Boost in the Treatment of Squamous Cell Carcinoma of the Vagina: A Single-Center Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brachytherapy; Carboplatin; Carcinoma, Squamo | 2016 |
Induction chemotherapy before surgery for unresectable head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuxi | 2016 |
Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2016 |
Clinical management of squamous cell carcinoma associated with sinonasal inverted papilloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemor | 2017 |
Integrin αvβ3 expression in tongue squamous carcinoma cells Cal27 confers anticancer drug resistance through loss of pSrc(Y418).
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cisplatin; Dasatin | 2016 |
NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2016 |
Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2016 |
Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuxima | 2016 |
Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marr | 2016 |
Importance of Chemotherapy and Radiation Dose After Microscopically Incomplete Resection of Stage III/IV Head and Neck Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2016 |
Prognostic Factors After Definitive Radio(Chemo)Therapy of Locally Advanced Head and Neck Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
Rapid Extracorporeal Membrane Oxygenation Overcomes Fulminant Myocarditis Induced by 5‑Fluorouracil.
Topics: Acute Disease; Anus Neoplasms; Carcinoma, Squamous Cell; Coronary Angiography; Electrocardiography; | 2016 |
Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, S | 2017 |
Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasm | 2016 |
Metformin in combination with 5-fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinoma.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Dru | 2016 |
[A Case of Squamous Cell Carcinoma of the Esophagus with Achalasia -- Conversion from Chemoradiotherapy to Surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2016 |
Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Fluorouracil; Humans; | 2017 |
Dynamic changes in immune cell profile in head and neck squamous cell carcinoma: Immunomodulatory effects of chemotherapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; CD8-Positive T-Lymphocytes; Cisplatin; Docetaxel; | 2016 |
A comparative study of the effectiveness of cisplatin and 5-fluorouracil on cutaneous squamous human carcinoma cell line: Potential chemotherapy alternative to surgery.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cisplat | 2016 |
Treatment: Outcome and Toxicity of Volumetric Modulated Arc Therapy in Oropharyngeal Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2016 |
Ablative Fractional Laser-Assisted Topical Fluorouracil for the Treatment of Superficial Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ: A Follow-Up Study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinom | 2016 |
MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; C | 2016 |
The Expression of Checkpoint and DNA Repair Genes in Head and Neck Cancer as Possible Predictive Factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2016 |
Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Caspase 8; | 2016 |
Synergistic effect of honokiol and 5-fluorouracil on apoptosis of oral squamous cell carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Carcinoma, S | 2017 |
Fluorouracil-Induced Reactive Follicular Squamous Cell Carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Facial Neoplasms; Fluorouracil; For | 2016 |
[Clinical analysis of multimodal treatment for orbital organ preservation in T4b squamous cell carcinoma of nasal cavity and paranasal sinuses].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2016 |
[A preliminary analysis on potentially targeted genes of induced chemotherapy in supraglottic laryngeal squamous cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Down-Regulation | 2016 |
ypN0: Does It Matter How You Get There? Nodal Downstaging in Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2016 |
Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2016 |
miRNA-24-3p promotes cell proliferation and regulates chemosensitivity in head and neck squamous cell carcinoma by targeting CHD5.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2016 |
Adult T-cell leukemia/lymphoma in patients with head and neck cancer after S-1 chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2017 |
Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline.
Topics: 3' Untranslated Regions; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Arecoline; | 2016 |
Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Esophageal | 2016 |
β-Carotene synergistically enhances the anti-tumor effect of 5-fluorouracil on esophageal squamous cell carcinoma in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; beta Carotene; Carcinoma, Squamous Cell; Cell Line, Tumor | 2016 |
The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Carcinoma, | 2017 |
Celecoxib enhances the inhibitory effect of 5-FU on human squamous cell carcinoma proliferation by ROS production.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Celeco | 2017 |
Exclusive concurrent radiochemotherapy for advanced head and neck cancers with 'fractionated' 5-fluorouracil and cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Successful Delivery in a 39-Year-Old Patient with Anal Cancer after Fertility-Preserving Surgery Followed by Primary Chemoradiation and Low Anti-Mullerian Hormone Level.
Topics: Adult; Anti-Mullerian Hormone; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carci | 2016 |
Clinical and Histologic Predictive Factors of Response to Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies | 2016 |
Radiation field size and dose determine oncologic outcome in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2016 |
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma, | 2016 |
Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease Pro | 2016 |
Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway.
Topics: Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Syne | 2016 |
Topical 1% 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamo | 2017 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2017 |
Target volume delineation for radical radiotherapy of early oesophageal carcinoma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squam | 2017 |
A prospective study of nutritional supplementation for preventing oral mucositis in cancer patients receiving chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Esophageal Neoplasms; Fe | 2017 |
Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cet | 2017 |
Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Marrow; | 2017 |
Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2017 |
Immunosuppression as a Possible Risk Factor for Interferon Nonresponse in Ocular Surface Squamous Neoplasia.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Conjunctiv | 2017 |
[Preoperative Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2016 |
[CR of All Target Lesions in a Patient with Metastatic Esophageal Cancer and Generalized Weakness Treated with Systemic Chemotherapy after Nutritional Support].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2016 |
[Long-Term Complete Response in Postoperative Multiple Lung and Mediastinal Lymph Node Metastases of Esophageal Cancer Using Systemic Chemotherapy with DCF Treatment - A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esop | 2017 |
Continuous infusion of a large dose of CF (folinic acid) and 5-FU combined with CDDP in the treatment of advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Di | 2017 |
Effect of Intensity Modulated Radiation Therapy With Concurrent Chemotherapy on Survival for Patients With Cervical Esophageal Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined | 2017 |
Matrix stiffness regulates the proliferation, stemness and chemoresistance of laryngeal squamous cancer cells.
Topics: Acrylic Resins; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Mem | 2017 |
Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2008 |
Squamous cell carcinoma antigen in patients with locally advanced cervical carcinoma undergoing preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Pre-treatment haemoglobin level predicts response and survival after TPF induction polychemotherapy in advanced head and neck cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemo | 2008 |
Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
[Curcumin promotes apoptosis of esophageal squamous carcinoma cell lines through inhibition of NF-kappaB signaling pathway].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Curcumin; Eso | 2008 |
Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Dihydrour | 2009 |
Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Stud | 2008 |
VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2008 |
Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fl | 2009 |
Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2008 |
Chemowraps as an adjuvant to surgery for patients with diffuse squamous cell carcinoma of the extremities.
Topics: Administration, Cutaneous; Aged; Antineoplastic Agents; Bandages; Carcinoma, Squamous Cell; Chemothe | 2008 |
Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcium-Binding Proteins; C | 2008 |
[Two cases of radiation-induced sarcoma after radiation therapy in nasopharyngeal carcinoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2008 |
Chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Hypoxia; Cell L | 2009 |
Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2009 |
Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; E | 2008 |
[Case of urachal cancer treated by neoadjuvant chemotherapy with FOLFOX4 (oxaliplatin, 5-FU and leukovolin)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluorouracil; Huma | 2008 |
Zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Benzoquin | 2009 |
Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cis | 2009 |
Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2008 |
[Successful treatment with 5-fluorouracil and cis-dichlorodiammineplatinum combined with 60Gy of radiation in a case of advanced esophageal cancer complicated with chronic renal failure treated with hemodialysis].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2008 |
Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Coh | 2009 |
[Two cases of squamous cell carcinoma of upper urinary tract with hypercalcemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2008 |
[Diagnosis and treatment of basaloid squamous cell carcinoma of the esophagus].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Basosquamous; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality T | 2009 |
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Dihydrouracil Dehyd | 2009 |
Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Proliferation; Fluorouracil; Head an | 2009 |
REG I enhances chemo- and radiosensitivity in squamous cell esophageal cancer cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Dos | 2008 |
Chemotherapy-induced takotsubo cardiomyopathy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; An | 2008 |
A new neoadjuvant chemotherapy regimen for penile cancer with nodal metastases: a step forward.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2009 |
Cetuximab in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion.
Topics: Apoptosis; Basigin; Carcinoma, Squamous Cell; Cell Line, Tumor; Down-Regulation; Drug Resistance, Mu | 2009 |
The efficacy and safety of concurrent chemoradiotherapy for maxillary sinus squamous cell carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2009 |
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Topics: Animals; Biomarkers, Tumor; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Dihydrouracil Deh | 2009 |
[Comparison of effectiveness between intra-arterial and intra-venous neoadjuvant chemotherapy in stage Ib2-IIb cervical carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2008 |
Metastatic squamous cell carcinoma of the buttock treated with chemoradiation using cisplatin and 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Buttocks; Carcinoma, Squamous Cell; Cisplatin; Combined Modal | 2009 |
[Clinical effects of concurrent chemoradiotherapy (hyperfractionation and cisplatin/5-fluorouracil) for patients with advanced oral squamous cell carcinoma].
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2009 |
Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2009 |
Searching for less toxic larynx preservation: a need for common definitions and metrics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2009 |
Efficacy of chemoradiotherapy with low-dose cisplatin and continuous infusion of 5-fluorouracil for unresectable squamous cell carcinoma of the esophagus.
Topics: Aged; Antimetabolites, Antineoplastic; C-Reactive Protein; Carcinoma, Squamous Cell; Cisplatin; Esop | 2009 |
Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2009 |
Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2009 |
Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxyc | 2009 |
High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carc | 2009 |
Anal cancer chemoirradiation with curative intent - a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2009 |
Squamous cell carcinoma arising in an ovarian mature cystic teratoma: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2009 |
Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Car | 2009 |
High orotate phosphoribosyltransferase gene expression predicts complete response to chemoradiotherapy in patients with squamous cell carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2009 |
Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2009 |
Neoadjuvant chemotherapy followed by limited surgery in a mouse model of head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Diseas | 2009 |
Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2009 |
Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemother | 2010 |
Retrospective review of surgery and definitive chemoradiotherapy in patients with squamous cell carcinoma of the thoracic esophagus aged 75 years or older.
Topics: Aged; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil | 2009 |
Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biomarkers, Tumor; Carci | 2010 |
Management of squamous cell carcinoma of the base of tongue with chemoradiation and brachytherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brachytherapy; Carboplatin; Carcinoma, Squamo | 2009 |
Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined | 2010 |
High-dose rate brachytherapy using inverse planning simulated annealing for locoregionally advanced cervical cancer: a clinical report with 2-year follow-up.
Topics: Adenocarcinoma; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Female; F | 2009 |
Gene expression changes in a chemoresistant model with human esophageal cancer xenografts using cDNA microarray.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell | 2009 |
Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous | 2009 |
Concurrent chemoradiation with carboplatin-5-fluorouracil versus cisplatin in locally advanced oropharyngeal cancers: is more always better?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2010 |
Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2009 |
Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin | 2009 |
Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplat | 2009 |
Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2009 |
Treatment options in metastatic squamous cell carcinoma of the anal canal.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carboplatin; | 2008 |
HIV and anal cancer outcomes: a single institution's experience.
Topics: Antineoplastic Agents; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvan | 2009 |
Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cartilage; Ci | 2009 |
Chemoradiation in advanced vulval carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2009 |
Cutaneous human papillomavirus in head and neck squamous cell carcinomas.
Topics: Aged; Alcohol Drinking; Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Carbopl | 2009 |
Preoperative radiochemotherapy in the treatment of advanced oral cancer: outcome of 276 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cohort Studie | 2009 |
Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Female; | 2009 |
Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2009 |
Therapeutic effect of topical 5-fluorouracil in conjunctival squamous carcinoma is associated with changes in matrix metalloproteinases and tissue inhibitor of metalloproteinases expression.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma in Situ | 2009 |
[A case of the oldest old patient with advanced esophageal cancer responding completely to the combination chemotherapy of docetaxel/5-fluorouracil/nedaplatin with radiation].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined C | 2009 |
[Clinical analysis of 22 cases of esophageal adenosquamous carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Adenosquamou | 2009 |
Sustained complete response following combined nedaplatin+ adriamycin+5-fluorouracil therapy in a patient with superficial esophageal cancer -case report-.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2009 |
Evaluation of spatially fractionated radiotherapy (GRID) and definitive chemoradiotherapy with curative intent for locally advanced squamous cell carcinoma of the head and neck: initial response rates and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2010 |
The effect of neoadjuvant therapy on the 5-fluorouracil metabolic and relative enzymes of oral squamous cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2009 |
Radiation-induced osteonecrosis of the hips following genital-preserving surgery and chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arthroplasty, Replacement, Hip; Carcinoma, Squ | 2009 |
Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2009 |
Quantitative analysis of survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer.
Topics: Actins; Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Squamous Cell | 2009 |
Influence of irradiated lung volumes on perioperative morbidity and mortality in patients after neoadjuvant radiochemotherapy for esophageal cancer.
Topics: Acute Lung Injury; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplat | 2010 |
Primary treatment of verrucous carcinoma of the penis with fluorouracil, cis-diamino-dichloro-platinum, and radiation therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Verrucous | 2009 |
Radiotherapy and concomitant intra-arterial docetaxel combined with systemic 5-fluorouracil and cisplatin for oropharyngeal cancer: a preliminary report--improvement of locoregional control of oropharyngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2009 |
Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2009 |
[Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Cisplatin; Cli | 2009 |
[Chemotherapy with MTX, 5-FU and CDGP for treatment of newly diagnosed head and neck cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2009 |
Case series of multiple recurrent reactive keratoacanthomas developing at surgical margins.
Topics: Acitretin; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorou | 2009 |
Anal cancer: one step forward--two steps sideways!
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Clinical T | 2009 |
A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2009 |
Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Circadian Rhythm; Ci | 2009 |
Concurrent chemoradiotherapy with helical tomotherapy for oropharyngeal cancer: a preliminary result.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2010 |
p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2010 |
Gallbladder squamous cell carcinoma in the setting of low-dose methotrexate use.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cholecystectomy, Lap | 2009 |
Selective versus comprehensive neck dissection after chemoradiation for advanced oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; C | 2009 |
p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doxorubic | 2010 |
[Feasibility and short-term efficacy of simplified intensity-modulated radiotherapy and concurrent chemotherapy for neck and upper thoracic esophageal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchitis; Carcinoma, Squamous Cell; Cisplati | 2009 |
Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassett | 2010 |
Chemoradiotherapy in the management of primary squamous-cell carcinoma of the rectum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2011 |
[A case of aggressive primary squamous cell carcinoma of the breast refractory to preoperative neoadjuvant chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2009 |
EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Carcinoma, S | 2010 |
[Concurrent chemoradiotherapy with nedaplatin and 5-fluorouracil (5-fu) for locally advanced squamous cell carcinoma of the esophagus].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2009 |
[A case of a 14-month survival patient on advanced esophageal cancer with uncontrolled brain metastasis completely responding to nedaplatin, adriamycin, plus 5-FU (NAF) therapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2009 |
Functional p53 status as a biomarker for chemotherapy response in oral-cavity cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoth | 2010 |
Case report of long term survivor of metastatic cloacogenic carcinoma of the anal canal with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemothera | 2007 |
Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Che | 2010 |
A case of esophageal cancer with multiple lymph node metastases which responded to neoadjuvant chemotherapy (DCF therapy).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2010 |
[Histological complete response in a case of primary squamous cell carcinoma of the stomach treated by chemotherapy with docetaxel and cisplatin plus 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; C | 2010 |
5-Fluorouracil buccal tablets for locoregional chemotherapy of oral squamous cell carcinoma: formulation, drug release and histological effects on reconstituted human oral epithelium and porcine buccal mucosa.
Topics: Administration, Buccal; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cel | 2010 |
Radiotherapy with or without concurrent chemotherapy for lymph node recurrence after radical surgery of thoracic esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; C | 2010 |
Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Role of concurrent chemoradiation in laryngeal preservation for supraglottic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2010 |
Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2010 |
Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Cell Line | 2010 |
Pre- and post-therapy nodal status equally affects survival of patients with oesophageal squamous cell carcinoma receiving preoperative chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
[Concurrent chemoradiotherapy for resectable locoregionally advanced squamous cell carcinoma of the head and neck-analysis of factors associated with toxicity and efficacy].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2010 |
Successful treatment of esophageal squamous cell carcinoma in a patient with Fanconi anemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Carcinom | 2010 |
[Drug eruption (erythema multiforme type) following chemoradiotherapy with mitomycin C and 5-fluorouracil administration for squamous cell carcinoma of the anal canal].
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modal | 2010 |
Anal cancer with cerebral metastasis: a case report.
Topics: Antineoplastic Agents; Anus Neoplasms; Brain Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Comb | 2011 |
Chemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2010 |
Predictors of sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarker | 2010 |
Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2010 |
Sporotrichoid metastases to the skin from cutaneous squamous cell carcinoma in an immunocompetent patient.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arm; Carcin | 2010 |
Current management of actinic keratoses.
Topics: Administration, Cutaneous; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic | 2010 |
Enteral feeding during chemoradiotherapy for advanced head-and-neck cancer: a single-institution experience using a reactive approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squa | 2011 |
High-dose chemoradiotherapy followed by surgery versus surgery alone in esophageal cancer: a retrospective cohort study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2010 |
Chemoradiation for esophageal cancer: institutional experience with three different regimens.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2011 |
Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2010 |
Prognostic significance of age in the radical treatment of oesophageal cancer with surgery or chemoradiotherapy: a prospective observational cohort study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2010 |
Antitumor effects of guanosine-analog phosphonates identified by molecular modelling.
Topics: Adenine; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Fluorouracil; HT29 Cells | 2010 |
Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2011 |
TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2010 |
Effects of lentinan alone and in combination with fluoropyrimidine anticancer agent on growth of human oral squamous cell carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2010 |
Case-based considerations in the treatment of actinic keratoses: utilizing combination or sequential therapy with 5-fluorouracil cream and destructive treatments.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Basal Cell; Carcinoma, Squamous | 2010 |
Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, S | 2011 |
Combinatory cytotoxic effects produced by E1B-55kDa-deleted adenoviruses and chemotherapeutic agents are dependent on the agents in esophageal carcinoma.
Topics: Adenoviridae; Adenovirus E1B Proteins; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cel | 2010 |
Agreement on the clinical diagnosis and management of cutaneous squamous neoplasms.
Topics: Algorithms; Aminoquinolines; Biopsy; Carcinoma in Situ; Carcinoma, Squamous Cell; Cryosurgery; Curet | 2010 |
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcin
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2010 |
High-dose preoperative chemoradiotherapy in esophageal cancer patients does not increase postoperative pulmonary complications: correlation with dose-volume histogram parameters.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Di | 2010 |
Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous | 2011 |
Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cros | 2010 |
Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Dose Fract | 2011 |
Matched survival analysis in patients with locoregionally advanced resectable oropharyngeal carcinoma: platinum-based induction and concurrent chemoradiotherapy versus primary surgical resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2011 |
Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Carcinoma, Squamous Cell; C | 2010 |
Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; C | 2010 |
Induction chemotherapy with TPF (Docetaxel, Carboplatin and Fluorouracil) in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplat | 2010 |
Squamous cell carcinoma of the anal margin: the university of Florida experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2010 |
Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3-4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2011 |
[Clinical value of the comprehensive treatment in intermediate and advanced cervical cancer with uterine arterial interventional chemoembolization and radiotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2010 |
Thymidylate synthase expression as a predictor of clinical response to 5-fluorouracil-based chemoradiotherapy in patients with maxillary sinus squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2011 |
Analysis of 5-fluorouracil-related enzymes in pulmonary neuroendocrine carcinoma: differences in biological properties compared to epithelial carcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Neuroendocr | 2010 |
Outcomes from chemoradiotherapy for patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
[Four resected cases with basaloid carcinoma of esophagus--comparison of 5-FU-related enzymes (thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT)) between basaloid carcinoma and squamous cell carcin
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dihydrouraci | 2010 |
Submucosal tumor appearance is a useful endoscopic predictor of early primary-site recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Early Detection of Canc | 2011 |
Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squam | 2012 |
[Promoting effect of all-trans retinoic acid on the chemosensitivity of esophageal cancer EC9706 cells].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cy | 2010 |
[Docetaxel as a component in the combined therapy of locally advanced squamous cell carcinoma of the glottis and oral cavity].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2010 |
[Three cases of radiotherapy combined with S-1 and mitomycin C for anal canal squamous cell carcinomas].
Topics: Administration, Oral; Aged; Anal Canal; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic | 2010 |
Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas.
Topics: Animals; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Female; Flow Cyt | 2011 |
TS gene tandem repeats in esophageal cancer patients receiving chemoradiotherapy.
Topics: Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; | 2011 |
Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmaco | 2011 |
Defining cure for esophageal cancer: analysis of actual 5-year survivors following esophagectomy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2011 |
Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell | 2011 |
[Successfully treated case of hypopharyngeal and cervical esophageal squamous cell carcinoma with laryngeal preservation].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2010 |
[ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2010 |
[Four cases of anal squamous cell carcinoma treated by chemoradiotherapy].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2010 |
[A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2010 |
Oral candidiasis mimicking tongue cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Candidiasis, Oral; | 2011 |
Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Squam | 2012 |
Is neoadjuvant chemotherapy prior to radio-chemotherapy beneficial in T4 anal carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2011 |
Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Su | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Functional organ preservation after chemoradiotherapy in elderly patients with loco-regionally advanced head and neck squamous cell carcinoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2011 |
Functional organ preservation in patients with locoregionally advanced head and neck squamous cell carcinoma treated by platinum-based multidrug induction chemotherapy and concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2011 |
Simultaneous integrated boost using intensity-modulated radiotherapy compared with conventional radiotherapy in patients treated with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2012 |
Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Pro | 2011 |
Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2011 |
Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; | 2011 |
[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplat | 2010 |
The role of computed tomography in the management of the neck after chemoradiotherapy in patients with head-and-neck cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Decision | 2012 |
Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Squamous Cell; | 2011 |
Head and neck cancer stem cells: the side population.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; | 2011 |
Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
[A case of multiple para-aortic lymph node metastases from squamous cell carcinoma of an unknown primary responding completely to chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Carcinoma, Squamous Cell; Cisplatin; Drug Com | 2011 |
Low-dose preoperative chemoradiation therapy compared with surgery alone with or without postoperative radiotherapy in patients with head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2011 |
COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2011 |
Primary lung cancer surgery after curative chemoradiotherapy for esophageal cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2011 |
Honokiol: a promising small molecular weight natural agent for the growth inhibition of oral squamous cell carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds | 2011 |
VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Cycloox | 2011 |
Minimally invasive esophagectomy is safe and effective following neoadjuvant chemoradiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2011 |
Co-overexpression of Bag-1 and heat shock protein 70 in human epidermal squamous cell carcinoma: Bag-1-mediated resistance to 5-fluorouracil-induced apoptosis.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, | 2011 |
How does TPF improve survival over PF?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
How does TPF improve survival over PF?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Confounding Fac | 2011 |
Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB-IIB cervical carcinoma: a retrospective study of 288 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carcinoma, Sq | 2011 |
Role of preoperative chemotherapy in squamous cell carcinoma of esophagus in kashmir, a cancer belt - a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2011 |
Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2011 |
[A case of advanced esophageal cancer with multiple liver metastases accompanying poorly general conditions and serious liver dysfunctions, successfully treated using concurrent radiotherapy and chemotherapy with low-dose nedaplatin and 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2011 |
PGE₂ targets squamous cell carcinoma cell with the activated epidermal growth factor receptor family for survival against 5-fluorouracil through NR4A2 induction.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2011 |
Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Weight; | 2012 |
Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carci | 2012 |
Correlation between tumor-associated proteins and response to neoadjuvant treatment in patients with advanced squamous-cell esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Blotting, W | 2011 |
Inhibition of nuclear factor-κB activity by small interfering RNA in esophageal squamous cell carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prolife | 2011 |
Cervical nodal metastases of unresectable thoracic esophageal squamous cell carcinoma: characteristics of long-term survivors after concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Di | 2011 |
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2011 |
High p16 expression predicts a positive response to chemoradiotherapy in stage IVa/b head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brachytherapy; Carci | 2011 |
Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis.
Topics: Amputation, Surgical; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2011 |
Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2011 |
Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2011 |
[Radiotherapy for cutaneous cancers with xeroderma pigmentosum].
Topics: Adolescent; Adult; Age of Onset; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachyth | 2011 |
Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2011 |
Treatment of a giant squamous cell carcinoma on the dominant thumb with intralesional 5-fluorouracil.
Topics: Antineoplastic Agents; Biopsy, Needle; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; D | 2011 |
Endoscopic ultrasonography is useful for monitoring the tumor response of neoadjuvant chemoradiation therapy in esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2012 |
Linear correlation between patient survival and decreased percentage of tumor [(18)F]fluorodeoxyglucose uptake for late-course accelerated hyperfractionated radiotherapy for esophageal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; China; Dose Fractionation, R | 2012 |
Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2011 |
Chemotherapy-induced modification of microRNA expression in esophageal cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Esophageal Neoplasms; | 2011 |
Isolation and characterization of cancer stem-like side population cells in human oral cancer cells.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily G, | 2011 |
Stereotactic radiosurgery in combination with chemotherapy as primary treatment for head and neck cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2012 |
Combined chemotherapy with cisplatin, docetaxel and capecitabine for metastatic nasopharyngeal carcinoma: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma | 2011 |
The bacterial protein azurin enhances sensitivity of oral squamous carcinoma cells to anticancer drugs.
Topics: Antineoplastic Agents; Apoptosis; Azurin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin B1; Dru | 2011 |
Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, A | 2011 |
The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CD8-Positive T-Lymph | 2012 |
Nonsurgical management of esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Optimizing treatments of locally advanced squamous cell carcinoma: where to go from here?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2011 |
Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2011 |
[Analysis of the factors related to esophageal injuries in radiotherapy of esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2011 |
3rd congress of the International Academy of Oral Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidin | 2011 |
Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2011 |
Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; C | 2012 |
Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2012 |
Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2011 |
Metallic taste as a side effect of topical fluorouracil use.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous C | 2011 |
NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Carcinoma, Squamou | 2011 |
Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Sq | 2011 |
A microfluidic system for testing the responses of head and neck squamous cell carcinoma tissue biopsies to treatment with chemotherapy drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Carcinoma, Squamous Cell; Cell Pr | 2012 |
Comparison of the efficacy and toxicity of two dose levels of cisplatin/5-fluorouracil as the chemoradiotherapy regimen for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2011 |
Twenty-five-year experience with radical chemoradiation for anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2012 |
Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Squamous Cell; | 2012 |
Nucleostemin and TWIST as predictive markers for recurrence after neoadjuvant chemotherapy for esophageal carcinoma.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squam | 2012 |
Endobronchial metastases of anal canal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bronchial Neoplasms; Bronchopneumoni | 2012 |
Neoadjuvant chemotherapy prior to surgery in head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv | 2012 |
Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Chlorocebus aethiops; Cytosine Deaminase; ErbB | 2012 |
Synthesis and in vitro anti-tumor activity of novel HPMA copolymer-drug conjugates with potential cell surface targeting property for carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, T | 2012 |
Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cost-Benefit An | 2012 |
Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment.
Topics: Aged; Antibodies, Bispecific; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Prognostic factors in definitive radiochemotherapy of advanced inoperable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Che | 2012 |
A planned neck dissection is not necessary in all patients with N2-3 head-and-neck cancer after sequential chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
Low-dose-rate californium-252 neutron intracavitary afterloading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2012 |
Outcomes and toxicities for the treatment of stage IVB cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Com | 2012 |
A small interfering RNA targeting NF-κB p65 alone or combined with 5-FU inhibits growth of esophageal squamous cell carcinoma in nude mice.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; Dow | 2012 |
Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy.
Topics: Adult; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease Progressi | 2011 |
Evaluation of overall tumor cellularity after neoadjuvant chemotherapy in patient with locally advanced hypopharyngeal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2012 |
Solar cheilosis: an ominous precursor part II. Therapeutic perspectives.
Topics: Administration, Topical; Aminoquinolines; Biopsy; Carcinoma, Squamous Cell; Cheilitis; Combined Moda | 2012 |
Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2-IIB cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S | 2012 |
Impact of radiotherapy, chemotherapy and surgery in multimodal treatment of locally advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2011 |
Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell | 2012 |
Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cel | 2012 |
Overexpression of Cks1 increases the radiotherapy resistance of esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CDC2-CDC28 Kinases; | 2012 |
The clinical characteristic differences between thrombosis-related edema and lymphedema following radiotherapy or chemoradiotherapy for patients with cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2012 |
Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2012 |
Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients.
Topics: Aged; Anus Neoplasms; Cadherins; Carcinoma, Squamous Cell; Combined Modality Therapy; Desmocollins; | 2012 |
Prognostic factors in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiation therapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esop | 2013 |
Radiochemotherapy induces a favourable tumour infiltrating inflammatory cell profile in head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin | 2012 |
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplas | 2012 |
Purification and biochemical characterization of a novel protein-tongue cancer chemotherapy resistance-associated protein1 (TCRP1).
Topics: Animals; Antibiotics, Antineoplastic; Antibody Specificity; Bleomycin; Carcinoma, Squamous Cell; Cel | 2012 |
Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Anus Neoplasms; Bone Marrow; Capeci | 2012 |
Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy.
Topics: Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemothera | 2012 |
Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Ne | 2012 |
[Refractory thrombotic thrombocytopenic purpura revealing an epiglotis neoplasia].
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; An | 2012 |
Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2012 |
The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Chemoradiother | 2012 |
Chromosomal rearrangements in lymphocytes of head and neck squamous cell carcinoma treated with chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control Studies; Chro | 2012 |
Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryo | 2012 |
[A successful resected case of advanced esophageal cancer with early gastric cancer responding to neoadjuvant chemotherapy of docetaxel, CDDP and 5-FU].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Ce | 2012 |
Feasibility and tolerance of sequential chemoradiotherapy in squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
Comparison of the effect of p65 siRNA and curcumin in promoting apoptosis in esophageal squamous cell carcinoma cells and in nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell L | 2012 |
Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apigenin; Apoptosis; Blotting, Western; Car | 2012 |
Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy | 2012 |
Role of positron emission tomography-computed tomography in the management of anal cancer.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 2012 |
Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2012 |
Efficacy analysis of simplified intensity-modulated radiotherapy with high or conventional dose and concurrent chemotherapy for patients with neck and upper thoracic esophageal carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neop | 2012 |
Medium-term culture of primary oral squamous cell carcinoma in a three- dimensional model: effects on cell survival following topical 5-fluororacile delivery by drug-loaded matrix tablets.
Topics: Acrylates; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Cell Communication; | 2012 |
Treatment of carcinoma of the anal canal at Groote Schuur Hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 2012 |
Clinical outcome of endoscopic mucosal resection for esophageal squamous cell cancer invading muscularis mucosa and submucosal layer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherap | 2013 |
Predictors of ocular surface squamous neoplasia recurrence after excisional surgery.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Squamous Cell; Conjunctival Neoplasms; | 2012 |
[Concurrent chemoradiotherapy with either CDDP or CDGP, plus 5-FU for squamous cell carcinoma of the oropharynx and hypopharynx].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
Squamous cell carcinoma of the rectum: a single institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2012 |
Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer.
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free S | 2012 |
Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2012 |
Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheter Ablation; Chemoth | 2013 |
Aldehyde dehydrogenase 1 expression is associated with poor prognosis in patients with esophageal squamous cell carcinoma.
Topics: Aged; Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2013 |
The role of sequential chemoradiation for local advanced oropharyngeal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
Multi-institutional analysis of early glottic cancer from 2000 to 2005.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2012 |
Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2013 |
Self-assessment quiz: answers, critiques, and references.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcino | 2012 |
IFNα2b augments immune responses of cisplatin+5-fluorouracil treated tongue squamous cell carcinoma patients--a preliminary study.
Topics: Carcinoma, Squamous Cell; Cisplatin; Flow Cytometry; Fluorouracil; Humans; Immune Tolerance; Interfe | 2012 |
HPV genotypes predict survival benefits from concurrent chemotherapy and radiation therapy in advanced squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherap | 2012 |
Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Topical; Animals; Antineoplastic Agents; Carcinoge | 2013 |
Target volume definition for intensity-modulated radiotherapy after induction chemotherapy and patterns of treatment failure after sequential chemoradiotherapy in locoregionally advanced oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
The effects of 5-fluorouracil alone and in combination with 13-cis retinoic acid and vitamin D3 on human oral squamous cell carcinoma lines.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cholecalciferol; Drug Com | 2012 |
Results of chemoradiotherapy for stage I esophageal cancer in medically inoperable patients compared with results in operable patients.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemora | 2013 |
Combined intra-arterial infusion and systemic chemoradiotherapy for stage IV squamous cell carcinoma of the mandibular gingiva.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2012 |
Survival of patients with pathologic T0N+ oral and oropharyngeal cancer after neoadjuvant therapy and surgery: the minority report.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2013 |
Capecitabine-induced chest pain relieved by diltiazem.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Calcium Channel Blockers; Cap | 2012 |
Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free | 2012 |
Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; D | 2012 |
Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; D | 2012 |
Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; D | 2012 |
Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; D | 2012 |
A patient with dementia: decision-making capacity and surrogate decision makers.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Dementia; Dermatology; | 2012 |
Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
Metastatic human papillomavirus-positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread.
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biomarkers, Tumor; Carb | 2012 |
Curcumin potentiates the antitumor effects of 5-FU in treatment of esophageal squamous carcinoma cells through downregulating the activation of NF-κB signaling pathway in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, T | 2012 |
Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2013 |
The oncoprotein and stem cell renewal factor BMI1 associates with poor clinical outcome in oesophageal cancer patients undergoing preoperative chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2012 |
[Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Antineoplasti | 2012 |
Mediastinal extravasation of oxaliplatin.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Central | 2012 |
[The role of neoadjuvant therapy in the treatment of locally advanced squamous cell cancer of the cervical oesophagus].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
Long-term follow-up and salvage surgery in patients with T2N0M0 squamous cell carcinoma of the glottic larynx following concurrent chemoradiation therapy with cisplatin and 5-fluorouracil for laryngeal preservation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; | 2013 |
Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Treatment strategy for superficial pharyngeal squamous cell carcinoma synchronously combined with esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2013 |
THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Topics: 3' Untranslated Regions; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcino | 2012 |
[Effects of pre-chemotherapy hemoglobin and platelet levels in patients with stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy followed by radical hysterectomy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2012 |
Predictive markers for neoadjuvant chemotherapy in advanced squamous cell carcinoma of maxillary sinus: Preliminary report.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinom | 2013 |
Laryngeal preservation in advanced piriform sinus squamous cell carcinomas using superselective intra-arterial chemoradiation therapy with three agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2012 |
[Efficacy of docetaxel and nedaplatin combined with concurrent intensity modulated radiation therapy in the treatment of esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2012 |
Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cape | 2012 |
Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamou | 2013 |
A novel treatment approach for extensive, eruptive, cutaneous squamous cell carcinomas in a patient receiving BRAF inhibitor therapy for metastatic melanoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorour | 2013 |
[Two cases of complete response for cStage I( T1bN0M0) esophageal carcinoma treated with chemoradiation therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2012 |
[Hypersensitivity to radiation therapy in a patient with tuberous sclerosis: biological considerations about a clinical case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
[Esophageal cancer: outcome according to therapeutic strategy].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2013 |
Preoperative intensity modulated radiation therapy and chemotherapy for locally advanced vulvar carcinoma: analysis of pattern of relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2013 |
Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2013 |
Comparison of treatment compliance and nutritional outcomes among patients with nasopharyngeal carcinoma with and without percutaneous endoscopic gastrostomy during chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Ci | 2012 |
The telomere/telomerase binding factor PinX1 is a new target to improve the radiotherapy effect of oesophageal squamous cell carcinomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Cycle Protei | 2013 |
Larynx preservation for patients with locally advanced laryngeal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvan | 2013 |
Hypofractionated palliative radiotherapy for advanced head and neck cancer: the IHF2SQ regimen.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2013 |
Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Squa | 2013 |
COX-2 overexpression Induced by gene transfer reduces sensitivity of TE13 esophageal carcinoma cells to 5-fluorouracil and cisplatin.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prolifera | 2013 |
Skin cancer treatment by albumin/5-Fu loaded magnetic nanocomposite spheres in a mouse model.
Topics: Albumins; Animals; Carcinoma, Squamous Cell; Disease Models, Animal; Drug Carriers; Fluorouracil; Ma | 2013 |
Complete regression of esophageal cancer with concomitant liver metastasis achieved by concurrent chemoradiation therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2002 |
Chemotherapy associated arterial thrombosis.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Humans; Middle Age | 2002 |
Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 2002 |
Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Sq | 2002 |
Preoperative therapy for patients with resectable squamous cell carcinoma of the esophagus: are we still confused?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2002 |
[Salvage operation for esophageal cancer after radical chemoradiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2002 |
Successful chemoradiotherapy for anal cancer despite previous radical radiotherapy for gynaecological malignancy.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Endometrial Neopla | 2002 |
[A case of advanced esophageal cancer with multiple lymph node metastases successfully treated with induction chemotherapy consisting of nedaplatin and 5-FU followed by chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedu | 2002 |
Prognostic value of TP53 transcriptional activity on p21 and bax in patients with esophageal squamous cell carcinomas treated by definitive chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carcinoma, | 2002 |
Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2002 |
[Superficial esophageal carcinoma successfully treated with combined chemotherapy and radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2002 |
Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2002 |
Surgical resection with and without chemotherapy in oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2002 |
Surgical resection with and without chemotherapy in oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2002 |
Surgical resection with and without chemotherapy in oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2002 |
Surgical resection with and without chemotherapy in oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2002 |
Early changes in [18F]FLT uptake after chemotherapy: an experimental study.
Topics: Antineoplastic Agents; Artifacts; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Deoxycytidine; | 2002 |
[A trial of continuous and biweekly low-dose cisplatin and 5-FU with UFT chemotherapy for esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Resp | 2002 |
[A case of hypopharyngeal carcinoma in which a complete response to chemotherapy was achieved with docetaxel, cisplatin, 5-FU and levofolinate].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2002 |
A case of advanced esophageal cancer with extensive lymph node metastases successfully treated with multimodal therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2002 |
[Clinical study of the combination of small amount of nedaplatin (CDGP)/5-FU with radiation for the treatment of esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2002 |
Gastrostomy-site tumor recurrence is not always fatal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brachytherapy; Carcinoma, Squamous Cell; Flu | 2003 |
Effects of preoperative chemotherapy on metastatic lymph nodes in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cel | 2002 |
Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Sq | 2001 |
Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2002 |
Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcin | 2002 |
[A case of large carcinoma of the tongue and mouth floor, in which chemotherapy using a combination of nedaplatin and 5-FU was effective].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Drug Admini | 2002 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Quality of life 2-10 years after combined treatment for advanced oral and oropharyngeal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2003 |
Clinical markers of hypoxia and other predictive factors of survival in conservative therapy of squamous-cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Hypoxia; | 2003 |
Chemoradiation for adenocarcinoma of the anus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Sq | 2003 |
Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 2003 |
Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 2003 |
Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 2003 |
Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 2003 |
Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2003 |
Non-Q-Wave acute anterior myocardial infarction associated with 5-fluorouracil and cisplatin chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; F | 2003 |
Patterns of failure following radiation with and without chemotherapy in patients with nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2003 |
Clear cell adenocarcinoma in a female urethral diverticulum.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2003 |
[Chemosensitivity testing of oral and maxillofacial cancer with biopsy specimens].
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Squamous Cell; Cell Division; Cisplatin; Dose-Response Rel | 2002 |
[Preoperative concurrent chemoradiotherapy with intra-arterial infusion of pirarubicin and continuous intravenous instillation of 5-fluorouracil for resectable advanced head and neck squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2003 |
Adjuvant chemotherapy after radical resection of squamous cell carcinoma in the thoracic esophagus: who benefits? A retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2003 |
[Diagnosis of a metastatic valvular tumor in a living patient].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain Ischemia; Car | 2003 |
Basaloid-squamous carcinoma of the esophagus treated by preoperative chemotherapy: report of two cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2003 |
Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxy | 2003 |
[Combined MTX.5-FU.CDGP for the treatment of head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
[Effect of nedaplatin, 5-FU, and leucovorin combined with radiation therapy in unresectable esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 2003 |
Relapse patterns after chemo-radiation for carcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2003 |
Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2003 |
Plummer-Vinson syndrome associated with celiac disease and complicated by postcricoid carcinoma and carcinoma of the tongue.
Topics: Anemia, Iron-Deficiency; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Celiac Diseas | 2003 |
Response to preoperative chemotherapy affects prognosis in esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control | 2003 |
[The clinical application and evaluation of combined chemotherapy in comprehensive treatment for oral squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2003 |
[Renal metastasis after curative resection of an epidermoid carcinoma of the esophagus].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined C | 2003 |
Enhanced susceptibility of oral squamous cell carcinoma cell lines to FAS-mediated apoptosis by cisplatin and 5-fluorouracil.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arabidopsis Proteins; | 2003 |
[Nedaplatin and 5-fluorouracil combined with radiotherapy for advanced esophageal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2003 |
Treatment outcome of N3 nodal head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 2003 |
[Combination chemotherapy with nedaplatin and 5-fluorouracil for oral squamous cell carcinomas].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration | 2003 |
Volumetric and histologic responses to radiotherapy or radiochemotherapy of metastatic cervical lymph nodes of oral squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2003 |
Clinical benefit of chemosensitivity test for patients with regional lymph node-positive esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2003 |
Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2003 |
Effect of 5-fluorouracil and epidermal growth factor on cell growth and dihydropyrimidine dehydrogenase regulation in human uterine cervical carcinoma SKG-IIIb cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Division; Dihydrouracil Dehydrogenas | 2003 |
A case report of primary hepatic squamous cell carcinoma that remarkably responded to low dose arterial injection of anti-cancer drugs.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Resp | 2003 |
The potentiation of radiation effects with 5-fluoro-uracil.
Topics: Aged; Carcinoma, Squamous Cell; Esophagitis; Fluorouracil; Humans; Lung; Lung Neoplasms; Male; Middl | 1960 |
Clinical method of testing radiation-sensitizing agents in squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Cobalt Isotopes; Fluorouracil; Humans; Mouth Neoplasms; Nucleosides; Phary | 1963 |
The response of squamous cell carcinoma to intra-arterial infusion with 5-fluorouracil.
Topics: Carcinoma; Carcinoma, Squamous Cell; Fluorouracil; Humans; Infusions, Intra-Arterial | 1962 |
VINCRISTINE (NSC-67574) THERAPY OF ADULT PATIENTS WITH SOLID TUMORS.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Bronchogenic; Carcinoma, Squamous | 1964 |
A REPORT OF THE SYSTEMIC USE OF 5-FLUOROURACIL IN THE TREATMENT OF CHINESE CANCER PATIENTS.
Topics: Adenocarcinoma; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; China; Fallopian Tube N | 1964 |
CLINICAL STUDIES OF COMBINED CHEMOTHERAPY AND IRRADIATION IN INOPERABLE BRONCHOGENIC CARCINOMA.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide; Fluo | 1964 |
[REGIONAL INTRA-ARTERIAL CYTOSTATIC THERAPY OF MALIGNANT TUMORS OF THE HEAD AND NECK].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans | 1964 |
REGIONAL INTRA-ARTERIAL INFUSION OF 5-FLUOROURACIL FOR CANCER.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Carcinoma, Squamous Cell; Female; Fluorouracil; Glioblast | 1964 |
ACUTE CEREBELLAR SYNDROME SECONDARY TO 5-FLUOROURACIL THERAPY.
Topics: Abdominal Neoplasms; Adenocarcinoma; Bone Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, | 1964 |
PERFUSION TREATMENT OF CANCER.
Topics: Carcinoma; Carcinoma, Squamous Cell; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Fluo | 1965 |
EFFECTIVENESS AND TOXICITY OF PROLONGED INFUSIONS OF 5-FLUOROURACIL IN THE TREATMENT OF CANCER.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma; Carcinoma, Sq | 1965 |
REGIONAL ARTERIAL INFUSION OF ANTIMETABOLITES. AN ANALYSIS OF THE RESULTS OBTAINED IN 33 PATIENTS WITH MALIGNANT TUMORS OF THE HEAD AND NECK.
Topics: Antimetabolites; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; H | 1965 |
SQUAMOUS CELL CARCINOMA OF ORAL CAVITY; INTRA-ARTERIAL INFUSION WITH FLUOROURACIL AND IDOXURIDINE.
Topics: Carcinoma; Carcinoma, Squamous Cell; Drug Therapy; Fluorouracil; Humans; Idoxuridine; Infusions, Int | 1965 |
Clinical studies with 5-fluorouracil in 47 patients.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Carcinoma; Carcinoma, Squamous Cell; Fluorourac | 1962 |
[A case report of an advanced esophageal carcinoma (stage II) without signs of recurrence in 5 years after chemoradiotherapy. With reference to p53 immunohistochemistry as an indicator for prognostic evaluation of chemoradiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2003 |
Pasteurella multocida infection following cisplatin and 5-fluorouracil chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Diseas | 2003 |
Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mism | 2003 |
[Evaluation of quality of life of patients with oral squamous cell carcinoma. Comparison of two treatment protocols in a prospective study-first results].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2003 |
[A case of multiple advanced esophageal carcinomas with abdominal LN metastases showing complete response after chemoradiotherapy with concurrent cisplatin, 5-FU and adriamycin chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2003 |
Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Disease Models | 2003 |
Treatment of squamous cell carcinoma with intralesional 5-Fluorouracil.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Face; Female; Fluorouracil; Humans; Injec | 2003 |
[Resection of esophageal cancer infiltrating the left main bronchus following complete response to preoperative radiochemotherapy--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cispl | 2003 |
Blue fingers.
Topics: Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fingers; Fl | 2003 |
Anti-tumor effect of vitamin A and D on head and neck squamous cell carcinoma.
Topics: Angiogenesis Inducing Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cal | 2003 |
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2003 |
Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous C | 2003 |
Successful treatment of multiple premalignant and malignant lesions in arsenical keratosis with a combination of acitretin and intralesional 5-fluorouracil.
Topics: Acitretin; Arsenic; Biopsy, Needle; Bowen's Disease; Carcinoma, Squamous Cell; Drug Therapy, Combina | 2003 |
Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas.
Topics: Aged; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Cyclin E; Cycl | 2004 |
[Clinical study of the area under the blood concentration-time curve of targeting intra-arterial infusion chemotherapy with nedaplatin for primary oral cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma | 2004 |
[Neoadjuvant chemoradiotherapy for advanced squamous cell carcinoma of thoracic esophagus].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 2004 |
[Metastatic oropharyngeal cancer successfully treated with docetaxel, cisplatin, 5-FU and l-leucovorin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2004 |
Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; | 2004 |
Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2004 |
Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cis | 2004 |
With regard to "Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer" by Oh et al. (AnnOnc 2003; 14: 464-569).
Topics: Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Disease-Fr | 2004 |
Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2004 |
Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2004 |
Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2004 |
Tolerance of radiotherapy and chemotherapy in elderly patients with bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Chemoprevention of cancer of the upper respiratory tract of the Syrian golden hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil.
Topics: Administration, Inhalation; Aerosols; Animals; Anticarcinogenic Agents; Carcinogens; Carcinoma, Squa | 2004 |
Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma.
Topics: Aged; Alleles; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Fas Ligand Protein; fas | 2004 |
[Radiotherapy of carcinomas of the anal canal. Tenon Hospital experience].
Topics: Aged; Anal Canal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Ch | 2003 |
Potentiation of induction of apoptosis by sequential treatment with cisplatin followed by 5-fluorouracil in human oral cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Caspases; Cispl | 2004 |
[Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor ZD1839 on nasopharyngeal carcinoma cells].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Li | 2004 |
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2004 |
Constitutive expression of interleukin-18 in head and neck squamous carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Squamous Cell; Caspase 1; Cell Line, | 2004 |
Chemoradiation with 5-fluorouracil and mitomycin C in the treatment of vulvar squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2004 |
Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2004 |
Use of LeVeen pleuroperitoneal shunt for refractory high-volume chylothorax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chylothorax; | 2004 |
Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arkansas; Carcinoma, | 2004 |
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for tongue cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2004 |
Experimental gene therapy using p21Waf1 gene for esophageal squamous cell carcinoma by gene gun technology.
Topics: Animals; Biolistics; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Prolifera | 2004 |
[A case report--a patient with gingiva carcinoma showing complete remission after combination chemotherapy with nedaplatin and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedu | 2004 |
[A resected case of thoracic esophageal cancer in which pCR was obtained using low-dose of nedaplatin (CDGP)/5-FU and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2004 |
Bilateral leg amputation following chemoradiation for squamous carcinoma of the anus.
Topics: Aged; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinom | 2004 |
The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cell Line, Tu | 2004 |
Pulmonary Langerhans cell histiocytosis associated with lingual carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 2004 |
[Preoperative chemoradiation in esophageal cancer: experience of a single center in 102 patients].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2004 |
Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Sq | 2004 |
Concurrent chemoradiotherapy with pirarubicin and 5-fluorouracil for resectable oral and maxillary carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Mo | 2004 |
Functional outcomes following chemoradiotherapy for head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, | 2004 |
Impact of chemoradiotherapy-induced anemia on survival in uniformly staged patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2004 |
Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemot | 2004 |
Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Squam | 2005 |
EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; | 2005 |
Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2005 |
Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Cycle; C | 2004 |
[Concurrent chemoradiotherapy for head and neck squamous cell carcinoma with indication of total laryngectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cell Line, T | 2005 |
Cost comparison of surgery vs organ preservation for laryngeal cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Costs and Cost A | 2005 |
Preoperative radiochemotherapy and radical resection for stages II-IV oral and oropharyngeal cancer: outcome of 222 patients.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2005 |
Correlation between histological effects on the main tumors and nodal status after chemoradiotherapy for squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2005 |
Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc | 2005 |
Preoperative radiochemotherapy and radical resection for stages II to IV oral and oropharyngeal cancer: grade of regression as crucial prognostic factor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fe | 2005 |
Radiotherapy for uterine cervical cancer: results of the 1995-1997 patterns of care process survey in Japan.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleo | 2005 |
A retrospective review of 15 years of radical radiotherapy with or without concurrent cisplatin and/or 5-fluorouracil for the treatment of locally advanced cervical cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Carcinoma, | 2005 |
[Role of an exclusive concomitant radio-chemotherapy treatment in non operable esophageal cancer: results of a 10-year experience in Antoine-Lacassagne Center].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cispl | 2005 |
Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Analysis of Variance; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma | 2005 |
Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2005 |
[Prognosis of epidermoid anal carcinoma regression after conservative treatment].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2004 |
Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2005 |
Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Biopsy; Calibration; Carcinom | 2005 |
[Combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF), and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2005 |
Delayed radiation myelopathy after concurrent chemoradiation for hypopharyngeal-esophageal carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Degluti | 2005 |
High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2005 |
Results of treatment intensification for progressive locoregional disease in head-and-neck cancer patients undergoing postoperative radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2005 |
Iris metastasis of esophageal cancer.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorouracil; Humans; Iris Neoplasms; Male; Middle A | 2005 |
Stage IVa squamous cell carcinoma of the vulva managed with primary chemoradiation.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free S | 2005 |
Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2005 |
Long-term survival in locally advanced oral cavity cancer: an analysis of patients treated with neoadjuvant cisplatin-based chemotherapy followed by surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2005 |
Effects of cisplatin, 5-fluorouracil, and radiation on cell cycle regulation and apoptosis in the hypopharyngeal carcinoma cell line.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Proteins; Cell Li | 2005 |
[Phase I study of CM-Na combined with concurrent radiochemotherapy for advanced esophageal carcinoma].
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2005 |
Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; F | 2005 |
[Long-term results of neoadjuvant radiochemotherapy in squamous carcinoma of the thoracic esophagus].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2005 |
Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Anus Ne | 2005 |
[A case of T4 esophageal squamous cell carcinoma in esophagogastric junction effectively treated by neoadjuvant FAP therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Dr | 2005 |
Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; | 2006 |
[Multivariate prognostic analysis for patients with unresectable esophageal carcinoma after concurrent chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Recurrent squamous cell carcinoma in the neopharynx treated successfully with topical 5-fluorouracil.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Fluorourac | 2005 |
[The value of postoperative arterial infusion chemotherapy in patients with T3 esophageal squamous carcinoma after radical surgery].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2005 |
Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
[A case of head and neck squamous cell carcinoma suffering from acute renal failure after methotrexate administrator].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cispl | 2005 |
Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2005 |
Post-operative adjuvant chemoradiotherapy with carboplatin and 5-fluorouracil for primary branchiogenic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Branchioma; Carboplatin; Carcinoma, Squamous Cell; C | 2005 |
Predictive value of p53 and 14-3-3sigma for the effect of chemoradiation therapy on esophageal squamous cell carcinoma.
Topics: 14-3-3 Proteins; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, | 2005 |
[Pathologic complete response of thoracic esophageal cancer developing after gastrectomy to neoadjuvant low-dose nedaplatin (CDGP), 5-fluorouracil and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2005 |
Revisiting induction chemotherapy for head and neck cancer. References and reviews.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ci | 2005 |
Unbiased estimation of tumor regression rates during chemoradiotherapy for esophageal carcinoma using CT and stereology.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2005 |
Neoadjuvant chemoradiotherapy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2005 |
Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; | 2005 |
Intensity-modulated radiation therapy in head and neck cancers: dosimetric advantages and update of clinical results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2005 |
An audit of postoperative radiotherapy after non-curative resection for cancer of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality The | 2005 |
Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2005 |
Accelerated radiotherapy for advanced laryngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2005 |
[A case of unknown primary squamous cell carcinoma in the neck showing a high response with combined chemotherapy including nedaplatin, adriamycin and 5-fluorouracil].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
[A case of recurrent breast cancer successfully treated with capecitabine monotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Deoxycyti | 2005 |
Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; | 2005 |
Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Squamous Cell; Fem | 2005 |
Preoperative chemoradiation for locally advanced carcinoma of the vulva.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2005 |
Efficacy and toxicity of fluorouracil, doxorubicin, and cisplatin/nedaplatin treatment as neoadjuvant chemotherapy for advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Doxo | 2005 |
Invited commentary.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2005 |
[A case of complete response after neoadjuvant chemotherapy for advanced esophageal cancer with low-dose FP therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response R | 2005 |
The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2005 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality | 2006 |
Nasopharyngeal carcinoma in the pediatric age group: the northern Israel (Rambam) medical center experience, 1989-2004.
Topics: Adolescent; Age Distribution; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, | 2005 |
[Laryngeal epidermoid carcinoma in a young adult without risk factors: a case report].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2005 |
Preoperative chemotherapy and radiation therapy for squamous cell carcinoma of the maxillary sinus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2005 |
Induction redux: once more with taxanes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2005 |
[Range of combined treatment of locally advanced skin cancer].
Topics: Age Distribution; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cel | 2005 |
Intratumoural expression of thymidylate synthase is an independent predictor of prognosis in patients with squamous cell carcinoma of the tongue: results from a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemother | 2006 |
The experience of concurrent chemoradiation for Japanese patients with superficial esophageal squamous cell carcinoma: a retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2005 |
Presentation of esophageal cancer with solitary splenic metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Carcinoma, Squamous Cell; Cispl | 2005 |
High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squa | 2005 |
Combined treatment of basaloid anal carcinoma using cisplatin, 5-fluorouracil and resection of hepatic metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biopsy, Needle; Carcinoma, Squamous | 2005 |
Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Es | 2005 |
Quantification and reduction of cardiac dose in radical radiotherapy for oesophageal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modalit | 2005 |
[Combination therapy with TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cl | 2005 |
[The outcome of treatments for carcinoma of the external auditory canal].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2005 |
Positron emission tomography scan to determine the need for neck dissection after chemoradiation for head and neck cancer: timing is everything.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy | 2005 |
Pharmacogenetics in esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Esophage | 2005 |
[Treatment and prognosis of stage III-IV laryngeal squamous cell carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 2006 |
Outcome of preoperative concurrent chemoradiotherapy and surgery for resectable lingual squamous cell carcinoma greater than 3 cm: the possibility of less extensive surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2006 |
Intensity-modulated radiotherapy for the treatment of vulvar carcinoma: a comparative dosimetric study with early clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2006 |
Palliative ethanol injections of unresectable advanced esophageal carcinoma combined with chemoradiation.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophage | 2006 |
Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma.
Topics: Carcinoma, Squamous Cell; Cisplatin; DNA Mutational Analysis; DNA, Mitochondrial; Female; Fluorourac | 2006 |
The bottom line: outcomes after conservation treatment in anal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 2006 |
Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2006 |
Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation.
Topics: Animals; Antineoplastic Agents; Carbon; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; C | 2006 |
Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro.
Topics: Antigens, CD20; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; CD40 Anti | 2006 |
[Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Li | 2006 |
In-vitro differential metabolism and activity of 5-fluorouracil between short-term, high-dose and long-term, low-dose treatments in human squamous carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Drug Admini | 2006 |
Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2006 |
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Squamous Cell; Cell | 2006 |
[Quality of life of 192 disease-freely survival nasopharyngeal carcinoma patients after radiotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2005 |
A case of an adverse reaction to topical 5-fluorouracil in irradiated skin.
Topics: Administration, Cutaneous; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Diagnosi | 2006 |
Concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate, and leucovorin in patients with advanced resectable squamous cell carcinoma of the larynx and hypopharynx.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2006 |
[Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; | 2006 |
Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, | 2006 |
Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles.
Topics: Administration, Inhalation; Aerosols; Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous | 2006 |
[Neoadjuvant chemotherapy before radiotherapy in treatment of patients with cervical carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal | 2006 |
Treatment results of preoperative concurrent chemoradiotherapy followed by surgery for stage III or IV esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2006 |
[Improvement of postoperative radiotherapy in the complex treatment of stage II-III cervical cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2006 |
Role of caspase 8 as a determinant in chemosensitivity of p53-mutated head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Caspase 8 | 2006 |
Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
Orotate phosphoribosyl transferase mRNA expression in oral squamous cell carcinoma and its relationship with the dihydropyrimidine dehydrogenase expression and the clinical effect of 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Case-Control Studies; Chi-Square Distr | 2006 |
Impact of preoperative radiochemotherapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2006 |
Acute coronary syndrome secondary to fluorouracil infusion.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2006 |
Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2006 |
Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc | 2006 |
Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 2006 |
Effective chemoradiotherapy protocol with 5-fluorouracil for cervical squamous cell carcinoma in vitro.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Survival; Female; Flap Endonucleases | 2006 |
Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2006 |
Retrospective analysis on prognostic impact of adjuvant chemotherapy in the patients with advanced and resectable oral squamous cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
Reversible findings of restricted diffusion in 5-fluorouracil neurotoxicity.
Topics: Adult; Antimetabolites, Antineoplastic; Anus Neoplasms; Carcinoma, Squamous Cell; Corpus Callosum; F | 2006 |
Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cis | 2006 |
Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: impact of nodal density and total tumor volume.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2006 |
Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, | 2007 |
[Superselective intra-arterial infusion therapy with docetaxel, cisplatin and 5-fluorouracil for head and neck cancer--for tongue cancer patients in comparison patients with other therapies].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2006 |
Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Dihydrouracil Dehydrogenas | 2006 |
HIV-associated anal squamous cell cancer: an otherwise preventable disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Anus Neoplasm | 2006 |
Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carci | 2006 |
Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biguanide | 2006 |
Successful outcome after combined chemotherapeutic and surgical management in a case of esophageal cancer with breast and brain relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Squamo | 2006 |
[Chemotherapy guidance of the drug sensitivity test in vitro in human laryngeal squamous cell carcinoma].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Screening Assay | 2006 |
Does clinical and radiological response predict complete tumor control in N2-N3 squamous cell head and neck cancer after non-operative management of the neck?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2006 |
Chemoradiation using low-dose cisplatin and 5-fluorouracil in locally advanced squamous cell carcinoma of the skin: a report of two cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2006 |
The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous | 2007 |
[Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squamous cell carcinoma patients--a report of 43 cases].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2006 |
Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy.
Topics: Administration, Cutaneous; Aged; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Co | 2006 |
Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2007 |
[Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2006 |
Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2007 |
Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2007 |
Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour.
Topics: Abdominal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinom | 2006 |
Pilot study of intraoperative chemotherapy with cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2007 |
[Angina pectoris and ST-elevation after chemotherapy with 5-fluorouracil].
Topics: Acute Coronary Syndrome; Aged; Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Carc | 2007 |
Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2006 |
[A case of metastatic lung cancer responding well from tongue carcinoma using a combination of stereotactic radiation therapy and docetaxel/cisplatin/5-FU chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2006 |
Concurrent chemoradiation for patients with squamous cell carcinoma of the cervical esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2007 |
Bazex syndrome (acrokeratosis paraneoplastica).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Ear, External; | 2007 |
[Prognosis analysis of nasopharyngeal carcinoma patients with distant metastasis].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, | 2007 |
Neoadjuvant chemotherapy in advanced penile carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2007 |
Editorial comment on: Neoadjuvant chemotherapy in advanced penile carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2007 |
Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Bronchi; Carcinoma, Sq | 2007 |
Humoral hypercalcaemia of malignancy associated with primary cutaneous squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fatal Outcome; Female; Fluorouraci | 2007 |
[A resected case of squamous cell carcinoma of the breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamous Cell; C | 2007 |
Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease- | 2007 |
Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Dihydrouracil Dehydrogenase | 2007 |
Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease | 2007 |
[Epidermoid carcinoma of piriform sinus after chemo-radiotherapy: acoustic evaluation and voice handicap].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2006 |
[The role of a surgical method in combined and complex treatment of patients with squamous cell oral and oropharyngeal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
[Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Topics: Adult; Antineoplastic Agents; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Cell Survival; Cells | 2007 |
[A successful case of lower gingival cancer with pulmonary metastases by adjuvant chemotherapy including paclitaxel, cisplatin and 5-fluorouracil following a surgical procedure].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2007 |
Reduction rate of lymph node metastasis as a significant prognostic factor in esophageal cancer patients treated with neoadjuvant chemoradiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Es | 2007 |
Patients with locally advanced esophageal carcinoma nonresponder to radiochemotherapy: who will benefit from surgery?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2007 |
The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus.
Topics: Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Esophageal Neoplasms; Fluo | 2007 |
Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2007 |
Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Sq | 2007 |
Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy.
Topics: Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; D | 2007 |
Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Ce | 2007 |
Salvage lymphadenectomy of the right recurrent nerve node with tracheal involvement after definitive chemoradiation therapy for esophageal squamous cell carcinoma: report of two cases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2007 |
Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
5-Fluorouracil cardiotoxicity complicating treatment of stage IIB cervical cancer--case report.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cardiac Output, Low | 2007 |
[A case of recurrent esophageal cancer successfully treated with concurrent radiochemotherapy with low-dose docetaxel plus 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2007 |
Results of the 1999 2001 Japanese patterns of care study for patients receiving definitive radiation therapy without surgery for esophageal cancer.
Topics: Aged; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Combined Modality T | 2007 |
Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2007 |
Squamous-cell carcinoma of the rectum: a rare but curable tumor.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Squam | 2007 |
Influence of delayed tumor clearance on reliability of complete response rate in chemoradiotherapy for head and neck cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; | 2007 |
[An effective treatment by chemoradiation therapy after stent insertion for advanced esophageal cancer with esophago-pulmonary fistula--report of a case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2007 |
Evaluation of prognostic factors of esophageal squamous cell carcinoma (stage II-III) after concurrent chemoradiotherapy using biopsy specimens.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squa | 2007 |
Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinom | 2007 |
Perfusion CT can predict the response to chemoradiation therapy and survival in esophageal squamous cell carcinoma: initial clinical results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2007 |
The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases.
Topics: Brain Diseases; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorouracil; Humans; Hypera | 2008 |
Treatment results and prognostic factors in locally advanced hypopharyngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Change of the expression of human telomerase reverse transcriptase mRNA and human telomerase RNA after cisplatin and 5-fluorouracil exposure in head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; DNA Pri | 2007 |
Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2007 |
[Two cases of primary female urethral cancer].
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou | 2007 |
Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2008 |
Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; | 2007 |
[Concurrent chemoradiotherapy for squamous cell carcinoma of the oropharynx].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2007 |
[Efficiency and side effects of concurrent radiotherapy and chemotherapy for advanced cervical cancers].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2007 |
Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2008 |
Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cisplatin; | 2007 |
[Clinical trial of chemotherapy by superselective intra-arterial infusion of nedaplatin (CDGP) and 5-FU with concurrent radiotherapy for advanced oral cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; D | 2007 |
Concurrent chemoradiotherapy or endoscopic stenting for advanced squamous cell carcinoma of esophagus: a case-control study.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Co | 2008 |
Induction chemotherapy followed by alternating chemo-radiotherapy in non-endemic undifferentiated carcinoma of the nasopharynx: optimal compliance and promising 4-year results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squam | 2008 |
Management of advanced nodal disease following chemoradiation for head and neck squamous cell carcinoma: role of magnetic resonance imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
Orbital invasion despite topical anti-metabolite therapy for conjunctival carcinoma.
Topics: Administration, Topical; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Con | 2008 |
A new method of selective intra-arterial infusion therapy via the superficial temporal artery for head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiography; Antineoplastic Agents; Brachytherapy; Carboplatin; Carc | 2008 |
Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2008 |
Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2008 |
Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2008 |
Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2008 |
[Neoadjuvant radiochemotherapy for squamous cell carcinoma of the oral cavity].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2008 |
Concurrent chemoradiotherapy for esophageal cancer with malignant fistula.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Anus N | 2008 |
Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2008 |
Scoring system for predicting response to chemoradiotherapy, including 5-Fluorouracil and platinum, for patients with esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2008 |
Intra-arterial chemoradiotherapy for locally advanced oral cavity cancer: analysis of therapeutic results in 134 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2008 |
[Retrospective study of chemoradiotherapy based on cisplatin compared with radiotherapy alone for cervical cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Squamou | 2007 |
Results of concomitant chemoradiation for cervical cancer using high dose rate intracavitary brachytherapy: study of JROSG (Japan Radiation Oncology Study Group).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2008 |
Treatment of conjunctival squamous neoplasias with interferon alpha 2ab.
Topics: Administration, Topical; Antineoplastic Agents; Carcinoma, Squamous Cell; Conjunctival Neoplasms; Fl | 2008 |
Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2008 |
Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Colonic Neopla | 2008 |
Concurrent chemoradiotherapy with cisplatin and fluorouracil for locally advanced hypopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Cohort Stu | 2008 |
Treatment results of continuous intra-arterial CBDCA infusion chemotherapy in combination with radiation therapy for locally advanced tongue cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2008 |
A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Dr | 2008 |
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous C | 2008 |
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinom | 2008 |
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinom | 2008 |
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinom | 2008 |
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinom | 2008 |
[Treatment of advanced maxillary sinus squamous carcinoma: an analysis of 92 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2008 |
Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Intra-arterial chemotherapy in advanced pelvic tumors.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Injections, Int | 1967 |
Bowenoid conditions of the skin: treatment with topical 5-fluorouracil.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Middle Aged; Skin Disease | 1967 |
Chemical treatment of skin cancer.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Colchicine; Fluorouracil; Humans; Methotrexate; Pod | 1967 |
[Attack treatment of broncho-pleuro-pulmonary cancer by polychemotherapy under the protection of phytohemagglutinin].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Betametha | 1967 |
Infusion of 5-fluorouracil into the hypogastric artery for massive anal carcinoma.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Fluorouracil; Humans; Infusions, Parenteral; | 1967 |
[Drug therapy in advanced squamous cell carcinoma of the ORL region].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 1984 |
Combined radiotherapy and CMF-B cytotoxic regimen in stage III-IV head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co | 1984 |
Safe and effective combination chemotherapy for squamous cell carcinomas of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Fluoro | 1980 |
External carotid artery infusion with single-and multiple-drug regimens in the rat.
Topics: Animals; Antineoplastic Agents; Bleomycin; Body Weight; Carcinoma, Squamous Cell; Carotid Artery, Ex | 1980 |
Combination chemotherapy for advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Drug Therapy, Combination; | 1980 |
Advanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with adriamycin, bleomycin, 5-fluorouracil, methotrextate, and vitamin A.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Drug Administr | 1980 |
Simultaneous combination radiotherapy and multidrug chemotherapy for stage III and stage IV squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, | 1980 |
[Experimental studies on rat ear duct tumor. Part 2: Effects of anticancer drugs on rat ear duct tumor induced by DMBA and DAS (author's transl)].
Topics: 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; 9,10-Dimethyl-1,2-benzanthracene; Animal | 1980 |
Chemotherapy for head and neck cancer relapsing after radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Ther | 1981 |
Sequential combination chemotherapy of advanced head and neck carcinoma: re-evaluation of a highly effective regimen.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Female; Fluorouracil; Head and Neck N | 1981 |
Cellular mutations and drug resistance probed by herpes simplex virus.
Topics: Animals; Bleomycin; Carcinoma, Squamous Cell; Chlorocebus aethiops; Drug Resistance; Fibroblasts; Fl | 1981 |
Metabolism of 5-fluorouracil in various human normal and tumor tissues.
Topics: Adenocarcinoma; Adenosine Triphosphate; Carcinoma, Squamous Cell; Digestive System; Fluorouracil; Ga | 1981 |
[Therapy of carcinoid and the carcinoid syndrome].
Topics: Aminocaproic Acid; Aprotinin; Carcinoma, Squamous Cell; Cyproheptadine; Doxorubicin; Embolization, T | 1983 |
Non-platinum-containing combination chemotherapy for stage III-IV head and neck squamous carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamid | 1983 |
Bleomycin infusion followed by cyclophosphamide, methotrexate, and 5-fluorouracil in advanced squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cy | 1984 |
An active chemotherapy regimen for squamous cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1984 |
Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Ce | 1984 |
Superior clinical response and survival rates with initial bolus of cisplatin and 120 hour infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; | 1984 |
Intra-arterial infusion in tumors of the pelvis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality T | 1983 |
[Combined chemotherapy of bronchial carcinomas (author's transl)].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Small Cell; Carcinoma, | 1980 |
Analysis of the results of our combined therapy for maxillary cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell | 1980 |
[Pre- and intra-operative chemotherapy using FT-207 suppositories--with special reference to lung cancer].
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Fluorouracil | 1982 |
[New chemotherapeutic method for the treatment of tracheal and bronchial cancers--nebulization chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Small Cell; Carcinoma, | 1983 |
[Transfer factor immunochemotherapy for primary lung cancer--evaluation of histologic types].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; | 1983 |
[Results of drug therapy with cisplatin and 5-fluorouracil in squamous cell carcinoma of the head and neck region].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1984 |
Preoperative chemotherapy and radiation therapy in the management of anal epidermoid carcinoma.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorourac | 1983 |
Combined modality therapy for esophageal squamous cell carcinoma.
Topics: Abdomen; Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Esophageal Neoplasms; Eso | 1983 |
Definitive nonsurgical therapy of epithelial malignancies of the anal canal. A report of 12 cases.
Topics: Adult; Aged; Antineoplastic Agents; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Drug Th | 1983 |
[Evaluation of tissue concentrations of FT-207 and 5-FU in head and neck cancer].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Female; Fluorouracil; Head | 1983 |
[Clinical application of tegafur suppositories for bladder tumor].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fluorouracil; Humans; Male; Mid | 1983 |
[Pharmacokinetics of FT-207 rectum suppository in squamous cell carcinoma of the uterine cervix. (I) Pharmacokinetics in single administration at a dose of 1 gram].
Topics: Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Kinetics; Rectum; Suppositories; Tegafur; Ut | 1984 |
[Pharmacokinetics of FT-207 rectum suppository in squamous cell carcinoma of the uterine cervix. (II) Pharmacokinetics in continuous administration at a daily dose of 1 gram].
Topics: Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; Humans; Kinetics; Lymp | 1984 |
Combined preoperative chemotherapy and radiation therapy for cancer of the esophagus: the Wayne State University, Southwest Oncology group and Radiation Therapy Oncology Group experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1984 |
Concurrent radiation, mitomycin C and 5-fluorouracil in poor prognosis carcinoma of cervix: preliminary results of a phase I-II study.
Topics: Antibiotics, Antineoplastic; Brachytherapy; Carcinoma, Squamous Cell; Cesium Radioisotopes; Combined | 1984 |
Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Car | 1984 |
Management of common skin tumours.
Topics: Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cryosurgery; Dermatitis, Seborrhei | 1980 |
Carcinoma of the hand: a 20-year experience.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cryosurgery; Female; Fluorouracil; Fol | 1984 |
The role of chemotherapy in untreated squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophospham | 1984 |
[Results of multidisciplinary treatment for squamous cell carcinoma of the maxillary antrum].
Topics: Adult; Aged; Brachytherapy; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorouraci | 1984 |
Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: a potentially curative approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1984 |
Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Ce | 1984 |
Multimodality approach to treatment of carcinoma of the esophagus.
Topics: Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; | 1984 |
Establishment of an etoposide-resistant human epithelial tumour cell line in vitro: characterization of patterns of cross-resistance and drug sensitivities.
Topics: Carcinoma, Squamous Cell; Cell Line; Cisplatin; DNA, Neoplasm; Drug Resistance; Etoposide; Fluoroura | 1984 |
Ineffectiveness of 5-fluorouracil and cis-platin as second-line chemotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1984 |
Methotrexate and 5-fluorouracil in head and neck cancer.
Topics: Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy; Fluoro | 1983 |
Sequential methotrexate-5-fluorouracil treatment of squamous cell carcinoma of the head and neck.
Topics: Carcinoma, Squamous Cell; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Head and Neck | 1983 |
[Procedure and results of combined radiation and surgical treatment of laryngeal cancer patients].
Topics: Adult; Aged; Carcinoma in Situ; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Combined Modality T | 1983 |
Combined multimodality (surgery, radiotherapy, intra-arterial chemotherapy) treatment of advanced carcinoma of paranasal sinuses.
Topics: Carcinoma, Squamous Cell; Carotid Artery, External; Cobalt Radioisotopes; Combined Modality Therapy; | 1983 |
Malignant tumors of the vagina. Classification and approach to treatment.
Topics: Adenocarcinoma; Adolescent; Adult; Carcinoma in Situ; Carcinoma, Squamous Cell; Child; Diethylstilbe | 1983 |
Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in Stage III and IV squamous cell carcinoma of the head and neck.
Topics: Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Drug Therapy, Combination; Female | 1983 |
Fluorouracil (F), Adriamycin (A), and cisplatin (P) (FAP): combination chemotherapy of advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 1983 |
A nontoxic adjuvant treatment for advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 1983 |
Phase II chemotherapy trials of 5-FU, cyclophosphamide, ifosfamide, and vincristine in carcinoma of the bilharzial bladder.
Topics: Carcinoma, Squamous Cell; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Fluoroura | 1984 |
[Evaluation of multi-disciplinary treatment combined with intra-arterial chemotherapy for carcinoma of the meso-pharynx].
Topics: Brachytherapy; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Humans; Infusions, | 1984 |
[Treatment of maxillary cancer].
Topics: Bromodeoxyuridine; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Humans; Infusi | 1984 |
Conservative management of low grade neoplasms of the male urethra: a preliminary report.
Topics: Adult; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fluorouracil; Humans; Male; Middle Ag | 1980 |
Vaginal intraepithelial neoplasia: Biologic aspects and treatment with topical 5-fluorouracil and the carbon dioxide laser.
Topics: Adult; Aged; Carbon Dioxide; Carcinoma in Situ; Carcinoma, Squamous Cell; Female; Fluorouracil; Huma | 1980 |
Carcinoma of the maxillary sinus with eosinophilia. Report of a case.
Topics: Carcinoma, Squamous Cell; Eosinophilia; Eosinophils; Fluorouracil; Humans; Leukocyte Count; Male; Ma | 1981 |
[A case of inoperable esophageal carcinoma responding to adriamycin and FT 207 suppository for more than one year (author's transl)].
Topics: Aged; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, Combination; Esophageal Neoplasms; Female | 1981 |
[Conservative treatment of primary and recurrent malignant stomach neoplasms].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male | 1981 |
Combined radical radiation therapy and chemotherapy for primary squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorourac | 1982 |
Definitive treatment of anal-canal carcinoma by means of radiation therapy and chemotherapy.
Topics: Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1982 |
[Clinical evaluation of Tegafur suppository in the treatment of uterine cancer--with special reference to the drug concentration in the blood, secretion from the pelvic dead space, and tissues of female genital organs].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorouracil; Genita | 1982 |
Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Middle Ag | 1983 |
Bowen's disease in multiple nail beds--case report.
Topics: Adult; Bowen's Disease; Carcinoma, Squamous Cell; Fingers; Fluorouracil; Humans; Male; Nails; Skin N | 1983 |
[Clinical study of HCFU and radiation therapy for head and neck cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Ne | 1983 |
Cis-platinum and 5-fluorouracil as induction therapy for advanced head and neck cancer.
Topics: Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Fluorouracil; Head and Neck | 1982 |
[Treatment of advanced epidermoid carcinoma of the oesophagus with combined 5-fluorouracil, adriamycin and cis-platinum (FAP)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 1982 |
Chemotherapy in gastric and oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, Combinat | 1982 |
Four-drug combination chemotherapy for advanced cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Doxorubicin; Drug Th | 1982 |
[Antitumor effect of UFT against malignant tumors of maxillary sinus--clinical and biochemical study].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorourac | 1982 |
[Clinical results of FAR (5-FU, vitamin A, and radiation) therapy in head and neck cancer].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Head and Nec | 1982 |
A new concept in the management of Marjolin's ulcers.
Topics: Administration, Topical; Adult; Carcinoma, Squamous Cell; Cicatrix; Female; Fluorouracil; Humans; Ma | 1981 |
Multimodality approach to surgical management of locally advanced epidermoid carcinoma of the anorectum.
Topics: Aged; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lymphat | 1981 |
Preoperative chemoradiotherapy for carcinoma of the vulva.
Topics: Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Humans; Mitomycins; | 1981 |
Eradication and palliation of squamous cell carcinoma of the esophagus with chemotherapy, radiotherapy, and surgical therapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagus; Femal | 1981 |
Dysplastic epidermal keratosis in a black woman.
Topics: Aged; Black People; Bowen's Disease; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Keratos | 1981 |
Microangiopathic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5-fluorouracil.
Topics: Anemia, Hemolytic; Carcinoma, Squamous Cell; Drug Therapy, Combination; Erythrocytes; Female; Fluoro | 1980 |
Chemosurgery and excess tissue.
Topics: Bowen's Disease; Carcinoma, Squamous Cell; Fluorouracil; Humans; Methods; Skin Neoplasms | 1980 |
Treatment of carcinoma of the rectum and squamous carcinoma of the anus by combination chemotherapy, radiotherapy and operation.
Topics: Adenocarcinoma; Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; | 1980 |
Combined treatment of squamous cell carcinoma of the anal canal: radical radiation therapy with 5-fluorouracil and mitomycin-C, a preliminary report.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorourac | 1980 |
[5'-deoxy-5-fluoruridine, a new antineoplastic pyrimidine antimetabolite].
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Fluorouracil; Lung Neoplasms; Mi | 1980 |
Use of phytohemagglutinin in the treatment of maxillary cancer.
Topics: Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Humans; Infusions, | 1980 |
[Exclusive chemotherapy in T1-T3N0 cancers of the vocal cord with complete clinical response after neoadjuvant treatment with a cisplatin-fluorouracil combination].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1995 |
Combined chemotherapy and radiation in the treatment of a large nasal cavity tumor: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1995 |
[Nursing care of esophageal carcinoma treated by local chemotherapy injection and microwave local heating].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1993 |
[Establishment and application of transplantable models of human esophageal carcinoma in nude mice].
Topics: Animals; Bleomycin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Disease Models, Animal; Esop | 1993 |
Palliative, intraarterial chemotherapy for advanced head and neck cancer using an implantable port system.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1994 |
Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus.
Topics: Animals; Azacitidine; Carcinoma, Squamous Cell; Chlorocebus aethiops; Female; Fluorouracil; Male; Mi | 1995 |
Treatment of invasive squamous cell carcinoma complicating anal Buschke-Löwenstein tumor: a case history.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Diseases; Anus Neoplasms; Carcinoma, Squamous C | 1995 |
Combined radiochemotherapy for postoperative recurrence of oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1995 |
Acute appendicitis secondary to metastatic nasopharyngeal carcinoma.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendiceal Neoplasms; | 1995 |
Positron emission tomography in the detection of residual laryngeal carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, | 1995 |
Radiotherapy alone compared with radiotherapy and chemotherapy in patients with squamous cell carcinoma of the esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1995 |
[A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1995 |
Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice.
Topics: Animals; Carcinoma, Squamous Cell; Circadian Rhythm; Colonic Neoplasms; Delayed-Action Preparations; | 1995 |
A biochemical evaluation of oral squamous cell carcinoma growth by measurement of specific activity of succinate dehydrogenase in the subrenal capsule assay.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Colorimetry; Coloring Agents; D | 1995 |
Cross-resistance to thymidylate synthase inhibitors in P-glycoprotein and non-P-glycoprotein cell lines.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, | 1994 |
[Treatment of tongue squamous cell carcinoma under hemodialysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1995 |
Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcino | 1993 |
Folinic acid plus 5-FU based chemotherapy in squamous cell carcinoma of the head and neck: Bologna experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1993 |
Fine needle aspiration (FNA) in diagnosing recurrent squamous cell carcinoma of the head and neck: truth or consequences?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cobalt Rad | 1993 |
Penile cancer chemotherapy: twelve years' experience at Institut Gustave-Roussy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplati | 1993 |
Concurrent radiation therapy and chemotherapy in the treatment of primary squamous cell carcinoma of the vulva.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carci | 1995 |
Combined chemoradiotherapy for locally advanced squamous cell carcinoma of the bulbomembranous urethra: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1995 |
Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; Cell Line; Cell Survival | 1995 |
Combination radiation and chemotherapy for the treatment of squamous cell carcinoma of the male and female urethra.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1995 |
[Cisplatin-fluorouracil chemotherapy in epidermoid cancers of glottic origin staged as T2].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
The influence of age on the management of anal cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamo | 1995 |
[Cisplatin-based chemotherapy for advanced basal and squamous cell carcinomas].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Basal Cell; Carc | 1994 |
Combination chemotherapy and radiotherapy for a locally advanced squamous cell carcinoma of the urethra: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 1995 |
[Accelerated hyperfractionated radiotherapy combined with simultaneous chemotherapy in locally advanced pharyngeal and oral carcinomas].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1994 |
Influence of inductive chemoradiotherapy on salivary polymorphonuclear leukocyte (SPMN) functions in oral cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Candidiasis, Oral; Carcinoma, Squamous | 1994 |
[Method for daily administration of low-dose CDDP and 5-FU combined with radiotherapy for oral squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1995 |
Carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1995 |
[Flow cytometric DNA analysis and chemosensitivity in squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Agents; Carbazilquinone; Carcinoma, Squam | 1994 |
Changes of blood viscosity in patients treated with 5-fluorouracil--a link to cardiotoxicity?
Topics: Adult; Aged; Blood Viscosity; Carcinoma, Squamous Cell; Fibrinogen; Fluorouracil; Head and Neck Neop | 1995 |
Induction chemotherapy in advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Humans; Infusion | 1994 |
Chemotherapeutic management of head and neck malignancies with positron emission tomography.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxyglucose; F | 1995 |
Topical use of 5-fluorouracil for treatment of squamous cell carcinoma of the external genitalia of horses: 11 cases (1988-1992).
Topics: Administration, Topical; Animals; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Debridement; Fem | 1994 |
Treatment of actinic keratoses. "Life in the fast lane".
Topics: Carcinoma, Squamous Cell; Fluorouracil; Humans; Keratosis; Neoplasms, Radiation-Induced; Recurrence; | 1995 |
Anti-proliferative activity of interferon-alpha on human squamous carcinoma of tongue cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Division; Cell Surviv | 1994 |
5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation.
Topics: Acute Disease; Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lip Ne | 1994 |
Patterns of failure in carcinoma of the upper esophagus after alternating chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1994 |
[A retrospective study on the importance of preoperative control in the prognosis of spinocellular carcinoma of the oral cavity].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; F | 1994 |
[Concomitant radiotherapy and chemotherapy with protracted low dose continuous infusion of 5-fluorouracil and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1994 |
[Neoadjuvant chemoradiotherapy in esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
[Tissue concentration of tegafur suppository in patients with head and neck cancer--concentration of 5-FU in cancer tissue].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neopla | 1994 |
[Effect of fagopyrum cymosum rootin on clonal formation of four human tumor cells].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drugs, Chinese Herbal; | 1993 |
Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Comb | 1994 |
The spectrum of 5-fluorouracil cardiotoxicity.
Topics: Adenoma; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Digestive System Neoplasms; Fema | 1994 |
Pilot study for the evaluation of simultaneous cisplatin/5-fluorouracil infusion and limited radiation therapy in regionally recurrent head and neck cancer (EST P-C385).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1994 |
[Effect of a cisplatin-5-fluorouracil combination chemotherapy on malignant transformation of the epithelium of mouth mucosa].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Di | 1994 |
Chemoradiotherapy of esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1994 |
Squamous-cell carcinoma of the anus in HIV-positive patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anu | 1994 |
[The tumor pathomorphosis and status of the regional lymph nodes after the preoperative polychemotherapy of patients with vulvar cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 1993 |
Inhibition of catabolic pathway of 5-fluorouracil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissues.
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lung; Lung Neoplasms; | 1994 |
[The optimal timing of irradiation in radiochemotherapy with cisplatin and fluorouracil/folinic acid].
Topics: Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; Humans; Leucovorin; Ti | 1994 |
[Operation combined with chemotherapy for 63 cases of cervical carcinoma in the Xinjiang Kashi area].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv | 1993 |
Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, | 1994 |
Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 1994 |
[Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1993 |
Histopathological findings after preoperative chemo-radiotherapy in oral and oropharyngeal carcinoma. A study of 28 resected specimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1993 |
Laparoscopic intestinal stomas.
Topics: Adenocarcinoma; Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Colonic Diseases; Colostomy; | 1994 |
[Nocturnal infusion of 5-fluorouracil in advanced digestive tract cancer--two case reports].
Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Circadian Rhythm; Drug Administration Schedule; Eso | 1994 |
Relationship between fluorouracil systemic exposure and tumor response and patient survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1994 |
Results of treatment of laryngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Female; Fluorouracil | 1994 |
[Expression of oncogenes C-myc, C-raf and N-ras in advanced cancers of the upper respiratory and digestive tracts. Correlation with tumor clinical response to chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1993 |
Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin.
Topics: Anal Gland Neoplasms; Animals; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Co | 1993 |
Carcinoma of the anus treated with primary radiation therapy and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Clinical P | 1993 |
[Results of preoperative radio-chemotherapy in locally advanced squamous epithelial cancer of the esophagus].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1993 |
The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxyglucose; F | 1993 |
Combined modality therapy for locally advanced penile squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1993 |
Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 1993 |
Predictive factors of a complete response to and adverse effects of a CDDP-5FU combination as primary therapy for head and neck squamous carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1993 |
Acute tumor lysis syndrome with squamous cell carcinoma of the vulva.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; F | 1993 |
[Local use of a drug combination consisting of fluorouracil, cyclophosphamide and silicone sorbent in patients with colonic cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Administration, Topical; Antineoplastic Combined Chemother | 1993 |
Locoregionally advanced paranasal sinus carcinoma. Favorable survival with multimodality therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Ci | 1993 |
Epidermoid carcinoma of the anal canal: treatment by combined radiation and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 1993 |
[Multimodality treatment of esophageal carcinoma: evaluation of preoperative (neoadjuvant) chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1993 |
[A case of nonresectable esophageal cancer treated by the combination of cisplatin, 5-fluorouracil and THP-adriamycin].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1993 |
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1993 |
Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemothera | 1993 |
[A case report of an advanced esophageal carcinoma treated by neoadjuvant chemotherapy (CDDP + 5-FU) and evaluation of effect on metastatic lymph nodes].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1993 |
In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesis.
Topics: Carcinoma, Squamous Cell; Cell Division; Deoxyuridine; DNA, Neoplasm; Drug Screening Assays, Antitum | 1993 |
Synchronous radiotherapy and chemotherapy in the treatment of nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1993 |
Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1993 |
Chemoradiotherapy of anal carcinoma: tumour response and acute toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1993 |
Carboplatin and 5-fluorouracil in advanced and recurrent squamous carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administ | 1993 |
Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1993 |
[5-fluorouracil + low-dose leucovorin and cisplatin sequential chemotherapy with dipyridamole for advanced nonresectable squamous cell carcinoma of the lung: a case report].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1993 |
An alternative treatment of anal squamous cell carcinoma: combined radiotherapy and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1993 |
High dose rate intraluminal radiation in a combined modality treatment plan for carcinoma of the esophagus.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous C | 1993 |
Long-term follow-up of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and possible postoperative radiotherapy and/or chemotherapy in squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1993 |
Treatment of relapsing anal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1993 |
Analysis of the results of combined therapy for maxillary carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Carcinoma, Squamous Cell; Combine | 1993 |
Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1993 |
Irradiation of carcinoma of the esophagus containing a tracheoesophageal fistula.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1993 |
Neoadjuvant and salvage chemotherapy with cisplatin (CDDP) and 5-fluorouracil (5-FU) in cervical carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcino | 1993 |
DNA content and tumor response to induction chemotherapy in patients with advanced laryngeal squamous cell carcinoma.
Topics: Aged; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplati | 1993 |
[Study of serum CDDP concentrations in patients with advanced or recurrent adeno-or squamous cell carcinoma under combination chemotherapy of 5-FU (CIV) and low-dose CDDP (IV)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1996 |
Intralesional sustained-release chemotherapy with therapeutic implants for treatment of canine sun-induced squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Delayed-Action Preparations; Di | 1995 |
Prolonged survival follows resection of oesophageal SCC downstaged by prior chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1996 |
Management for patients with advanced T4 epidermoid carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1996 |
Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 1996 |
Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; DNA Damage; Drug Resistance; Fluorouraci | 1996 |
High complete response rate of concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the uterine cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carcinoma, Sq | 1996 |
Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
[Acute cerebellar syndrome after treatment with 5-fluorouracil].
Topics: Alcoholism; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cerebellar Ata | 1996 |
Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 1996 |
[Effect of preoperative oral 5-fluorouracil on cell cycle of advanced cervical squamous cell carcinoma].
Topics: Administration, Oral; Adult; Carcinoma, Squamous Cell; Cell Cycle; Chemotherapy, Adjuvant; Female; F | 1996 |
[Concomitant radiochemotherapy in locally advanced ORL cancers: a prospective study of 68 cases].
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1996 |
[Perioperative chemotherapy of squamous cell carcinoma of the hypopharynx].
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemot | 1996 |
[CF/5-FU-DDP therapy for esophageal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Es | 1995 |
[Radiotherapy of inoperable esophageal cancer. Retrospective analysis apropos of 108 cases].
Topics: Actuarial Analysis; Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplast | 1990 |
Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 1996 |
Concurrent 5-fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 1995 |
[Cancer of the penis].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modalit | 1995 |
Peritumoral angiogenesis in carcinomas of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Flow Cytometry; Fluorouracil; | 1996 |
Management of carcinoma anal canal with combination chemotherapy and concurrent radiotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 1996 |
Preliminary report of outpatient weekly adjuvant chemotherapy for high-risk nasopharyngeal carcinoma.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1996 |
Epidermoid anal cancer in HIV infected patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Combined M | 1996 |
Management of invasive squamous cell carcinoma of the bulbomembranous male urethra with co-ordinated chemo-radiotherapy and genital preservation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Comb | 1996 |
Combined effect of clinically relevant doses of emitefur, a new 5-fluorouracil derivative, and radiation in murine tumours.
Topics: Animals; Antineoplastic Agents; Body Weight; Carcinoma, Squamous Cell; Combined Modality Therapy; Dr | 1996 |
[Biochemical modulation applied to experimental cancer chemotherapy].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Screening As | 1996 |
Enhanced acute toxicity in oropharynx carcinoma treated with radiotherapy and concomitant cisplatin, 5-fluorouracil and mitomycin C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1996 |
[Results of adjuvant chemotherapy of operated high risk cervix carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 1996 |
[A case of primary squamous cell carcinoma of the ureter: biochemical modulation with cisplatin and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1997 |
[Accelerated hyperfractionated simultaneous radiochemotherapy in advanced head-neck carcinomas in comparison: split course and concomitant boost concept].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1996 |
Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1997 |
[A case report of tongue cancer presenting with SSD type brain embolism induced by chemotherapy with CBDCA and 5-FU].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
[A case of advanced esophageal cancer successfully treated by concurrent use of radiotherapy and low-dose CDDP and continuous infusion of 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1997 |
[Continuous infusion high-dose leucovorin with cisplatin and 5-fluorouracil for a recurrent oropharynx carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administra | 1997 |
[Outcome of simultaneous radiochemotherapy of anal carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 1997 |
Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 1997 |
[Induction chemotherapy based on histoculture drug response assay for a patient with advanced thymic cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Dr | 1997 |
p53 overexpression and mutation, chemoresistance and patient survival in oral and maxillofacial squamous cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Sq | 1997 |
Growth inhibition and apoptotic cell death in uterine cervical carcinoma cells induced by 5-fluorouracil.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous | 1997 |
Carcinoma of the esophagus treated with radical chemoradiation 19 years after irradiation for recurrent breast cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamou | 1997 |
[Changes in the nuclear morphometry in oropharyngeal epidermoid carcinoma after induction chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Humans; Immun | 1997 |
Inhibition of growth in oral squamous carcinoma cells by cyclopentenone prostaglandins: comparison with chemotherapeutic agents.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Dinoprostone; Fluorouracil; Humans; | 1997 |
Intensive chemotherapy using cisplatin and fluorouracil followed by radiotherapy in advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1997 |
Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1997 |
[Split-course concomitant radiochemotherapy plus surgery vs. surgery alone in squamous cell carcinoma of the esophagus. A non-randomized retrospective study of 184 patients].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1997 |
[A case of FIGO stage IV A vulvar cancer successfully treated by neoadjuvant chemotherapy with continuous intra-arterial infusion (cisplatin, 5-fluorouracil)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemother | 1997 |
[Therapy pf cervical lymph node metastases of unknown primary tumor].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1997 |
Esophageal intramural pseudodiverticulosis with esophageal cancer improved by target rotation irradiation: case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1997 |
Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cisplatin; DNA Repair; DNA Topoisomerases | 1997 |
Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplas | 1997 |
Accelerated fractionation in esophageal cancers: a multivariate analysis on 88 patients.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemothera | 1997 |
Quality of life of disease-free survivors of advanced (stage III or IV) oropharyngeal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 1997 |
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1997 |
Effectiveness of selective neck dissection for management of the clinically negative neck.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1997 |
Hypercalcemia and carcinoma of the penis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 1997 |
Multimodality treatment in the management of esophageal cancer: neoadjuvant chemoradiotherapy followed by transhiatal esophagectomy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemothera | 1997 |
Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1997 |
[Evaluation of a new anti-cancer drug regimen against uterine cervical cancer in nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Ca | 1997 |
[A case of local advanced cervical esophageal cancer treated with concurrent radiochemotherapy followed by surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1997 |
[A case of advanced primary ureteral squamous cell carcinoma responding to combination chemotherapy with cisplatin and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1997 |
Conjunctival squamous cell carcinoma treated with topical 5-fluorouracil.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamo | 1997 |
[Polarographic detection of reoxygenation of lymph node metastases in the initial phase of primary radio- and radiochemotherapy in patients with advanced squamous epithelial carcinomas of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
[Combination of induction chemotherapy with surgery and/or radiotherapy in locally advanced head and neck cancers. A retrospective analysis of a series of 125 patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Treatment of superficial ulcerative squamous cell carcinoma in three horses with topical 5-fluorouracil.
Topics: Administration, Topical; Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Female; | 1997 |
Intratumoral chemotherapy with fluorouracil/epinephrine injectable gel: a nonsurgical treatment of cutaneous squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Delayed-A | 1998 |
Squamous cell carcinoma of the vulva in the south of Israel: a study of 50 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1998 |
[Importance of AUC of carboplatin in head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous C | 1998 |
[Epidermoid cancer of the esophagus: role of radiotherapy and chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1998 |
[A case report of esophageal carcinoma with grade 3 response by preoperative chemotherapy using CDDP/5-FU/LV].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1998 |
Intranodal injection of anticancer drugs into fixed cervical metastatic lymph nodes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1997 |
[Thymidylate synthase expression in patients with hypopharyngeal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; F | 1998 |
Induction chemotherapy and radiotherapy in loco-regionally advanced epidermoid carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carb | 1998 |
Expression of platelet-derived endothelial cell growth factor in oral and oropharyngeal carcinoma.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Female; Fluorouraci | 1998 |
Interaction of tomudex with radiation in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Lewis Lung; Carcinoma, Squamous Cell; Cell Surv | 1998 |
[A case of left main bronchus obstruction due to recurrent esophageal cancer successfully treated by Nd-YAG laser followed by radiotherapy, low-dose CDDP and continuous infusion of 5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Diseases; Bronchial Neoplasms; Carcinoma, | 1998 |
Pre-operative sequential chemo- and radiochemotherapy in locally advanced carcinomas of the lower oesophagus and gastro-oesophageal junction.
Topics: Adenocarcinoma; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1998 |
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcino | 1998 |
Fatal acute tumor lysis syndrome following treatment of vulvar carcinoma: case report.
Topics: Aged; Carcinoma, Squamous Cell; Cisplatin; Diabetes Complications; Fatal Outcome; Female; Fluorourac | 1998 |
Neoadjuvant chemotherapy and hyperfractionated radiotherapy with concurrent low-dose chemotherapy for squamous cell esophageal carcinoma.
Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, A | 1998 |
Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 1998 |
High dose rate intraoperative radiation therapy (HDR-IORT) as part of the management strategy for locally advanced primary and recurrent rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Carcinom | 1998 |
[Combined chemotherapy with low-dose cisplatin, tegafur and uracil in a case with neck recurrence of laryngeal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1998 |
p53 tumor suppressor protein and H-RAS oncogene in maxillofacial tumors: immunohistochemical and genetic investigation, induction chemotherapy response and prognosis evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1998 |
Squamous-cell carcinoma of the pelvis in a giant condyloma acuminatum: use of neoadjuvant chemoradiation and surgical resection: report of a case.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1998 |
[How toxic and effective is simultaneous radiochemotherapy with hydroxyurea, 5-FU and cisplatin in cervix carcinoma?].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1998 |
[Second recurrence of a local spinocellular cutaneous epithelioma: treatment with intra-arterial sequential chemo-infusion].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 1998 |
[Augmented antitumor efficacy of combination chemotherapy of nedaplatin with 5-fluorouracil in in vivo murine and human tumor model].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carcinoma, Squamous | 1998 |
Supraventricular arrhythmia: a complication of 5-fluorouracil therapy.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atr | 1998 |
Treatment of anal carcinoma in the elderly: feasibility and outcome of radical radiotherapy with or without concomitant chemotherapy.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 1999 |
Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Anus Neoplasms; Calcium Channel Blockers; Car | 1999 |
p53- and p21-independent apoptosis of squamous cell carcinoma cells induced by 5-fluorouracil and radiation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibi | 1998 |
[Prognostic factors in combined radiochemotherapy of the anal canal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1998 |
Effect of 5-fluorouracil on gastrointestinal carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinogens; Carcinoma, Squamous Cell; Flu | 1999 |
Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 1999 |
Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1999 |
Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1999 |
Management of the neck after alternating chemoradiotherapy for advanced head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cispl | 1999 |
Induction chemotherapy and radiation therapy for T4 oropharyngeal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisp | 1999 |
Comparison of survival rates of patients with nasopharyngeal carcinoma treated with radiotherapy, 5-fluorouracil and vitamin A ("FAR" therapy) vs FAR therapy plus adjunctive cisplatin and peplomycin chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 1999 |
Induction of apoptosis in maxillary sinus cancer cells by 5-fluorouracil, vitamin A and radiation (FAR) therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; | 1999 |
Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta-A | 1999 |
Metaplastic breast cancer: prognosis and response to systemic therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 1999 |
The inhibitory action of BOF-A2, a 5-fluorouracil derivative, on squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; DNA, Neoplasm; Drug Screening | 1999 |
Manganese superoxide dismutase negatively regulates the induction of apoptosis by 5-fluorouracil, peplomycin and gamma-rays in squamous cell carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Survival; Fluorouracil; Ga | 1999 |
Expression of hMSH2 correlates with in vitro chemosensitivity to CDDP cytotoxicity in oral and oropharyngeal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; DNA-Bind | 1998 |
Role of preoperative chemoradiation in the management of upper third thoracic esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1999 |
Clinical remission of xeroderma pigmentosum-associated squamous cell carcinoma with isotretinoin and chemotherapy: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Child; Cisplatin; Fluorour | 1999 |
Neoadjuvant chemotherapy before surgery for resectable carcinoma of the lower esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 1999 |
Mature results of a pilot study of pelvic radiotherapy with concurrent continuous infusion intra-arterial 5-FU for stage IIIB-IVA squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; F | 1999 |
[Chemoradiation therapy for advanced esophageal cancers--report of 3 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1999 |
[Usefulness of combination therapy with expandable metallic stent replacement and FLEP chemotherapy (consisting of 5-FU, leucovorin, etoposide and cisplatin) for advanced esophageal cancer invading the bronchus: a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cispl | 1999 |
Preoperative chemotherapy for advanced esophageal cancer and relation with histological effect.
Topics: Actuarial Analysis; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Agen | 1999 |
High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 1999 |
Comparison between chemoradiation protocol intended for organ preservation and conventional surgery for clinical T1-T2 esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cause of Death; Cisp | 1999 |
Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1999 |
The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1999 |
The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Carcinoma, | 1999 |
Resectable esophageal carcinoma: local control with neoadjuvant chemotherapy and radiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Invasive squamous cell carcinoma with sporotrichoid metastasis in a patient with cutaneous T cell lymphoma treated with chronic extracorporeal photopheresis.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Carci | 1999 |
[Chemotherapy and surgery compared to surgery alone in localized cancer of the esophagus].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1999 |
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma of the undifferentiated type.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 1999 |
Intra-arterial infusion chemotherapy for penile carcinoma with deep inguinal lymph node metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1999 |
Neoadjuvant chemotherapy and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Car | 1999 |
[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer].
Topics: Actuarial Analysis; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1999 |
Guidelines for management of Bowen's disease. British Association of Dermatologists.
Topics: Antimetabolites; Bowen's Disease; Carcinoma, Squamous Cell; Cautery; Cryotherapy; Disease Progressio | 1999 |
[Curative treatment of non-metastatic esophageal cancer: concomitant chemoradiotherapy and high-dose-rate endoluminal curietherapy boost].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 1999 |
p53 expression in locally advanced pharyngeal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Antiepidermal growth factor receptor antibodies augment cytotoxicity of chemotherapeutic agents on squamous cell carcinoma cell lines.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Division; C | 2000 |
Anaphylaxis following continuous 5-fluorouracil infusion chemotherapy.
Topics: Anaphylaxis; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Fluorouracil; Humans; Male; | 1999 |
Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Colitis; Cytome | 1999 |
[Nasopharyngeal carcinoma: only irradiation or simultaneous radiochemotherapy?].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 1999 |
p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2000 |
Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2000 |
Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Conjunctiv | 2000 |
Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 2000 |
Nodal volume reduction after concurrent chemo- and radiotherapy: correlation between initial CT and histopathologic findings.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2000 |
Radiation with concurrent late chemotherapy intensification ('chemoboost') for locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2000 |
Primary chemo-radiotherapy and selective oesophagectomy for oesophageal cancer: goal of cure with organ preservation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2000 |
Primary lymphoepithelioma-like carcinoma of the lung.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Diagno | 2000 |
Conservative surgery in T3-T4 pharyngolaryngeal squamous cell carcinoma: an alternative to radiation therapy and to total laryngectomy for good responders to induction chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2000 |
p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophosphamide; F | 2000 |
5-Fluorouracil-induced apoptosis in cultured oral cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Caspase Inhibitors; Dose-Respo | 2000 |
[Histoculture drug response assay on non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Non- | 2000 |
[Pharmacologic markers predictive of neutropenia chemically induced by cisplatin (CDDP)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Choriocarcino | 1999 |
Induction chemotherapy followed by concurrent chemotherapy and high-dose radiotherapy for locally advanced squamous cell carcinoma of the upper-thoracic and midthoracic esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell | 2000 |
Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Bone Marrow; Bon | 2000 |
Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2000 |
Binary/ternary combined effects of vitamin K3 with other antitumor agents in nasopharyngeal carcinoma CG1 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Doxorubicin | 2000 |
Ischemic stroke following cisplatin and 5-fluorouracil therapy: a transcranial Doppler study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorour | 2000 |
[A case of advanced esophageal carcinoma successfully treated with chemoradiation therapy with low-dose cisplatin and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2000 |
Actinic keratosis: time to call a spade a spade.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Epidermis; Fluorouracil; Humans; Keratino | 2000 |
Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison.
Topics: Carcinoma, Squamous Cell; Chemexfoliation; Cryosurgery; Facial Dermatoses; Female; Fluorouracil; Fol | 2000 |
Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2000 |
Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; | 2000 |
Squamous cell carcinoma of the pancreas with cystic degeneration.
Topics: Abdominal Pain; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamou | 2000 |
Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2000 |
Successful treatment of oral squamous cell carcinoma with intralesional fluorouracil in a Malayan tapir (Tapirus indicus).
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Squamous Cell; Cephalosporins; Fluorour | 2000 |
Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2000 |
The bulky 6-cm barrel-shaped lesion of the cervix: primary surgery and postoperative chemoradiation.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combine | 2000 |
Malignant proliferating trichilemmal tumor in the skin over the breast: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Squamous | 2000 |
[Preservation of the larynx in advanced cancer--experiences at the Oncology Department, Rambam Medical Center, Haifa].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorou | 2000 |
[Postoperative simultaneous radiochemotherapy improves survival in patients with cervical carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Aden | 2000 |
[Chemotherapy for unresectable recurrent or metastatic squamous cell carcinomas of the head and neck].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2000 |
Histologically negative specimens after induction therapy: frequency and impact on survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cel | 2000 |
[Hepatic arterial infusion chemotherapy for liver metastasis from esophageal squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 2000 |
Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleoside phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Division; Dihydrouracil Dehydrogenas | 2000 |
A case of inoperable esophageal carcinoma with hepatic and nodal metastases which showed a long-term survival after chemoradiotherapy including nedaplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedu | 2000 |
Acute reversible cardiomyopathy and thromboembolism after cisplatin and 5-fluorouracil chemotherapy--a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cardiomyopathies; Cisplati | 2000 |
Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2000 |
Treatment of neck nodes after induction chemotherapy in patients with primary advanced tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2000 |
[Chemotherapy with nedaplatin for an oral floor cancer patient undergoing chronic hemodialysis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration | 2000 |
CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers.
Topics: Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Squamous Cell; cdc25 Phosphatases; Cell Cycle; C | 2000 |
In vivo evaluation of a novel antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Hypoxia; Chromatography, High Pressur | 2001 |
Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man.
Topics: Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma in Situ; | 2001 |
Assessment of the predictive value of clinical and histopathological factors as well as the immunoexpression of p53 and bcl-2 proteins in response to preoperative chemotherapy for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2000 |
Late esophageal toxicity using a combination of external beam radiation, intraluminal brachytherapy and 5-fluorouracil infusion in carcinoma of the esophagus.
Topics: Brachytherapy; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagus; Female; Fluorouracil; Huma | 2000 |
Experience with split-course external beam irradiation +/- chemotherapy and integrated Ir-192 high-dose-rate brachytherapy in the treatment of primary carcinomas of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2001 |
Squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Analysis of Variance; Antineoplastic Combined Chemothera | 2001 |
[A case report of radiation-induced cancer of the buccal mucosa, effectively treated with CF therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2001 |
Base of tongue carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Che | 2001 |
[Two cases of squamous cell carcinoma of the anal canal treated with chemoradiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisp | 2001 |
The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Bindin | 2001 |
Localized squamous-cell cancer of the esophagus: retrospective analysis of three treatment schedules.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cause of Death; Cisplatin; | 2001 |
[Development of new treatment modalities for advanced head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bacterial Proteins; Bridged-Ring Compound | 2001 |
A preclinical model for experimental chemotherapy of human head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Body Weight; Carboplatin; | 2001 |
Topical 5-fluorouracil to treat multiple or unresectable facial squamous cell carcinomas in xeroderma pigmentosum.
Topics: Administration, Topical; Adolescent; Adult; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cel | 2001 |
The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2001 |
Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Erythropoietin; Female; Fl | 2001 |
Influence of chemotherapy on endosteal implant survival and success in oral cancer patients.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2001 |
Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients: A long-term quality of life analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; En | 2001 |
Bazex syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Ear, External; | 2001 |
[Neoadjuvant treatment in surgery of esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2000 |
Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; California; Carcinom | 2001 |
Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer.
Topics: Aged; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squa | 2001 |
Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer.
Topics: Adult; Aged; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 2001 |
Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck--preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoth | 2001 |
Second primary cardiac B-cell lymphoma after radiation therapy and chemotherapy--a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cisp | 2001 |
[Concomitant bifractionated radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in locally progressive, non-resectable epidermoid carcinomas of the pharynx: ten years experience at the Antoine Lacassagne center].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2001 |
[Chemoradiotherapy and salvage surgery in a patient with advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administra | 2001 |
[Tissue platinum distribution and the effect following intra-arterial injection of cisplatin to metastatic liver cancer--a case report].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2001 |
Squamous cell carcinoma of the oesophagus treated with radiation and 5-fluorouracil, with and without mitomycin C.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as T | 2001 |
[A case of mandibular gingival cancer T4N0M0 which markedly responded to a combined therapy of nedaplatin with 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration | 2001 |
Dihydropyrimidine dehydrogenase mRNA level correlates with the response to 5-fluorouracil-based chemo-immuno-radiation therapy in human oral squamous cell cancer.
Topics: Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Combined Mo | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
[Significant role of cisplatin and 5-FU combination chemotherapy for first-line intensive treatment for advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2001 |
[A case of postoperative multiple hepatic metastasis from esophageal cancer successfully treated by surgical resection and hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2001 |
[A patient with esophageal cancer with subcutaneal abscess and esophago-tracheal fistula who survived more than 2 years following treatment by drainage and chemoradiation therapy].
Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Draina | 2001 |
[Severe interstitial pneumopathy due to herpes virus after radiochemotherapy for esophageal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2001 |
Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Therapy, Combination; F | 2001 |
Mn-SOD antisense upregulates in vivo apoptosis of squamous cell carcinoma cells by anticancer drugs and gamma-rays regulating expression of the BCL-2 family proteins, COX-2 and p21.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apopto | 2001 |
Restoration of vision following combination chemotherapy of nasopharyngeal carcinoma choroidal metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Choroid Neoplasms; | 2001 |
Telomerase activity in esophageal squamous cell carcinoma: down-regulation by chemotherapeutic agent.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Case-Control Studies; DNA-Binding P | 2002 |
Chemoradiation for metastatic SCCA: role of comorbidity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Comorbidity; Fluorouracil; | 2001 |
[A case of advanced hypopharyngeal carcinoma successfully treated with superselective intra-arterial infusion of docetaxel].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2002 |
Radiochemotherapy for anal carcinoma - effectivity and late toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2002 |
Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis.
Topics: Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Clostridium; Cytosine Deaminase; Flucytosine; Fluor | 2002 |
Results of multimodality therapy for squamous cell carcinoma of maxillary sinus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Concomitant chemoradiotherapy in pyriform sinus carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2002 |
Advanced esophageal cancer with esophago-bronchial fistula successfully treated by chemoradiation therapy with additional endoscopic resection: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Fistula; Carcinoma, Squamous Cell; Cisplat | 2002 |
Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2002 |
Prediction of survival in patients with head and neck cancer using the histoculture drug response assay.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Survival; Cis | 2002 |
Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2002 |
[Induction chemotherapy and larynx preservation: is such practice useful?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2002 |
Multiple neoplasms: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; Blepharoplasty; Carcinoma in Situ; Carcinoma, Squamous Cell; | 2002 |
Trimodal combination therapy for maxillary sinus carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combin | 2002 |
A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, S | 2002 |
Squamous carcinoma of the external auditory canal: a different approach.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Combined Modality | 2002 |
[Non-randomized clinical study comparing chemotherapy plus radiotherapy with radiotherapy alone in neoadjuvant therapy for oral cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2002 |
Management of oral and pharyngeal cancer: a multidisciplinary approach.
Topics: Bleomycin; Carcinoma, Squamous Cell; Fluorouracil; Humans; Lymphatic Metastasis; Mouth Floor; Mouth | 1975 |
[Topical chemotherapy for carcinoma of the skin (author's transl)].
Topics: Administration, Topical; Adolescent; Aged; Bleomycin; Bowen's Disease; Carcinoma, Basal Cell; Carcin | 1975 |
[Radiotherapy of inoperable orofacial squamous epithelial carcinomas following pharmacologically induced partial synchronization].
Topics: Aged; Carcinoma, Squamous Cell; Cell Movement; DNA; Fluorouracil; Humans; Male; Mouth Neoplasms; Neo | 1975 |
Seven-drug polychemotherapy in the treatment of advanced and recurrent squamous carcinoma of the female genital tract.
Topics: Adult; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Dac | 1975 |
Letter: 5-Fluorouracil versus immunotherapy for non-clinical vaginal cancer.
Topics: Carcinoma, Squamous Cell; Dinitrochlorobenzene; Drug Evaluation; Female; Fluorouracil; Humans; Nitro | 1976 |
[Chemoradiation therapy of inoperable lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Dactinomycin; Fl | 1975 |
Irradiation treatment of inoperable squamous cell carcinomas of the oral cavity and oropharynx after partial synchronisation.
Topics: Bleomycin; Carcinoma, Squamous Cell; Fluorouracil; Mitosis; Mouth Neoplasms; Pharyngeal Neoplasms; T | 1976 |
Letter: 5-F.U. or D.N.C.B. for non-clinical vaginal and cervical cancer.
Topics: Carcinoma, Squamous Cell; Dinitrochlorobenzene; Drug Evaluation; Female; Fluorouracil; Humans; Nitro | 1976 |
Regional chemotherapy with combined drugs in cancer of the head and neck.
Topics: Aged; Bleomycin; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Head and | 1976 |
Quadruple chemotherapy in advanced squamous cell carcinoma of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Combinations; Fluorouracil; Head and Nec | 1976 |
Bleomycin (NSC-125066) followed by cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and 5-fllorouracil (NSC-19893) for non-oat cell bronchogenic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; | 1976 |
[Recent personal results in advanced bronchial cancer. Palliative immuno-chemotherapy. 63 cases].
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamou | 1976 |
Dramatic palliation for painful, fixed bladder squamous cell carcinoma with 5-fluorouracil infusion.
Topics: Carcinoma, Squamous Cell; Cobalt Radioisotopes; Fluorouracil; Humans; Infusions, Parenteral; Male; M | 1977 |
Cell-kinetical analyses of squamous cell carcinomas of the oral region and the effect of a combined therapy of 5 fluorouracil and irradiation. A contribution to the discussion about tumorcell-synchronization.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Cell Division; Cell Movement; Cytological Techniqu | 1977 |
Enhancement of the cancer chemotherapeutic effect by anticancer agents in the form of fat emulsion.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Animals; Bleomycin; Breast Neoplasms; Carcinoma, | 1977 |
Long-term topical 5-FU therapy: report of two cases.
Topics: Administration, Topical; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Neoplas | 1978 |
Adriamycin alone or in combination in 100 patients with carcinoma of the cervix or vagina.
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Dactin | 1978 |
Palliation of inoperable head and heck cancer: combined intra-arterial infusion chemotherapy and irradiation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Carotid Artery, External; | 1978 |
Combination chemotherapy of head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bleomycin; Bone Marrow; Carcinoma, Squamous Cell; Cy | 1978 |
Management of carcinoma of the extrahepatic bile ducts.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Child; Commo | 1978 |
[Long-term results of synchronized radiotherapy in inoperable orofacial squamous cell carcinoma].
Topics: Bleomycin; Carcinoma, Squamous Cell; Drug Evaluation; Fluorouracil; Humans; Mouth Neoplasms; Pharyng | 1978 |
Treatment of carcinoma of base of tongue with radiation therapy and 5-fluorouracil. Potential for optimization with 18F-FU.
Topics: Carcinoma, Squamous Cell; Cobalt Radioisotopes; Female; Fluorouracil; Humans; Male; Middle Aged; Pro | 1979 |
[Experimental study relating to the anti-cancer effect of FT-207 suppository (author's transl)].
Topics: Animals; Carcinoma, Squamous Cell; Female; Fluorouracil; Methylcholanthrene; Mice; Neoplasms, Experi | 1979 |
Susceptibilities of normal and malignant human lung cells in culture to the cytocidal action of antitumor agents.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line; Cell Survival; Doxorubicin; Drug Evaluat | 1978 |
Walter Hubert lecture Chemotherapy of upper gastrointestinal carcinoma.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Hepatocellular; Carcinoma, S | 1976 |
In vitro incorporation of [3H]TdR in human and murine solid tumours. Influence of 5-fluorouracil and/or hyperbaric oxygen on spatial distribution of labelling.
Topics: Animals; Autoradiography; Carcinoma, Squamous Cell; Fluorouracil; Humans; Mice; Neoplasms; Neoplasms | 1979 |
Squamous cell carcinoma. Case report of an unusually aggressive skin cancer.
Topics: Aged; Carcinoma, Squamous Cell; Chin; Facial Neoplasms; Female; Fluorouracil; Humans; Keratosis; Ski | 1979 |
Carcinoma of the anus treated with a combination of radiotherapy and chemotherapy.
Topics: Adult; Anus Neoplasms; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1979 |
Squamous-cell carcinoma arising in a basal-cell epithelioma treated with 5-fluorouracil.
Topics: Adult; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Male; Neoplasms, Multi | 1979 |
Extensive malignancies of facial skin treated by perfusion with 5-fluorouracil and conservative excision.
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Facial Neoplasms; Female; Fluorouracil; Human | 1979 |
Treatment of Bowen's disease of the ear by the combined use of cryosurgery and topical 5-fluorouracil.
Topics: Administration, Topical; Bowen's Disease; Carcinoma, Squamous Cell; Cryosurgery; Ear Neoplasms; Ear, | 1979 |
Postirradiation squamous cell carcinoma in situ of the vagina: treatment by topical 20 percent 5-fluorouracil cream.
Topics: Administration, Topical; Adult; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Middle Aged; | 1979 |
[Synchronization of squamous-cell carcinoma cell populations by 5-fluorouracil in radiation therapy].
Topics: Aged; Carcinoma, Squamous Cell; Cell Cycle; Fluorouracil; Humans; In Vitro Techniques; Interphase; L | 1979 |
Bowen's disease and 5-fluorouracil.
Topics: Administration, Topical; Adult; Aged; Bowen's Disease; Carcinoma, Squamous Cell; Female; Fluorouraci | 1979 |
[Therapy of morbus Bowen with 5-fluoro-uracil ointment (author's transl)].
Topics: Bowen's Disease; Carcinoma, Squamous Cell; Cicatrix; Fluorouracil; Humans; Male; Skin Neoplasms; Tim | 1979 |
Heparin and polychemotherapy for treatment of lung cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; | 1977 |
[Recent result of simultaneous irradiation and 5-fluorouracil arterial infusion for cancer of the head and neck].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusi | 1977 |
Bowen's disease of the nail bed: a case presentation and review of the literature.
Topics: Bowen's Disease; Carcinoma, Squamous Cell; Dermatologic Agents; Fluorouracil; Humans; Keratolytic Ag | 1978 |
Could 5-FU therapy replace, or supplement, radical surgery in the treatment of squamous cancer of the head and neck?
Topics: Administration, Topical; Carcinoma, Squamous Cell; Fluorouracil; Head and Neck Neoplasms; Humans | 1978 |
Multidisciplinary preoperative approach to the management of epidermoid carcinoma of the anus and anorectum.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Middle Ag | 1978 |
Management of urinary bladder cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fem | 1978 |
Combined surgery, radiotherapy and regional chemotherapy in carcinoma of the maxillary sinus.
Topics: Bromodeoxyuridine; Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fluorouracil; | 1978 |
Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder.
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Drug Administration Sc | 1975 |
[Continuous local application of cytostatics for bronchial carcinoma and mediastinal lymph node metastasisization (author's transl)].
Topics: Adenocarcinoma; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regi | 1976 |
Bowen's Disease of the Finger.
Topics: Adult; Aged; Bowen's Disease; Carcinoma, Squamous Cell; Female; Fingers; Fluorouracil; Humans; Male; | 1977 |
Topical treatment of vaginal intraepithelial neoplasia.
Topics: Adult; Age Factors; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Pregnancy; Vaginal Neopl | 1977 |
[Topical use of antineoplastic agents in precancerous conditions of the skin].
Topics: Administration, Topical; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Kera | 1977 |
Chemotherapy of carcinoma of the cervix.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Squamous Cel | 1977 |
Bowen's disease.
Topics: Aged; Bowen's Disease; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Skin; Skin Neoplasms | 1977 |
Preoperative immunotherapy: a new concept.
Topics: Adult; Carcinoma, Squamous Cell; Fluorouracil; Humans; Male; Skin Neoplasms | 1977 |
Bowen's disease of shaft of penis. Successful treatment with 5-fluorouracil.
Topics: Administration, Topical; Adult; Bowen's Disease; Carcinoma, Squamous Cell; Fluorouracil; Humans; Mal | 1976 |
[Late results of lung cancer therapy (according to material from the Kazakh Scientific Research Institute of Oncology and Radiology)].
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Follow-Up Studi | 1976 |
[An clinical evaluation of the combined therapy for maxillary sinus carcinoma with irradiation and the intraarterial infusion of 5-FU (author's transl)].
Topics: Carcinoma, Squamous Cell; Drug Evaluation; Female; Fluorouracil; Humans; Injections, Intra-Arterial; | 1976 |
Erythroplasia of Queyrat: treatment with topical 5-fluorouracil.
Topics: Administration, Topical; Adult; Aged; Carcinoma in Situ; Carcinoma, Squamous Cell; Erythroplasia; Fl | 1976 |
Combined chemotherapy and cryosurgery for oral cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cryosurgery; Drug Therapy, Combination | 1975 |
[Continuous intra-arterial antiblastic chemotherapy in the treatment of rhinopharyngeal tumors invading the skull base. Association with radiotherapy].
Topics: Carcinoma, Squamous Cell; Fluorouracil; Humans; Injections, Intra-Arterial; Middle Aged; Neoplasm Me | 1975 |
Intraepithelial vaginal neoplasia following immunosuppressive therapy treated with topical 5-Fu.
Topics: Administration, Topical; Adult; Azathioprine; Biopsy; Carcinoma, Squamous Cell; Cervix Uteri; Female | 1975 |
Systemic chemotherapy of advanced head and neck malignancies.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Doxor | 1975 |
Delayed hypersensitivity in xeroderma pigmentosum.
Topics: Carcinoma, Squamous Cell; Child; Child, Preschool; Eye Diseases; Female; Fluorouracil; Humans; Hyper | 1975 |
Delayed hypersensitivity to 5-fluorouracil following topical chemotherapy of cutaneous cancers.
Topics: Administration, Topical; Biopsy; Carcinoma in Situ; Carcinoma, Basal Cell; Carcinoma, Basosquamous; | 1975 |
Squamous-cell carcinoma of the anus arising in a giant condyloma acuminatum: report of a case.
Topics: Administration, Topical; Anal Canal; Anus Diseases; Anus Neoplasms; Carcinoma, Squamous Cell; Condyl | 1975 |
[Chemotherapeutic combinations of mutually potentiating drugs. 2-Application to the treatment of bronchial cancers].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Squamous Cell; Drug Sy | 1975 |
[Conservative treatment of lung cancer].
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Therapy, Combination; Drug-Related | 1975 |
Arterial infusion of 5-FU as a therapeutic adjunct in the treatment of advanced carcinoma of bladder and prostate.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Fluorou | 1975 |
Multi-modality therapy for epidermoid carcinoma of the anus.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle | 1976 |
Treatment of Bowen's disease with topical dinitrochlorobenzene and 5-fluorouracil.
Topics: Arsenicals; Bowen's Disease; Carcinoma, Squamous Cell; Dinitrochlorobenzene; Fluorouracil; Humans; I | 1976 |
Current thoughts on the surgical treatment of rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; | 1976 |
[Intra-arterial infusion chemotherapy for recurrent cervical lymph nodes after surgery in esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug | 1992 |
Sequential MTX-5 FU chemotherapy in pallination of advanced cancer cervix.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 1992 |
Combined radiation and chemotherapy for epidermoid carcinoma of the anal canal.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorourac | 1992 |
[The efficacy of polychemotherapy with cisplatin, methotrexate and 5-fluorouracil in inoperable forms of squamous cell cancer of the head and neck area].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Eva | 1992 |
[Retrospective study of 139 cases of epidermoid carcinoma of the upper respiratory and digestive tracts treated by induction chemotherapy with cisplatin-5FU. Influence of the result on the therapeutic protocol].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1992 |
[Fundamental study of subrenal capsule assay by measuring specific activity of succinate dehydrogenase].
Topics: Animals; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Male; | 1992 |
Neoadjuvant chemotherapy in multiple synchronous head and neck and esophagus squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchial Neoplasms; Carcinoma, Squamous | 1992 |
[A case of locally advanced esophageal cancer effectively treated with concurrent chemotherapy and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1992 |
[Experimental study of CF chemotherapy, combined with another one chemotherapeutic drug against head and neck cancer cell lines].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Cycl | 1992 |
Dual sequential non-cross-resistant chemotherapy for advanced stage squamous cell carcinoma of the cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Cycl | 1992 |
Induction chemotherapy with carboplatin and 5-fluorouracil in combination with radiotherapy in loco-regionally advanced epidermoid carcinoma of the anus--preliminary results.
Topics: Adult; Aged; Anus Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; | 1992 |
[Treatment of advanced anal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Comb | 1992 |
Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line.
Topics: Carcinoma, Squamous Cell; Cell Count; Cell Survival; Cisplatin; Cross-Linking Reagents; DNA, Neoplas | 1992 |
Effects of folinic acid on 5-fluorouracil induced cell lethality with or without cisplatin against head and neck laryngeal squamous carcinoma multicellular tumor spheroids.
Topics: Carcinoma, Squamous Cell; Cell Count; Cell Death; Cisplatin; Dose-Response Relationship, Drug; Drug | 1992 |
[Effectiveness of cisplatin with continuous infusion of 5-fluorouracil in neoadjuvant chemotherapy of carcinoma of the oral cavity].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1992 |
[Acute intestinal ischemia after two treatments with 5-fluorouracil by continuous venous infusion].
Topics: Adult; Carcinoma, Squamous Cell; Fluorouracil; Humans; Infusions, Intravenous; Intestine, Small; Isc | 1992 |
[Transanorectal ultrasonography in the evaluation of extension and the monitoring of epidermoid cancers of the anus treated by radiation or chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1992 |
T1 squamous cell carcinoma of the arytenoid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arytenoid Cartilage; | 1992 |
Curative non-surgical combined treatment of squamous cell carcinoma of the oesophagus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1992 |
Comparison of intra-arterial versus intravenous 5-fluorouracil administration on epidermal squamous cell carcinoma in sheep.
Topics: Animals; Carcinoma, Squamous Cell; Disease Models, Animal; Drug Administration Schedule; Ear Neoplas | 1992 |
Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1992 |
The pre-operative treatment of oesophageal carcinoma with synchronously administered chemotherapy and radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1992 |
[Chemotherapy-associated hemolytic uremic syndrome--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1992 |
Prolonged chemotherapy for localised squamous carcinoma of the oesophagus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous-carcinoma cell line.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug S | 1992 |
Cisplatin and 5-fluorouracil in advanced cancer of the penis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fl | 1992 |
Cisplatin and 5-fluorouracil in advanced cancer of the penis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fl | 1992 |
Cisplatin and 5-fluorouracil in advanced cancer of the penis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fl | 1992 |
Cisplatin and 5-fluorouracil in advanced cancer of the penis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fl | 1992 |
Role of chemotherapy in oesophageal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Continuous infusion of low-dose 5-fluorouracil and radiation therapy for poor-prognosis squamous cell carcinoma of the uterine cervix.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorouracil; Humans; Infusions, Intrav | 1992 |
[Chemosensitivity of head and neck squamous cell carcinomas using subrenal capsule assay--comparative assay of 5-FU, FT, UFT, and HCFU and immunohistochemical study].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1992 |
Combined chemoradiation therapy for anal cancer. A report of 56 cases.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1992 |
Mode of interaction of 5-fluorouracil, radiation, and mitomycin C: in vitro studies.
Topics: Animals; Carcinoma, Squamous Cell; Cell Survival; Fluorouracil; In Vitro Techniques; Mice; Mitomycin | 1992 |
[Predictive factors of response to chemotherapy in epidermoid cancer of the esophagus. Study apropos of 60 patients and evaluation of a response score].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1992 |
[Analysis of cellular DNA content by flow cytometry in epidermoid carcinoma of the esophagus].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cispl | 1992 |
Preoperative chemotherapy and radiotherapy for esophageal carcinoma.
Topics: Actuarial Analysis; Adenocarcinoma; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Com | 1992 |
Triple therapy for advanced squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
[CT guided direct intervention chemotherapy of lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
[Evaluating the effectiveness of chemotherapy in patients with head-neck tumors using positron emission tomography (PET scan)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Carcinoma; Carcinoma, Squamous Cell; | 1992 |
Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery .
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1992 |
Influence of sex and age on fluorouracil clearance.
Topics: Adult; Aged; Aged, 80 and over; Aging; Analysis of Variance; Carcinoma, Squamous Cell; Female; Fluor | 1992 |
[Antineoplastic effectiveness and unwanted side effects of polychemotherapy of extensive oro- and hypopharyngeal cancers--results of a prospective therapy study with 5-FU/cisplatin versus 5-FU/carboplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Audiometry, Pure-Tone; Auditory Threshold; Bone Marr | 1992 |
High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; | 1992 |
[The clinical effect of cisplatin and 5-FU infusion in oral cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1992 |
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
Topics: Administration, Oral; Bone Marrow; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fluorouracil; H | 1992 |
Squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 1991 |
Heavy water enhances the antineoplastic effect of 5-fluoro-uracil and bleomycin in nude mice bearing human carcinoma.
Topics: Adenocarcinoma; Animals; Bleomycin; Carcinoma, Squamous Cell; Colonic Neoplasms; Deuterium; Drug Syn | 1990 |
[Comparative evaluation of radiotherapy and chemoradiotherapy in inoperable cancer of the esophagus].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1990 |
Oropharynx carcinoma: irradiation alone versus induction chemotherapy plus irradiation--5 year results.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous C | 1990 |
[Evaluation of multidisciplinary treatment involving chemotherapy with cis-diamminedichloroplatinum, bleomycin (peplomycin) and 5-fluorouracil for advanced esophageal carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1990 |
Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1990 |
Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1990 |
Phase II study of cisplatin and continuous-infusion 5-fluorouracil and bleomycin for recurrent and metastatic head and neck squamous-cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1990 |
Subrenal capsule assay as a chemosensitivity test for primary esophageal squamous cell carcinoma.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; | 1991 |
Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 1991 |
Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1991 |
[The combined radio-chemotherapy of inoperable esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co | 1990 |
[Radiotherapy of epidermoid cancers of the anal canal].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bleomycin; Carcinoma, Squamous Cell; | 1991 |
[Problems with topical therapies for extensive squamous cell carcinoma of the buttocks].
Topics: Administration, Topical; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Buttocks; Carcin | 1991 |
[Successful treatment of recurrent kidney pelvic squamous cell cancer with chemotherapy and radiotherapy: a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug | 1991 |
[Systemic therapy in recurrent and primary advanced cervix cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Cisplatin and 5-FU combined with radiotherapy and surgery in the treatment of squamous cell carcinoma of the esophagus. Palliative effects and tumor response.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1991 |
5-fluorouracil + folinic acid with cisplatinum and bleomycin in the treatment of advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1991 |
[Clinico-pathological studies on the effects of preoperative hyperthermo-chemoradiotherapy of advanced esophageal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1991 |
[Neo-adjuvant chemotherapy with cisplatin, 5-fluorouracil, vindesine in head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1992 |
Preoperative concurrent chemotherapy and radiotherapy for local-regional and advanced squamous cell carcinoma of the thoracic oesophagus: preliminary results of a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1991 |
Radiation myelitis: a complication of concurrent cisplatin and 5-fluorouracil chemotherapy with extended field radiotherapy for carcinoma of the uterine cervix.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 1991 |
Nasopharyngeal carcinoma: results of treatment by radiotherapy vs chemotherapy plus radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1991 |
[Cardiac toxicity of 5-fluorouracil. Two cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cispl | 1991 |
Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carc | 1991 |
[Regional immunochemotherapy for liver metastasis of esophageal cancer in a patient with variant hepatic artery].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1991 |
[Study of intermittent intra-arterial infusion chemotherapy in liver metastases from squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doxorubic | 1991 |
Combined modality treatment of advanced cancers of the oral cavity and oropharynx.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1991 |
Intraoperative radiation therapy in the treatment of recurrent carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1991 |
The force of change in the management of squamous-cell cancer of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1991 |
Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1991 |
Extrahepatic biliary system cancer: an update of a combined modality approach.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Brach | 1991 |
Concomitant chemo/radiotherapy for advanced carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 1991 |
Drug response of head and neck tumors in native-state histoculture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cell Division; | 1991 |
Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; | 1991 |
Cisplatin, vindesine, and 96-h continuous infusion of 5-fluorouracil as initial chemotherapy for locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1991 |
[The role of extensive Denkers operation in combined therapy for maxillary sinus carcinoma].
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Humans; Infusi | 1991 |
[Continuous Holter cardiac monitoring and chemotherapy by combination with platinum and fluoro-uracil].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Electrocardiography, Am | 1991 |
A pilot study of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and postoperative radiation therapy and/or chemotherapy in adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1991 |
Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1991 |
Cisplatin and 5-FU infusions in therapy of advanced squamous cell carcinoma of head and neck in 50 Indian patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1990 |
Osteoradionecrosis of sphenoid and temporal bones in a patient with maxillary sinus carcinoma: a case report.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Humans; Male; Maxillary Sinus Neo | 1990 |
Effectiveness of combined radio-chemotherapy in the management of epidermoid carcinoma of the anal canal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Combined M | 1990 |
Gustatory impairment and salivary gland pathophysiology in relation to oral cancer treatment.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Female; Fluorouracil; Humans; Male; Mid | 1990 |
Thermochemotherapy in inoperable head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheters, Indwellin | 1990 |
Low prevalence of cisplatin-induced neuropathy after 4-day continuous infusion in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; El | 1990 |
Comparison of pyrimidine nucleotide synthetic enzymes involved in 5-fluorouracil metabolism between human adenocarcinomas and squamous cell carcinomas.
Topics: Adenocarcinoma; Carbon-Nitrogen Ligases; Carcinoma, Squamous Cell; DCMP Deaminase; DNA-Directed DNA | 1990 |
Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human lung cancer cell lines.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Carcinoma, Squamous Cell; Cell Line; Dose-Respo | 1990 |
Toxicities of trichosanthin and alpha-momorcharin, abortifacient proteins from Chinese medicinal plants, on cultured tumor cell lines.
Topics: Abortifacient Agents, Nonsteroidal; Animals; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Ce | 1990 |
Cisplatin-fluorouracil interaction in a squamous cell carcinoma xenograft.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug A | 1990 |
A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1990 |
Hypercalcemia in head and neck squamous-cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorou | 1990 |
Long-term results after chemoradiotherapy for locally confined squamous-cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1990 |
Treatment of 29 patients with bulky squamous cell carcinoma of the cervix with simultaneous cisplatin, 5-fluorouracil, and split-course hyperfractionated radiation therapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; H | 1990 |
[A case of esophageal carcinoma with the lung and liver metastases surviving more than 3 years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Cell; Ci | 1990 |
Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin.
Topics: Arrhythmias, Cardiac; Carcinoma, Squamous Cell; Chest Pain; Cisplatin; Electrocardiography; Esophage | 1990 |
Intramural myocardial infarction under combined radiochemotherapy of an oesophageal carcinoma.
Topics: Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; | 1990 |
Efficacy and side effects of two chemotherapy regimens with cisplatin plus fluorouracil in advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 1990 |
5-Fluorouracil neurotoxicity.
Topics: Adult; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Middle Aged; Nervous System Diseases; | 1990 |
Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
Neutropenic enterocolitis. A new complication of head and neck cancer chemotherapy.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin | 1990 |
Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Fibrinogen; Fibrinopeptide A; Fluo | 1990 |
5-Fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; D | 1990 |
A phase II study of 5-fluorouracil/cisplatinum in recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
Treatment of oral squamous cell carcinoma with simultaneous chemotherapy and radiation: results and surgical implications.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1990 |
Tumor necrosis factor and cytotoxic agents. Effect on squamous carcinoma lines.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Colorimetry; Dactinomycin | 1990 |
Response and toxicity of cisplatin and 120-h 5-fluorouracil infusion in pretreated and untreated patients with advanced epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
Adjuvant methotrexate-5-fluorouracil for extracapsular squamous cell carcinoma in cervical metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1990 |
Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; F | 1990 |
Relation between responses to induction chemotherapy and subsequent radiotherapy in advanced or multicentric squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1990 |
[Assessment of individual sensitivity to chemotherapy of human pulmonary tumors transplanted to subrenal capsule of CBA mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamid | 1990 |
[Induction chemotherapy in cancer of the upper respiratory and digestive tract. Preliminary results of the protocol combining cisplatin, 5-fluorouracil and bleomycin (CFB)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 1985 |
Alternating combination chemotherapy using cisplatin-bleomycin with sequential methotrexate-5-FU plus leucovorin rescue in patients with head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluo | 1985 |
[Multidisciplinary treatment of head and neck cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1985 |
[Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II), cytosine arabinoside and 5-fluorouracil, for advanced urothelial cancer].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous | 1985 |
Multimodality therapy for unresectable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Cisplatin-containing chemotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Pretreatment with chemotherapy in patients with advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Cycl | 1985 |
Sequential methotrexate and 5-fluorouracil with bleomycin and cisplatin in the chemotherapy of advanced squamous cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Induction therapy in head and neck cancer. A comparison of two regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
[Induction chemotherapy in cancers of the respiratory and digestive tracts by continuous infusions combining cisplatinum (C), fluorouracil (F), bleomycin (B) or C and F].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Dige | 1986 |
Carcinoma of the nasopharynx. An analysis of 91 cases and a comparison of differing treatment approaches.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomyc | 1986 |
Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1986 |
Preoperative chemotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carci | 1986 |
Combined modality therapy utilizing a cisplatin combination for effective chemotherapy in patients with previously untreated head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluo | 1986 |
Combination chemotherapy with CDDP, 5-FU and PEP in head and neck malignant tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Nasopharyngeal carcinoma: a review of cases treated by radiotherapy and chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1987 |
Nonoperative therapy for squamous-cell cancer of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1987 |
CDDP and 5-FU after prior VBM or VBM after prior CDDP and 5-FU in the management of recurrent squamous cell carcinoma of the head and neck?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
[Critical remarks on chemotherapy of malignant tumors of the head and neck].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluo | 1987 |
Hyperthermia as an adjuvant to radiation- and/or chemotherapy in far advanced recurrences of the head and neck region.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 1987 |
Inoperable esophageal carcinoma: results of aggressive synchronous radiotherapy and chemotherapy. A pilot study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1987 |
[Sensitivity of antineoplastic agents in squamous cell carcinoma of the uterine cervix xenografted into nude mice].
Topics: Animals; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Drug Sc | 1987 |
Effect of intracellular folate concentration on the modulation of 5-fluorouracil cytotoxicity by the elevation of phosphoribosylpyrophosphate in cultured human KB cells.
Topics: Adenosine; Carcinoma, Squamous Cell; Cell Survival; Fluorouracil; Folic Acid; Glucose; Humans; KB Ce | 1987 |
Nonsurgical management of esophageal cancer: report of a study of combined radiotherapy and chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1987 |
[Combination chemotherapy including cisplatin in lung cancer by bronchial artery infusion].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S | 1988 |
Acute and late toxicity associated with sequential bleomycin-containing chemotherapy regimens and radiation therapy in the treatment of carcinoma of the nasopharynx.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 1988 |
Chemotherapy for paranasal sinus carcinoma. A 10-year experience at Wayne State University.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S | 1988 |
[Combined therapy of locally advanced squamous epithelial cancers in the area of the head and neck].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1988 |
Excellent response to cis-platinum-based chemotherapy in patients with recurrent or previously untreated advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carci | 1988 |
Chemotherapy of advanced head and neck squamous carcinoma with cisplatin, fluorouracil and bleomycin administered in an outpatient schedule.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, | 1988 |
Induction cytotoxic chemotherapy: the significance of apparent complete clinical regression after using the Price Hill Schedule A protocol for squamous carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1988 |
Superselective intra-arterial chemotherapy of advanced paranasal sinus tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ch | 1989 |
Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1989 |
Immunologic determinants of head and neck cancer response to induction chemotherapy.
Topics: Adult; Aged; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinom | 1989 |
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid | 1989 |
The use of simultaneous radiotherapy and 5-flurouracil in patients with inoperable squamous cell lung cancer.
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorouracil; Humans; Lung Neopla | 1989 |
Inhibited methionine incorporation in human squamous carcinomas of the oral cavity as a measure for response to 5-fluorouracil.
Topics: Carcinoma, Squamous Cell; Cell Division; Fluorouracil; Humans; Methionine; Mouth Neoplasms; Neoplasm | 1989 |
[Intra-arterial chemotherapy of maxillary sinus carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1989 |
[Effects of intra-arterial infusion chemotherapy in local recurrence of anal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bleomycin; Carcinoma, Squamous Cell; | 1989 |
[Treatment of squamous cell carcinoma of the head and neck with multi-drug chemotherapy and radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 1989 |
[Factors modifying remission in cytostatic chemotherapy of squamous cell carcinoma recurrence in the area of the head and neck].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1989 |
[The effects of etretinate and anticancer drugs on the cell line of a squamous cell carcinoma of human skin (HSC-1)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamou | 1989 |
96-hour continuous infusion of cis-platinum, 5-fluorouracil and bleomycin in recurrent or metastatic head and neck squamous cell carcinoma, unexpected anemia.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous | 1989 |
[Chemosensitivity of human head and neck tumors detected by human tumor clonogenic assay].
Topics: Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Histiocytoma, | 1989 |
Concomitant 5-fluorouracil infusion, mitomycin C and radical radiation therapy in esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; | 1989 |
Histologic tumor regression grades in squamous cell carcinoma of the head and neck after preoperative radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1989 |
Low dose combined chemotherapy/radiotherapy in the management of locally advanced urethral squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Comb | 1989 |
[Experimental study on the effect of UFT with concomitant radiotherapy of uterine cervical cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Carcinoma, Squamous Cell | 1989 |
[The concentration of 5-fluorouracil in blood and tissues of the patients with carcinoma of the cervix after administration of UFT and 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1989 |
Response to preoperative concomitant radiochemotherapy with mitomycin C and 5-fluorouracil in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1989 |
Cisplatin, 5-fluorouracil, mitomycin C, and concurrent radiation therapy with and without esophogectomy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1989 |
[Amoebic dysentery: a relapsing case by cancer chemotherapy].
Topics: Aged; Carcinoma, Squamous Cell; Dysentery, Amebic; Fluorouracil; Humans; Immune Tolerance; Immunity, | 1989 |
Epidermoid carcinoma of the anal canal. Results of treatment by combined chemotherapy and radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1989 |
Concurrent radiation and chemotherapy in vulvar carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 1989 |
Histological grading of therapy induced regression in squamous cell carcinomas of the oral cavity. A morphological and immunohistochemical study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; H | 1989 |
[Ventricular fibrillation of a favourable course during perfusion with fluorouracil].
Topics: Carcinoma, Squamous Cell; Fluorouracil; Humans; Male; Middle Aged; Ventricular Fibrillation | 1989 |
Severe dermatologic toxicity from 5-fluorouracil in the presence of seborrheic dermatitis.
Topics: Aged; Carcinoma, Squamous Cell; Dermatitis, Seborrheic; Fluorouracil; Humans; Male; Tongue Neoplasms | 1989 |
Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisp | 1989 |
[In vitro studies of 5-FU sensitivity on uterine cervical cancer cell lines--comparison between squamous cell carcinoma and adenocarcinoma].
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cell Survival; DNA, Neoplasm; Drug Screening Assays, Antit | 1989 |
Enhancement of fluoropyrimidine inhibition of cell growth by leucovorin and deoxynucleosides in a human squamous cell carcinoma cell line.
Topics: Carcinoma, Squamous Cell; Culture Media; Deoxyribonucleosides; Drug Synergism; Floxuridine; Fluorour | 1989 |
Prognostic indicators in head and neck cancer patients receiving combined therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
[Current status in the treatment of inoperable non-small cell lung cancer (NSCLC)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Small Cell; Ca | 1985 |
[Synchronization therapy as a palliative measure in incurable head and neck tumors].
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Head and | 1985 |
Postcricoid carcinoma: a retrospective study of 13 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co | 1985 |
Analysis of complete responders after initial treatment with chemotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
A phase II trial of cyclophosphamide and adriamycin in refractory squamous cell carcinoma of the head and neck. An effective salvage regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Radiotherapy for anal cancer: experience from 1979-1987.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Transitional Ce | 1989 |
[Various doses cisplatin combined with multi-drug chemotherapy of malignant solid tumors].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1989 |
Analysis of 16 patients with metastatic squamous cell carcinoma of the head and neck: implications for treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 1989 |
[Intra-arterial chemotherapy of ORL cancer. Value of an implantable infusion system and scintigraphic monitoring].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorou | 1989 |
Treatment of advanced squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 1989 |
[120-hour continuous 5-FU infusion and cisplatin in the treatment of advanced esophageal carcinoma--clinical analysis of 19 cases].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1989 |
[Experimental study on combination chemotherapy with platinum compounds and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cell Survival | 1989 |
Carboplatin and continuous infusion 5-fluorouracil for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1989 |
Simultaneous chemo-radiotherapy with 5-FU/folinic acid/cis-platinum and accelerated split-course radiation in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcino | 1989 |
Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314.
Topics: Anal Canal; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cobalt Radioisot | 1989 |
Lethal cardiac toxicity after cisplatin and 5-fluorouracil chemotherapy. Report of a case with necropsy study.
Topics: Aortic Diseases; Carcinoma, Squamous Cell; Cardiomyopathy, Dilated; Cisplatin; Embolism; Fluorouraci | 1989 |
Growth and chemosensitivity of human head and neck cancers implanted under the kidney capsule of cyclosporine-immunosuppressed mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cyclosporins; Fluorouracil; Hea | 1989 |
Postburn scar carcinoma.
Topics: Adult; Aged; Burns; Carcinoma, Squamous Cell; Cicatrix; Combined Modality Therapy; Female; Fluoroura | 1989 |
Concomitant radiation therapy and chemotherapy in the treatment of advanced squamous carcinoma of the lower female genital tract.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisp | 1989 |
[Toxicity of cisplatin with continuous infusion of 5-fluorouracil in neoadjuvant chemotherapy of carcinoma of the oral cavity].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1989 |
Neoadjuvant therapy of squamous cell carcinoma of the esophagus: role of resection and benefit in partial responders.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Treatment of advanced squamous cell carcinoma of head and neck with cisplatin and continuous 96 hour infusion of 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1989 |
A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1989 |
Accuracy of the subrenal capsule xenograft assay in predicting the clinical growth and chemosensitivity of human squamous head and neck carcinomas.
Topics: Animals; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Male; M | 1989 |
[Induction chemotherapy with Cis DDP-5FU in cancers of the upper respiratory and digestive tract after 70 years of age].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1989 |
Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1989 |
Cisplatin, fluorouracil with leucovorin calcium enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1989 |
Multimodality treatment of advanced head and neck carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Induction chemotherapy with cisplatin and continuous infusion 5-fluorouracil in locally far-advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1989 |
Preoperative combined modality therapy for stage III M0 non-small cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1988 |
Ischaemic pancolitis: a serious complication of chemotherapy in a previously irradiated patient. Case report.
Topics: Carcinoma, Squamous Cell; Cisplatin; Colitis; Combined Modality Therapy; Dysgerminoma; Esophageal Ne | 1989 |
5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1989 |
[Observations on 32 cases of advanced carcinoma of the esophagus and the proventriculus treated by the MOF III plan in combination with fu zheng kang ai tang].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cardia; Esoph | 1985 |
Watery diarrhea-hypokalemia-achlorhydria syndrome and carcinoma of the esophagus.
Topics: Achlorhydria; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; | 1985 |
High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamo | 1985 |
[Postoperative chemotherapy of pathological stage I non-small cell carcinoma of the lung].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; | 1986 |
Combination chemotherapy with CDDP and 5-FU in head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cyst | 1986 |
cis-platinum, 5-fluorouracil, and hydroxyurea in the treatment of advanced non-small-cell lung cancer. A phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 1987 |
Chemotherapy of the squamous cell lung cancer LC-12 with 5-fluorouracil, cisplatin, carboplatin or iproplatin combinations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisp | 1988 |
[Results of a phase II study with the new cytostatic drug carboplatin in combination with 5-fluorouracil in the primary treatment of advanced squamous cell cancers of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1988 |
Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squ | 1986 |
Squamous cell carcinoma of the rectum: a multimodality approach.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1986 |
Clinical evidence of feasibility and efficacy of simultaneous irradiation and chemotherapy in advanced squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinom | 1986 |
[Combined radio- and chemotherapy of anal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Colo | 1986 |
[Studies on oral-adjuvant chemotherapy of uterine cervical cancer after surgical treatment].
Topics: Adenocarcinoma; Administration, Oral; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Eval | 1986 |
A pilot study of mitomycin-C/5-fluorouracil infusion combined with split course radiation therapy for carcinomas of the larynx and hypopharynx.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Therapy, Combination; Female; | 1986 |
[Radiotherapy and chemotherapy in anal carcinoma].
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorourac | 1987 |
Feasibility of non-surgical definitive management of anal canal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1987 |
Preoperative chemotherapy and radiotherapy in the management of epidermoid carcinoma of the anal canal.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 1987 |
Definitive combined modality therapy of carcinoma of the anus. A report of 30 cases including results of salvage therapy in patients with residual disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1987 |
[Preoperative radiochemotherapy in advanced oral and oropharyngeal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1987 |
[Function-preserving treatment of anal cancer using simultaneous radio- and chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, | 1987 |
Esophageal carcinoma: modest benefits from combined modality therapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1987 |
Preliminary results of concomitant radiotherapy and chemotherapy in advanced cervical carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cesium Radi | 1987 |
Preliminary experience with a combined-modality approach to the management of oesophageal cancer.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1988 |
Concurrent combined chemotherapy and radiation therapy in gastrointestinal cancers.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Gastrointestinal Neoplasms; Human | 1987 |
[Simultaneous radio- and chemotherapy of squamous cell carcinoma of the esophagus].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1988 |
A new treatment for invasive squamous cell bladder cancer: the Nigro regimen: preoperative chemotherapy and radiation therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1988 |
Combined treatment in carcinoma of the nasopharynx.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1988 |
Preoperative radio-chemotherapy in anal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Basal Cell; Carcino | 1988 |
Chemo/radiation with and without surgery in the thoracic esophagus: the Wayne State experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1988 |
Synchronous 5-fluorouracil, mitomycin-C and radiation therapy in the treatment of locally advanced carcinoma of the cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1988 |
[Intra-arterial drug infusion via the bronchial artery in the treatment of bronchogenic carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Carcinoma, Bronchog | 1988 |
[Clinical studies of the treatment of bladder tumor and its effects--experience in 86 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Tr | 1988 |
Alternating cisplatin-5-fluorouracil and radiotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamous Cell; Cisp | 1988 |
[Alteration of immunological parameters following CDDP-5-FU chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
[Chemotherapy of ORL cancers].
Topics: Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Fluorouracil; Humans; | 1988 |
Effectiveness of cis-platinum and 5-fluorouracil as induction chemotherapy prior to radiation therapy in advanced head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1988 |
Cardiac arrest--a manifestation of 5-fluorouracil cardiotoxicity.
Topics: Carcinoma, Squamous Cell; Electrocardiography; Fluorouracil; Heart; Heart Arrest; Humans; Male; Midd | 1988 |
Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
[Results of simultaneous radio-polychemotherapy in advanced inoperable cancer of the head and neck].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1988 |
Respiratory tract fistulae in recurrent aerodigestive cancers after chemotherapy.
Topics: Bronchial Fistula; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Etoposide; Fluorouraci | 1988 |
Preoperative radiation and chemotherapy for localized squamous cell carcinoma of the esophagus: a RTOG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1988 |
Effects of cisplatin plus fluorouracil vs cisplatin plus cytarabine on head and neck squamous multicellular tumor spheroids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; | 1988 |
The effect of cisplatin and fluorouracil on xenografted human squamous cell carcinoma of the head and neck.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Ci | 1988 |
Continuous cisplatin (24-hour) and 5-fluorouracil (120-hour) infusion in recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
Evaluation of bolus cis-platinum and continuous 5-fluorouracil infusion for metastatic and recurrent squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
Topical 5-fluorouracil in treatment of carcinoma of nasal floor and nasal alae.
Topics: Administration, Topical; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Combined Modality Th | 1988 |
Simultaneous radiotherapy and chemotherapy with 5-fluorouracil and cisplatin for locally confined squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Chemotherapy with low doses of radiation followed by definitive radiotherapy for advanced unresectable carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1988 |
[Epidermoid cancers of the esophagus: combined chemotherapy, surgery and radiotherapy. Preliminary results in 50 cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1988 |
[The clinical and histological effect of preoperative combination chemotherapy with low dose MTX.5-FU in oral cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administ | 1988 |
[Intraarterial infusion of oncostasis in patients with recurrent cervical cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; F | 1988 |
Cisplatin and 5-fluorouracil in recurrent head and neck cancer: results of an outpatient schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil.
Topics: Carcinoma, Squamous Cell; Erythema; Fluorouracil; Foot; Hand; Humans; Male; Middle Aged; Paresthesia | 1988 |
Advanced head and neck cancer: response to and toxicity of multimodality therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Systemic chemotherapy with cisplatin, 5-fluorouracil and allopurinol in the management of advanced epidermoid esophageal cancer.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1988 |
[Multidisciplinary, intra-arterial chemotherapy (IAC) with CDDP and 5-FU against cervical cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1988 |
Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1987 |
[Local treatment of cervical intraepithelial neoplasia with a 5 percent fluorouracil ointment].
Topics: Biopsy; Carcinoma in Situ; Carcinoma, Squamous Cell; Cervix Uteri; Condylomata Acuminata; Female; Fl | 1987 |
Accelerated split-course radiotherapy and simultaneous cis-dichlorodiammine-platinum and 5-fluorouracil chemotherapy with folinic acid enhancement for unresectable carcinoma of the head and neck.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cobalt R | 1987 |
[Central squamous cell carcinoma of the lung and its management by transbronchoscopic topochemotherapy and combination radiotherapy].
Topics: Adult; Aged; Bronchoscopy; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Combined Modality Therapy | 1987 |
[Clinical efficacy of combined treatment in a late-stage malignant tumor of the head and neck].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1987 |
[Principles of the simultaneous radiation and polychemotherapy in advanced head and neck carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1987 |
Cisplatin, high dose folinic acid and 5-fluorouracil in squamous cell carcinoma of the esophagus. A pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 1987 |
A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1987 |
[Sequential administration of methotrexate and 5-fluorouracil in epidermoid carcinomas of the head and neck. Results of a prospective study].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; Head and | 1986 |
Neoadjuvant therapy for advanced head and neck cancer with allopurinol-modulated high dose 5-fluorouracil and cisplatin. A phase I-II study.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1987 |
Simultaneous cisplatin and 5-fluorouracil as second-line treatment of head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1987 |
[Intra-arterial chemotherapy combined with surgery in the treatment of stage II cervical carcinoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality T | 1987 |
[Phase II study of 5-FU tablets in cancer of the uterine cervix].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Evaluation; Female; Fluoroura | 1987 |
Squamous cell carcinoma following fluorouracil-responsive 'keratoacanthoma'.
Topics: Aged; Carcinoma, Squamous Cell; Diagnostic Errors; Fluorouracil; Humans; Keratoacanthoma; Male; Skin | 1987 |
Adverse effect from use of 5% fluorouracil.
Topics: Animals; Brain; Carcinoma, Squamous Cell; Cat Diseases; Cats; Dogs; Ear Neoplasms; Ear, External; Fl | 1987 |
Comparison of three treatment strategies for esophageal cancer within a single institution.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1987 |
5-Fluorouracil infusions and fractionated doses of radiation: studies with a murine squamous cell carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Male; Mice; Mice, Inbred | 1987 |
[A case of esophageal cancer of superficial depressive type in an advanced age successfully treated with HCFU].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluo | 1987 |
Chemotherapeutic response of squamous cell carcinoma xenografts (subcutaneous and subrenal capsule assay).
Topics: Aged; Animals; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Humans; Male; Mice; Mice, I | 1987 |
Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1987 |
[Radiochemotherapy of inoperable esophageal cancer with 5-FU infusions].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil | 1987 |
The role of radiotherapy in the management of maxillary sinus carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Evaluation Studies as Topic; Femal | 1986 |
Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Methotrexate and 5-fluorouracil in the treatment of squamous and other carcinomas of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Synergism; Fluorourac | 1986 |
Carcinoma in situ of the glans penis and distal urethra.
Topics: Adult; Carcinoma in Situ; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Humans; | 1986 |
Preoperative chemotherapy followed by surgery with possible postoperative radiotherapy in squamous cell carcinoma of the esophagus: evaluation of the chemotherapy component.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1986 |
Treatment of recurrent carcinoma of the cervix with bromocriptine.
Topics: Adult; Aged; Bromocriptine; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Middle Aged; Neo | 1986 |
Phase II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evaluati | 1986 |
Allergic reaction to 5-fluorouracil infusion.
Topics: Angioedema; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dru | 1986 |
Combination chemotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1986 |
Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule.
Topics: Adenocarcinoma; Adult; Allopurinol; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Administration | 1986 |
Chemoradiotherapy as initial management in patients with squamous cell carcinoma of the head and neck.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1986 |
[Etretinate and 5-fluorouracil in intra-anal Bowen's disease].
Topics: Adult; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bowen's Disease; | 1986 |
[Clinical study of HCFU in combination with irradiation therapy in squamous cell carcinoma of the head and neck].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorouracil; He | 1986 |
[Chemotherapy of recurrent squamous cell carcinomas in the ENT area with cisplatin/adriamycin (DDP/ADM) and methotrexate/5-fluorouracil (MTX/5-Flu): a retrospective comparison of 2 protocols].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1986 |
Growth delay in a murine squamous cell tumor after local radiation and concurrent infusional 5-fluorouracil treatment.
Topics: Animals; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Infusion Pumps; Mice | 1986 |
Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisp | 1986 |
Phase II trial of a combination of low dose cisplatin (DDP) and bolus 5-fluorouracil (FU) in recurrent and metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Alteration of chemotherapy (cisplatin and 5-FU) and radiotherapy in the management of advanced or recurrent head and neck cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
[An evaluation of the multidisciplinary treatment of carcinoma of the maxillary antrum in head and neck surgery].
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Humans; Maxillary Sinus; Maxillar | 1986 |
Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1986 |
Treatment of advanced bladder carcinoma with irradiation and concomitant 5-fluorouracil infusion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitio | 1987 |
The use of 5-FU in treating advanced esophageal carcinoma.
Topics: Adult; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Ag | 1986 |
Analysis of the long-term results of our combination therapy for maxillary cancer, with particular reference to treatment of T4 and N1-3 maxillary cancer.
Topics: Adolescent; Adult; Age Factors; Aged; Carcinoma, Squamous Cell; Child; Child, Preschool; Combined Mo | 1985 |
Combined cryosurgical, chemotherapeutic, and radiotherapeutic management of T1-4N0M0 oral cavity cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cobalt Radioi | 1985 |
[Chemotherapy for advanced bladder cancer: clinical evaluation of chemotherapy for locally advanced or metastatic bladder cancer and adjuvant chemotherapy for deeply invasive bladder cancer following radical cystectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitio | 1985 |
Carcinoma of the tongue and floor of the mouth. Preliminary results of a multidisciplinary approach.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1985 |
[Therapy of recurrent squamous cell cancers in the ENT area with the sequential methotrexate (MTX)/5-fluorouracil (5-Fu) protocol].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluor | 1985 |
Maintenance chemotherapy for high-risk patients. A preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1985 |
[Clinical study on the permeability of FT-207 and 5-FU in primary lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Cell Membrane Permeability; Female; Fluoroura | 1985 |
Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 1985 |
Squamous cell cancer of female urethra. Successful treatment with chemoradiotherapy.
Topics: Aged; Biopsy; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Combined Modality Therapy; Female; Flu | 1985 |
[Thermotherapy for cancer of the urinary bladder in combination with tegafur suppository and picibanil--concentrations of tegafur in the serum and tissues in bladder carcinoma].
Topics: Adult; Aged; Biological Products; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Fl | 1985 |
Effective multimodality treatment for advanced epidermoid carcinoma of the female genital tract.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1985 |
Chemoradiation therapy and resection for carcinoma of the esophagus: short-term results.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 1985 |
The use of radiation therapy combined with chemotherapy in the management of squamous cell carcinoma of the anus and marginally resectable adenocarcinoma of the rectum.
Topics: Aged; Antibiotics, Antineoplastic; Anus Neoplasms; Carcinoma, Squamous Cell; Combined Modality Thera | 1985 |
[Radiotherapy in trimodal combination therapy of maxillary sinus squamous cell carcinoma].
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorouracil; Humans; Infusions, Intra- | 1985 |
[Chemotherapy with FT-207 suppository (Futraful Supo) in head and neck cancer--cooperative studies by six medical schools in Kanagawa Prefecture].
Topics: Adult; Aged; Anorexia; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; | 1985 |
Combined treatment approach in surgical management of carcinoma of the esophagus: a preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1985 |
Anorectal squamous cell carcinoma at Mississippi Baptist Medical Center: results of the last five years of the Nigro schedule.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; C | 1985 |
[Level of 5-FU in uterine cervical cancer tissue after oral administration of UFT].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cervix Ute | 1985 |
Treatment of epidermoid carcinoma of the anal canal.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 1985 |
Radical radiation therapy with 5-fluorouracil infusion and mitomycin C for oesophageal squamous carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1985 |
Salvage of stage IV intraoral squamous cell carcinomas with preoperative 5-fluorouracil.
Topics: Administration, Topical; Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; F | 1986 |
The activity of a single-agent 5-fluorouracil infusion in advanced and recurrent head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasm | 1986 |
Mitomycin and fluorouracil with concomitant radiotherapy in head and neck cancer.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Fluorouracil; Head and Neck | 1985 |
Skin lesions from sun exposure: a treatment guide.
Topics: Acute Disease; Adult; Aged; Carcinoma, Squamous Cell; Cheilitis; Chronic Disease; Fluorouracil; Huma | 1985 |
Sequential methotrexate and 5-fluorouracil in the treatment of non-small cell carcinoma of the lung.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evalu | 1985 |
Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Chromatography, | 1985 |
Neoplasia of the equine urinary bladder as a cause of hematuria.
Topics: Animals; Biopsy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cystoscopy; Female; Fibroma | 1985 |
Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Ce | 1985 |
A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1985 |
Sequential methotrexate (MTX) and 5-fluorouracil (FU) in human tumor xenografts.
Topics: Animals; Carcinoma 256, Walker; Carcinoma, Squamous Cell; Cell Line; Dose-Response Relationship, Dru | 1985 |
Combined chemotherapy, cryosurgery, and radiotherapy/surgery for oral cancer.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Cryosurgery; Cyclophosphamide; Female; Fluorour | 1985 |
Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1985 |
[Neoplasms of the vulva].
Topics: Aged; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Erythroplasi | 1985 |
[Combined treatment of patients with inoperable stomach cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorourac | 1970 |
[Experiences in the palliative chemotherapy of 228 cases of unmeasurable and 52 measurable intrapulmonary tumors].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Humans; Lung Neopla | 1971 |
Factors influencing the success of arterial infusion chemotherapy for cancer of the head and neck.
Topics: Age Factors; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell | 1972 |
Esophageal carcinoma.
Topics: Adult; Aged; Alkylating Agents; Carcinoma, Squamous Cell; Diagnosis, Differential; Esophageal Neopla | 1972 |
[A case of the squamous cell carcinoma of the renal pelvis associated with staghorn calculus. Bleomycin treatment of the metastatic recurrence].
Topics: Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Hu | 1972 |
[Intermittent polychemotherapy in inoperable bronchial cancer].
Topics: Aged; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cyclophosphamide; Female | 1972 |
[Esophageal tumors--therapeutic problems].
Topics: Adenocarcinoma; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cobalt Isotopes; Esophageal Neoplasm | 1972 |
[Vulvar Bowen's disease: diffuse sessile form].
Topics: Aged; Bleomycin; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Skin Neoplasms; Vulvar Neop | 1972 |
Cancer of the tongue.
Topics: Bleomycin; Carcinoma, Squamous Cell; Dental Caries; Electrocoagulation; Fluorides, Topical; Fluorour | 1973 |
Alternative approaches to radiotherapy alone and radiotherapy as a part of a combined therapeutic approach for lung cancer.
Topics: Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Humans; Lung Neop | 1973 |
Chemotherapy of lung cancer: the experience of the National Cancer Institute of Milan.
Topics: Adenocarcinoma; Bleomycin; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Doxorubicin; Fluoroura | 1973 |
[Intra-arterial chemotherapy of head and neck tumors: statistical study of 129 cases treated at the Institut Gustave Roussy].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Facial Neoplasms | 1973 |
Chemotherapy in recurrent heat and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Drug Thera | 1974 |
[Three years of experience in the polychemotherapy of inoperable bronchial carcinoma].
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Austria; Br | 1974 |
The roles of radiotherapy and cytotoxic drugs in the management of carcinoma of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Esophageal Neoplas | 1973 |
Continuous arterial infusion chemotherapy. Experience with 44 cases.
Topics: Adenocarcinoma; Arteries; Brain Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Cath | 1967 |
[Study of the action of antitumor compounds on primary explants from human tumors].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Antibiotics, Antineoplastic; An | 1967 |
Chemotherapy of induced skin tumors in mice.
Topics: Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Benz(a)Anthracenes; Busulfan; Ca | 1968 |
Chemotherapy for lung cancer at the Institute of Experimental and Clinical Oncology, Academy of Medical Sciences, USSR.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcino | 1973 |
Actinic keratoses in Bantu albinos. Clinical experiences with the topical use of 5-fluoro-uracil.
Topics: Adult; Albinism; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Catechol Oxidase; Child; Female; F | 1973 |
[Clinical picture and radiotherapy of malignant vulvar neoplasms].
Topics: Adult; Age Factors; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Melanoma; Middle A | 1973 |
Minor surgery for benign and malignant facial lesions.
Topics: Acne Vulgaris; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cicatrix; Cortisone; Curettage; Cyst | 1974 |
Current problems in the use of the oncolytic drugs.
Topics: Antineoplastic Agents; Busulfan; Carcinoma, Squamous Cell; Child; Chlorambucil; Choriocarcinoma; Dac | 1968 |
Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-fluorouracil in solid tumors.
Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Cyclophosphamide; Female; Fibrosarcoma; Fluorouraci | 1969 |
[Polychemotherapy of malignant tumors and hemoblastoses].
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Bronchial Neoplasms; Carcinom | 1968 |
Metabolically active liver metastases treated by 5-fluorouracil hepatic artery infusion.
Topics: Adenoma, Islet Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; Hepatic Artery; Hormones, Ectop | 1970 |
[Pathologic anatomy of rectal cancer treated by intra-arterial administration of 5-fluoruracil].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Female; | 1970 |
[Local treatment of skin neoplasms with 5 per cent fluorouracil ointment (report of 6 cases)].
Topics: Adenocarcinoma, Scirrhous; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorourac | 1972 |
[Radiotherapy following synchronisation of the cell-division rhythm].
Topics: Animals; Carcinoma; Carcinoma, Squamous Cell; Cell Division; DNA; Fluorouracil; Humans; Mice; Neopla | 1972 |
The role of heparin in the chemotherapy of solid tumors: preliminary clinical trial in carcinoma of the lung.
Topics: Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Fibrinogen; Fluorouracil; H | 1972 |
Axillary metastases from unknown primary sites.
Topics: Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Axilla; Breast Neoplasms; Carcinoma, Squamous Cel | 1973 |
Effects of sodium warfarin and other carcinostatic agents on malignant cells: a study of drug synergy.
Topics: Animals; Carbon Radioisotopes; Carcinoma, Bronchogenic; Carcinoma, Hepatocellular; Carcinoma, Squamo | 1974 |
Heparin anticoagulation as adjuvant to chemotherapy in carcinoma of the lung.
Topics: Aged; Antineoplastic Agents; Blood Coagulation; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Small | 1974 |
Triple drug intra-arterial infusion combined with x-ray therapy and surgery for head and neck cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Therapy, Combination; Fluorouracil; Head and N | 1974 |
Tumors of the skin. Premalignment and malignant.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Diagnosis, Differential; Fluorouracil; Humans; Kera | 1974 |
Topical chemotherapy of basal and squamous skin cancers with 5-fluorouracil cream.
Topics: Administration, Topical; Carcinoma in Situ; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinom | 1974 |
Histologic evaluation of treatment of epidermoid carcinoma in the oral cavity with methotrexate and 5-fluorouracil.
Topics: Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Fluorouracil; Humans; Injections, Intra- | 1974 |
Arterial infusion and radiation therapy in the treatment of advanced cancer of the nasal cavity and paranasal sinuses.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Carotid Artery, External; Carotid Artery, Internal; Chemot | 1973 |
Results in 169 patients with cancer of the head and neck treated by intra-arterial infusion therapy.
Topics: Antineoplastic Agents; Brachial Artery; Brachiocephalic Trunk; Carcinoma, Squamous Cell; Carotid Art | 1972 |
Intra-arterial infusion for head and neck cancers.
Topics: Aged; Antineoplastic Agents; Brachiocephalic Trunk; Carcinoma, Squamous Cell; Carotid Arteries; Cath | 1973 |
Multiple cutaneous squamous cell carcinomas during immunosuppressive therapy.
Topics: Adult; Azathioprine; Carcinoma, Squamous Cell; Fluorouracil; Humans; Hyperplasia; Immunosuppressive | 1973 |
[Polychemotherapy of broncho-pulmonary cancer: report of clinical research].
Topics: Adenocarcinoma; Adult; Aged; Bronchial Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Hu | 1972 |
[Principles, technic and clinical performance of synchronized radiotherapy].
Topics: Adenocarcinoma; Adult; Aged; Androstanols; Bone Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, S | 1972 |
[Histological findings during the treatment of skin neoplasias with 5-fluorouracil ointment].
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Melanoma; Middl | 1972 |
[Graphic assessment of esophageal cancer regression].
Topics: Carcinoma, Squamous Cell; Colchicine; Esophageal Neoplasms; Fluorouracil; Humans; Mathematics; Metho | 1972 |
Local chemotherapy in cutaneous neoplasms.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Skin Neoplasms | 1972 |
Reversibility of vulvar atypia by DNCB-induced delayed hypersensitivity.
Topics: Adult; Biopsy; Carcinoma in Situ; Carcinoma, Squamous Cell; Chlorine; Female; Fluorouracil; Humans; | 1973 |
Immunotherapy and 5 percent topical 5-fluoro-uracil ointment in the treatment of condylomata acuminata.
Topics: Adolescent; Adult; Antibodies, Viral; Carcinoma, Squamous Cell; Condylomata Acuminata; Female; Fluor | 1973 |
Bowen disease of the hand.
Topics: Adult; Carcinoma, Squamous Cell; Child; Female; Fluorouracil; Hand; Humans; Middle Aged; Skin Neopla | 1973 |
Topical use of 5-fluorouracil.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Skin Neoplasms | 1973 |
Combination therapy of solid tumors using 1,3-bis(2-chloroethyl)-1-nitrosourea (NCNU), vincristine, methotrexate, and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carmustine; Female; Fluorouracil; Gastrointes | 1973 |
Results in fifty cases of advanced squamous cell carcinoma of the head and neck treated by intravenous chemotherapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Combinations; Epiglottis; Female; Fluo | 1973 |
Letter: 5-Fluoro-uracil 5 per cent (Efudix).
Topics: Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Keratosis; Skin Neoplasms | 1973 |
Radiotherapy for bronchogenic carcinoma: actual difficulties and plans for the future.
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide | 1973 |
Effect of 5-fluorouracil and actinomycin D on repair of DNA single-strand breaks in cervix cancer cells.
Topics: Carcinoma, Squamous Cell; Cell Division; Cell Line; Dactinomycin; DNA Repair; DNA, Neoplasm; Female; | 1973 |
Topical use of 5-fluorouracil.
Topics: Carcinoma, Squamous Cell; Fluorouracil; Humans; Keratosis; Skin Neoplasms | 1973 |
Proceedings: Use of 5 fluorouracil in the topical therapy of skin cancer: a review of 157 patients.
Topics: Administration, Topical; Adult; Aged; Carcinoma in Situ; Carcinoma, Basal Cell; Carcinoma, Basosquam | 1972 |
Proceedings: Chemotherapy and immunotherapy for cancer involving the skin.
Topics: Administration, Topical; Antigens, Bacterial; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinom | 1972 |
[External treatment with 5-fluorouracil].
Topics: Carcinoma, Squamous Cell; Fluorouracil; Humans; Keratoacanthoma; Keratosis; Ointments; Xeroderma Pig | 1973 |
The treatment of premalignant and malignant lesions of the vulva.
Topics: Administration, Topical; Adult; Aged; Carcinoma in Situ; Carcinoma, Squamous Cell; Female; Fluoroura | 1974 |
Synchronization of human tissues and its consequences for cancer therapy in ENT. Cell kinetic and clinical studies.
Topics: Aged; Animals; Carcinoma; Carcinoma, Squamous Cell; Cell Division; DNA Replication; DNA, Neoplasm; E | 1974 |
[Clinical and experimental studies on radiotherapy of inoperable tumors following partial synchronization].
Topics: Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; DNA, Neoplasm; Fluorouracil; Head and Nec | 1974 |
Erythroplasia of Queyrat.
Topics: Administration, Topical; Aged; Carcinoma in Situ; Carcinoma, Squamous Cell; Fluorouracil; Humans; Ma | 1974 |
Intra-epithelial carcinoma of the vagina following immunosuppression treated with topical 5-fluorouracil.
Topics: Adult; Azathioprine; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Prednisolone; Vaginal N | 1974 |
Xeroderma pigmentosum--five-year arrest after total resurfacing of the face.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Child, Preschool; Dermabrasion; Electrosurgery; Fac | 1970 |
Systemic chemotherapy for carcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Fema | 1967 |
[Our experiences with polychemotherapy of malignant endothoracic tumors (103 cases)].
Topics: Adenocarcinoma; Adult; Androgens; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma; C | 1968 |
[3 years of polychemotherapy of pleuro-pulmonary cancer. Apropos of 95 cases].
Topics: Androgens; Antibiotics, Antineoplastic; Antineoplastic Agents; Ascorbic Acid; Azirines; Bronchial Ne | 1968 |
[Trial treatment of bronchial cancer by polychemotherapy].
Topics: Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Colchicin | 1968 |
[Effects of 5-FU (5-fluorouracil) in 4.3MeV Linac x-ray treatment of advanced cancer].
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fl | 1968 |
[Basic principles of percutaneous radiotherapy in cervical lymph node metastases].
Topics: Carcinoma, Squamous Cell; Cesium Isotopes; Cobalt Isotopes; Electrons; Fluorouracil; Head and Neck N | 1971 |
The use of chemotherapy in lung cancer (controlled trials).
Topics: Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Dactinomycin; Drug Synergism; Female; Fluorouraci | 1971 |
Hypogastric artery infusion and radiation therapy for advanced squamous cell carcinoma of the cervix.
Topics: Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Injections, Intra-Arterial; Methods; Methotr | 1972 |
Chemotherapy as the definitive form of therapy in esophageal carcinoma.
Topics: Anemia, Hypochromic; Anti-Bacterial Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Esophageal N | 1972 |
Treatment of squamous cell carcinoma of the head and neck by chemotherapy.
Topics: Administration, Oral; Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans; | 1972 |
Intra-arterial infusion. A seven-year study.
Topics: Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans; Injections, Intra-Art | 1972 |
Chemotherapy in the management of metastatic cancer of unknown primary site.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Chlorambucil; Cyclopho | 1972 |
Topical chemotherapy of cutaneous neoplasms.
Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Leukop | 1972 |
[Therapeutic effects of 5-florouracil ointment on various skin diseases].
Topics: Adolescent; Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; Huma | 1972 |
Treatment of cancer with weekly intravenous 5-fluorouracil. Study by the Western Cooperative Cancer Chemotherapy Group (WCCCG).
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Gastrointestinal D | 1971 |
Treatment of basal and squamous cancers of the nose and ear with 5-fluorouracil cream.
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Ear Neoplasms; Female; Fluorouracil; Follow-U | 1971 |
[Lung cancer].
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Cobalt Isotopes; Cyclop | 1971 |
Comments on morbidity in present-day radiotherapy.
Topics: Breast Neoplasms; Buttocks; Carcinoma, Squamous Cell; Dactinomycin; Erythema; Female; Fluorouracil; | 1971 |
Review of a 3-year experience with topical chemotherapy and immunotherapy of superficial cutaneous neoplasms.
Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chlorine; Facial Neoplasms; | 1971 |
Tumors of the skin. XII. Topical 5-Fluorouracil for epidermal neoplasms.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dermatitis; Esthetics; Female; Fluorouracil; Humans | 1971 |
Topical chemotherapy of advanced cutaneous malignancy with 5-Fluorouracil creme.
Topics: Aged; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinoma, Squamous Cell; Esthetics | 1971 |
Porokeratosis plantaris, palmaris, et disseminata. A third type of porokeratosis.
Topics: Adolescent; Adult; Age Factors; Aged; Biopsy; Carcinoma, Squamous Cell; Child; Female; Fluorouracil; | 1971 |
Radiation plus 5-fluorouracil (NSC-19893): clinical demonstration of an additive effect in bronchogenic carcinoma.
Topics: Adenocarcinoma; Aged; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Female; Fluorouracil; Human | 1971 |
[5-Fluorouracil in local therapy of precancerous conditions and carcinoma of the skin].
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Keratosis; Neoplasm Recurrenc | 1971 |
[Treatment of cutaneous tumors with fluorouracil ointment].
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Keratosi | 1971 |
The use of topical 5-fluorouracil in actinic keratoses.
Topics: Adult; Aged; Aging; Biopsy; Carcinoma, Squamous Cell; Fluorouracil; Humans; Keratosis; Middle Aged; | 1971 |
Xeroderma pigmentosum.
Topics: Adult; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Child, Preschool; Eyelid Neoplasms; Female; | 1971 |
The influence of cytostatic treatment on serum LDH patterns of patients with bronchial carcinoma and its relation to tumor regression.
Topics: Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Fluorouracil; Humans; Isoenzymes; L-Lactate Dehyd | 1968 |
[Apropos of 40 cases of malignant tumors treated by local-regional and general chemotherapy in a surgical department].
Topics: Adolescent; Adult; Aminopterin; Back; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chemotherapy, | 1969 |
Cancer and precancer of the skin, review of 40 years experience in therapy.
Topics: Carcinoma, Squamous Cell; Fluorouracil; Humans; Methods; Precancerous Conditions; Radiotherapy Dosag | 1971 |
[Topical therapy of precancerous lesions and skin carcinomas using a 5-fluorouracil ointment].
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Facial Neoplasms; Female; Fluorouracil | 1969 |
Historic and current intra-arterial chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Catheterization; Chemotherapy, Cancer, Regional Per | 1970 |
Bronchial artery infusion therapy for lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Bronchial Arteries; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cath | 1969 |
[Cytological control of expectoration in primary broncho-pulmonary cancers treated by chemotherapy, radiotherapy or surgical exeresis].
Topics: Bronchial Neoplasms; Carcinoma, Squamous Cell; Cobalt; Cyclophosphamide; Cytodiagnosis; Female; Fluo | 1969 |
[Mitotic index determination of in vivo synchronized human neoplastic tissue].
Topics: Autoradiography; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Mitosis; Neoplasms; T | 1969 |
[Synchronization of histologically normal human tissue].
Topics: Antineoplastic Agents; Autoradiography; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; DNA; DNA, N | 1969 |
[Squamous cell carcinoma of the renal pelvis associated with gross hydrocalycosis due to a calculus: report of a case].
Topics: Calculi; Carcinoma, Squamous Cell; Cyclophosphamide; Female; Fluorouracil; Humans; Hydronephrosis; K | 1969 |
[Bowen's disease of the palm of the hand. Treatment by 5-fluoro-uracil ointment].
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Hand; Humans; Middle Aged; Ointments; Skin Neo | 1969 |
Experiences with local chemotherapy and immunotherapy in premalignant and malignant skin lesions.
Topics: Antigen-Antibody Reactions; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dermatitis; Dermatitis, | 1970 |
[Use of 5-fluorouracil ointment. Indications and limitations].
Topics: Carcinoma, Squamous Cell; Erythema; Fluorouracil; Humans; Keratosis; Ointments; Photosensitivity Dis | 1970 |
The aging skin: problems and their causes.
Topics: Aged; Aging; Arsenicals; Balanitis; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorou | 1970 |
Local chemotherapy of cutaneous neoplasms.
Topics: Adenocarcinoma; Allergy and Immunology; Antineoplastic Agents; Carcinoma, Squamous Cell; Dactinomyci | 1970 |
[On the treatment of superficial neoplasms with 5-FU ointment. Preliminary review].
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Ointments; Skin Neoplasms | 1970 |
Preferential attack on cancer by selected SH inhibitors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Ascites; Breast Neoplasms; Carcinoma, Ehrlich Tumor; | 1970 |
Occurrence of squamous carcinoma in hyperkeratoses and Bowenoid lesions treated with 5-fluorouracil.
Topics: Aged; Carcinoma, Squamous Cell; Fluorouracil; Humans; Keratosis; Male; Middle Aged | 1970 |
Comparison of the clinical and histological effects of 5-fluorouracil (5-FU) alone and of 5-FU preceded by dimethyl-sulphoxide (DMSO) on senile keratosis.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dimethyl Sulfoxide; Fluorouracil; Humans; Keratosis | 1970 |
The place of chemotherapy with 5 per cent 5-fluorouracil ointment in the treatment of malignant disease of the skin.
Topics: Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Necrosis; Ointments; Skin Neoplasms; T | 1970 |
5-fluorouracil (5-FU) ointment in the treatment of basal cell epithelioma. Histological control over a long duration.
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Middle Ag | 1970 |
5-fluorouracil (5-FU) ointment in the treatment of benign and malignant skin lesions.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Keratoacanthoma; Keratosis; L | 1970 |
Preliminary experience with 5-fluorouracil ointment in the treatment of neoplasias and precancerous lesions of the skin.
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Neoplasm Metast | 1970 |
Clinical and structural evaluation of the treatment of some hyperplastic and neoplastic skin diseases with 5-fluorouracil (5-FU) ointment.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Ointments; Skin Neoplasms; Ti | 1970 |
5-fluouracil (5-FU) ointment in the treatment of skin tumours and keratoses.
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Keratoacanthoma | 1970 |
An evaluation of combination chemotherapy with procarbazine (NSC-77213) and 5-fluorouracil (NSC-19893) in advanced carcinoma of the lung.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Benzoates; Blood Cell Count; Carcinoma; Carcinoma, Bro | 1970 |
[In vivo synchronization of human tissue. Influence of blocking-up time].
Topics: Carcinoma, Squamous Cell; Culture Techniques; DNA; DNA, Neoplasm; Fluorouracil; Humans; Infusions, P | 1971 |
The treatment of skin carcinoma with podophyllum derivatives.
Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Colchicine; Fluorouracil; Hu | 1971 |
Pre-irradiation 5-fluorouracil infusion in advanced head and neck carcinomas.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cobalt Isotopes; Female; Fluorouracil; Humans; Injections, In | 1971 |
[Innovation in radiotherapy of advanced malignant tumors].
Topics: Carcinoma, Squamous Cell; Fluorouracil; Head and Neck Neoplasms; Humans; Hyperbaric Oxygenation; Lar | 1967 |
[Continuous intra-arterial infusion of 5-fluorouracil in oral cancer].
Topics: Adult; Aged; Animals; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Injections, Intra-Arte | 1967 |
Treatment of Bowen's disease with topical 5-fluorouracil under occlusion.
Topics: Aged; Carcinoma, Squamous Cell; Fluorouracil; Humans; Precancerous Conditions; Skin Neoplasms; Thigh | 1968 |
Sequential chemotherapy and radiation therapy of buccal mucosa carcinoma in South India. Methods and preliminary results.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cheek; Cobalt Isotopes; Deoxyuridine; | 1968 |
[Trial polychemotherapy of inoperable cancer (apropos of 71 cases)].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma, Squamo | 1968 |
[Modalities and results of anticancer polychemotherapy in 73 cases of advanced broncho-pleuro-pulmonary cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bronchial Neoplasms | 1968 |
[Polychemotherapy of bronchopulmonary cancer].
Topics: Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Cyclophos | 1968 |
Xeroderma pigmentosum. Treatment with topically applied fluorouracil.
Topics: Adolescent; Adult; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Keratosis; Skin Neoplasms | 1968 |
[218 cases of prolonged polychemotherapy in advanced cancer (especially bronchopulmonary). Modalities and results].
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neop | 1968 |
[Topical cytostatic treatment of epitheliomas with a 5 per cent 5-fluorouracil ointment].
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Keratoacanthoma | 1968 |
Combination of 5-fluorouracil and radiation as primary therapy of carcinoma of the cervix.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cobalt Isotopes; Female; Fluorouracil; Humans; Mesonephrom | 1968 |
[Combined therapy of lung carcinoma with 5-fluorouracil and 60Co irradiation].
Topics: Adult; Aged; Animals; Carcinoma, Ehrlich Tumor; Carcinoma, Squamous Cell; Cobalt Isotopes; Female; F | 1968 |
[Experiences with a cytostaticly active ointment in the dermatologic practice. (5 per cent--5-fluorouracil ointment)].
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lichen P | 1969 |
Combined intra-arterial infusion and radiotherapy for the treatment of advanced cancer of the head and neck.
Topics: Aged; Brain Neoplasms; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorouracil; Follow-Up Studi | 1969 |
Topical chemotherapy of cutaneous malignancy of the head and neck.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Head and Neck Neoplasms; Humans; Kera | 1969 |
The topical application of 5-fluorouracil in the treatment of skin lesions.
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Male; Skin Neoplasms | 1969 |
The use of parenteral 5-fluorouracil in solid tumours. A preliminary report.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Female; Fluorouracil; Gastrointestinal Neoplasms; Genital | 1969 |
Preliminary studies in the use of 5-fluoro-uracil cream in the treatment of malignant and premalignant skin tumours.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Keratoacanthoma; Keratosis; O | 1969 |